26|efficacy of PCIT,adherence rate,parental anger and physical discipline/force, and family problems,overall levels of parental anger and physical discipline/force,autonomy-support,low attrition rate,structure,moderate stability and parent-child correspondence,autonomy|Twenty-six maltreating families were randomly assigned to one of two conditions: the 16-hour weekly intervention group, or the 4-month wait list control group.
45|mean migraine headache frequency,frequency of headache attacks, the frequency of use of drugs for the acute management of migraine, the patients' opinion of treatment and the Hamilton anxiety and depression rating scales,functional restriction,headache intensity,Tolerance and safety,Responder rate,migraine headache frequency,Valproic acid serum levels,headache days,Frequency, intensity, and duration of migraine headaches as well as MIDAS score and symptomatic medications,Frequency, intensity, duration, associated symptoms with headaches, analgesics use, as well as drugs' side effects,headache duration,nausea,Migraine frequency,migraine headache rate,reductions with extended-release divalproex sodium,symptoms with migraine,migraine attacks,number of responders,frequency of migraine attacks,duration, monthly frequency, and intensity of headache,symptomatic medication per episode,migraine attack frequencies,4-week migraine attack frequency,mean standard deviation (SD) of monthly migraine frequency,Migraine headaches,Migraine headache days,average peak severity or duration of individual migraine headaches,efficacy and safety,initial migraine frequency,mean score of the 21-item Hamilton rating scale for depression,frequency, severity and duration of the attacks,reduction of headache severity,Adverse events,visual analog scale (VAS), and headache duration,number of days with migraine,severity and duration of the migraine attacks,nausea, dizziness and tremor in which incidence rates,migraine headache,migraine headache rates,mean SD of monthly headache frequency,migraine frequency,frequency of migraine attacks and the number of migraine headache days,incidence of any specific treatment-emergent adverse event,various side effects,Side effects|The outcome of group 1 (low serum level) was significantly better than that of group 2 with respect to both parameters (P<.05).
not found|response to treatment: at least 20% improvement from basal conditions on clinical, laboratory, or specific neurological testing variables,response rate|Of the 32 patients studied, 18/19 receiving Cy and 7/13 receiving MP responded to treatment (p<0.03).
220|average total cost of delivering care,nurse job satisfaction,Length of hospital stay, discharge destination, functional dependence (Barthel index) and direct healthcare costs,functional independence,daily cost of care,mortality, functional status, or living arrangements at any time,initial length of stay,Quality of care scores,discharge destination or dependence,Inpatient length of stay,cost savings,decision making and quality of care,length of stay, mortality, readmission, complications, satisfaction, and cost,Patients' length of stay, functional status, subsequent move to more dependent living arrangement,quality of care, job satisfaction, length of patient stay,length of stay, mortality, or complications,mean total cost,Length of inpatient stay,functional dependence (Barthel Index), discharge destination and length of hospital stay|Few significant differences were found between the two groups in length of stay, mortality, or complications.
161|complete response,clinical complete response,survival or response,Toxicity and treatment efficacy assessed by pathological response rate, progression-free survival, and survival,anemia,pathologic response rate,myelosuppression,median time to progression,overall survival and activity index,overall median response rate,larger proportion of 48-month survivors,Time to progression and survival,response rate to CMF,Survival and time to treatment failure,overall response rate,overall toxicity,alopecia,nadir blood counts,Mortality,survival rates,clinical toxicities and abnormalities in laboratory findings,complete pathological response rate,superior progression-free survival,side-effects and haematological toxicity,complete and partial response rate,time to progression and survival,clinical complete response (CR) rate for CA,Median survival times,clinical complete response rates and longer time to failure,efficacy and toxicity,progression free survival,Survival,Toxicity,survival,median response duration,myelosuppression, especially thrombocytopenia,better survival,myelosuppression, particularly thrombocytopenia,response rate,toxicity deaths,macroscopic disease left,thrombocytopenia,median duration of response,median survival durations,Median survival CAP,early nausea and vomiting and later hematologic toxicity,complete remissions (CRs,nausea and emesis,life-threatening toxicities, including hematologic toxicity,clinical response rate,efficacy and tolerance,median progression free survival (PFS,hearing loss,survival or progression-free survival,response rate of AC, FU, and CY,response duration,CAP,overall pathological response rate,median survivals,Nausea, vomiting and alopecia,renal toxicity,Overall response rates,Pathologic complete response rates,median duration of CRs,response rates,toxicity,neuromuscular toxicities,lethal toxicities, including gastrointestinal hemorrhage (1 patient) and neutropenic sepsis,progressive disease (PD), nonresponse, or toxicity,overall survival,complete and partial response rates,survival of CRs,response to therapy, time to treatment failure, and overall survival,response rate, time to progression, disease-free survival and overall survival,Optimal survival with minimal toxicity,Cell differentiation and volume of postoperative disease,partial response,Response rates,bone marrow disorders and death due to toxicity,survival curves,toxicity/refusal,Likewise, time to treatment failure,unacceptable toxicity,hematologic and gastrointestinal toxicity,Clinical response rates,progression-free interval,therapeutic index,small survival,incidence of side effects,survival superiority,severe hematological toxicity,median survival,5-year relapse-free survival rates,leucopenia,clinical complete response rates,5-year survival rates,tinnitus,toxicity and efficacy,Efficacy,partial response rates|Failure to achieve a significant degree of leucopenia was associated with worse progression free survival (P less than 0.001).
56|number of withheld feeds,gastric emptying, maturation of gastrointestinal motor patterns, and time to achieve full enteral feedings,episodes of gastric residuals (P<0.05) and shorter duration of parenteral nutrition (PN,mean time to attain full enteral feedings,Feed toleration, time taken to establish full enteral feeding, vomiting, prescription of glycerine suppositories and occurrence of necrotising enterocolitis,gastrointestinal function,feeding outcome,mean birth weight,Time to achieve full feeds,episodes of large residual gastric aspirates,median gestational age, birth weight and postnatal age at start of feeds,time to full feeding,gestational age at birth,gastric emptying and feed tolerance,symptoms of gastroesophageal reflux,episodes of sepsis, necrotizing enterocolitis, and cholestasis,Gastroesophageal reflux,time to establish full enteral feeds,efficacy and safety,total parenteral nutrition or to the time needed to regain birthweight,length of time taken to establish full enteral feeding since enrollment,full enteral feeding earlier,time taken to attain full enteral feedings,Times to full feeding,feeding tolerance,feed tolerance,tolerated,necrotizing enterocolitis,gastrointestinal dysmotility,Gastric emptying,time taken to attain full enteral feedings of at least 130 mL/kg/d,Gastric emptying and characteristics of antroduodenal motor contractions,cholestatic jaundice,cardiac dysrhythmia, pyloric stenosis, or septicaemia,full enteral feeding|Oral erythromycin is effective in facilitating enteral feeding in preterm very low birthweight infants with moderately severe gastrointestinal dysmotility.
39|VO2, CI and mixed venous O2 saturation,overall incidence of death and major complications,Respiratory inductive plethysmographic data,Plasma catecholamines,gastrin AUC,Postoperative analgesia at rest and during coughing and movement,IL-1beta and TNF-alpha,mean arterial pressure and in calculated systemic vascular resistance,incidence of new myocardial infarction, stroke, and respiratory failure,overall postoperative complication rate,endotracheal intubation time,surgical intensive care stay,Myocardial ischaemia,postoperative pain control,cardiovascular failure,adverse cardiac outcome,Gastrin levels,total number or type of postoperative complications,analgesic medication,CRP, IL-1beta, IL-6, and TNF-alpha levels,heart and respiratory rate,visual analog pain scores,Postoperative pain scores,Myocardial ischemia,Postoperative myocardial ischemia,electrogastrographic activity and serum gastrin secretion,pain relief,complications,Postoperative analgesia,Perioperative ischaemia,hypotension,length of hospitalization,morbidity or mortality,postoperative hospital length of stay, direct medical costs, selected postoperative morbidities, and postoperative recovery milestones,72-hour fluid requirement,Total operative time,perioperative myocardial ischaemia,major infectious complications,Intraoperative ischaemia,frequency of electrical waves (tachygastria,power ratio (postprandial/fasting total power,EGG activity and serum gastrin secretion,Visual analog pain scores,postoperative morbidity,systemic hemodynamic function and systemic oxygen supply-demand relationship,stress response indices,overall incidence of myocardial ischemia,death, myocardial infarction, myocardial ischemia, reoperation, pneumonia, and renal failure,Length of stay and direct medical costs,neuroendocrine response,haemodynamic stability,O2 delivery (QO2) and consumption (VO2,VO2 during recovery,lung volume,Urinary cortisol excretion, a marker of the stress response,gastric electrical activity and serum gastrin secretion,Postoperative ischaemia,early myocardial ischemia,Postoperative outcomes,duration of intensive care unit and hospital stay,hypertension and tachycardia,Heart rate,plasma noradrenaline,total duration of ischemia,incidence of death and major complications,oxygen supply-demand ratio (QO2/VO2,intraoperative vasopressors,intraoperative cardiovascular changes and postoperative complications,Values of cardiac index (CI) and QO2,shorter time to extubation,postoperative myocardial ischemia,hypotensive,Analgesic efficacy and side effects,blood loss, volume replacement or in the number of patients requiring postoperative ventilation,Times to intensive care unit discharge, ward admission, first bowel sounds, first flatus, tolerating clear liquids, tolerating regular diet, and independent ambulation,operative outcome,perioperative outcome,Surgical "risk,plasma vasopressin,myocardial ischemia,length of stay in intensive care,duration of postoperative ventilation,SvO2,EGG parameters or the serum gastrin integrated value (area under the curve [AUC,serum gastrin secretion,cortisol, epinephrine, norepinephrine, total catecholamines, CRP, and IL-6 in the postoperative period,myocardial ischaemia or morbidity,postoperative apneas, slow respiratory rates, desaturation, and S-T segment depression,postoperative pain relief,postoperative pain, time of ambulation, and length of hospital stay,cardiac index,time of hospitalization,risk of respiratory or cardiac complications,stress response,cardiac filling pressure and systemic vascular resistance,Cardiovascular and hormonal responses,incidence of most side effects,hospital costs,plasma vasopressin and adrenaline,death and major complications,respiratory rate, vital capacity, peak expiratory volume in the first second, PaO2, PaCO2, arterial pH, heart rate, and systolic and diastolic blood pressure,Postoperative forced pulmonary volumes,intubation time and intensive care stay,intraoperative decrease in SvO2,lowest value of SvO2 after extubation,serum cortisol, epinephrine norepinephrine, total catecholamines, interleukin (IL)-1beta, IL-6, tumor necrosis factor (TNF)-alpha, and C-reactive protein (CRP|All patients showed a significant increase in cortisol, epinephrine, norepinephrine, total catecholamines, CRP, and IL-6 in the postoperative period (P < 0.05).
80|amblyopic eye acuity,4-month visual acuity,1-year visual acuity outcome,median spherical equivalent refractive error,unilateral visual loss,acuity,Visual acuity,Resolution of amblyopia,severe amblyopia,visual acuity and contrast sensitivity,visual acuity,mean change in visual acuity of the amblyopic eye,visual acuity, contrast sensitivity and resolution of amblyopia,amblyopic eye visual acuity,median anisometropia,mean time to the resolution of amblyopia,mean time for patching,binocular function,average number of training sessions,Visual acuity in the amblyopic eye,Corrected amblyopic logMAR visual acuity and contrast sensitivity function,residual visual acuity deficit,responder rates,moderate to severe amblyopia,unilateral acuity loss,visual acuity outcome,visual acuity of the amblyopic eye,rapid visual acuity recovery,mean dose rates,Visual outcome,contrast sensitivity and slight linear acuity improvement,Amblyopia,BCVA, binocular function, and refractive errors,visual outcome,BCVA,mean visual acuities of the amblyopic eyes,Single letter and linear acuity (near and distance) and contrast sensitivity|The median spherical equivalent refractive error increased significantly during the study in the amblyopic eyes (P<0.05) and the fellow eyes (P<0.001).
32|intensive care unit admissions, artificial ventilation, antibiotic treatment, description of side effects during procedures, and parental perception of comfort,Median time to recovery,respiratory rate,wheezing,wheezing, respiratory rate, retractions, and general condition) and measured S(pO(2)) and heart rate,exhalation technique (IET) and assisted cough (AC,bradycardia with or without desaturation,heart rate,Average hospital stay,time to recovery, defined as 8 hours without oxygen supplementation associated with minimal or no chest recession, and ingesting more than two-thirds of daily food requirements,intensive care admission,mean length of illness in hospital,mean clinical score for respiratory disability,Wheezing score,ventilatory support,Frequency of vomiting and transient respiratory destabilization,retractions,child's comfort|The treatment group showed a mean clinical score for respiratory disability at admission of 5.56 (+/-
10|bronchoconstriction,bronchodilator response,overall bronchodilatory effects,forced expiratory volume in 1 s and forced vital capacity,Pulmonary function,Systolic and diastolic blood pressure (BP,cardiovascular parameters,exercise heart rate,Ventilation, heart rate, and arterial blood gas tensions,pre- and postexercise values of MEF50 and MEF25,airway resistance,forced vital capacity and peak expiratory flow,slopes of the salbutamol dose-response curves of specific airway conductance,evening peak flow rate,baseline forced expiratory volume in 1 second (FEV1,HR, SBP, and DBP 2 h postmedication,resting minute ventilation,Nonspecific bronchial reactivity,FEF,respiratory function,dilevalol,resting heart rate,diastolic blood pressure,ventilatory function,bronchial obstruction largely,dyspnea,cardiac and pulmonary function,heart rate and fall in diastolic blood pressure,highest plasma levels,forced expiratory volume,heart rate and systolic blood pressure,beta-blocking activity,FEV1 or forced vital capacity,Changes in FEV1,MEFV curves,plasma levels,forced vital capacity (FVC) and maximal midexpiratory flow (MMEF,basal forced expiratory volume,arterial O2 or CO2 tension (Pao2 and PaCO2, respectively,FEV1 and the forced vital capacity (FVC,heart rate (HR), systolic blood pressure (SBP), and diastolic blood pressure (DBP,Pulse rate, forced expiratory volume in one second (FEV1) and specific airways conductance,beta 1-Selectivity,maximal expiratory flow-volume (MEFV) curves,Vital capacity (VC) and forced expiratory volume in one second (FEV1,CO2 production,Changes in forced one-second expiratory volume (FEV1) and mid-maximal expiratory flow (MMEF,pulmonary function,effect of bronchodilator,blood pressure,density dependence of expiratory airflow,airways obstruction (FEV1, specific airways resistance,12-min walking distance,cardioselectivity,ventilation,lung function, heart rate and blood pressure,peak expiratory flow rate (PEFR,maximal expiratory flow rates,time to exhaustion on a cycle ergometer,resting pulse rate,AWR and increased PEFR, FEV1, and VC,FEV1,FEV1 and in PEFR,Resting heart rate and forced expiratory volume in one sec (FEV1,AWR,pulmonary function, heart rate and blood pressure,histamine bronchial provocation,exercise tolerance,FEV1 and vital capacity (VC,Mean plasma levels,FEV1 and FVC,Monthly asthma attacks,expiratory volume (FEV1) and maximal midexpiratory flow rate,Ventilatory effects,ventilatory effect,Overall changes in FEV1,degree of reactivity with each active drug,lung function parameters--vital capacity (VC), airway resistance (AWR), peak expiratory flow rate (PEFR), forced expiratory volume (FEV1)--at baseline and at predetermined intervals following each medication and salbutamol challenge,Specific airway conductance, finger tremor amplitude, heart rate, and blood pressure,bronchial tone,heart rate and FEV1,clinical exam, spirometry, or ejection fraction,lung function,median cumulative salbutamol concentrations,bronchoconstrictor response,left or right ventricular ejection fraction,hyperventilation and exercise tolerance,heart rate, blood pressure, and derived indexes at peak plasma drug levels,PEFR, FEV1, and VC,resting heart rate and FEV1,heart rate (HR,resting or exercise Pao2 or Paco2,HR and BP,ventilatory indices, HR or BP,FEV1 and PEFR,forced expiratory volume in 1 second and specific airway conductance,specific airway conductance,Mean reduction in resting pulse rate,bronchial reactivity,improvement of airflow,expiratory airflow parameters,ventilatory indices,O2 consumption,bronchomotor tone, skeletal muscle, and the circulatory system,average monthly asthma attacks,1 Cardiovascular and airways response,heart rate,resting airways obstruction and reduction in bronchodilator response|Mean reduction in resting pulse rate was statisitcally greater after acebutolol compared with placebo but not after practolol compared with placebo.
not found|Plasma potassium levels,visual analogue scores for dyspnoea, fatigue, and general well-being,New York Heart Association functional class status,blood pressure to hypertensive values,Right-sided and pulmonary artery wedge pressures and systemic arterial pressures,serum creatinine levels,Perceived exertion during submaximal exercise,pulmonary oedema,plasma magnesium,right-sided, pulmonary arterial wedge pressure or cardiac outputs,symptom-limited exercise tolerance,pulmonary artery pressure on exercise,pulmonary wedge pressure,Cardiac output,heart size and echocardiographically measured ventricular volume,ventricular arrhythmias on 24-hour ambulatory electrocardiography,diastolic pressure,time taken to walk 100 m at a self-selected slow speed,systolic blood pressure,urinary sodium/potassium ratio,cardiac sympathetic activity, and increased ventricular arrhythmias,Exercise tolerance,Heart rate,24-hour urinary potassium excretion,reduced urinary magnesium excretion,blood, physical, ECG, and audiometric examinations,hemodynamics,plasma renin activity, plasma aldosterone,24-hour urinary sodium excretion,occasional kaliuretic response,cardiac norepinephrine uptake,pulmonary oedema of breathlessness,plasma urea,BUN,ankle oedema,Pulmonary wedge pressure,Blood pressure,Heart failure,NYHA functional class,myocardial norepinephrine uptake,diuretic therapy,mild hypokalemia,Pulmonary arterial pressure,Echocardiographic-determined measurements of left ventricular systolic and diastolic function|Cardiac output decreased at rest, but not significantly, and on exercise not at all.
1294|rates of RDS at 24 hours and the rates of death related to RDS,corresponding mortality rate,efficacy and safety,RDS-related mortality rates,excess mortality rates,incidence of RDS,incidence of being alive without bronchopulmonary dysplasia (BPD,major dosing complications,BPD,air leaks, and causes of death,mortality rates, bronchopulmonary dysplasia (BPD) rates, and rates of other complications of prematurity,mortality rate,alive without BPD,incidences of common complications of prematurity, including intraventricular hemorrhage (grades 3 and 4) and cystic periventricular leukomalacia,death at day 28 and 36 weeks postmenstrual age (PMA), air leaks, neuroimaging abnormalities, and other complications related to either prematurity or RDS,morbidity and mortality rates,incidence of BPD|Lucinactant is a more effective surfactant preparation than colfosceril palmitate for the prevention of RDS.
13|muscle power, functional ability, locomotor score, contractures, and forced vital capacity,muscular power, muscle state, muscular functional ability (Vignos), serum myoglobin and serum creative phosphokinase,Satisfactory blood levels,flushing, dizziness, and leg edema,Muscle strength, contractures, functional ability, cardiopulmonary changes, and laboratory data,number of calcium-positive muscular fibres,muscular X-ray density|Compared with before therapy, the number of calcium-positive muscular fibres was remarkably reduced in the treated DMD patients, but not in the placebo group.
not found|relieving pain,Kaplan-Meier survival analysis and Mantel-Cox log rank analysis,low-back and suprapubic pain,intensity of pain,visual analog scale (VAS), sensory level (pinprick), motor blockade (Bromage score), cervical dilation, and duration of analgesia,pain relief,pain concept or relief,intensity and unpleasantness of pain,rate of VAS score,back pain,unpleasantness,duration of labor,Labour Agentry Scale and the Labor and Delivery Satisfaction Index,Course of labor, uterine activity and fetal heart patterns,relief of pain,degree of pain relief,quality or duration of labour analgesia,Mean pain intensity,intensity of low back pain and abdominal pain,pain component,pain relief, amount of administered analgesics, obstetrical and neonatal outcome, and side effects,intensity of low-back pain,VAS score reduction,quality of analgesia,Apgar score, assays of blood samples from the umbilical vein including blood lactate, plasma hypoxanthine and blood gas, and neurobehavioral assessment,suprapubic pain,duration of analgesia,Analgesia,operative delivery rate,analgesic effects,Visual analogue scale (VAS,Pain relief,pain,epidural labor analgesia,change of pain,Operative delivery,number of requests for pethidine/promethazine,pain (VAS), sensory level (pinprick), motor blockade (Bromage), cervical dilatation, and duration of analgesia, and at delivery on fetal and neonatal outcome,duration of the spinal portion of the CSE,labour pain,minimal or moderate low-back pain,visual analogue pain scale,level of control and satisfaction with labor and delivery|No significant differences occurred between groups in the number of requests for pethidine/promethazine.
not found|CBZ dosage reductions,plasma CBZ concentration,CBZ concentration|CBZ dosage reductions ranging from 14 to 50% were required by 63% of patients who received REM.
89|Recurrence rates,Clinical activity index (CAI) and endoscopic index (EI|Recurrence rates evaluated on the basis of intention to treat showed significant difference between curcumin and placebo (P=.049).
144|rate of recovery from mood episodes of bipolar I disorder,mental health problems,depressive and anxiety symptoms and family conflict,psychosocial functioning, prophylaxis against recurrences of mood episodes, or compliance with pharmacotherapy|This study was designed to answer, in part, the following question: What is the relative efficacy of hospitalization with family intervention as compared with hospitalization without family intervention for patients with major psychiatric disorders who are in need of hospital treatment and for whom both treatments are judged clinically feasible?
20|plasma renin-activity,plasma ANP levels,incidence of RCIN,Plasma ANP levels,incidence of postoperative hemodialysis,serum creatinine values,glomerular filtration, urinary output, and renal histopathology,Acute renal failure (ARF,serum creatinine and urea,systolic blood pressure,overall rate of dialysis-free survival,anuria,rapid onset of diuresis,systemic vascular resistance,duration of hemofiltration and frequency of hemodialysis,urine output,Age, sex, etiology of ARF, entry serum creatinines (SCr,Mortality rates,acute renal failure,incidence of mechanical renal replacement therapy,Acute renal failure,Postoperative creatinine clearance,natriuresis and systemic vasodilation,serum creatinine levels,total number of hemodialyses due to oligo-/anuria,Central venous pressure, systemic vascular resistance index, and pulmonary vascular resistance index,Plasma cyclic guanosine monophosphate levels,creatinine clearance,frequency of hemodialysis/hemofiltration,morbidity and mortality rates,RBF,Dialysis,Hemodynamics, levels of atrial and brain natriuretic peptides (BNP), angiotensin-II and aldosterone, renin activity, and left ventricular (LV) function,probability of dialysis, and improves dialysis-free survival,systolic blood pressures,free-rate of cardiac events,incidence of RCIN: placebo,diuresis,renal function,ANP levels,oliguria, dialysis-free survival,Plasma ANP, brain natriuretic peptide and cyclic guanosine monophosphate (cGMP) levels, hemodynamic variables and renal function,hemodynamics, urine output, intensive care unit (ICU) and hospital stay, bleeding volume, homologous blood transfusion volume, furosemide dose, corrected KCl volume, and postoperative respiratory, hepatic, and renal function,Delayed hypertension (HT) and renal dysfunction (RD,Mean arterial blood pressure,preoperative median serum creatinine,postoperative hypertension and renal dysfunction,renal excretory function,postoperative LV remodeling,frequency of hemodialysis,glomerular filtration rate or RBF,incidence of postoperative arrhythmias,Aldosterone level,hemodynamics, urine volume, dosage of furosemide, respiratory index, pleural effusion, ANP, cyclic guanosine monophosphate, renin activity (renin), angiotensin-II, aldosterone, and glomerular filtration rate,safety and efficacy of ANP,LV function,and/or hyperkalemia,hemodynamic status,incidence of postoperative ventricular arrhythmia and the postoperative peak level of creatine kinase-MB,bleeding volume, homologous blood transfusion volume, furosemide dose, and corrected KCl volume,Cumulative duration of hemofiltration,Dialysis-free survival rates,oliguria,renal blood flow,baseline serum creatinine, change in serum creatinine, or the incidence of RCIN,glomerular filtration rate and renal blood flow,dialysis-free survival,rate of dialysis-free survival,serum creatinine,Peak serum creatinine,Diuresis,stable diuresis,glomerular filtration rate,oliguria / anuria and required subsequent hemofiltration / hemodialysis,levels of ANP, cyclic guanosine monophosphate, glomerular filtration rate, and respiratory index, and significantly lower levels of renin, angiotensin-II, aldosterone, and pleural effusion,CCr,urine volume,Baseline serum creatinine level,BUN levels,needed dialysis,fractional sodium excretion,dialysis-free survival at day 21 and creatinine clearance,renin activity and lower levels of angiotensin-II and aldosterone,dialysis or death,renal blood flow (RBF) and radiocontrast-induced nephropathy (RCIN,plasma cyclic guanosine monophosphate levels, urine output and fractional sodium excretion, and decreased preload, afterload and plasma brain natriuretic peptide levels,postoperative peak levels of creatine kinase-MB,hemodynamic status and renal function,Dialysis and mortality status,serum creatinine concentration, and mortality,creatinine clearances (CCr,renal vasodilatory response,postoperative brain natriuretic peptide,medications, and quantity of radiocontrast|ANP levels rose significantly from baseline at 5, 15, 65 and 120 minutes in both groups (p less than 0.05).
21|Mania Rating Scale, Brief Psychiatric Rating Scale, Physician Global Impression Scale, and side effects scales,HP, and gastrointestinal symptoms,serious haematological changes, nor abnormalities in clinical chemistry,drowsiness,Rates of remission (Young-Mania Rating Scale score of < or =12 and 21-item Hamilton Rating Scale for Depression score,antimanic response,adverse events,quality of life,manic symptoms without sedation,Standard ratings of psychopathology and side effects,Young Mania Rating Scale,extrapyramidal symptoms,total score for all rating scales,Relapse into an affective episode (mania and/or depression,rapid remission of symptoms on the BRMAS,extrapyramidal side effects,YMRS scores,Young Mania Rating Scale scores,side effects,psychotic features, rates of remission,severity of illness scores,hypokinesia,efficacy and safety,extrapyramidal side-effects (EPS,Brief Psychiatric Rating Scale (BPRS), the Bech-Rafaelsen Mania Rating Scale (BRMAS) (only manic patients) and globally on the Clinical Global Impression (CGI,quality of life on several dimensions,Brief Psychiatric Rating Scale, the Clinical Global Impression scale, and safety measures,survival analysis techniques,manic and psychotic symptoms,magnitude of or time to response,Extrapyramidal Symptom Rating Scale total scores,tolerated,Weight gain,rate of extrapyramidal symptoms,overall remission of bipolar mania,mean Young Mania Rating Scale (YMRS) score reductions,Serum valproate concentrations,Young Mania Rating Scale total scores,Side effects|Groups B and C did not differ from each other, either in degree of improvement or in side effects.
75|risk of zoster,neutralizing antibody levels,stimulation index,Seroconversion rates,VZV reactivation,mean (+/-SE) stimulation index (SI,mean stimulation index,antibody response,vaccination response,influenza A/H3 neutralizing antibody levels,poliovirus antibody titres,seroconversion and seroresponse rates,respective rates,clinical disease,protective antibody titre,antibody titers,Induration, erythema, or local pain,severity scores,Zoster,protective antibody titres of > or = 4 to poliovirus type 1 (PV1), poliovirus type 2 (PV2) and poliovirus type 3 (PV3,seroresponse rates|Disease severity associated with VZV reactivation was decreased dramatically in vaccinees given three doses; severity scores were 6.4 +/-
not found|ability to take single-strength TMP-SMZ daily,baseline CD(8,mean PVL,serious reaction,Plasma viral load (PVL) and CD(4)/CD(8) counts,Liver enzymes and hematological parameters,adverse reactions,mean CD(4) counts,hypersensitivity reactions,incidence of new allergic reactions,liver enzymes|Seventy-five percent of the dose-escalation group and 57% of the direct-rechallenge group continued to receive daily single-strength TMP-SMZ for 6 months (P= .014).
44|persistent loss of hepatitis B virus DNA,normalized alanine aminotransferase,hepatorenal syndrome,normal transaminase levels,normal alanine aminotransferase (ALT) activity,HBeAg disappearance and HBeAg to anti-HBe seroconversion,periportal necrosis,rate of anti-HBe seroconversion,Reversion to HBeAg and HBV DNA negativity,Transaminase levels,posttreatment histologic scores,normal serum aminotransferase levels,HBeAg clearance and seroconversion to anti-HBe,Loss of hepatitis B,Alanine aminotransferase values,efficacy of interferon therapy,galactose elimination capacity and aminopyrine breath test,late seroconversion,Baseline clinical, biochemical, and histological features,chronic active hepatitis,alanine aminotransferase normalization,safety and effectiveness,loss of DNA-polymerase activity,chronic hepatitis B (HB) infection,response rates,active viral replication,HBeAg clearance,HBV-DNA or degree of histological activity,loss of HB surface antigen (HBsAg,inflammation and disappearance of core antigen in liver tissue,elevated transaminase levels,Anti-HBe seroconversion,HBeAg disappearance and HBeAg to anti-HBe seroconversion rates,Clearance of serum hepatitis B virus-DNA and HBeAg (complete response,Hepatitis B e antigen and hepatitis B viral DNA,flu-like syndrome, granulocytopenia (1), depression (3) and thyroid dysfunction (2,loss of HB virus DNA and HBeAg from serum,response rate,spontaneous seroconversion rate,severe cytolytic episode,active cirrhosis,baseline aspartate aminotransferase (AST) level,lost hepatitis B virus DNA,e antigen (HBeAg) and hepatitis B virus (HBV)-DNA,hepatic decompensation,hepatitis B viral DNA,Biopsy score,Baseline transaminases levels and HBV-DNA concentrations,surface antigen (HBsAg,loss of HBeAg with anti-HBe seroconversion,chronic persistent hepatitis,inflammatory and fibrotic activity,Partial or complete antiviral responses,complete response rate,Response rates|Interferon induced a sustained cessation of HBV replication as judged by loss of DNA-polymerase activity in 26 (59%) patients, 20 (45%) patients seroconverted to anti-HBe.
not found|Leicester Cough Questionnaire (LCQ,R5,residual volume (RV), functional residual capacity (FRC) and total lung capacity (TLC) (p<0.05,radioaerosol clearance,removal of pulmonary secretions,total LCQ score,yield of sputum,24-h sputum volume,sputum bacteriology, FEV(1), FVC, FEF(25-75%), MIP or MEP,did exercise capacity,respiratory mechanics and sputum production,lung hyperinflation,SGRQ total score,Impedance at 5 Hz (R5), resistance as a function of oscillation frequency (dR/dF), reactance at 5 Hz (X5), resonant frequency (f(0) ) and integral of reactance between 5 Hz and resonant frequency (AX,sputum production,Flutter Valve,24-h sputum volume, forced expiratory volume in 1 s (FEV(1)), forced vital capacity (FVC), forced expiratory flow at 25-75% of FVC (FEF(25-75%)), maximum inspiratory pressure (MIP), maximum expiratory pressure (MEP), exercise capacity, sputum microbiology and St George's Respiratory Questionnaire (SGRQ,total and peripheral airway resistance|No significant differences were seen in sputum bacteriology, FEV(1), FVC, FEF(25-75%), MIP or MEP.
19|structured continence and medical histories,number of wet episodes,Mini-Mental Status Exam,frequency of correct toileting,cost of assessing and treating these acute conditions,frequency of incontinence,urinary incontinence,change in incontinence,dermatological, genitourinary, gastrointestinal, respiratory and cardiovascular systems; falls; pain; and psychiatric and nutritional disturbances,endurance, strength, and urinary incontinence,strength, mobility endurance, urinary and fecal incontinence,Timed measures of walking or wheeling a wheelchair (mobility), sit-to-stand exercises, independence in locomotion and toileting as assessed using the Functional Independence Measure (FIM), one-repetition maximum weight for several measures of upper and lower body strength, frequency of urine and stool incontinence, and appropriate toileting ratios,functional outcomes,Older American Research and Service Physical and Instrumental Activities of Daily Living scales, Folstein Mini Mental State Examination, Clock Drawing Test, Geriatric Depression Scale, Performance-Based Toileting Assessment, bladder diaries, and physical examination,daytime incontinent episodes,continence levels,Urodynamic analysis (including cystometrogram), provocative stress test, and behavioral assessment|Among all subjects completing the treatment protocol, there was a 22% reduction in daytime incontinent episodes compared with true baseline (immediately following the control phase for those crossing over from the control group).
not found|Size of postoperative scar,Complete wound healing,unadjusted hazard ratio,healing earlier,Mean healing times,satisfactory epithelialization,eradication of bacterial infections,mean healing time,control of infection,Wound healing,Mean wound area covered in slough,mean healing times,time (days) taken for complete re-epithelialisation of the nail bed,control of infection and quicker wound healing,graft take rate,wound dehiscence, six of them needed re-suturing under general anesthesia,reparative activity with inflammatory changes,complete wound healing without wound disruption or need for re-suturing,positive wound cultures,mild dehiscence,Cosmetic and functional results,complete cure,average duration of healing,time to healing, change in ulcer area, incidence of infection, costs per healed ulcer, adverse events and quality of life,bacterial infections, (2) reduce period of antibiotic use and hospital stay, (3) accelerate wound healing, (4) prevent wound dehiscence and need for re-suturing and (5) result in minimal scar formation,wound healing,healing rates,amniotic membrane,mean percentage of blood volume,skin grafting take rate,admission point of time,safety and effectiveness,healing,Bacterial colonisation, wound size, wound ASEPSIS score and pain,median rate of healing,Median reduction in wound size,Residual scars,Healthy granulation tissue,Relief of pain,venous ulcer healing,itching,epithelialization,average cost,itching and pain,Infection,healing rates of wounds healing,median time to healing,probability of healing,pain,Histological evidence of reparative activity,healing outcomes,healing rate,ulcer healing,complete wound healing,healing times,mean hospital stay,hazard ratio,skin grafting,proportion of ulcers healed,bacterial contamination and promoting wound healing,healing times of shallow wounds and abrasions; side-effects; patient satisfaction with treatment; and amount of honey and IntraSite Gel used,incidence of healing, effective desloughing and a lower incidence of infection,Reparative activity,adverse events|Honey impregnated gauze dressed wounds showed healing earlier as compared to OpSite (mean 10.8 versus 15.3 days).
41|adenoma detection rate,miss or detection rates,neoplasm miss rate,neoplasm detection rates,increased adenoma detection rate means of NBI colonoscopy,withdrawal time,rates steadily,adenoma rates,Detection rates,prolongation of extubation time,colorectal neoplasm miss rate,total number of adenomas,flat adenoma detection rates,general adenoma detection rate,adenoma detection rate (ie, number of adenomas/total number of patients,Extubation time,Demographics, indication for colonoscopy, and quality of preparation,number of diminutive,adenoma detection rates,number of total and mean per-patient adenomas,neoplasm detection rate,prevalence of non-polypoid and the total number of adenomas|The adenoma detection rates were 57.3% for patients examined by NBI and 58.3% for those examined by WL (P = .88).
205|rate of failure with deterioration,CRP levels,PCT levels,Clinical and microbiologic response, serum C-reactive protein (CRP) level (cutoffs 5 and 50 mg/L), and serum procalcitonin level (PCT,death in hospital and need for an additional course of antibiotics, both separately and in combination,clinical cure at end of therapy visit (EOT,peak flow and symptom scores,Resolution of symptoms,success rate,shortness of breath, wheezing, or exacerbations of cough with or without sputum production,Changes in symptoms, peak expiratory flow, and sputum flora,need for additional courses of antibiotics,death in hospital and need for additional antibiotics,Gasometric and spirometric measures,number of relapses,low PCT levels,clinical success rate,duration of mechanical ventilation and hospital stay,Peak flow,dyspnea, sputum production, and sputum purulence,Symptoms,median time to the next exacerbation,symptom scores (wheeze, dyspnoea, cough with and without mucus production, and awakening with dyspnoea), peak expiratory flow values (PEF, expressed as % predicted), and sublingual temperature,Side effects|Although CRP levels were higher in the presence of bacteria (median, 33.0 mg/L [interquartile range, 9.75-88.25] vs 17 mg/L [interquartile range, 5.0-61.0] [P = .004]), PCT levels were similar.
50|observer rated severity and frequency of symptoms on numerical rating scales, administered standard measures of disability (Barthel Index), mood and cognition, and recorded adverse events,electromyographic recording of deep tendon reflexes,Overall spastic state, spasms and clonus,spasticity, clonus, and hyperreflexia, and the complaints of muscle stiffness,objective rating scale,variables: spasticity, clonus, flexor spasms, gait and bladder function,antispasmodic efficacy and safety,painful spasms,Increase weakness,toxic effects on hepatologic, hematopoietic, or renal function,hepatic, renal, or hematological function,good overall tolerability,antispastic effect,resistance to passive stretch, clonus and hyperreflexia,side-effects,symptom, well-being and intoxication scores on a daily basis using visual analogue scales,functionality and nursing care,efficacy of baclofen,muscle tone (Ashworth Scale) and type and frequency of muscle spasms (patient diaries,antispastic effect and tolerability,Impaired bladder control, muscle spasms and spasticity,mild depressive effect on blood pressure,Levels of threonine,physical or psychological dependence,clonus,spasticity of the leg adductors,dry mouth and drowsiness,alleviating flexor and extensors spasms,muscle strength, bladder function and the activities of daily living,Muscle weakness,Cybex flexion scores,total number and severity of side-effects,adverse reactions,elevated liver function test,muscle strength,joint and muscle pain,muscular tonus,muscle tone,Safety, tolerability, and efficacy,Cybex II isokinetic unit, timed gait, Ashworth scale,Adverse events,Efficacy and tolerability parameters,spasticity,Somnolence and xerostomia,frequency of spasms, and clonus,Tiredness,Pain relief,efficacy and tolerability,motor weakness,Sedation,flexor spasms, pain and stiffness, resistance to passive joint movements, and tendon stretch reflexes,focal spastic muscle contractions,clinical spasticity and hyperreflexia,tolerated,functional status,intractable neurogenic symptoms,antispastic efficacy of tizanidine,antispastic efficacy,sleepiness, muscular weakness and dry mouth,efficacy and tolerance,hyperactive stretch reflexes and ankle clonus,adverse effects,moderate quadriceps spasticity,sedation, nausea and vomiting,ease of nursing care,spasms and clonus (patient diaries,range of joint movement,subjective sensation of relief with reference to the symptoms of spasms,Side effects|There was not statistically significant superiority of either diazepam or ketazolam, but both relieved symptoms significantly better than the placebo, as measured clinically and by electromyographic recording of deep tendon reflexes.
201|serious toxicity,Acute toxicity (dysphagia, myelosuppression,complete response,Rates of survival,peripheral neuropathy and hematologic and renal toxic effects,distant metastasis rate,median time to progression,survival time,survival and 58 for response and toxicity,time to recurrence or overall survival,severe neurotoxicity,Toxic reactions,overall response rate,response and toxicity,survival or delayed recurrence of disease,long-term survival,median number of chemotherapy cycles,survival rates,Five-year survival,reversible renal toxicity grade 2,serious infections requiring hospitalization,overall survival time,whole survival,quality of life,leukopenia of severe,Survival analysis,toxic symptoms of varying severity,severe weight loss,5-year survivals,Survival,survival advantage,Toxicity,performance status (Karnofsky), and weight loss,survival,response rate,histology, performance status, extent of operation, and tumor and nodal status,death,Time to progressive disease,objective response,2-year survival rate,toxic death,mean survival,Toxic effects,excellent performance status, minimal weight loss, and visible disease on radiography,progressive disease in arm B. Median survival,improved survival,5-year survival rate,Acute toxicity,Karnofsky performance status score,Local tumor response,acute or late radiation pulmonary or oesophageal toxicity,drug mortality,toxicity,response rates or in survival,overall survival, disease-free survival, and relapse pattern,severe vomiting,recurrence,overall survival,adjusted survival rate and disease-free survival rate,survival and response rates,survival benefit,response rate and survival,response rate and morbidity,partial response,Response rates,local response,Median time to progression,unacceptable toxicity,median survival times (5-year survival,overall response rates (complete response [CR] plus partial response [PR,Major clinical responses,Median survival,Response rate,response rate, time to progressive disease and overall survival,5-year disease-free survival rate,local control rate and survival,gastrointestinal toxicity grade 3 to 4 (WHO,incidence of death with metastases, metastasis-free survival (MFS) nor overall survival (S,median survival,5-year survival rates,median survival time,Myelosuppression,3-year disease-free survivals,disease-free and overall survival,5-year survival|The overall response rate to chemotherapy was 28%; there were no significant differences according to major prognostic criteria.
40|maternal tolerance scale,remaining dry and time to dry, non-attendance and dropout rates,Functional enuresis (FE,Maternal anger|Two studies examined the effectiveness of the body-worn alarm in out-patient treatment of childhood nocturnal enuresis.
64|body weight gain,efficacy and safety,slight drowsiness,bronchodilatation and normalizing pulmonary function,total IgE or IgG4,oxatomide,monitoring cough, dyspnea at rest, dyspnea following exercise, wheezing, sleep disorders,Efficacy,Persistent coughing,Sleep disorders,levels of eosinophil cationic protein and total asthma symptom scores,Dyspnea,intensity of wheezing|The levels of eosinophil cationic protein and total asthma symptom scores were significantly reduced during treatment with oxatomide.
106|mean DAS28,HAQ scores,diarrhea, nausea, and alopecia,DAS28 response rate, and secondary efficacy outcomes,incidence of side reactions,Larsen scores,functional disability,efficacy and safety profile,disease activity parameters,Mean HAQ scores,general effective rate and notable effective rate,Comparable Disease Activity Score 28 reduction rates,Efficacy and safety,mean time to initial response,Gastrointestinal symptoms, weight loss, allergic reactions, skin rash, and reversible alopecia,Transiently abnormal liver function,Health Assessment Questionnaire (HAQ,erosive joint counts,improvement and remission,safe and well tolerated,Adverse events,Disease activity assessed by DAS 28,rheumatoid arthritis,serious adverse drug effects,alopecia,overall incidences of adverse events,Adverse events (AEs) resulting in treatment withdrawal,adverse events,ACR response rates,ACR response and success rates,disease activity,ACR20 responder rates,symptoms, signs and joint functions,improvement in EULAR criteria and secondary endpoints were patient and physician global evaluation, incidence of remission and biochemical and clinical adverse events,Diarrhoea, nausea, and alopecia,Diarrhea and nausea,safety and effectiveness,reversible agranulocytosis,elevated transaminases,mean,efficacy and safety,response rate,function and health-related quality of life,Sustained retardation of radiographic progression,global assessments, ACR20% response,ACR20 response rates,Discontinuation rates,incidence of adverse events,American College of Rheumatology improvement response rates,Asymptomatic transaminase elevations,tender joint count,functional ability,adverse events or late toxicity,rheumatoid arthritis activity,tolerated,DAS28 response,slowing of disease progression,overall rates of effectiveness,gastrointestinal symptoms, skin rash, alopecia, nervous system symptoms, decreased leukocyte count, and elevation of alanine aminotransferase (ALT,rate of withdrawal due to adverse events,functional ability,MHAQ scores, 5 of 8 scales and disability index of the HAQ,initial rate of enhancement (IRE) and the maximal signal intensity (SI) enhancement (ME,HAQ DI with LEF4(-0.60,RA activity,SF-36 scales and component scores,Function and health-related quality of life,disease progression,response rates,signs and symptoms of active RA, delayed disease progression,toxicity,severe gastrointestinal symptoms and hepatotoxicity,Radiographic disease progression,patients' functional ability,tender joint count (TJC), swollen joint count (SJC) and Health Assessment Questionnaire Disability Index (HAQ DI,measures of function and heath-related quality of life (MHAQ scores, all scales and disability index of the HAQ, weighted top 5 score of the PET, 5 of 8 scales and physical component score of the SF-36, and work productivity,synovial inflammation,symptoms, signs, and joint function,Safety and effectiveness,Health Assessment Questionnaire (HAQ) disability index (HAQ DI) and the physical component score of the Medical Outcomes Survey 36-item short,PET score, SF-36 physical component score, and work productivity,diarrhoea,radiographic progression,gastrointestinal complaints, skin rash, and reversible alopecia,remission,adverse events (AEs,Larsen scores and erosive joint counts,DeltaHAQ disability index,physical function,nausea,incidence of infections,upper respiratory tract infections, diarrhea, nausea and vomiting, rash, reversible alopecia, and transient liver enzyme elevations,Health Assessment Questionnaire Disability Index,IRE,safety and efficacy,HAQ Disability Index (DI,ACR 50% response rate,Mean DAS28,incidence of AEs,DEMRI scans,side effects,physical function and health-related quality of life,mean change in total Sharp radiologic damage scores,opportunistic infections,rates of remarkable improvement,clinical signs and symptoms,Improved HAQ scores,Health Assessment Questionnaire (HAQ), modified Health Assessment Questionnaire (MHAQ), Problem Elicitation Technique (PET), Medical Outcomes Study Short Form 36 (SF-36), and questions regarding work productivity,rate of achievement of 20% improvement in ACR criteria (ACR20,tender and swollen joint counts and investigator's and patient's overall assessments,MHAQ scores, HAQ disability index, weighted top 5 score of the PET, physical component score of the SF-36, and bodily pain scale,ESR, tender and swollen joint counts, the duration of morning stiffness, disease activity score-28 (DAS 28), visual analogue scale (VAS) and health assessment questionnaire (HAQ,serious treatment-related adverse events|Comparable Disease Activity Score 28 reduction rates were noted at trial termination for all 3 treatment arms:
12|survival,overall survival of ECMO,Intracerebral hemorrhage|Extracorporeal membrane oxygenation allows lung rest and improves survival compared to conventional ventilator therapy in newborn infants with severe respiratory failure.
not found|bone pain,body height,occasional gastroenteric discomfort,survival or in objective bone response rate,Histologic bone parameters,incidence of bone-related complications (pathological fractures, tumor-induced hypercalcemia, need for radiotherapy), sclerotic response of lytic lesions, WHO performance status, and analgesic score,vertebral index,urinary calcium,Subjective benefit,bone remineralization,degree of hypercalcaemia and hypercalciuria, and decreases pain,frequency of pathologic fractures, hypercalcemia, and bone pain,hypercalcemia or hypercalciuria,skeletal-related morbidity,Thickening of the preexisting osteolytic lesions,Adverse events,Pain relief,control of bone pain,Quality of life,sclerosis or stabilisation of lytic metastases,mean baseline pain,pain with dichloromethylene diphosphonate,gastrointestinal toxicity,myalgia,pain scores or analgesic requirements,pain palliation,skeletal morbidity rate,skeletal complications,Resorption markers,urinary calcium, hydroxyproline (OHP) and serum cross-linked carboxyterminal telopeptide region of type I collagen (ICTP) levels,EFP,Daily visual analogue scales (VAS) and analgesic diaries,VAS scores for general pain, pain at rest, and pain,Bone-derived isoenzyme alkaline phosphatase values,daily oral morphine equivalent analgesic requirement,pain intensity,activity scores,episodes of severe pain,bone pain, episodes of hypercalcemia, or development of pathologic fractures,Visual analog pain scores and adverse events,Median time to bone progression,quality of life,Gastrointestinal toxicity,urinary calcium/creatinine and hydroxyproline/creatinine ratios, and bone alkaline phosphatase concentrations,Analgesic use increased with disease progression,Compliance,deterioration of performance status,pain and mobility,Toxicity,clinical and laboratory parameters of toxicity,efficacy,Karnofsky performance status,nausea and vomiting,event-rates,totally free of bone pain,osteolysis of multiple myeloma,skeletal morbidity and the radiologic course of metastatic bone disease,Analgesics requirement,bone pain and no deterioration in performance status and quality of life,trabecular bone volume,Bone resorption,performance status and reduced consumption of analgesics,percentage of patients feeling no pain,skeletal events,Fasting urinary calcium excretion,Urinary calcium, OHP and serum ICTP levels,tolerated,average change in DMED,radiologic skeletal lesions,healing of lytic lesions,symptomatic response rate or analgesic requirement,mean pain,symptomatic improvement,median time to the occurrence of the first skeletal complication,bone resorption,Karnofsky performance status, pain score (measured by a visual-analogue scale) and analgesic requirement,excretion of hydroxyproline,Bone resorption markers measured included urinary calcium (uCa), hydroxyproline (Hyp), and the collagen breakdown products: NTx, Crosslaps and Free Dpd,intensity of pain,severe adverse reactions or worsening of chemotherapy-induced toxicities,total-body bone mineral density,analgesic effect,metastatic bone pain,Serum calcium and urinary calcium excretion,Progression of vertebral fractures,skeletal complications: pathologic fractures, spinal cord compression, irradiation of or surgery on bone, or hypercalcemia,bone pain, analgesic-drug use, performance status, and quality of life,toxicity,Visual Analogue Scales (VAS,Gastrointestinal adverse events,fasting calcium excretion,median survival or survival rates,patient survival,Pain score,Mean pain scores,Pain intensity,rate of bone resorption,time to progressive bone disease (evaluated by blind extramural review), and improvement in pain (according to a 6-point self-assessment scale,clinical (pain, Karnofsky, survival), biological and radiological,skeletal morbidity,pain intensity, pain frequency, general well-being and WHO pain score,skeletal complication,Visual analog pain score,Median duration of pain response,median time to radiotherapy,proportion of patients with progression of osteolytic bone lesions,iliac bone biopsy,Serum calcium concentration,Bone pain, use of analgesics, quality of life, performance status, bone tumor response, and biochemical parameters,vertebral deformity,Delayed progression of bone metastases,Skeletal events (pathologic fracture, irradiation of or surgery on bone, and spinal cord compression), hypercalcemia (symptoms or a serum calcium concentration,deoxypyridinoline,event-free period (EFP), radiologic course of disease, and survival,safety and efficacy,pain score, performance status, and changes in analgesic use,osteoclast number,time to the first skeletal complication,Symptomatic response,event-rates of systemic treatment and radiotherapy,pain score,Pain parameters, analgesic consumption and performance status,Skeletal complications, including pathologic fractures, the need for radiation to bone or bone surgery, spinal cord compression, and hypercalcemia (a serum calcium concentration,bone alkaline phosphatase levels,urinary hydroxyproline levels,Mean overall pain,occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures,height loss,bone pain (visual analog score), analgesic use, and compliance with therapy,analgesic efficacy,visual analogue scale assessments,number and/or size of bone lesions,palliative effects,pain,bone pain and mobility scores,narcotic scores, urinary calcium/creatinine and hydroxyproline/creatinine ratios, serum osteocalcin and bone alkaline phosphatase concentrations, and bone lesion (radiologic) response,daily consumption of analgesics,pain scores,urinary calcium levels,Bone pain, use of analgesic drugs, performance status, and quality of life,Skeletal pain relief,opioid requirements,Side-effects|Oral pamidronate produced either sclerosis or stabilisation of lytic metastases for at least 24 weeks in 5 of 24 and 3 of 23 patients at the 300 and 150 mg dose levels, respectively.
not found|numeric rating scales,morphine requirements,pain relief,serious side effects,Pain scales,average pain scales|No serious side effects were observed in this study.
not found|IOP,efficacy and safety,intraocular pressure (IOP), peripheral anterior synechiae, corneal endothelial cell count, and complications,peripheral anterior synechiae,IOP, medications, need for surgery, or visual function|There was no significant difference in IOP, medications, need for surgery, or visual function between groups at the 1-year visit.
241|forced expiratory volume in one second (FEV1,arterial oxygen tension,cost and effectiveness,asthma-related emergency department visits,knowledge of asthma shown,quality of life,scores of knowledge of drugs,mortality or morbidity,hospital admissions,number of urgent care visits,Health status,patients' perceptions of asthma severity and both medication severity rating,self-management ability or asthma morbidity,number of days lost through sickness,scheduled visits,number of days in hospital,knowledge scores,quality of life, knowledge and need for nursing,number of days in hospital and emergency visits,asthma morbidity,asthma-related emergency visits,severity of their asthma,diurnal variation rating,evening peak expiratory flow rate percentage,mean duration of illness,Psychosomatic Discomfort Scale,resources, productive output and in health status,severe asthmatics|The intervention group had significantly fewer asthma-related emergency visits (16 visits per 100 persons) than did the control group (39 per 100 persons); p = 0.0005 for the 12 months of follow-up.
not found|eczema,serum total and milk-specific IgE concentrations,pruritus, sleeplessness and antihistamine consumption,SCORAD index,mean reduction in surface area affected by eczema,percentage of surface area,circulating eosinophilocytes, serum IgE, orosomucoid, HLA-antigens, and immunofluorescence of skin biopsies,mean concentration of essential amino acids in plasma,length standard deviation score,severity score,activity of atopic dermatitis,atopic eczema,eczema activity, number of areas affected, pruritus, sleeplessness, and antihistamine usage,Disease activity,skin severity score,weight-for-length values,dermatitis severity,energy intake,gastrointestinal reactions|Thirty seven breast fed infants with eczema were studied to see whether changes in their mothers' diets affected their skin condition.
100|moderate or severe pain (pain intensity rating,Morphine consumption, VAS, PS, and self-assessed QOL scores,pain relief,visual analogue scale (VAS) pain scores,pain scores and delayed or prevented the subsequent onset of pain,morphine consumption, visual analogue pain scale (VAS), performance status (PS) determined by medical and nursing staffs, and answers to QOL questionnaires,quality of life,quality of life (QOL,pain intensity and QOL scores,Pain intensity (0-10 numerical rating scale), QOL, opioid consumption and related adverse effects, and survival time,transient diarrhoea and hypotension,VAS scores,frequency of opioid adverse effects,side effects,PS and QOL scores,Self-assessed QOL scores,hospital mortality or complications, return to oral intake, or length of hospital stay,Morphine consumption and the VAS score,survival,pain, mood, and disability,PS score slightly,Mean (SD) baseline pain,Mean pain scores,existing pain,pain relief, QOL, and survival,QOL or survival,Standardized assessment of pain, mood, and disability due to pain,Mean analgesic consumption,pain relief, quality of life, and survival,pain,Immediate and long-term efficacy, mean analgesic consumption, mortality and morbidity,Morphine consumption,QOL,opioid consumption,nausea and/or vomiting,pain relief and quality of life (QOL,gastric ulcer and one gluteal abscess|The first week after randomization, pain intensity and QOL scores were improved (pain intensity, P< or =.01 for both groups; QOL, P<.001 for both groups), with a larger decrease in pain for the NCPB group (P =.005).
101|Grade 1 and 2 audiologic toxicity,serum cardiac troponin T,incidence and degree of cardiotoxicity, response rates to four cycles of chemotherapy, event-free and overall survival, and incidence and severity of noncardiac toxicities,minimum QT interval,Resting left ventricular ejection fraction (LVEF,Control EF,severe incidence of congestive heart failure,antitumor activity,rates of fever, infection, or hemorrhage,severe supraventricular arrhythmia,noncardiac toxicity,mean EF,progressive disease,occurrence and severity of anthracycline-induced cardiotoxicity,Left ventricular ejection fraction (EF) and systolic and diastolic diameters,Time to progression and survival,assessable endomyocardial biopsy,ICRF-187 cardiac protection,noninvasive testing and clinical CHF,Left ventricular ejection fraction,E velocities and E/A ratios,QT and QTc dispersion,Cardiotoxicity,Elevations of troponin T,Mode-M echocardiograms and 24-hour ambulatory ECGs,Noncardiac toxicity, objective response, progression-free survival, and overall survival,noncardiac toxicity or antitumor efficacy,QT interval dispersion,Grade 1 cardiac toxicity,value of radioimmunoscintigraphy (RIS,arrhythmic risk,myocardial injury,elevated troponin T levels,systolic and diastolic functions,survival,event-free or overall survival,Toxicities,excellent survival,incidence of transient grade 1 serum transaminase elevations,frequency of adverse events,plasma carnitine,abnormal antimyosin uptake,Septum wall motion abnormalities,incidence of clinical congestive heart failure,hazards ratio (HR) of PLA to DZR,plasma lipid profile and relative mRNA levels of key enzymes of oxidative metabolism (carnitine acyltransferases,Tumor response rate,Response rates to chemotherapy, event-free and overall survival, and noncardiac toxicities,cumulative probability of developing cardiotoxicity,congestive heart failure (CHF,renal toxicity,toxicity,ejection fraction changes or congestive heart failure (CHF,risk of developing short-term subclinical cardiotoxicity,Troponin T levels,antitumor response rates, time to progression, and survival,subclinical cardiotoxicity,overall survival,rate of event-free survival,Systolic and diastolic echocardiographic parameters,relative mRNA levels,Toxicity prevention,LVEF,resting left ventricular ejection fraction (LVEF,hematologic toxicity,cardiac function,Cardiac toxicity,LVFS,doxorubicin cardiotoxicity,cardiac toxicity,E velocities,ototoxicity and nephrotoxicity,renal, hearing and cardiac toxicity,mean EF at control echocardiography,died,Objective response rates,pain on injection,Percentage left ventricular fractional shortening (%LVFS,QTc dispersion,clinical activity and the noncardiac toxicity of epirubicin,objective response rates,QT dispersion,Interventricular septum wall thickening,cardiotoxicity,oxidative metabolism,cardiac events,response rate with DZR, but time to progression and survival,systolic and diastolic diameters|Serial measurements of serum cardiac troponin T were obtained in 76 of 101 patients in the doxorubicin group and 82 of 105 patients in the group given dexrazoxane and doxorubicin.
not found|30-day use of alcohol and marijuana and lower intentions to smoke, drink, and take illicit drugs,adolescent smoking and drinking prevalence,violent behavior,heavy weekly drinking, weekly drinking and frequency of drinking,sexual risks,chances of initiating sex or substance use,substance use and/or sexual activity,positive 2-year outcomes,drug use harm or delinquency,self-efficacy,girls' and mothers' substance use and mediator variables related to girls' substance use risk and protective factors,rates of weekly alcohol consumption,prevalence of smoking cigarettes and drinking alcohol,rate of change in attitudes about drug use or frequency of delinquent or violent behavior,initiation of alcohol, tobacco, drug use, and/or sexual activity found AA youth,alcohol initiation and frequency, and marijuana initiation and frequency (p's<.05,Incidence of (heavy) weekly alcohol use and frequency of monthly drinking|Following program delivery and 1 year later, girls randomly assigned to the intervention arm improved more than girls in a control arm on variables associated with reduced risks for substance use, including communication with their mothers, knowledge of family rules about substance use, awareness of parental monitoring of their discretionary time, non-acceptance of peer substance use, problem-solving skills, and ability to refuse peer pressure to use substances.
25|pain and function,isokinetic quadriceps strength, quadriceps length, pain measured during four activities and maximum eccentric, posturally controlled, pain-free knee flexion angle during a step-down,patellofemoral pain,WOMAC and HAD,visual analog scales for pain and the functional index questionnaire,WOMAC, visual analogue, and the anxiety score,pain and function scores,subjective visual analog scale and changes in isokinetic strength and electromyographic activity of the quadriceps muscle,WOMAC, visual analogue, and HAD scores,symptoms,activity,quadriceps muscle isokinetic strength,visual analogue pain score; the WOMAC lower limb function score; the Hospital Anxiety and Depression scale (HAD); and quadriceps strength|Likewise, both groups demonstrated significant improvement in quadriceps muscle isokinetic strength (P < 0.05) and activity (P < 0.001), but no difference in improvement was noted between groups.
53|postoperative changes of the proximal and distal segments,Radiographic measurements,lateral gonial deviation,horizontal and vertical stability of the B-point and the pogonion,condyle position|One year later the condyle position demonstrated a tendency to approximate the preoperative position, especially with respect to the posterior part, but there was still a significant (p less than 0.01) difference when related to the original position.
not found|Positive end-expiratory pressure (PEEP) and recruitment maneuvers (RMs,Systolic blood pressure,Protective ventilation involved end-expiratory pressures,EELV,LR manoeuvre end-expiratory lung volume,rates of clinical barotrauma,rate of barotrauma,rates of refractory hypoxemia,death with refractory hypoxemia,gas exchange, hemodynamics, respiratory mechanics, and the end expiratory lung volume (EELV,arterial carbon dioxide tension (Pa(CO2,survival to hospital discharge,lower Q(VA)/Q(T,lower venous admixture (Q(VA)/Q(T,survival,tracheal aspirate mass,rates of weaning from mechanical ventilation,PaO2,higher PEEP and mean airway pressures,Barotrauma,CPPV(VRM,Arterial blood gases,partial arterial oxygen tension (PaO2) and end-expiratory lung volume,Barotrauma rates,target tidal volumes of 6 mL/kg of predicted body weight, plateau airway pressures not exceeding 30 cm H2O, and conventional levels of positive end-expiratory pressure,hospital mortality rates,gas exchange and respiratory mechanics,arterial oxygen tension (Pa(O2,body weight and normal arterial carbon dioxide levels,Tidal volumes,mean positive end-expiratory pressures,Pao2/Fio2 and Qs,negative pressure,Fio2/PEEP requirements,mortality,oxyhemoglobin saturation by pulse oximetry (SpO2), Fio2/PEEP, blood pressure, and heart rate,oxygenation and venous admixture|Compared to CPPV(LO), CPPV(VRM) resulted in higher PaO2 (117.9 +/-
812|Transition Dyspnea Index,health status,Predose and postdose spirometry, plethysmography, and constant-load cycle cardiopulmonary exercise test evaluations,lung function measurements, symptoms and rescue treatment use, the number of exacerbations, patient withdrawals, and disease-specific health status,morning predose FEV(1,morning peak expiratory flow rate (PEF); transition dyspnea index; chronic respiratory disease questionnaire; chronic bronchitis symptom questionnaire; exacerbations,frequency of adverse events, bruising, or clinically significant falls in serum cortisol concentration,FEV1,lung hyperinflation and exercise endurance,2-h postdose FEV(1,Daily beta(2) short acting prn consumption,dyspnea, quality of life, and symptoms of chronic bronchitis,morning PEF (l/s), the daily symptom score, and the number of exacerbations,biopsy CD8+ cells,lung hyperinflation,Morning PEF,respiratory function (such as FEV(1), morning PEF), and and symptom score,Efficacy and safety,severity of dyspnea,lung function and health status,predose FEV(1,postdose IC,lung function, symptoms, and health status and reduced use of rescue medication and frequency of exacerbations,pretreatment forced expiratory volume in 1s (FEV1,tidal volume and minute ventilation,daily symptoms score,Severe exacerbations and FEV1 (primary variables), peak expiratory flow (PEF), COPD symptoms, health-related quality of life (HRQL), mild exacerbations, use of reliever beta2-agonist and safety variables,biopsy CD45+ and CD4+ cells and cells expressing genes for tumor necrosis factor-alpha and IFN-gamma and sputum total eosinophils,efficacy and safety,exercise endurance time,exercise time,average daily morning PEF,adverse events, serum cortisol concentrations, skin bruising, and electrocardiograms,symptom scores and use of reliever beta2-agonists,exercise performance,antiinflammatory effects,CD68+ cells,morning predose (ie, trough FEV(1)) for FSC compared with SM and 2-h postdose FEV(1,mean prebronchodilator forced expiratory volume,daily symptoms,Postmedication FEV1 improved by 0.21 L and health-related quality of life using the St George's Respiratory Questionnaire (SGRQ,mean FEV(1,pretreatment FEV1,mean number of severe exacerbations,postdose FRC and increased inspiratory capacity (IC,prebronchodilator peak expiratory flow,exacerbations,tolerated,lung function,FEV(1,morning lung function,mean number of exacerbations/yr,2-hour postdose FEV(1,adverse effects,prolonged time to first exacerbation,IC,prebronchodilator FEV1|Morning PEF improved significantly on day 1 versus placebo and budesonide; after 1 week, morning PEF was improved versus placebo, budesonide and formoterol.
not found|mean age and mean duration of pregnancy,symptoms of urinary tract infection,Mean birth weight and mean gestational age at delivery,Cure rates,Bacteriologic cure rates,cure rate difference,Significant bacteriuria,bacteriologic cure on day 14 of treatment,maternal and foetal toxicity,Therapeutic success,Asymptomatic bacteriuria,asymptomatic bacteriuria,development of symptomatic urinary infections,eradication rate,number of reinfections,cure rates,efficacy and tolerability,Bacteriological cure rates,clinical and microbiological efficacy,adverse effects,number of persistences,Side effects|According to recent studies, long course antibiotherapy did not prove to be more effective than a single-dose one in the case of non-complicated bacteriuria.
30|Renal function,mean clinical-activity score fell,renal function,clinical improvement, discharge from the hospital, and remission,severe attacks of ulcerative colitis,serious drug-related toxicity|At 12 months, 7 of 9 patients (78%) initially controlled with cyclosporine maintained their remission vs. 3 of 8 (37%) initially treated with methylprednisolone.
not found|free or fast walking,gait kinematics,walking velocity,loading response knee flexion,free velocity,oxygen consumption,symmetry indexes of the knee range of motion, cadence, and walking speed,Stride characteristics, joint motion, and ground reaction forces,Gait analysis and energy consumption,initial peak of the vertical ground reaction force on the sound limb,energy expenditure and gait efficiency,metabolic parameters,metabolic efficiency,terminal stance dorsiflexion,Oxygen uptake (VO2,subjective responses and gait patterns,physiologic responses,decline walking tests,energy cost,walking under different speeds and different inclines,energy consumption,knee flexion and prolonged heel only support,whole body gait kinematics and lower limb kinetics,Prosthetic mobility,self-selected walking velocity (SSWV), and steps per day (daily activity,energy expenditure,Contralateral toe off times,Mean free walking speed,peak shank velocity, peak ankle plantarflexion and peak knee flexion compromised shank and knee stability,rate of energy expenditure,metabolic rate or efficiency,residual limb EMG data,Comfortable walking speed and the nadir of metabolic rate and efficiency,Free walking,Foot and shank mobility,distal pressure measurements, pulse plethysmography, transcutaneous oxygen tension,shank velocity,ankle mobility,energy expenditure, gait efficiency, and relative exercise intensity,walking abilities,energy cost, efficiency, and relative exercise intensity,bioenergetic efficiency,peak knee flexion,rate of energy consumption,gait performance,peak foot and shank velocities,cardiocirculatory effects,SACH, single axis and multiple axis foot in the velocity, cadence, stride length and single limb stance,foot and shank velocity as the thigh velocity,knee flexion reflected delayed dorsiflexion and tibial advancement,stride length,Physiologic responses (energy expenditure, gait efficiency, exercise intensity, rating of perceived exertion [RPE,physiologic measurements, self-selected walking velocity, and physical activity|Compared with conventional hydraulic knee controls, the oxygen consumption of transfemoral amputees provided with an electronically controlled hydraulic knee joint is reduced.
not found|birth weight, treatment with antibiotics, and the starting time of breast-feeding,incidence of death or NEC,incidence and severity of necrotizing enterocolitis,SB tolerance and weight gain, faecal flora analysis, intestinal D-xylose absorption and faecal lipid excretion,incidence of death or necrotizing enterocolitis,D-Xylose and lipid absorption,somatic growth, tolerance, rates of sepsis and necrotizing enterocolitis,colonisation rates of administered bacteria,Lactobacilli,Incidence of late-onset sepsis,bifidobacterial numbers,Feeding intolerance,duration of Lactobacillus GG and placebo supplementation,number of Enterobacteriaceae present,incidence of fungal enteric colonization,faecal reservoir of potential pathogens,necrotizing enterocolitis (NEC,gastrointestinal tolerance,percentage of infants receiving >50% of their nutritional needs via enteral feeding on the 14th day of life,supplementation median bifidobacteria counts,time to reach full enteral feeding,Head growth,weight gain,Median counts of stool bifidobacteria and lactulose/mannitol ratios,deaths,L/M ratio,death or NEC,Intestinal permeability,fecal excretion of calprotectin,intestinal permeability,urinary tract infection, bacterial sepsis and necrotizing enterocolitis,viable counts of Enterobacteriaceae (log(10) values,incidence of NEC,Gram-negative enteric organisms,gastrointestinal microbiota,death or necrotizing enterocolitis (Bell's stage,cell counts of bifidobacteria,Median log of colony forming units per gram of faeces for Escherichia coli and enterococci,numbers of fungal isolates,Bacterial sepsis,colonisation rates,gastrointestinal bacterial colonization,hospital stay,bacterial and fungal sepsis,acceptance and tolerance of the formula,incidence and severity of NEC,incidence of UTIs, NEC and sepsis,necrotizing enterocolitis,urinary tract infections (UTIs), bacterial sepsis and necrotizing enterocolitis (NEC,intestinal microbiota,number of bifidobacteria and staphylococci in the stools,incidence of a first episode of late-onset sepsis,Bifidobacterial numbers,cell counts of enterobacteria and clostridia,death or NEC (Bell's stage ≥2,adverse effect, such as sepsis, flatulence, or diarrhea|The incidence of NEC was reduced in the study group (4% vs 16.4%; P=.03).
not found|ROP stage II or graver,gestational age, birth weight, Apgar scores, the time of exposure to oxygen and in the incidence of PDA or in the number of exchange transfusions and RBTs,retinopathy of prematurity|The two groups did not differ significantly in gestational age, birth weight, Apgar scores, the time of exposure to oxygen and in the incidence of PDA or in the number of exchange transfusions and RBTs.
571|disease-free survival and/or overall survival,progression-free survival rates,2-year overall survival rates,died,median disease-free survival,dermatologic events,cumulative probability of recurring,RFI,progression-free survival or overall survival,recurrence-free interval (RFI) and safety profile,PFS,median PFS,Death,number of recurrences,Median overall survival time,side effects,survival,Late intestinal radiation reactions,thrombocytopenia,pathologic remission, progression-free survival,late radiation reactions,Hazard ratio of progression,progression-free survival (PFS,infection/fever,incidence of grade 2 or worse peripheral neuropathy,Peritoneal relapses,Neutropenia,Grade 2 or greater motor neurotoxicity and sensory neurotoxicity,Overall survival,partial response,overall survival or disease-free survival,probability of surviving 5 years|The incidence of grade 2 or worse peripheral neuropathy (15.5% vs. 6%), infection/fever (19.9% vs. 8.7%), and dermatologic events (70.8% vs. 52.1%) was higher on the maintenance regimen (p<0.001).
32|Motor Activity Log and Action Research Arm (ARA) test,ARA scores,caregiver ratings of quality of movement,Fugl-Meyer and ARA scores,Action Research Arm test and the upper extremity section of the Fugl-Meyer Assessment,daily arm function,Fugl-Meyer Assessment of Motor Recovery (Fugl-Meyer) and Action Research Arm Test (ARA,peak force of the pinch grip and generalized,peak force of the pinch grip using a force transducer and manipulation functions of the upper extremity (Jebsen-test,feasibility and efficacy,demographic variable or movement scale,activities of daily living (Barthel Index|Subjects receiving MP showed significant reductions in affected arm impairment and significant increases in daily arm function (both at the P<0.0001 level).
15994|likelihood of haemoglobin testing,perinatal outcomes, anxiety and maternal satisfaction,anxiety scores,fetal and maternal morbidity, health service use, psychosocial outcomes, and maternal and professional satisfaction,levels of satisfaction,cesarean delivery,low birth weight,labour referrals for severe hypertension or eclampsia,Number of antenatal visits, antepartum and intrapartum referrals, utilization of health centre for delivery and perinatal outcomes,treated urinary-tract infection,pregnancy outcome, including antenatal referrals for other causes, labour referrals, obstetric interventions, low birthweight, and perinatal and maternal mortality and morbidity,rates of low birthweight,perinatal mortality,median maternal age, parity and gestational age at booking,patient satisfaction regarding the number of prenatal visits,rates of hospital admission, diagnosis, and length of stay,low birthweight (<2500 g), pre-eclampsia/eclampsia, severe postpartum anaemia,satisfaction with quality of prenatal care,urinary-tract infection,postpartum anaemia,rates of preterm delivery or low birthweight,Preterm delivery, preeclampsia, cesarean delivery, low birth weight and patient's satisfaction with care,satisfaction with provider subscale,number of prenatal visits,proportion of women with five or less visits,number of antenatal day admissions and ultrasound scans,ultrasound scans,pregnancy outcomes of infant and maternal morbidity and mortality, anxiety and satisfaction,median number of visits,satisfaction with the prenatal care system subscale,quality of care and an economic evaluation,referrals for pregnancy-induced hypertension,level of satisfaction,preeclampsia,proportion of antenatal referrals,perinatal outcomes or anxiety,adverse perinatal outcomes,intrapartum transfers|There were no other significant differences between the programmes in other major indices of pregnancy outcome, including antenatal referrals for other causes, labour referrals, obstetric interventions, low birthweight, and perinatal and maternal mortality and morbidity.
18|total dyskinesia score,Motor fluctuations and dyskinesias,parkinsonian and dyskinesia scores,Motor fluctuations,motor response complications,Dyskinesia severity,daily off-time,levodopa dyskinesias,dyskinesia assessments on the Unified Parkinson's Disease Rating Scale, part IV,patient-kept diaries and Unified Parkinson's Disease Rating Scale (UPDRS) interviews,self-scoring dyskinesia diaries,dyskinesia severity|In the 14 patients completing this trial, amantadine reduced dyskinesia severity by 60% (p = 0.001) compared to placebo, without altering the antiparkinsonian effect of levodopa.
86|hospital at home care and hospital care,fatal complications,SD) total length of stay,Oxford Hip Score,quality of life with hospital at home care,lower readmission rate,earlier ambulation,mean length of stay,functional status, health-related quality of life, or lower extremity functioning,function and quality of life,Total length of stay and cost from orthopedic and rehabilitation hospital admissions, functional performance,satisfaction with access to care,Functional status, lower extremity functioning, health-related quality of life, satisfaction with care, and use and cost of healthcare services,carer burden,rapid attainment of short-term functional milestones,Mean hospital stay,hospital stay on function, pain and quality of life (QOL,Home healthcare costs,RAND 36-item health survey I and the functional status index,SD) total cost|These data showed that high-risk individuals were able to tolerate early intensive rehabilitation, and this intervention yielded faster attainment of short-term functional milestones in fewer days using less total cost.
32|cerebral vasospasm,CBF ((133)xenon clearance,net fluid balance or on blood volume,Symptomatic vasospasm,mean global CBF,cardiac filling pressures and fluid intake,Cerebral blood flow (CBF,incidence of clinical vasospasm,incidence of preoperative vasospasm,CBF or blood volume,pulmonary artery diastolic and central venous pressures,cerebral blood flow,regional cerebral blood flow,minimum regional CBF values,clinical outcomes, clinically evident and transcranial Doppler sonography-evident vasospasm, SPECT findings, complications, and costs,SPECT findings and neuropsychological function results,minimum regional CBF|No differences were observed between the two groups with respect to cerebral vasospasm (as observed clinically or on transcranial Doppler recordings).
20|atypical symptoms,number and severity of side effects,productivity,UKU Side Effect Rating Scale,remission rate,29-item modified Hamilton Depression Rating Scale, administered by experienced clinicians, and the self-rated Beck Depression Inventory; adverse events and safety data,SIGH-SAD score,Hamilton Depression Rating Scale (SAD version; SIGH-SAD), the Clinical Global Impression (CGI) and the Social Adaptation Self Evaluation Scale (SASS,Hamilton Depression Rating Scale (SAD version; SIGH-SAD) and the Clinical Global Impression (CGI,SIGH-SAD score, CGI-S and CGI,effectiveness and tolerability,remission rate (SIGH-SAD<8,clinical response rates,SIGH-SAD, CGI severity, SASS, and SDS scores,Clinical response,overall response,efficacy and safety,rate of clinical response,response rate,SIGH-SAD score and CGI severity score,HDRS scores,greater treatment-emergent adverse events (agitation, sleep disturbance, palpitations,remission rate (SIGH-SAD <8,Hamilton depression rating scale, SAD version (SIGH-SAD), the clinical global impression of severity (CGI-S) and improvement (CGI-I) and the UKU side effect rating scale,remission rates,Social Adaptation Self Evaluation Scale (SASS), the Sheehan Disability Scale (SDS), and assessments of days lost due to illness and days with reduction in productivity,lower depression scores,seasonal affective disorder (SAD, fall-winter depression,24-item Hamilton Depression Rating Scale,rate of remission,efficacy and tolerability,time to response and to remission,depression score,negative social consequences of SAD,tolerated,SASS score,response rate (SIGH-SAD,Side effects|The response rate (SIGH-SAD<50% of baseline value) after treatment for 8 weeks was 95%, the rate of remission (SIGH-SAD < or =7) was 85%.
not found|Serum concentrations of unchanged CBZ and its main metabolite, carbamazepine-10,11-epoxide (CBZE,mean fluctuation of serum CBZ concentration (Cmax-Cmin/Css,Mean CBZ concentrations,time-lapse before CBZ reached its peak,bioavailability of CBZ,mean CBZ daily dose,total score of STRS,mean carbamazepine levels,Fluctuations of total CBZ and 10, 11-epoxide plasma level daily profiles at steady-state,fluctuations in serum CBZ and CBZE,mean serum carbamazepine levels,occurrence of dizziness,mean total values of NTRS,bioavailability,side effects,serum concentration of CBZ,mean serum CBZ concentration,cognitive performance,frequency of seizures,serum carbamazepine concentrations,blood samples,Peak serum CBZ concentrations,intermittent side effects,number of epileptic seizures,CBZ levels and summation of CBZ and CBZ-E levels,stability in serum CBZ and CBZE concentrations,tolerability and pharmacokinetics,Peak concentrations of CBZ and CBZE,systemic toxicity (STRS) and neurotoxicity (NTRS,occurrence of seizures,serum CBZ concentration,Diurnal fluctuations,mean total number of seizures,seizure frequency,occurrence of headache, dizziness and disturbances of vision, speech and coordination,quality and severity of side effects,fluctuation in serum CBZ concentrations,Side effects|A systematic tendency was found toward higher test performance in the CR condition.
not found|electronic data and linear regression,osteoporosis management,BMD measurement or osteoporosis medication, provider reminder plus patient education,BMD measurement and osteoporosis medication|The effect of provider advice combined with patient education was not significantly different from provider advice alone (P=.88).
not found|WOMAC physical function scores,Walking distance and quality of life,femorotibial angle,femorotibial angle and symptomatic relief,talar tilt angle,Compliance,maximum distance walked,number of days with NSAIDs intake,aggregate severity score,alignment, degree of OA, origin of OA, and age,WOMAC subscales,VAS pain score,pain on getting up from a seated position,Visual analog scale (VAS) score for subjective knee pain,disease-specific quality of life,patient's assessment of activity,assessment of disease activity, in WOMAC pain, joint stiffness, and physical functioning subscales,walking distances,NSAIDs consumption,Symptoms of knee OA,pain,aggregate score,Western Ontario and McMaster University Osteoarthritis Index (WOMAC) and the McMaster-Toronto Arthritis Patient Preference Disability Questionnaire (MACTAR), and function,Pain severity and knee function score,disease activity (5 grade scale), WOMAC index subscales and concomitant treatments,symptomatic improvement,Compliance and tolerance|The reported walking distances at 3 months, 12 months and overall were significantly longer in the brace group (P=0.03, P=0.04 and P=0.02, respectively).
not found|effectiveness (RSE control, adverse events,mechanical ventilation,While infections and arterial hypotension,tolerability measures,proportion of patients with RSE,Mortality|While infections and arterial hypotension did not differ between groups, barbiturate use was associated with a significantly longer mechanical ventilation (P = 0.03).
90|plasma clearances of pethidine, and the time to peak concentration,median time for first passage of flatus,incident pain,convalescence and hospital stay,Perioperative blood loss, frequency and quantity of transfusions,Late postoperative pain, fatigue and conservative attitudes and routines,stress hormones,pain relief,pruritus,Postoperative analgesia,Pain,pulseoximetry, arterial blood gas analysis and rate of breathing,area under the curve (AUC) of pain score versus time,postoperative venous thrombosis,beta-endorphine release,visual analogue pain scales, total morphine consumption, and stress hormones,pain relief (visual analogue scale), attainment of physical therapy goals and cardiopulmonary complications,pain control,total incidence of deep vein thrombosis,hypotension,surgical outcome and duration of rehabilitation,degree of analgesia, the adverse effects,postoperative pain and knee rehabilitation,visual analogue scale (VAS,side effects,postoperative complications,pain score,postoperative pain relief,actual discharge time,Nausea and vomiting,Nausea, vomiting, itching and urinary retention,early postoperative knee mobilization levels,respiratory depression,Total blood loss,Supplemental analgesia,Minimum respiratory rates,hypoalgesia to pin prick,pain and consumption of postoperative analgesics,knee flexion,total pain score (TOTPAR,Somnolence,Antithrombotic efficacy,durations of stay,Plasma concentrations of pethidine,Postoperative pain intensity,hypercapnia exceeding 6.0 kPa,Pain reduction,postoperative knee rehabilitation,pain,urinary retention,visual analog scales,analgesic requirements,pain scores,TOTPAR VPS,bradycardia,early postoperative maximal amplitude of knee flexion,incidence of calf vein thrombosis,catabolic response,Pain scores, supplemental analgesia, side effects, degree of maximal knee flexion, day of first walk, and duration of hospital stay,postoperative convalescence parameters, such as ambulation, patient activity including need for nursing care, fatigue or hospital stay,Low pain scores,pain relief and faster knee rehabilitation,pain scores, pain reduction and additional analgesia requirement (i.v. paracetamol,faster ambulation, and shorter hospital stay,adverse effects,postoperative pain,visual analogue pain scales,perioperative blood loss,visual analog scale scores,nonfatal pulmonary embolism,Side effects|The median time for first passage of flatus was shorter in the EDA group than in the GA/PCA group (26 vs. 47 h).
20543|serum antibodies,serious adverse reactions,seroconversion rate,degree of fever,typhoid fever,immune responses,attack rate of typhoid,Clinical and serum antibody responses,mild local reaction,frequencies of adverse reactions and mean Vi antibody levels,Vaccine efficacy,protective rate and index of vaccine,anti-Vi antibodies,protective efficacy,overall incidence of side-effects,Efficacy and side effects,safety, immunogenicity, and efficacy,Fever (oral temperature,fever seen,frequencies of rises of fourfold or greater and of maximal Vi antibody levels,rate of blood-culture-positive typhoid fever,Mild and moderate fever,levels of serum IgG Vi antibodies,Safety and immunogenicity,Erythema and/or induration,Protective efficacy,Rates of typhoid fever,serum Vi antibody levels (RIA,Antibody levels|Rates of typhoid fever were 379/100,000 per year for subjects who received the liquid formulation of vaccine and 468/100,000 per year for subjects who received enteric coated capsules.
not found|mean costs of antimicrobials per episode,peak incidence,microbiologically documented infections (MDI,Severity of illness using APACHE (acute physiology and chronic health evaluation) II score,Serological evidence of viral infection,reduced length of stay, a potential cost savings,performance of a sputum (P<.01) and blood (P<.001) cultures, antibiotic administration within 4 hours of hospital admission,length of stay,nosocomial infection and mortality,incidence of nosocomial infections,Pneumonia Severity Index, the hazard ratio of antibiotic discontinuation,mortality odds ratio (OR,mean durations of hospital stay,surgical site infection rate,medication costs,acquisition rate of GRE,rate of MRSA infection,30-day mortality rates,total antibiotic exposure,antibiotic treatment duration,Mortality and length of ICU stay,adjusted relative risk of antibiotic exposure,30-day mortality preintervention,VRE infection,nosocomial MRSA infections,incidence of regimens involving 12-hour intervals,mean risk of infection-related mortality,gentamicin and tobramycin resistance,Antibiotic use,proportion of antibiotic courses,total number of courses of therapy,diarrhea,resistance to gentamicin and tobramycin,mean numbers of defined daily doses of appropriate antibiotic therapy,pharmacy's 1985 average cost per antibiotic day and its monthly expenditures,partial or total cessation of antibiotic treatment,Mortality rates,rate of unnecessary use of the 2 target antibiotics,Decreased mortality,Hospital mortality,antibiotic choice, duration, timing, antibiotic volume and costs,overall SSI rates,proportion of patients receiving appropriate antibiotics within 4 h of admission to hospital,C. difficile diarrhoea,Antibiotic expenditures,Infections,nosocomial infections,Length of hospital stay, costs related to future resistance and total antibiotic costs,postoperative infection rate or death,Ticarcillin,Diagnostic yields, feasibility, and costs of real-time polymerase chain reaction (PCR,cost of antimicrobials per inpatient day fell,training of the whole health care team, emphasizing measures to reduce cross-colonization, and the importance of rational usage of antibiotics and (2) suppression of usage of third-generation cephalosporins,Rates of ventouse delivery,rates of discontinuation and hospital discharge,Mortality rates and length of hospital stay,laboratory studies, imaging procedures, days of intubation, and days in an intensive or intermediate-care area,reintroduction of gentamicin,quality of care,30-day mortality,quality of surgical prophylaxis,patients response and mortality,cephalosporins,Time to modification of intravenous antibiotic therapy,mean overall mortality rate,hospital admissions,numbers of intravenous piggyback cefazolin, cephalothin, cefamandole, cefoxitin, carbenicillin, and ticarcillin doses,mortality, rehospitalization, and return to usual activities,Mean,Mortality from staphylococcal bacteraemia,overall and timely administration of prophylaxis,Clostridium difficile-associated diarrhea and cost,nosocomial MRSA infection rate,incidence of toxicity,30-day all-cause mortality, length of hospital stay, and readmission rate,cost savings,actual cost of Alert Antibiotics,acuity of patient care,Concordance with national antibiotic guidelines,mean lengths of hospitalization,VRE infections,hospital length of stay or mortality,Coagulase-negative Staphylococcus and Enterococcus infection rates,Reducing door-to-antibiotic time,turnaround time,Clinical and microbiological response, antibiotic-associated toxic effects, in-hospital mortality, and readmission rates,Bloodstream infections,incidence of colonization and infection,hospital admission, severity of pneumonia, and 30-day mortality,incidence of C. difficile diarrhoea,number of courses of therapy or cost,CDAD fell,antibiotics in caesarean section and use of polyglycolic acid sutures,incidence of surgical site infections (SSI,IV antibiotic duration, and appropriateness of the IV route and switching,cervical cytology history,median duration of IV therapy,clindamycin susceptibility,incidence density of tobramycin-resistant organisms,parenteral broad-spectrum antibiotics,Per patient antibiotic charges,time elapsed from randomization until a first modification of the initial intravenous antibiotic therapy,amikacin resistance,VRE prevalence,infection rate,Lastly, patient costs for hospitalization,Intraoperative redosing,vancomycin use,CEFX use,antimicrobial therapy costs, antimicrobial resistance, and superinfections without adversely affecting the length of stay or mortality,Calculated cost savings,antibiotic expenditure,mean number of cases of C. difficile-associated diarrhea,total expenditures,compliance with other recommendations, patient satisfaction and costs of the implementation strategy (secondary outcomes,Antibiotic use, hospital admissions, and mortality,proportion of ceftazidime-resistant organisms acquired late,monthly incidence of C. difficile infection,Prolonged prophylaxis,antibiotic prescriptions on admission,turnaround time of the microbiological cycle,turnaround time of microbiological procedures,number of antibiotic entities stocked,medical complications,antibiotic costs,time to first dose of antibiotics, proportion receiving antibiotics within 8 h, timely switch to oral antibiotics, timely discharge, length of stay, or patient education outcomes,number of doses prepared and quarterly purchase data,response rates,clinical, laboratory, and radiographic outcome,diagnostic costs,annual rate of fluoroquinolone use,Clinical and laboratory outcome,febrile neutropenic episodes,nosocomial Clostridium difficile-associated diarrhea,VRE infection rate,cefamandole, cefoxitin, and ticarcillin costs,mean durations of therapy,Median length of stay,Antibiotic cost savings,rate of appropriate empirical antibiotic treatment,number of infants treated with antibiotics and 2) the number of infants with infections missed at the initial evaluation,appropriateness of cefotaxime prescribing,clinical pulmonary infection score,number of days that unnecessary levofloxacin or ceftazidime,antibiotics and analysis was by intention to treat,total antibiotic prescribing costs,Overall, mean monthly acquisition cost savings,Antimicrobial use,duration of antibiotic treatment for VAP,usage of cephalosporins, imipenem, clindamycin, and vancomycin and increased usage of beta-lactam/beta-lactamase-inhibitor antibiotics,shorter length of stay,crude mortality rates,acute exacerbation of chronic obstructive pulmonary disease,SD) hospital stay,Readmissions,genital tract infection,Guideline compliance,hospital admission,carriage of GRE,Average length of stay,hospital antibiotic prescribing,serum aminoglycoside concentration data,ICU vancomycin use and VRE prevalence,antibiotic costs, length of stay, need to restart intravenous antibiotics, in-hospital mortality, and 30-day readmissions,clinical outcomes,gram-negative resistance to gentamicin,Real-time PCR results,rate of nosocomial methicillin-resistant Staphylococcus aureus infection,Glycopeptide usage,incidence and prevalence of patients with multiresistant Enterobacteriaceae,rate of unjustified prescriptions,IV antibiotic expenditure,febrile neutropenia and nosocomial infections,level of compliance,Aminoglycoside resistance,mean antibiotic costs,labor costs,number of antibiotics,intervention markedly improved door-to-antibiotic time,mean risk of Clostridium difficile-associated diarrhea,Amikacin resistance,quality, efficiency, and patient understanding of care,infection rates,Length of hospital stay, adverse events, mortality (interventional trial) and antibiotic costs (both studies), including costs related to future antibiotic resistance,VRE rates,Annualized savings,overall antibiotic use,quality and efficiency of pneumonia care,MRSA isolation,occurrence of a secondary episode of VAP,Serum calcitonin precursor concentrations,time-specific mortality risk,total use and cost,quality of prophylaxis,mean lengths of time to provision of susceptibility and identification test results,clinical, laboratory, and microbiology characteristics, and Pneumonia Severity Index,antibiotic choice,Length of stay, intensive care unit transfers, readmission rates, and in-hospital death rates,Duration of stay,duration of intravenous antibiotic therapy,annual cost savings,Mortality OR,minimal fever diagnostic tests,resistance among P. aeruginosa,readmission rate,ICU length of stay,rate of MRSA isolation,prevalence of MRSA and CRP,Mean length of total hospital stay,Clostridium difficile-associated diarrhoea (CDAD,antimicrobial portion of the total pharmacy drug budget,mortality, morbidity, and cost,mortality rates,rate of surgical-site infection,Median patient charges for radiology, laboratory, pharmacy, and room were reduced by $4404/intervention, and median hospital costs,antibiotic use and VRE prevalence,mortality,serum procalcitonin concentrations,acquisition rate falling,cost of development, dissemination and implementation|In the years since, the incidence has remained at this low level, and the antibiotic costs have decreased to a level lower than before intervention.
300|24-month life-table pregnancy rate,midluteal progesterone levels,mean duration of the procedure,operating time,Hormone levels,Surgical difficulties and injuries and technical failures,Serum estradiol and progesterone and urinary pregnanediol and estradiol,perioperative outcomes,average surgical time for minilaparotomy,progesterone levels,surgical complications,peri-operative complications,serum estradiol and progesterone levels and urinary estradiol and pregnanediol levels obtained during the luteal phase before, 1 year and 2 years after sterilization,Pain,Demographic characteristics, educational level and operator experience,hormonal changes|The results showed little differences among patients in the three groups for age, number of living children, contraceptive and abortion histories and pre-existing medical conditions.
23|GFR or the incidence of rejection,Serum calcium, phosphorus, osteocalcin, and PTH levels,Renal function deterioration,IGF,Length gain,calculated creatinine clearance,Mean fasting and postprandial insulin values,height,glomerular filtration rate,pretreatment elevation of IGF-binding protein-1 (IGFBP-1) levels,height velocity,Anthropometric measurements and blood for serum calcium, phosphorus, parathyroid hormone (PTH), osteocalcin, and insulin-like growth factor-I,Bone mass,incidence of rejection,fructosamine levels,serum ALS, IGFBP-3, total IGF, IGF-I, IGF-II and free IGF-I levels,serum IGFBP-2 levels,serum insulin-like growth factor binding protein (IGFBP)-1 and -2 levels,Glomerular filtration rate and effective renal plasma flow,Phosphate, ALP, PTH, and insulin,IGFBP-3 levels,HVSDS,IGF-I/IGFBP-3 ratio,Serum IGF-I levels,Standardized height,number of adverse events,forearm bone mass and increased serum concentrations of total and free IGF-I and IGF-binding protein 3 (IGFBP-3), whereas IGF-II, IGFBP-1, IGFBP-2, GH-binding protein, ghrelin, and leptin,serum levels of IGF-I, IGF-II, free IGF-I, IGFBP-3 and acid labile subunit (ALS,Anthropometric measurements and circulating growth factors,growth rates,deterioration of graft function,serum IGFBP-1 levels,body length, body weight, bone age, biochemical and hormonal analyses, renal function, bone mass, and adverse effects,Growth, bone maturation, renal graft function, plasma insulin-like growth factors, serum binding proteins,Bone formation rates,mean (SE) HV and delta HSDS,prestudy height velocity and height-velocity increase,pretreatment elevation of IGF-binding protein-1,Phosphate, alkaline phosphatase (ALP), parathyroid hormone (PTH), and fasting insulin concentrations,severe growth retardation,overt insulin dependent diabetes mellitus,Annual growth velocity increased and standard deviation scores for height,Growth rate, standardized height, bone age, fasting and 2-hour postprandial glucose and insulin levels, biochemical values, and insulin-like growth factor,efficacy and safety of rhGH,height SDS,elevated pretreatment IGFBP-3 levels,Bone maturation,Height velocity,Mean fasting and 2-hour postprandial glucose values,Growth rate and standardized height,plasma insulin-like growth factor-I,accelerated bone maturation,rejection episodes,bone formation rates,linear growth and maintains bone mass,GH-induced height-velocity increase,integrated insulin levels (AUC,Height velocity SDS (HVSDS,growth rate,bone maturation, renal failure progression, or metabolic control,IGF-II plasma concentrations,acute rejection episode,height velocity SD score,efficacy (height velocity (HV), change in height standard deviation score (delta HSDS)), and safety (glomerular filtration rate (GFR), incidence of rejection, and calcium and glucose metabolism) of recombinant human growth hormone (rhGH,GFR,lipid and parathyroid concentrations,growth and glomerular filtration rate,IGF-I. Fructosamine, lipid, and parathyroid concentrations,delta SDS (standardized height,Plasma IGF-II levels,mean delta height age minus the delta bone age,adverse events|Serum calcium, phosphorus, osteocalcin, and PTH levels did not differ between the treated and control groups.
2722|transmission through breastfeeding, and mortality,Cumulative 3-month mortality,Primary efficacy (HIV infection by age 7 months and HIV-free survival,Cumulative infant mortality,mortality rates and HIV-1-free survival,mortality rate,higher mortality,postnatal HIV-1 infection,frequency of breast-feeding,rates of HIV-1 infection,relation to transmission of HIV-1 through breastfeeding and early child mortality,total risk of HIV-1 transmission,HIV infection,child mortality and HIV-1 transmission through breastfeeding,2-year mortality rates,safety (occurrence of infant adverse events,postnatal HIV transmission,number of adverse events (primarily neutropenia,Median duration of breastfeeding,estimated rate of breast milk transmission,HIV-free survival,HIV infection or death of the child by 24 months,death and prolonged HIV-free survival,erythrocyte sedimentation rate,rate of HIV-1-free survival,time-to-mortality distributions,efficacy and safety,median duration of breast-feeding,Infant HIV-1 infection and death,acquire infection,risk of transmission,estimated rate of HIV-1 infection,cumulative probability of HIV-1 infection,HIV-1 infection,rate of HIV-free survival,risk of HIV-1 transmission,breastfeeding transmission,transmission of HIV-1,median duration of cumulative exclusive breastfeeding,HIV infection rates,HIV-1-free survival,HIV-1 transmission risks and survival,child survival,Cumulative mortality or HIV infection rates,mortality,maternal CD4-cell counts,grade 3 or 4 serious adverse events|Breastfed infants who also received solids were significantly more likely to acquire infection than were exclusively breastfed children (HR 10.87, 1.51-78.00, p=0.018), as were infants who at 12 weeks received both breastmilk and formula milk (1.82, 0.98-3.36, p=0.057).
not found|prolongation of pregnancy,Number of days from admission to delivery, gestational age at delivery, rates of preterm delivery, low birthweight, maternal infections and neonatal infections,genital microflora,success of magnesium sulfate tocolysis,respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular hemorrhage, sepsis, and admission and duration of newborn intensive special care unit hospitalization,maternal outcomes, including duration of randomization-to-delivery interval, frequency of preterm delivery (< 37 weeks), frequency of preterm premature rupture of membranes, clinical chorioamnionitis, endometritis, and number of subsequent admissions for preterm labor,frequency of contractions, cervical Bishop's score, and white blood cell count on admission,overall prevalence of microbial invasion of the amniotic cavity,necrotising enterocolitis,incidence of preterm birth,neonatal death, respiratory distress syndrome, proven sepsis, and birthweight,birth weight,likelihood of a beta error,upper genital tract infection,Survival analysis,rate of delivery,duration of pregnancy,interval to delivery, birth weight, and neonatal outcomes,mean cervical dilatation,neonatal hospitalization time,episodes of recurrent labor requiring parenteral tocolysis,maternal and neonatal infectious morbidity,frequency of preterm birth,neonatal morbidity,rate of cesarean section,prolongation of gestation,safe and well tolerated,prolongation of pregnancy, the rate of preterm birth, and neonatal morbidity,infectious morbidity,pregnancy outcome,higher gestational age at delivery,perinatal mortality and morbidity,postpartum infections,interval to delivery or duration of pregnancy,maternal outcomes, including duration of randomization-to-delivery interval, frequency of preterm delivery, and frequency of clinical chorioamnionitis and endometritis,rate of admission to neonatal intensive care unit,preterm premature rupture of membranes,time to delivery,tolerated,rate of neonatal suspected sepsis,delivery interval or rate of delivery,Rate of cesarean section,efficacy, safety, and tolerance,shorter interval to delivery, lower gestational age at delivery, lower mean birth weight,composite of neonatal death, chronic lung disease, or major cerebral abnormality on ultrasonography before discharge from hospital,neonatal outcomes,Suspected sepsis,interval to delivery|In our population adjunctive ampicillin-sulbactam with indomethacin did not improve the success of magnesium sulfate tocolysis.
19|complete pain relief,satisfactory pain relief|de Quervain's disease of pregnancy and lactation is usually self-limited and responds well to nonsurgical treatment.
not found|lower drive for thinness and greater body satisfaction,metabolic control,weight, Eating Attitudes Test and Eating Disorders Inventory,media-related attitudes and behaviors including internalization of sociocultural ideals, self-efficacy to impact weight-related social norms, and print media habits,body weight,body-related knowledge and attitudes,disturbed eating behaviour,Eating Disorder Examination Questionnaire (EDE-Q), the children's version of the Eating Attitudes Test (EAT), the Rosenberg Self-Esteem Scale (RSES), and a Knowledge Questionnaire (KQ,body size acceptance, puberty knowledge, and perceived weight status,Self-Report Symptom Check-List (SCL-90-R,physical appearance to their self-esteem,body mass index,body dissatisfaction,body image and eating attitudes and behaviors,Restraint and Eating Concern subscales of the Eating Disorder Examination (EDE) and on the Drive for Thinness and Body Dissatisfaction subscales of the Eating Disorder Inventory,self-esteem; social acceptance, physical appearance, and athletic ability,body image, eating attitudes, and behaviors,knowledge,physical appearance,disturbed eating attitudes and behavior,frequency of purging by insulin omission or hemoglobin A1c levels,body satisfaction,weight-losing behaviors,eating disorder risk factors,weight concern,risk of bulimic attitudes,dieting behaviors, body image attitudes, and media knowledge, attitudes, and habits,dieting behaviors,eating disturbance,lasting changes in body image and dieting behaviors,self-esteem measures,students' anxiety or depression,symptom scales|The program significantly improved the body satisfaction of the intervention students and significantly changed aspects of their self-esteem; social acceptance, physical appearance, and athletic ability became less important for the intervention students and more important for control students.
not found|Kujala patellofemoral score (KPS), and pain, through a visual analog scale (VAS,knee functional capacity,PFP and PFC,patellofemoral pain syndrome,isokinetic strength on a Cybex II+ dynamometer,Cincinnati Rating System and traditional measures of leg strength and flexibility,contraction values of the vastus medialis and the vastus lateralis muscles,muscular strength,visual analog scale (VAS) and the Functional Index Questionnaire (FIQ), respectively,WOMAC and HAD,Contraction values,quadriceps muscle performance,VAS and FIQ differences,physical activity, pain, and muscle function,PFC and joint function improved, and PFP,peak torque,WOMAC, visual analogue, and the anxiety score,PFC, KPS, and VAS,Pain and functional status,vastus lateralis muscles,WOMAC, visual analogue, and HAD scores,functional performance,closed kinetic chain testing and perceived functional status,walking, stair activity, running, jumping/twisting, and overall activity level,patellar pain, position, and function,visual analogue pain score; the WOMAC lower limb function score; the Hospital Anxiety and Depression scale (HAD); and quadriceps strength,overall knee function,pain,Muscle characteristics, subjective symptoms, and functional performance,quadriceps strength and hamstring range of motion,Patellofemoral pain (PFP) and abnormal patellofemoral congruence (PFC,Perceived functional status,pain and improvements in torque, vertical jumping ability, and physical activity level,Mean contraction values|The clinical improvement was better on patients of groups I and III.
not found|Y-BOCS, SCL-90-R OC and GSI scales, and POMS,anxiety,Yale-Brown Obsessive Compulsive Scale (Y-BOCS), Symptoms Checklist-90-Revised Obsessive Compulsive (SCL-90-R OC) and Global Severity Index (SCL-90-R GSI) scales, Profile of Moods scale (POMS), Perceived Stress Scale (PSS), and Purpose in Life (PIL) test,treatment efficacy, onset of symptom amelioration, or maintenance of therapeutic gains,PSS and PIL test,Y-BOCS, SCL-90-R OC, SCL-90-R GSI, POMS, PSS, and PIL|Within-group statistics (Student's paired t-tests) showed that Group 1 significantly improved on all six scales, but Group 2 had no improvements.
not found|Costs/QALY gained discounted,left quadriceps strength,Aquatic exercisers reported equal (QWB) or better (CHDR, HAQ, PQOL) health-related quality of life,Aquatic exercise,Pain related to motion and pain on load,knee range of motion (ROM), thigh girth, subjective pain scale, and time for a 1-mile walk,physical function,Disability in functional activities,right quadriceps strength,functional levels,Compliance rates,strength,functional activity and quality of life,High levels of co-morbidity,strength and function,walk speed and self efficacy satisfaction,arthritis-specific Health Assessment Questionnaire (HAQ), Center for Epidemiologic Studies-Depression Scale (CES-D), and Perceived Quality of Life Scale (PQOL,Pain score on the Western Ontario and McMaster Universities OA index (WOMAC,mean pain score,strength and physical function,quality of life, cost-effectiveness and physical function measurements,disability rating index (DRI), global self-rating index (GSI), and visual analogue scale (VAS,Functional gains,WOMAC pain,Subjective pain levels,pain,Quality of Well-Being Scale (QWB) and Current Health Desirability Rating (CHDR,outcome assessments (muscle strength dynamometry, six minute walk test, WOMAC OA Index, total drugs, SF-12 quality of life, Adelaide Activities Profile, and the Arthritis Self-Efficacy Scale,Quality of life,lower limb OA,knee ROM, thigh girth, and time for a 1-mile walk,Cost per quality-adjusted life year (QALY,WOMAC physical function|Pain related to motion and pain on load was reduced up to 3 months after last the treatment in the hydrotherapy group and up to 6 months in the EA group.
15|average (median) time taken to complete voice therapy,Ratings of laryngeal features, Buffalo voice profile, amplitude and pitch perturbation, voice profile questionnaire, hospital anxiety and depression scale, clinical interview schedule, SF-36.
                Voice therapy improved voice quality,voice therapy (perceptual auditory rating of voice quality measurement,laryngeal status,voice care knowledge areas,voice quality,Voice-Related Quality of Life (VRQOL) and the Voice Symptom Severity Scale (VoiSS,perceptual evaluation of voice quality and a questionnaire on the occurrence of vocal symptoms,psychological distress and lower quality of life,voice severity, electrolaryngograph, and shimmer measurements and on ratings provided by a patient questionnaire|Results revealed a significant difference between the 3 treatment groups in the amount of change for the voice severity, electrolaryngograph, and shimmer measurements and on ratings provided by a patient questionnaire (P<0.05).
40|time to return to uninterrupted sleep,resolution of pain,chronic pain and quality-of-life outcomes,loss of vesicles,pain severity achieving statistical significance,incidence of ulceration,post-zoster pain,total crusting,Total analgesic use,chronic pain,frequency or severity of post-herpetic neuralgia,Pain,active ocular disease,quality of life,laboratory adverse events,duration and severity of acute pain,local neurological symptoms,Safety,full crusting,frequent formation of new lesions,times to last new lesion formation,lesion healing, resolution of pain, return to usual activity, and return to uninterrupted sleep,Time to total crusting and healing,medical events,resolution of postherpetic neuralgia,extent and duration of the rash,proportion of patients with pain scores,persistent pain,analgesic requirements each day, and adverse events and laboratory abnormalities,risk ratios,Famciclovir accelerated lesion healing,intraocular complications,prevalence of pain,duration of viral shedding,median duration of postherpetic neuralgia,time to return to usual daily activity,rash healing,period of viral shedding,accelerated time to cessation of acute neuritis,weekly prevalence of pain,reduction pain|Total analgesic use in the first 4 weeks was reduced by acyclovir, but during follow up there was no difference in the prevalence of analgesic use between groups.
not found|CD4 counts,incidence of heterosexual transmission,rate of HIV seroconversion and last recorded CD4 cell count level,number of sexual partners or other risk behaviors,Seroconversion,HIV-1 incidence and sexual risk behaviors,seroconversion rate,HIV seroprevalence,Seroconversion rates,transmission rates,Incidence rates of seroconversion,sexual activity,highest HIV-1 transmission rate,signs of disease progression (symptoms of acquired immunodeficiency syndrome, p24 antigen positivity, or CD4+ cell counts,CD4 cell count,HIV-1,plasma HIV-1,genetically-linked HIV-1 transmission,quality of life score,Viral load,incidence rate difference,rate of transmission,median viral loads,risk of seroconversion,incidence of seroconversion,Heterosexual transmission,HIV-1 transmission rates,HIV Heterosexual Transmission,Median viral loads,Six HIV-1 seroconversions,Unprotected sexual intercourse as a risk factor for HIV-1 infection|Men with signs of disease progression transmitted infection to their partners more frequently and were more frequently treated with zidovudine.
11|attacks|Stilboestrol 5 mg daily was better than the placebo in preventing attacks.
181|pregnancy rate and the miscarriage rate,Total pregnancy rates and time for success,pregnancy rate and pregnancy maintenance,pregnancy rates|Although the results were not statistically significant in the group of women with intramural and intramural-subserosal fibroids, this study confirms the important role of the position of the uterine fibroid in infertility as well as the importance of fibroids removal before the achievement of a pregnancy, to improve both the chances of fertilization and pregnancy maintenance.
60|ALP level,cumulative mortality from liver disease,BSP elimination kinetics,mean alkaline phosphatase values,mean alanine aminotransferase values,pruritus score,severity of symptoms or physical findings,disease activity,mean bilirubin and immunoglobulin M values,liver function test,histologic changes noted at liver biopsy,serum immunoglobulin G levels,mean pruritus score,levels of serum albumin, serum bilirubin, alkaline phosphatase, cholesterol, and aminotransferases,liver histology,histological grading score,elevated serum level of aminoterminal propeptide of type III procollagen,improvement of liver enzymes related to cholestasis and cytolysis and of amelioration of pruritus,liver function and immunoglobulin levels,histological scores,symptoms, laboratory findings (serum bilirubin level, alkaline phosphatase and alanine transaminase [ALT] activities, immunoglobulin [Ig] M level), serum markers of fibrosis, or histological features, except lobular inflammation,alkaline phosphatase and alanine aminotransferase activities,mean serum levels of alkaline phosphatase, total bilirubin, gamma-glutamyltranspeptidase, alanine aminotransferase, aspartate aminotransferase, and IgM,Bilirubin values,progression of esophageal varices,variceal bleeding,Pruritus,alanine aminotransferase (ALT) level,number of treatment failures (i.e. dead, orthotopic liver transplantation (OLT), complications of cirrhosis, doubling of bilirubin, untreatable pruritus,immunoglobulin G levels,total globulin levels,Mayo score values,Clinical events, laboratory test results, and liver histology,serum alkaline phosphatase (ALP) levels,blood test results, symptoms, and/or liver histology,serum activities of aminotransferases, alkaline phosphatase, and gamma-glutamyltransferase,histologic progression,number of markers of liver disease,diarrhea,ductular proliferation,Serum total bilirubin levels,serum albumin and bilirubin levels,albumin levels,Procollagen type III aminoterminal peptide (PIIINP), hyaluronic acid, and sulfobromophthalein (BSP) elimination kinetics,serum cholesterol levels, and UDCA also reduced high-density lipoprotein cholesterol levels,Serum bilirubin levels,hepatic reasons,mean alkaline phosphatase and alanine aminotransferase values,serum levels of immunoglobulin (Ig) M and IgG, and colchicine reduced IgG levels,survival estimate,serum level of carboxyterminal propeptide of type I procollagen|However, there was no such improvement in the severity of symptoms or physical findings; moreover, there was no significant difference in the histologic changes noted at liver biopsy in the two treatment groups.
80|episodes of bleeding,urinalysis, complete blood count, erytrocyte sedimentation rate (ESR), plasma creatinine, glomerular filtration rate (GFR), electrolytes, proteins, IgG, C3, C4 antinuclear-antibodies (ANA), antistreptolysin-O and antibodies to hantaviruses,rate of postoperative nausea and vomiting,Plasma morphine concentration,incidence of vomiting or dreaming,quality of recovery,Postoperative nausea and vomiting (PONV,number of children rating severe pain,demographics, tracheal extubation times, and pain scores,side-effects,time to awaken from anaesthesia or incidence of postoperative vomiting,Functional parameters,concentration ability,perioperatively scores (open scale 1-9) for stridor, sedation, bleeding, nausea, pain, heart rate, the need for analgesics and registered psychotomimesis and well-being at home,secondary hemorrhage,total incidence of nausea/vomiting,headache, arthralgias and maculopapular rash,Aseptic tissue necrosis,objective pain scale (OPS,Postoperative comfort,symptoms of disorientation, restlessness, inconsolable crying and thrashing resemble an acute psychosis,Efficacy and safety,median (range) episodes of vomiting,postoperative complications,postoperative analgesic requirement,duration of postoperative analgesia,pain scores in recovery and pain scores,Renal function,postoperative pain and behaviour,operating theatre blood loss, the frequency of bleeding on the ward, or the need for operative haemostasis,Pain and demeanour,salivation,Postoperative pain relief,rate of recovery,postoperative haemorrhage and vomiting,satisfactory sedation scores,median time to first analgesia,Low urine specific gravity,Severe delirium,visual-analogue 10-point scale and the 0-4 point verbal pain assessment scale,incidence of PONV,pain scores and postoperative morphine requirements,incidence of motor block, urinary retention, postoperative vomiting or postoperative sedation,post-operative pain scores,frequency of vomiting and the degree of nausea,End-tidal volatile agent concentration,phenotype nor morphine concentration,post-operative pain,incidence of airway irritation or emergence delirium,Pain scores, emetic episodes and supplemental morphine requirements,Acta Anaesthesiologica Scandinavica,child behavior,Postoperative vomiting,postoperative pain,sedation score or frequency of use of postoperative analgesics,pain score [verbal analogue scales (VAS), 0-10] and sedation level at 5-min intervals and recorded the total morphine consumption of the first hour in the PACU,normal activity,validated Wong and Baker scale (FACES,Plasma diclofenac and beta-endorphin concentrations,postoperative morphine titration,maximum pain score and pain score,nausea/vomiting, analgesics and parents' aspects,Pain scores,pain relief,swallowing-evoked pain,Postoperative analgesia,Pain,Immediate postoperative analgesia,longest analgesia duration,pain severity,postoperative pain scores,plasma beta-endorphin level,degree of postoperative sedation,mPCA,CHEOPS pain scoring,mean VAS score,glycosuria, aminoaciduria and decreased tubular reaposrption of phosphate (TRP,Hannallah objective pain scale,movement pain scoring,diclofenac, 4'-hydroxydiclofenac and 5'-hydroxydiclofenac concentrations,serious adverse events,sedation score,postoperative analgesia made by analgin and promedol,time to first solid intake,Ketamine efficacy,rapid return to calm wakefulness,hemodynamic changes,severe agitation,formation clearances of diclofenac to hydroxyl metabolites,age, weight, type of operation or induction of anaesthesia, 4-h sedation and pain scores and further analgesic requirements,scores for salivation,Pain and appearance,effective pain relief,postoperative pain and anxiety,Postoperative analgesia and side-effects,respiratory depression,nausea and vomiting,point Verbal Pain Rating Scale (VPRS,Mean operative time,postoperative bleeding,postoperative pain, oral intake, vomiting, temperature and complications,Mean (SD) morphine concentrations,full Aldrete scores,bleeding and restlessness,plasma proteins and IgG levels,incidence of postoperative vomiting,pain and restlessness,Acceptable pain scores,need analgesia,leucocyte and differential counts, lymphocyte and their subset counts, lymphocyte proliferative responses, and in serum cortisol, C-reactive protein, plasma interleukin-6 and group II phospholipase A2 concentrations,sedation scores and the heart rates,self-report visual analogue scale to record pain,median duration of analgesia,fatigue, fever, gastrointestinal disturbances, anorexia and weight loss,nausea/vomiting,postoperative morbidity,demographics, induction technique, duration of anaesthesia and time between premedication and induction of anaesthesia,Nausea, vomiting and pain,Side effects,Cumulative morphine consumption,nausea and vomiting and allowed safer and earlier hospital discharge,Times to leave recovery,plasma morphine concentrations,nausea, vomiting, apnea, desaturation, reintubation within 24 h and constipation,Mean postoperative hospital stay,volumes of distribution of parent diclofenac and its hydroxyl metabolite,total morphine consumption,postoperative analgesia,Recovery time,Colon perforation,median of the VAS,nausea and vomiting scores,analgesic effect,modified Aldrete score, a Pain/Discomfort scale,mean total morphine consumption,pain and postoperative morbidity,severity of the postoperative pain,blood loss,rescue analgesic,pain intensity and morphine requirements,Pain Rating Scale,agitation score,abdominal pain and peritonism,pain-free children,duration of anaesthesia,Worst pain,spontaneous and swallowing-evoked pain,Analgesic requirements,total paracetamol consumption,Analgesic efficacy,degree of pain,Nausea and vomiting scores, sedation scores and pain scores,incidence of reactionary post-operative haemorrhage,overall incidence of postoperative vomiting,morbidity and pain,bleeding,postoperative nausea,Muscle relaxation,absorption half-life,Overall, CHEOPS scores,severe vomiting,discomfort,analgesic effects,Oral fluid intake,pain, less elevation of temperature, more oral intake, and started drinking,Vt and total plasma clearance,hypertension, oedema or evidence of acute infection,reduced enzyme activity,phenotype and plasma morphine,marked restlessness,onset of eating at home,ischaemia and ulceration,postoperative nausea and vomiting or psychomotor reactions,OPS scores and requirement for supplementary analgesics,formation clearance to 4'-hydroxydiclofenac, diclofenac volume of distribution, absorption half-time and lag time for the suppository,formation clearance to 4'-hydroxydiclofenac,intra-operative bleeding,otitis media,Postoperative pain,pain scale,C3 and C4 levels,postoperative analgesic efficacy,Total plasma clearance,arousal,quality of oral intake,relative bioavailability,ESR, plasma urea and creatinine concentrations,vomiting,rescue analgesia,unpleasant psychotomimesis,heart rate and blood pressure,Pain control,Blood loss,CBCL rating and experience of pain,Postoperatively, time to first eye opening, sedation score, pain score, time for further analgesia requests and incidence of nausea and vomiting,Clearance,analgesia [behavioral pain scale (BPS) score of 3,stridor scores,Adverse effects and duration of PCA,Renal biopsy,side effects,pain score,emergency department visit for pain and dehydration,visual pain scale (VAS) (0-100), side-effects such as vomiting and postoperative haemorrhage,normal blood pressure, non-oliguric renal failure, proteinuria, hypostenuria and abnormal urinary sediment,postoperative pain scores, analgesic requirements, sedation scores, signs of respiratory depression and nausea and vomiting, as well as antiemetic requirements,Child Behavior Checklist (CBCL,analgesic requirements and modified objective pain score,enlarged hyperechoic kidneys,analgesic efficacy,Elimination clearance of hydroxyl metabolites,Nurse pain assessments,severe arthralgia,median pain scores,Wong and Baker Pain Scale,Tissue necrosis,pain,pain scores,efficiency of postoperative analgesia,score for stridor,pain score or the need for rescue analgesia,pre-operative anxiety and pain,incidence and frequency of vomiting,incidence of above average bleeding,objective pain score,Hourly visual analogue pain scores and morphine patient controlled analgesia (mPCA) usage,Pre-surgical child behavior ratings and pain management,relevant pain-relief medication|In children 1-3 yr, sevoflurane provided more rapid early recovery but not discharge after anaesthesia of <30-min duration.
14|Complete remission|At the 6-month follow-up timepoint, tumour volume had decreased by >/=10% in a total of 7 patients with a 37.9% (95% CI 31.3-44.5%) mean volume reduction in this subgroup.
34|peak inspiratory pressure of </=16 cm H(2)O, positive end expiratory pressure of </=5,apnea/bradycardia episodes,extubation failure,Mean birth weight,incidence of abdominal distension or feeding intolerance,H(2)O, intermittent mandatory ventilation rate,blood gases,Pulmonary function tests (PFT,lower incidence of failed extubation,demographics, severity of initial illness and associated complications, time to extubation, ventilatory management before extubation, weight, age, or nutritional status at the time of extubation,Respiratory failure|Thirty-two (94%) of 34 infants were extubated successfully with the use of SNIPPV versus 18 (60%) of 30 with the use of NCPAP (P <.01).
120|Zinc deficiency affects adversely T-helper1 (TH1) functions and cell mediated immunity and interleukin (IL)-2 production,mean number of episodes of crisis,BMI,growth and body composition,circumference z scores,knee height,Sickle cell crisis,Mean GPX activity,serum testosterone level,number of hospitalizations and decreased number of vaso-occlusive pain crisis,bacteriologically positive infections,interleukin-2 production,antioxidant status,lymphocyte and granulocyte zinc,Mean duration of hospital stay,acceleration of growth in height,serum zinc and vitamin E, superoxide dismutase (SOD), glutathione peroxidase (GPX), total antioxidant capacity (TAC) and body mass index (BMI,linear growth in beta-thalassemia,serum testosterone, neutrophil zinc, and neutrophil alkaline phosphatase activity,mean number of infective episodes and associated morbidity,growth velocity (height,incidence of infections and hospital admissions,Mean SOD activity and TAC,sitting height,mean height velocity of early-zinc supplemented children,body weight increased and serum lactic dehydrogenase activity,anthropometric, high-precision knee-height, and plasma zinc measurements,Body composition,Height-for-age and weight-for-age z scores,Serum vitamin E levels,height,Serum zinc levels,serum testosterone levels|Mean GPX activity in group1, 2 and 3 decreased significantly (P<0.015, P<0.032 and P<0.029, respectively).
569|serum lipid profile,body weight,Ginseng therapy elevated mood, improved psychophysical performance, and reduced fasting blood glucose (FBG) and body weight,absenteeism,general health,Psychomotor speed and concentration,Subscales of acuity,mean (+/-SE) HbA1c and fasting blood glucose levels,vitality,Cognitive function,VAS emotional health,glucose and hemoglobin A1c (HbA1c) levels and symptom distress, QOL, and health economic indicators by questionnaires and diaries,Health economic benefits and quality of life,cognitive functioning,productive capacity,Quality-of-life treatment differences (SD units) for symptom distress,overall visual analog scale (VAS,depression,sleep,psychophysical tests and measurements of glucose balance, serum lipids, aminoterminalpropeptide (PIIINP) concentration, and body weight,disorientation and detachment,cognitive deficits,glycated hemoglobin, serum PIIINP, and physical activity,Glycosylated hemoglobin,general perceived health|Quality-of-life treatment differences (SD units) for symptom distress (+0.59; P<.001), general perceived health (+0.36; P= .004), cognitive functioning (+0.34; P=.005), and the overall visual analog scale (VAS) (+0.24; P=.04) were significantly more favorable for active therapy.
not found|beta-cell response,metabolic control,insulin sensitivity,Muscular strength and endurance,VO2 peak,time or frequency domain measures of HRV or in systemic hemodynamics,muscle density,BRS, HRV, and hemodynamics,peak oxygen uptake (P<0.05) and exercise test duration (P<0.001) increased following training, whilst glycated hemoglobin (P<0.05) and fasting blood glucose,body weight,fasting glucose and HbA 1c,Vo(2 max,abdominal fat distribution, glycemic control, and insulin sensitivity,Coronary risk factors,insulin sensitivity and Hb A(1c) concentration,risk for coronary artery disease,Percent body fat,Glycosylated haemoglobin (HbA 1c ), fasting glucose and insulin, glucose and insulin 120 minutes (2h) after a 75 g oral glucose load, body composition and muscular strength and endurance,Resting systolic blood pressure,Submaximal exercise heart rate and rate pressure product,Fat free mass (FFM,glycemic control and fitness,abdominal fat and glucose metabolism,Fasting serum glucose and insulin,baroreflex sensitivity (BRS) and heart rate variability (HRV,visceral abdominal fat,physical fitness,glycemic control,subcutaneous AT, visceral AT, and muscle density,glycaemic control and lowers fasting insulin levels,Improved glucose disposal,Fat mass (FM,fasting glucose and insulin,Increased insulin response,responses of plasma insulin and C-peptide to oral glucose,cardiovascular risk factors: physical fitness, systolic blood pressure, plasma triglycerides, and glycemic control,VO(2max,beta-cell responses,glycaemic control,VO2max,lipids, glucose, insulin, glycosylated hemoglobin and cardiovascular fitness,visceral adipose tissue (VAT,2 hour plasma glucose in oral glucose tolerance test,self-monitored glucose levels,insulin sensitivity and Hb A(1c) levels,change in self-monitored glucose levels and insulin area under the curve,Body weight, total and HDL cholesterol, glucose, and insulin,mean fall in fasting plasma glucose,resting heart rate,2-h glucose and insulin,glycemic control and body composition,Triglycerides,fasting glucose, insulin, serum lipids and lipoproteins, or resting blood pressure,glycosylated hemoglobin A1 fell,VO(2max), standard time and frequency domain measures of HRV during 24-h recording, and BRS,functional capacity, lean body mass, strength and glycemic control,glucose metabolism,BRS sensitivity,baroreflex sensitivity,beta-cell function,reduced abdominal subcutaneous and visceral AT and increased muscle density,glycemic control, cardiorespiratory fitness, muscular strength and body composition,glucose disposal by hyperinsulinemic-euglycemic clamp and computed tomography scans of abdominal AT and mid-thigh skeletal muscle,insulin resistance,Glucose infusion rates,heart rate,plasma levels of triglycerides, fructosamine and glycohemoglobin,lean body mass (LBM,BRS,exercise capacity and muscle strength and improving glucose control,Glycosylated hemoglobin,waist:hip ratio,Muscular strength,Cardiac index, systemic vascular resistance index, stroke index, and pulse wave velocity,ventilatory threshold,muscle strength, and glycemic control|During the 3 mo of sedentary lifestyle, insulin and C-peptide responses to the clamp procedures were unchanged in both moderate and low secretors.
not found|patency rate,Overt bleeding,average size of the thrombi,Complete lysis,clot lysis,short- and long-term efficacy,mean change in venographic score,symptoms of the postphlebitic syndrome,major bleeding complications,risk of bleeding,Significant thrombolysis,venographic severity,deep venous insufficiency,clinical symptoms of post-thrombotic syndrome,number of closed vein segments and the occurrence of postthrombotic syndrome,level of serum glutamic oxaloacetic transaminase,Segmental valve preservation,degree of thrombosis, evaluated phlebographically,Minor bleeding and slight rise in temperature,lysis rate,pulmonary emboli,blood transfusions,efficacy and safety,major bleeding and pulmonary emboli,initial thrombi,major bleeding,plasma fibrinogen concentration,No lysis,nonfatal intracranial hemorrhage,rates of complete recanalization,Venous reflux,deep vein thrombosis,serious post-thrombotic changes,Clot lysis and deep venous reflux,Postthrombotic syndrome,number of closed vein segments,peripheral edema,Signs or symptoms of venous insufficiency|We found no superiority in the regimen consisting of urokinase preceding heparin infusion, compared with that of heparin infusion alone.
150|Deep vein thrombosis,deep venous thromboses,incidence of a venous thromboembolic event,pulmonary embolism and venous thrombosis,thromboembolic incidence,postoperative thromboembolic complications,frequency of deep-vein thrombosis,safe; operative blood loss,Deep venous thrombosis (DVT,overall incidence of DVT,frequency of postoperative deep-vein thrombosis,frequency of deep vein thrombosis, in blood loss or bleeding complications,deep venous thrombosis,postoperative swelling,Calf and thigh circumferences,venographycally proven deep vein thrombosis (DVT,Distal and proximal thrombosis,major hemorrhagic complication,DVT,wound hematoma or infection rate,haemorrhagic complications and blood loss indices,Bleeding and transfusions,fatal pulmonary embolism,pulmonary embolism and/or deep vein thrombosis,protection against postoperative deep vein thrombosis,mean blood transfusions,deep-vein thrombosis,Efficacy and safety,efficacy or safety,occurrence of DVTs,incidence of P. E,pulmonary embolism,bilateral thrombosis,deep-vein thrombosis and swelling,incidence of DVT,overall frequency of venous thrombosis,deep vein thromboses,frequency of thrombosis,venous thromboembolism,efficacy and safety,thromboembolic event,overall frequency of thrombosis,Pulmonary embolism,haemorrhagic complications,bleeding or other complications,thromboembolic disease,incidence of wound complications,Doppler ultrasonography,thromboembolic event incidence,deep venous thrombosis (DVT,absence of propagation or tail formation,incidence of pulmonary embolism,incidence of thromboembolism,antithrombotic efficacy,frequency of major thrombosis,deep vein thrombosis,Postoperative haemorrhagic complications,thromboembolic events,incidence of observed bleeding complications,incidence of proximal deep-vein thrombosis,bleeding complications or transfusion requirements,rate of venous thrombosis,frequency of pulmonary perfusion defects,Mortality,thigh DVTs|There was significantly less D. V. T. in the heparinized group than in the control group (p < 0.01) and the incidence of P. E. was smaller in the heparinized group, 0 and 4 per cent respectively.
not found|physical examination, PSA assay and compilation of IPSS, IIEF-5 and EORTC-QLQ-C30/PR25 questionnaires,longer lasting rate of urinary irritative disorders and better erective function,functional outcomes,quality of life aspects,5-year biochemical disease-free survival rates|With regards to oncological outcomes, similar 5-year biochemical disease-free survival rates were reported for RRP (91.0%) or BT (91.7%).
not found|annual incidence of erroneous extraction,incidence of erroneous extraction,annual incidence rates of erroneous extraction,incidence of wrong-site tooth extraction,Cognitive failure|There was a significant difference in the incidence of erroneous extraction between the preintervention and intervention periods (P<.01).
not found|patency rate,patency rates,secondary patency rates,no perioperative (30 day) limb loss or death,secondary patency,preoperative risk factors and operative and postoperative treatment,mortality, primary assisted patency and secondary patency,Primary patency rate, measured with Kaplan-Meier survival analysis,previous cerebro-vascular events,Cumulative patency rates,primary patency rate,ankle-brachial pressures or imaging in case of doubt,Major limb amputation,secondary patency or limb salvage,3-year secondary patency,primary patency,primary 3-year patency for Dacron grafts,Overall secondary patency rates,PTFE failure,history of myocardial infarction,limb salvage rate,distal gangrene,PTFE patency rate,patency rates for Dacron and PTFE,Primary patency rates for HUV,bypass graft patency and limb salvage,cumulative 5-year patency rate,Limb salvage rate,Secondary patency rate for HBD,Graft occlusions,prosthetic patency,5-year patency rate,limb salvage,cumulative 3-year patency rate,30-days mortality and complications (wound infections,died with patent grafts,cumulative primary patency rates,median postoperative ankle-arm blood pressure index,long-term graft performance,hospital mortality,number of patent crural vessels,rest pain, ulceration, or gangrene,primary "assisted" patency rate,mortality rates,incidence of major limb amputation,major amputation,number of patent crural arteries,overall cumulative limb salvage|Miller cuffs had no effect on patency rates for femoral to above-knee popliteal bypasses at 5 years and did not improve limb salvage in either group.
43|cell degeneration (p<0.001), necrosis (p<0.01) and the expression of nm23 (p<0.001,R0 resection rate,Five-year survival,curative resection rate, disease-free survival, and OS,stomach tumor localization,palliative or radical resection,overall survival (OS,lymphatic spread,number of tumour emboli,survival rate,Disease-free survival, relapse pattern,Gastric cancer,overall survival, tumour response, toxic effects, patterns of failure, and quality of life,disease-free survival,5-year survival rate,survival, response, and patterns of failure of trimodality therapy,expression rates of Fas and FasL,progression-free survival nor overall survival,intensity of CD44 expression,Complete or partial response,apoptotic index (AI,positive lymph nodes,type of resection (R0, R1, R2, or no resection,lymph node metastases,PCNA index (PI,OS,numbers of deaths,ECF-related adverse effects,Survival,year survival rate,Median survival,resectability and survival,3-year survival rates,complete resections with clear margins,progression-free or overall survival,Rates of postoperative complications,median survival rates,invasion depth,patient mean age, gender, white blood cell count, haematoglobin (HB),thromboplastin, perioperative complication incidence, radical or palliation resection, invasion depth (T), lymphonode involvement (N),metastasis (M) and TNM staging,postoperative 5-year survival rate,survival,median survival since randomisation,Resectability rates,frequency of Fas expression,Fas/FasL,PD-ECGF and PCNA,expression rate of FasL,overall survival,Postoperative complications,median survival,curative resection rate,UICC stages,Expressions of nm23 and CD44,Grade 3 to 4 toxicity,survival benefit,International Union Against Cancer R0 resection rate,expression rate of PD-ECGF,progression-free and overall survival,alive and free of disease,tolerated,disease-free and overall survival,progression-free survival,postoperative morbidity,5-year survival|Survival at 3 years was 16% in arm I and 30% in arm II (P = .15).
not found|Trichomonas vaginalis vaginal infection,delivery before 37 weeks of gestation,Delivery,birth weights and gestational age at delivery,preterm delivery resulting from spontaneous preterm labor|The birth weights and gestational age at delivery were similar in all three groups.
812|Transition Dyspnea Index,health status,lung function measurements, symptoms and rescue treatment use, the number of exacerbations, patient withdrawals, and disease-specific health status,morning predose FEV(1,frequency of adverse events, bruising, or clinically significant falls in serum cortisol concentration,morning peak expiratory flow rate (PEF); transition dyspnea index; chronic respiratory disease questionnaire; chronic bronchitis symptom questionnaire; exacerbations,incidence of pneumonia,pre-dose forced expiratory volume in 1 second (FEV(1)) and 1-hour post-dose FEV(1,FEV1,incidence of individual non-fatal serious adverse events,number of exacerbations resulting in hospitalization,2-h postdose FEV(1,prolonged time to first exacerbation,Dyspnoea (measured using the Breathlessness Diary) and health-related quality-of-life (HR-QOL) scores (based on the St George's Respiratory Questionnaire total score,dyspnea, quality of life, and symptoms of chronic bronchitis,Efficacy and safety,Morning PEF,severity of dyspnea,lung function, symptoms, and health status and reduced use of rescue medication and frequency of exacerbations,lung function and health status,predose FEV(1,efficacy,pretreatment forced expiratory volume in 1s (FEV1,Severe exacerbations and FEV1 (primary variables), peak expiratory flow (PEF), COPD symptoms, health-related quality of life (HRQL), mild exacerbations, use of reliever beta2-agonist and safety variables,efficacy and safety,average daily morning PEF,Dyspnoea scores and HR-QOL,adverse events, serum cortisol concentrations, skin bruising, and electrocardiograms,symptom scores and use of reliever beta2-agonists,tolerated relative,morning predose (ie, trough FEV(1)) for FSC compared with SM and 2-h postdose FEV(1,daily symptoms,mean prebronchodilator forced expiratory volume,Postmedication FEV1 improved by 0.21 L and health-related quality of life using the St George's Respiratory Questionnaire (SGRQ,efficacy and tolerability,pretreatment FEV1,mean number of severe exacerbations,prebronchodilator peak expiratory flow,exacerbations,tolerated,lung function,morning lung function,2-hour postdose FEV(1,adverse effects,efficacy for pulmonary function|Morning PEF improved significantly on day 1 versus placebo and budesonide; after 1 week, morning PEF was improved versus placebo, budesonide and formoterol.
15|geometric mean titer of antibodies,Safety, tolerability, and immunogenicity,incidence rates,cumulative attack rate for hepatitis A,attack rates,Anti-HAV seroconversion,safety, tolerability, and immunogenicity,Symptomatic infection,RIA seropositivity in iHAV vaccines,detectable ELISA anti-HAV antibodies,attack rate,quantitative anti-HAV response,anti-HAV seroconversion|Administration of a booster dose given 1 or 2 months after primary immunization did not significantly improve the quantitative anti-HAV response at 6 months as compared to the effect of the primary dose.(ABSTRACT TRUNCATED AT 250 WORDS)
not found|diabetes care processes,generic prescribing,influenza and pneumococcal immunisation rates,mean number of tests per physician,health care provider behavior,cost of tests per patient ordered,AMI care,proportion of elderly survivors of AMI,number of requests,Antibiotic prescribing,rates of three screening behaviors (cholesterol, blood pressure, and cervical screening,fractional prescribing rates for proton-pump inhibitors,adjusted prescription rates,patient care processes (lab work, nursing, dietary management, ventilator management, ventilator weaning,rates of BMD testing,asthma steps,Practice facsimile (fax) referrals,malaria and diarrhoea,inappropriate prescribing according to the Medication Appropriateness Index (MAI,pneumococcal vaccination rates,rates of GIOP management,mean systolic pressure,Prescribing rates,Mammography rates,rates of foot examination and eye examination,mean overall physical examination rating,time on dialysis,systolic blood pressure,cost-effectiveness ratio,glycemic control,overall intern-documented cholesterol management,objective assessment of attacks,mean center URR,rate of antibiotic prescribing for all indications, for URTI and prescribing of select antibiotics for tonsillitis/streptococcal pharyngitis,mean proportion,guideline adherence and resource utilization,Counseling rates,safety or quality of diabetes care,total length of stay and ICU length of stay fell,overall cost,antibiotic prescribing,risk factors (blood pressure, cholesterol, and smoking status); prescribing of hypotensive agents, lipid lowering drugs, and antiplatelet drugs; blood pressure, serum cholesterol level, and plasma cotinine levels,immunization level,Mammography, breast exam, colorectal screening, and Pap testing compliance rates,vaccination rates,inappropriate transfusions,number of tests per patient ordered,glycemic, lipid and blood pressure control,mean percentage reduction,rates of BMD testing and osteoporosis medication prescribing,hemoglobin A1c, low density lipoprotein-cholesterol and systolic blood pressure,blood cholesterol levels,Median weighted rates of generic prescribing,quality of cervical smears,Delayed feedback of physician performance,quality,percentage of records containing at least one periodontal diagnostic notation,quality indicators,angina pectoris,Overall attitudes of Dutch and Norwegian doctors,Information-giving and communication skills,number of consultations involving AIDS prevention and the number of talks about AIDS initiated by the GP, and some elements of the content were registered on a chart,influenza and pneumococcal vaccination rates,Rationality,mean number of encounters with an inappropriate antibiotic with respect to diagnosis, doses and/ or duration of therapy,acute ischemic stroke care quality,preventive cardiovascular care,urinary tract infection,A1C values,acetylsalicylic acid,bone mineral density (BMD) testing and osteoporosis medication prescribing,quality or safety of diabetes care and worsened A1C control,Guideline adherence,Care quality,number of radiograph requests,test usage and cost savings,mean 30-day AMI mortality rates,Task performance,influenza vaccination,quality of selective case finding and quality of diagnostic procedures,composite AMI and CHF indicators based on 12 AMI and 6 CHF process-of-care indicators,Compliance rates,physician performance,quality of care,prescribing preferences,communication skills,transfusion appropriateness,individual process-of-care indicators, a hospital report card impact survey, and all-cause AMI and CHF mortality,Diagnostic performance,rate of adherence,systolic blood pressure (sBP) and LDL cholesterol,rates of preventive services,acute myocardial infarction (AMI) care,percentage of smears lacking endocervical cells,CHF quality indicators,performance of clinical breast examination,rates of skin cancer prevention counseling,special blood chemistry,glucose control, cholesterol level, and triglyceride level,hemoglobin A(1c) level,Behavior changes,number of patients with hemoglobin A(1c,pneumococcal immunization,number of targeted tests requested by primary-care practices,Patient satisfaction scores,tonsillitis/streptococcal pharyngitis,quantity of cholesterol testing,serum cholesterol and triglycerides,prescription rate,overall chlamydia testing (odds ratio (OR),influenza immunization,Odds ratios (ORs,blood pressure control,tetanus immunization,prescribing behaviour,proportion of long-acting benzodiazepine prescriptions,malaria, diarrhoea and pneumonia,acute, in-hospital, or discharge care,prescription rate recordings,time in total compliance scores,per cent of time,End-stage renal disease (ESRD,clinical and histologic diagnosis, and excisions of skin lesions,mean total number of inappropriate tests,physician compliance,patient care processes, patient morbidity and mortality outcomes, and resource use,fecal occult blood testing, pneumococcal vaccination,overall antibiotic prescribing,cervical cytology history,initial blood pressure,compliance rates,physician documentation and knowledge of child sexual abuse,cost-effectiveness,Immunization rates,intern documentation concerning a low-fat hospital diet, cholesterol history, screening blood cholesterol level assessment,effectiveness and cost-effectiveness,Referral and completion rates,total preventive health, diabetes, hypertension, and total disease management,cholesterol screening,health care quality,Mean blood pressure,hospital mortality rates for CHF,quality of osteoporosis care,Delivery of individual emergency plans,HbA1C testing rates,red blood cell (RBC) transfusions,proportions of patients dialyzed with prescribed blood flow,QIs measuring falls, behavioral symptoms, little or no activity, and pressure ulcers,SMA-6s,Median prescribing rates,Physician questionnaires,Mean scores per CEP dimension,mammography utilization,clinical breast examination,telephone referrals,technical quality of data,LDL,risky prescribing events,compliance with other recommendations, patient satisfaction and costs of the implementation strategy (secondary outcomes,clinical data and receipt of complete blood count (CBC), creatinine testing, and cytoprotective agents (process measures,ordering of laboratory and radiologic tests,cost of unnecessary tests,response to an asthma symptom questionnaire or the Seattle Angina Questionnaire, and levels of patient satisfaction,adjusted mortality,compliance,low hemoglobin levels,lumbar decompressions,cumulative PPV claims coverage,antibiotic prescription rate and 2) the fraction of prescriptions for narrow-spectrum antibiotics,prescribing preference for thiazides,emergency visits,frequency of consultations involving AIDS prevention,lower costs for carotid endarterectomies,total cholesterol,LDL cholesterol test ordering,Time to next visit,risk of falls and fractures, motor vehicle accidents and cognitive impairment,continuity and medical care,RBC transfusions,A1C test ordering,Glycosylated hemoglobin (HbA1C) measurements,charges, SMA-6, or complete blood cell counts (CBCs,accurate classification of hazardous or harmful alcohol drinkers,blood pressure screening,diabetes outcomes,LDL cholesterol values,mean total number of tests ordered by physicians,prescribing of lipid lowering drugs,mean charge for a prescription,osteoporosis medication prescribing,quality of cardiac care,provision of preventive care,meeting patient preferences, metabolic status, and complication rates,hemoglobin A1c testing,efficacy of QCs,proportion of episodes with antibiotics,Medication appropriateness,SMA-12s,quality assurance intervention, quality of performance,Moderate rates of improvement,upper abdominal complaints,LDL testing,peritoneal dialysis,time spent in target INR range,requests for spinal examinations,Minimum Data Set (MDS,total prescribing charges,genital tract infection,Overall compliance,costs per practice,Kruskal-Wallis test, Mann Whitney test, Wilcoxon test and Chi-square test,attainment of American Diabetes Association goals,post-intervention chlamydia testing rates,unscheduled emergency visits,Postintervention immunization levels,overall glycemic control,duration of pain, prior history of low back pain, and number of visits,beta-blockade,BMD testing or osteoporosis medication prescribing,guideline-consistent behavior,total tests,eye examination,Duration of hospital stay,proportion with peak flow,missed immunization opportunity rates and appointment failure rates,G1 average treatment cost,clinical outcomes of mortality or nosocomial events,sustained control of hypertension,Request numbers,SBP,WA-MRSA rates,reduced emergency visits,recording of peak flow,diastolic pressure,quality of management of oral anticoagulation,risk factors,hypertension, peptic ulcer/dyspepsia and depression,compliance rates with evidence-based recommendations pertaining to discussion of body weight control, discussion of problems with medication, blood pressure measurement, foot examination, eye examination, initiating anti-diabetic medication or increasing the dosage in cases of uncontrolled blood glucose, and scheduling a follow-up appointment,final HbA1c (A1C) with feedback + reminders,cotinine levels,Actual performance of audits improved ordering of mammography,Rates of delivery of selected preventive services,statin prescribing,Blood pressure data,rates of influenza immunization,internal QI,Mammography,median prescription cost,provider behavior and lowered HbA1c levels,cholesterol management,venous thromboembolism,facility-specific mean urea reduction ratio (URR,total charges,hypertension,NSAID-related safety practices,lumbar spine,antibiotic resistance,IMA intervention sites,low-density lipoprotein (LDL) cholesterol level, blood pressure, annual hemoglobin A(1c) testing, annual LDL screening, annual eye exam, annual foot exam, and annual renal assessment,asthma education and peak flow meter usage,mean total number of requested tests per 6 months per physician,length of in-hospital stay, physician visits after discharge, waiting times for invasive cardiac procedures, and readmissions for cardiac complications,total number of encounters with antibiotics,chlamydia screening,physician's median antibiotic cost and proportion of episodes of care in which a prespecified first-line antibiotic was used first,diabetic population,proportion of oral corticosteroid use for exacerbation treatment,overall cesarean section rate,glycated hemoglobin (HbA1c) levels,adequate surgical excision of skin lesions,mean change in MAI and number of medications,mortality rates,Hemoglobin A1c and lipid monitoring, and the achievement of intermediate clinical outcomes (hemoglobin A1c <7.0%, LDL cholesterol <100 mg/dL, and blood pressure,number of inappropriate prescriptions,practice performance,total number of requests per practice,diagnoses of hypertension,quality of documentation and physician knowledge,quality of rural ICU care,rates of practice specific PPV coverage,performance scores,change in fraction of asthmatics treated with inhaled steroids and incidence rate of treatment with inhaled steroids,post-intervention 'out-of-control' episodes,hospital ventilator days,Quality circles (QCs,CBCs,baseline performance,vaginal birth rates|Centralized mailings of guideline summaries, performance feedback reports, and chart reminders had no observable impact on quality of care in this setting.
92|mean time to defervescence,serum creatinine level,Drug-related clinical adverse events,Bacteremia,circulatory compromise and renal cortical scintigraphic defects,urinary tract infection (acute pyelonephritis or cystitis,reduction in inflammatory indices, and percentage with sterile urine,recurrence of urinary infection,Renal scarring,Eradication rates,health care expenditure,no relapse,trough level,Nephrotoxicity,Clinical and bacteriological response rates,upper urinary tract infection,percentage of patients with sequelae,Trough serum levels,Mean peak gentamicin concentrations,Mean costs,history of recurrences,prevalence of scarring,urine culture,Ototoxicity,safety and efficacy,severity of the urinary tract infection (risk of renal scars,Mean trough concentrations,Median gentamicin treatment durations,radiological abnormality,frequency of side effects,nephro- or ototoxicity,development of renal scarring,bacteriologic eradication,Rates of efficacy by severity, presence or absence of underlying and/or complication diseases, daily dose and causative microorganisms,therapeutic effect and usefulness evaluated by physicians in charge,Total or partial persistence of renal abnormalities,successful eradication,Peak serum levels,persistent infection, and 6 infection relapses,satisfactory clinical response,recurrence rate of first lower UTI,efficacy and safety,Rates of cures and recurrence,recurrence rate,overall cure rate,duration of hospitalization,GOT and 1 with increased GPT,bacteriological efficacy (sterilization of the urine), and biological efficacy,resolution of vomiting, fever, general appearance, abdominal tenderness, and hydration state (P>.05,white blood cell count and erythrocyte sedimentation rate,rate of renal scarring,rate of recurrent infection,Therapeutic effectiveness rates,bacteriologic efficacy,urinary tract infections,blood cell count, and erythrocyte sedimentation rate (P>.05,Peak serum netilmicin concentrations,Bacteriologic eradication,Late DMSA,rate of reinfection,urine sterilization rate, degree of clinical improvement, or subsequent hospital admission rate,renal scarring,Clinical efficacy,GPT,bacteriologic failures,mean extent of scarring,efficacy and tolerance,serious adverse effects,time-courses of improvement of clinical signs and symptoms,suppression upon rectal,symptomatic reinfections|In group B, the percentage of patients with sequelae was significantly higher (P<0.01) when the delay was more than 1 week.
not found|intraventricular haemorrhage rate,clinical characteristics,apnoeas and respiratory acidosis requiring rescue nasal CPAP,ventilator rate of 6/minute,severe apnea, or predefined clinical deterioration, and extubation success,birth weight and duration of intubation,stable condition, fraction of inspired oxygen (FIO2) of < or = 35%, peak inspiratory pressure (PIP,oxygen dependency,successfully extubated to NCPAP,oxygen requirement greater,Extubation failure,pulmonary status, fraction of inspired oxygen (FIO2,total number of days of assisted ventilation or the duration of inpatient stay,respiratory acidosis,Failures,severe apnea and/or respiratory failure,Overall, nasal CPAP,alveolar-arterial oxygen gradient,FiO2, PaO2, and respiratory rates,failure rate of extubation,likelihood of extubation failure,total number of days of ventilation,rates of successful extubation,mean respiratory rate,Postextubation nasal continuous positive airway pressure,failure rates,individual successful extubation rate of post-extubation,PaCO2 values,overall success rate of early extubation,failure rate,respiratory distress syndrome,oxygen requirements|There was no significant difference between the groups in the total number of days of assisted ventilation or the duration of inpatient stay.
not found|gestational age, birth weight, delivery mode, sex distribution, and Apgar scores,transcutaneous PO2,bradycardia,proportion of infants with recurrent hypoxaemic episodes,Transcutaneous oxygen tension (tcPO2) and heart rate,mean proportion of infants with more than six hypoxaemic episodes,mean serum concentration,death or disability,Odds ratios,hypoxaemic episodes,neurodevelopmental benefits|The size and direction of the caffeine effect on death or disability differed depending on PPV at randomization (P = .03).
260|frequency of pregnancy-induced hypertension, preeclampsia and preterm birth,systolic and diastolic blood pressure,serum ionized calcium levels,preterm birth,diastolic and systolic blood pressure,preeclampsia, pregnancy-associated hypertension, or adverse perinatal outcomes,Blood pressure (BP,low birth weight,pregnancy induced hypertension,hypertensive disorders,pregnancy-induced hypertension,incidence of preeclampsia,Dietary calcium intake,diagnosis of preeclampsia,incidence of preterm delivery,systolic BP,hypertensive disorders of pregnancy (gestational hypertension and preeclampsia,Eclampsia,duration of pregnancy,Compliance,average daily calcium intake,risk of hypertension and preeclampsia,neonatal mortality rate,reduction of pre-eclampsia,risk of pregnancy-induced hypertension,hypertensive disorders of pregnancy,frequency of pregnancy-induced hypertension,Urinary excretion of calcium and creatinine,rates of hypertensive disorders of pregnancy,occurrence of pre-eclamsia,Preeclampsia,incidence of gestational hypertension,mean duration of calcium supplementation,mean systolic and diastolic blood pressures,numbers of preterm deliveries, small-for-gestational-age births, or fetal and neonatal deaths,risk of preeclampsia,incidence or severity of preeclampsia or delay its onset,mean systolic and diastolic BP value,rate of pregnancy induced hypertension,early preterm delivery,low ratios of urinary calcium to urinary creatinine,incidence of pregnancy induced hypertension,hypertension,calcium intake and BP reduction,systolic/diastolic blood pressure,preeclampsia and preterm delivery; secondary outcomes focused on severe morbidity and maternal and neonatal mortality rates,risk of preterm birth,risk of both gestational hypertension and preeclampsia,blood pressure and urinary protein excretion,Pre-eclampsia,urinary tract infection, and chlamydial infection,spontaneous labor and preterm delivery,blood pressure,severity, maternal morbidity, and neonatal mortality,initial blood pressure (BP,preeclampsia,severe preeclamptic complications index,incidence of pregnancy-induced hypertension,prevalence of pregnancy-associated hypertension without preeclampsia,risk of preeclampsia and preterm birth,severe maternal morbidity and mortality index,severe gestational hypertension|Calcium supplementation was associated with a significantly decreased risk of preeclampsia (risk reduction 12.35%; P < .001), with 3.2% (n = 4) developing preeclampsia in the treatment group versus 15.5% (n = 21) in the placebo group.
105|success rate|The effect of ZBD is superior to that of progesterone in treating women of early threatened abortion with dark area surrounding pregnancy sac.
not found|bronchoconstriction,FENO measurements,exercise-induced bronchoconstriction,FENO,Serum caffeine levels,serum levels of caffeine and theophylline, forced expired volume and flow, specific airway conductance (Gaw/VL), vital signs, and reported symptoms,caffeine consumption increases or decreases FENO,forced expiratory flow,baseline FEV1 and prevented exercise-induced bronchoconstriction,peak theophylline level,airway reactivity,Gaw/VL,Exhaled nitric oxide (FENO) measurements,reduction in bronchoconstriction,pulmonary function,histamine responsiveness,tolerated,exhaled nitric oxide measurements,average peak serum concentration,Peak caffeine concentration,serum caffeine concentrations,bronchoconstrictor response|Caffeine (10 mg/kg) significantly reduced bronchoconstriction compared to placebo (p = 0.02).
112|memory function (AVLT short term recall,Sandoz Clinical Assessment Geriatric Scale (SCAG) and Mini-Mental State Examination (MMSE) scores,Global improvement (CGI item 2,WAIS-R Digit Symbol subtest,efficacy and safety,P300 latency,Mini-Mental State and the SCAG score,delta and theta, increase in alpha 2 and beta activity and an acceleration of the centroid of the total power spectrum,MMSE scores (ITT and VC,Tolerance of nicergoline,Benton Visual Retention Test, P = 0.002) and attention and concentration (Letter Cancellation Test,therapeutic efficacy and safety,delayed recall of the Auditory Verbal Learning Test (AVLT,mean total SCAG score,Rezek score,nine neuropsychological tests exploring memory, concentration, verbal and motor performances,Clinical Global Impression, 3 subtests of the Weschsler Adult Intelligence Scale and Blessed A scale for activities of daily living, and all endpoints in 2-month intervals,adverse events|EEG mapping demonstrated in NIC-treated SDAT and MID patients a significant decrease in delta and theta, increase in alpha 2 and beta activity and an acceleration of the centroid of the total power spectrum as compared with pretreatment, while opposite changes occurred in PLAC-treated SDAT and MID patients.
80|survival rates,1-month mortality rates,Complications of cirrhosis and worsening of the performance status test,Survival curves,1-year survival rate,median survival times,probability of disease progression,baseline performance status maintenance,Response,Median survival,Cumulative survival,survival,progression of hepatocellular carcinoma,median survival,survival outcome,baseline performance status, and tumor stage,tolerated,complete remission,risk of death,tolerated and no marked side effects,Adverse drug reactions|The 1-year survival rate was similar in both groups (30% in group 1 vs 37.8% in group 2; p = 0.31).
76|nasogastric decompression,time to first passage of flatus, the time to first passage of stool, the time elapsed postoperative stay, and postoperative complications such as anastomotic leakage, acute dilation of stomach, wound infection and dehiscense, fever, pulmonary infection and pharyngolaryngitis,morbidity and delayed return of gastrointestinal function,tolerance of NGT withdrawal and postoperative complications,rate of abdominal distention, nausea, and vomiting,length of the first passage of gas by anus and defecation,first passage of stool,median and average days to the first passage of flatus,morbidity and mortality and hospital stay,risk of pulmonary complications,Abdominal distention,feasibility, safety, and tolerance,subjective complaints, eg, ear pain, painful swallowing, and nasal soreness,postoperative complications,reinsertion rate,Major complications, eg, pneumonia, atelectasis, gastrointestinal bleeding, and wound breakdown or infection,time until the first bowel movement,Complications,mean time of gas passage, defecation, BS auscultation, and the duration of postoperative hospitalization,postoperative abdominal distention and vomiting,aspiration pneumonia, gastric dilatation, or wound dehiscence,occurrence of nausea and vomiting,Duration of postoperative stay,rates of major postoperative complications,fever,nasogastric intubation,hospital mortality,feasibility, safety, and tolerance of early feeding,overall postoperative mortality,vomiting or abdominal distention,incidence of vomiting and nasogastric tube insertion,presence of atelectasis, postoperative fever, wound infections and anastomotic leaks,earlier bowel sounds, return of flatus, oral intake and first bowel movement,volume of gastric juice,adverse events,pulmonary complications,febrile morbidity,medical morbidity,pain with and frequency of swallowing, and nose/throat discomfort,occurrence of respiratory complications,longer times to first passage of flatus and tolerance of a clear liquid diet,nasogastric reintubation,length of hospitalization,overall surgical complications,Preoperative risk factors, aortic cross-clamp time, estimated blood loss, length of procedure, length of intensive care unit stay, numbers of days with nasogastric tube, number of days until clear liquid and regular diets commenced, and the length of hospital stay,Overall failure rate,prolonged operating times, or difficult endotracheal intubation,pain, abdominal distention, and vomiting,emesis,sore throat,intensive care unit stay,nausea and vomiting,postoperative nasogastric decompression,incidence of pharyngolaryngitis,postoperative complications such as anastomotic leakage,nasogastric output,tolerated,duration of hospitalization, time to begin peroral fluid intake, occurrence of hiccups, vomiting, nausea, parotiditis, nasal septum necrosis, anastomotic leak and wound dehiscence,overall incidence of complications,pneumonias,frequencies of postoperative complications,premature removal of the tube,mean length of hospitalization,history of upper gastrointestinal bleeding and pyloric obstruction,Severe discomfort,Postoperative loss of fluid,gastrointestinal tract pressure,Overall failure,Injury severity score, morbidity, and lab values,gas passage, defecation and bowel sounds (BSs) auscultation, as well as the duration of postoperative hospitalization, nausea and vomiting, abdominal distension, pulmonary complications, wound complications, anastomosis leak, and the need for placing/replacing the NG tube,decompression,Time to pass flatus,average daily nasogastric output,postoperative mortality or morbidity, especially fistula or intra-abdominal sepsis,Passage of flatus,wound complications,shorter postoperative stay,Clinical therapeutic outcome and incidence of complication,longer time until passage of flatus, bowel movement, and cessation of intravenous fluids,Pneumonia,time to tolerance of a regular diet and hospital stay,Morbidity, mortality, and speed of recovery,severe discomfort,abdominal distension, pyrosis, otalgia, dysphagia, odynophagia and atelectasis,Postoperative fever,postoperative pain, or postoperative abdominal distention,feasibility and safety,risk of respiratory complications and the length of hospital stay,duration and severity of postoperative paralysis,Postoperative course, morbidity, and mortality,Postoperative abdominal distention,incidence rate of fever, pharyngolaryngitis and pulmonary infection,Duration of postoperative perfusion,acute dilation of stomach,subsequent insertion of a nasogastric tube,postoperative fever, nausea, vomiting, anastomotic leaks, or pulmonary or wound complications,Gastrointestinal decompression,nausea, vomiting, time to first passage of flatus and stool, time elapsed before adequate tolerance of a regular diet, postoperative stay, and complications,occurrence and duration of nausea and vomiting, postoperative peroral fluid intake and time for defecation,incidence of postoperative complications,Hindered deglutition and nasal soreness,earlier passage of flatus and feces and the lower incidence of postoperative gastrectasy,atelectasis,Time to passage of first flatus, time to taking liquid diet, length of operation, and postoperative hospital stay,Anastomotic disruption,incidence of incisional hernia,nausea,incidence of complications,postoperative complications, mortality, and postoperative course,length of hospital stay,hematological indices and electrolytes,length of hospital stay, duration of postoperative ileus, adequacy of intraoperative intestinal decompression, gastric dilatation, and operative complications,pulmonary infection,vomiting,rate of reinsertion of nasogastric tube and morbidity,postoperative length of hospital stay,return of bowel function, return to a regular diet, and postoperative length of hospital stay,incidence of mortality, complications (including vomiting) or time to return of intestinal motility,Mechanisms of injury, Injury Severity Score, operative findings, NGT removal times, morbidity, laboratory data, and reasons for failure,mean+/-SD time to passage of flatus,incidence of abdominal distention or nausea and vomiting,Length of hospital stay,postoperative ileus,nausea postoperatively,incidence of anastomosis leak,length of postoperative stay,incidence of vomiting,duration of ileus,recurrent nausea and vomiting,subsequent nasogastric decompression,pharyngolaryngitis,incidence of nasogastric tube insertion,abdominal distention, nausea, and vomiting,start of oral intake,Rates of nausea and vomiting,occurrence of postoperative nausea, vomiting, abdominal distension, complications and day of clinical release,hospital stay,operative times,rate of minor symptoms of nausea, vomiting, and abdominal distention,Gastrointestinal function, postoperative course, and complications,incisional hernias,incidence of vomiting or the duration of intubation,rates of anastomotic leak,nasopharyngeal or gastric bleeding, inability to cough effectively, respiratory infections, wound disruptions, reoperation, and wound infection rates|The return of bowel function, return to a regular diet, and postoperative length of hospital stay were similar in both groups.
400|rate of symptomatic hemorrhage,distribution of outcomes at 3 months after stroke using the modified Rankin Scale (mRS) based on an ordinal regression model of outcomes, adjusting for baseline severity of stroke, age, and interval from stroke,mRS scores,higher rate of minimal residual disability,bleeding complications,Asymptomatic hemorrhagic transformation,major intracranial hemorrhage,Asymptomatic parenchymal hemorrhages,Symptomatic intracranial hemorrhage,asymptomatic hemorrhagic lesions|Symptomatic intracranial hemorrhage within 5 days was diagnosed in 7 of 195 (3.6%) patients treated with abciximab and 2 of 199 (1%) patients given placebo (odds ratio [OR], 3.7; P=0.09; 95% confidence interval [CI], 0.7 to 25.9).
69|Efficacy, safety, and tolerance,number of "off" hours,state,Activities of Daily Living,adverse events, vital signs, laboratory measurements, and ECG recordings,wearing off and symptom severity,safety data,bradykinesia,side effects (orthostatic hypotension, exogenous psychotic symptoms,beneficial response,quality of life and activities of daily living,UPDRS part III (motor) scores,efficacy and safety of Zydis selegiline,dizziness, insomnia, nausea, and postural hypotension,fluctuations,Mean UPDRS total score,advanced PD,clinical efficacy and safety,off-periods,Efficacy and safety,Frequency of adverse events,levodopa,subitems motivation/initiative and depression in a subpopulation with increased Unified Parkinson's Disease Rating Scale I scores,quality-of-life measures,home diaries ('on' and 'off' times), Unified Parkinson's Disease Rating Scale (UPDRS) and changes in levodopa dosage, and safety by adverse-event inquiry, vital signs, electro cardiography (ECG) and laboratory tests,ADL scores,Mean hourly overall symptom control,safe and well tolerated,Increased dyskinesias,improvement of "on" and "off" time while awake (Patient Diary and UPDRS part IV Item 39), Investigators' Global Assessment, the SF-36 Health Survey, and changes in levodopa dosages,clinical laboratory test results (blood chemistry, hematology, and urinalysis), vital signs, and electrocardiograms,Adverse events,time,UPDRS motor scores,Motor Examination,mean reduction in daily "off" time,time increased (1.7 h) and 'off' time,number of daily levodopa intakes,total score of the unified Parkinson's disease rating scale (UPDRS,unified Parkinson's disease rating scale motor and total scores,objective quality of the "on" state,Efficacy, safety, and tolerability,Levodopa dosage,therapeutic effectiveness,safety evaluation of adverse events (AEs), vital signs, ECG, and laboratory parameters,Principal adverse events (mainly dyskinesia and nausea,Dyskinesia,Dopaminergic adverse events,CGI scores,mean daily off-time and improves symptoms of Parkinson's disease,both motor and non-motor PD symptoms,safety and tolerability profile,Responder rates,levodopa requirements,safety and tolerability,retirement rate,self-perception of disability progression,change in hours and percent of daily "on" time and "on" time without troublesome dyskinesia, Unified PD Rating Scale motor and activities of daily living subscales, Beck Depression Inventory-II, PDQ-39 subscales of mobility, activities of daily living, emotional well-being, stigma and communication, and PD Sleep Scale,quality of life (sickness impact profile) scores,duration of off periods as assessed by self-scoring diary cards,Adverse reactions,clinical global improvement (CGI) score and unified Parkinson's disease rating scale (UPDRS) scores,dyskinesia,rasagiline efficacy and safety,cardiac or electrocardiographic abnormalities,effective and well tolerated,daily on-time without troublesome dyskinesia,frequency of withdrawals because of adverse events,mean UPDRS total scores,total scores of the UPDRS Part II, Part III, and Parts II and III combined,Employment, medical absenteeism, and disability perception,stride length and angular excursion of the hip and knee joints,efficacy and safety,total "on" time,Total score on the Unified Parkinson's Disease Rating Scale (UPDRS,total number of off hours,adverse reactions,mean daily L-dopa dose,dopaminergic and nondopaminergic adverse events,efficacy and tolerability,rasagiline treatment, including scores on an investigator-rated clinical global impression scale and the Unified Parkinson's Disease Rating Scale (activities of daily living in the off state and motor performance in the "on" state,gastrointestinal and cardiovascular tolerability,UPDRS part II,Safety and tolerability,tolerated,percent "on" time,mean daily levodopa dose,daily off time,nausea, light-headedness, dyskinesias, and hallucinations, all of which abated after the Sinemet dose,employment rate,mean daily levodopa dose requirement,absolute ON time (mean (SD,levodopa/benserazide in walking speed, stride length and the range of motion of hip, knee and ankle joints,severity of "off" periods, decreased disability and PD severity,motor function and overall efficacy,safety, tolerability, and efficacy of rasagiline,mean reduction in L-dopa requirement,motor fluctuations and PD symptoms,daily OFF time,side-effect,UPDRS (activities of daily living; ADL,lower absenteeism rate,number of discontinuations,mean daily off-time,PDQ-39 subscores, the SF-36 variables or the EQ-5D utility score,average number of dyskinesia-free,Unified Parkinson's Disease Rating Scale (UPDRS) parts II and III,reduction in hours of daily "off" time,number of full-time-employed patients at study end, cumulative days of medical absenteeism, patient-completed disability assessments, diary records, and the Unified Parkinson's Disease Rating Scale-based measures of motor fluctuations and dyskinesias,ADL, global function, motor performance and was well tolerated,platelet MAO-B inhibition,motor function,Diarrhea,levodopa requirements, improvement in patients' clinical status, duration of improvements, and tolerability of tolcapone,Mean scores,wearing-off phenomena and frozen gait,toxicity,adverse events, laboratory safety and vital signs,UPDRS total scores, subscores part II, III (activities of daily living and motor examination), and IV (complications of therapy,United Parkinson's Disease Rating Scale motor subscale and "on/off" and dyskinesia assessments,Unified Parkinson Disease Rating Scale,total levodopa requirements,Mean hourly self-assessment of gait,daily levodopa dose,time spent in "off" periods,UPDRS "overall dyskinesia score,overall safety profile,total Parkinson's score, scores of activities of daily living, motor function, number of "off" hours, Hoehn and Yahr stage, and numerous parameters of parkinsonian function including bradykinesia, rigidity, gait, and dexterity,Entacapone efficacy,UPDRS sum scores,activities of daily living, motor function,wearing off,dyskinesia and nausea,proportion of daily ON time,Mean daily Sinemet dosage decreases,mean total daily levodopa dose,safety, tolerability,efficacy, safety,percent awake time spent "off,Global Assessment of Change, PDQ-39 subscores, and the Short-Form (SF)-36 and the European Quality of Life,occurrence of drug-related adverse events,Dryness of mouth, urine discoloration and diarrhoea,fatigue, dyskinesia, and vivid dreams,five-dimension questionnaire (EQ-5D,Efficacy and tolerability,off" time,absolute change in total hours "off" (assessed by home diaries,mean percentage of "Asleep" time,Unified Parkinson's Disease Rating Scale (UPDRS,nausea,UPDRS scores,safety, tolerance, and efficacy,percentage of "on" time (relief of parkinsonism,hepatic enzyme activity, ECG or haemodynamic parameters,total daily off-time (intention-to-treat population,average Hoehn and Yahr stage of disease, and Schwab and England activities of daily living index,nonserious dopaminergic adverse events,dyskinesias,Unified Parkinson's Disease Rating Scale Subscale II,levodopa dosage,side effects,nausea, cramps, dyskinesia, and dystonia,somnolence,Aggravated parkinsonism,Disability,unified Parkinson disease rating scale (UPDRS), and recording of daily levodopa dose,mean adjusted total daily off time,hours "off,total Unified Parkinson's Disease Rating Scale (UPDRS) score,levodopa requirement,UPDRS activities of daily living and motor scores,parkinsonian disability and health-related quality of life (QoL,vital signs, ECG or laboratory results,Dopamine antagonistic actions,activity and tolerability,Bromocriptin dosage,Unified Parkinson's Disease Rating Scale (UPDRS) part II activities of daily living (ADL) and the Parkinson's Disease Questionnaire (PDQ)-39 summary index,total score of the Webster and the NUDS scales,Efficacy,efficacy, Parkinsonian symptoms,adverse effects,dyskinesia, nausea, dizziness, somnolence, hallucinations, and orthostatic hypotension and AEs led to study withdrawal,motor fluctuations|Total score on the Unified Parkinson's Disease Rating Scale (UPDRS) for the intent-to-treat population was significantly improved in the pramipexole-treated group compared with the placebo-treated group (16.9 +/-
60|HbA(1c,fasting plasma glucose (FPG), lipids, body mass index (BMI), body composition, blood pressure, insulin sensitivity estimates using the minimal model, glucose and insulin responses to a meal challenge, quality of life, adverse events, or other safety indices,glycosylated haemoglobin (HbA1c) and fasting blood sugar (FBS), alteration of lipid profile by serum cholesterol, LDL, VLDL, HDL and triglycerides,HbA(1c) reductions,change in HbA(1c,liver enzymes, kidney function tests, hematologic parameters, blood glucose, insulin, and C-peptide assays,mean change, with Inolter, in serum cholesterol,safety and effectiveness,total cholesterol,fasting blood sugar,efficacy and safety,serum triglyceride,glucose control,hypoglycemic effect,liver function tests, hematologic parameters, or the kidney function tests,fasting glucose,levels of fasting and postprandial blood glucose, cholesterol, triglycerides, glycated hemoglobin (Hb A(1C)) and fasting insulin,tolerated,HDL,low-density lipoprotein (LDL) cholesterol,satisfactory and no adverse effects,HbA1c, fasting glucose, lipids, blood pressure, and weight|Cogent db did not alter the liver function tests, hematologic parameters, or the kidney function tests.
not found|adephagia obesity and cerebral infarction,Blood chemistry, liver, kidney, pituitary and endocrinal functions,Blood chemistry, liver, kidney and endocrine functions,hyponatremia,severe complications,index and lactate dehydrogenase (LD) of the cystic fluids, blood and cerebrospinal fluids and the endocrine function|At follow-up, the volumes of the cysts in groups A and B regressed from 92 to 0%, while the drug-free cysts enlarged.
not found|Fatal falls,fatality rate,mean cost per fall,overall injury rates,incidence of occupational injuries,injury rates,rate of falls from height,rate of fatal injury,fatal falls,cost savings,fatal construction falls,rate of decline in falls|The drug-free workplace intervention was associated (p < .05) with a statistically significant decrease in injury rates for three industry groups: construction, manufacturing, and services.
not found|plasma orosomucoid levels,clinically important worsening of Crohn's disease, defined as a 100-point increase in the Crohn's Disease Activity Index,Crohn's Disease Activity Index,serious adverse events,use of prednisone and 5-amino-salicylates, mean score on the Crohn's Disease Activity Index and mean quality-of-life score, and the need for surgery,median time to worsening of disease,Disease activity,mean Crohn's Disease Activity Index and quality-of-life scores,full remission|The condition of more patients worsened with cyclosporine than with placebo (91 of 151, or 60.3 percent, vs. 80 of 154, or 51.9 percent; P = 0.10).
192|Grade 3+ (World Health Organization) acute skin and mucosal reactions,year survival,rate of local and regional control,Overall immediate effectiveness,Gender, haemoglobin drop, tumour site, tumour and nodal stage,median time to loco-regional and distant progression,Overall response rate,Acute mucositis grade,complete remission rate and overall survival,radiotherapy,died of recurrence or regional metastasis,CR + PR rates,G3+ skin, s.c. tissue, and mucosal late side effects (RTOG scale,response (CR + PR) rate,local/regional failure rate,median progression-free survival,3-year disease-free survival,survival rates,locoregional recurrence rates,phlebitis,hospitalized with MTX toxicity, none died of MTX toxicity,activity and toxicity,pathological macroscopic regression,survival and postoperative quality of life,median survival and doubles the probability of survival,survival,LRPFS and DMFS,Complete responses,nausea and vomiting,higher locoregional progression-free survival (LRPFS,5-year LRFS,overall survival and locoregional control rates,Toxicities,excellent survival,toxic deaths,Progression-free and freedom from metastases rates,Overall crude survival,Grade 3 and 4 toxicity rates,toxic effects and lethal reactions,local and regional recurrences,risk of death,Side effects,local efficacy,toxicity and response,disease free survival,local control,Confluent mucositis,relapse-free survival rate,local late mucosal and skin toxicities,Tolerance,5-year survival and late toxicity,locoregional control and overall survival rates,Acute toxicity,rate of radiologic complete response (CR,overall survival, progression free survival, or locoregional control,CR rates,Mucositis and vomiting,disease-free survival (DFS) and overall survival,disease progression,complete lymph node response,response rates,overall survival (from randomisation), and event-free survival (EFS; recurrence, new tumour, or death,patient survival,CR rate,3-year locoregional control rate,tumor-free survival,Rates of residual and recurrent disease,Actuarial 3-year locoregional control rates,Overall response,Leukopenia,Grade 3-4 neutropenia,cumulative incidence of local or regional relapses,incidence of first failure in the neck nodes,2-year actuarial survival rate,disease-free survival,rate of locoregional control of disease,initial tumor clearance rates,median survival time (MST,Confluent mucositis and dry skin desquamation,clinical regression rate (RR,incidence of distant metastasis,superior disease-free survival,Response rate,acute toxicity,rates of secondary localization and distant metastasis,Serious late side effects,voicing and oral intake,corresponding recurrence-free rates and five-year survival rates,l- and 2-year local-regional control (LRC) rates,overall median survival duration,3-year projected overall survival,postoperative quality of life,2-year survival rates,median overall survival,Stage IV, hemoglobin level,Rates of neutropenia and febrile neutropenia,higher distant metastasis-free survival (DMFS,stage IV disease,prognostic factors of short survival and locoregional failure,survival at acceptable toxicity,Voice quality,rate of block dissection of the neck,overall survival, specific disease-free survival, and locoregional control rates,rate of overall survival,mucosal toxicity,recurrence at death,longer survival,disease-free survival rates,Overall chemotherapy response,tumour response rates,alopecia,complete remissions (CR) and four partial remissions (PR,Locoregional control and distant disease-free survival,3-year overall survival rate,overall survival (OS,chemotherapy responses and toxicities, surgical complications, radiotherapy toxicities, patient compliance, survival time, and patterns of treatment failure,Median time to any treatment failure,survival of such patients,response rate to induction chemotherapy for lymph node metastases,efficacy and toxicity,Median disease-free survival,survival advantage,incidence of distant metastases,Overall QOL,Estimated 2-year disease-free and overall survival rates,death,EFS events,poor survival,disease control and survival,Overall survival,occurrence of local toxic effects (i.e., mucositis and epidermatitis,remission rate,survival rate,similar activity (complete response, progression-free and overall survival rates,loco-regional failure or in disease-free or overall survival,5-year overall survival rate,favourable response rate,clinical CR rate,incidence of local recurrences,serious late morbidity,recurrences, new tumours, and deaths,uncontrolled disease and local recurrence,Serious toxicities,Grade 3-4 acute mucositis,overall survival,survival time differences,clinically tumor free,progression-free and overall survival,mucosal and skin toxicity,complete remission rate,Haematological toxicity Grade 3-4,relapse while no relapses,survival curves,acute high grade toxicity,complete response (CR) rates,Severe (grade 3 or higher) adverse effects,overall tumor response rates,safety and efficacy,feasibility and efficacy,Median progression-free survival and overall survival,longer survival time,event-free survival,metastatic rate,radical neck dissections of recidive metastases,disease-free and overall survival,adverse effects,loco-regional tumour control, survival or morbidity,cerebral vascular damage,mean duration response,remaining tumour cells,Total treatment time,loco-regional control,Total clinical healing of the lesion,rates of local and regional control and disease-free survival,Mucosal tolerance,10-year local-regional recurrence-free survival rates in stage IV disease,haematological side effects of MMC,overall survival rate,2-year disease-free survival,overall survival (OS), disease-free survival (DFS), and specific survival (SS,febrile neutropenia and grade 3 or 4 late mucous membrane toxicity,distant metastases,failure-free survival, time to locoregional failure, or quality of life as measured by Functional Assessment of Cancer Therapy-Head and Neck,tolerated, with moderate hematologic and gastrointestinal toxicity,overall survival and locoregional control of stage III or IV oropharynx carcinoma,2-year OS rates,locoregional failure-free rates,survival improvement,Late toxicity,locoregional control rate,overall survival rates,response rates and locoregional control,moderate myelosuppression and renal toxicity,Late high grade toxicity,10-year local-regional recurrence-free survival rates,overall survival and disease-free interval,incidence of acute adverse effects,5-year disease-free actuarial survival rate,year rate of local and regional control,locoregional control,Objective response rate,Toxicity,late reactions and overall rates of secondary neoplasms,tube feeding,severe side effects, affecting mainly digestive tract, and bone marrow,fatal nephrotoxicity, only hematologic G3+ (Grade 3 or higher) acute sequelae,disease-free survival or survival,Severe complications,Disease-free survival,rates of complete and partial responses,granulocytopenia, asthenia and stomatitis,median overall survival and progression free survival,duration of objectives remission,rates of complete tumor resorption,median peak MTX dose,6-year survival rate,Four-year progression-free survival,oropharyngeal carcinoma only: disease-free survival,overall survival improvement,Hematologic and non-hematologic toxic effects,patient refusal or cumulative toxicity,Median time to local recurrence (MTLR) and 5-year local recurrence-free survival (LRFS,hematological toxicity,Severe mucositis (WHO level 5 reactions,incidence of moderate to severe mucositis,10-year disease-free survival rates,acute morbidity,significant long-term toxicity rate,locoregional recurrence,cardiac toxicity,local disease control or actuarial survival rates,Long-term survival rates,acute mucositis, pneumonitis and dermatitis,mucositis, moist desquamation, and erythema,3-and 5-year survival rates,local control and survival,Acute morbidity and deaths,local tumour control and survival,acute skin effects and late mucosal and skin toxicities,Overall duration of mucositis,severe late morbidity,corresponding median EFS,severe hematological toxicity,actuarial overall survival rates,grade 3 to 4 complications,regional lymph node and distant metastasis control,median survival,Myelosuppression,complete remission,leukopenia, thrombopenia, vomiting and nephrotoxicity,5-year Kaplan-Meier estimates of progression-free survival,Progression-free survival,unresectable disease,time to any treatment failure; secondary end points were locoregional failure, metastatic relapse, overall survival, and late toxicity,complete response,relapse-free survival,Grade 3 or worse toxicity,satisfactory efficacy and acceptable toxicity profile,anemia,Severe mucositis,postoperative complications,rates of distant metastasis,failure-free rate,thrombocytopenia, nausea, vomiting, stomatitis, and hearing loss,rate of mutilating surgery,overall 3-year primary locoregional tumour control, disease-specific and overall survival rates,cause-specific survival rate,4-year actuarial survival rate,Favorable outcomes (complete response [CR] plus any grade of toxicity and PR plus grade 0 to 3 toxicity,G3+ acute mucositis,progression-free survival,actuarial DFS,confluent mucositis,complete response rate,septic shock,1-year survival with local control (SLC,peripheral neuropathy,Loco-regional tumour control,rates of death from toxic effects,Mucositis,complete clinical and pathologic response rate,response rate,thrombocytopenia,5-year disease-free actuarial survival rates,2-year survival rate,response and survival rates,tolerated,rate of freedom from recurrence,local control and overall survival,frequency of complete responses,Survival data,occurrence of persistent G3 xerostomia,Five-year recurrence-free rates and disease-free survival,severe mucosal adverse effects,leukopenia and neutropenia,overall long-term survival,quality of life (QOL,overall response rates,Actuarial 3-year overall survival and progression free survival,toxicity,Hematologic high-grade toxicity,mucosal reaction,year failure-free survival rates,3-year survival,hematologic toxicity,incidence of either acute or late high-grade RT-induced toxicity,proportion of patients without relapse,morbidity,1-year SLC,survival and toxicity,survival and recurrence,rate of progression-free survival,Hematologic toxicity,tumor objective response rate,3-year overall survival and of 3-year loco-regional control,5-yr progression-free survival,side effects,Tumour regression,grade 4 cardiac dysfunction,overall incidence of distant metastases,radiation toxicity,hematologic adverse events,Local disease-free and disease-free intervals,locoregional control or survival,5-year survival rates,median survival time,incidence or severity of acute and late radiation side effects,5-yr overall survival,incidence of late adverse effects,acceptable toxicity profiles|At 24 months, the proportion of patients without relapse was 42% for Arm C vs. 23% for Arm A and 20% for Arm B. Patients in Arm A less frequently developed G3+ acute mucositis than their counterparts in Arm B or C (14.7% vs. 40.3% vs. 44%).
16|Basal GH,serum GH|In response to L-dopa and arginine hydrochloride stimulation, serum GH rose to above 7 mg/ml in all patients.
66|Neutropenia and thrombocytopenia,sustained virological response (SVR,predictive values of early virological response (EVR,fibrosis index,CD4 counts,serum HCV RNA level,normal transaminase levels,Drug interactions, toxicity, tolerance and acceptance,EVR,clinical and biological events,serum HCV-RNA,positive predictive value of EVR,Premature interruptions,reversible CD4 lymphopenia,Viral response,Lymphopenia concerned mainly CD8 T-cells,peak concentrations,CD3 CD8 HLA-DR T-cell percentages,Early virological response,deaths or opportunistic infections,Sustained virologic response,rate of sustained virologic response (an HCV RNA level,HIV infection,sustained virologic responses,sustained virologic response,safety and efficacy,Intracellular peripheral blood mononuclear cells' stavudine-triphosphate (TP) concentrations,safety, tolerability, and efficacy,pancreatitis or symptomatic hyperlactatemia,virologic response,HCV RNA,CD4 cell count,CD4 lymphocyte counts and HIV-1 RNA remained stable,CD3, CD3 CD4, CD3 CD8, CD3 CD4 human leucocyte antigen,serious adverse event,sustained virologic response (SVR), defined as an undetectable HCV RNA level,virologic efficacy and safety,Histologic activity,virologic response or histologic improvement,Histologic responses,rates of sustained virologic response,Hyperlactataemia,sustained virological response,efficacy and safety,rate of drop-outs,tolerability and feasibility,sustained response rates,serum HCV RNA levels,chronic HCV infection,SVRs,frequent blood lactate measurement and relative quantitation of mitochondrial DNA (mtDNA) content in peripheral blood mononuclear cells,response rate,HCV-RNA levels,overall rate of sustained virologic response,SVR,Negative serum HCV-RNA values,sustained virological response (SVR: negative HCV-RNA,Adverse events,overall SVR,moderate and transient CD4 lymphopenia,early virological response,Serum HCV RNA,plasma HIV RNA level,CD3 CD4 and CD3 CD8 T-cells counts,sustained response,HLA)-DR and CD3 CD8 HLA-DR lymphocyte subsets,Plasma HIV RNA levels,HCV-RNA,median residual concentration of intracellular stavudine-TP,Sustained virological response (SVR,SVR rate,early virologic response,Side effects|Treatment with peginterferon and ribavirin was associated with a significantly higher rate of sustained virologic response (an HCV RNA level of less than 60 IU per milliliter 24 weeks after completion of therapy) than was treatment with interferon and ribavirin (27 percent vs. 12 percent, P=0.03).
not found|pain of childbirth,pain,pain using a visual analogue scale (VAS) and a verbal descriptor scale (VDS,childbirth pain,labour and delivery performance measures,acute pain|However, no difference between effectively trained electromyographic, ineffectively trained skin-conductance and control groups was found on labour and delivery performance measures.
100|final visual outcome, symblepharon formation, corneal clarity and vascularisation with or without amniotic membrane transplantation,rate of epithelial healing,Rate of healing of corneal epithelial defect, visual acuity, extent of corneal vascularisation, corneal clarity and formation of symblepharon|There was no overall difference in the final visual outcome, symblepharon formation, corneal clarity and vascularisation with or without amniotic membrane transplantation.
400|Preoperative hemoglobin levels,Hemoglobin levels,perioperative hemorrhage,febrile morbidity,incidence of postoperative infections with spontaneous placental removal,frequency of febrile morbidity,postdelivery infections,blood loss during cesarean section and postoperative endometritis rate,incidence of postpartum endometritis,blood loss,mean gestational age, frequency or duration of ruptured membranes, frequency or duration of labor, or mean number of vaginal examinations,incidence of endometritis, wound infection, and the need for blood transfusion,postoperative hemoglobin levels,postoperative endometritis,postpartum maternal infectious morbidity,operative blood loss,Blood loss,Blood loss measured at cesarean delivery,postcesarean infection, defined as postecsarean endometritis or wound cellulitis requiring drainage and antibiotic therapy,rate of postoperative endometritis and amount of blood loss,Manual removal of the placenta and postcesarean endometritis,incidence of postoperative endometritis,postoperative endometritis rate,post-cesarean endometritis,postoperative complications,hemoglobin levels,Endometritis,incidence of endometritis,endometritis,hematocrit values,postoperative endometritis or blood loss,mean maternal age, parity, gestational age, presence and duration of membrane rupture and number of vaginal examinations,placenta extracted,postoperative hemoglobin,postcesarean endometritis and operative blood loss,febrile morbidity, endometritis, maximums and durations of elevated temperatures, as well as other demographic, intrapartum, and postpartum variables,postcesarean endometritis,hematocrit,Operative blood loss,risk of post-cesarean endometritis,Postoperative infections,change in hemoglobin, reflecting operative blood loss,Outcome measures (frequency of endometritis and quantitative decrease in hemoglobin,postoperative hemoglobin and hematocrit values, and postcesarean endometritis,incidence of postpartum infectious morbidity,Febrile morbidity and endometritis rates,postcesarean febrile morbidity,Cesarean section intraoperative blood loss and mode of placental separation,incidence of endometritis, wound infection, and need for blood transfusion,incidence of postcesarean infections,perioperative blood loss and postpartum maternal infectious morbidity,operative time|No difference in postoperative complications was noted between the groups.
19|peak flow,postexercise calf blood flow and symptoms of claudication,heart rate, blood pressure, calf blood flow and vascular resistance,Maximal exercise heart rate,Blood flow,calf blood flow,symptomatic limbs, reactive hyperemic flow,claudication distance,skin temperature,walking distance,blood pressure changes,Heart rate,calf blood flow and vascular resistance,heart rate, blood pressure as well as on resting and hyperaemic calf blood flow and vascular resistance,Mean arterial pressure,objective and subjective measures of walking performance and foot temperature,blood pressure,vascular resistance,Calf blood flow,symptoms of claudication,limb circulation,hyperaemic flow|Calf blood flow was not affected by either drug compared with placebo at rest or at either workload.
128|bronchial obstruction,clinical score, oxygen saturation or reduction in duration of hospitalization,respiratory score,Median (SE, 95% CI) duration of resolution of overall illness,Respiratory rate, heart rate, oxygen saturation and presence of cyanosis, wheezing, retractions,length of hospitalisation,clinical scores or oxygen saturations,rate of improvement and the final score,mean duration of fever, cough, coryza, noisy breathing, time to achieve normal feeding and normal sleep; and frequency of hospitalization or adverse effects,wheeze and retraction score, respiratory and heart rates, and pulse oximetry,Tidal breathing flow-volume loops,bronchodilation, peak inspiratory pressure and inspiratory respiratory system resistance,mean LOS,oxygen saturation rates and clinical scores and duration of hospitalization,need for hospital admission or home oxygen,Desaturation,improvement in respirations,VPTEF/VE and tPTEF/tE,clinical score,accessory muscle score,length of hospital stay (LOS,shorter hospitalization,shortest hospital stay,oxygen saturation,mild accessory muscle use, and respiratory distress assessment instrument (RDAI) score,improvement in oxygen saturation (SaO2) during hospitalization and survival analysis to assess the time required to reach preestablished discharge criteria on three measures: SaO2, accessory muscle use, and wheezing,oxygen saturation rates,condition of hospitalised mild bronchiolitis,total scores,and RDI scores,clinical scores,changes in clinical scores and oxygen saturations,RDAI score, oxygen saturation in room air, rate respiratory and heart rate,PTEF,respiratory syncytial virus (RSV) positivity and enrollment score,fraction of tidal volume exhaled at peak tidal expiratory flow (PTEF) to total tidal volume (VPTEF/VE), and the fraction of exhaled time at PTEF to total expiratory time (tPTEF/tE,tidal breathing flow-volume loops,Clinical scores and oxygen saturation levels,Respiratory Distress Assessment Instrument (RDAI) score, respiratory rate, oxygen saturation, heart rate and the duration of hospitalization,severity score, number of nebulisations required,tidal expiratory flow,SaO2,Respiratory and heart rates, clinical score, oxygen saturation (Spo2), and the infant's state,Respiratory and heart rates, clinical score, and oxygen saturation,peak inspiratory pressure and respiratory system resistance,respiratory failure,fall in SaO2,time to normal feeding, normal sleeping, quiet breathing, resolved cough, and coryza,Heart rate,mean SaO2,heart rate or respiratory rate,Health care revisit and admission rates,respiratory rate and clinical score,wheeze scores,clinical score or hospital duration,demographic characteristics, initial oxygenation, and clinical score,time from admission until the infant had normal hydration, oxygenation, and minimal respiratory distress,Oxygen saturation,clinical score and length of hospital stay,respiratory rate,respiratory rate, pulse oximetry, and a clinical score based on the degree of wheezing and retractions,Chest radiographs, leukocyte counts, blood culture specimens, and nasal aspirate for viral antigen detection,time to reach discharge criteria as defined by SaO2, accessory muscle use, or wheezing,peak inspiratory pressure,wheezing, retractions and respiratory rate,RDI,respiratory rate, RDI, and oxygen saturation,actual length of hospital stay,Time for resolution of illness (ROI), duration of fever, cough,coryza, noisy breathing, time to achieve normal feeding and normal sleep, and frequency of hospitalization and adverse effects,Improvement rates and duration of hospitalization,remaining tidal volume (TEF10, TEF25, and TEF50), and the wheeze score,heart rate, respiratory rate, oxygen saturation, and clinical variables related to respiratory compromise with the use of a standardized respiratory distress index (RDI,length of hospital stay,arterial oxygen saturation (SaO2,lengths of hospitalization,decrease in respirations,time to resolution of illness,respiratory distress,bronchodilation,duration of hospitalization,Inspiratory respiratory system resistance,tidal expiratory flows,ie, asleep, awake, or feeding,heart rate,symptomatology of acute viral bronchiolitis,adverse effects,Clinical score, oxygen saturation and heart rate|Nebulized albuterol significantly improved the clinical score and reduced the respiratory rate of those with recurrent wheezing relative to those in the randomized groups.
53|pain reduction,disability,headache-related and demographic characteristics,headache intensity,Pain scores,standard headache diaries,cervicogenic headache,pain on neck movement, upper cervical joint tenderness, a craniocervical flexion muscle test, and a photographic measure of posture,headache reduction,pain intensity,headaches,Pain level,side effects that included drowsiness, dry mouth and weight gain,headache pain levels,headache frequency and intensity, and the neck pain and effects,mean number of analgesics,headache,mean pain index,change in headache frequency,neck soreness and stiffness,frequency and intensity of cephalalgia,side effects,subjective level of headache,headache pain,myogenic headache,McGill-Melzack Pain Questionnaire,migraine activity,average pain reduction,headache intensity per episode,frequency, intensity (visual analogue score), duration, disability, associated symptoms, and use of medication for each migraine episode,Headache pain intensity,Episodic tension-type headache,overall function,pain or stiffness in the neck, and pain/paraesthesia,pain index,headache intensity and duration, the Northwick Park Neck Pain Index, medication intake, and patient satisfaction,intensity of headache,EMG activity,muscle tension,tension headache,overall function (Sickness Impact Profile), and mental well-being (Mood Adjective Check List) and the intensity and frequency of headache,mean daily headache,daily headache intensity, weekly headache frequency, over-the-counter medication usage and functional health status (SF-36,average response,symptoms of cervicogenic headache,tension headache pain,number of headache hours per day,quantity of muscle tension (motor unit potential spikes per time unit,morbidity of each episode,intensity and frequency of headache,lateral flexion,Migraine headache,headache index scores,pain,measured rotation,migraine frequency,Safety and effectiveness,Daily hours of headache, pain intensity per episode, and daily analgesic use, as recorded in diaries,pain/paraesthesia,number of headaches,headache frequency,episodic tension-type headache,headache index score,headache activity|The use of analgesics decreased by 36% in the manipulation group, but was unchanged in the soft-tissue group; this difference was statistically significant (p = .04, chi 2 for trend).
not found|forced expiratory volume,daily sputum production,exacerbation frequency, forced expiratory volume in 1 second, forced vital capacity, or sputum purulence score,FEV1, FVC, 24 h sputum volume or number of bronchiectatic segments,24 hour sputum volume,quality of life,pulmonary function, number or severity of exacerbations, or microbiological profile of the sputum,HRQoL,eNO,sputum production,sputum purulence score,sputum volume,exacerbation frequency,sputum leukocyte density and IL-1beta, IL-8, and LTB4,adverse reactions,eNO levels,episodes of exacerbation,spirometry, 24-h sputum volume, sputum leukocyte density, bacterial densities, and concentrations of interleukin (IL)-1beta, IL-8, tumor necrosis factor-alpha (TNF-alpha), and leukotriene B4 (LTB4,exhaled nitric oxide (eNO) levels,dyspnea,Symptom scores for cough,symptoms, pulmonary function and sputum production,morning peak expiratory flow rate|The group administered FP 1000 microg daily showed significant improvement in dyspnea (1.03 [2.1]-1.24 [2.2] points; P = 0.01-0.04), sputum production (P = 0.001),
29|equally sharing decision responsibility,patient knowledge and satisfaction,decisional conflict score,patient-reported level of control over the decision to be screened,realistic personal expectations of the benefits and risks, decisional conflict, and perceived acceptability of the intervention,DCS,Back surgery rates,rates of noncompliance and rehospitalization,decision, decisional conflict scores, treatment choice and prostatectomy rate, American Urological Association symptom scale, costs, anxiety, utility, and general health status,acceptability of information delivery (1-7), knowledge about statins and coronary risk (0-9), and decisional conflict about statin use,Perception of absolute risk of breast cancer,patient decision process and the decision outcome,Decisional self-efficacy, preparedness to participate in decision-making, and arthritis self-efficacy,rate of vaginal birth,decisional conflict regarding colorectal cancer screening decisions,Unadjusted mean knowledge scores,knowledge and perceived risk,Levels of depression,uptake rates of treatment options, length of consultation with the surgeon, time point of treatment decision making, perceived involvement in decision making, neither decision related nor general patient satisfaction,breast cancer prevention knowledge postvisit,PSA screening,psychological or acceptability outcomes,perceived limitations and risks of BRCA1 testing,risk of stroke,Perceived clarity of values, a sub-scale of the decisional conflict scale; congruence between personal values of benefits and risks (measured on 0-10 importance rating scale) and choices (accept, decline, unsure regarding preventive hormone therapy [HRT,level of knowledge, decisional conflict score, women's preference for mode of birth, and recorded mode of birth,risk of procedure-related miscarriage,adherence and optimize glycemic control,CHD risk,participants' knowledge, realistic expectations, and decisional conflict,complete screening (i.e., having a digital rectal exam (DRE) and prostate specific antigen (PSA) testing), and (2) complete or partial screening (i.e., having a PSA test with or without DRE,knowledge of NHPs,state anxiety,change in knowledge,knowledge, satisfaction, and anxiety,general knowledge of the risks and benefits of HRT, personal expectations and values concerning these risks and benefits, and women's views on HRT,positive attitudes,change in antithrombotic therapy,knowledge or SEU scores,knowledge about risk management options,Anxiety,mortality due to early-stage prostate cancer, PSA screening performance, treatment-related complications, and disadvantages of screening,Knowledge (Kn) scores,rate of uptake of trial of labor or elective repeat cesarean section,PSA test choice, prostate cancer treatment preferences, knowledge and concern about prostate cancer, and decisional conflict,satisfaction with decision making,Shared decision-making program scores,greater knowledge,mean consultation duration,knowledge, risk awareness, intervention satisfaction, decisional conflict, and among women aged at least 35 years, use of invasive diagnostic testing,survival rates,decision making and quality of life,elevated self-image expectations,knowledge score,Decisional conflict,postdecisional regret or actual genetic testing decision,match between the patient's preferred and actual roles during consultation with the physician,surgery rates,number of patients receiving therapy appropriate to their stroke risk,quality of life,questionnaire assessed knowledge, attitudes, perceived risk and intention to have a PSA test,knowledge levels,Knowledge scores,values clarity,anxiety, general health status, prostatic symptoms, utility, or costs (excluding costs associated with the video disc equipment,hemoglobin A(1c) (HbA(1c)) levels,patient interest in undergoing PSA screening measured on a 5-point Likert scale,anxiety, use of health service resources, general health status, or utility,median duration of NVAF,percentage of preference matches,intent to begin or continue fecal occult blood testing (FOBT), flexible sigmoidoscopy, or both,knowledge about hypertension,Anxiety levels,comparable demographics, prior computer experience, medical literacy, and baseline knowledge of breast cancer and genetic testing, and both counseling and computer use,undergone revascularization,amniocentesis or chorionic villus sampling,referral for coronary revascularization,decisional conflict scores,mean scores for decisional conflict,anxiety,anxiety, knowledge, or decisional regret,knowledge scores,Mean state anxiety scores,undergoing PSA screening,Fecal occult blood testing or flexible sigmoidoscopy,General health and angina scores,overall surgery rate,mean knowledge scores,Participants' knowledge, risk perception, intention to undergo genetic testing, decisional conflict, satisfaction with decision, anxiety, and satisfaction,screening frequency,Preferences for watchful waiting,general knowledge increased and of women with realistic expectations,state anxiety levels,knowledge scores relative,Total score on decisional conflict scale, and mode of delivery,likelihood of reaching a management decision,Median consultation times,realistic expectations about the benefits and risks of lung transplantation,decisional conflict scale (DCS,test scores of knowledge,decisional conflict, knowledge, state anxiety, intentions regarding starting treatment, and actual treatment decision,decisional conflict and greater self-advocacy,Knowledge of coronary artery disease, satisfaction, self-reported physical and mental health functioning, and the proportion of patients who were referred for coronary revascularization,HbA(1c) levels,general health,informed choice and decisional conflict, and the secondary outcomes, anxiety, depression, attitudes to the pregnancy/fetus and acceptability of the resource,SDMI improved decision making,knowledge about menorrhagia,perceived clarity of values and overall congruence between values and choices,decisional conflict post intervention,PSA knowledge,percentage of women making an informed choice about whether to continue or stop screening and the percentage of women participating in the screening,higher knowledge and lower risk-perception scores,IMDA,physicians' decisional conflict scores,Knowledge, decisional conflict, satisfaction with health care provider, and self-efficacy,knowledge, satisfaction with decision, decisional conflict or HT use,total decisional conflict score,Hysterectomy rates,prostate cancer screening,Test decision, subjective expected utilities, knowledge, informed decision-making, risk perception, decisional conflict, anxiety, perceived usefulness and directiveness of consultation information,Congruence between personal values and decisions about HRT,knowledge,complete or partial screening,mental health functioning,satisfaction,participants' ratings of convenience, effort, or satisfaction,final management decision, decisional conflict, decisional satisfaction, and receipt of risk reducing mastectomy,Decisional Conflict Scale and State-Trait Anxiety Inventory anxiety scale,frequency of screening, patient knowledge, decisional conflict, and time spent discussing screening,colorectal cancer,satisfaction or anxiety,realistic expectations,good' level of knowledge,decreased anxiety, increased knowledge, and enhanced satisfaction,patient satisfaction,10-year CHD risk,lower decisional conflict,diagnostic procedure,Questionnaires assessing knowledge, anxiety, and satisfaction,Menorrhagia Specific Utility quality-of-life scale, knowledge about menorrhagia, and anxiety and process measures,screening interest,active decision-making role,physical functioning,decisional conflict and knowledge about genetic testing,knowledge questions correctly,menorrhagia quality of life,adherence or HbA(1c) levels,satisfaction with decision-making process scores,health status,postoperative satisfaction,anxiety scores,lower levels of decisional conflict,surgery rate,decision quality,decisional conflict scale,planned screening tests,overall beneficial effect,satisfaction-with-decision scale,number of surgical procedures used, improve knowledge, or influence satisfaction or anxiety,outcomes and satisfaction; surgery rates,mean level of anxiety and increased satisfaction,realistic risk perceptions,screening decisions overall,Decisional conflict and satisfaction,knowledge, decisional conflict, state anxiety, satisfaction, use of PND, and pregnancy outcomes,decisional conflict,factual knowledge, reduced anxiety,proportion of patients choosing allogeneic blood,initial decision for and the final uptake of the prenatal screening test,patient knowledge (measured using 20 questions about knowledge deemed necessary for an informed treatment decision), treatment decision, patient-angiographer agreement on decision, and general health scores,higher knowledge scores,ICC,psychological distress,realistic expectations about the risk of stroke and hemorrhage,patient satisfaction with the decision-making process,number of knowledge questions,Symptom and functional outcomes,mean costs,decisional conflict and mode of delivery,national rates of caesarean section,number of patients receiving appropriate care,Mean (SD) decisional conflict scores,CRC mortality risk reduction,facial appearance,intrusive thoughts,proportion of colorectal cancer screening plans carried out,prostate cancer|Information-giving was the most frequent activity for both GPs and patients, although GPs did this at twice the rate compared to patients and at higher rates in consultations involving computerised decision aids.
not found|quality of life,6MWD and steps,6MWD or steps achieved while breathing supplemental oxygen,exercise performance (step tests and 6 min walking distance [6MWD,Degree of desaturation,6MWD or steps,laboratory exercise performance,quality of life indices|Supplemental oxygen increased 6MWD and steps by small, statistically significant increments acutely at baseline and after 6 and 12 wk, without corresponding falls in Borg score.
219|Baseline cross-sectional changes and 1-year changes in insulin resistance, fasting serum levels of insulin, C-peptide, proinsulin, glucose, and lipids as well as weight, mean blood pressure, and plasminogen activator inhibitor 1 (PAI-1) values,insulin resistance,change insulin resistance,rate of development of diabetes,incidence of diabetes,intake of fish and reduced total fat intake,baseline BMI and fasting glucose, the diet, exercise, and diet-plus-exercise interventions,PAI-1,calculated insulin resistance and BMI,insulin resistance and changes in BMI,calculated insulin resistance,mean blood pressure (mBP,total cholesterol,cumulative incidence of diabetes|The 1-year diet intervention gave a significant decrease in the calculated insulin resistance from 4.6 to 4.2 and a positive correlation between the changes in insulin resistance and changes in BMI (r = 0.40).
38|Sedation,Brief Psychiatric Rating Scale (BPRS) and the Clinical Global Impression Scale (CGI,Brief Psychiatric Rating Scale and Clinical Global Impression Scale,efficacy and side effects,Serum creatinine phosphokinase levels,reduction of aggression based on BPRS rating,tardive dyskinesia,rapid remission of symptoms on the BRMAS,minimal side effects,Brief Psychiatric Rating Scale (BPRS), the Bech-Rafaelsen Mania Rating Scale (BRMAS) (only manic patients) and globally on the Clinical Global Impression (CGI,extrapyramidal side effects,hypokinesia,BPRS and CGI scores,acute psychosis with aggression,BPRS or CGI scores,Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI) and UKU Side Effects Scale,severity of illness scores|Both ZPTA and HAL were effective in the treatment of acute psychosis with aggression, but frequency of administration was lower in the ZPTA group
420|tumor resistance and morbidity,severe complication nor death,incidence of persistent trophoblastic disease,time interval from evacuation of the mole to diagnosis of persistent trophoblastic disease,complication of the prophylactic chemotherapy,complete remission with therapeutic chemotherapy,occurrence of choriocarcinoma,secondary trophoblastic disease,persistent trophoblastic disease,incidence of malignant sequelae,toxicity,metastatic trophoblastic disease,stomatitis, nausea/vomiting, sore throat with oral ulcer and hair loss,until complete remission|Choriocarcinoma after the molar pregnancy developed in two patients (0.7%) of the prophylactic chemotherapy group and two (1.6%) of the control.
279|objective tumoral response,Disease-free survival rates and prognostic factors,partial response,abdominal pain,recurrence rate, the time to tumor recurrence and the median survival,2-year overall survival,expressions of Bcl-2 and Bax protein,probability of tumor progression,Tumor size, tumor number, PVTT location,Pugh score,Actuarial survival rates,survival: alpha-fetoprotein,self-limited postembolization syndrome,apoptotic index(AI) and level of Bax protein in HCC cells,apoptosis of hepatocellular carcinoma (HCC) cells,probability of complications,overall recurrence,intrahepatic recurrence rate,Survival,liver failure,survival nor the quality of life,disease-free survival curve,spontaneous 1-year survival rate,Spitzer Index level assessing the quality of life,survival time,risk of hepatocellular carcinoma (HCC) recurrence,actuarial survival,Survival probabilities,survival,local recurrence,overall survival and quality of life,recurrence rate,level of Bcl-2 protein and ratio of Bcl-2 to Bax protein of HCC cells,relative risk of death,rate of portal-vein invasion,overall survival,death from liver failure,Pugh's grade, Okuda stage, or performance status test (PST,time to tumor recurrence,median survival,recurrence of hepatocellular carcinoma (HCC,Liver failure,nausea and loss of appetite,tumour response (assessed by arteriography, ultrasonography and serum alphafetoprotein,estimated survival rates,risk of death,HCC recurrence and survival,incidence of portal obstruction,catheter obstruction,liver decompensation,apoptosis of hepatocellular carcinoma cells,disease-free survival rate,survival benefits,tumor size and serum alpha-fetoprotein concentration,4-year survival rates|Chemoembolization resulted in a marked tumor response, and the actuarial survival was significantly better in the chemoembolization group (1 year, 57%; 2 years, 31%; 3 years, 26%) than in the control group (1 year, 32%; 2 years, 11%; 3 years, 3%; P =.002).
395|Neuropsychiatric Inventory (NPI,rate of adverse events,Tinnitus Handicap Inventory (THI), Glasgow Health Status Inventory (GHSI) and average of hearing threshold at 0.5, 1, 2, 4 kHz,Efficacy and tolerability,SKT total score,Efficacy,change of the THI, GHSI and hearing,Verbal Fluency Test, the Clock-Drawing Test, the NPI, the Hamilton Rating Scale for Depression (HAMD), and the Gottfries-Bråne-Steen Scale (GBS|Under EGb 761 treatment the SKT total score improved by -3.0+/-2.3 and -3.4+/-2.3 points in patients with AD and VaD, respectively, whereas the patients on placebo deteriorated by +1.2+/-2.5 and +1.5+/-2.2 points, respectively (p<0.01 for both drug-placebo differences).
not found|Electromyogram (EMG) patterns and stride parameters,mean UPDRS scores,velocity,UPDRS scores (activities of daily living and motor sections,Unified Parkinson's Disease Rating Scale (UPDRS,stride length,gait velocity|Patients who trained with RAS significantly (p < 0.05) improved their gait velocity by 25%, stride length by 12%, and step cadence by 10% more than self-paced subjects who improved their velocity by 7% and no-training subjects whose velocity decreased by 7%.
not found|polyp size|We found that betamethasone nasal drops showed a statistically significant reduction in polyp size in comparison to placebo.
not found|Age, tumor grade, histology, CA-125 level, ascites, and tumor size,residual disease,prolonged survival,residual disease (median survival,endometrioid histologic type,median diagnosis-to-recurrence interval,number of recurrence sites,secondary cytoreduction,median survival and estimated 5-year survival,number of radiographic recurrence sites (median survival,Prognosis of survival,median patient age at recurrence,recurrent ascites,Survival,lengthened survival,completeness of cytoreduction,survival,median and estimated 5-year survival,median postrecurrence survival,longer survival,probability of complete cytoreduction,Complete optimal cytoreduction (COC,overall survival,Residual disease after SCR, treatment-free interval (TFI,median survival,performance status (PS) [Eastern Cooperative Oncology Group (ECOG,survival benefit,Median survival time (MST,International Federation of Gynecology and Obstetrics (FIGO) stage at initial diagnosis,largest size of recurrent tumor,cytoreductive outcome and survival,recurrent epithelial ovarian cancer,5-year survival,recurrence-free interval (RFI,Complete cytoreduction,median progression-free interval,survival benefits,2-year survival rates|Age, tumor grade, histology, CA-125 level, ascites, and tumor size were not associated significantly with survival.
not found|death rate,symptomatic intracranial hemorrhage (ICH,lethal pulmonary embolism,number of deep-vein thromboses, pulmonary emboli and deaths,mortality rate,functional activity level of survivors,haemorrhagic,thromboembolic complications,frequency of proximal thrombi,development of DVT,fatal pulmonary embolism,deep-vein thrombosis,neurologic deficits,serious intracranial bleeding events,asymptomatic ICH (7 events), major systemic hemorrhage (no event), or 90-day mortality,mean Factor Xa inhibitory activity levels at peak concentration,deep-vein thrombosis rate,absence of pulmonary embolism or drug-induced haemorrhage,tolerated and no side-effects,degree of neurologic change; incidence of stroke progression,frequency of DVT,Symptomatic ICH,deaths and pulmonary emboli,laboratory values (PT, PTT, alkaline phosphatase, GOT, GPT, cholesterol and triglycerides, fibrinogen, blood glucose, azotemia and creatinine,deep venous thrombosis (DVT,tolerated,Cerebral bleeding,mortality,major hemorrhagic complications,Glasgow Outcome Scale score of I or II and a modified Barthel Index,deaths,Time interval (from stroke to admission) and lactic dehydrogenase (LDH) concentration|A statistically significant reduction was observed in deep-vein thrombosis as assessed by isotope leg scanning.
not found|renal function impairment,tubular damage markers,Inulin clearance and urinary beta(2)-microglobulin and N-acetyl-beta-D-glucosaminidase (NAG) excretion,myeloperoxidase (MPO) release,perioperative renal function,renal function,lactic acid levels,Venous stasis,inulin clearance,low mean arterial pressure at anesthesia induction,MPO levels|Lactate determinations did not contribute to the quantification of the systemic and regional tissue oxygenation during OLT.
not found|working smoke alarms,Physician counseling and parent satisfaction, knowledge, beliefs, and behaviors,socket safety,injury prevention knowledge or behavior,safety practices,storage of medicines,safety consultation and provision of free and fitted stair gates, fire guards, smoke alarms, cupboard locks, and window locks,injury rate per 100 fires,smoke alarm safety,discharge book improved the burn-care-related knowledge of caregivers,fireplace safety,safe practice in storage of sharp objects,home safety modifications,hot-water temperature, poison storage, and presence of smoke alarms, safety gates for stairs, and ipecac syrup,injury visits,unintentional injuries,Safety knowledge and practices,functioning alarms,Parents' knowledge, beliefs, and home safety behaviors,overall occurrence of injuries,medical attendance,safety knowledge and behavior scores,working alarms,annualized fire-injury rates,home hazards requiring major effort to correct,self reported safety practices, possession and use of safety equipment, knowledge and confidence in dealing with first aid, and perceptions of risk of injury and risk of hazards assessed by postal questionnaire,number of safety practices,hot water temperatures,mean hazard score,similar risk factors for injury, sociodemographic characteristics, safety practices, possession and use of safety equipment, knowledge and confidence in dealing with first aid, and perceptions of risk,installed alarms,child in the family had at least one injury that required medical attendance and rates of attendance in primary and secondary care and of hospital admission for injury over a two year period,frequency of minor unintentional injuries,Knowledge gains,socket covers,rate of burn injuries,range of safety practices,admissions to hospital and deaths,Demographic and fire safety data,attendance rate,presence and functional status of smoke alarms,rates of fires and rates of fire related injury,hot water temperature,total costs of care for injuries,operational smoke detectors,feasibility, acceptability, and effectiveness,Parental safety knowledge,parents' safety practices,injury prevention counseling,Rates of fires and related injuries,window safety,probability of having a working detector,possession of safety equipment and safety practices,smoke alarms,frequency and severity of medically attended injuries,Incidence of fires and related injuries,proportion of families|Households that reported participatory exposure to the interventions had higher safety knowledge and behavior scores than those that received other community exposure or no exposure to intervention activities.
179|recurrent preterm uterine activity,mean days to delivery, the number of repeat triage visits, the incidence of preterm labor,pregnancy outcomes,shortest length of triage stay,frequency of preterm deliveries|There were no intergroup differences in the mean days to delivery, the number of repeat triage visits, the incidence of preterm labor at < 34 weeks, or the frequency of preterm deliveries at < 34 weeks and < 37 weeks.
61|resting systolic blood pressure,work capacity (W.kg(-1,functional work capacity,specific physiological, psychological and cognitive functions,fatigue, sleep, disability, and mood,net blood lactate production,Rating of perceived exertion scores,Fatigue, functional capacity, and fitness,depression,fatigue,efficacy and acceptability,satisfactory outcome in physical functioning,physical work capacity, as well as in specific psychological and cognitive variables,health perception,functional work capacity and fatigue,SF-36 physical functioning subscale|Following the graded exercise intervention, scores were improved for resting systolic blood pressure (P = 0.018), work capacity (W.kg(-1))
not found|rate of bone turnover and bone loss,bone turnover,rate of bone loss,distal forearm,bone mineral density and bone metabolism,Low bone mineral density (BMD,lumbar spine,BMD and bone biochemical markers,BMD and bone metabolism,total hip|After 12 months, the treatment group (n=15) showed a reduced rate of bone loss compared with the control group (n=15) in the lumbar spine (mean difference 1.9% [CI -0.9% to 4.6%])
16608|Height loss,fasting glucose levels,body weight, blood pressure, lipoprotein levels, antithrombin III activity, and the endometrium,weight and waist circumference,total cholesterol level, high-density lipoprotein cholesterol level, blood pressure, and body mass index,serum cholesterol level,triglyceride levels,triglycerides,Baseline biochemical values,triglyceride,daily creatinine excretion,levels of lipids and lipoproteins,spine density and total body density,change high-density lipoprotein cholesterol (HDL-C), triglycerides, or plasminogen activator inhibitor-1 (PAI-1,Fasting glucose level,extremity/trunk ratio,HDL-cholesterol levels,Fibrinogen, factor VII (FVII), factor VIII,Fasting plasma total homocysteine concentrations,systolic blood pressure,total body calcium,incidence of diabetes,serum lipids or lipoproteins,alcohol consumption,Total exercise time (time spent on the treadmill until exhaustion during testing,lowered lipoprotein(a,Fasting glucose levels,bone mineralization defects,time for homocysteine levels,high-density lipoprotein-2 cholesterol (HDL2-C,ratio of high-density lipoprotein cholesterol to low-density lipoprotein cholesterol,serum triglycerides and HDL-cholesterol levels,LDL cholesterol,muscle performance, improve balance or reduce falls,Estimated hazard ratios (HRs,total body bone mineral content (TBBMC,cortical and trabecular bone,exercise performance,HDL cholesterol,body cell mass and body fat mass,Levels of follicle-stimulating hormone,GH and IGF,metacarpal cortex,maximum oxygen uptake,postmenopausal bone loss,serum lipids and coagulation factors,leg extensor power,bone mineral density,lumbar BMD,Serum cholesterol levels,hip, work activity,body composition,Plasma fasting homocysteine concentrations,bone density, endometrium, and lipids of continuous hormones,total and low density lipoprotein cholesterol levels,Bone mineral density (BMD,fibrinogen levels,lipid profile,percent of body fat,vaginal cytology profile (maturation index,serum lipoproteins,body weight,endometrial hyperplasia,Breakthrough bleeding,nonfatal myocardial infarction and CHD death,final values of fibrinogen, FVII, ATIII, protein S and HCII,muscle performance and balance,apolipoprotein A1,waist girth,high-density lipoprotein (HDL) cholesterol-LDL ratio,fibrinogen,TBBMC,serum oestradiol and serum oestrone,endometrium against hyperplasia,spine density, total body calcium, or radial density,total body fat mass or total lean body mass,baseline blood pressures and body weights,efficacy and safety,urinary creatinine/body weight ratio,incidence of estrogen-related side effects,glucose tolerance or on fibrinogen levels,growth hormone secretion patterns,serum lipids and lipoproteins,changes of other lipid profiles,GH- and IGF,Serum lipids and lipoproteins,Total serum cholesterol levels,high density lipoprotein (HDL) cholesterol levels,rate of hyperplasia and proliferative status,HDL-C and PAI-1,low-density lipoprotein (LDL) cholesterol,Overall health risks,PAI-1,cardiovascular risk,endometrial proliferation and hyperplasia,Levels of lipids, lipoproteins, apolipoproteins, fibrinogen and glucose tolerance,bone mineral density (BMD,levels of apolipoprotein B and lipoprotein(a,plasma homocysteine,bone turnover, including bone-specific alkaline phosphatase, and urinary hydroxyproline:creatinine ratios,fasting plasma homocysteine concentrations,total cardiovascular disease (arterial and venous disease,Hand grip strength,overall activity,weight or girth changes,loss of femoral neck BMD,antithrombin III (ATIII), protein C, protein S, heparin cofactor II (HCII) and plasminogen activator inhibitor,ratio of fat in the trunk/extremities,elevated LDL cholesterol levels,Serum triglycerides levels,sway, leg extensor power and self-paced walking speed,physical activity level,weight gain,Hispanic ethnicity,plasma homocysteine levels,LDL cholesterol levels,levels of serum triglycerides,estradiol/estrone ratio,HDL cholesterol level,total cholesterol,stroke, pulmonary embolism (PE), endometrial cancer, colorectal cancer, hip fracture, and death due to other causes,muscle strength,Cardiovascular risk factors,coronary heart disease (CHD),hot flushes,lipids and lipoproteins,frequency of moderate-to-severe hot flushes,balance, muscle performance and falls,Glycemic effects,antithrombin III activity (mean levels,urinary creatinine excretion rate,fasting glucose level and incident diabetes,levels of total serum cholesterol and LDL-cholesterol,femoral neck BMD,body weight and waist and hip girths,Total serum cholesterol and LDL-cholesterol,bone loss,plasma homocysteine concentration,hip and spine BMD,skin tolerability,serum E2 levels,Total and LDL cholesterol levels,Bone mineral density,secretion of growth hormone (GH) and IGF,Breast pain,trunk fat mass,Levels of HDL cholesterol, HDL2, HDL3, triglycerides, lipoprotein populations and apolipoproteins AI and AII,high-density-lipoprotein (HDL) cholesterol,spine density,Serum estradiol concentrations,low-density lipoprotein cholesterol (LDL-C,low-density-lipoprotein (LDL) cholesterol,cholesterol, triglycerides, and LDL cholesterol, and an increase in the HDL-LDL ratio,Vaginal bleedings,radial density,total mortality,Blood pressure and body mass index,lipid changes, measurement of serum total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL), high density lipoprotein (HDL), apolipoprotein A-1 (Apo-A) and apolipoprotein B (Apo-B,abdominal fat after menopause,Plasma homocysteine levels,lipid metabolism,lumbar spine,Physical fitness levels,lipid measures,HDL2-C and lipoprotein(a,height loss,anthropometry, lipoprotein levels, antithrombin III activity, and endometrial histology,lipid levels and coagulation parameters,overall values for body weight and blood pressure,initial levels of oestradiol,biochemical markers of cardiovascular risk by decreasing LDL-C, fibrinogen, and lipoprotein(a,PAI-1) levels,rate of new vertebral fractures,Total serum cholesterol and LDL-cholesterol levels,BMD,Body weight,high-density lipoprotein cholesterol/total cholesterol fraction|Corresponding HRs (nominal 95% CIs) for composite outcomes were 1.22 (1.09-1.36) for total cardiovascular disease (arterial and venous disease), 1.03 (0.90-1.17) for total cancer, 0.76 (0.69-0.85) for combined fractures, 0.98 (0.82-1.18) for total mortality, and 1.15 (1.03-1.28) for the global index.
161|duration of air leaks,mean time to chest drain removal and mean time to hospital discharge,Postoperative air leakage intensity,Persisting air leakage,median duration of intercostal drainage and in-hospital stay,percentage of patients free of air leakage throughout hospitalization,duration of stay in hospital,mortality, morbidity, duration of chest tubes, or immune responses,postoperative air leaks,mean time to chest tube removal,Efficacy and safety,overall incidence of AAL,Intraoperative air leaks,shorter median duration of air leaks,incidence and duration of AAL, prolonged AAL (PAAL), the volume of pleural drainage, the time to tube removal, and the postoperative length of stay (LOS), as well as any complications related to treatment,Air leaks,mean bleeding/exudate volumes,postthoracotomy alveolar air leak,mean time to last observable AAL,mean duration of AAL,mean duration of postoperative air leakage,control of air leaks intraoperatively and the time to postoperative air leak cessation,leak-free,control of air leaks,incidence of postoperative leakages,volume of chest tube drainage or LOS,reduction of intra-operative air leakage,quality of aerostasis, the post-operative drainage, the persistance of residual collection or faulty reexpansion,surgical morbidity and costs,Postoperative hospitalisation time,intercostal chest drainage,incidence of PAAL,length of hospitalization,procedure costs,Median length of hospitalization,Time to chest tube removal, time to hospital discharge, and safety outcomes,air leaks,duration of air leaks, chest tube drainage, or hospitalization,safety and effectiveness,mean times to chest drain removal and to hospital discharge,efficacy and safety,healing of healthy bronchial and lung tissues,air leakage,Alveolar air leaks,overall incidence of air leaks,incidence of air leakage,air leakage volume,mean percentage of patients free of AAL,Postoperative air leakage,airway-tolerance-pressure test,postoperative leakage,air leak duration, chest drainage time, and hospital stay,postoperative morbidity and mortality,free of air leaks during hospitalization,alveolar air leaks,Duration of air leak, intercostal drainage, and hospital stay,postoperative quantification of air leakage on postoperative days 1 and 2,intraoperative leaks,mean air leak duration,postoperative hospitalization,duration of postoperative chest tube time, hospital stay, or cost,reduced time to chest tube removal and earlier discharge,morbidity,Overall incidence of air leakage,Air leakage,incidence of dead pleural space,length of the postoperative hospital stay,localized empyema and incomplete lung expansion,fever, intraoperative and postoperative intubation times,reduction of intra-operative air leak intensity,chest tube drains,mean times to last observable air leak,mean intraoperative post-treatment air leakage,air leakage volumes,hospital stay,PAAL,mean numbers of intraoperative AAL after application of SLS|Intraoperative air leaks were sealed in 77% of the sealant group compared with 16% in the control group (p < 0.001).
812|Transition Dyspnea Index,lung function measurements, symptoms and rescue treatment use, the number of exacerbations, patient withdrawals, and disease-specific health status,morning predose FEV(1,incidence of pneumonia,total number of exacerbations,annual rate of exacerbations requiring oral corticosteroids,number of exacerbations resulting in hospitalization,annual rate of moderate/severe exacerbations,annual rate of moderate to severe exacerbations,Efficacy and safety,predose FEV(1,postdose IC,pretreatment forced expiratory volume in 1s (FEV1,tidal volume and minute ventilation,Severe exacerbations and FEV1 (primary variables), peak expiratory flow (PEF), COPD symptoms, health-related quality of life (HRQL), mild exacerbations, use of reliever beta2-agonist and safety variables,rate of COPD exacerbations,Dyspnoea scores and HR-QOL,exercise performance,Adverse events,daily symptoms,mean prebronchodilator forced expiratory volume,mean FEV(1,pretreatment FEV1,postdose FRC and increased inspiratory capacity (IC,moderate/severe exacerbations,mean number of exacerbations/yr,adverse events,health-related quality of life, peak expiratory flow, and use of rescue medication,incidence of individual non-fatal serious adverse events,morbidity and mortality,COPD exacerbations and impact on patient outcomes,lung hyperinflation and exercise endurance,2-h postdose FEV(1,prolonged time to first exacerbation,dyspnea, quality of life, and symptoms of chronic bronchitis,mean time to first exacerbation,morning PEF (l/s), the daily symptom score, and the number of exacerbations,lung function, symptoms, and health status and reduced use of rescue medication and frequency of exacerbations,rate of moderate to severe exacerbations,efficacy,efficacy and safety,exercise time,symptom scores and use of reliever beta2-agonists,tolerated relative,efficacy and tolerability,tolerated,controlling dyspnoea and improving health status (St George's Respiratory Questionnaire,Predose and postdose spirometry, plethysmography, and constant-load cycle cardiopulmonary exercise test evaluations,frequency of adverse events, bruising, or clinically significant falls in serum cortisol concentration,pre-dose forced expiratory volume in 1 second (FEV(1)) and 1-hour post-dose FEV(1,FEV1,Daily beta(2) short acting prn consumption,Dyspnoea (measured using the Breathlessness Diary) and health-related quality-of-life (HR-QOL) scores (based on the St George's Respiratory Questionnaire total score,reporting of pneumonia,Morning PEF,Pneumonia,severity of dyspnea,daily symptoms score,exercise endurance time,average daily morning PEF,pulmonary function and reduced symptoms and exacerbations,morning predose (ie, trough FEV(1)) for FSC compared with SM and 2-h postdose FEV(1,albuterol use, dyspnea scores, and nighttime awakenings and numerical benefits on quality of life,worsening symptoms of COPD requiring antibiotics, oral corticosteroids and/or hospitalization,exacerbations,lung function,FEV(1,morning lung function,efficacy for pulmonary function,IC,moderate and severe exacerbations,health status,rate of moderate/severe exacerbations,Efficacy and tolerability,morning peak expiratory flow rate (PEF); transition dyspnea index; chronic respiratory disease questionnaire; chronic bronchitis symptom questionnaire; exacerbations,annual rate of moderate/severe exacerbations requiring hospitalization,COPD exacerbations,lung hyperinflation,respiratory function (such as FEV(1), morning PEF), and and symptom score,lung function and health status,annualized rate of moderate and severe exacerbations,Moderate/severe exacerbations,adverse events, serum cortisol concentrations, skin bruising, and electrocardiograms,Postmedication FEV1 improved by 0.21 L and health-related quality of life using the St George's Respiratory Questionnaire (SGRQ,mean number of severe exacerbations,risk of time to first exacerbation,prebronchodilator peak expiratory flow,frequency of moderate/severe exacerbations,2-hour postdose FEV(1,adverse effects,pre-dose forced expiratory volume in 1 second (FEV1) and 1-hour post-dose FEV1.|Morning PEF improved significantly on day 1 versus placebo and budesonide; after 1 week, morning PEF was improved versus placebo, budesonide and formoterol.
91|morphologic remissions,response of active Crohn's disease to sulphasalazine,median AUC of the CDAI,morning plasma cortisol value,serious adverse reactions,disease activity,remission of CD (CDAI < 150) and decrease of at least 60 points,mean 17-week CDAI scores,Activity Index,Clinical improvement,corresponding CDAI change,intention-to-treat basis remission rates,serum albumin, ESR, body weight released to height, abdominal mass, temperature, stool consistency, bowel resection, and extraintestinal symptoms related to Crohn's disease,active CD response rates,Crohn's Disease Activity Index,clinical activity (Harvey-Bradshaw Index) or laboratory indicators of inflammation,median CDAI decrease,side effects,mean activity index,Diarrhoea,disease deterioration,CDAI median score value,Remission,efficacy and safety,activity index,72 CDAI points,change in the Crohn's Disease Activity Index (CDAI,respective rates,total numbers,rates of remission,numbers of patients with adverse events,response of active symptomatic disease,faecal granulocyte excretion,clinical remission, defined as a score of 150 or less on the Crohn's Disease Activity Index,Clinical improvement in Crohn's disease,small bowel and colon disease,achieving partial or complete remission,Crohn's disease activity index (CDAI,severe adverse events,Crohn's Disease Activity Index (CDAI,entered remission or improved their symptoms,remission rate or withdrawal rate for active disease,CDAI,small bowel disease|There was no difference in the remission rate or withdrawal rate for active disease in the two groups.
74|positive and negative predictive values,incidence of invasive fungal infections,serum enzyme-linked immunosorbent assay (ELISA) test,cutoff OD index for positivity,radiologic signs,Galactomannan positivity,overall sensitivity,sensitivity and specificity of the GM EIA,serum galactomannan (GM,PCR and ELISA,Overall specificity of the ELISA,fever and pulmonary infiltrates,median index of the initial NASBA,False-positive reactions,abnormal CT signs,ROC curve,Detection of serum galactomannan (GM,Serum ELISA results,Specific DNA,major pulmonary signs,radiologic examination or Aspergillus isolation,concentration of galactomannan,Invasive aspergillosis,sensitivity and specificity,signs of IFI,Sensitivity of the ELISA,Galactomannan antigenemia,GM,overall specificity,kinetics of NASBA values: failure of negative conversion,diagnosis of invasive aspergillosis (IA,Aspergillus antigenemia,Sensitivity and specificity for the ELISA test,incidence of proven IFI,survival,positive predictive and negative predictive values,patient survival,Positive and negative predictive values,positive predictive value,likelihood ratio of a positive test,Sensitivity and specificity rates,positive results for AGA (OD index,sensitivity, specificity, PPV and NPV of GM detection in CT-based BAL fluid,sensitivity, specificity, and positive and negative predictive values for GM and BG,Sensitivity,sensitivity of diagnosis,invasive aspergillosis,false-positive and false-negative results,During hospitalization, serum galactomannan levels,ELISA cutoff value,consecutive serum GM titres,overall sensitivity, specificity, and positive and negative predictive values,ELISA,Diagnostic levels of both BG and GM,GM antigenemia,negative predictive value,sensitivity,sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of GM detection in CT-based BAL fluid,EIA and latex agglutination test,overall positive and negative predictive values,Galactomannan antigenemia preceded post-mortem histological diagnosis of invasive aspergillosis,serologic positivity,Positive GM titres,PCR and BDG tests,rate of false-positive results,false single-positive rate,specificity,Diagnostic levels of GM,False-positive tests,predictive positive and negative values,occurrence of invasive fungal infection (IFIs,Minor pulmonary signs|Although the ELISA test did not have any role in the anticipation of the diagnosis, it clarifies the diagnosis of IA in allo-HSCT.
81|Median Premature Infant Pain Profile scores,crying time and pain,clinical characteristics and time spent squeezing the heel,pain score and crying time with parents' assessment,lowest cry duration,heart rates, oxygen saturation levels and length of crying,Sucking frequency,pain and the PIPP score and crying time,duration of breastfeeding,Douleur Aiguë Nouveau-né scores,medians for crying time and the pain scores,pain response,Neonatal Facial Activity Coding System and sleep-wake state scores and heart rates changes,né (DAN) score,pain relief,Crying time,mean duration of crying,crying and pain scores,Median crying times,Pain,median recovery time,multidimensional acute pain rating scale of the Premature Infant Pain Profile, heart rate increase, oxygen saturation decrease, crying behavior (duration of first cry, cry percentage in 2 minutes, and during blood sampling), duration of sampling, and the number of performed heel lances,mild pain,Pain related behaviours evaluated with two acute pain rating scales: the Douleur Aiguë Nouveau-né scale (range 0 to 10) and the premature infant pain profile scale,median crying times,crying time, duration of the first cry, percent change in heart rate or maximum heart rate,premature infant pain profile scale,highest pain manifestation,nociceptive reaction,Analgesic effect,duration of crying,mean oxygen saturation levels,parasympathetic tone,relieving pain,sampling duration and numbers of heel lances,analgesic effect,pain of heel pricks,analgesic effect of skin,Crying times,babies' pain on a Visual Analogue Scale (VAS,PIPP score,mean pain scores,total duration of crying,Median crying time, duration of the first cry, percent change in heart rate, maximum heart rate and neonatal facial coding system scores,Crying and grimacing,Heart rate,heart rate differences,Duration of cry and Douleur Aiguë du Nouveau,median values of crying time, recovery time and percentage change in heart rate,analgesic effects,response to pain,lowest pain score,Median pain scores,pain and duration of crying,analgesic effect of breast feeding,pain reduction,oxygen saturation and heart rate and neonatal infant pain scale,relative crying time and recovery time: behavioural state,pain reaction,heart rate and oxygen saturation changes and behavioural responses,lowest neonatal facial score,Neonatal Facial Actions (Neonatal Facial Activity Coding System-upper face), sleep-wake state,Heart rate, oxygen saturation changes and length of crying,Neonatal Facial Coding System score; cry duration; and autonomic variables obtained from spectral analysis of heart rate variability before, during, and after heel-lancing,pain score,median heart rate increase, oxygen saturation decrease, and duration of first cry,crying time,Relative crying time and recovery time,behavioural responses to pain,physiological (heart rate and oxygen saturation) and behavioural parameters [duration of crying and modified Neonatal Facial Coding Scores (NFCS,median pain scores,Premature Infant Pain Profile (PIPP,heart rate despite pain reactivity and extreme crying,heart rate and oxygen saturation,pain,pain scores,heart rate,mean heart rate,Neonatal Infant Pain Scale (NIPS|The change in heart rate and oxygen saturation was significantly lower in the EBM group and returned to baseline values sooner than in the DW group.
1417|severe trachoma|A clean face at two or more follow-up visits was protective for any trachoma (odds ratio 0.58 [0.47-0.72]) and severe trachoma (0.35 [0.21-0.59]).
2|Amenorrhoea,Menstrual disruption,Menstrual irregularities|Menstrual disruption was the main side effect among both treatment groups.
not found|vaginal birth,back and pelvic pain and headache,rates of preterm births,rate of vaginal birth,Pregnancy outcomes,Women's self-assessed motivation to attempt vaginal birth,dystocic deliveries and cesarean section,Rates of vaginal birth after cesarean section,Measurable clinical, obstetrical, and neonatal advantages,supportive behaviors,cesarean deliveries and stays in neonatal intensive care units,probability of vaginal delivery,women's satisfaction, knowledge of risk conditions, and perceived mastery in their lives|Rates of vaginal birth after cesarean section were similar in the verbal and document groups: verbal, 339 of 641 (53%); document, 310 of 634 (49%); relative risk 1.1, 95% confidence interval 1.0 to 1.2.
207|parotid salivary flow,saliva production and relieved symptoms of xerostomia,Saliva production,symptomatic relief,safety and efficacy,sweating, rhinitis, headache, nausea, and urinary frequency,serious drug-related adverse experiences,symptomatic relief by questionnaires and visual analog scales (VAS), and for saliva production by sialometry,Speaking ability,oral dryness,oral comfort agents such as artificial saliva, hard candy, and water,side effects,production of saliva and other manifestations of xerostomia,comfort of the mouth and tongue,overall global assessments|Pilocarpine improved saliva production and relieved symptoms of xerostomia after irradiation for cancer of the head and neck, with minor side effects that were predominantly limited to sweating.
241|composite event "death from all vascular causes, nonfatal stroke, nonfatal myocardial infarction, or nonfatal major bleeding complication,bleeding incidence,number of patients with TIA/RIND,major hemorrhage,myocardial infarctions,major bleeding complications,death or recurrent ischemic stroke,severe stenosis or occlusion of a large artery,myocardial infarction or sudden death,rate of death from vascular causes,cerebral infarctions,efficacy and safety,cerebral hemorrhage,incidences of TIA and TIA-IR,Severe hemorrhage,HR for ischaemic events,gastrointestinal disorders,composite of death from all vascular causes, non-fatal stroke, non-fatal myocardial infarction, or major bleeding complication, whichever occurred first,rate of death from nonvascular causes,recurrent ischemic stroke or death or in the rate of major hemorrhage,death,rates of major hemorrhage,ischemic stroke, brain hemorrhage, or death from vascular causes other than stroke,recurrent cerebral ischemic events,recurrent ischemic stroke,mean achieved INR,Recurrent cerebral ischemic events,Cerebral infarction,adverse events,frequency of or time to the primary end point or major hemorrhage|Cerebral infarction was recorded in 4 patients in each of these treatment groups during a mean follow-up period of 20 months.
not found|actual maternal behaviors,favorable attitudes toward feeding and communication,maternal behavior scores,adolescents' mothering behaviors|Brief culturally sensitive videotapes may be effective strategies to promote parenting skills and to prevent social and health problems among adolescents.
not found|weight, coronary heart disease (CHD) risk factors, and incidence of diabetes,obesity and whole body insulin sensitivity,type 2 diabetes as diagnosed using World Health Organization criteria,total/saturated fat intake and increased polyunsaturated fat/fiber intake and exercise level,body weight,measures of eating, exercise, and fitness; weight losses,Weight, waist circumference, high-sensitivity C-reactive protein, and most of the metabolic syndrome components,plasma glucose values and higher BMI values,3-year cumulative incidences of diabetes,net loss,metabolic syndrome,consecutive fasting plasma glucose (FPG) values,total fat consumption,Weight losses,incidence of diabetes,short insulin tolerance test (ITT,weight loss,risk of type 2 diabetes,hypertriglyceridemia,metabolic abnormalities,multiple metabolic/inflammatory abnormalities,rate of development of diabetes,prevalence of central obesity,behavior, weight, or physiological parameters,risk of diabetes,mean (+/-SD) amount of weight lost,changes from baseline in: nutrient intake; physical activity; anthropometry, glucose tolerance and insulin sensitivity,modest weight loss,Body mass,progression to diabetes,gradual deterioration of behavioral and physiological changes,baseline BMI and fasting glucose, the diet, exercise, and diet-plus-exercise interventions,relative risk reduction,risk of developing diabetes, and weight loss,Body weight,glucose tolerance,cumulative 4-year incidence of diabetes,cumulative incidence of diabetes|The relative risk reduction was 28.5% with LSM (95% CI 20.5-37.3, p=0.018), 26.4% with MET (95% CI 19.1-35.1, p=0.029) and 28.2% with LSM + MET (95% CI 20.3-37.0, p=0.022), as compared with the control group.
57|hearing loss,total effective rate,vertigo, nausea and headache with spontaneous recovery,recovery time,rate of side effects,pure-tone average and subjective symptoms,mean hearing loss,side effects|No significant differences were observed in the improvements of pure-tone average and subjective symptoms between the PGE1 and the placebo groups.
236|mean (+/- SD) pain visual analog score,OA flare pain,pain reduction,WOMAC Physical Function and the Medical Outcome Study Short Form-36 Role-Physical measures,minimum effective naproxen dose (MEND,Electrical sensation and pain thresholds,rapid pain relief,synovial fluid concentrations of SP and IL-6,pain relief,physical function,Efficacy and tolerability,tolerated and effective,nausea,alleviating pain,Global tolerability,mean pain intensity score,functional parameters,pain and functional capability,antinociceptive action,Pain,antinociceptive effects,adverse events,Lequesne functional discomfort index, global efficacy assessed by the patient and the investigator, time to improvement, and use of acetaminophen as rescue analgesic medication,Colonic transit times,adverse event,efficacy of tramadol LP,effective and safe,synovial fluid concentrations of SP,Pain at rest,serious adverse events,pain relief and functional improvement in osteoarthritis,Efficacy and safety,nausea, vomiting, and dizziness,median pain intensity,plasma and synovial fluid the concentrations of M1,synovial fluid concentrations,Average daily pain intensity and pain relief scores,average daily pain intensity and average daily pain relief scores,efficacy and safety Demographic data,Western Ontario and McMaster Universities Osteoarthritis Index Questionnaire,Orocaecal transit time,final VAS score; secondary measures included final pain relief rating scores, subject/investigator overall medication assessments, rate and time to discontinuation due to lack of efficacy, and selected quality-of-life/physical functioning scores,somnolence,efficacy and safety,Pain intensities,Rates of response,WOMAC Pain, Stiffness and Physical Function subscales, the WOMAC Composite Scale, dropouts due to insufficient therapeutic effect, Patient and Physician Global Assessment of Therapy, and Sleep,bowel functions and symptoms,pain, stiffness, physical function, global status, and sleep,synovial fluid concentrations of interleukin (IL)-6 and substance P (SP,intestinal function,Arthritis Pain Intensity Visual Analogue Scale (VAS), Western Ontario and McMaster Universities Arthritis Scale (WOMAC) Pain, Stiffness, Physical Function VAS subscales, Patient and Physician Global Assessment of Therapy, Sleep, dropouts due to insufficient therapeutic effect, and adverse events,global efficacy,MEND,plasma and synovial fluid concentrations of tramadol and its active metabolite (O-desmethyl-tramadol, M1,intensity of joint pain,IL-6 synovial fluid concentrations,efficacy and tolerability,Arthritis Pain Intensity VAS,Sensation and pain thresholds,osteoarthritis flare pain,Mean final VAS scores for tramadol/APAP plus COX-2 NSAID,pain scores,analgesic effectiveness,adverse event-related withdrawals,mean final pain relief rating scores,Huskisson visual analog scale for pain,multidimensional 'Western Ontario and McMaster Universities Osteoarthritis Index' (WOMAC) questionnaire (pain, stiffness and functional impairment,constipation|There was a significant difference (P = 0.040) in the treatment effect between the naproxen responders and nonresponders, thus demonstrating a difference in the way responders and nonresponders react to a decrease in naproxen dosage after the addition of tramadol.
905|change in CDAI,rates of sustained response and remission if natalizumab,rate of clinical remission,highest remission rate,Crohn's Disease Activity Index (CDAI) score,sustained response through week 36,quality of life,Elevated circulating lymphocyte levels,safety and efficacy,changes in scores for the Crohn's Disease Activity Index,CDAI,Serious adverse events,response rates,highest response rate,quality of life and C-reactive protein levels,higher rates of sustained response,rates of clinical remission and response,health-related quality of life, and C-reactive protein levels,remission rates,rates of response,circulating B and T lymphocytes,rescue medication,disease remission (a CDAI score of less than 150,rates of adverse events,response and remission rates,adverse events,remission|Natalizumab, a humanized monoclonal antibody against alpha4 integrin, inhibits leukocyte adhesion and migration into inflamed tissue.
not found|nutritional status, morbidity, and quality of life,functional status, QoL and rehospitalization,Calorie and protein intake,BMI,nutritional intake and status,food intake, body weight, response rate, survival, and quality of life,BMD at the spine, femoral neck and total hip,total caloric and protein intake,immune responses,Intake,Body cell mass and weight gain,intake of protein,Body weight and BCM,body weight development,Energy intake after RT,total lean mass,total body weight,hand-grip strength,acceptability and palatability of the HP blend formula, ease of use, and cost,morbidity, and quality of life (QoL,total protein and total calorie intake,weight overall,Serum IGF-I levels,Protein intake,mean protein intake,weight loss,Crohn's disease activity index,daily energy intake,incidence of disease remission,nutritional intake and gain in lean body mass (LBM,Age, body cell mass (BCM), muscle function, gender distribution and QoL,G3,fat-free mass,SA levels,function and symptom scales,QoL ratings,regain of lean body mass,St George's Respiratory Questionnaire total score,Katz activities of daily living (ADL) index, mini mental status examination (MMSE) and quality of life (QoL,bone metabolism,body cell mass,tumor response rate,Inspiratory muscle strength,body weight, but triceps skinfold measurement,rates of anorexia, nausea, vomiting, and diarrhea,energy intake increased in G1/G2,tumor response rates,overall QOL,Serum osteocalcin,Serum albumin Levels,Quality of life,serum CTX, a marker of bone resorption,weight loss, serum albumin concentration, and presence of liver metastases,function, symptoms, and single-item scores,Short Form-36 health change score,Fat free mass,CD4 counts and viral load,Anthropometry, grip strength, and QOL,body composition (body cell mass,serum albumin level,total energy intake,nutritional intake,body weight,weight, skinfold thickness measurements, or quality of life,Total energy intake,weight, anthropometry, and grip strength,Complications, namely wound infection, chest infection, and antibiotic use,Whole body leucine kinetics and leucine oxidation rate,readmissions,Progressive loss of kidney function,handgrip strength,Nutritional intake,physical performance,triceps skinfold thickness, dietary intake, fecal fat, and pain score,Subjective Global Assessment,survival advantage,whole body protein metabolism,mean total energy,maximum mean (SD,energy intake or percent ideal body weight,lean mass and physical function,fiber intake,Response rate and overall survival,baseline food intake,serum albumin,body weight, nutritional status, and quality of life,reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia,mean intervention time,Quality of life (QOL,Weight, skinfold thickness, fat-free mass, grip strength, quality of life, and cognitive function (Buschke test,Weight loss and protein malnutrition,Serum osteoprotegerin (OPG,physical performance such as muscle strength, balance, mobility and activities of daily living, as well as nutritional aspects such as energy intake, body weight and fat-free mass,fat-free mass and grip strength,weight and arm muscle circumference,body weight gain,Total daily protein and caloric intake, food-derived protein and caloric intake, and supplement-derived protein and caloric intake,serum albumin, calorie and protein intake, and nPNA,energy intake,quality of life (QoL,Main Outcome Measures: (1) Nutritional status parameters, BMI and serum albumin; (2) functional status on a 10-point Karnofsky scale; (3) adverse metabolic effects, hyperphosphatemia at start and end of study; and (4) subjective scoring for appetite, and acceptability of and tolerance to supplement,bone resorption,change of ventilatory parameters,Katz ADL index,response rates, median time to progression, or overall duration of survival,Karnofsky Performance Status Scale,Lean body mass determined by bioelectrical impedance analysis,weight,caloric intake,QoL,initial nutritional status,BMD at the lumbar spine and total hip,energy intake and weight,serum albumin level and functional scoring,Mild hyperphosphatemia,rapid weight gain,efficacy and cost-effectiveness,body composition, muscle function and quality of life (QoL,body composition and dietary intake,Nutritional status,expiratory muscle strength,protein malnutrition assessed by midarm muscle circumference, creatinine-height index and serum albumin,weight gain,RT toxicity,energy and protein intake,dry weight and BMI,Involuntary weight loss,antibiotic prescriptions,skin fold thickness,factors: 'malaise', 'psychological distress', 'therapy side-effects,respiratory function or skeletal and respiratory muscle strength,grip strength,changes in handgrip strength, general well-being score, perception of health and number of falls,nutritional status, QOL, and morbidity,reactivity to skin test antigens,Energy intake and nutritional status,O(2) saturation and a decrease in PaCO(2,For colorectal cancer, serum albumin, alkaline phosphatase, lactic dehydrogenase (LDH) levels, and percent targeted caloric intake (TCI,bone-specific alkaline phosphatase,anthropometric parameters and improved Subjective Global Assessment evaluation,body composition (increased lean mass, decreased fat mass,functional status,Dietary intake (protein, energy, fiber,oral intake, body weight, response rate, survival, and quality of life,gain in fat mass,Ottery's Subjective Global Assessment), and QOL (determined by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire version 3.0 [EORTC QLQ-C30,weight (B), [mean (SD) % change in BMD lumbar spine,frequency of patients with moderate or severe malnutrition,peak flow,Nutritional behaviour,dietary intake,e.g. insulin-like growth factor,Mean daily energy intake,body weight and somatic protein compartments,food intake,fat mass,maintain nutrient intake,energy intake and gained weight,severe loss,Body composition and bone mineral density (BMD,Medical Research Council dyspnoea score,QOL function scores,lower- extremity muscle strength,Refeeding and weight gain,body weight and tricipital skinfold,subjective global assessment, body composition by bioelectrical impedance and anthropometry, muscle function with hand-grip strength and peak flow,median time to progression and overall duration of survival,enhanced gain of LBM,patient outcomes,Triceps skinfold thickness (TSF) and midarm muscle area (MAMA,nutritional status,shorter time of survival,Leucine oxidation (protein catabolism,Nutritional intake (diet history), status (Ottery's Subjective Global Assessment), and QoL (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire version 3.0,goal for energy intake and gained weight,Equal weight loss,reduced symptomatology,Quality-of-Life index (QL-index,improvement/deterioration of QoL,muscle function and quality of life,number of falls,nutritional repletion,peritoneal transport rate and MAMA,protein intake,absolute lymphocyte count,weight loss and improved ADL functions,Biochemical markers of bone turnover,weight maintenance,Body weight, biochemical indices,nutritional status, respiratory and skeletal muscle strength, respiratory function, perceived dyspnoea, activities of daily living (ADL) and quality of life,adequate intake or nutritional status,nutritional outcome, morbidity, and quality of life (QOL,Nutritional behaviour and quality of life,weight and QoL,nutritional status (Subjective Global Assessment), and energy and protein intake (3-day food record,dietary intake (24-h recalls), body weight, and QoL (EORTC-QLQ C-30,lymphocyte CD4 counts, on plasma TNFR 55, TNFR 75 and ILR 2 concentrations and on quality of life,Body composition,non-protein nitrogen appearance rate (nPNA,Mean intake per kilogram of body weight,metabolic rate|The nutrition intervention group had a higher mean total energy (P=0.029) and protein intake (P<0.001) compared with the standard practice group.
132|development of severe hypertension,gestational age at delivery,serious perinatal complications,Clinician compliance,preterm birth,Preterm delivery and birth weight,Mean dBP,systolic and diastolic BP levels,neonatal intensive care unit (NICU) admission,serious maternal complications,diastolic blood pressure (dBP,serious perinatal and maternal complications,Control of Hypertension,severe hypertension,rate of antenatal hospitalization|Mean dBP was significantly lower with tight control:
not found|patients' adherence and minimise toxicity,virologic failure (loss of HIV suppression,undetectable plasma HIV-1 RNA concentration,detectable HIV-1 RNA,viral loads,initial virion-clearance rate,viral suppression,loss of viral suppression,rates of viral clearance,suppression of plasma HIV RNA,CD4 cell counts,risk of virologic failure,plasma HIV-1 RNA concentration,virologic failure|Similar results were obtained when the one abstract was excluded (odds ratio, 5.48; 95% confidence interval, 2.82 - 10.65).
not found|hospital mortality rates for CHF,AMI volume,CABG volume,individual process-of-care indicators, a hospital report card impact survey, and all-cause AMI and CHF mortality,health plan choices,HMO choices,mean 30-day AMI mortality rates,quality of cardiac care,composite AMI and CHF indicators based on 12 AMI and 6 CHF process-of-care indicators|The strongest effects were among white patients and those with HMO coverage in California, and among white or other patients and those with Medicare in New York.
200|total drainage volume, hourly zero drainage, heart rate, or occurrence of arrhythmias,drainage, incidence of cardiac tamponade, incidence of surgical reentry, hemodynamic values, and number of manipulation episodes,volume of drainage|Statistical analyses revealed no difference in any of the dependent variables when milking and stripping were used.
60|Relief of PDPH measured as delta VAS (initial VAS - VAS,pain,PDPH,Headache,severity of the headache,mean of headache intensity,10-cm visual analogue scale, severity of headache,mean headache intensity,headache,headache intensity,mean pain score,Intensity of headache, quantitated using a visual analogue pain scale (VAS,severity of headache or requirement for epidural blood patch,visual analog scale,post-puncture headache,postdural puncture headache|After 24 hours, mean headache intensity was 3.87 (+/- 1.63) in conventionally treated group versus 0.73 (+/- 0.74) in hydrocortisone group (p <0.001).
271|infection rate,average length of hospitalization and convalescence,rate of postoperative infectious complications,post-operative wound sepsis rate,erythematous rash,rate of post-operative infections,hospital wound infections,frequency of non-clostridial anaerobic infection,majority of wound infections,incidence of complications,rate of postoperative infections,incidence of anaerobic wound infection,incidence or severity of wound infection or post-operative intra-abdominal sepsis,wound infection rate,incidence of wound infection,overall rate of wound infection,days of hospitalization,safety and efficacy,morbidity and prolongs hospital stay,number of aerobic organisms,occurrence of both anaerobic and aerobic bacteria,infection rates,incidence of postoperative wound infection,toxicity,wound-infection rate,Septic morbidity,rate of infectious complications,Anaerobic infection,overall incidence of infection,anaerobic infection,Nonperforative appendicitis,overall infection rates,postoperative wound infection,wound infection,anaesthetic complication,Blood levels,incidence of infectious complications,overall infection rate,septic complications,Postoperative infections,postoperative wound infections,rate of wound infection,Postoperative wound infections,duration of postoperative hospital stay,Wound sepsis,rate of postoperative wound infection,wound infection, the hospital stay,Therapeutic concentrations,wound infections,Late sepsis,Sepsis rates|In those receiving both drugs the infection rate was 3%, a highly significant difference from that in the other three groups.
63|mean glucose levels,Self-perception,blood pressure, glycemic control, lipids and insulin sensitivity,insulin sensitivity,urine ketones,Glucose concentration,energy intake adequacy,glycaemia,fasting plasma glucose and glucose tolerance,effectiveness, safety and tolerability,Dietary intakes,Mean birthweight,pregnancy outcomes,adverse pregnancy outcomes,Obstetrical outcomes,birth weight,ketonemia,prevalence of macrosomia,diastolic blood pressure and no adverse effects on blood lipids,pre-pregnancy BMI,Key obstetric and fetal outcomes,blood glucose,birth weight centile,postprandial glucose values,Metabolic effects,prevalence of gestational diabetes mellitus (GDM,Adherence,diastolic blood pressure,Energy restriction,fasting blood glucose,Ketonuria,effectiveness, tolerability and safety,Self-monitored-blood-glucose (SMBG), maternal and infant weight,frequency of insulin therapy,Average adherence,Fasting levels of beta-hydroxybutyrate,glucose concentration,blood pressure,Glycemic control,pregnancy outcomes, neonatal anthropometry, and maternal metabolic profile,Fasting plasma insulin,Glycaemic control,Energy intake adequacy,blood pressure and glucose metabolism,ambulatory blood pressure, blood lipids, glycemic control and insulin sensitivity estimated by an intravenous glucose tolerance test,Optimal glycemic control,Dietary intake|A low-glycemic index diet is effective as a treatment for individuals with diabetes and has been shown to improve pregnancy outcomes when used from the first trimester.
37|persistent Staphylococcus aureus bacteremia,Severe neutropenia,clinical sites of infection, degree of neutropenia underlying malignancy, and organisms,overall success rate,infections and unexplained fever,depth and duration of granulocytopenia as well the distribution of the infection categories and rate of bacteremia,Duration of fever,median durations of neutropenia,febrile neutropenia,median duration of antibiotic therapy,renal tubular damage,durations of fever, neutropenia, and hospitalization,clinical efficacy,febrile neutropenia episodes,microbiological eradication of gram-negative,response rate regarding gram-negative infections,urinary excretion of AAP,gram-positive,complete response rates,Overall treatment success,Urinary beta-NAG,clinical response,fever and neutropenia,Gram-positive infections,tolerated and produced response rates,granulocytopenic episode,Adverse events,initial clinical response rate,Gram positive cocci,Control of infection,tolerability,occurrence of gram-negative bacteria,nephrotoxicity,overall response rate,febrile infective episodes,infection-related mortality,skin rash and vomiting,Median duration for defervescence,Clinical cure or improvement,efficacy, safety, and tolerance,median neutrophil count,duration of neutropenia,adverse events,Mortality,leukemia or lymphoma,prolonged neutropenia,Overall success,satisfactory response, eradication of the infecting organism, development of superinfections, and occurrence of adverse events,infection, and unexplained fever,Superinfection,percentages of patients responding to therapy,renal side effects,Microbiological adverse effects,Efficacy and costs,haematological malignancies,rate of treatment modification,Excellent response,mean total antibiotic drug cost,initial clinical response,rates of clinical cure or improvement and of elimination of causative pathogens,morbidity and mortality,total episode cost,serum levels of creatinine, urea and beta 2-microglobulin and the urinary excretion of alanine aminopeptidase, N-acetyl-beta-D-glucosaminidase (beta-NAG) and beta 2-microglobulin,febrile episodes,febrile events,876 febrile, neutropenic episodes,granulocytopenia,cure rates for gram-negative bacteremias,Hodgkin's lymphoma (NHL,clinical response rates,efficacy,overall initial response,efficacy and safety,Six febrile episodes,Superinfections and toxicity,response rate,duration of fever, clinical symptoms, antibiotic therapy, and granulocytopenia,infection-related death,69 febrile granulocytopenic episodes,severe hypokalemia,cure rates,treatment failure,efficacy and tolerability,adverse experiences; drug-related adverse events,overall treatment costs and duration of hospitalization,tolerated,overall successful outcome,mean neutrophil counts,failure rate,average cost of antibiotics,nausea or vomiting,cost of change of antibiotics,Duration of fever, hospitalization, and antimicrobial drug administration,infection rate,acute leukemia,Global response,Bacteremia,persistent bacteremia,proportion of patients that became afebrile,median duration of neutropenia and defervescence of fever,leukopenia,median time to fever defervescence,median total duration of neutropenia,lower potassium level,Clinical and laboratory adverse effects,febrile neutropenia (FN,fever of unknown origin,Blood cultures,adverse events, duration of hospitalization, and cost between both groups,Partial response rates,cost effective,overall response rates,efficacy, safety and tolerance,response rates,toxicity,febrile neutropenic episodes,costs of the antimicrobial drugs, hospitalization, and total cost,clinical efficacy and tolerability,success rate,episodes of profound neutropenia,withdrawals or deaths,overall cure rate,Infection,renal failure,rates of superinfection,Amikacin levels,superinfections of fungal origin,reversible side effects,rates for gram-negative rod bacteremia,Serum peak and trough concentrations of the antibiotics,success or failure,Costs of hospitalization, antimicrobial drugs, and supportive therapy,neutrophil counts of <100/microL. Microbiologically documented infection,efficacy, safety, and cost of cefepime,Infectious mortality,Response rates,serum creatinine,overall clinical rate of response to imipenem,unexplained fever,Gram-positive bacteremia,Efficacy and tolerability,infection eradication success,efficacy and cost effectiveness,gram-negative,nausea,bacteremia,adverse event,success rates,mean duration of neutropenia,early death,side effects,nephrotoxicity nor hypokalemia alone,Fifty febrile netropenic episodes,Allergic reactions,incidence of side effects,nausea/vomiting or seizure,duration of hospitalization,per episode antibiotic cost,successful outcomes,Duration of fever, neutropenia, and hospitalization, mortality, and the need for additional antibiotics or antifungal drugs,Efficacy,adverse effects,Defervescence,incidence of gram-negative and gram-positive isolates,occurrence of further infections|Gram-positive bacteremia responded poorly in the meropenem and ceftazidime/amikacin group (29% versus 25%), whereas all gram-negative bacteremias responded except for one in the meropenem group caused by Pseudomonas aeruginosa.
33|peak oxygen consumption,Piper Fatigue Scale, General Sleep Disturbance Scale, Center for Epidemiological Studies-Depression Scale, and Worst Pain Intensity Scale,Self-esteem,physical global QOL score,symptoms of side effects of cancer treatment and inflammation biomarker (CRP,depressive and state anxiety scores,mental health dimension of quality of life,Physical performance,depression, (Beck Depression inventory), anxiety (Speilberger State-Trait Anxiety Inventory), and self-esteem (Rosenberg Self-Esteem Inventory,fatigue, social physique anxiety, and physical fitness,helplessness/hopelessness,cardiorespiratory fitness, strength endurance, task specific functional muscle capacity, body composition and quality of life (QOL,physical fitness test and QOL measures (e.g. Functional Assessment of Cancer Therapy scales,back/leg muscle strength,physical global score,global QoL,bodily pain,Exercise and quality of life,fatigue score,sleep quality,Maximal oxygen uptake (VO(2)max/kg,fatigue,inflammation (CRP,self-perceptions of appearance, health, physical strength, sexuality, relationships, and social functioning,Exercise and dietary behavior, fatigue, health-related quality of life (QOL), aerobic exercise tolerance, functional capacity, muscle strength, and anthropometery,VO(2max,body fat,social functioning,quality of life, fatigue, mood and inflammation,Functional Assessment of Cancer Therapy-Breast, social/family well-being, functional well-being, and breast cancer subscale scores,lean mass,cardiorespiratory fitness and health-related quality of life,Physical activity,Tai Chi Chuan, health-related quality of life and self-esteem,patient-rated physical functioning assessed by the Trial Outcome Index-Anemia,sleep,mental distress, as assessed by the Hospital Anxiety and Depression Scale, and HRQOL, as assessed by the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire,Quality of life and symptoms,Health-related quality of life (HRQL) and self-esteem,Shoulder pain and disability,higher satisfaction,Quality of life and physical performance and activity,overall QOL,Serotonin levels,upper extremity endurance,Fatigue (p<0.001), depression (p<0.001), body mass index,Quality of life,quality of life benefits,fatigue (t(153),cardiovascular fitness,cardiopulmonary function and quality of life (QOL,HRQL and self-esteem,mood disturbance (t(122),QOL and the overall physical fitness,waist-to-hip ratio,sleep quality and quality of life of cancer patients,sleep quality and quality of life,Strength and QOL improvements,fatigue (P=.005), aerobic exercise tolerance (P=.010), chair sit-to-stand performance (P=.003), and waist-to-hip ratio,fatigue and pain,fatigue (Multidimensional Fatigue Symptom Inventory-Short Form and Functional Assessment in Chronic Illness Therapy-Fatigue subscale,intrusion or avoidance, state anxiety, depression, or fatigue,Strength and QOL variables,Strength and Health subscale,depressive and anxiety symptoms and self-esteem,measures of Spiritual Integration,biomarkers, fatigue, sleep disturbances, and depressive symptoms,quality of life,QoL. Physical activity level,Baseline BIRS scores,Functional Assessment of Cancer Therapy-General and Functional Assessment of Cancer Therapy-Fatigue,physical performance,QOL and fatigue,physical activity,fatigue, energy level, and emotional distress,aerobic fitness,performance in leg press,QoL, depression, exercise behavior, aerobic fitness; outcomes,objective physical functioning,neck dissection impairment, fatigue, and quality of life,decreased depression,Changes in QOL (eg, Functional Assessment of Cancer Therapy,Overall QOL,quality of life (QOL), fatigue, distressed mood, and spiritual well-being,Functional Assessment of Cancer Therapy-Breast scale,individual body image,overall quality of life (QoL,QoL. Physical performance and activity level,anxiety,physical, cognitive and emotional status and somatic complaints with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core Module (EORTC-QLQ-30) questionnaire, and maximal physical performance,changes in QOL (CARES short form) and depressive symptoms (CES-D,Quality of life (QOL,physical fitness and quality of life outcomes,cancer-related fatigue,subjective sleep quality,dietary behavior, fatigue, aerobic exercise tolerance, functional capacity, and waist-to-hip ratio,physical quality of life,Peak oxygen consumption,time interaction for overall QoL,depressive and anxiety symptoms,longer sleep duration,physiological and psychological function,quality of life (QoL,self-esteem,strength and QOL changes,faster sleep latency,quality of life, mood, and spiritual integration,exercise behavior,psychosocial adjustment and quality of life,physical functioning and quality of life,distressed mood,global health,fatigue and health-related quality of life,general health,overall QoL, psychosocial functioning, cardiovascular fitness, and body composition,Quality of Life questionnaire,overall QoL,risk of disease recurrence/progression,PSQI,quality of life (QOL,QoL,global quality of life, physical well-being, and functionality,accelerometer physical activity counts,Reductions in distress,depression and state and trait anxiety,overall mood and body esteem,quality of life, physical functioning, positive and negative affect, depression, body composition, sleep dysfunction and self-reported physical activity,dietary fiber intake,vigor and a reduction in fatigue,PA and improved fitness and specific aspects of psychological well-being,peak oxygen uptake (VO2peak), a dynamic strength endurance test (maximum number of repetitions for chest and leg press exercise,physical performance measures,Sleep actigraphy,muscle strength,decreased confusion,joint stiffness,Isometric muscle strength and aerobic capacity,depression,HRQL,mild fatigue levels, sleep disturbance, and mild pain,psychosocial global score,Good adherence,Median adherence,CES-D scores,sleep disturbance,Fatigue, sleep disturbances, depressive symptoms, biomarkers, and exercise,fatigue, sleep disturbance, depression, and pain,spiritual,quantified physical performance and self-reported physical functioning,aerobic capacity,fatigue and improving energy level, quality of life (mental and physical), fitness (VO 2submax), and emotional distress,global QOL scores,peak oxygen consumption and overall QOL,body mass index and percent body fat,psychosocial (i.e. global quality of life, emotional function, and diarrhea) variables,decreased anxiety,QOL,12-month BIRS total and subscale scores, upper and lower body strength, and general quality of life (QOL,sleep scores,physical functioning and quality of life (QoL,cortisol, serotonin, interleukin-6, and bilirubin biomarkers and fatigue, sleep disturbances, and depressive symptoms,mental distress or HRQOL,lower morning and 5 p.m. salivary cortisol and improved emotional well-being and fatigue scores,cardiorespiratory fitness (CRF), mental distress, and health-related quality of life (HRQOL) parameters,maximum heart rate,upper extremity strength and endurance, range of motion, fatigue, and quality of life,QOL and depressive symptoms,Psychological adjustment and sleep quality,Fatigue and global health scores,lean body mass,upper body strength,BIRS total score,shoulder pain and disability and improved upper extremity muscular strength and endurance,Taiwanese version of the Pittsburgh Sleep Quality Index, the Medical Outcomes Study Short Form-36, the Taiwanese Version Ratings of the Perceived Exertion Scale, and a walking exercise log,quality of life and social body image,Psychological health outcomes,change in QOL,Cancer QLQ-C30 (EORTC-C30) questionnaire,self-perceived psychosocial function and diurnal salivary cortisol secretion,shoulder pain and disability,EORTC QLQ-C30, FACIT-F, RBDI, and WHQ (for vasomotor symptoms) questionnaires,self-esteem and depressive and anxiety symptoms,lower-body flexibility,sleep disturbance scores,inflammatory marker serum C-reactive protein (CRP,sleep medications,Functional Assessment of Cancer Therapy-Colorectal,chronic fatigue and quality of life,mental health, depression, positive affect, and spirituality (peace/meaning,total minutes of PA, more minutes of moderate-intensity PA, and higher energy expenditure,initial fighting spirit,Pittsburgh Sleep Quality Index (PSQI), the Piper Revised Fatigue Scale, and the Center for Epidemiological Studies-Depression Scale,psychosocial wellbeing, individual body image, and physical fitness,cardiopulmonary function and QOL,fatigue and diurnal salivary cortisol concentration,happiness, depressive symptoms, anxiety, stress, self-esteem, and quality of life,overall well-being and quality of life,body image (Physical Condition and Weight Concerns subscales,Adherence,Anxiety, depression, body image, and quality of life,psychological distress,Baseline quality of life,fatigue and physical performance,anxiety, depression, body image, and health-related quality of life,upper extremity strength,quality of life (QoL) and physical performance and activity,quality of life over time,body composition measurement, quantified walking activity and patient-reported outcomes (physical activity, fatigue and health-related quality of life,patient-rated shoulder pain and disability,enhanced sleep quality,peak cardiovascular fitness,change in CRF, as determined by Astrand-Rhyming indirect bicycle ergometer test (maximum oxygen uptake [VO(2max)]), between baseline (T0) and follow-up (T1,range of motion of the shoulder joint, and psychosocial adjustment and quality of life,self-reported emotional, health-related quality of life, and symptom outcomes,Adherences,Body Image and Relationship Scale,psychosocial variables of emotional irritability, gastrointestinal symptoms, cognitive disorganization, mood disturbance, tension, depression, and confusion|Significant differences favouring the intervention group were observed for fatigue at 12 weeks and 6 months follow-up (12 week:
28|forced expiratory volume,positive expiratory pressure,FVC,total lung capacity,expectoration and lung function,symptoms and lung function,quantity of sputum,airway resistance (Raw), or specific airway conductance (sGaw,radioactivity content,Functional residual capacity and total lung capacity,symptom scores, sputum production, or simple lung function tests,sputum production, symptom score or peak expiratory flow rate,number of spontaneous coughs,forced expiratory flow,Wet and dry weights of sputum,Lung volumes,Residual volume,Clinical status and pulmonary function (forced vital capacity [FVC], FEV1, and FEF25-75,Mean clearance of tracer from the right lung by postural drainage, PEP and physical exercise,whole lung TBC,mean (SEM) functional residual capacity,Slow vital capacity,Mucus clearance,Lung function parameters (peak expiratory flow, forced vital capacity (FVC), forced expiratory volume in one second, maximal midexpiratory flow, maximal expiratory flow at 25% of FVC, thoracic gas volume, total lung capacity, residual volume/total lung capacity, airway resistance and specific airway conductance) and changes in transcutaneous oxygen haemoglobin saturation,acceptability and subjective efficacy,Lung function,Clinical status, pulmonary function, and compliance,postural drainage (PD,pulmonary function,lung function, sputum expectoration, and SpO(2,sputum production or change in lung function,PSO2,pulmonary function tests (PFTs,PEP-induced lung function improvement per milliliter of sputum,clearance of lung radioactivity,Huang scores,whole lung or regional TBC,pulmonary function studies,mean annual rate of decline in forced vital capacity,Skin oxygen tension, PSO2,number of hospitalizations and antibiotic use,Wet and dry weight of sputum,Sputum clearance,Shwachman-Kulczycki clinical score,ventilation distribution, gas mixing, lung volumes, expiratory airflow, percentage of arterial blood oxyhemoglobin saturation (SpO(2)), and sputum volume,positive expiratory pressure breathing,Mucus transport,whole lung and regional tracheobronchial clearance (TBC,FEV(1,regards growth, Shwachman score, Chrispin-Norman score or pulmonary function tests,forced expiratory volume in the first second of expiration (FEV1), forced expiratory flow,arterial oxygen saturation, FEV1 or forced vital capacity,lung function parameter,increased hospitalizations|At the end of the trial, no significant difference was found between the programmes as regards growth, Shwachman score, Chrispin-Norman score or pulmonary function tests.
467|survival curves,percentage of patients alive,survival rate,Median survival times,toxicity,longer survival period,median time to progression,survival,long-term (18-month) survival,longer survival,longer survival time,median time,median survival,severe myelotoxicity,transient myelosuppression,histologic type (Astrocytoma with anaplastic foci, versus glioblastoma multiforme), initial performance status, time since first symptoms and presence or absence of seizure,reversible leukopenia and thrombocytopenia,total survival,median survival time,time to progression,severe or worse thrombocytopenia,cure rate|The combination of carmustine plus radiotherapy produced a modest benefit in long-term (18-month) survival as compared with radiotherapy alone, although the difference between survival curves was not significiant at the 0.05 level.
19|areal BMD,bone turnover and bone mineral density,protein C antigen,efficacy, safety, and user satisfaction,areal bone mineral density (aBMD) of the femoral neck and the lumbar spine,SHBG levels,urinary levels of pyridinoline and deoxypyridinoline, in calcium levels and in BGP levels,mean lumbar spine BMD,bone geometry and volumetric bone mineral density (vBMD,BMD and BMC of lumbar spine and femur and on bone metabolism,BMD loss,serum and urinary calcium, osteocalcin and urinary pyridinoline (PYD) and deoxypyridinoline (D-PYD) levels,percentage of change from baseline bone mineral density at the lumbar spine,intermenstrual bleeding and spinal bone density,bone mineral density and bone metabolism,total body,percentage of change from baseline bone mineral density,urinary pyridinoline and deoxypyridinoline,BMD,Adverse events,serum and urinary calcium, osteocalcin (BGP), urinary pyridinoline and deoxypyridinoline,vertebral aBMD,bone turnover and bone mineral density (BMD,bone metabolism and bone mineral density,bone mineral density,lumbar BMD,2-year treatment-failure cumulative pregnancy rate,urinary levels of PYD and D-PYD, in calcium levels and in osteocalcin levels,greater trochanter,urinary levels of PYD and D-PYD,maximum bone mass,total triglycerides, HDL and HDL(2) cholesterol, and IDL lipoproteins,endometrial hyperplasia,lumbar bone mineral density values,spinal BMD values,Bone mineral density (BMD) and bone mineral content (BMC,baseline BMD, body mass index (BMI) and difference in BMI,SHBG,incidence of bleeding anomalies,bone turnover,duration of bleeding days,urinary PYD and D-PYD levels,bone mineral density (BMD) changes and contraceptive efficacy,lumbar bone mineral density,levels of sex hormone-binding globulin (SHBG,alkaline phosphatase,bone formation,biological estrogenic effect,bone resorption,bone mineral density (BMD,femoral neck,Pyridinoline and deoxypyridinoline levels,BMD and BMC of lumbar,Forearm bone density (BMDprox,urinary levels of PYR and D-PYR,Recovery of BMD,total cholesterol,serum osteocalcin (BGP), urinary pyridinoline (PYD) and deoxypyridinoline (D-PYD,bone turnover and bone-sparing effect,bone resorption (urinary levels of pyridinoline (PYR) and dexoxypyridinoline (D-PYR,serum lipid and bone density patterns,Lumbar spine BMD,total cross-sectional area,serum and urinary calcium, osteocalcin, urinary pyridinoline, and deoxypyridinoline,bone density,maintaining BMD,periosteal bone formation,low-density lipoprotein cholesterol,skeletal effects,baseline demographic or anthropometric characteristics, or in BMD of users of either model of implant,Radial trabecular vBMD,Urine hydroxyproline and creatinine ratio (Hop/Cr,safe and well-tolerated,bone density and bone metabolism,serum calcium levels,lumbar spine,Areal bone density,bone mineral density (BMD) and metabolic bone parameters,mean NTx urine concentrations,Total and LDL cholesterol, and apolipoproteins,mean BMD loss,haemostasis, lipids, carbohydrates, bone metabolism, and sex hormone-binding globulin (SHBG|Differences of lesser statistical magnitude were seen at the femoral neck (between group differences at 2 yr: 2.7%, P = 0.24), Ward's triangle (5.0%, P = 0.055), greater trochanter (3.6%, P = 0.056), total body (1.3%, P = 0.046), legs (1.3%, P = 0.065), and trunk (2.0%, P = 0.029).
not found|overall actuarial survivals,died,3-year actuarial disease-free and overall survivals,actuarial disease-free survival,5-year disease-free and overall survival,Actuarial 3-year overall survival,5-year overall survival,suffered recurrences,5-year disease-free survival,disease-free survival,cardiotoxicity presenting as pulmonary edema,overall actuarial survival,freedom from local recurrence and/or metastases and overall survival,vaginal recurrence,distant metastases,Survival,actuarial percentage survival figures,3-year actuarial disease-free survival,survival advantage,Relapse-free survival rates,overall survival advantage,survival,congestive heart failure,local recurrence,Partial suppression of distant metastasis,overall survival,overall survival rates,local control, metastasis-free survival, disease-free survival, and survival,Local control,recurrence rates in specific cell types (leiomyosarcoma, homologous mixed mesodermal sarcoma, or heterologous mixed mesodermal sarcoma,survival benefit,local recurrence of disease,local recurrence rate,progression-free interval or survival|The difference between the two groups is statistically significant (P less than .005, log rank test).
173|MSS variation,myasthenic muscular scores,QMG Score for Disease Severity,Quantitative Myasthenia Gravis (QMG) Score for Disease Severity,dropout rate,duration of improvement,QMGS, and IVIg,tolerated,variation of a myasthenic muscular score (MSS,efficacy and tolerance,QMGS,quantified MG clinical score (QMGS,quantitative MG Score (QMG,myasthenic muscular score|However, the difference between the 2 groups was not significant (effect size, 3.84 [95% confidence interval, -1.03 to 8.71];
not found|Activity indexes (ESR and clinical parameters,duration of morning stiffness, number of joints with pain, number of joints with swelling and Lansbury's index,efficacy and safety,bone density,serum Ca value,ratio of OKT-4/OKT-8,BMC,percentage of patients with slight improvement,ESR, tenderness on palpation and subjective pain,bone density (GS max, GS min and sigma GS/D,side effects,mineral metabolism parameters (serum calcium, phosphorus, alkaline phosphatase, 24-h urinary calcium, phosphate and 24-h hydroxyproline excretion) and radial bone mineral content (BMC,serum alkaline phosphatase and 24-h hydroxyproline excretion,bone atrophy|Furthermore, serum alkaline phosphatase and 24-h hydroxyproline excretion decreased significantly only in Group A, and BMC decreased significantly in Group B but rose slightly in Group A.
70|liver function tests,consciousness,semiquantitative nitrogen balance,index of portal-systemic encephalopathy,safety and efficacy,encephalopathy,driving capacity,acute hepatic encephalopathy,Survival and discharge,Semiquantitative nitrogen balance,coma score,mental state,adverse reactions,neuropsychologic function,renal failure,plasma AAA/BAA ratio,psychomotor disturbances,renal and two respiratory failure, and one remained encephalopathic,negative nitrogen balance,Acute hepatic encephalopathy,cerebral state and on nitrogen homeostasis,psychomotor functions (line tracing, tapping, steadiness, auditory reaction time), attention (digit table), and practical intelligence (digit symbol, number connection test,recovery rate|No significant difference was noted based on clinical evolution, even though the plasma AAA/BAA ratio was corrected using the modified AA solution.
19|tidal volume,lung compliance,tidal volume and pulmonary compliance,airway resistance,pulmonary function measurements,pulmonary mechanics,birth weight,lung compliance and decreased airway resistance,Urinary sodium, potassium, and chloride losses,excretion of urinary electrolytes,pulmonary resistance,hypokalemia, chloride deficiency, hypercalciuria, nephrocalcinosis, and rickets,urine volume,Six hour urine output,efficacy and safety,pulmonary function,urinary electrolyte losses,tidal volume and compliance,diuresis or renal side effects,urine output,static respiratory compliance,Pulmonary mechanics,Total respiratory resistance|Single dose nebulised frusemide improves pulmonary function in premature infants with evolving chronic lung disease without adverse effects on fluid and electrolyte balance.
788|cognitive function deteriorated,cognitive function,global functioning,cognitive performance as assessed using the eleven-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog/11,cognition,ADAS,activities of daily living,cognition, daily function, and behavior,Safety and tolerability,improving cognition, including executive function,Clinician's Interview Based on Impression of Change-Plus Caregiver Input (CIBIC-plus), Neuropsychiatric Inventory, and EXIT-25 for assessment of executive functioning,safety and tolerability,efficacy and safety,ADCS-ADL score,Efficacy,Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-cog/11) and the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) total score|Patients treated with galantamine had a greater improvement in ADAS-cog/11 after 26 weeks compared with placebo (-1.8 vs -0.3; p < 0.001).
426|risk of bond failures,strength of adhesion,frequency of failed brackets,debonding time for GIC,survival time distributions,bracket survival,survival time and cariostatic potential,Survival time distributions,Bracket failures,bracket failure rates,bracket survival time|The survival time distributions for brackets bonded with each bonding agent were not significantly different (P = .74, paired Prentice-Wilcoxon test; P = .75, Akritas test), with bracket failure rates of 17% and 20% recorded for compomer and resin adhesive, respectively.
23|Mini-Mental State Examination,cognitive and functional performance,Mini-Mental State Examination (MMSE) scores,emotional symptoms of apathy and irritability,MMSE score,cognitive function and quality of life,secondary endpoint Montgomery Asberg Depression Rating Scale (MADRS,cognitive and neuropsychological tests,tests of information and orientation and various aspects of memory,Quality of Life - Alzheimer's Disease scales,Cognitive-communication, neuropsychiatric, functional performance, and quality of life evaluations,change in global cognitive function as determined by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and the Mini Mental Status Examination (MMSE,cognitive tests, activities of daily living scale, neuropsychological battery and scales to evaluate caregivers' depressive and anxiety symptoms,relevance of discourse, (b) performance of functional abilities, (c) emotional symptoms, (d) quality of life, and (e) overall global function,IG(MCI,behavioural and functional outcomes,scores of MMSE, OSGP and GDS,cognitive and behavioural measures,negative emotional symptoms,Alzheimer's Disease Assessment Scale - Cognition (ADAS-Cog,specific cognitive and psychopathological ratings,cognitive and non-cognitive functions,discourse abilities, functional abilities, emotional symptoms, and overall global performance,backward digit span scores,apathy, irritability, and patient-reported quality of life,psychiatric symptoms,Alzheimer's Disease Assessment Scale--Cognition|At the end of the 3 months of therapy significant differences emerged in the scores of MMSE, OSGP and GDS obtained by the two groups.
not found|caries increment,effectiveness against caries,incidence of dental caries,dental caries incidence,approximal dental caries,dental caries|There was no significant difference in effectiveness against caries between the use of the organic or inorganic fluoride products.
1469|Oswestry Back Pain Index, Neck Disability Index, Short-Form-36, and Visual Analogue Scales,pain reduction,flexion and pain,disability,intensity of low back pain, disability, handicap, medication, and quality of life,visual analog scale, range of motion, maximum voluntary extension effort, straight leg raising and Biering-Sorensen fatigue test,pain and activity scores,recurrent pain and moderate to severe symptoms,Pain scores,patient confidence,mean functional status,pain relief,mean improvement in RMDQ,leg pain,back pain,pain and better function,pain and disability index,regarding pain [risk difference,stabilizing and flexibility exercises, the use of modalities, and cardiovascular training,back pain and disability,Patient-rated low back pain, disability, and functional health status,low back-related disability assessed with the 24-item Roland Morris Disability questionnaire,Adjusted mean Roland Morris Disability change scores,LVVA-SM and HVLA-SM,average in functional status,physical functioning and mental health,dropout rate,back pain, greater satisfaction with back care,levels of disability and perceived pain,Pain, health and functional disability level,mean pain intensity,pain- and disability-score changes,6-month disability outcomes,average and most severe low back pain intensity in the past week, assessed with 0 to 10 numerical rating scales, and low back-related disability, assessed with the 24-item Roland-Morris Disability Questionnaire,low back pain intensity and disability,mean disability questionnaire scores,leg and low back pain,SF-36 Health Survey, a 10-cm visual analog scale for overall back pain, the Roland-Morris Disability Questionnaire, lost work or school days because of back pain, and satisfaction with back care,vertebral manipulation effectiveness,back pain and physical functioning and greater satisfaction,Roland-Morris Disability Questionnaire (RMDQ) and Numerical Rating Scale,Oswestry disability scores,perceived disability,spinal flexion,physical outcome measures (range of motion, fatigue, strength or pain,best extension effort and fatigue time,relief from pain,function (Oswestry scale score decrease,visual analog pain scales and Roland-Morris activity scales,patient-specific function (PSFS, 3-30) and global perceived effect (GPE, -5 to 5) at 8weeks,visual analogue scale (VAS) for perceived pain, the Roland Morris (RM) Questionnaire for low back function, and the SF-36 for overall health status,perception of pain and disability,Sick-leaves and visits to health centers,pain,Rates of full compliance,Oswestry Disability Questionnaire,measure of dysfunction,Pain improvement,Sick-leaves,physical functioning,pain, general health and functional disability levels,FD,pain (visual analogic scale score decrease,Roland Morris disability questionnaire,Pain, disability, and perceived recovery,disability index,leg and low back pain intensity and disability (Roland-Morris Disability questionnaire|The mean changes in low back pain intensity and disability of participants in the medical and chiropractic care-only groups were similar at each follow-up assessment (adjusted mean differences at 6 months for most severe pain, 0.27, 95% confidence interval, -0.32-0.86; average pain, 0.22, -0.25-0.69; and disability, 0.75, -0.29-1.79).
29|seizure-free,dizziness (0/14), difficulty with coordination (0/29), depression (7/14) lack of energy or strength (20/43), insomnia (40/43), mood instability|In the LEV group, 13 patients (87%) were seizure-free.
38|Operating time,intensity of pain,intensity of postoperative pain and the length of convalescence,operative and hospitalization times and postoperative course,Surgical difficulty,demographic characteristics,intensity of postoperative pain,relative risk for intraperitoneal spillage,levels of the interleukin-6 and C-reactive protein,postoperative pain and minor complications,milder pain, faster hospital discharge,frequency of inadvertent rupture of the ovarian masses,Recurrence of ovarian teratomas,hospitalization time,size of ovarian masses, adnexal adhesion score, or frequency of bilateral disease,Post-operative pain, duration of stay in hospital and duration of convalescence,Post-surgical pain,operative morbidity, postoperative pain, analgesic requirement, and recovery period,Endometriotic cysts and dermoid cysts,operative time, intraoperative complications, ileus, length of stay and recovery time,C-reactive protein; interleukin-6 before, during, and after surgery; intensity and duration of postoperative pain; and complications and recovery period,Operative times,intraoperative rupture rate of the cyst,Mean blood loss,recurrence of mature ovarian teratomas,Mean hospitalization,operative morbidity,Surgical times, estimated blood loss, post-surgical pain, time in hospital, speed of recovery and complications,postoperative pain and analgesic requirement, hospital stay, and recovery period,postoperative stay|No complications were reported in either group.
not found|pain relief and intensity,pain intensity, pain relief, and global assessments,analgesic efficacy and tolerability profile,faster onset of analgesic effect,supplemental analgesia sooner,total pain relief (TOPAR), sum of pain intensity difference (SPID), and patient global assessment of response to therapy (PGART,perceptible pain relief, and patient evaluations of pain intensity, pain relief, and global assessments,gastrointestinal safety profile,total pain relief over 8 hours (TOPAR8) and 24 hours (TOPAR24) and patient global assessments,total pain relief (TOPAR) score over 8 hours (TOPAR8; primary end point), TOPAR score over 12 hours (TOPAR12), sum of pain intensity difference (SPID) over 8 and 12 hours (SPID8 and SPID12), patient's global assessment of study drug at 8 hours, time to confirmed perceptible pain relief (ie, time to onset of analgesic effect), peak pain intensity difference (PID), peak pain relief, time to first dose of rescue medication (ie, duration of analgesic effect), and percentage of patients using rescue medication,longer median time to use of rescue medication,duration of effect,duration of analgesic effect,duration of analgesia,adverse-events (AE) profile,pain intensity, pain relief, and global evaluations,Overall analgesic efficacy,severe pain,time to rescue medication,Adverse events,total pain relief over 8 hours (TOPAR8,number-needed-to-treat (NNT,nausea, postextraction alveolitis, and vomiting,Tolerability,shorter time to onset of analgesia,median times to use of rescue medication,peak pain relief score,median times to confirmed perceptible pain relief,total pain relief,median times to first rescue medication,adverse events,Onset of analgesia,Adverse experiences,gastrointestinal and nervous system adverse events,adverse events and nausea,median times to meaningful pain relief,pain relief,Pain,overall analgesic effect was total pain relief over 6 hours (TOPAR6,analgesic activity,pain severity,overall analgesic effect, onset of action, peak effect, and duration of effect,frequency of patient-reported adverse events,supplemental analgesia,meaningful pain relief,peak pain relief,Onset of action,pain on global evaluations,time-weighted pain relief score,scores of pain intensity, pain relief, and global assessment at prespecified time intervals,maximum pain relief,adverse experiences of nausea,nausea and vomiting,analgesic onset and peak,Peak pain relief,pain intensity difference and pain relief scores,peak pain relief scores,efficacy and tolerability,Brief Pain Inventory Severity,analgesic efficacy and adverse effects,Adverse effects,postsurgical pain,tolerated,TOPAR6,time to rescue medication, time to pain relief, and mean pain intensity difference (MPID), as well as safety profile,longer duration of analgesic effect,Summed Pain Intensity Difference,orthostatic blood pressure,TOPAR12 scores,total pain relief over 6 hours (TOPAR6, the primary end point) and 4 hours (TOPAR4), patient's global assessment of treatment at 6 hours (GLOBAL6) and 24 hours (GLOBAL24), summed pain intensity difference over 6 hours (SPID6), onset of analgesic effect (time to perceptible/meaningful pain relief, using a 2-stopwatch method), peak pain relief (PEAKPR), peak pain intensity difference (PEAKPID), and duration of analgesic effect (time to use of rescue analgesia,scores [TOPAR8, TOPAR12, SPID8, SPID12, and patient's global assessment,analgesic effect,moderate postoperative pain,time to rescue analgesia,adverse events overall,Analgesic efficacy,pain, osteoarthritis, and rheumatoid arthritis,dizziness,onset of analgesic effect,median time to use of rescue medication,clinical adverse experiences (AEs) and vital signs,total pain relief (TOTPAR,analgesic efficacy and tolerability,supplemental narcotic analgesia,tolerated and adverse events,overall analgesic efficacy,TOPAR4, patient global assessment, peak pain relief, and duration of analgesic effect,dizziness and orthostatic blood pressure reduction,maximum possible pain relief,peak analgesic effect,greater TOPAR8 scores,analgesic effects,24-h Pain Severity scores,patient global assessment of response to therapy (PGART) at 6 hours, onset of analgesia, peak analgesic effect, and duration of analgesia,level of pain and pain relief,TOPAR12,time-weighted sum of total pain relief,peak effects,time to confirmed perceptible pain relief,quicker onset of analgesia,overall efficacy (total pain relief and patient global assessment,tolerated; the overall incidence of adverse experiences,duration of action,TOPAR over 6 h; SPID,time to onset of effect,nausea,pain relief, and lower pain intensity,vomiting,rescue analgesia,peak pain relief and peak PID,overall analgesic effect,incidence of clinical and drug-related adverse events,pain intensity and pain relief for 24 h using visual analogue scales (VAS) and verbal rating scales (VRS,ex vivo COX-isoform specific assays (serum thromboxane B2 [TXB2,pain and inflammation,global assessment, onset of analgesia, or AEs,patient global assessment for rofecoxib,mean time-specific pain intensity difference and pain relief scores,onset of analgesia, pain intensity levels, and pain relief over 24 hours, time-weighted sum of total pain, sum of pain intensity difference, the percentage of patients requiring rescue medication and experiencing regimen failure, and patients' global evaluation,median time to first rescue medication,overall analgesic effects, onset of analgesia, and peak analgesic effects,Interference Domain,moderate pain,onset of analgesia, peak pain relief, and duration of response,Severe pain,adverse experiences,analgesic efficacy,Rescue analgesia,analgesic effect and peak analgesic effect,total pain relief, onset time, and duration of response,Median onset of analgesia,pain,MPID,mean TOPAR12 scores,adverse experiences, physical findings, and laboratory measurements,safety profile,Peak analgesic effect,Efficacy,time to meaningful pain relief,total pain relief over 8 h (TOPAR8|Onset of action was significantly faster with valdecoxib 40 mg (30 minutes) compared with rofecoxib 50 mg (45 minutes), as measured by pain intensity difference and pain relief scores (P <or= 0.05).
298|number of hospital acquired infections,Frequencies of dietician referral and documentation of weight,health status,Body mass,frequency of problem detection or intervention,average weight,Hearing loss,Frequency of dietician referral,Costs,number of patients with pressure sores,malnutrition/weight loss, visual impairment, hearing loss, cognitive impairment, urinary incontinence, depression, physical limitations, and reduced leg mobility,nutritional status, hospital-acquired infections and pressure sores,detection of, and intervention for conditions screened, and health status 6 months,admittance and discharge and hospital-acquired infections and pressure sores were scored and costs related to nutrition, infections and length of hospital stay,Cost-effectiveness|The number of hospital acquired infections was significantly lower in the intervention group (33/140 versus 58/158, p=0.01) but no significant difference in number of patients with pressure sores (23/140 versus 33/158) was found.
not found|highest risk to develop a TLS,area under the serial plasma uric acid concentration curves,hyperphosphatemia,Incidence of tumor lysis syndrome,antirasburicase antibodies,metabolic problems,rate of renal and metabolic complications,renal dialysis,anuria,efficacy, safety, and pharmacokinetic profile of rasburicase,metabolic problems that included hypocalcemia,initial plasma uric acid levels,plasma uric acid,severe allergic reaction to urate-oxidase,Initial uric acid level,Blood levels of uric acid, creatinine, phosphorus, calcium, lactate dehydrogenase and complete blood count,metabolic complications,TLS or anuria,TLS,incidence of sepsis,acute renal failure,incidence of TLS and anuria,Response rates,Uric acid levels|Initial uric acid level decreased significantly by 4 hours (from 343 micromol/L to 58 micromol/L, p<0.001), except for one steroid-resistant patient who required hemodialysis on day 14 after having introduced combined cytostatic treatment.
160|median gastric fluid pH,Mean gastric pH,gastric secretion,Mean pH1 and pH2 values,Gastric volumes,pain relief,gastric pH,higher intragastric pH but larger intragastric volumes,narrowest range of pH values of gastric contents,mean pH,Mean pH,risk of acid aspiration,effective means to control and neutralize gastric secretion,Intragastric pH and volume,smaller volumes of aspirated gastric contents,gastric volume and pH,Apgar score, cord blood gas analysis, and neurobehavioural assessment,Gastric aspirate pH and volume,PI pH,alkaline values of gastric pH,Gastric pH,Pain intensity score on sitting and sedation,neutralize acidity,pH values of gastric fluid,Gastric content,gastric contents,gastric pH and aspirated gastric volumes,volume and pH of the gastric contents,innate pH of gastric juice,gastric pH less,mean pH1 and pH2 values,volume of the gastric content,incidence and severity of nausea and vomiting,gastric volume,Mean pH1 and mean pH2 values,Nalbuphine consumption,gastric volumes,adverse effects,intragastric pH less,risk of acid aspiration of gastric contents|Patients receiving omeprazole in single oral dose regimen retained a greater gastric volume (> or = 0.4 ml/kg) than those who received famotidine or ranitidine (p < 0.005).
24|forced expiratory volume,forced expiratory volume in one second (FEV1) and forced vital capacity (FVC,Bronchopulmonary exacerbations,FEV1,time to reach peak FEV1,time to reach peak FVC,total lung capacity (RV:TLC,respiratory function,1-hour rates of mucus clearance,24-hour rates of mucus clearance,Forced vital capacity (FVC), the forced expiratory flow,Mucus clearance and lung function,mucus clearance and improved lung function,lung function,forced vital capacity (FVC), forced expiratory volume in 1 sec (FEV(1)), and forced mid-expiratory flow (FEF(25-75,frequency of infective exacerbations,volume of airway surface liquid, restore mucus clearance, and improve lung function,forced expiratory volume in one second, forced vital capacity, oxygen saturation, body weight, sputum volume, culture and rheology, serum urea, and electrolytes, white cell count and erythrocyte sedimentation rate,respiratory symptoms,FVC and secondarily on FEV(1), FEF(25-75), the number of days on antibiotic therapy, the Shwachman score, a nutritional index (weight/height(2)), the change in sputum bacterial flora, and nocturnal cough|A comparison of the changes in lung function in the two groups showed no significant difference.
not found|abnormal epithelial changes,cytological detection of persistent cervical intraepithelial neoplasia,Endocervical or metaplastic cells,endocervical cell pickup rates,dyskaryotic smears,condyloma, dysplasia, and cancer; dysplasia and cancer; moderate dysplasia, severe dysplasia, and cancer,detection rate of dyskaryosis,Endocervical cells,risk of bleeding,detection of endocervical cells,effectiveness in obtaining satisfactory Papanicolaou smears,number of positive Papanicolaou smears,cervical intraepithelial neoplasia,adequacy of ectocervical smears,Multispatula samples,concentration of endocervical cells,endocervical cells,serious adverse events,percentage of smears containing endocervical cells,yield of endocervical cells,rate of adequate smears,Rocket samples,number of adequate smears,production of smears containing endocervical cells (EC,cellular composition of cervical smears,incidence of scanty or unsatisfactory smears,success rate,rate of any pathology,detection rate of cervical condyloma acuminatum and squamous dysplasia,Red blood cells,Cytologic abnormalities,presence of columnar cells or squamous metaplasia,detection rate,epithelial abnormalities,incidence of smears with endocervical cells,contain immature metaplastic cells,incidence of smears containing cylindrical and/or metaplastic cells,proportion of smears containing one or other type of indicator cell,sensitivities of cervical cytology,bloody Papanicolaou smears,Rates of condyloma and dysplasia,presence or absence of endocervical cells,detection of grade III cervical intraepithelial neoplasia (CIN III,Endocervical detection of CIN,rate of pathology and abnormal cytology,number of moderately and severely atypical epithelial changes,endocervical cells, and rate of cervical neoplasia,cellular quality of the smears,Efficacy,false negative rate,Cervex-Brush,rate of cervical intraepithelial neoplasia (CIN) diagnosis,smear quality and endocervical cell recovery,endocervical cell yield|The sampling methods had similar abilities to obtain a satisfactory smear (Cytobrush/spatula 63%, cotton swab/spatula 57%; P = .23).
1123|mean sitting diastolic BP (msDBP,BP (maximum MSSBP/MSDBP reduction,Hypokalemia,successful treatment response (diastolic blood pressure,safety and tolerability,safety and tolerability profile,Rates of adverse events and laboratory abnormalities,BP,mean sitting DBP and systolic BP (SBP,DBP and SBP,trough mean sitting DBP and systolic blood pressure (SBP,BP lowering,msDBP,Efficacy and safety,trough SBP,change in MSDBP,Adverse event rates,antihypertensive effect,mean sitting systolic,BP reductions (mean sitting systolic BP/mean sitting diastolic BP,mean sitting diastolic BP (DBP,control rates,mean sitting DBP,mean sitting diastolic BP,incidence of adverse events,adverse events and number of patients discontinuing therapy,PRA,blood pressure,mean sitting systolic/diastolic blood pressure,MSDBP and mean sitting systolic blood pressure (MSSBP,mean sitting systolic blood pressure,Tolerability,blood pressure (BP) reduction,efficacy and tolerability,tolerated,BP reductions,mean sitting diastolic blood pressure,antihypertensive efficacy and safety,plasma renin activity (PRA,antihypertensive efficacy, safety and tolerability,BP reduction|Once-daily oral treatment with aliskiren 300 mg significantly (P < .0001) lowered mean sitting DBP and systolic BP (SBP) compared with placebo; aliskiren monotherapy demonstrated a safety and tolerability profile comparable to placebo.
1774|preterm birth rate,Preterm birth rates|There was no evidence to suggest that the secondary interventions provided added benefit over the primary intervention protocol of preterm birth prevention education and increased visits.
55|clinical cure rates,inflammation score,relief of significant pain (moderate or severe pain,efficacy, safety, and ear-pain resolution,eradication rates,overall cure rates,relief of severe pain,tolerability and efficacy,visual analogue scale and a six-step infection score,Efficacy and tolerability,pain relief,duration of symptoms (days) according to patient diaries,resolution of discharge,severe symptom score,Staphylococcus aureus and Pseudomonas pyocyanea,pain severity,pain parameters,microbiologic eradication rates,relief of pain,safety and efficacy,swelling, pain, and redness,cure rate according to general practitioner completed questionnaires and recurrence of symptoms between days 21 and 42,equivalent cure rates,effective and safe,clinical symptom score (consisting of the subscores redness, swelling, pain, and secretion) and of the visual analogue scale (VAS) rating for pain,frequency and type of adverse events,low systemic exposure, absence of ototoxicity,Efficacy and safety,glacial acetic acid,change of the CSS from Visit 1 to the study termination, and the changes in the subscores and of a visual analog scale for pain,overall clinical-microbiological response,severe redness,clinical response,efficacy and safety,resolution of discharge, swelling, pain, and redness and the incidence of adverse side effects,audiometric measurements,CSS,glacial acetic acid, dexamethasone and neomycin sulphate,Median time to end of pain,Signs and symptoms of AOE, including ear inflammation, tenderness, edema and discharge,edema,efficacy, safety, and pain relief,severe pain,clinical or microbiological and clinical cure,reduction of swelling,severe secretion,infected mastoid cavities,Cure,Success rates,Recurrence of symptoms,efficacy and tolerability,pain-relieving tablets,redness, pain and secretion,frequency of adverse events,time to end of pain, symptom scores (otalgia and tenderness) and microbiological eradication,Ear pain,pain,rates of adverse events,tolerated,clinical symptom score,swelling,reduction in ear inflammation,efficacy and tolerance,change of an aggregate clinical symptom score (CSS) (subscores: redness, swelling, pain and secretion,inflammation,overall clinical response,Cure]); microbiologic eradication|S. aureus seemed to be most resistant to treatment, while P. pyocyanea was less of a therapeutic problem.
10|number of tender joints,Assessments of duration of early morning stiffness (EMS), pain on a 10 cm visual analog scale (VAS), the Ritchie articular index (RAI), swollen joint score, the Stanford Health Assessment Questionnaire, global patient and physician assessment, body weight, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and haemoglobin,inflammatory activity,disease activity,ESR, CRP and haemoglobin,objective signs of improvement,average level of pain,subjective symptoms of rheumatoid arthritis,ESR, CRP, thermographic joint score or functional score,Body Mass Index,vitality,weight,Ritchie score,subjective relief of rheumatic symptoms,Pain, stiffness, medication, and clinical and biochemical findings,reduced pain, stiffness, consumption of analgetics, several clinical variables, and serum concentration of orosomucoid,controls concerning symptoms, drug consumption, or clinical and biochemical variables,DAS28,erythrocyte sedimentation rate (ESR,grip strength,immunoglobulin G (IgG) antibody levels against gliadin and beta-lactoglobulin,rheumatic disease activity,disease activity variables,A composite disease activity index (DAS28), a physical function index (Health Assessment Questionnaire (HAQ)), a health survey of quality of life (Short Form-36 (SF-36)), and the daily consumption of non-steroidal anti-inflammatory drugs,food intolerance, reduced gastrointestinal permeability,disease activity (Health Assessment Questionnaire, duration of morning stiffness, pain at rest and pain on movement,thrombocyte count,disease activity measures,adverse effects (nausea, diarrhoea,pain intensity, morning stiffness, HAQ-score, number of swollen joints, joint tenderness, erythrocyte sedimentation rate, and patient's global assessment of health,Furthermore, levels of antibodies against gliadin and beta-lactoglobulin,fibre intake,disease activity according to composite symptoms (Paulus index) of arthritis,VAS and RAI,radiological destruction,tolerated and the rate of drop-outs,swollen joint score,HAQ-score,rheumatologic, laboratory, immunologic, radiologic, or nutritional findings,physical function, and improved vitality,clear remission|A significant improvement was found in the number of tender joints (p = 0.04) in the experimental group, whereas improvement was found in the erythrocyte sedimentation rate (ESR) (p = 0.03) and in the thrombocyte count (p = 0.02) in the control group.
50|recovery of isometric grip strength,mean Jebsen Taylor scores and SF 36 bodily pain scores,sustained maximal voluntary isometric contraction,Pain,distal radial fractures,overall function, range of movement and activities of daily living,upper extremity MFA domain scores, overall Jebsen Taylor scores, and pinch and grip strength tests,Global function and pain,Colles' type distal radial fracture,function,isometric grip strength,Upper extremity MFA scores, Jebsen Taylor scores, SF-36 bodily pain scores, and grip strength,grip strength,better length and palmar tilt restoration,Upper extremity function,radiological signs of post-traumatic arthritis,roentgenographic loss of position during fracture union,angulation of the distal radius,complication rate,noncomplicated pin-tract infection,Radiographic evaluation and range of motion,radial shortening,transient sensory disturbance,excellent or good outcome and patient satisfaction,Grip strength|The functional result correlated with the anatomical result, which was significantly better in patients treated by external fixation.
not found|adverse reactions|Over a battery of cognitive tests, indomethacin patients improved 1.3% (+/-
6|BCAA meal tripled plasma BCAA levels, increased BCAA catabolism,intensity of exercise-induced pain in working muscles,skeletal muscle function,heart rate and perceived exertion,body mass index,tolerance to everyday activities,monitoring heart rate and perceived exertion during exercise,exercise capacity,heart rate, level of perceived exertion, and venous blood glucose levels,electromyographic amplitude,neurologic adverse effects,phosphorus 31 magnetic resonance spectroscopy variables,exercise tolerance,depletion of phosphocreatine,level of perceived exertion fell,muscle complaints with creatine,maximal oxidative work capacity,mean peak free fatty acid levels and reduced exercise capacity,Calorific intake,exercise endurance of the forearm muscles,plasma glutamine and alanine,Phosphocreatine depletion,work capacity,peak oxygen consumption or level of leg fatigue,serum creatine and serum creatine kinase levels, phosphorus 31 magnetic resonance spectroscopy, and surface electromyograms,median frequency in surface electromyograms during contraction,mean plasma glucose level,mean (+/-SE) heart rate,limitation of daily activities|Both sucrose treatments dramatically improved exercise tolerance, compared with the placebo.
40|length of stay in hospital,asthma severity score (ASS,clinical asthma score over time, length of pediatric intensive care unit stay, and incidence of adverse events,mean proportionate increase in FEV,relative tachycardia,rate of recovery,ASS,pulse rate of 8 beats per minute and 2 beats per minute,longer duration of oxygen therapy,Blood gas pressures,synergistic bronchodilator effect,nausea,clinical asthma score over time, length of pediatric intensive care unit stay, or incidence of adverse events,length of hospital stay,Peak expiratory flow rates,median hospital cost of medication and theophylline blood levels,adverse events,oxygen tension|The median hospital cost of medication and theophylline blood levels was significantly lower in group 1 compared with groups 2 and 3 (280 US dollars vs. 3,908 US dollars vs. 4,045 US dollars, respectively, p < .0001).
983|Low density lipoprotein cholesterol,lipid management,quality of life (SF-36,satisfaction score,blood pressure management,lipid concentrations (serum total cholesterol,Body mass index,total cholesterol concentration,smoking cessation,quality of life,consultations for coronary heart disease, the recording of risk factors, and advice given,physical activity,limits: systolic blood pressure,systolic blood pressure,patient risk of cardiovascular death and satisfaction,cotinine levels,blood pressure and total cholesterol concentration,health outcome,total cholesterol,non-fatal cardiovascular event,numbers on aspirin or lifestyle measures,taking daily physical exercise,Blood pressure and high-density lipoprotein cholesterol,risk factors (blood pressure, cholesterol, and smoking status); prescribing of hypotensive agents, lipid lowering drugs, and antiplatelet drugs; blood pressure, serum cholesterol level, and plasma cotinine levels,Restriction of everyday activities, dietary habit, smoking habit, frequency of physical exercise; blood pressure, body mass index, and serum total cholesterol concentration,blood pressure (diastolic pressure,serum cholesterol concentrations,aspirin management,diastolic blood pressure,cholesterol lowering drugs,Serum total cholesterol concentration, blood pressure, distance walked in 6 minutes, confirmed smoking cessation, and body mass index,number of patients admitted to hospital,appropriate treatment [derived from the National Service Framework (NSF)], health status (SF-36, EQ-5D) and an economic evaluation,low density lipoprotein cholesterol,smoking habit, systolic or diastolic blood pressure, cholesterol concentration, or body mass index,event rates and all-cause mortality,coronary heart disease,consultation rates, process of care measures,total National Health Service cost,dietary habits,Concentration of low density lipoprotein cholesterol,Mean blood pressure|Blood pressure and high-density lipoprotein cholesterol were more frequently within recommended levels in the intervention group than in controls: odds ratio 1.63, 95% confidence interval 1.05-2.51, and odds ratio 2.61, 95% confidence interval 1.32-5.18, respectively.
32|depression measured by the Cornell Scale for Depression in Dementia, mood measured by the Dementia Mood Assessment Scale and the Alzheimer's Mood Scale, and affect measured by the Observed Affect Scale,oxygen consumption,CES-D rating scale, urinary cortisol and epinephrine levels, and cardiorespiratory factors at rest and during exercise endurance test,HAM-D(17) score,Aerobic capacity,depression according to HRSD,Depression,health and wellbeing,measures of both emotional (clinician and self-report) and physical (observed and self-report) functioning,HAM-D or BDI scores,trait anxiety and a standard psychiatric interview,psychological subscale of the Beck Depression Inventory (BDI,adverse events,vitality,depressive symptoms,Median compliance,strength measured by 1 repetition maximum for chest press,strength,Hamilton Rating Scale for Depression (HRSD,Geriatric Depression Scale, Clinical Global Impression and Patient Global Impression,mood, body weight and oxygen consumption,BRMS scores,Strength,lower HAM-D scores,Mood and energy regulation in seasonal and non-seasonal depression,Muscle strength,HAM-D, GAF and CGI score,mean change in HAM-D(17) score,major depressive disorder (MDD) and a HAM-D score,reduction of depression scores,SF-36 mental health scores and clinician-rated depression scores,percentage of days absent from work during the last 10 working days,17-item Hamilton Rating Scale for Depression (HRSD,CES-D total depressive score,HAM-D and BDI scores,social functioning,physiologic capacity, quality of life, morale, function and self-efficacy without adverse events,depression measures (Beck Depression Inventory,Quality of life subscales of bodily pain,depressive state,resting heart rate,depression scores,mood nor metabolic parameters,GAF and CGI scores,strength, morale, and quality of life,somatic symptoms of the BDI,depression,Depressive status, physical and mental health and quality of life,remission rates,depression, neuroendocrine stress hormones and physiological fitness,lower depression scores,cognitive abilities,aerobic capacity,aerobic capacity, life satisfaction, self-esteem, anxiety, and dysfunctional cognitions,Symptoms of depression,Inventory of Depressive Symptoms (clinician and self-report), HRSD scores at 24 weeks, cardiorespiratory fitness, self-efficacy, and quality of life,Weight loss,role emotional,maximal oxygen uptake,psychiatric scores,depressive state, hormonal response to stress and physiological fitness,physical functioning,peak oxygen uptake and lung capacity,severe depressive symptoms,Hamilton Rating Scale of Depression,Hamilton Depression Rating Scale (HAM-D,presence and severity of MDD using Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria and Hamilton Rating Scale for Depression (HAM-D) and Beck Depression Inventory (BDI) scores,17-item Hamilton Rating Scale for Depression (HAM-D(17,Severity of depression assessed with the Bech-Rafaelsen Melancholy Scale (BRMS) and the Center for Epidemiologic Studies Depression scale (CES-D,fastest initial response|Quality of life subscales of bodily pain (p = .001), vitality (p = .002), social functioning (p = .008), and role emotional (p = .02) were all significantly improved by exercise compared to controls.
15524|number of submissions,inpatient deaths,Morbidity and Mortality (M&M) entries and anonymous adverse/near-miss events|Only 25% of complications and 42% of inpatient deaths were reported.
204|sore throat and cough,ET discomfort and postoperative sore throat incidence,arterial blood pressure and cardiac frequencies,Effectiveness and safety,haemodynamic changes,systolic arterial pressure,Plasma lidocaine levels,frequency of sore throat,frequency of postoperative cough and sore throat,postoperative cough and sore throat,cuff pressure,Sore throat and dysphagia,Hoarseness, bucking, dysphonia, dysphagia, cough, restlessness, and postoperative nausea and vomiting,postoperative sore throat, hoarseness and dysphagia,number of side-effects,Severity of sore throat,incidence and severity of postoperative sore throat, hoarseness and dysphagia,peak cuff pressure,pressure and volume of a tracheal tube cuff,postoperative sore throat,visual analog scale,Plasma lidocaine concentrations,incidence of sore throat, hoarseness, or tracheal irritability,Nausea, postoperative vomiting, dysphonia, and hoarseness,postoperative sore throat and cough,sore throat, hoarseness or dysphagia,incidence or severity of sputum,peak cuff pressures, the incidence of reaction ('bucking,sore throat,occurrence of high cuff pressures,arterial blood pressure and heart rate,verbal analogue scale, Melzack's Present Pain Intensity Scale of the McGill Pain Questionnaire,effectiveness and safety,Cough and restlessness before tracheal extubation,postoperative throat problems,Plasma concentrations,Sputum incidence,incidence or severity of postoperative sore throat, hoarseness or dysphagia,incidence of sore throat,ET discomfort before tracheal extubation, and sore throat, hoarseness and coughing incidence,ETT tolerance,sore throat, cough and hoarseness,sore throat and hoarseness,adverse emergence phenomena,Postoperative sore throat occurs,Tracheal complaints,nausea, vomiting, dysphonia and hoarseness,Pressures in Lido cuffs,postoperative airway symptoms of sore throat, cough, and sputum,incidence and severity of sore throat,No laryngospasm, rupture of ETT cuff, or depression of the swallowing reflex,Cough incidence,Pressure and volume changes of tracheal tube cuff,Induced hypotension,disturbance of haemodynamic responses,sore throat incidence,incidence of side-effects,post-operative side-effects,Endotracheal cuff pressures,hemodynamic effects, restlessness, dysphonia, and hoarseness,postoperative airway symptoms,ET cuff pressures,postoperative sore throat, including endotracheal cuff design, endotracheal tube size, intubation technique, laryngoscopy blade, airway placement, suctioning technique, and anesthetic technique,lower ET discomfort and sore throat incidence|The frequency of sore throat was significantly different among the six groups at 1 hour and at 24 hours, with greater frequency in the G3, G2, and G6 groups.
51|sperm concentration increased and sperm motility,infertility such as anovulation or tubal blockage,sperm parameters and pregnancy rate,seminal volume, sperm motility and abnormal sperm morphology,sperm density and total motile sperm count,male fertility,Sperm parameters (sperm density, motility and morphology,pregnancy rate,Spontaneous pregnancy,semen parameters, regardless of pregnancy occurrence,sperm concentration,subclinical or recurrent varicoceles, normal semen parameters, and azoospermia,pregnancy rates,seminal improvement and pregnancy rate,Improvement of semen and pregnancy rate,incidence of pregnancy 1 year after randomisation,spontaneous pregnancy rate,Pregnancy,Mean,pregnancy rate (PR,seminal improvement and pregnancy rates,semen analysis and hormonal parameters,sperm density and motility,progressive motility,semen parameters,cumulative pregnancy rates,occurrence of adverse events|During an observation period of 53 months (range 36 to 74 months) we found no statiscally significant improvement in the semen crude variables, the morphology or the progressive motility in the series of men submitted to surgery.
not found|tolerated,Mean plasma concentrations of LTG,adverse events, vital signs, and physical, neurologic, and laboratory examinations,sleep latency|Mean plasma concentrations of LTG, were linearly related to dose, although there was substantial interindividual variation.
100|cerebral malaria,Complications, including pneumonia and gastrointestinal bleeding,parasitemia,level of consciousness became normal,neurologic sequelae,Coma or hyperparasitemia|There were eight deaths in the dexamethasone group and nine in the placebo group (no significant difference; P = 0.8); at post-mortem examination the brain showed features diagnostic of cerebral malaria in all but one patient who died.
151|gastrointestinal irritation rate,Snellen equivalent visual acuity,CS score,net subjective improvement,functional parameters,final mean NEI VFQ-25 composite scores,macular function,Macular light flash recovery time,VA, CS, and visual function,visual acuity,mean eye macular pigment optical density,Macular degeneration,mean zinc serum level,serous pigment epithelial detachment developed without angiographic evidence of CNV,VFO-14 questionnaires conceming subjective glare recovery,choroidal neovascular membrane (CNV,contrast sensitivity (CS,mean changes in visual acuity (VA,contrast sensitivity,visual acuity, contrast sensitivity, color discrimination, and retinal grating acuity, as well as serum levels of zinc and copper, red blood cell count, hemoglobin, and morphologic changes detected by grading of monochrome fundus photographs and fluorescein angiograms,visual acuity, contrast sensitivity, and light flash recovery time,nonexudative alterations (drusen size, drusen confluence, hyperpigmentation, and focal degeneration of the retinal pigment epithelium,stabilization of VA,visual acuity outcome,contrast sensitivity (CS) and National Eye Institute visual function questionnaire (NEI VFQ-25) scores,visual and retinal acuity, color vision, and contrast sensitivity,visual acuity and visual function,visual loss,Serum levels of copper, hemoglobin, and red blood cell count|Although some eyes in the zinc-treated group lost vision, this group had significantly less visual loss than the placebo group after a follow-up of 12 to 24 months.
44|pulse rate,dorsal penile nerve block (DPNB,Oxygen perfusion, blood pressure, respiratory rate, heart rate, and cardiac rhythm,Behavioral observations,baseline behavioral state,loss of oxygen saturation data,Facial expressions,Distress scores and heart rates,Infant state, salivary cortisol levels, and respiratory rates,Pain ratings,baseline cry duration, tissue oxygenation, and heart rate,pain control,pain, crying, agitation, and physiologic stress,mean Gomco time, 209 seconds) and percentage of respiratory rate change,infant pain response,penile edema,heart rate, rhythm, dysrhythmias, blood pressure, transcutaneous oxygen (tcpO2), rate pressure product, and behavioral state,Efficacy and safety,Pain response,SBP and DBP,higher oxygen saturation,behavioral distress and adrenocortical responses,Brazelton Neonatal Assessment Scale (BNAS,Facial-activity scores,elevation of heart rates,crying duration and type, vomiting, gagging, breath holding, and jitteriness,redness and blistering of the foreskin,neonatal stress indicators,systolic,severe pain,Methemoglobin level,Indices of perceived pain including crying time, behavioral state, oxygen saturation, and heart and respiratory rates,heart rate, respiratory rate, and crying during circumcision,physiologic and subjective stress reactions,NIPS scores,pain response,Heart rate, oxygen saturation, and crying time,Blood pressure,Cortisol levels,pain-related measurements,heart rate and oxygen saturation changes,transcutaneous oxygen levels, crying time, heart rate, and respiratory rate,behavioral and physiologic indicators of neonatal pain,neonatal circumcision pain with and without dorsal penile nerve block (DPNB,Methemoglobin levels,physiologic variables (heart rate, blood pressure, oxygen saturation, and respiratory rate) and behavioral score 20 minutes,Physiologic and behavioral parameters,respiratory rate and oxygen saturation levels,pain relief,Plasma for cortisol levels,preoperative and postoperative serum beta-endorphin and lidocaine concentrations,heart rate and crying time,crying and lower heart rates,Pain,rate of improvement or recovery curve,oxygen saturation,Mean peak heart rates,untoward reactions,observational pain intensity rating scale and the physiologic parameters of heart rate, respiratory rate, oxygen saturation levels, salivary cortisol levels, and length of cry,distress,percentage of the procedure time neonates spent crying,Heart rate, respiratory rate, and oxygen saturation (SaO2,facial activity,neonatal stress,postoperative cortisol levels,systolic blood pressures (SBP,Physiologic stress reduction,Heart rate and blood pressure,efficacy and safety,pulse rate and oxygen saturation,Blood methemoglobin concentrations,pre- and postcircumcision cortisol levels,Newborn distress,Seconds of crying time,Pain reduction,pain distress (percentage of time crying and heart rate,pain responses,blood pressure,percentage of circumcision procedure time a neonate spent crying,heart rate, respiratory rate, and behavioral distress scoring,diastolic,heart rate, respiratory rate, and behavioral score,pain of neonatal circumcision,neonatal pain,excursion from baseline heart rate, tissue oxygenation, and cry duration,adrenal cortisol response to surgery,Heart rate, transcutaneous oxygen saturation, facial activity, and crying,agitation,heart rate, respiratory rate, and crying time,pain and physiologic stress,transcutaneous oxygen pressure levels,uncomplicated pregnancies and vaginal deliveries,heart-rate,Heart rate changes and total crying time,Crying,Safety and efficacy,circumcision (choking and apnea,heart rate and less crying,neonatal circumcision pain,Surgical complications and adverse effects,Behavioral (facial activity and time spent crying) and physiologic (heart rate and blood pressure) responses,heart rate better,mild erythema,facial actions indicative of pain,heart rate and oxygen saturation, and subjective determinations of behavioral state,subjective observation, measurement of heart rate, and the percent of time spent crying,Physiological and behavioral monitoring,small hematomas,Oxygen saturation,average oxygen saturation,behavioral characteristics and amount of crying,mean systolic blood pressure,behavioral distress,respiratory rate,Heart rate, oxygen saturation, systolic and diastolic blood pressure, and crying time,Postoperative comfort scores,percentage of crying time and percentage of SaO2 change,plasma cortisol levels,pain reduction,Postoperative pain,Heart rate, cry, and methemoglobin level,arousal,Heart rates and oxygen saturations,Neonatal Infant Pain Scale (NIPS) score; secondary: heart rate, respiratory rate,effective level of anesthesia,time spent crying,Mean heart rate,crying,pain of circumcision,sensitivity to cues and social-emotional growth-fostering scales,Neonatal cortisol response,spent less time crying,safety and efficacy,Respiratory rates,heart rate, respiratory rate, oxygen saturation levels, seconds of crying time, and overt generalized reaction,stress reactions,distress scores,salivary cortisol changes,cardiac rate, rhythm, blood pressure, and transcutaneous oxygen,Peak plasma concentrations,spectral crying parameters,Feeding behavior,diastolic blood pressures (DBP,heart rate, smaller drops in oxygen saturation, and less crying,mean increase in their occurrence,heart rate and high-pitched cry,Oxygen saturation differences,Behaviors (clarity of cues and responsiveness,heart rate during circumcision,local or systemic complications,adrenal response,total number,distress and cortisol response,shortened crying time,pain,Heart rate, transcutaneous oxygen saturation, and crying,duration of the crying and grimacing,pain and stress,plasma,Serum beta-endorphin concentrations,heart rate,percentage change in heart rate from baseline, the percentage of oxygen saturation, and the score from the modified behavioral pain scale,Heart rate, respiratory rate, SaO2, cortisol changes, and duration of crying,Demographic characteristics such as gestational age and birth weight,pain responses; sucrose alone|Feeding behavior deteriorated in breast- and bottle-fed neonates in both groups, and acetaminophen did not seem to influence this deterioration.
220|parathyroid hormone (PTH) levels,Mean plasma iPTH level,incidence of hypercalcemia (serum calcium concentration,preservation of Ob,p-osteocalcin and bone alkaline phosphatase,renal bone disease,hypercalcemia,symptomatic or had radiological evidence of bone disease,Serum iPTH (Allegro Nichols), 1-25 vitamin D (IRMA-MAB), total and ionized calcium (Nova 8 Pabish), serum phosphate, alkaline phosphatase and creatinine clearance,Histological indices of bone turnover,bone mineral density,serum calcium and phosphorus levels,hypercalcaemia or hyperphosphataemia,hypercalcaemia,PTH levels,Serum calcium and ionized calcium concentrations,mineralizing boundaries (M.Bd,plasma levels of parathyroid hormone,iPTH level,final S-creatinine or change in S-creatinine,calcium levels, phosphorus balance, and kidney function,iPTH,elevated resorption and osteoid indices,mean serum alkaline phosphatase activity and intact parathyroid hormone concentration,terminal renal failure,urinary calcium and phosphorus excretion or deterioration in kidney function,Adverse-event rates and changes in GFR,serum Ca rose steadily and Cr.cl,serum phosphorus and alkaline phosphatase concentrations,Serum iPTH,plasma levels of vitamin D metabolites,mean iPTH decrease,GFR,renal function,Hypercalcaemic episodes,bone disease,bone mineral content,S-calcium, S-phosphate, and urinary excretion of calcium,femoral neck,creatinine clearances,Bone histology,1,25(OH)2D3 quickly corrected hypocalcaemia, reduced serum-alkaline-phosphatases and serum-immunoreactive-parathyroid-hormone,parathyroid hormone levels,respective median iPTH concentrations,parathyroid hormone (PTH) suppression,Biochemical, radiographic, and histological indices of bone metabolism,Serum C- and N-telopeptide and bone-specific alkaline phosphatase levels,plasma-phosphorus, plasma-alkaline-phosphatase, or in the degree of bone mineralisation,Incidences of hypercalcemia, hyperphosphatemia, and elevated calcium-phosphorus product levels,Glomerular filtration rate (GFR,rate of progression of renal failure,serum A1 levels,mineralizing activity,Bone mineral density,glomerular filtration rate,mean serum calcium or phosphorus or urinary calcium levels or incidence of hypercalcemia, hyperphosphatemia, or hypercalciuria,Resorption indices,risk of hypercalcemia,iPTH level reductions,Serum PTH, urinary cAMP excretion, and bone resorption indices,iPTH concentration,PICP,iPTH levels,bone metabolism and bone density,initial serum 1,25(OH)2D levels,intestinal absorption of calcium and in plasma-calcium,femoral neck and lumbar spine,Serum Al levels,height z scores,percentage fall in creatinine clearance,iPTH without causing hypercalcemia,Bone alkaline phosphatase,serum iPTH, calcium, and phosphorus levels,Baseline 1,84 iPTH concentrations,median intact PTH (iPTH) level,plasma iPTH, serum calcium and phosphorus, urinary calcium, bone-specific serum markers, and serum lalpha,25-dihydroxyvitamin D levels,BMD,bone mineral density (BMD) estimated by dual energy X-ray absorptiometry and plasma levels of biochemical markers of bone turnover [osteocalcin, bone alkaline phosphatase, propeptide of type-I collagen (PICP) and telopeptide of type-I collagen] and parameters of calcium homeostasis,urinary excretion rate of calcium|Paricalcitol capsule was well tolerated and effectively decreased iPTH levels with minimal or no impact on calcium levels, phosphorus balance, and kidney function in patients with stages 3 and 4 CKD.
90|cord artery PO2,umbilical arterial and venous blood,Oxygen saturation in maternal blood by pulse oximetry,Apgar score,cord vein PO2,fetal oxygen stores,Neonatal rSO(2), UA pH, UV pH and UA base excess (BE,Maternal arterial samples and fetal UV and UA samples,demographic or hemodynamic variables, time from uterine incision to fetal extraction, neonatal birth weight, presence of umbilical cord abnormalities, type of resuscitation required by the neonate, or Apgar score,pulmonary function, maternal oxygenation,UV PO(2) or oxygen content,maternal and fetal oxygenation and lipid peroxidation,Neonatal rSO(2) and Apgar scores,fetal arterial blood gases,maternal and fetal oxygenation and oxygen free radical activity,blood gases and the products of lipid peroxidation (8-isoprostane, malondialdehyde (MDA), hydroperoxide (OHP)) and purine metabolites,Maternal arterial blood,UA PO2 levels,umbilical venous PO2,maternal PaO2 levels and umbilical vein (UV) and umbilical artery (UA)PO2 levels,Fetal gasometric parameters,Mean values of the UV blood samples,Umbilical artery (UA) and venous (UV) blood samples,oxygen free radical activity,Mean values of the UA blood samples,UV PO(2,cord vein-artery PO2 differential,Oxygenation,umbilical cord arterial blood,fetal gasometric parameters,fetal partial oxygen pressure,Maternal and umbilical plasma concentrations of lipid peroxides (8-isoprostane, MDA, OHP,Maternal PaO2 levels,maternal FiO2 and umbilical arterial (UA) and venous (UV) PO2, PCO2, pH, and neonatal Apgar score,U-D interval, umbilical arterial (UA) and venous (UV) blood gases and oxygen content and Apgar scores,Umbilical arterial and venous blood samples,free radical activity and lipid peroxidation,maternal inspired fraction of oxygen,mean maternal rSO(2,cord gas values,UA and UV blood samples,Arterial blood gases,maternal and neonatal regional cerebral oxygenation (rSO(2,PO2 in venous blood,fetal oxygenation,1- or 5-minute Apgar scores,inspired fraction of oxygen, maternal partial oxygen pressure, and fetal partial oxygen pressure,umbilical arterial or venous pH, partial pressure of oxygen and partial pressure of carbon dioxide,UA and UV PO2,maternal mean arterial pressure, heart rate and peripheral oxygen saturation,UV oxygen content,Maternal arterial, UV, and UA base excess values,maternal arterial PO2,UV PO2 levels,UV or UA blood gases, oxygen content or Apgar scores,oxygen content,Oxygen saturation and blood O2 contents|The Apgar score (1 min) in Group FM was lower than that of Group RA (p = 0.046).
not found|hypoglycemia after admission,cerebral malaria,Transient partial hearing loss,lethality rate,evolution of parasitemia,quinine toxicity,Mild toxic effects,body temperature,Coma mean durations,insulin concentrations,mean trough and peak plasma quinine levels,mean high and low quinine concentrations,Peak concentrations,Parasite clearance time,clinical and parasitological response,Case-fatality rates,mean peak concentrations,mean cost,All blood concentrations,Fever clearance time,cardiovascular side effects,cardiovascular toxicity,Hypoglycaemia,time taken to clear parasites|Transient partial hearing loss occurred significantly more in the study than control group (p < 0.05).
5|Carotid recanalization,mental status, headache, unprovoked fall, focal weakness, neglect, and dysphasia,visual aura,neurologic outcome,Ischemic optic neuropathy,Ischemic and hemorrhagic complications, occurrence of seizure and rates of arterial recanalization,risk of suffering a disabling stroke,severe ipsilateral headache and orbital pain,Migraine,Arterial recanalization,hemorrhagic adverse events,recanalization rate,Brachiofacial hemiparesis,variables stroke and arterial occlusion,internal carotid artery dissection,Ischemic optic neuropathy (ION,Bleeding complications,Bilateral VAD,result of distal thromboembolism,brain infarction,Hemorrhagic complications,subsequent stroke,verified CAD recurrence,functional independence,seizures,transient ischemic attacks,overt cerebral ischemia manifest by paresis (three), sensory deficits,disabling stroke,contralateral ICAD,efficacy and safety,overall mortality,modified Rankin Scale (mRS) and Barthel Index (BI,massive stroke, embolic mechanism and lack of local recanalization,neck pain,Irregular expansion, double lumen and aneurysmal dilation,clinical symptoms of sudden unilateral headache and facial pain,good recovery and early reopening of the occluded ICA,extracranial bleeding complications,retinal ischemia,risk of stroke, TIA, or dissection recurrence,new cerebral ischemic events, defined as ischemic stroke, TIA, or retinal ischemia, 2) symptomatic intracranial hemorrhage, and 3) major extracranial bleeding,occipital and nuchal pain, with vertebral artery dissection,initiation of heparin,subjective bruit or painful,Intracranial haemodynamics,ischemic events or dissection recurrences,Risk of stroke and recurrent dissection,fibromuscular dysplasia,central retinal artery occlusion or ischemic ocular syndrome,Frontal and parietal localizations,Resolution of the angiographic appearances,Functional outcome,rates for death and stroke,chronic arterial stenosis,Recurrence of a dissection,retinal ischemia in 8, and local symptoms and signs (headache, neck pain, Horner syndrome, cranial nerve palsy,CAD recurrences,recanalization rate of CAD,Cerebral ischaemia,traumatic extracranial CCAD,arterial hypertension,recurrent ischemic stroke,recurrent CAD without stroke,Cerebral infarction,bilateral dissections,Complete recanalization of vertebral dissections,initiation of anticoagulation,Headache, facial pain, a subjective bruit, oculo-sympathetic palsy and transient monocular blindness,New ischemic events,transient ischemic symptoms or arrested progression of established neurologic deficits,Neurologic outcomes,PH pattern,Noniatrogenic traumatic extracranial internal carotid artery dissections,recurrence (stroke and death) and clinical outcome at 6 months,cervical perforating wound nor atheromatous predisposing lesion,cerebral infarction,Stagnating blood flow velocities,Painful SCAD,Recanalization,deficit), fair (moderate deficit needing some assistance), poor (requiring institutionalization), and dead,TIA without CAD recurrence,Preceding traumata, vascular risk factors, presenting local and ischemic symptoms, and patient-outcome|Five patients with spontaneous dissection of the cervical internal carotid artery (CICA) are reported.
242|VQLQ score,objective systemic reactions,size and duration of the large local reactions,size and duration of large local reactions,median of the peak maximal diameter of the LLRs,systemic reaction after a deliberate sting challenge,health-related quality of life (HRQL,accidental stings,positive skin-test reaction,HRQL,health-related quality of life,generalized urticaria,18 systemic reactions,systemic reaction,recurrences of systemic reactions,Vespid allergy Quality of Life Questionnaire (VQLQ), Burden of Treatment and Expectation of Outcome|Sixteen of these 18 reactions were judged to be milder than the patient's reaction to the first sting, 2 were similar in severity, and none were more severe.
12|NHPT baseline repetitions,effective rate,Cognitive performance and electroencephalogram,hyperexcitability of LH parieto-frontal circuits,excitability of the non-stroke hemisphere and increased excitability of the stroke hemisphere,cumulative rebalance of excitability,depressive symptoms,pinch force,cortical excitability,excitability of the stroke hemisphere,motor-evoked potential frequency,Stimulus intensity,age, laterality indices, or mean Aachen Aphasia Test scores,safety and efficacy,rating scales,HAM-D scores, response and remission rates,clinical efficacy,mean grip strength,grip strength and the Melbourne assessment of upper extremity function (MAUEF,motor function,motor learning,Safety,cognitive functioning,poststroke recovery and mortality,simple and choice reaction time and improved performance of the Purdue Pegboard test,Wolf Motor Function Test (WMFT) and the Motor Activity Log (MAL)--Amount of Use, and on secondary outcome measures including the Box and Block Test (BBT) and the MAL,Motor disability,Arterial ischaemic stroke (AIS,grip strength,motor-evoked potential (MEP), lower-extremity Fugl-Meyer score, and gait performance,Fugl-Meyer scores,frequency of motor-evoked potentials in biceps and triceps, muscle function (torque about elbow), and purposeful movement (Action Research Arm Test,excitability,Motor control and walking ability,Disability,BIT scores,Aachen Aphasia Test total score,Cortical excitability,Disability scales,neglect symptoms,motor function improvement and corticospinal excitability change,motor function and corticospinal excitability,reduction of Ham-D scores and frontal gray and white matter volumes,motor function recovery,spatial asymmetry of gait,Day 10 MAUEF score,neuropsychologic battery and electroencephalogram,motor function performance,Corticospinal excitability,dexterity, force, interhemispheric inhibition, and corticospinal excitability,Motor function,Fugl-Meyer score, Barthel index, and central spinal cord motor conduction time (CMCT,change in laterality indices as quantified by activation positron emission tomography,standardized Behavioral Inattention Test (BIT,mild adverse effects,Greater behavioral and neurophysiologic outcomes,cortical excitability and walking performance,activation shift toward the right hemisphere,basal rating scales,clinical disability|Increasing evidence suggests that the contralesional motor cortex (M1) inhibits the ipsilesional M1 in stroke patients.
138|change in ADAS-cog scores,slow cognitive decline,1-year change in the Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) subscale score,Alzheimer's disease progression,Cog score, 1-step worsening on the global Clinical Dementia Rating scale, 15-point decline on the ADCS activities of daily living inventory, institutionalization, or death,mean BADLS score,fatal cerebral bleeds,bleeds that led to admission to hospital,cognition (assessed with the mini-mental state examination [MMSE]) and functional ability (assessed with the Bristol activities of daily living scale [BADLS,cognitive progression of Alzheimer's disease,1-year change in the cognitive subscale of the AD Assessment Scale,behavioral decline,Clinical Dementia Rating scale sum-of-boxes, the Neuropsychiatric Inventory, the Quality of Life-AD, and the time to attainment of significant end points (4-point decline from baseline ADAS,1-year mean (SD) change in ADAS-Cog scores,serious adverse events,ADAS-Cog score worsening,cognitive decline,Withdrawal rates,cognitive subscale of the AD Assessment Scale (ADAS-cog,mean MMSE score,rate of cognitive decline,efficacy and safety,Mini-Mental State Examination, the Clinician's Interview Based Impression of Change with caregiver input, the noncognitive subscale of the ADAS, the Neuropsychiatric Inventory, and the Interview for Deterioration in Daily life in Dementia,Alzheimer's disease,adverse reactions,Alzheimer disease progression,time to formal domiciliary or institutional care, progress of disability, behavioural symptoms, caregiver wellbeing, and care time,Alzheimer's Disease Assessment Scale cognitive and noncognitive subsections, Global Deterioration Scale, Clinical Global Impression of Change, Mini-Mental State Examination, Instrumental Activities of Daily Living, Physical Self-Maintenance Scale, and a caregiver-rated Global Impression of Change,Alzheimer's Disease Assessment Scale-Cognitive Behavior (ADAS-cog) composite score and the week 52 Clinician's Interview-Based Impression of Change Plus (CIBIC,tolerated,cognitive subscale of the AD Assessment Scale (ADAS-cog) and score on the Clinician's Interview Based Impression of Change with caregiver input (CIBIC,changes in MMSE, CDR, Basic and Instrumental Activities of Daily Living scales, and Neuropsychiatric Inventory (NPI,Alzheimer Disease Assessment Scale- Cognitive (ADAS-Cog) subscale score,CIBIC+ scores,total assessment scores of measures of cognition, clinical status, activities of daily living, affect, and behavior,Fatigue, dizziness, and hypertension,intention to treat|There was no difference in cognitive decline between the prednisone and placebo treatment groups in the primary intent-to-treat analysis, or in a secondary analysis considering completers only.
46|immediate recall condition,mean (SD) time,cognitive function and quality of life,change in cognitive or 36-Item Short-Form General Health Survey scores,dementia or MCI incidence,income management scale of the Profile of Adaptation to Life,health risks,memory and mood: verbal memory changes,baseline Modified Mini-Mental State Examination scores,overall HR for probable dementia,hazard ratio (HR) for probable dementia,error rates,noopsyche, thymopsyche, personality and psychophysiological measures,cognitive function or in health-related quality of life,somatic complaints and trait anxiety,State anxiety,aggressivity,memory, visuospatial abilities and frontal lobe function,Cognitive speed and accuracy, attention, and memory,estradiol levels,mood, cognition and quality of life,Instrumental Activities of Daily Living,Minnesota Multiphasic Personality Inventory-168, the Profile of Adaptation to Life, and the Beck Depression Inventory,mental state and quality of life,verbal memory,memory function,HPA response to task-induced stress,cognitive effects,physical performance,Cortisol plasma levels,Memory, frontal lobe functions (inhibition and planning) and visuospatial abilities (mental rotation,Wechsler Adult Intelligence Scales,executive functioning,health-related quality of life in physical and mental domains,cognitive functioning,frontal lobe functions,cognitive test scores or on the 36-Item Short-Form General Health Survey,cognition,postural stability,Serum estradiol (E2) and FSH levels,adverse reactions,balance scores, performance measures,mild cognitive impairment (MCI,visuospatial abilities,change from baseline and rate of change from baseline for the following psychometric tests: Verbal Fluency Test, Weschler Paired Associate Learning and 20 min Delayed Recall, Trailmaking A and B Tests, Cancellation Random Letter and Random Form Tests,negative affect, or depressive symptoms,memory performance,estradiol levels and mood changes,associative verbal memory,verbal and visual memory,specific cognitive functions,performance, mood and personality,central processing speed or postural stability,overall quality of life,quality of life scores (as measured by the SF-36) and cognitive function (CAMCOG, Block Design, Memory for Faces, California Verbal Learning Test (CVLT) and verbal fluency (VF,cognitive performance measures,cognitive performance and serum E2 levels,Memory function,Physical Activity Scale of the Elderly,Wechsler Adult Intelligence Scales, measuring both digit span and digit symbol,Postural instability and falls,verbal memory performance,Folstein Mini-Mental State Examination,mental rotation task,Estrogen plasma levels,cognitive performance,Cognitive performance,mood, cognitive function and quality of life,mild cognitive impairment,dementia or cognitive decline,physical performance measures, functional ability, physical activity, falls, and cognitive function,cognition or balance,rising time,Beck Depression Inventory (BDI) scores,bone density,Extraversion,pupillary and skin conductance variables,global cognitive function, verbal and visuospatial memory, language, executive function, and semantic memory,physical measures of mobility, ability to rise from a chair, self-reported activities of daily living, physical activity scores, or falls,psychological function,walking normal,working memory,cognition and health-related quality of life,plasma estrone and estradiol levels,immediate or delayed recall of visual material, delayed recall of paragraphs, or digit span scores,time to rise from a chair, timed walking, balance, Instrumental Activities of Daily Living, Physical Activity Scale of the Elderly, Folstein Mini-Mental State Examination, and falls,cortisol plasma levels,correct reproductions,Incidence rates,brain activation patterns,Plasma estradiol levels,incidence of dementia and mild cognitive impairment,cognitive function, mood and quality of life,figural memory,Beck Depression Inventory,actual performance of the verbal and nonverbal memory tasks|Treatment with estrogen increased activation in the inferior parietal lobule during storage of verbal material and decreased activation in the inferior parietal lobule during storage of nonverbal material.
281|Protein S100 levels,incidence of low SVR, and patterns of SVR changes,CEC numbers and proportions of apoptotic hEC,hemodynamic data (cardiac index, systemic vascular resistance, left- and right-ventricular stroke-work indices, inotropic and mechanical support needs) and enzyme levels (CK-MB and SGOT), as well as mortality, perioperative infarction rate, homologous transfusion requirements, and the symptomatology in the first follow-ups,contractile cardiac function,Retinal microvascular damage,reoperation for bleeding,Myocardial preservation,frequency of neurocognitive deficit,deterioration renal function,Mean SVR index,mortality or morbidity,Inflammatory response and myocardial injury,CD11b levels,Blood glucose and lactate,stenosis-free patency rate,homologous blood consumption,neurologic deficit,Ophthalmic function,leukocyte elastase, platelet beta-thromboglobulin, and complement C3a,inhospital outcomes, similar completeness of revascularization, and shorter lengths of stay,neurocognitive deficit,mortality and morbidity,shorter ventilatory support,postoperative VA,CD97 expression of granulocytes (PMN) and monocytes (MC,transcardiac pH differences,level of TNF-alpha,rate of atrial fibrillation,haemoglobin concentration,Clinical morbidity and costs,coagulation parameters,TNF-system and sIL-2r,CABG,SVR index responses,respiratory morbidity,ET levels,Cardiac release of interleukin-6, tumor necrosis factor-alpha, and blood lactate,CABG and OPCAB in inflammatory markers,Isoprostanes and oxidative stress,Platelet activity,elevated D-dimer levels,early mortality and morbidity,Interleukin-1 (IL-1,Early graft patency,overall graft patency rate,Plasma tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) levels,Platelet count,vitro bleeding time,peripheral tissue metabolism and microvascular blood flow,Levels of creatine kinase mass,intensive care unit stay,overall fibrinolysis potential,negative fluid balance,early activation of CD69+ and late activation of CD25+ on T lymphocytes,Demographic, hemodynamic, and respiratory parameters,Volume of homologous blood transfusion,graft patency, clinical and quality-of-life outcomes, and cost,systemic NOx levels,salvaged mediastinal blood available for autologous transfusion,neutrophil counts,CD11b surface expression on neutrophils,inflammatory response,serum CK-MB mass fraction, Troponin I, and interleukin (IL)-6, IL-8, and IL-10 levels,Graft patency,Interleukin-6 (IL-6) levels,systemic release of IL-8,major adverse events and neuropsychological functioning,right ventricular systolic and diastolic function,All-cause mortality,cardiovascular event,Interleukin-6, interleukin-8, C3a, and troponin I levels after surgery,resolution visual acuity (VA), and cerebral injury, by transcranial Doppler ultrasound-detected emboli and S100 protein values,overall rate of graft patency,echocardiographic markers of right ventricular function,Apoptotic and normal cells,Cognitive outcomes,glucose homeostasis,peak and total S100 levels, and N-acetyl-glucosaminidase activity,postoperative clinical outcome (ICU stay, ventilation duration, length of hospital stay,Operative mortality and morbidity,Aspartate transaminase and alanine-amino transferase levels,respiratory failure,Permanence on the ventilator,mean (+/-SD,Differential white cell counts,quality-of-life,lymphocyte activation,plasma level of proinflammatory cytokine tumor necrosis factor (TNF)-alpha,stroke nor transient ischemic attack,average stay in the intensive care unit,cumulative blood release of troponin-T,1-year angiographic patency,levels of tumor necrosis factor-alpha,area under the curve of troponin T levels,mammary artery patency,hospital deaths,Renal tubular function,health related quality of life,Quality-of-life assessments,cumulative release of myoglobin,Platelet function,Static and dynamic lung compliance measurements,Glucose, lactate, pyruvate and glycerol as markers of basic metabolism and tissue perfusion,postoperative VO(2), DO(2), and ExO(2) levels,Protein C1 esterase inhibitor and von Willebrand factor concentrations,IL-6,Interleukin-1, interleukin-6 and myocardial enzyme response,systemic inflammatory response,Postoperative morbidity,CABG and OPCAB,intraoperative blood loss and homologous blood transfusion,Postoperative ET levels,serial measurements of insulin/glucagon ratio, amylase, and glucose,Oxygen metabolism variables,protein carbonyls,OPCAB and sharp increases during CABG,abnormal regional function,ratio of insulin-like growth factor-1 concentration,preoperative characteristics and risk factors,health status,homologous blood,Levels of the same markers and blood lactate,Inflammatory response and myocardial ischaemia,white blood cell (WBC) and neutrophil count,IL-6 expression,diastolic function,peak S-100 protein,prevalence of postoperative hemodialysis,inflammatory response reactions,mean intraoperative S100,frequency of no need for transfusion,Right ventricular function,postoperative peak values of creatine kinase-MB mass,Platelet expression of P-selectin,time to extubation,Permeability and absorption,coronary bypass graft patency,interstitial concentrations of the glucose, glycerol, pyruvate and lactate,microvascular damage,S-100 protein levels,Serum cytokine levels,occluded graft,Endothelial apoptosis and circulating endothelial cells,platelet activity,hospital deaths or major postoperative complications,S100 levels,Complement C3a and elastase levels,median postoperative length of stay,systemic inflammatory response syndrome and early catecholamine requirement,Small intestine function,mortality,Mean number of grafts,Aspirin efficacy,PAI-1 values,likelihood of graft occlusion,composite of death from any cause, a repeat revascularization procedure, or a nonfatal myocardial infarction,Maximum creatine kinase-MB levels,Fibrin D dimer and prothrombin fragment 1+2 concentrations,right ventricular function,inflammatory markers, troponin I, protein S100, and free hemoglobin,postoperative red cell count, hemoglobin level and Hct,troponin T levels,prior anesthesia values of lipid hydroperoxides,Mean number of bypass grafts,mean number of grafts per patient,deterioration in scores,composite of major adverse cardiac and cerebrovascular events (MACCE) including all-cause mortality, acute myocardial infarction, cardiac arrest with successful resuscitation, low cardiac output syndrome/cardiogenic shock, stroke and coronary reintervention,retinal microvascular damage,Blood glucose,postoperative pulmonary shunt,atrial fibrillation,Bleeding,Intraoperative and postoperative data,Serum Cr and blood urea,neurologic and clinical morbidity,circulating markers of inflammation and organ injury, (2) operative results, and (3) outcome at 1-year follow-up,lactate/pyruvate ratio and the lactate/glucose ratio, indicating the aerobic and anaerobic tissue metabolism status,Saphenous graft patency per patient,Levels of tissue-plasminogen activator,postoperative atrial fibrillation,hospital mortality,roTEG signs of hyperfibrinolysis,neurocognitive function,free water clearance values,leukocyte activation,Myocardial energy metabolism and tissue injury during CABG,functional class and exercise capacity,systemic nitric oxide production, total nitrate/nitrite (NOx,maximum myocardial lactate production,Rey Auditory Verbal Learning Test (total and recognition scores,Soluble P-selectin levels in plasma,Release of troponin T,Overall hemostasis potential and overall coagulation potential,Hemoglobin levels,White cell and neutrophil counts,nitric oxide,Neuropsychologic and quality-of-life outcomes,monobasic (MB) fraction of the creatinine kinase 24 h after the operation,lower release of cardiac troponin,arterial partial pressure of oxygen,Interleukin 8 concentrations,renal function and clinical outcomes,Inotropic,quality of life,PTX3 levels,collateralized chronic total occlusions of native coronary arteries,Cardiac outcomes and health-related quality of life,incidence of in-hospital death and outcomes (low cardiac output syndrome, prolonged mechanical and pharmacologic cardiac support, prolonged mechanical ventilation support, and postoperative length of stay in intensive care unit and hospital,Peak S100 levels,perioperative complications,alpha2-macroglobulin, protein C1 esterase inhibitor, fibronectin, and von Willebrand factor concentrations,mechanical ventilation support and length of intensive care unit and postoperative stay,neuropsychologic and quality-of-life outcomes,Postoperative blood loss,Raw graft patency rate,postoperative bleeding,Neurocognitive status,coronary artery bypass graft patency,graft-patency rates,exercise capacity improvement and attenuation of symptoms,CPB, PTX3 levels,complete revascularization,D-dimers release,Splanchnic organ injury,Arachidonic acid-induced platelet aggregation,renal dysfunction,Forced vital capacity (FVC) values,myocardial ischemic markers,graft patency,peripheral tissue (skeletal muscles) energy metabolism,length of stay in ICU,Intensive care unit stay, duration of intubation, hospital stay and bleeding,Mean total hospitalization cost per patient at hospital discharge,Postoperative increases in fibrinogen and hs-CRP,TNF-alpha and IL-8 release or endothelial function,Cardiac outputs and clinical outcomes,transient neurologic dysfunction,CD11b expression,serum cytokines and myocardial tissue markers,activation of coagulation and fibrinolysis,mean health-related quality of life,TNF-alpha and IL-8,fresh frozen plasma,survival free of any cardiac-related event,cardiac-related death,pulmonary artery pressures, ventilation requirement, and hospital stay,organ function and inflammatory response,Mean number of anastomoses,adhesion molecule expression,blood transfusions,gastric mucosal hypoxia,major adverse cardiac-related events or death,median value of HITS,hospital death,evaluation of myocardial infarct size measured by the perioperative serum release of cardiac troponin,energetic metabolism,completeness of revascularization, graft patency at 1 year, neuropsychological outcomes, and the use of major resources,Intramyocardial lactate/pyruvate ratio,Overall hemostasis potential, overall coagulation potential, and overall fibrinolysis potential,Creatine Kinase-MB (CK-MB) release, the amount of bleeding and intensive care unit (ICU) stay (p<0.05,peripheral endothelial function,Thrombin formation,MACCE,Glucose homeostasis,number of arterial grafts,Hospital mortality and morbidity,IL-10,Vein graft patency,neutrophil activation,Oxygenation and release of inflammatory mediators,Plasma levels of complement (C3a), cytokines (IL-8, TNF-alpha), endothelin-1 and neopterin,high-sensitivity C-reactive protein (hs-CRP) and fibrinogen,Expression of CD25, CD26, CD69, and DR on T (CD3+) and B (CD19+) lymphocytes on peripheral blood,blood collection times,Neurocognitive deficit,safety and efficacy,plasmatic creatinine, urinary creatinine, creatinine clearance, proteinuria or osmolality,urinary excretion of microalbumin and retinol binding protein (RBP) indexed to creatinine (Cr,CEC and proportions of apoptotic hEC,nuclear derangement,response of T lymphocytes and their activation markers, as well as B lymphocytes and their activation markers,Temperature, SVR index, cardiac index, and blood pressure,Cerebral perfusion with OPCAB,neuron-specific enolase levels,30-day mortality, no stroke, and no acute renal failure,and -10, C-reactive protein (CRP) and neutrophils,Interstitial lactate levels,postoperative mortality and morbidity,Peak creatine kinase,cardiac troponin I concentration,perioperative oxidative stress,hospital stay,Pulmonary abnormalities,total antioxidant status,Mean cardiac index,homologous transfusion,Plasma tissue factor levels,Volume of intraoperative autologous blood transfusion, postoperative mediastinal blood loss and homologous blood transfusion requirements,elastase,intramyocardial levels of glucose, pyruvate and urea,1-year graft patency, cost, and quality-of-life outcomes,Troponin I,Pre- and postoperatively prothrombin time and partial thromboplastin time,insulin-like growth factor binding protein-1,gastric mucosal oxygenation,expression of lymphocyte activation markers,postoperative impairment,anginal status or quality of life,dialysate concentrations of glucose and lactate,inflammatory markers,Risk ratios,CD11a and CD18 expression of leukocytes,release of IL-6,cerebral perfusion,local blood flow,overall early graft patency rate,pancreatic function,inflammatory reaction and myocardial metabolism,Major postoperative complications,P-selectin expression,TNF-alpha and elastase levels,myocardial damage,Major adverse cardiac-related events and health-related quality of life,Graft occlusion,Oxidative stress,Hepatic metabolic function,Renal functions,postoperative renal functions,renal failure and lesions of the circumflex artery and its branches,rate of the 1-year composite outcome,release of creatinine kinase,Blood samples,urinary RBP,shorter hospital stay,inflammatory response (interleukin (IL)-6, interleukin-10, ICAM-1, P-selectin) and of myocardial injury (myoglobin, creatine kinase-MB (CK-MB), troponin I,severely stenosed carotid arteries,major deterioration,cardiac troponin,Postoperative atrial fibrillation,gastrointestinal complications,Revascularization,levels of Troponin I and activation of cytokines,Preoperative clinical characteristics,angiographic graft patency,CPB inclusive of cardioplegic arrest, left ventricular ejection fraction <50%, emergency surgery, prolonged aortic cross clamp and CPB time, post-operative low cardiac output syndrome, post-operative inotropic requirement, new onset atrial fibrillation (AF), excessive post-operative blood loss and redo thoracotomy,Gastric intramucosal pH (pHi), gastric-arterial carbon dioxide partial pressure difference (CO(2) gap), whole-body oxygen delivery (DO(2)) and consumption (VO(2)) and whole-body oxygen extraction fraction,age, gender, New York Heart Association class, Canadian Cardiovascular Society functional classification of angina grade and number of CABG,Insulin-like growth factor-1 standard deviation score,PAI-1,CK-MB mass release,Hemodynamic variables (including creatine kinase-MB and troponin levels), intubation time, postoperative bleeding, and blood transfusions,Pulmonary artery pressures, ventilation requirement, and hospital stay,angina recurrence,aerobic metabolic activity,Central venous blood samples,Nonfatal myocardial infarctions,Plasma levels of interleukin-6 and tumor necrosis factor-alpha,health-related quality of life,Glutathione peroxidase levels,neutrophils,blood loss,oxygen consumption (VO(2)) and delivery (DO(2,serial blood samples, plasma malondialdehyde (MDA) as index of lipid peroxidation, red blood cells glutathione peroxidase (GPx) and superoxide dismutase (SOD,Postoperative hepatocellular injury,Insulin-like growth factor-1,postoperative gas exchange,Postoperative cognitive testing,platelet count,plasma total antioxidant status,Postoperative systemic arterial ET levels,IL-6. IL-1,proportion of patent grafts,neuropsychological outcomes or use of major resources,roTEG signs of fibrinolysis,low SVR index,earliest extubation time,C-reactive protein levels,inflammatory response and organ function,appearance of graft patency, myocardial function, and clinical outcome,S100 concentration,Overall tissue factor production,patency rate,CPB time,endothelial response,occurrence of cardiovascular events (all-cause mortality, stroke, myocardial infarction, and coronary reintervention), anginal status, and quality of life,troponin release,MDA levels,clinical outcomes and neuropsychological functioning,bilirubin level,expression of systemic proinflammatory cytokines,Fibrinogen and t-PA levels,GSH levels,mortality or perioperative myocardial infarction,Forced expiratory volumes,cognitive decline,myeloperoxydase content,Fasting blood glucose,death, myocardial infarction, further revascularization (surgery or angioplasty), or stroke,postoperative hospital stay,number of grafts per patient,incidence of in-hospital death,Plasma IL-6 levels,Thirty-day complications, neuropsychological functioning, and one-year clinical and functional outcomes,global systolic right ventricular function,oxygenation, shunt (%) and ventilation-perfusions mismatch, described as DeltaPO(2) (kPa,Release of interleukin-6,mean CEC-number,higher incidence of atrial fibrillation,urinary albumine excretion,PAI-1 antigen levels,postoperative neutrophil counts,C3a and neopterin concentrations,graft patency, major adverse cardiac-related events, and health-related quality of life,resternotomy for bleeding,5-year cognitive or cardiac outcomes,rate without stenosis,total amount of cardiac troponin I released,Free hemoglobin levels,dialysate concentrations of ethanol,shorter duration of mechanical ventilation,risk of graft occlusion,CEC numbers and proportions of endothelial apoptosis,allogeneic blood transfusion,Neurocognitive outcomes,expression of adhesion molecules,WBC and neutrophil counts,Early mortality,Gastrointestinal complications,patency of grafts, better clinical outcome, shorter hospital stay, and better neurocognitive function,plasminogen activator inhibitor-1,Overall, T lymphocytes,systemic inflammatory response, postoperative morbidity, and hospital stay,strength of the relationship between VO(2) and DO(2,serum levels of cardiac troponin I,OPCAB,systolic and diastolic function,Myocardial function,Patency,myocardial metabolism and inflammation (glutathione (GSH), superoxide dismutase (SOD) and myeloperoxidase (MP)) and plasma samples for indicators of oxidative stress (conjugated dienes (s-BDC), oxidative products of proteins (s-ox-Prot) and low-density lipoprotein (LDL)-total peroxyl radical trapping antioxidant potential (s-TRAP,platelet function and increased thrombin formation,Average blood glucose,Immediately postoperatively IL-10 levels,expression of adhesion molecules (CD11, CD18) of leukocytes,Systemic inflammation,adverse renal outcome,CABG iPF2alpha-III levels,total operation time 205.10,Troponin-T and creatine kinase isoenzyme MB (CK-MB) levels,Systemic release of interleukin (IL)-6, -8,graft-patency rate,cognitive deficits,length of the operation,Postoperative morbidity and blood loss,aggregation,deterioration of DeltaPO(2,functional class and positive treadmill exercise tests,Hospital mortality,neutrophil elastase levels,Urinary isoprostane iPF2alpha-III levels, plasma levels of free malondialdehyde, and total antioxidant status,neuropsychological outcomes or short-term use of major resources,cardiac-related late deaths,blood loss and homologous blood transfusion requirements,composite of death or complications (reoperation, new mechanical support, cardiac arrest, coma, stroke, or renal failure,endothelial activation,Blood pressure responses,postoperative inflammatory response,SOD levels,index admission mortality, stroke, low-output cardiac failure, return to the operating room for bleeding, and postoperative troponin release,Saphenous graft patency,main morbidity and hospital moratlity,renal complication or serum markers of kidney dysfunction,oxidative stress and inflammation,total amount of heart-type fatty acid-binding protein, cardiac troponin,operation time,demographic makeup, Parsonnet score, functional status and extent of coronary revascularization,pulmonary function,Neurologic and clinical morbidity,worsening of renal function,minor adverse events (wound infection,post-operative gastrointestinal complications,death, neurological injury, renal failure, respiratory failure, and operative myocardial infarction,chest tube drainage,intraoperative mediastinal blood loss,inflammatory response, myocardial, neurologic, and renal injury,Pancreatic function,MDRD GFR and serum creatinine levels,pyruvate concentrations,rate of the 30-day composite outcome,blood requirements,CABG and OPCAB in oxygen consumption (VO(2)), delivery (DO(2)), or extraction (ExO(2,Amylase levels,renal function,postoperative morbidity,expression of CD97 and adhesion molecules (CD11, CD18,platelet activity and aspirin efficacy,Troponin I release,length of ICU stay,TCC,Inferotemporal retinal arterial embolization and microinfarction,myocardial metabolism,graft patency, survival, and health-related quality of life,Creatinine clearance,IL-8, TNF-alpha, and sE-selectin,hazard of death,CABG performance,worse composite outcomes and poorer graft patency,mean static and dynamic lung compliance postoperatively,postoperative tissue factor and P-selectin expression,mortality or renal complication,cerebral microemboli,Glomerular and tubular injury,Myocardial metabolism,Venous serum levels of S-100 protein,inflammation activation,oxidative stress,Mean temperature,Cr,expression of P-selectin,OPCAB iPF2alpha-III excretion,Oxygen metabolism,Global myocardial function,clinical outcomes and S-100 protein, neuron-specific enolase, and maximum creatine kinase-MB levels,pyruvate and glycerol interstitial concentrations, lactate/pyruvate ratio and lactate/glucose ratio,incidence of neurocognitive impairment,Length of hospital stay and use of blood products,nitrotyrosine,global systolic function and tricuspid early/late (atrial) ratio as a marker of the global diastolic function,number of circulating endothelial cells and apoptotic endothelial cell death,Intensive care stay,postoperative stay,neurocognitive impairment,hospital mortality and morbidity,incidence of high SVR,Interleukins (IL)-6, IL-8, IL-10, myeloperoxidase, elastase, and terminal complex of the complement (TCC,morbidity,I concentrations,hEC apoptosis,clinical, angiographic, neurocognitive, and quality of life outcomes,creatinine levels,arterial graft patency,number of HITS,heart-type fatty acid-binding protein levels,myocardial infarction,regional function,intramyocardial concentrations of glucose, urea and lactate,stroke risk score,Renal tubular and glomerular functions,C-reactive protein and systemic levels of TNF-alpha, TNF specific receptors Rp1 and Rp2, Interleukin-6 (IL-6) and soluble IL-2 receptors (sIL-2r,time of mechanical ventilation,cardiac index,alveolar-arterial oxygen gradient,discharge in vitro bleeding times,Doppler high-intensity transient signals (HITS,Release of inflammatory markers,Liver function,time of inotrope drugs support,monoethylglycinexylidide/lidocaine ratios and by serial measurements of transaminases (aspartate transaminase and alanine-amino transferase), bilirubin, and alkaline phosphatase,Serum insulin, insulin-like growth factor-1 and its binding protein,Rates of death, stroke, myocardial infarction, angina, and reintervention,time on the relation between VO(2) and DO(2,mean mechanical ventilation time,Endothelial function,VO(2) and DO(2,Platelet activity and aspirin efficacy,Mean on-pump and off-pump SF-36 scores,incidence of low cardiac output syndrome,Postoperative S-100 serum levels,rate of active CD97-positive lymphocytes,neurocognitive function assessed using a 19-test neurocognitive battery at baseline, discharge, and 6 months,Fluid balance, serum Cr and blood urea,Peak systolic and early diastolic velocities,CRP|In low-risk patients undergoing CABG surgery, avoiding the use of cardiopulmonary bypass had no effect on 5-year cognitive or cardiac outcomes.
4447|systolic and diastolic blood pressure (captopril,glycosylated hemoglobin and 12-hr urinary microalbuminuria,total cholesterol, HDL cholesterol, and LDL cholesterol,baseline systolic or diastolic BP,values of GFR, AER, and systolic and diastolic BP,diabetic glomerulopathy,lowering blood pressure,response (SBP and/or DBP normalized, or DBP fall,time to the onset of microalbuminuria,dBP,target blood pressure,systolic blood pressure,urinary albumin excretion rate,microalbuminuria and albumin excretion rate,baseline UAE,Renal function,blood sugar and glycosylated hemoglobin,Albuminuria,LDL cholesterol,24-hour UAE, creatinine clearance (CCr), and the regression coefficient of the yearly plasma creatinine reciprocal (beta-1/Cr,prevalence of microalbuminuria,mean BP (diastolic + 1/3 pulse pressure,urinary albumin excretion (UAE,blood-pressure control,Adverse events,normal glomerular filtration rate (GFR,serum lipids and diabetes control,risk for renal events,Resting blood pressure,Transition to microalbuminuria,creatinine clearance or serum creatinine,mesangial fractional volume,major renal outcomes,fasting plasma glucose and glycated hemoglobin (HbA1c) levels, and both maintain constant AERs,serum creatinine level,glycated haemoglobin,composite renal outcome,Fasting and post-prandial plasma glucose, glycosylated haemoglobin and plasma lipids,GFR decline per year,mean low-density lipoprotein cholesterol,albumin excretion rate,times to the onset of renal and cardiovascular events,highest frequency of clinical events,albumin excretion rate (AER,long-term antihypertensive efficacy, tolerability, and metabolic effects,rate of change in albuminuria,urinary albumin excretion, progression of retinopathy and neuropathy and the incidence of cardiovascular disease,creatinine clearance,renal function and albuminuria,Lower systolic BP levels,Urine albumine/creatinine ratio (ACR), mean blood pressure (MBP) and index of glomerular filtration rate (GFR) based on S-creatinine,risk of major vascular events,Glycemic control and blood pressure,mean CCr,total serum cholesterol, HDL cholesterol, HbA1c, fasting serum glucose, or plasma insulin,fraction of glomerular volume occupied by mesangium in kidney-biopsy specimens,nonfatal cardiovascular events--81,efficacy and safety,higher rate of fatal cardiovascular events,particularly HbA1c, BMI, triglycerides, and cholesterol plasma values,annual rate of change in albuminuria,efficacy and tolerability,blood pressure,microalbuminuria incidence or rate of change in albuminuria,tolerated,retinopathy progression,GFR,renal function,microalbuminuria to overt albuminuria,diastolic blood pressure (BP,blood pressure (systolic/diastolic,progression of UAE,new microalbuminuria (3 or 4 collections of urinary albumin excretion rate,Mean blood pressure,systolic and diastolic blood pressure,systolic blood pressure (24-h systolic blood pressure) reduction,incidence of stroke,MBP or GFR,BP response,composite of dialysis, doubling of serum creatinine, and death,serum lipids,risk for microalbuminuria,geometric mean x:tolerance factor,Metabolic parameters,BP,absolute risk reduction,albumin excretion,progression to incipient and overt diabetic nephropathy,antihypertensive effects,microalbuminuria,Chronic cough,plasma glucose, insulin or lipid concentrations,estimated GFR,UAE rate,serum lipids and glucose metabolism,progression of diabetic retinopathy,Office blood pressure,sBP,glomerular filtration rate (GFR,plasma clearance of 51Cr-labeled EDTA,microalbuminuria and/or hypertension,Urinary albumin excretion rate,blood pressure, kidney biopsies and kidney function tests,seated and 24-h ambulatory systolic blood pressure,urinary albumin excretion (UAE) measurements,renal events,total cholesterol,Systolic blood pressure (sBP) and diastolic blood pressure (dBP,FBS and 2-hr PMBS,Mean BP,antihypertensive effect,number of events,doubling of serum creatinine,antihypertensive efficacy,rate of death from cardiovascular causes,high-density lipoprotein cholesterol,HbA1c, triglycerides, and BMI,renal disease,secondary renal outcome, dialysis or doubling of serum creatinine,biochemical measures,Urinary albumin excretion rate (AER,Estimated glomerular filtration rate (eGFR,rate of deterioration in renal function,likely to revert to being normoalbuminuric,AER,serum lipid fractions,Renal disease,5-year cumulative incidence of microalbuminuria,serum triglycerides,hypoglycaemic events,kidney function,blood pressure (BP), creatinine clearance (Ccr) and urinary albumin excretion (UAE,mesangial matrix volume and mesangial volume,renal outcomes,clinical outcomes,retinopathy severity scale,beneficial effect on triglycerides,death, cardiovascular events, and/or renal events (need for renal replacement therapy or doubling of baseline plasma creatinine,diabetic vascular complications,albuminuria,hazard ratio [HR,ACR,duration of diabetes,left ventricular end-diastolic volume index nor the left ventricular ejection fraction,side effects,overnight albumin excretion rate,cardiovascular events,complete renal-biopsy and retinopathy data,urinary albumin excretion,incidence of side effects,mean BP,Hemoglobin A1c values,duration of diabetes and hypertension, systolic and diastolic blood pressure at rest, degree of LVH, metabolic control, and albumin excretion rate (AER,time to the first onset of microalbuminuria,24-hour UAE,Microalbuminuria,glomerular filtration rate and effective renal plasma flow determined with inulin and para-aminohippuric acid clearances,acute myocardial infarction, stroke, or hospitalized angina,antiproteinuric effect of losartan,Degree of albuminuria at 24 hours, creatinine clearance, blood pressure, and hemoglobin A1c values,GFR decline,mean fall in the systolic and diastolic blood pressure,normoalbuminuria to microalbuminuria,change in creatinine clearance,risk of hypoglycaemic events,mean entrance BP,Composite renal outcome of dialysis or doubling of serum creatinine, changes in estimated glomerular filtration rate (GFR), and changes in albuminuria|Slightly fewer patients in the olmesartan group than in the placebo group had nonfatal cardiovascular events--81 of 2232 patients (3.6%) as compared with 91 of 2215 patients (4.1%) (P=0.37)--but a greater number had fatal cardiovascular events--15 patients (0.7%) as compared with 3 patients (0.1%) (P=0.01), a difference that was attributable in part to a higher rate of death from cardiovascular causes in the olmesartan group than in the placebo group among patients with preexisting coronary heart disease (11 of 564 patients [2.0%] vs. 1 of 540 [0.2%], P=0.02).
31|bone mineral density (BMD,Bone density,bone density,severe side effects,dual-energy X-ray absorptiometry (DXA) of the lumbar spine and hip, and spine radiographs to detect vertebral fractures,biochemical parameters,cortical and cortical and trabecular bone mineral content,incidence of vertebral fracture,risk of osteoporosis and fracture,back pain,axial bone loss,mean BMD,bone preservation,Bone loss at the femoral neck and distal radius,bone mass,generalised pruritus,lost lumbar bone,efficacy and safety,spinal bone loss,BMD,lumbar bone loss,spinal bone mass,bone turnover assessed by biochemical markers, bone loss assessed by serial measurement of lumbar spine density, and rates of bone fractures,bone remodeling (alkaline phosphatase and osteocalcin,S.D. bone mineral density of the lumbar spine,loss of bone in the lumbar spine,percentage change in bone mineral density of the lumbar spine,bone loss,Bone mineral density (BMD,DXA lumbar spine density|Nasal salmon calcitonin prevented loss of bone in the lumbar spine as measured by dual-energy X-ray absorptiometry.
106|free of vomiting,frequency of emesis during an 8-h-period after enrollment,tolerance of oral fluids,greater oral intake,rank sum of episodes of diarrhea,hospitalization rates,Hospital admission rate, fluid intake, general well-being of the children, and potential adverse effects,rates of hospitalization,frequency of vomiting,vomiting,rates of intravenous fluid administration and hospital admission,Change of weight,mean length of stay in the emergency department,proportion of patients experiencing no emesis,proportion who vomited while receiving oral rehydration,number of emetic episodes,weight gain,hospital admission rate,Vomiting,vomiting and diarrhea,Admission rates,return visits to the emergency department,efficacy and safety,nausea and vomiting,diarrheal episodes,admission rate,vomiting episodes,Hospital admission,tolerated oral hydration,Antiemetic activity,diarrhea,median number of episodes of vomiting,number of mean episodes of vomiting or repeat visits to health care,number of diarrhea episodes,number of episodes of vomiting,number of vomiting episodes, fluid intake, parents' assessment of well-being, number of diarrheal episodes, and admission rate to hospital,tolerated,number of episodes of emesis,revisit rate,intravenous hydration,Oral fluid tolerance,mean number of vomiting episodes|Eleven of 51 (21.6%; 95% confidence interval [CI] 11.3% to 35.3%) of subjects who received ondansetron required intravenous hydration and 30 of 55 (54.5%; 95% CI 40.6% to 68%) of placebo subjects required intravenous hydration (p <0.001) for a difference of 32.9% (95% CI 14.54% to 48.37%).
10881|fatal or nonfatal myocardial infarction,total serum cholesterol,cardiac mortality and morbidity,mean GFR decline,Fatal and non-fatal stroke,lowering blood pressure,plaque regression,hypokalemia,mean DBP,cardiovascular events and total mortality,systolic blood pressure,Time to cardiovascular death, myocardial infarction, congestive heart failure, strokes, and coronary revascularization,blood pressure, clinical safety,Systolic and diastolic blood pressure,total cholesterol: high-density lipoprotein cholesterol ratio,fatal and non-fatal myocardial infarction,diastolic blood pressure,cardiovascular morbidity and mortality,vascular events,Adverse events,serum lipids and diabetes control,Deaths,cardiovascular disease-related death,rate of progression of mean maximum IMT,cardiovascular disease,Blood pressure,mortality and morbidity outcomes,fatal and non-fatal stroke, myocardial infarction, and other cardiovascular death,Morbidity and mortality,cardiovascular mortality,antihypertensive efficacies, tolerabilities and cardiovascular event rates,blood pressure goals,fatal and nonfatal myocardial infarctions,non-fatal myocardial infarction (including silent myocardial infarction) and fatal CHD,Overall mean blood pressure,peripheral oedema,incidence and progression of complications of diabetes,yearly IMT progression rate,nonmajor vascular events and procedures (eg, transient ischemic attack, dysrhythmia, aortic valve replacement, and femoral popliteal bypass graft,adverse cardiovascular events,cardiovascular disease-related events,cardiovascular death, myocardial infarction, heart failure, or stroke,cardiovascular mortality and morbidity,major cardiovascular events,risk of major vascular events,serious adverse events,blood pressure 168.9,total serum cholesterol, HDL cholesterol, HbA1c, fasting serum glucose, or plasma insulin,Total mortality,serum creatinine levels, end-stage renal disease, and death from any cause,blood pressure control,blood pressure, blood glucose and lipid concentrations, and smoking behavior,fatal or nonfatal stroke,blood pressure,urinary protein to creatinine ratio,GFR,cardiovascular outcomes,marked systolic blood pressure reduction,composite of cardiovascular and cerebrovascular events,composite index of the clinical end points of reduction in GFR of more than 50% or 25 mL/min per 1.73 m(2), end-stage renal disease, or death,rates of cardiovascular events,cardiac disease,blood pressure change, side effects and quality-of-life indices; incidence of electrocardiographic and echocardiographic abnormalities; and incidence of cardiovascular clinical events, including death,composite of cardiovascular events,composite cardiovascular event rate,occurrence of cardiovascular events,mean SBP,serum lipids and glucose metabolism,rate of progression of mean maximum intimal-medial thickness (IMT,asthenia,renal disease progression,cardiovascular disease and total mortality,Nonstroke hemorrhage,incidence of vascular events,congestive heart failure,blood pressure of the sitting subject, heart rate, and a standard clinical safety profile (electrocardiogram, laboratory tests, adverse events, cardiovascular events, and deaths,JNC VI blood pressure goals,incidence of developing diabetes,occurrence of death (all cause), nonfatal myocardial infarction, or nonfatal stroke; other: cardiovascular death, angina, adverse experiences, hospitalizations, and blood pressure control at 24 months,biochemical measures,carotid IMT progression and number of plaques per patient,stroke, myocardial infarction, or cardiovascular disease-related death,rate of change in GFR,SD systolic and diastolic blood pressure (SBP and DBP, respectively) of 149.7,fatal and nonfatal myocardial infarction,renal outcomes,treatment blood pressures,rates of hyperuricemia (plasma urate,cardiovascular morbidity or mortality,SBP,fatal and non-fatal stroke,plaque progression,major vascular events (eg, myocardial infarction, stroke, congestive heart failure, angina, and sudden death,myocardial infarction,triglyceride level,overall cardiovascular or cerebrovascular complications,relative risk for stroke, major cardiovascular events, and mortality,cardiovascular events,mean diastolic values,24-hour ambulatory systolic/diastolic blood pressure changes,Cardiovascular outcomes,systolic and diastolic blood pressures,cardiac morbidity and mortality,acute myocardial infarction, stroke, or hospitalized angina,strokes,heart rate,Rate of progression of mean maximum IMT,risk of clinical end points,4-year CBM(max) progression,total cardiovascular events,hyperuricemia and hypokalemia,rate of myocardial infarction,Clinic blood pressure reductions|Fatal and non-fatal stroke occurred in 159 patients in the diltiazem group and in 196 in the diuretic and beta-blocker group (6.4 vs 7.9 events per 1000 patient-years; 0.80 [0.65-0.99], p=0.04) and fatal and non-fatal myocardial infarction in 183 and 157 patients (7.4 vs 6.3 events per 1000 patient-years; 1.16 [0.94-1.44], p=0.17).
not found|number of arterial blood gas samples drawn,ICU,rate of reintubation,rate of successful weaning,rates of reintubation, non-invasive ventilation post-extubation, tracheostomy, sedation, neuromuscular blockade and use of corticosteroids,Simplified Acute Physiologic Score II,synchronized intermittent mandatory ventilation rate and pressure support (PS) based on predetermined limits of patient respiratory rate (RR) and tidal volume (TV,PaO2/FiO2 ratio,Total costs,Complications -- removal of the breathing tube by the patient, reintubation, tracheostomy, and mechanical ventilation,median duration of mechanical ventilation,severe disease,Mortality and ventilator discontinuation failure rates,average time on mechanical ventilation prior to weaning,VAP,Rate of reintubation,weaning time and incidence of ventilator-associated pneumonia,rates of reinstituting mechanical ventilation,SIMV rate and PS reduction,Overall complications included death,incidence of ventilator-associated pneumonia (VAP,number of minutes per hour outside acceptable limits,shorter durations of mechanical ventilation,Intubation time,Pulse oximeter oxygen saturation,Hospital cost savings,median time of mechanical ventilation,need for reintubation, length of hospital stay, hospital mortality rate, and hospital costs,VAP frequency,incidence of VAP,duration of mechanical ventilation,hospital costs,Glasgow Coma Scale (GCS) score,median time,duration of mechanical ventilation from tracheal intubation until discontinuation of mechanical ventilation,ICU length of stay,Tracheostomies,median time to successful extubation,hospital mortality rates,hospital mortality,number of days of intensive care and hospital care,Duration of mechanical ventilation, length of intensive care unit stay, mortality, rate of tracheotomy (secondary end points,partial pressure of arterial oxygen/fraction of inspired oxygen ratio,MV interval and hospital length of stay,median interval,successful extubation,estimated probability of reaching "separation potential,arterial blood gas samples, shorter weaning times, and less time spent outside acceptable RR and TV parameters,discontinuation of mechanical ventilation|Twelve patients in the surgical control group had VAP, compared with 5 in the surgical VMP group (p = 0.061).
436|time to confirmed progression in disability,first time in a large-scale MS trial,Annual relapse rate,EDSS (hazard ratio (HR),Median MSFC Z-score change,neurological deterioration,time to progression by > or =1.0 EDSS point (0.5 point if EDSS score,MSFC progression, relapses, quality of life, and MRI activity,Neutralizing antibodies,sensitive disability measure and relapse rate,time to confirmed progression of disability,clinical relapses, newly active MRI lesions, and accumulated burden of disease on T2-weighted MRI,Neutralizing antibodies to IFNbeta-1b,time to sustained disability,efficacy and safety,EDSS scores,MS Functional Composite (MSFC), comprising quantitative tests of ambulation (Timed 25-Foot Walk), arm function (Nine-Hole Peg Test [9HPT]), and cognition (Paced Auditory Serial Addition Test [PASAT,Regional Functional Status Scale,Expanded Disability Status Scale (EDSS,time to becoming wheelchair-bound, relapse rate and severity, number of steroid treatments and hospital admissions,tolerated,New or enlarging T2-hyperintense brain MRI lesions and gadolinium-enhancing lesions,mean change in EDSS score from baseline, relapse-related measures, MRI activity, and a standardized neuropsychological function test,11 MS Quality of Life Inventory subscales,disability measures|New or enlarging T2-hyperintense brain MRI lesions and gadolinium-enhancing lesions were reduced at months 12 and 24 (both p < 0.001).
200|hospital admissions or mortality,cause hospitalizations and total hospital days,Emergency department admission,cardiovascular-related emergency room visits,ACE inhibitor adherence,length of time between hospital discharge and readmission or death, reduced total number of rehospitalizations, and decreased healthcare costs,readmissions for any reason,ACE inhibitor use,lower mortality,total number of readmissions,death or unplanned readmission (event-free survival) and rate of recurrent, all-cause readmission within 6 months of hospital discharge,re-admission rates,number of short hospitalizations,mortality and morbidity,risk of death or readmission,death or hospital readmission,hospital readmissions,Unplanned outpatient visits,number of hospital readmissions and hospital days and improved quality of life,rate of rehospitalization for heart failure,readmission and death rates,median total public health care and personal care costs,EQ-5D scores,events (readmission or death,quality of life, which was self-assessed using the Minnesota Living with Heart Failure questionnaire,satisfaction scale,Time to first rehospitalization or death, number of rehospitalizations, quality of life, functional status, costs, and satisfaction with care,quality of life (QoL) and secondary end points were hospitalisation and mortality,59 CHF hospital admissions and 13 deaths,deaths,admissions,cardiovascular hospitalizations,composite of the number of CHF hospital admissions and deaths,readmitted with heart failure,risk of readmission,lower risk of re-admission,moderate to severe HF,1-year cumulative incidence of readmission or death,quality of life and death or hospital readmissions,Hospital re-admissions, days of hospital stay, treatment compliance, satisfaction with the care received, and quality of life (EuroQol,target doses of angiotensin converting enzyme (ACE) inhibitors,readmission or died,readmissions,quality of life,cause hospital admission rates and total number of days in hospital at 6 months,frequency of unplanned readmission plus out-of-hospital death,number of unplanned re-admissions, six-minute walking distance, London Handicap Scale and public health care and personal care costs,greater uptake of beta-blocker therapy,hospital admissions,QoL or readmission rate,year survival rate,cost savings,cost-effective,hospitalization days,cost/utility ratios,self-care abilities, self-care behavior, and quality of life,self-care abilities (Appraisal of Self-care Agency Scale), self-care behavior (Heart Failure Self-care Behavior Scale), 3 dimensions of quality of life (functional capabilities, symptoms, and psychosocial adjustment to illness), and overall well-being (Cantril's ladder of life,number of days in hospital,Self-care abilities,Time to first readmission or death,mortality and quality of life (Minnesota living with heart failure questionnaire and EQ-5D,physical dimension of quality of life,hospitalizations,cause death and heart failure hospital admissions,handicap in independence,heart failure,rate of first rehospitalization for heart failure,Hospital-based costs,NYHA functional class,effectiveness and cost-effectiveness,effectiveness and cost/utility ratio,quality of life and reduced total hospital admissions and total bed days,43 CHF hospital admissions and 7 deaths,mortality, morbidity and self-care behaviour,All-cause mortality,quality-of-life score,heterogeneous changes in NYHA functional class,unplanned readmission,134 admissions,spent fewer days in hospital for heart failure,overall quality of life,quality of life improved and overall cost of care,mean time to readmission,Time to readmission, days in hospital, and health care costs,survival and self-care behaviour,appearance of hard events,recurrent readmission and event-free survival,hospital readmission costs,readmitted because of HF or died,required readmission to hospital,total number of emergency department visits, quality of life and total mortality,cardiac death,Hard cardiac events,QoL or health care consumption,rate of unplanned re-admission,incidence of readmission, mortality, and emergency department admission,total hospital readmissions,mean total costs,median number of re-admissions,Self-care and quality of life,patient satisfaction,unplanned readmissions and survival,higher self-care scores,unplanned readmissions,cost/utility ratio,chronic heart failure (CHF) hospital readmissions and mortality,rate of all-cause rehospitalization,health care costs,C+HBI,time to first event, time to first all-cause and HF readmission, and time to death,hospitalisation and health care costs,higher level of treatment compliance,admissions for heart failure,hospital readmissions, improved survival and quality of life,died,readmitted or died,Minnesota living with heart failure questionnaire scores,rate of unplanned readmissions and associated health-care costs, prolong event-free and total survival,length of hospital stay,recurrent hospital stay,Management (rate of readmissions, therapeutic interventions), functional parameters (New York Heart Association [NYHA] functional class, left ventricular diameters, and ejection fraction, deceleration time of early diastolic mitral flow, peak oxygen uptake, and mitral regurgitation) and hard outcomes (cardiac death and urgent cardiac transplantation,six-minute walking distance,total number of emergency department visits,symptom frequency and symptom distress,recurrent hospitalisation,year readmission or mortality and costs of care,adverse clinical outcomes and costs,mean days of hospital stay,hospital days,events (death or admission,cost of care,functional status, quality of life and beta-blocker prescription rate,number of days lost to death or hospitalization,hospital costs,rate of readmission or death and hospital costs,performance, effectiveness, and cost/utility ratio,cause readmissions and all-cause deaths,time to death or rehospitalization because of HF and the number of days lost to death or hospitalization,mortality|There were 43 CHF hospital admissions and 7 deaths in the intervention group, as compared with 59 CHF hospital admissions and 13 deaths in the nonintervention group (p = 0.09).
335|Brief Psychiatric Rating Scale (BPRS) and Abnormal Involuntary Movement Scale,Prolactin elevations,negative symptoms,overall symptomatology improvement (Brief Psychiatric Rating Scale [BPRS]-total), Olz-M, Olz-H, and Hal,moderate EPS and drowsiness,positive symptoms,body weight,incidence of extra-pyramidal side effects,BPRS scores and plasma AAG levels,Safety and tolerability evaluations included extrapyramidal symptoms (EPS), weight gain, serum prolactin level, and QTc interval,number of symptom-free days dose,Mean plasma haloperidol levels,Blood samples,quicker onset of antipsychotic activity,relapse rate,somnolence, agitation, asthenia, and nervousness,Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI), and Modified Scale for the Assessment of Negative Symptoms (SANS) summary scores,incidence of extrapyramidal symptoms,efficacy, safety, and tolerability,safety and efficacy,Plasma alpha-one acid glycoprotein and haloperidol concentrations,tardive dyskinesia,Efficacy and safety,acute dystonia,Blood samples to measure plasma alpha-one acid glycoprotein (AAG), haloperidol and reduced haloperidol concentrations,antidyskinetic effect,clinical improvement,BPRS total, BPRS positive-symptom cluster, and CGI Severity of Illness item scores,positive symptom improvement (BPRS-positive), Olz-M, Olz-H, and Hal,signs of tardive dyskinesia,Positive and Negative Syndrome Scale (PANSS) total, PANSS positive, PANSS negative, PANSS-derived Brief Psychiatric Rating Scale (BPRS) core, Clinical Global Impressions (CGI)-Severity of Illness, and mean CGI-Improvement scores,Global evaluation, BPRS, and target symptom ratings,Plasma AAG levels,Positive symptom scores,total scores on the Positive and Negative Syndrome Scale for Schizophrenia,variables (basic data, MMPI, AMDP, HAM-A, HAM-D,BPRS scores,Serum prolactin levels,plasma AAG levels,efficacy, rapidity of therapeutic onset, and safety,total Positive and Negative Syndrome Scale (PANSS) score and positive subscale, superiority to placebo,Extrapyramidal Symptom Rating Scale,rate of Hal, and akathisia,remission state,PANSS total, PANSS positive, PANSS-derived BPRS core, and CGI-Severity scores,EPS or prolactin elevation,number of days of remission,assessment scales of extrapyramidal side effects,total PANSS, General Psychopathology, and Brief Psychiatric Rating Scale subscales,Negative Symptoms [SANS]-composite), Olz-L and Olz-H,QTc interval,PANSS negative score,Prolactin levels|The most common treatment-emergent adverse events included somnolence, agitation, asthenia, and nervousness.
not found|progression of renal failure (1/serum creatinine v time) or change in serum potassium,Energy levels and work capacity,51Cr red cell mass,Serial GFRs,serum creatinine and reciprocal of serum creatinine,survival rate,THb,hematocrit increased with r-HuEPO,cumulative renal survival rates,Maximal oxygen consumption during exercise,slope of l/serum creatinine with time,appetite, activity level, and sense of well-being,average systolic and diastolic blood pressure,anemia,erythroid, megakaryocyte, and granulocyte-monocyte progenitor cells,Cardiac output, plasma renin activity and aldosterone,glomerular filtration rate (GFR,safety and efficacy,exercise capacity,rate of the decline in renal function,hematocrit rose,deterioration of renal function,GFR, mean arterial blood pressure, and daily protein intake,Hypertension,Renal function,physical exercise capacity,hematocrit; mean hematocrit,total hemoglobin (THb,chronic renal failure,renal survival rate,hematocrit,hemoglobin concentration,serum ferritin and percent transferrin saturation (plasma iron/total iron-binding capacity,blood pressure,packed cell volume (PCV,Blood pressure,blood pressure and hematocrit,tolerated,erythrocyte mass,Anemia,Quality of life,Renal function, cardiac output, plasma renin activity and aldosterone,GFR,degree of control of dietary protein and blood pressure and the frequency of angiotensin-converting enzyme inhibitor administration,residual renal function,clearances of inulin and p-aminohippurate, fractional excretions of albumin and immunoglobulin G, cardiac output, plasma renin activity and aldosterone concentration,renal function,median hematocrit,slope of l/serum creatinine,rate of the response|Six of seven treated patients had a significant decrease in serum ferritin and percent transferrin saturation (plasma iron/total iron-binding capacity).
not found|mortality of tetanus,mortality|In the other age group of 13-30 years, there were 27 and 38 patients in the treatment and control groups respectively.
40|eating attitudes, eating behavior, and general psychopathology,binge eating and depression,dietary preoccupation and hunger,binge eating and purging rates,eating behavior,items 'restraint', 'weight concern' and 'shape concern,target-eating behaviors,bulimic symptomatology,body weight,Eating Disorder Examination (EDE,recurrence of symptoms,symptoms of depression and anxiety,energy intake and lost a modest amount of weight,tolerated and had only minor adverse effects|In self-ratings and expert ratings concerning attitudes towards eating, eating behavior, and general psychopathology, significant improvements over time were observed in both groups.
579|several instances (oppositional/aggressive symptoms, internalizing symptoms, teacher-rated social skills, parent-child relations, and reading achievement|For most ADHD symptoms, children in the combined treatment and medication management groups showed significantly greater improvement than those given intensive behavioral treatment and community care.
242|mean scores,relative onset of analgesic response, overall analgesic efficacy, duration of effect, and safety,time to onset of relief and overall analgesic efficacy,postsurgical dental pain,intensity of pain, relief of pain, and side effects,pain intensity and pain relief and summary measures,median time to meaningful pain relief,total and peak analgesia,pain relief,Ratings of pain intensity and pain relief,serious adverse effects,pain intensity,Overall pain scores,sum pain intensity difference, total relief of pain, and overall evaluation parameters,pain relief and pain intensity difference,small additive effects,number of hours until remedication,SUMPI, TOTPAR and maximum PAR (MAXPAR,meaningful relief,overall analgesic effect,Pain intensity, pain relief, and side effects,patient self-rating of pain intensity, pain relief, time to meaningful pain relief, need for additional analgesic medication, and patient global evaluation,analgesia,peak pain intensity difference (visual analog scale), summed pain intensity differences, total pain relief, peak pain relief, time to reduction of pain,Analgesic efficacy,serious adverse events,postoperative dental pain,rapid analgesia,side effects,analgesic efficacy and safety,median times to onset of relief,marginal numerical superiority,analgesic efficacy and tolerability,pain relief (PAR,efficacy and safety,pain intensity differences, peak pain intensity differences, total relief, peak relief, and hours of 50% relief,frequency of adverse effects,adverse reactions,pain intensity difference, pain relief, and global evaluation,Pain intensity,duration of analgesic effect,analgesic efficacy,pain intensity (PI) and pain intensity difference (PID,number of patients requiring rescue medication,Analgesia,incidence of adverse events,pain intensity and relief and stopwatch onset of meaningful relief,analgesic effects,mean response with zomepirac,tolerability,rapid onset to meaningful relief,Pain relief,Drug tolerability,pain,pain relief, pain intensity difference, total pain relief (TOTPAR), and summed pain intensity difference (SPID,median time to onset of analgesia,pain scores,tolerated,analgesic efficacy measures sum PI (SUMPI), sum PID (SPID), and total PAR (TOTPAR,Analgesic efficacy and safety,faster relief and superior overall efficacy,onset of meaningful relief,Analgesic effect,overall pain relief,peak and overall analgesic effects,overall pain scores (AUC(0,360 min), maximum pain relief, pain relief at 1 h after dosage and the number of patients taking escape analgesics,severe postoperative pain,adverse reaction,later time to taking escape analgesics,relative analgesic efficacy and safety,onsets of first perceptible relief and meaningful relief|At 4 hours after administration, the pain relief was significantly better with tablet acetaminophen than with effervescent acetaminophen.
240|hospitalisations and, secondly, exacerbations, general practitioner (GP) calls and related cost-effectiveness of tele-assistance (TA,forced expiratory volume,Self-reported endurance exercise time,exercise behavior, exercise performance, COPD exacerbations, and mediators, such as self-efficacy and social support,pulmonary rehabilitation programme,unnecessary clinic visits,average visit costs,self-efficacy scores,risk factors of COPD readmission,hospitalisations,readmissions and mortality,number of hospitalizations; secondary outcomes included emergency visits and patient health status,unscheduled physician visits,admissions for other health problems,quality indicators (medication compliance, knowledge of disease, and ability for self-care); extent of use of services; degree of patient satisfaction,total mean costs of care, excluding home health care costs,knowledge, behavior and status scales,Pulmonary function tests and dyspnea index scores,body mass index,acute exacerbations,Morbidity,Chinese Self-Efficacy Scale,self-efficacy for managing dyspnea,serum theophylline levels,scores for activities of daily living at study discharge,hospital utilization,patient self-efficacy,average overall cost,chronic obstructive pulmonary disease (COPD,impact subscale and total quality-of-life scores,urgent GP calls,Hospital admissions for exacerbation of COPD,dyspnea with ADL,technical quality of VVs,hospitalisation rate,quality indicators, patient satisfaction, or use,Chronic Respiratory Questionnaire,physical functioning,mortality,Emergency department visits,numbers of visits to an accident and emergency department, hospitalizations, and unscheduled visits by physicians,health care use,SF-36 general health subscale,clinical and functional status, quality of life, lifestyle, and self-management,Telehomecare: quality, perception, satisfaction,questionnaires, visual analog scales, and other psychosocial measures,hospitalisations, emergency room admissions, urgent GP calls or exacerbations,evolution of dyspnea, lung function, quality of life scores, lifestyle factors, or medical treatment|Only COPD patients, as a separate group, had fewer hospitalisations, emergency room admissions, urgent GP calls or exacerbations.
89|70-point reduction in Crohn's Disease Activity Index,efficacy and safety,overall clinical response rate|Lenalidomide was generally well tolerated with only one serious adverse event, a deep vein thrombosis, being attributed to treatment.
not found|FEV1,area under the curve for FEV(1,area under the curve for forced expiratory volume in 1 s (FEV(1,efficacy and safety,bronchodilator response,dyspnea,Adverse effects,tolerated,FEV1 and sGaw,lung function,daytime symptom scores and morning peak expiratory flow,airways obstruction,specific airway conductance (sGaw,Salmeterol xinafoate,diary symptoms and quality of life,symptoms,Bronchodilator response,quality of life|There was added benefit from the combination therapy in terms of improvement in airways obstruction, but not for improvement in symptom control or need for rescue salbutamol.
70|Serum levels of FT4, T3, sTSH and TSH receptor antibody (TRAb,High TRAb levels and goiter weight,serum basal thyrotrophin (TSH) level and TSH receptor antibody activity,mean duration of treatment,relapse rate,suffered relapse,recurrence of Graves' disease,Serum basal TSH levels and TBII activities,normalized antithyroperoxidase (TPO) antibody and anti-TSH receptor stimulating antibody (TSAb) levels and early iodine uptake,TSHR-Ab titers,serum thyrotropin concentration,regular cigarette smoking,disease relapse,remission rates or delays relapse,relapse of hyperthyroidism,Plasma TRAb levels,serum free T4 and T3 and TSH concentrations,gastrointestinal side effects or leucopenia,rate of normalization of serum thyroid function tests, changes in serum thyroid auto-antibody levels and the rate of side-effects,serum thyrotropin concentrations,percentage of recurrence equalled,clinical parameters, thyroid hormones, or TSH binding inhibitory immunoglobulins (TBII) levels,goiter size, frequency of ophthalmopathy, TSH and TRAb levels,course of endocrine eye signs,thyroid echostructure,level of antibodies to TSH receptors further,relapse of overt hyperthyroidism,normalize elevated TSH serum concentrations,production of antibodies to TSH receptors and the frequency of recurrence of hyperthyroidism,Recurrence rate,thyroid-stimulating antibody levels,antibodies to TSH receptors,rapid goitre growth,relapse of hyperthyroidism, initial thyroid size,frequency of Graves' disease complications and thyrotoxicosis recurrence,remission rates,frequency of relapse,final outcome and recurrence rates,recurrences of hyperthyroidism,Relapse rates of Graves' disease,relapse rates of Graves' disease,rate of normalization of serum thyroid function tests or in serum thyroid auto-antibody levels,area of low-to-moderate iodine intake (prevalence of 24h urinary iodine excretion,recurrence rate 20 times lower,rate of relapse,Thyroid volume,remission rate,Cigarette smoking,serum TSH level and TBII activity,median relapse-free interval,overall relapse rate,number of side-effects,serum tri-iodothyronine (T3) and thyroxine (T4) concentrations,mean serum thyroxine concentration,percentage of recurrence,target TSH concentration,level of antibodies to TSH receptors,TRAb levels and goiter weight,relapse and remission groups, regardless of treatment duration, for HLA ABDr, serum T3 and T4, and T3/T4 ratio,recurrence risk,thyrotropin-receptor antibody (TRAb) positive,Serum TSH,recurrence,complications of Graves' disease,lasting remission,Total T3, TSH-receptor antibodies,serum total T4 and tri-iodothyronine (T3), free T4 and T3, TSH, TSH-receptor antibodies (TSHR-Ab), thyroid scintigraphy and echography,levels of antibodies to TSH receptors,serum TSH,relapse rates,serum TSH level and thyrotrophin binding inhibitor immunoglobulin (TBII) activity normalized,Dropout rate,ophthalmic symptoms,long-term remission rates,2-year post-treatment remission rates,thyroid volume,recurrence rates,positive TSHR-Ab,Thyroid antibodies, serum thyroglobulin and pertechnetate uptake,goitre size, pertechnetate uptake and presence of detectable plasma TSH,recurrence of hyperthyroidism,TSH secretion,early iodine uptake,Hyperthyroidism,clinical characteristics or hormonal or antibody values,Median duration,recurrence rate,Recurrence,relapse of Graves' disease,goiter size,normal serum thyrotropin concentration,relapse,drug intolerance symptoms,goitre size during treatment, and TSH levels and TBII values,goiter size with recurrence,Relapse,remission|By 2 years after stopping treatment, recurrence had occurred in 50% of the HD and 66% of the TD group.
not found|bronchial hyper-responsiveness,WLC, BTI reduced wheezing, anxiety, and chance LoC, and increased asthma knowledge, attitude, and self-efficacy,Spirometry (FEV1); 2) medication use; 3) Asthma Quality of Life Questionnaire; 4) Beck Depression Inventory; 5) Spielberger Anxiety Scales (A-State and A-Trait,Mesoexpiratory Flow,reduction of anxiety and depression scores,symptoms (obstruction, fatigue), better quality of life (activity, symptoms, emotions), decreased negative affectivity, and increased adherence,POMS-BI scores except anxiety, increased internal LoC, and reduced problematic behaviors,relaxation during EMG or RSA biofeedback,relaxation,heart rate variability (HRV) biofeedback,External Control Subscale,panic and asthma outcomes,occurrence of severe asthma flares,respiratory impedance,forced expiratory flow,For BTI, data collection (symptoms, lung function,External Chance Scale,baseline characteristics (anxiety, depression, psychophysiological disorders), emotional reactions to asthma attacks (panic-fear, etc,) and cognitive variables (external control, psychological stigma, internal beliefs, external chance, etc.) involved in the perceived illness,total power scores,bronchial hyper-reactivity,feasibility and efficacy,asthma morbidity, and asthma-related behaviour and cognitions,morning peak-flow expiratory rate and asthma-related quality of life,respiratory function,pulmonary function, asthma symptoms, quality of life, depression, anxiety, and power differ over time,pulmonary function,Oscillation resistance,peak expiratory flow rates,McMaster Asthma Quality of Life Questionnaire, Asthma Symptom Checklist, Negative Emotionality Scale, Knowledge, Attitude and Self-Efficacy Asthma Questionnaire, Adherence Scale, and peak flow measurements,asthma symptoms (wheezing, coughing, sleep, activity, attacks, peak flow) and self-report assessments of Profiles of Mood States (POMS-BI) (anxiety, hostility, depression, uncertainty, fatigue, confusion); Knowledge, Attitude, and Self-Efficacy Asthma Questionnaire (KASE-AQ); Health Attribution Test (HAT) for locus of control (LoC); and the Revised Asthma Problem Behavior Checklist (RAPBC,measures of perceived stress,number of visits of the general practitioner,choices sub-scale,feasibility and effectiveness,cognitive variables (knowledge, attitude towards asthma, self-efficacy) and day and night peak flow ratings,respiratory sinus arrhythmia (RSA,daily asthma symptoms and twice-daily peak expiratory flows,lung function,Psychophysiological Questionnaire,asthma symptoms,asthma knowledge, attitude, self-efficacy, internal LoC, and peak flow,CTAM, BTI reduced wheezing and chance LoC, increased internal LoC,symptoms and asthma management,Forced Vital Capacity (FVC), Forced Expiratory Volume in the first sec (FEV1), Forced Expiratory Flow,pulmonary impedance,6 POMS-BI scores|No significant changes were observed in the control group.
not found|Methacholine challenges and random circulating and sputum eosinophils,adverse reactions,positive reactions,histamine sensitivity (PC20,random nasal eosinophils,Bronchial reactivity,baseline lung function|Only 4 of 156 patients (all Polish) had positive reactions in a double-blind test, as evidenced by a fall in FEV1 greater than 25% from baseline and corresponding clinical symptoms.
672|pain scale 1-10) need for analgesia, ambulation (evaluated by a four-point scale), complications and return to work,Ambulation grades,Patient satisfaction,pain of a higher scale,Hernia recurrence rate,Nerve injuries,lowest recurrence rates,Postoperative pain and patient's comfort,recurrence rates,Chronic groin pain,wound hematomas, seromas, and superficial wound infection,number of recurrences,re-recurrence rate,hernia recurrence, nerve damage, testicular atrophy and patient satisfaction,Recurrence rates, symptoms (including patient satisfaction), and infections,sick leave,longer operation time,duration of surgery, the technique of anesthesia, the perioperative complications, the duration of postoperative care,actuarial recurrence rate,postoperative complications, return to work, and recurrences rate,Actual (not actuarial) recurrence rates,cost-effective,Hernia recurrence,recurrence rate,Recurrence,actual 2-year recurrence rate,direct hernia, repair for recurrent hernia, hernial sac diameter,Postoperative pain, analgesia requirements, limitation of daily activities, and return to work did not differ between laparoscopic and open tension-free repair,complication rate,operating time,narcotic analgesics,recurrence rate, technical difficulty, convalescence and chronic pain,Duration of operation, postoperative pain assessed by visual analogue scale (VAS), complications within 30 days, duration of sick leave, and recurrence within one year,operative time; postoperative pain,sliding hernias,Postoperative pain, narcotic use, and time to resumption of usual activities and employment,duration of operation, pain score, or incidence of postoperative complications,Recurrence of hernia,postoperative pain, duration of narcotic use, and time to resumption of usual activity and employment,redoubtable and litigious sequelae of testicular atrophy and chronic ilioinguinal pain,chronic groin pain|Both types of hernia repair are comparable and effective, but long-term results favor the Lichtenstein technique for reducing recurrences (to a P value of .10), ease of technical mastery, and application to the outpatient setting by use of a local anesthetic.
not found|rate, length, or severity of URIs,Plasma ascorbic acid levels,duration of infections,number of episodes,severe illness episodes,colds,sickness experience,severity of URIs,Duration of symptoms and cold episodes; cumulative symptom severity scores,duration and severity of colds,throat cultures yielding beta-hemolytic streptococcus,mean illness,overall complicated illness rate,total number of days of upper respiratory tract infection,duration and severity of respiratory infections,development of symptoms of URT infection,incidence and severity of winter illness,cold duration or severity,reduction of colds,personality trait of neuroticism,side effects,duration and severity of symptoms of URT infections,daily observations of cold symptoms, and multiple biochemical, anthropometric, and psychological measurements,upper respiratory or general constitutional symptoms,Whole-blood ascorbic acid levels,duration or severity of the common cold,Respiratory symptoms,incidence of symptoms of upper-respiratory-tract (URT) infections,rate of respiratory infections,duration or severity of cold symptoms,postrace symptoms of upper-respiratory-tract infection,severe illness,cold symptoms,incidence or duration of colds,Symptoms of URT infections,shorter duration of severe symptoms,Total number of common colds,mean illness duration,shortest duration of nasal, systemic and overall symptoms,severity,incidence of URIs,duration of respiratory infections,incidence or morbidity of the common cold and other respiratory illnesses|No apparent reduction was seen for the severity and duration of the common cold.
not found|pain reduction,gastro-enteric side effects,pain rating scores,medication-related side-effects,pain intensities,psychotropic drug intake,intensity of pain,tablet count,NHP,analgesic effect,MPQ scores,pain intensity,Neck Disability Index, and (3) three visual analogue scales of local pain intensity,low back pain,analgetic drugs,scores of the (1) Oswestry Back Pain Disability Index, (2,Aberdeen LBP scale, lumbar spinal active range of movement (AROM), and the isokinetic strength,McGill Pain Questionnaire,activity related to pain; mobility; verbal descriptors of pain and the patient's subjective assessment of his condition,VAS,McGill Pain Questionnaire (MPQ) and visual analog scales (VAS) for pain,neck disability index, and (3) reductions on the visual analogue scale,modified Roland Disability Questionnaire (RDQ,Initial pain levels correlated with state-anxiety, depression, pain duration, and abnormal illness behavior measures,mean global transition score,mean spinal flexion,pain score,estimates of pain (on a Visual Analogue Scale) and disability by both physician and patient, physical measures of trunk strength and spine range of motion, as well as the patient's perceptions of the relative contribution of the education, exercise training, and the electrical stimulation,pain intensity and in pain disability, and secondary in psychological distress and in spine flexion,average pain score,new episodes of low back pain,pain, disability, and functional improvement scores,pain diaries to score pain intensity twice daily, analgesic intake, and quality of sleep daily, and activity level weekly,spinal flexion,VAS and NHP,pain relief scale (100 mm visual analogue scale: VAS) and a LBP score recommended by the Japanese Orthopaedic Association (JOA Score,pain disability,pain or stiffness (VAS, physical tests,relapse of low back pain and number of days on sickness leave,psychological distress,disability scale,chronic low back pain,pain severity on visual analogue scale (VAS); (2) pain subscale of Nottingham Health Profile (NHP); (3) number of analgesic tablets consumed in previous week; (4) spinal flexion from C7 to S1,RDQ score,neck pain,initial pain severity,pain,JOA Score,spinal AROM and isokinetic trunk concentric strength,pain or stiffness,pain scores,NRS and Aberdeen LBP scale,Numerical Rating Scale (NRS,change in RDQ score,depression, neuroticism, and hypochondriasis scores,Mean VAS value,spinal manipulation,visual analogue scale measure of average pain,Analgesic drug intake,adverse effects,return to work, quality of sleep, and analgesic intake,individual patient's pain score,Side effects|During the first phase of treatment, patients receiving acupuncture had a greater but not significantly different reduction in pain rating scores compared with those receiving placebo (t = 0.52; p greater than 0.6).
not found|SF-36 and GIQLI questionnaires,Major complications,Median length of the incision,Demographic data, recurrence rates, need for additional surgery related to primary procedure, and medication use,reoperation, readmission and repeat resection rates for recurrent Crohn's disease,GIQLI score,incisional hernia and adhesion-related problems,morbidity, hospital stay, and costs,incisional hernia repair,Overall reoperation rates,Incidences of anorectal disease, anorectal surgery, endoscopic or radiologic recurrence, and medication use,QoL,forced expiratory volume (one second) and forced vital capacity,Median length of stay,Median overall costs,postoperative quality of life (QoL,Flatus and first bowel movement,relapse free after ileocolic resection,amount of morphine equivalents,Conversion rate,SF-36 and GIQLI questionnaire,Median operating time,body image and cosmesis scores,quality of life (QOL), body image and cosmesis,QOL,operating time, morbidity, hospital stay, postoperative morphine requirement, pain, and costs,clinical recurrences,number of patients with postoperative morbidity,Minor complications,Hospital stay|OC patients requiring operation during follow-up were significantly more likely than LC to require multiple operations (P = .006).
not found|bilirubin measurements,number of bilirubin determinations,median hours to case closure,severe hyperbilirubinemia,exchange transfusion or interruption of breast-feeding,moderated hyperbilirubinemia and reduced phototherapy (PT) time|No adverse effects of SnMP use were observed.
14|work-related anxiety,pre- and post-treatment anxiety scores,TMD scores,stress hormone levels,burnout rates,mental health,levels of stress,mean scores on the Nurse Stress Checklist (NSC) and the Chinese General Health Questionnaire (CGHQ,Perceived Stress Scale (PSS) and Rathus Assertiveness Schedule (RAS,mean change in physiologic parameters,Mental health status,attitudes, communication skills and occupational stress,Visual Analog Scale (VAS) and increased relaxation,job turnover,scores on 2 of 3 subscales of the Maslach Burnout Inventory,Chinese version of State-Trait Anxiety Inventory and the Chinese version of the General Health Questionnaire,inhibitory behaviours,stress levels,Nursing Stress Scale and communication skills,level of occupational stress,sick leave,anxiety, stress, self-care and caring relationships,educated guesses,Total Mood Disturbance (TMD,psychoendocrine stress,cost savings,Anxiety measures,emotional exhaustion and lack of personal accomplishment, two dimensions of burnout,Cost savings,knowledge and attitudes about serious mental illness,anxiety,multiple burnout and mood dimensions,job satisfaction, burnout, and sick leave,semantic differential questionnaire, occupational stress,nurses' satisfaction levels,facilitative behaviours (open questions,knowledge and attitudes, and increase in burnout,Blood pressure,psychophysiologic health level,Nursing Stress Scale, attitudes with a Semantic Differential Questionnaire, CS,importance of touch in nursing care, stress reduction, increased self-awareness, the need for self-care,prolactin levels|Results suggested that stress management training was effective in reducing work-related anxiety among inexperienced nurses but not among experienced nurses.
not found|pain reduction,hand pain,pain perception and function, and lastly numbers of patients continuing to surgery,Patient satisfaction,frequency of awakening at night,Pain Relief Scale,hand function or median nerve latency,functional status scale, and a symptom severity scale,Score of subjective symptom ratings assessed by visual analogue scale; electroneurographic measures (for example, motor distal latency and sensory antidromic nerve conduction velocity,electrophysiologic signs, clinical signs, or significant symptoms,global symptom score (GSS,carpal tunnel syndrome,grip strength and pain,pain/paresthesia,Symptoms and functional deficits,pain severity and greater satisfaction,Pain,pre- and postassessments of self-reported physical and mental distress, nerve conduction studies and vibrometry,functional score,pain and other symptoms of carpal tunnel syndrome (CTS,manipulation of the soft tissues and bony joints of the upper extremities and spine,Relief of symptoms,numbness, tingling, burning, and pain,mean median nerve motor distal latency (MNMDL), median nerve sensory velocity (MNSV), and global symptom score (GSS,electroneurographic variables (motor distal latency,sensory distal latency,BCTQ symptomatic score,mean score,Levine's self-administered questionnaire, and physiologic impairment,functional deficits,grip strength,Boston Carpal Tunnel Questionnaire (BCTQ) score,Subjects' Global Impression of Change Questionnaire (SGICQ), median distal motor latency, sensory conduction velocity and amplitude, and neurophysiological class of severity,superior distal latency improvement,global symptom scores,active range of wrist movement (ROM flexion and extension), upper limb tension test with a median nerve bias (ULTT2a,sleep disturbance, Tinel sign, and median nerve motor and sensory conduction time,symptoms, function, and impairment in carpal tunnel syndrome (CTS,sensory distal latency improvement,median nerve sensory and motor distal latency,sensory antidromic nerve conduction velocity,mean MNMDL, MNSV, and GSS,standardized symptom questionnaire, rating five categories of symptoms (pain, numbness, paresthesia, weakness/clumsiness, and nocturnal awakening) on a scale from 0 (no symptoms) to 10 (severe,occasional daytime wear,overall neurophysiological classification,efficacy and tolerability,Phalen test time,visual analogue scale,pain,symptom severity,motor nerve conduction velocity and increased motor distal latency,clinical findings, pain severity, functional hand status, and comfort,perceived comfort and function, nerve conduction and finger sensation overall,grip strength, pain intensity, sleep disturbance, Phalen sign, and Tinel sign, and in median nerve motor and sensory conduction time,pain severity and hand function,electrophysiological measurements,beginning pain, pain at 15 minutes, pain at 30 minutes, or pain,lateral pinch strength value,Phalen sign,carpal bone mobilization and median nerve mobilization|We evaluated the effectiveness of low-dose, short-term oral prednisone in ameliorating the pain and other symptoms of carpal tunnel syndrome (CTS) in a randomized, double-blind, placebo-controlled study of patients with mild to moderate CTS.
244|forced expiratory volume,hearing loss,Nephrotoxicity,Efficacy, tolerance, and pharmacokinetics,change in forced expiratory volume in 1s (FEV1), over the 14 days of treatment, expressed as a percentage of the predicted normal value for age, sex, and height,leukocyte count and inflammation markers,hearing impairment,Mean body weight,respiratory function and changes in renal function and hearing,forced expiratory flow,acute dizziness,forced vital capacity (FVC,safety and efficacy,creatinine,Forced expiratory volume,Cochlear and renal tolerance,respiratory function,efficacy and safety,mean change in FEV1,serum potassium and magnesium levels, equivalence,PA density,plasma prealbumin,bilateral impairment,variables forced expiratory volume in one second and forced mid-expiratory flow % pred and serum creatinine levels,Serum peak concentration of tobramycin,serum trough,Tobramycin concentration,Mean% change in FEV1,Toxicity and practicability,nephrotoxic,leukocyte count, and the secondary end-points were clinical and lung function parameters, Pseudomonas quantification in sputum, and inflammation markers (immunoglobulin G, C-reactive protein) in serum,forced vital capacity,Tobramycin concentrations,renal function,Efficacy,forced mid expiratory flow rate,weight/height,change in serum creatinine|The mean change in FEV1 (% predicted) over 14 days was similar on the two regimens (10.4% [once daily] vs 10.0% [three-times daily]; adjusted mean difference 0.4% [95% CI -3.3 to 4.1]).
not found|gait speed,self-care independence,mobility including gait speed, functional ambulation categories, the Nottingham extended activities of daily living index, and individual items from the Barthel activities of daily living index and the Frenchay activities index,socialization and self-esteem,time taken to walk 10 m,manual dexterity, depression, and anxiety,Functional Independence Measure (FIM), Brunnstrom stages of motor recovery, timed mobility tasks, and the Jebson hand evaluation,level of depression, self-esteem, and socialization,Rivermead Mobility Index scores,Barthel Activity of Daily Living Index (BI) scores, "poor global outcome", (defined as deterioration in BI score, or death) and the Rivermead Mobility Index|At 3 months BI score in survivors had increased by 0.6 (SD 3.9) in the intervention group and decreased by 0.9 (2.2) in the control group; a difference of 1.5 (95% CI allowing for cluster design, -0.5 to 3.5).
151|discontinuation-emergent adverse events,17-item Hamilton Rating Scale for Depression (HAM-D-17) total score,GBR assessment,rate of discontinuation due to adverse events,acute phase; efficacy and safety/tolerability outcomes,TEAE reporting rates,treatment-emergent adverse events (TEAE), vital signs, weight, laboratory analyses and electrocardiograms,systolic blood pressure,duloxetine, escitalopram, and placebo rates of remission or response,adverse events (TEAEs), vital signs, and weight,CGI-I, MADRS, and HAM-D(6,total MADRS score,discontinuation rates, adverse event rates, vital signs, and laboratory tests,HAM-D-17 total score,Adverse events,Tolerability,change from baseline to week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) total score,deaths,MADRS, HAMA, CGI-S, and PGI-I scales,Montgomery-Asberg Depression Rating Scale, CGI-Severity of Illness and CGI-Improvement, and Patient Global Impression of Improvement,Visual Analog Scales for pain, Clinical Global Impression of Severity, Patient's Global Impression of Improvement, and Quality of Life in Depression Scale,safety and tolerability,increased sweating,morbidity and mortality,17-item Hamilton Depression Rating Scale improvement,nausea and palpitations,laboratory values, vital signs, weight or electrocardiograms,HAMD(17) subscales, Hamilton Rating Scale for Anxiety, Clinical Global Impressions-Severity, Patient Global Impressions-Improvement, Somatic Symptoms Inventory and Visual Analog Scales (VAS) for pain,major depressive disorder (MDD,efficacy and safety,primary efficacy measure (Maier subscale,Discontinuation rates,Maier subscale,occurrence of discontinuation rates and treatment-emergent adverse events and by measurement of vital signs and laboratory analytes,overall pain severity,efficacy and tolerability,Safety and tolerability,onset of antidepressant efficacy,tolerated,estimated probability of remission,Efficacy, safety and tolerability measures,tolerated and safe,17-item Hamilton Rating Scale for Depression (HAMD(17,MADRS,withdrawal rate due to adverse events,Tolerability assessments included discontinuation rates, adverse events (AEs), vital signs, and laboratory tests,Nausea,mean change on the HAMD(17,insomnia and asthenia,overall withdrawal rates,HAMD17 total score and subscales, HAMA, CGI-S, and PGI-I. Safety and tolerability were assessed via analysis of reasons for discontinuation, treatment-emergent adverse events (TEAEs), discontinuation-emergent adverse events, and changes in vital signs, weight, and laboratory analytes,Safety,number of early discontinuations and overall TEAE,CGI-I, MADRS, CGI-S, and HAM-D(6,Remission rates (MADRS score,HAM-D(17) total score,MADRS total score,HAMD(17) total score,depression,Probabilities of meeting onset criteria,remission at endpoint [17-item Hamilton Depression Rating Scale,HAM-D(17,mean change from baseline in the 17-item Hamilton rating scale for depression (HAMD(17)) total score,VAS back pain,nausea, dry mouth, vomiting, yawning, and irritability,response and remission rates,Hamilton Rating Scale for Depression, Hamilton Rating Scale for Anxiety, and Clinical Global Impressions-Severity of Illness total scores and the proportion of patients with Clinical Global Impressions-Improvement scores,Estimated probabilities of remission,Response rates,mean MADRS total score,Mean baseline MADRS total scores,Estimated probabilities of response and remission,safety and efficacy,Hypertension incidence,safety measures,mean 17-item Hamilton Depression Rating Scale total change,insomnia,Clinical Global Impressions (CGI)-Severity of Illness scale score,somnolence,dry mouth, sedation, and somnolence for quetiapine XR and nausea, headache, dizziness, and dry mouth for duloxetine,therapeutic efficacy and safety/tolerability,17-item Hamilton Depression Rating Scale,adverse events, vital signs, ECGs, laboratory tests, and the Arizona Sexual Experiences Scale (ASEX,Clinical Global Impressions-Improvement (CGI-I) score, Montgomery Asberg Depression Rating Scale (MADRS) score, Clinical Global Impressions-Severity (CGI-S) score, and 6-item Hamilton Rating Scale for Depression, Bech version (HAM-D(6,total score, HAMD(17) subscales, the Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Anxiety Rating Scale (HAMA), Visual Analog Scales (VAS) for pain, the Clinical Global Impression of Severity (CGI-S) and Patient Global Impression of Improvement (PGI-I) scales, the 28-item Somatic Symptom Inventory (SSI), and the Sheehan Disability Scale (SDS,Efficacy,incidence of acute treatment-emergent sexual dysfunction,constipation|The difference in mean change from baseline in MADRS total score favoured escitalopram at weeks 1, 2, 4, 8, 12 and 16 (p < 0.05).
not found|serum retinol concentrations,levels of maternal and infant plasma vitamin A, H pylori infection, pneumococcal carriage, and gut epithelial integrity,H pylori infection,mean number of diarrheal episodes,breast milk retinol levels,incidence of diarrhea,breastmilk retinol concentration,Breastmilk retinol concentration,infant mortality,adverse events,infant gut mucosal damage,subclinical vitamin A deficiency,morbidity and mortality,liver stores) and higher milk vitamin A concentrations,Serum retinol levels,safety and efficacy,milk retinol,Hazard ratios,serum retinol,Serum retinol concentrations,Mean,Maternal serum retinol,Antibody titers,antipolio antibody titer, antitetanus toxoid antibodies, and avidity of antibodies to tetanus,VAD,maternal pneumococcal carriage,maternal vitamin A concentration,mean incidence of febrile illness,gram fat, milk retinol,maternal and infant plasma vitamin A, reduce infant Helicobacter pylori infection and nasopharyngeal pneumococcal carriage, and improve infant gut epithelial integrity,mean maternal serum retinol concentrations,lower maternal MRDR ratios,Subclinical Vitamin A deficiency,relative risk of VAD,milk retinol concentrations,serum retinol of infants and the breast milk retinol levels,infant pneumococcal carriage,serum retinol levels,milk vitamin,duration of respiratory tract infection and febrile illness,Maternal serum and breastmilk retinol levels and infant morbidity and anthropometry,MRDR ratios,Milk retinol,mean duration of respiratory tract infection,serum retinol and infant stores,Infant retinol stores,clinic attendances,Serum retinol and incidence of illness,tolerated,low serum retinol concentration,vitamin A status,Infant serum retinol,prevalences of low vitamin A stores,Mothers' serum retinol concentrations,mean MRDR ratio,cord blood levels,infant serum retional and the breast milk retinol level,Incidence of diarrhea and Acute Respiratory Infection (ARI,maternal and infant serum retinol concentrations, modified relative dose-response (MRDR) ratios and breast milk vitamin A concentrations|The milk retinol concentrations of the vitamin A group were higher than those of the placebo group by 0.48 to 1.18 mumol/L at 1-8 mo postpartum (P < 0.05).
76|heart rate and lower vagal tone,pain scores, crying, or time to return to baseline behavior,crying time and pain,Median Premature Infant Pain Profile scores,pulse rate,Behavioral observations,Motor development and vigor, and alertness and orientation components of the Neurobehavioral Assessment of the Preterm Infant,Neonatal Acute Physiology,loss of oxygen saturation data,time crying,adverse events, clinical outcomes, or neurobiological risk status,Facial grimacing scores,Adverse events and lidocaine levels,Facial activity,Frontal EEG asymmetry scores,Mean crying times,Electroencephalographic (EEG) activity, heart rate activity, and infants' facial behaviors,Crying and the total procedure time,pain control,overall crying time and heart rate,behavioural and physiological pain scores,procedural pain,Nociceptive brain activity,Efficacy and safety,overall mean pain score,Neonatal Facial Coding Score during nasogastric tube passage,neonates' facial activity (NFCS), behavioral state, and heart rate,Mean (SD) DAN pain scores,elevation of heart rates,Facial actions,heart,mean pain score,medians for crying time and the pain scores,frequency distribution of CT,Pain assessment,pain response,NIPS scores,Pain relief,pain or heart rate,mean PIPP score,neonatal facial coding system (NFCS,crying time and pain score,mean crying time, recovery time, maximum heart rate, and percent change in heart rate,heart rate and oxygen saturation changes,CT and subsequent NIPS scores,newborn infant pain responses,Duration of crying,Douleur Aiguë Nouveau-né (DAN) behavioral scale,crying in response to heel stab,Pain responses,facial expression of pain,crying time, duration of the first cry and tachycardia, time needed for return to baseline heart rate, and the average and 1- and 5-minute NFCS scores,né (DAN) score,Pain scores,vital signs,pain relief,Plasma for cortisol levels,crying and pain scores,Median crying times,Pain,Neuro-Biological Risk Score (NBRS,effectiveness and safety of sucrose,oxygen saturation,Pain response measurements,lowest mean Premature Infant Pain Profile scores,median recovery time,distress responses,Facial scores,PIPP scores,severity of illness, postnatal age, or number of painful procedures,multidimensional acute pain rating scale of the Premature Infant Pain Profile, heart rate increase, oxygen saturation decrease, crying behavior (duration of first cry, cry percentage in 2 minutes, and during blood sampling), duration of sampling, and the number of performed heel lances,distress,lowest pain scores,Cerebral blood volume,pain and discomfort,pain-induced crying,average score on the scale of discomfort,validated infant pain measure, the Premature Infant Pain Profile (PIPP), which includes measures of facial expressions, heart rate, and oxygen saturation and takes behavioral state and gestational age into consideration,Neonatal Facial Coding System (NFCS,baseline behavioural and physiological measures, observational pain scores (PIPP), and spinal nociceptive reflex withdrawal activity,crying time and the level of behavioural state,sucrose pain scores,pain behaviors,efficacy and safety,pulse rate variability,pain-related behaviour,pain/distress,pain-specific brain activity evoked by one time-locked heel lance, recorded with electroencephalography and identified by principal component analysis,crying time, behavioural state, skin conductance and heart rate,cry with catheterization,HR, BP, and pain score,Pain reduction,pain responses,mean (SD) plasma lidocaine level,skin conductance (number and amplitude of the waves) and heart rate,magnitude or latency of the spinal nociceptive reflex withdrawal,discomfort and crying,majority of time actively crying,Pain and discomfort,efficacy (pain response as measured using the Premature Infant Pain Profile,Mean SaO2,pain response and clinical outcomes (e.g., health status and neurodevelopmental status,neonatal pain,duration of crying,NFCS scores,relieving pain,sampling duration and numbers of heel lances,Crying duration,Analgesic effects,efficacy and immediate and long-term adverse events,analgesic effect,pain of heel pricks,Crying,Physiological (heart rate) and behavioural (facial actions) responses,behavioural and physiological pain responses,Crying times,Premature Infant Pain Profile scores,quiet sleep,negative electroencephalographic response,Venipuncture-induced pain,PIPP score,mean gestational age at birth, mean birth weight or corrected gestational age,HR, RR, O(2) saturation, BP, pain (premature infant pain profile) and percent of time spent crying during the eye exam,facial expression score, incidence and duration of crying, heart rate and oxygen saturation changes,immediate pain response,mean pain scores,total duration of crying,Heart rate,physiologic or behavioral responses to the eye exam,pain-specific brain and spinal cord activity,Median (interquartile) pain scores,facial actions indicative of pain,duration of crying whilst the blood collection,O(2) saturation,vagal tone,Duration of cry and Douleur Aiguë du Nouveau,median values of crying time, recovery time and percentage change in heart rate,neonatal infant pain scale (NIPS) score, on crying time (CT) and subsequent NIPS score,median Neonatal Pain, Agitation and Sedation Scale (N-PASS) score,analgesic effects,response to pain,lowest pain score,cerebral blood volume,safety,mean PIPP scores,Newborn Acute Pain scale (DAN) and with the Neonatal Facial Coding System (NFCS,scores of the scale of discomfort,NFCS score,pain and duration of crying,cortisol response,plasma cortisol levels,pain and distress,mean glucose levels,Vital signs (i.e., pulse rate, respiratory rate, and oxygen saturation), crying time, and time for the vital signs to return to baseline values,Premature Infant Pain Profile (PIPP) scoring system,maximum heart rate,crying and the autonomic effects,Neonatal pain,effective and safe for relieving pain,oxygen saturation and heart rate and neonatal infant pain scale,pain reaction,facial scores,SG neonates crying,neonatal heel prick responses,facial expression,blood collection, incidence and duration of crying,lower PIPP scores (single sucrose pain scores,overall physiological stability,time spent crying,behavioral (crying and facial activity) and physiological (heart rate, vagal tone) responses,procedural pain relief,SG neonates with facial actions signaling pain,average crying time,distress scores,duration of cry and by facial expression (pain score,pain score,procedural pain control,behavioural and physiological pain response,Mean DAN and NFCS scores,median heart rate increase, oxygen saturation decrease, and duration of first cry,standard deviation of pulse rate and number of doses of sucrose,duration of first cry, the percentage of time spent crying,longer crying time,motor development and vigor, and alertness and orientation at 36 weeks', lower motor development and vigor,mean recovery time,responses of neonates to pain and distress,episodes of desaturations or bradycardia,crying time,CT and NIPS scores,neurobiological risk status,behavioural responses to pain,Premature Infant Pain Profile (PIPP), a validated behavioral acute pain scale,Heart rate, thoracic movements, and transcutaneous blood gases,median pain scores,heart rate and oxygen saturation,Local skin reactions,Baseline pain scores,incidence of spitting up,Mean PIPP scores,pain,duration of the crying and grimacing,heart rate and duration of crying,median Premature Infant Pain Profile score,pain scores,relative right frontal EEG activation,Heart rate, oxygen saturation (SaO2), Neonatal Facial Coding Score and presence or absence of cry,duration of cry, vagal tone, and salivary cortisol,Adverse effects, such as apnoea or oxygen desaturation,heart rate,Physiological responses of heart rate and oxygen saturation,Premature Infant Pain Profile (PIPP) scores,pain vocalizations,premature infant pain profile (PIPP,Salivary cortisol,pain scores, less crying|The combination of sucrose and EMLA cream revealed a higher analgesic effect than sucrose alone during venipuncture in these preterm infants.
60|Total Motor Score 4 subscale (TMS-4,total functional capacity (TFC) score,Total functional capacity,chorea,peak oxygen uptake,benefit of ethyl-EPA,motor function,rate of deterioration,progression of early Huntington disease,functional, neuromuscular, and cognitive status,neurologic symptoms,quantified neurological examination and a set of cognitive and motor tests,behavioral severity and frequency,muscle functional capacity,TFC,Huntington's Disease Activities of Daily Living Scale (ADL-an index of functional status) and the Quantified Neurologic Examination (QNE,Unified Huntington's Disease Rating Scale (UHDRS,functional checklist of the UHDRS,neurologic and neuropsychiatric symptoms,Cognitive functioning, bimanual coordination ability, and general motor function (total motor scale, UHDRS,TMS-4,maximal static torque,neurologic and neuropsychologic symptoms,symptomatic improvement,adverse events|Total functional capacity was not favorably influenced by baclofen treatment.
not found|PBSC,rate of TRM,regional lymph node invasion,Hematopoietic toxicity,Median OS,partial remission,median hospital stay,Synovial sarcoma (SS,total 5-year survival rate,Karnofsky index > 80%, R (0) resection and first-line ASCT,progressive disease,median number of granulocyte-macrophage colony forming units in the reinfused PBSC,Median progression-free survival,patient died of infection,mortality (TRM,recurrences or deaths,Reversible Grade 4 myelosuppression,absolute neutrophil granulocyte count,prolonged infection,progression-free survival,died of progressive disease and one child died of therapy-associated complications,sustained complete remission (CR,symptoms of acute appendicitis,complete remission (CR,abdominal distention, vague abdominal pain, and vomiting,early discontinuation of therapy due to toxicities,partial remission (PR,rhabdomyoblastic differentiation,peripheral blood stem cells (PBSCs,hematopoietic recovery time,Median time to WBC recovery,food intolerance,toxicity, six died of disease,Median overall survival (OS,efficacy and toxicity,5-year survival and 5-year event-free survival estimates,hemopoietic recovery,Haematological and gastrointestinal toxicities,delayed hematologic recovery,Toxicity,haematological complications, no WHO grade III-IV complications,survival,Major nonhematologic toxic effects were mucositis, nutritional impairment, hypotension, and peripheral neuropathy,mean DI,frequency of relapse,Growth of metastatic nodules,delayed-type hypersensitivity responses,complete remission (CR) and three in partial remission (PR,toxic death,Desmoplastic round cell tumor (DSCT,Response durations,Overall survival (OS,2-year EFS rate,hematologic recovery,interval between HDCT1 and HDCT2,Median time to progression and median overall survival time,severe toxicity,Objective tumor regression,TTP and survival rates,median PBSC collection,probability of disease-free survival,antitumor effect,multiple organ toxicity, including venoocclusive disease, refractory thrombocytopenia, and hypertension,toxicity,partial response and partial response,CR rate,overall survival,recurrence,hepatic veno-occlusive disease, no serious complications,Life-threatening or fatal toxicity,survival benefit,complete response (CR,Median PFS,maximum plasma concentration (Cmax) and area under the curve (AUC,local recurrence and metastasis rate,toxicity of and event-free survival,Leukopenia,partial response,platelet transfusion independence,feasibility, safety and efficacy,rate of relapse in site of distant organs,multiple lung metastases,severe mucositis and erythema with superficial peeling,Hematologic recovery in HDCT2,glomerular filtration rate,disease-free survival,peripheral leukocyte count,time to disease progression,side effects,median time to progression (TTP) and overall survival,Median survival,total 2-year survival rate,partial remission (PR) and stable disease,disease recurrence or progression,Peripheral blood stem cells (PBSC,5-year progression-free survival (PFS) and overall survival (OS,5-year survival rates,complete remission,Neutrophil recovery,mortality,2-year event free survival (EFS) rate,excessive renal and gastrointestinal toxicity,died of toxicity,Tumor response to chemotherapy|The probability of disease-free survival at 2 years after HDCT2 in the SHG and DHG were 66.7 and 25.0%, respectively (P-value=0.031).
129|basilar skull fractures,rates of meningitis,frequency of asymptomatic bacteriuria,frequency of extra-neurological infections and of asymptomatic pulmonary bacterial colonization,patient's Glasgow Coma Scale score, sex, and age, as well as for an intradural location of air, air volume, presence of cerebrospinal fluid (CSF) rhinorrhea or CSF otorrhea, radiological sign of a skull base fracture, or intracranial hemorrhage,incidence of meningitis,overall rate of meningitis,overall incidence of infectious complications,Meningitis|The efficacy of chemoprophylaxis in the treatment of basilar skull fractures was studied in 129 patients over a 2-year period; antibiotics were found ineffective in preventing central nervous system infections, and in some cases may have proved harmful.
66|survival rates,infection rate,severe infections,incidence of post-operative bacterial infections,white blood cell count,Rates of infection, death, and charges for medical care,biopsy-proven rejection,aerobic gram-positive flora, anaerobes, and yeast,graft loss,length of stay,Total costs,Infection and rejection,gastrointestinal intolerance and noncompliance,Portal and systemic endotoxemia, colonization and infection rates, severity of illness (organ system failures, Acute Physiology and Chronic Health Evaluation II score, Therapeutic Intervention Scoring System score), antibiotic costs, and hospital survival rates,median peak white blood cell count,Rates of infection,mean number of postoperative infectious episodes,pulmonary infections and enteric, aerobic, and Gram-negative bacillary colonization,serious adverse events,Overall rates of bacterial and/or yeast infections,infection, rejection, or survival,mean number of postoperative bacterial and fungal infections,duration of antibiotic therapy,bacterial infection rates,Thirty-day infection rate, length of hospital stay, duration of antibiotic therapy, non-infectious complications and side effects of enteral nutrition,Biopsy-proven rejection and nosocomial pneumonias,death,stool colonization,tolerated,charges for medical care,incidence of infection,sepsis episodes, sepsis-related deaths, and rejection,infection rate at SBD key sites (abdomen, bloodstream, surgical wound, and lungs,postoperative infection,microbiologically-documented infection, biopsy-proven rejection, number of treatments for rejection, length of stay in the intensive care unit and hospital, graft survival, death, and adverse events,nosocomial pneumonias|The incidence of post-operative bacterial infections was significantly reduced; being 48% with only fibers and 3% with LAB and fibers.
621|multiple positive findings,abnormal physical examination,yield of explanatory x-ray findings,tenderness,Low back pain (LBP,radiological interval changes,contusion or abrasion,lumbar spine degeneration|The yield of explanatory x-ray findings was over three times greater among patients with indications for radiography than among those without.
110|cell count,elevation in alkaline phosphatase, and hospitalization,bacteremia,Risk of MAC disease,CD4+ cell count,Plasma HIV-1,MAC infection,disseminated MAC infection,CD4 lymphocyte count,HIV RNA value,ranges of minimal inhibitory concentrations,frequency of more severe adverse events,incidence of taste perversion,safety and efficacy,rate of M. avium complex infection,Episodes of non-MAC bacterial infection,median CD4+ cell count,survival differences,M. avium complex bacteremia,efficacy and safety,median prior nadir CD4+ cell count,M. avium complex infection,hemoglobin level,bacterial pneumonia,rectal disorders,delayed fatigue, fever, decline in the Karnofsky performance score,CD4,rate of progression of HIV disease nor the mortality rate,episodes of confirmed M. avium complex disease,Adverse effects,substantial morbidity and reduces survival,M. avium complex disease or bacterial pneumonia,signs and symptoms associated with disseminated M. avium complex infection, adverse events, hospitalization, and survival,mortality,RNA levels,time to death or number of deaths,adverse effects,Overall survival,MAC infection followed by death,MAC disease,adverse events,frequency of disseminated M. avium complex infection|Reduction in CD4 lymphocyte count to < 50/mm3 is a significant predictor of the development of disseminated MAC infection.
16|peak flow,lying and standing blood pressures,peripheral blood flow,peripheral arterial circulation,calf blood flow,safety and efficacy,normotension [diastolic blood pressure (DBP,tolerated and the side-effects,cardiovascular and gastrointestinal complaints, headaches, and sleep and sexual disorders,blood pressures,drug fever,lying diastolic pressure,systolic, diastolic and mean arterial blood pressures,blood pressure, arterial blood flow and peripheral resistance,rate of normalization,calf blood flow and vascular resistance,lowering supine and standing systolic and diastolic blood pressure,heart rate, blood pressure as well as on resting and hyperaemic calf blood flow and vascular resistance,psychometric performance,efficacy and adverse reactions,Antihypertensive efficacy,blood pressure, impaired card-sorting time and digital symbol substitution score,blood pressure,vascular resistance,Adverse effects,arterial blood flow,blood pressure and peripheral resistance,adverse effects,supine and standing blood pressure and heart rate,blood pressure and in peripheral resistance,mean supine blood pressure,hyperaemic flow|Methyldopa (250 mg tid) for 14 days significantly reduced blood pressure, impaired card-sorting time and digital symbol substitution score, and caused trends for impairment of other psychometric tests.
14|D2 occupancies,antipsychotic effect,negative symptoms,positive psychotic symptoms,Striatal and extrastriatal occupancies,Clinical response, side effects, striatal ([11C]-raclopride-positron emission tomography (PET)), and extrastriatal ([11C]-FLB 457-PET) D2 receptors|Striatal D2 occupancy predicted response in positive psychotic symptoms (r=0.62, p=0.01), but not for negative symptoms (r=0.2, p=0.5).
28|duration of CMV excretion,CMV viremia or pneumonitis,graft loss,incidence of viremia,Moderately severe CMV infections,incidence of CMV disease and visceral involvement,incidence of positive shell vial assays,severity score,incidence of CMV excretion,actuarial patient or allograft survival,renal transplantation,incidence of CMV isolation, viremia, or disease,incidence of invasive CMV infection,CMV reactivation,severity or duration of fever, leukopenia, or hepatic enzyme elevations,cytomegalovirus reactivation syndromes,rates of viral isolation or seroconversion,mild leukopenia,incidence of virologically confirmed CMV-associated syndromes,CMV infection,Patient and allograft survival,serum creatinine levels,Moderate hypogammaglobulinemia,viral infections,serious CMV-associated disease,severity of the CMV infection,site of CMV excretion,transplant survival or patients survival rates,CMV-related death,rejection treatment with OKT3 or ATG, severity of CMV disease, and graft loss,Survival,major non-CMV (including no EBV) viral infections,occurrence of viral infections,efficacy, safety, and cost,Cytomegalovirus viremia,patient and allograft survival,Opportunistic superinfections (Aspergillus fumigatus and Pneumocystis carinii,Disease onset,survival; episodes of rejection, bacteremia, or fungemia; use of immunosuppressive agents; and incidence of leukopenia or thrombocytopenia,episode of viremia,tolerated,incidence of reactivation infections,Cytomegalovirus pneumonitis,incidence of posttransplant CMV disease,cytomegalovirus disease,severe disease,severe hypogammaglobulinemia,rate of CMV disease,severity of primary CMV infection,CMV viremia,average episodes of > or =grade 2 rejection,mild CMV disease,symptomatic herpes-simplex infections,incidence of rejection and graft loss,death or graft loss,toxicity,CMV reactivation infections,acute rejection or bronchiolitis obliterans syndrome,severity of CMV infection,incidence, timing, or severity of symptomatic CMV infections,CMV disease,graft survival,attack rate of CMV pneumonitis,marked leukopenia,Reactivation infections,Cytomegalovirus excretion began earlier and viremia,incidence of CMV transmission,cytomegalovirus and herpes simplex virus infections,minimal toxicity,onset of CMV excretion,incidence of CMV disease,1-year survival,symptomatic CMV infections,Clinical signs of cytomegalovirus infection,incidence of CMV pneumonia,number of days febrile and days hospitalized secondary to CMV illness,Fungal or parasitic superinfections,CMV disease slightly later,CMV infection and disease,number of positive CMV isolates from urine and saliva,Cytomegalovirus-associated glomerulopathy,Reversible leukopenia and thrombocytopenia,incidence of infection,adverse effects,acute rejection and bronchiolitis obliterans syndrome and the survival rate,Incidence of primary CMV infection|Among those who developed CMV infections, prophylactic IgG had no effect on the severity or duration of fever, leukopenia, or hepatic enzyme elevations.
265|rates of full breast feeding,opinions about content and acceptability of the videotape, and smoking behavior change during pregnancy,30-day abstinence rates,mean birth-weight,acceptability and efficacy,diet, cigarette and alcohol consumption, maternal physical strain, lactation at 40 days postpartum, and utilization of health facilities,Urine cotinine concentrations,cotinine validated rates,smoking cessation,reducing smoking,birth weight,cigarette consumption,cost-to-benefit ratios,Salivary cotinine levels,Self-reported cessation rates during pregnancy,cessation rates,stress scores,estimated fetal weight, femur length and abdominal circumference,intervention increased end-of-pregnancy cessation rates,smoking behaviour,Self-reported cigarette consumption,prevalence abstinence,mean birthweight,rates of cessation or reduction,quitting rates,rate of failed biochemical validation,urinary cotinine/creatinine ratio,number of cigarettes smoked per day, confidence in ability to quit, exposure to passive smoke, and educational level,Validated smoking cessation rates,Self esteem,Efficacy and cost-effectiveness,smoking rates,number of cigarettes smoked,rates of smoking cessation,patients quit smoking,levels of smoking status assessment by clinic staff; (2) proportion of women identifying as having been smokers at their first visit who reported receiving cessation advice; (3) proportion of these women who had quit (self report and expired air carbon monoxide (CO)); and (4) smoking prevalence,frequency of smoking during pregnancy,rate of negative birth outcomes,psychosocial measures,quit rates,Smoking status,smoking cessation rate,adjusted odds ratio (OR) for smoking cessation,mean infant birthweight,size at birth,incidence of preterm delivery,number of cigarettes smoked daily,chance of quitting smoking,Smoking cessation rates,Birth weight,quit rate,smoking status and cigarette consumption,degree of clustering at the midwife level,cigarette smoking,body length,7-day point-prevalence abstinence,7-day abstinence, continuous abstinence, and partner smoking at 6 weeks post-intervention (T1) and 6 weeks postpartum (T2,Cessation rates,birthweight and length,smoking cessation or smoking reduction,Smoking habits,mean value of cotinine in saliva,late pregnancy,Long-term relapse rates,distribution of risk factors and demographic, obstetric, and psychologic characteristics,median self reported daily cigarette consumption,behavior and utilization of health resources,point prevalence and consecutive quit rates,smoking cessation rates,Cotinine-validated 7-day tobacco abstinence rates,smoking abstinence,Infant birth weight,birth weight and length of gestation,rate of preterm delivery,exhaled carbon monoxide levels,Self-report and saliva cotinine assessments of tobacco exposure,rate of low birthweight,smoking consumption,smoking behavior,self-report, exhaled carbon monoxide, and urinary cotinine,number who quit smoking,point-prevalence abstinence,validated abstinence rates,self-reported smoking cessation,knowledge of seven of the nine alarm signs,7-day abstinence,stopped smoking or maintained smoking changes,rate of low birth weight,Efficacy and effectiveness,cotinine-verified quit rates,Cotinine-validated cessation rates during pregnancy,mean action, stage of readiness, and motivation to quit scores,larger quit rates,relapse rates,birth weight and preterm delivery,smoking status based on self-report combined with a urinary cotinine level of <115 ng/mL, and birth-weight,average number of days abstinent,number of cigarettes they smoked,self-report and urinary cotinine/creatinine ratios,Relapse prevention,smoking cessation validated by cotinine measurement at the end of the second trimester of pregnancy,postpartum relapse to smoking,smoking habit and 4% increased their consumption,Quitting rates,lower trait anxiety,mean birth weight,birthweight,weight related to smoking,Fetal growth outcomes,quit smoking,kidney infections,Mean birth weight difference,Postnatal telephone questionnaire measured client satisfaction,smoking habits,salivary thiocyanate level and reported smoking,Smoking outcomes,CO level,absolute quit rates,urinary cotinine/creatinine ratios,serum thiocyanate or end expiratory carbon monoxide,cigarette abstinence rates,relapse,perinatal outcome, health-related behavior, or utilization of health facilities,SCN levels,Rates of cigarette smoking,Efficacy,quitting,expired carbon monoxide,Prevalent abstinence|A significantly higher percentage of patients quit smoking in the experimental group (17.3%) than in the control group (8.8%).
not found|verbal IQ, performance IQ, and achievement scores,full-scale IQ scores,Mullen Scales of Early Learning, Wechsler Preschool and Primary Scale of Intelligence-Revised, Wechsler Intelligence Scale for Children, Wide-Range Achievement Test, and Child Behavioral Checklist,cognitive, attention, and achievement scores,Neurodevelopmental outcomes|Subjects with moderate CH had higher full-scale IQ scores than subjects with severe CH, regardless of the initial treatment dose.
not found|students' general and specific attitudes toward drugs, the capability to resist peer pressure, and estimated level of drug use by peers,decisional balance against smoking and decreased temptations to smoke,enhanced school commitment and class participation,Smoking prevalence rates,new "smokers,prevalence rate of smoking,daily cigarette smoking,rate of passive smoking,smoking cessation,smoking prevalence rates,tobacco knowledge, attitudes, offers, use, and intentions,smoking-related beliefs,regular smoking,smoking behaviour, health knowledge, beliefs, or values,health knowledge and attitude toward smoking,number of students who started smoking,adolescents' smoking-related knowledge,New regular cigarette smoking,alcohol consumption,30-day smoking,extracurricular activities,adolescent smoking,positive norms, and social pressure to smoke,lifetime and 30-day use of cigarettes, alcohol, marijuana, and inhalants,smoking behaviour,self-reported past-month and past-year use of tobacco, alcohol, and marijuana,uptake of smoking,coronary heart disease risk factors,measures of non-smoking intentions, attitudes, predictions, problem-solving abilities, and peer interactions,rate of attempting smoking,Outcome assessment batteries measured youths' reported use of smoked and smokeless tobacco, alcohol, and marijuana,alcohol consumption, alcohol initiation behaviors, alcohol use risk and protective factors, drug use behaviors, and exercise habits, and at 12-months for alcohol use risk and protective factors, cigarette use, and cigarette initiation,attitude scores,rate of smoking,Social pressure,stop smoking,grade 8 smoking rates,prevalence rate,sensation seeking, physical maturity, antisocial behavior and parental smoking,smoking rates,rates of substance use and antisocial behavior,prevalence of weekly cigarette use,past month use of cigarettes based on a self-reported questionnaire,several cognitive, attitudinal, and personality variables,smoking prevalence and use of smokeless tobacco (ST,lowering marijuana use,growth trajectories of smoking, drinking, and antisocial behavior,students' resistance or decision-making skills; substance use intentions, expectancies, or normative beliefs; or lifetime and recent substance use,smoking initiation rates,Grade 10 smoking rates,resistance skill training,Changes in knowledge,self-efficacy condition,lower probabilities of tobacco use,adolescent alcohol and cigarette use and other health behaviors,prevalence rates of the uptake of smoking relative,knowledge and personality variables,rate of smoking onset,friends who smoke, outcome expectations for smoking, and smoking progression,odds of baseline nonsmokers initiating smoking,Prevalence, initiation and cessation rates,high risk of regular smoking uptake,mean 30-day smoking prevalence rates,tobacco use,diastolic blood pressure, plasma total and high-density lipoprotein (HDL) cholesterol, serum thiocyanate, ponderosity index, triceps skinfold thickness, and postexercise pulse recovery rate,sex distribution,episodes of drunkenness,odds ratio of being a smoker,weekly smoking onset,cigarette smoking,efficacy,illegal drugs excluding marijuana,smoking intentions,pre-test smoking [odds ratio (OR),response rate,self-efficacy,knowledge and attitudes related to tobacco use,systolic and diastolic blood pressures, ponderosity index, triceps skinfold thickness, postexercise pulse recovery rate, serum total and high density lipoprotein (HDL) cholesterol, and serum thiocyanate,Blood pressure reduction,adolescents' smoking behaviour,1-year covariate-adjusted smoking rate,drinking or antisocial behavior,diastolic blood pressure and thiocyanate,mean knowledge scores,past 30-day use of alcohol,substance initiation index (SII) measuring lifetime use of alcohol, cigarettes, and marijuana and by rates of each individual substance,total cholesterol/HDL cholesterol ratio and for thiocyanate,alcohol, cigarettes, marijuana, cocaine, and other drugs, as well as on knowledge,uptake smoking,prevalence of smokeless tobacco,cannabis initiation and prevalence,knowledge of alcohol pressures, effects, and skills to resist,marihuana and organic solvents,knowledge and prevalence estimates and significant interactions of classroom and TV programming on knowledge (negative), disapproval of parental smoking, and coping effort,risk of smoking initiation,refusal/self-efficacy, smoking intentions, or behavior,behavioral intentions, perceptions of harm, or perceived peer norms,levels of smoking onset,prevalence of daily smoking,refusal skill quality,Total cholesterol,SFA effectiveness and the general thrust of school-based, life skills-based prevention programs,Cigarette smoking,weekly smoking and monthly smoking,rates of tobacco, alcohol, and marijuana use,multiple measures of initiation and current use of alcohol, tobacco, and marijuana,rapid increases in smoking,smoking behavior,smoking prevalence,behavioral determinants and smoking,30-day smoking prevalence,Diastolic pressure,self-reported use of cigarettes, bidis (small hand-rolled, often flavored, cigarettes), and chewing tobacco and future intentions to smoke or use chewing tobacco,adolescents' lifetime and 30-day use of cigarettes, alcohol, marijuana, and inhalants,adolescent alcohol, marijuana, and cigarette use,girls' smoking rates,Intervention response,negative effect,smoking uptake,Smoking rates,control schools,knowledge level, attitudes, and the development of refusal, decision-making, and problem-solving skills,incidence of initiation of smoking,ponderosity and improved fitness, and increased HDL cholesterol,health knowledge, beliefs, and values,objectively assessed smoking (carbon monoxide breath measure,proportion of smokers,overall refusal skill quality,technical assistance (TA) variables (e.g., effective collaboration with TA, frequency of TA requests,weekly cigarette smoking,early adolescent substance use and antisocial behavior,regular smoking rates,initial and current drinking or for current and regular marijuana use,relapse rates,normative expectations and knowledge concerning substance use, interpersonal skills, and communication skills,tried smoking and 30-day smoking prevalence,smoking, drinking, drunkenness, inhalant use, and polydrug use relative,effectiveness of Project Towards No Drug Abuse (TND,rates of smoking initiation and regular smoking,Student smoking behavior and curriculum implementation,smokeless tobacco, alcohol, and marijuana,school-level clustering effects, socio-economic status, gender and family smoking,probability of baseline non-smokers' initiating smoking,smoking intentions, smoking knowledge, perceived peer and adult smoking norms, drug refusal skills, and risk taking,cigarette smoking or bidi smoking,new cigarette smoking,Questionnaires, and saliva samples to validate self-reported smoking behavior,health knowledge and nonsmoking intentions,Resistance to smoking, behavioral intentions to smoke, and cigarette use,social and school work skills,smoking,systolic pressure,communication, self-instruction, self-praise, cigarette refusals, and noncompliance to smoke,negative attitude towards smoking, increased social self-efficacy levels,likelihood of heavy cigarette use adoption,quit smoking,Smoking experimentation,30-day use of alcohol, marijuana, and illegal drugs excluding marijuana, and drinking to intoxication,probability of baseline experimental smokers' escalating to regular smoker,smoking progression,smoking knowledge,dichotomous measures of substance use (cigarette, alcohol, marijuana, and hard drugs,risk factors: systolic and diastolic pressures, HDL cholesterol, ratio of total to HDL cholesterol, fitness (postexercise pulse recovery rate), and smoking,Smoking initiation,smokeless tobacco use rates,proportion of non-smokers,social variables (e.g., peer resistance skills,delaying or preventing the onset of tobacco use,systolic and diastolic blood pressures, plasma total and high-density lipoprotein (HDL) cholesterol, serum thiocyanate, ponderosity index, triceps skinfold thickness, and postexercise pulse recovery rate,self-efficacy and resistance skills,adjusted Prevalence Odds Ratio (POR,students' smoking-related knowledge, attitudes and behaviour,tobacco use and violence,rate of first-time consumers of cigarettes,cigarette smoking, marijuana use, and immoderate alcohol use|Further, in both classes, more rapid increases in smoking were observed for the control group as compared to the intervention group (OR=1.22, p<0.01 slow escalators; OR=1.54, p=0.08 rapid/moderate escalators).
16|quality of care,Anxiety measures,work-related anxiety,morale, quality of care, and reduced absenteeism,attitude scale concerning work (alienation), a personality measure (hardiness), and one of each scale for work satisfaction and for sources of satisfaction and dissatisfaction,emotional exhaustion and lack of personal accomplishment, two dimensions of burnout,levels of stress,psychophysiologic health level,mean scores on the Nurse Stress Checklist (NSC) and the Chinese General Health Questionnaire (CGHQ,Perceived Stress Scale (PSS) and Rathus Assertiveness Schedule (RAS,burnout symptoms, relaxation, and life satisfaction,absenteeism,efficacy and effectiveness,quality of working relationships|In comparison with 14 wait-list control participants, 16 participants in the mindfulness intervention experienced significant improvements in burnout symptoms, relaxation, and life satisfaction.
16|gains in knee and ankle joint angle measurements,EMG feedback and the restoration of motor control,mild EMG, severe EMG, mild control and severe control,active range of motion and surface EMG potentials,higher arm function scores,Adams scale,knee and ankle minimum flexion angles,muscle strength,Basmajian scale,physical scores for active movement, mobility and ADL over time,recovery of foot-drop,timed ambulation,Velocity of gait, cycle time, and symmetry of stance phases,ankle active range of motion,active movement, muscle tone, sensation, proprioception, mobility and activities of daily living (ADL,recovery of functional locomotion,orientation, memory, spatial performance, language and IQ,electromyographic activity|Electromyographic biofeedback patients showed significantly increased scores on the Adams scale (P < .05) and Basmajian scale (P < .01).
32|distal part score of the FMA,Reduced skilfulness of arm motor behaviour,online error correction,motor performance, daily function, functional use of the affected arm, and quality of life,motor control and functional performance,MSS and measures of strength,movement time,functional gains,motor capabilities,Modified Barthel Index, Hospital Anxiety and Depression Scale, and Nottingham Health Profile,Reaction time,upper limb function,slower movement, lower maximal movement velocity, feedback control dominant and discontinuous movements,positive intralimb transfer,kinematic analyses assessing motor control strategies for unilateral and bimanual reaching and clinical measures involving the Fugl-Meyer Assessment (FMA) of motor-impairment severity and the Functional Independence Measure (FIM) and the Motor Activity Log (MAL) evaluating functional ability,brain activation during elbow movement assessed by functional magnetic resonance imaging (fMRI) and functional outcome assessed using arm function scores,voluntary EMG activation levels,motor performance, daily functions, and quality of life,EMG activation levels,Action Research Arm Test (ARAT), Rivermead Motor Assessment upper-limb scale, and Nine-Hole Peg Test (9HPT,varying levels of weight on the nonparetic hand,motor impairment scale,fMRI response,functional task, (2) chronometric reaction times to initiate movements, and (3) sustained muscle contraction capability,peak acceleration, velocity, and movement time,Chronic hemiparesis,total movement time,impairments (motor function, grip strength, gross and fine manual dexterity and motor co-ordination), (2) arm disabilities in tasks related to daily activities, and (3) functional independence in activities of daily living (ADL) and instrumental ADL (IADL,Nonparetic peak acceleration,active elbow range of motion,motor impairment,Fugl-Meyer Assessment (FMA), Functional Independence Measure (FIM), Motor Activity Log (MAL), and Stroke Impact Scale (SIS,hemispheric activation,movement time of the impaired limb and increased upper limb functional ability,Motor Assessment Scale (MAS), Motor Status Scale (MSS), and muscle strength,motor reaction time (peripheral component), and (4) faster total reaction time,peak acceleration (P<.001) and velocity,higher muscle activation levels,muscle activity,Electromyographic (EMG) activity,functional outcome,motor control and motor function,motor control performance,FMA,bilateral symmetrical activities,ARAT pinch section,Changes in activation,electromyogram (EMG) activation levels,activation in precentral (P<.001) and postcentral gyri,Upper Arm Function scale,velocity,temporal and spatial efficiency,movement time, higher peak limb velocity,time to complete components of the tasks; comparison between sides; deviation of the hands from a linear trajectory; coordination of the two sides as indicated by relative phase angle,proximal UL motor impairment,reasonable strength, inter-limb coordination|Nonparetic peak acceleration was higher (P=.015), velocity was unchanged, and movement time increased (P=.005) in the bilateral compared with the unilateral task.
11|akathisia,neuroleptic-induced akathisia|Neither propranolol nor placebo treated patients showed a significant improvement in akathisia.
not found|rate of opioid-positive urine samples,abstinence reinforcement,Relative efficacy,opiate-negative urine specimens (thrice weekly urinalysis,Objective and subjective measures of efficacy (urine toxicology, retention, craving, and withdrawal symptoms,rates of opioid-positive urine samples,Retention time,retention, opioid use, and opioid craving,illicit drug use, program retention and attendance, and global staff judgments,duration of sustained abstinence,cocaine-positive urine samples,Lifetime sedative dependence,retention rate,Safety,percentage of opiate-negative urine specimens,Prognostic factors,illicit opioid use,percentage of urine samples negative for opioids,median time,overdose mortality,rates of cocaine abstinence,illicit heroin,reduced self-reported frequency of use and self-reported craving,detoxification,rates of abstinence from illicit opioids,Abstinence Orientation Scale,rates of cocaine-positive urine samples,retention rates,Rates of abstinence from illicit opioids|Patients taking > or = 60 mg/day and 30-59 mg/day were respectively 70 and 50% more likely to remain in treatment than those receiving a < 30 mg daily dose.
1168|Cramping and nausea,side effects, timing of expulsion and duration of bleeding,overall success rate,Successful medical abortions,complete medical abortion by the first or by the second follow-up visits,mean duration of uterine bleeding,days of bleeding,Successful abortion,time elapsed between RU 486 intake and expulsion of the conceptus,rate of complete abortion and the side-effects,beta-hCG level,prolactin,pregnancy rate,Abortion success,continued pregnancy,Methotrexate levels,efficacy rate,incomplete abortion rate,rates of complete abortion,frequency of complaints, bleeding patterns, and changes in hemoglobin, beta-human chorionic gonadotropin, estradiol, and progesterone,early medical abortion,number of women who passed the fetus within 4 h of receiving the prostaglandin,abortions,pregnancy advanced,Pain and subject acceptability,success rate of complete abortion,severe pain,overall ongoing pregnancy rate,Satisfaction and acceptability,diarrhea,median amount,Success rates,Pregnancy outcome, time of onset and duration of vaginal bleeding, subjective complaints, and hormone changes,fever,Nausea, vomiting, and heavy bleeding,Cortisol,complete abortion,Nausea, vomiting and diarrhoea,Intrauterine pregnancy and gestational age,rate of continued pregnancy,mean gestational age of the successful abortions,Vaginal bleeding followed by complete abortion,Efficacy outcomes,onset of crampy abdominal pain,Successful abortion, duration of vaginal bleeding, side effects, and change in beta-human chorionic gonadotropin (beta-hCG) level,human chorionic gonadotropin-beta level,shivering,incidence of complete abortion, hemoglobin levels, duration of vaginal bleeding, and incidence of side effects,efficacy, adverse effects and acceptability,efficacy, safety, and acceptability,risk of failure of complete abortion,rate of continuing pregnancies,Pain,complete abortion rates,gastrointestinal side effects,complete abortion without surgical intervention,Abortion status,serious adverse events,duration and amount of bleeding,measured blood loss,Overall, complete abortion without surgical intervention,efficacy,effectiveness, side effects, and acceptability,nausea and vomiting,Complete abortion rates, the frequency and severity (patients' perception) of gastrointestinal side effects, and blood pressure changes,pregnancy-related symptoms,complete medical abortion rates,suction aspiration,Complete abortion,uterine sensitivity,unpleasant mouth taste,nausea/vomiting and headache/dizziness,side effects such as vomiting and fall in haemoglobin, as well as the need for emergency curettage and blood transfusion,blood pressure,rates for complete abortion, incomplete abortion and treatment failure,Vomiting and diarrhea,Adverse effects,tolerated,fever and chills,successful abortion (complete abortion without requiring a surgical procedure) and side effects,nausea and/or vomiting,surgical abortion,bleeding duration,maximum concentration of methotrexate and the area under the curve,longer duration of induced bleeding,uterine contractility,shorter bleeding time and a lower volume of blood loss,Side effects,vaginal bleeding,abortion rates,Blood samples for blood group, hemoglobin, beta-chorion-gonadotrophin, aspartate-aminotransferase and creatinine,relative risk of failure,efficacy and side effects,overall complete abortion rate,median duration of vaginal bleeding,troubled by diarrhoea,clearance rates,efficacy or side effects,Methotrexate clearance rates,Nausea,overall successful termination rate,Efficacy and adverse effects,failure to complete abortion,duration and amount of vaginal bleeding,Prolonged vaginal bleeding,incomplete abortion,percentage of women with continuing pregnancies,frequency of side effects,incidence of side-effects, such as vomiting, nausea, headache, diarrhea and lower abdominal pain,gynecological examination, the level of beta-hCG and ultrasonography,tolerance and efficacy,serious complication,satisfaction,blood transfusions,rate of complete abortion,heavy bleeding, necessitating emergency curettage,success rate,mean duration (range) of vaginal bleeding,nausea, diarrhea, and warmth or chills,blood transfusion,pregnancy,experience diarrhoea,duration of bleeding,Timing of expulsions and duration of bleeding,incomplete abortions with symptoms requiring a surgical aspiration,diarrhoea,success rate (complete abortion,successful abortions,incomplete abortions,side effects and acceptability,Complete abortion rates,rate of continuing pregnancy,Nausea, vomiting or diarrhoea,fever or chills,vomiting,success rate determined by the number of women who aborted without surgery,safety and efficacy,diastolic pressure,treatment failures,likelihood of complete abortion,success rates,risk of failure to abort,efficacy of medical termination of pregnancy,complete abortions,side effects,Overall acceptability and route acceptability,Expulsion of the conceptus without the need for a surgical procedure,Lower abdominal pain,Successful abortion without surgery,incidence of diarrhoea,efficacy and side-effects,complete abortion rate,efficacy, adverse effects, and acceptability,crude complete abortion rate,Complete abortion without surgical intervention,serum levels,efficacy of treatment to achieve complete abortion and to terminate pregnancy,surgical termination,pregnancy-related symptoms (nausea, vomiting, breast tenderness, fatigue, dizziness, headache), drug-related side effects (diarrhoea, fever, rash and blood pressure change), side effects related to the abortion process (lower abdominal pain) and women's perceptions of the method,expulsion of the conceptus without the need for a surgical procedure, and abortion,bleeding necessitating a blood transfusion, no serious side effects,Efficacy outcome,pain,amenorrhoea length,Vaginal bleeding,rates of success, side effects, or acceptability,side-effects and number of complete abortions,Fever, chills and gastrointestinal side-effects (nausea, vomiting and diarrhoea,need for surgical evacuation,incidence of side-effects such as diarrhoea,number requesting opiate,detectable fetal heart activity,total bleeding 11.2,Ongoing pregnancy,number of women who had aborted by Day 8, side effects and acceptability,actual blood loss|Surgical intervention was indicated for continuing pregnancy at the second follow-up visit, excessive bleeding, or persistent products of conception 5 weeks later.
40|serum calcium, phosphorus, alkaline phosphatase, and urinary calcium/creatinine ratios,verbal rating scale,cumulative bone loss,chronic pelvic pain,hot flushes and sweating,estradiol and biochemical markers of bone metabolism,Bone formation markers,BMD changes,urinary calcium-creatinine ratio and serum alkaline phosphatase,endometriosis scores,frequency of hot flushes and sweating episodes,bone mineral density changes,bone metabolism,BMD,total pelvic pain scores,tolerability,Hypoestrogenic effects,Urinary levels of pyridinium crosslinks,bone assessments,bone mineral density,adverse hypoestrogenic effects,bone formation markers,loss of bone density,urinary calcium/creatinine ratio,androgenic side effects,bone resorption markers,lumbar spine bone mineral density (BMD,Bone loss,Serial serum levels of E2 and calcitonin,libido,mean subjective signs and symptoms scores,physical examination, laboratory indices, occurrence of adverse events, and bone mineral density changes,serum alkaline phosphatase,lumbar spine values,bone mineral density and pyridinium crosslinks,Serum luteinizing hormone (LH) and 17 beta-oestradiol concentrations,efficacy and safety,bone biochemical markers,Serum estradiol levels,Bone mass,control values; urinary calcium-creatinine ratio,vertebral bone mass and serum estradiol and calcitonin,serum calcium, phosphorus, alkaline phosphatase, and fasting urinary calcium/creatinine ratios,bone demineralization seen,Serum estradiol and the biochemical parameters of bone metabolism,Bone mineral density of the lumbar spine,hypoestrogenic effects,serum follicle stimulating hormone (FSH) levels,bone resorption,bone mineral content (BMC,lumbar spine bone mineral density,Mean (SD) endometriosis scores,frequency of genital bleeding,Endocrine effects,Trabecular BMC of the 3rd lumbar vertebra,Daily symptom diary for hot flushes and bleeding episodes, laparoscopic scoring of endometriosis, endocrine and biochemical changes, and bone mineral density scans,vertebral trabecular bone mass,bone loss and vasomotor symptoms,trabecular vertebral bone mass, serum E2, and serum calcitonin,Serum E2 levels,Bone loss with LA,Bone turnover,Crosslaps (CTx) and deoxypyridinoline (D-Pyr,bone loss and symptomatic side effects,Significant loss of bone mineral,Gain or loss of bone mass,serum estrone and estradiol levels,Pelvic pain scores,Mean (SD) deep dyspareunia scores,pelvic pain scores,Revised American Fertility Society score,BMC,trabecular bone mineral content of the lumbar spine and femoral neck,Calcitonin levels,bone mineral density loss,pelvic endometriosis,Biochemical markers except urinary calcium and hydroxyproline,spinal trabecular bone mineral content,pelvic signs and symptoms scores and revised AFS endometriosis scores,bone loss,endometriosis, dysmenorrhea, and pelvic pain; effects,bone loss at the lumbar spine,lumbar spine and femoral neck,Mean bone mineral density,bone densities,Bone density,Mean lumbar bone loss,serum E2 levels,bone density,Bone mineral density,slight gain in BMC,bone alkaline phosphatase (B-ALP) and osteocalcin (OC,menstrual pain scores,endometrial implants score,sustained hypoestrogenemia and significant bone loss,Z scores,Total revised AFS score,serum estradiol (E2) levels,bone mass,positive spine BMD changes,Bone resorption markers,serum calcium levels,association of B-ALP and D-Pyr,revised AFS endometriosis score,hypoestrogenic side effects,bone mineral,bone mineral measurement,Bone formation and resorption markers,serum estrogen levels,lumbar spine and femoral neck bone mineral content,Efficacy,efficacy and acceptability,Lumbar spine bone mineral density,Bone mineral density (BMD,hot flushes,mean serum oestradiol levels|Total revised AFS score as well as total pelvic pain scores decreased significantly (P < .001) in both groups.
not found|activity related pain (VAS); and improvement in SPW and SPS test time, passive range of motion, and PASE,knee pain,function, pain, and stiffness subscores of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC,quadriceps strength of the index knee,function scores,WOMAC scores,Change in Western Ontario and McMaster Universities osteoarthritis index (WOMAC,visual analog scale pain and rates of attrition,car task,changes in joint space width,leg flexion and extension,walking speed,aerobic capacity, 50-foot walking time, depression, anxiety, and physical activity,time to lift,exercise efficacy,peak torque and CSA of knee muscles,extension and flexion strength of the right and left legs, the 50-foot walk time, range of motion at the knee joint, the Osteoarthritis Screening Index (OASI), and the Arthritis Impact Measurement Scale (AIMS,physical fitness,Global improvement,right leg flexion and left leg extension,visual analogue scales (VAS) for pain on stairs and walking and WOMAC physical function scores,total activity vector magnitude,average distance walked,mean rate of joint space narrowing (JSN,Lequesne's index, knee range of motion, peak muscle torques of knee flexion and extension, and ambulation speed,Functional capacity (rising from a chair, walking, stair climbing and descending) and pain during rest and activities, peak torque, and cross-sectional area (CSA,range of motion and ambulation speed,safe, effective, and well tolerated,joint tenderness,arthritis pain,isokinetic quadriceps strength,frequency of palpable joint effusions,Physical activity,6-minute walk distance and WOMAC score,visual analogue scale, ambulation speed, and Lequesne index,strength, pain, physical function and quality of life,pain and physical function scores,physical function, pain, and mobility,observed disability,muscle peak torques,walking speed and decrease of disability,faster times on the lifting and carrying task,self-reported physical function,lower extremity stiffness,pain and stiffness,pain or function,Knee pain,self-reported pain, function and quality of life,pain and functioning,self-reported physical function as measured with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC,Levels of KS and hydroxyproline,pain and disability,knee pain scores and quadriceps muscle strength,functional capacity,disability,isometric strength gain,pain and physical function (Western Ontario and McMaster Universities Osteoarthritis Index), general health status (Medical Outcomes Study Short Form 12 Health Survey [SF-12], version 2), psychological well-being, and physical performance (Up and Go test, 50-foot walk time, timed stair climb,6-min distance walk,Muscle strength across the knee (extension and flexion), Algofunctional Index (AFI), pain (0 to 10 point scale), walking speed, clinical findings,body weight,activity and activity related pain,balance,change scores for flexibility, number of clinically active joints, duration of morning stiffness, or grip strength,quality of life,positive functional outcomes,physical activity,6-minute walk distance,pain, quality of life, strength of the left M. quadriceps, knowledge, self-efficacy, BMI, physically active lifestyle, and visits to the physical therapist,self-report measures (WOMAC, SF-36) and objective measures of physical performance (gait analysis and muscle strength,pain, physical function, and health related quality of life,pain in the worse knee by 100 mm visual analog scale score, the disability domain of the Western Ontario and McMaster University OA index (WOMAC), and quadriceps muscle strength by maximum voluntary contraction,hamstring and low back flexibility,Knee injury and Osteoarthritis Outcome Score (KOOS,functional status, pain, and use of medication,mean baseline function score,VAS scores for pain,mean (+/-SE) time to climb and descend stairs,weight-loss,angular velocity peak torques,Mean baseline WOMAC pain score,rate of loss,self-efficacy,knee joint pain,baseline WOMAC scores and walking distance,knee extensor strength and fast walking speed,arthritis impact subscale,self reported score for knee pain on the Western Ontario and McMaster universities (WOMAC) osteoarthritis index,incidence and progression of knee OA,joint stability or walking endurance,Synovial fluid,abdominal muscle strength,6-minute test of walking distance and scores on the physical activity, arthritis impact, pain, and medication subscales of the Arthritis Impact Measurement Scale (AIMS,Frequency of crepitus,knee pain (Western Ontario McMaster Osteoarthritis index (WOMAC,efficacy and adherence measures,adverse health effects,Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index pain and physical function subscales,changes of muscle power of leg flexion and extension,arthritis activity,muscle strength of the hip,arthritic symptoms, balance, and physical functioning,ability to walk and bend,disability, physical performance, and pain,mean (+/-SE) time to get in and out of a car,pain reduction, disability reduction,health status, and a visual analog scale for pain assessment,walking distance relative,overall status,KOOS subscale quality of life,muscular strength,physical performance, quality of life, and self-efficacy,pain using the Western Ontario McMaster (WOMAC) pain, physical disability, and stiffness subscales and a 10 point visual analog scale (VAS) before and after self-paced walking (SPW) and stepping (SPS) functional tasks; (2) physical function using the time to complete a self-paced 40 m walk (SPW) and 20 cycles of 2 steps (SPS): (3) physical activity level using the Physical Activity Scale for Elderly (PASE); (4) clinical measures of knee functioning (range of motion,pain, medication use (nonsteroidal antiinflammatory drugs, NSAID) and observed disability,pain, quality of life, activity restrictions, knowledge about OA, self-efficacy, body mass index (BMI), and mobility measures,strength and exhibited less frequent progressive JSN,stair-climb time,incidence and progression of knee osteoarthritis,flexibility and upper-body or knee muscle strength,physical activity, muscle strength, and functional performance,pain, balance, muscle strength, and perceived difficulties in physical functioning,strength gains,physical performance measures,pain and physical functioning,functional capacity and decrease pain,knee extension strength,extremity strength,time to descend and ascend stairs,Exercise tolerance, disease-related measures, and self-reported health status,psychological disability,aerobic capacity,WOMAC pain score,lower extremity pain,undergone knee arthroplasty,physical functioning,isokinetic lower-extremity strength and highly standardized knee radiographs,SF-12 physical component summary score,Overall compliance,range of motion and functional tasks,self-reported disability score (range, 1-5,Synovial fluid keratan sulfate (KS) and hydroxyproline,pain reduction,all strength measures,daily steps,physical function,KOOS subscales assessing pain, other symptoms, or function in daily life or in sport and recreation,perception of changes relating to osteoarthritis of the knee and general condition,mobility,quadriceps strength, on knee pain and disability,knee pain questionnaire,isokinetic and isometric quadriceps strength, pain and function determined by categorical and visual analog scales, and overall status using physician and patient global evaluations by the Arthritis Impact Scale, version 2, Western Ontario McMaster's Arthritis Index, and Medical Outcome Study Short Form 36,exercise knee pain,pain reductions,global improvement,mean reductions in pain scores,pain measured by visual analogue scale and patient global change,leg; isometric strength,quadriceps and hamstring strength,muscle-strength gain,average 6-minute walk distances,reduction of pain,weight loss, 6-minute walk distance, stair-climb time, WOMAC pain and stiffness scores, and joint space width,physical symptoms and fitness, body mass index, cardiovascular functioning, and perceived difficulties in physical functioning,retention rate,time to perform all 4 functional tasks,pain score,clinical knee examination, muscle strength, physical performance measures, and questionnaires to measure quality of life variables,health perception,AIMS physical activity subscale,pain and function,muscle strength and walking performance,Physical function scores,physical activity (daily step counts and total activity vector magnitude as measured by a pedometer and Tritrac-R3D accelerometer), quadriceps femoris strength (isometric peak torque), and functional performance tasks (100-foot walk-turn-walk, timed stair climb, timed chair rise, and pain status,average WOMAC scores,functional health status,functional capacity, especially stair climbing,physical fitness, strength, pain coping, and self-efficacy,pain measurements,clinical signs and symptoms of osteoarthritis (OA,reduction in pain,frequency of knee OA progression in JSN consensus ratings,pain,physical function, gait, and knee extensor strength,knee pain score (range, 1-6), performance measures of physical function, x-ray score, aerobic capacity, and knee muscle strength,knee specific physical function and stiffness (scored on WOMAC index), general physical function (scored on SF-36 questionnaire), psychological outlook (scored on hospital anxiety and depression scale), and isometric muscle strength,pain scores,physical disability questionnaire,functional capacity and symptoms,WOMAC, knee pain scale, SF-36, assessment of quality of life index, quadriceps strength, and balance test,health status, physical capacity, and joint tenderness,isokinetic strength of the quadriceps,Pain levels,adverse effects,exercise adherence,x-ray scores|Program participants also experienced a significant decrease in lower extremity pain and a borderline significant improvement in efficacy to adhere to exercise over time at 6 months (p =.052).
59|milk output,24-hour milk production,volume of milk expressed and its fat content,maternal milk volume,Volume of milk expressed per expression and its fat content,milk extraction, milk fat content, maternal hormone response, maternal satisfaction, long-term milk production, and duration of breastfeeding following return to the workforce,average STAI scores; average prolactin levels; and weekly averages for number of pumping sessions, hours of pumping, and milk production in milliliters,mean milk volumes,milk volume or fat content,several demographic characteristics, STAI scores, prolactin levels, number of pumping sessions per week, or weekly milk production,exclusive breastfeeding,fat concentration,milk flow,mean daily MMV,milk yield and prolactin and oxytocin release,shorter expression times,breastfeeding duration,24-hour milk volume,bacterial colony counts,EBM,morbidity and mortality rates,daily milk production log, weekly serum prolactin levels, and a weekly State-Trait Anxiety Inventory (STAI,duration of breastfeeding,adequate production,milk volume,breastfeeding knowledge questionnaire, observational checklist of mother's breastfeeding practices, breastfeeding diary, infant's and mother's profile form, and demographic information,milk production,Mother's knowledge,Prolactin response,BIBS,efficiency, efficacy, comfort, and convenience of the Symphony breast pump (Medela, McHenry, IL) (SBP,breastfeeding knowledge and practices,Milk volume, fat content, and pattern of milk flow,breastfeeding problems,milk fat concentrations,efficiency, efficacy, comfort, and convenience,rate of bacterial contamination of EBM,Milk extraction efficiency,Breastfeeding Study (BIBS,fat content of the breast milk,rate of bacterial contamination,Gram-negative bacilli,Maternal response,efficiency and efficacy,Milk production,gradual improvement in breastfeeding practices, i.e., started breast milk expression earlier and had more breast milk expression frequency,onset of milk ejection,contamination rates,milk volume and fat content,milk flow and total volume|Milk extraction efficiency was greater (p = 0.001) with the standard pump.
61|perioperative morbidity,QoL change,mean operative time,blood loss and shorter hospitalization,Pelvic and para-aortic nodes,Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire,Operating time,mean number of harvested lymph nodes,Conversion to laparotomy,mean blood loss,recurrence or disease-free survival,severe postoperative adverse events,blood loss,disease-free survival,proportion of patients with a minor complication,shorter hospital stay,QoL,Safety and efficacy data,metastatic cancer,Pelvic lymph node metastases,disease-free (P = .512) survival,proportion of patients with an intraoperative major complication,Overall and recurrence-free survival,longer hospital stay,mean length of hospital stay,Operative morbidity,intraoperative complications,cumulative recurrence rates,Yield of pelvic and para-aortic lymph nodes, duration of surgery, and incidence of postoperative complications,pain medication,proportion of major complications,shorter hospital stay, less pain, and quicker resumption of daily activities,feasibility, safety and morbidity,Postoperative serious adverse events,bleeding,emotional and social wellbeing measures of FACT and the visual analogue scale,operative time, blood loss, blood transfusion, intraoperative complications, postoperative complications, duration of hospital stay, and number of lymph nodes obtained,Blood loss and transfusion rates,Wound infections,overall detection of advanced stage (stage IIIA, IIIC, or IVB,complication rate,postoperative major complication,intraoperative adverse events,6-week morbidity and mortality, hospital length of stay, conversion from laparoscopy to laparotomy, recurrence-free survival, site of recurrence, and patient-reported quality-of-life outcomes,major complication rate,Quality of life,Lymph node number and detection of lymph node metastasis,Hospitalization,quality of life (QoL,deaths,adverse events,operative time|This procedure is associated with significantly less blood loss and shorter hospitalization; however, it is associated with significantly longer operating time.
344|Pad testing, Stamey Continence Grading, and urodynamics, including abdominal leak point pressures,Continence,improvement of 1 continence grade,standardized incontinence questionnaire, 1-hour pad test and cough test,proportion of women who achieved a 50% reduction in urinary leakage on provocation testing,stress urinary incontinence and urethral hypermobility,continence grade and pad weight testing,MUCP and FUL,Incontinence Quality-of-Life questionnaire score,standardized questionnaire, pad test, cough test and urodynamics,pad usage,maximum urethral closure pressure (MUCP), functional urethral length (FUL), maximum flow rate and cough test,Adverse events,Postoperative contentness,urinary retention,short-term risk of urgency and urinary retention,urge incontinence,flow rate,adverse events|Outcomes at 12 months from last treatment failed to demonstrate that mid-urethral injected Zuidex was equivalent to cystoscopically injected Contigen in primary and secondary outcome variables.
39|safety, efficacy, and costs,neonatal deaths,gestational age at delivery,prolongation of pregnancy, number of patients bleeding,mean number of maternal hospital days,recurrent episodes of bleeding,mean birth weights,presence of respiratory distress syndrome, intracranial hemorrhage, or culture-proved sepsis,maternal and neonatal morbidity,blood transfusion,neonatal morbidity,units of blood transfused, birth weight, hospital stay and costs, and admission to neonatal intensive care unit|No statistically significant differences were observed between the two groups studied.
not found|TNA response,occurrence of injection site AEs,IgG geometric mean concentration (GMC), geometric mean titer (GMT), and proportion of responders with a 4-fold rise in titer,peak anti-PA IgG antibody response,rate of injection site reactions such as erythema, induration and subcutaneous nodules,geometric mean titers (GMT) for lethal toxin neutralization activity (TNA,clinically serious or dose-related toxicity or reactogenicity,geometric mean concentrations (GMC,occurrence of systemic AEs,immunogenicity and safety,Immunogenicity and tolerance,Peak antibody responses,antibody response,Reaction rates,Systemic reactogenicity (mostly headache,Local reactogenicity (mostly pain,odds ratio for ordinal end point pain,peak anti-PA IgG antibody levels,safety, reactogenicity, and immunogenicity,Safety, reactogenicity and immunogenicity,injection site reactions|Peak antibody responses to adjuvanted rPA given intramuscularly were equivalent to AVA, given either intramuscularly or subcutaneously, when measured by either assay.
36|number of migraine attacks,propranolol sleep disturbances including nightmares (6), tiredness (8), mental changes (e.g. irritability) (3) and weight gain (4,mean frequency of attacks,headache index,migraine symptoms,efficacy variables (headache attacks, days with headache, analgesic consumption,headache parameters,frequency of migraine attacks,frequency of headaches,efficacy parameter,Mean duration of attacks,severity nor duration of migraines,symptomatological profile of individual migraine attacks,VEPs,Headache response to medication,mean attack frequency,Weight gain,frequency of attacks and their total duration,frequency of migraines and use of rescue analgesics,number of headache days or the number of migraine attacks,frequency of the attacks,systolic blood pressure and heart rate,medication relieving attacks,average number of monthly crises,adverse events,migraine,Adverse experiences,migraine index, frequency, duration, severity of attacks and headache days,adverse drug reaction,attack frequency and headache index,platelet and plasma cAMP levels,prophylactic effectiveness,tolerated and the number of reported side-effects,headache,plasma concentration or serum production of TxB2,ADP-induced platelet aggregability, platelet cAMP, ATP and ADP levels, plasma cAMP and TxB2 concentration, as well as the serum production of TxB2,efficacy,headache frequency, headache severity, nausea frequency or severity,Vasomotor headaches,efficacy and safety,hormones levels,average duration or severity of migraine attacks,Headache index,frequency, intensity, and duration of migraine attacks, nor on amplitude and latency of the VEPs,Migraine index,efficacy and tolerability,migraine headache,headache or nausea,tolerated,reduced duration of headache,tolerated and safe,global evaluation,median intensity of pain and the number of attacks,severity of attacks and the number of analgesics,blood pressure and heart rate; flunarizine,percentage and severity of side-effects,weight gain,platelet function,VEP amplitudes,number of attacks,efficacy parameters (migraine hours, migraine days, and migraine intensity,cardiovascular function,mild adverse reactions,anxiety or depression,blood brain barrier,VEP latency,severe side effects,Efficacy and tolerability,mean duration of migraine in hours (h) per month,Migraine frequency,5-HT supersensitivity,migraine index, frequency of attacks and global evaluation,patient profile, onset of response to therapy, final response to therapy, incidence of dropout from the trial or incidence of side-effects,migraine attacks,migraine index,number of attacks, the total duration of attacks and additional drugs taken,platelet aggregability,side effects,Serum prolactin,frequency and severity of headaches,attack frequency,duration of the attacks and the number of analgesics,VEP amplitudes and longer latencies,number of sickleave days and the use of symptomatic drugs,Plasma concentrations,frequency of attacks,consumption of analgesic drugs,vasomotor headache,VEP amplitude,migraine frequency,dizziness, fatigue, and fall in blood pressure,prolactin (PRL), luteinizing hormone (LH) and growth hormone (GH) levels,Mean severity of attacks,Efficacy,number, duration, and severity of attacks,attack frequency, migraine days, severity score, consumption of acute medication and subjective evaluation,headache diaries|It is concluded from the results that there are no differences in efficacy between metoprolol and propranolol regarding the studied parameters.
325|time of diagnosis,probability of overall survival,Efficacy and cost of risk,actuarial 5 year survival,incidence of curative re-operations,diagnostic efficacy and costs,rectal cancer,quality of life, SF-12; physical and mental component scores, (2) anxiety and depression: Hospital Anxiety and Depression Scale and (3) patient satisfaction: Patient Visit-Specific Questionnaire,earlier detection of hepatic metastases,recurrence, time to detection and death rates,asymptomatic chest radiography-detected lung metastasis,five-year survival rate,asymptomatic CT-detected liver metastasis,survival,local recurrence,Recurrence,Local recurrences,anxiety,overall survival,recurrence,scores for quality of life (physical component score,survival and recurrence resectability,patient satisfaction,survival benefit,investigations, number and timing of recurrences and deaths,Curative re-resection,number of curative hepatectomies|On completion of 5-year follow-up, there was no significant difference in survival between the two groups.
157|Hamilton Rating Scale for Depression (HAM-D), Clinical Global Impression, and subjective mood ratings (45-item self-rating scale,mood and on objective, subjective, and clinician-rated measures of sleep,symptoms of major depressive illness effectively,assessment criteria Geriatric Depression Scale (GDS) and Clinical Global Impression (CGI,HAM-D, MADRS, and CGI-SI,STIs,antidepressant and antianxiety efficacies,nausea and diarrhoea,initial Hamilton Rating Scale for Depression (HAM-D,Sleep polygraphic recordings,Psychic Anxiety item,positive treatment response rates,Weight gain,Hamilton Rating Scale for Depression (HAM-D), Hamilton Rating Scale for Anxiety,Hamilton Rating Scale of Depression scores,Overall tolerance,HRSD, Zung Self Rating Scale for Depression, Montgomery-Asberg Scale for Depression, Clinical Global Impression for severity and improvement of depressive symptoms,nausea, vomiting and diarrhoea,mean scores on the Montgomery-Asberg Depression Rating Scale,symptoms of dizziness,agitation, anxiety, suicidality, and global impressions,equivalent antidepressant efficacy,health transition scale of the 36-item Short-Form Health Survey Questionnaire,HAM-D responder rate,Compliance,depressive symptoms and concomitant anxiety,rapid-eye-movement (REM) sleep or increase REM latency,sleep efficiency,total Hamilton Depression Rating Scale score,CGI,retardation pole of the mood, anxiety, retardation, danger scale,nausea and vomiting,adverse reactions,Hamilton Depression Rating Scale (HDRS), Montgomery-Asberg Depression Rating Scale and Clinical Global Impression (CGI,incidence of adverse events,weight changes,individual HAM-D Items 9 (agitation), 10 (psychic anxiety), and 11 (somatic anxiety,depression (HAM-D, HAD, CGI,antidepressant efficacy and safety,Good antidepressant efficacy,electrocardiogram (ECG) and systolic time intervals (STIs,Sleep disturbances,sedation, nausea and vomiting,Hamilton Rating Scale for Depression (HAM-D) sleep disturbance factor score,Side effects,MADRS,acute treatment efficacy and tolerability,Overall effectiveness,HAMD sleep disturbance scale,objective, subjective, and clinician-rated measures of sleep,quality-of-life improvements,incidence of early patient withdrawals due to treatment-emergent adverse events,response rates,quality of life and cognitive function,drowsiness/sedation and excessive sweating,Hamilton Rating Scale for Depression, Hamilton Rating Scale for Anxiety, Clinical Global Impressions-Severity, and Clinical Global Impressions-Improvement,HAM-D17, HAM-D17 response, and HAM-D17 remission rates,dry mouth,scores of the items "suicide", "psychic anxiety", "somatic anxiety", "agitation" and "insomnia,Mean,MADRS total score,overall depression and anxiety,HAMD-total score,tolerability ratings,sleepiness,Sleep electroencephalographic (EEG) recordings,sleep efficiency, number of awakenings, percentage of awake and movement time, percentage of REM and Stage 1 sleep, and REM latency,number of patients reporting at least one adverse event,Hamilton Depression Rating Scale (HDRS) and the Montgomery & Asberg Depression Rating Scale (MADRS,Anticholinergic side-effects,sleep continuity,Depression improvement,Montgomery Asberg Depression Rating Scale (MADRS), the HARD diagram, the check list for somatic symptoms and side-effects,Hamilton Rating Scale for Depression (HAM-D) and the Clinical Anxiety Scale,agitation, anxiety and insomnia,REM sleep parameters,proportion of REM sleep,Discontinuations for adverse events,overall response,haematological or clinical chemistry changes,therapeutic efficacy and safety/tolerability,central nervous system events,dry mouth, drowsiness/sedation, constipation, and dizziness/lightheadedness,Mean total 17-item HAM-D scores,final on-therapy scores on the HAM-D, Montgomery-Asberg Depression Rating Scale (MADRS), and Clinical Global Impressions Severity of Illness (CGI-S) and Improvement (CGI-I) scales,HDRS total score,Headache and blurred vision,Hamilton Rating Scale for Depression,Weight loss,remission, Clinical Global Impression severity of illness and global improvement scores and Montgomery-Asberg Depression Rating Scale,body weight, blood pressure, pulse rate, temperature, physical conditions, laboratory tests, adverse experiences and concomitant medication,effective antidepressant activity,constipation,dropout rates,Additional efficacy assessments (Montgomery-Asberg Depression Rating Scale, Clinical Global Impression,ESRS scale for akathisia,number of awakenings, Stage 1 sleep, and REM latency,Final MADRS scores,effectiveness and good tolerability,HRSD items "psychic anxiety", "somatic anxiety", "agitation,incidence of AEs suggestive of activation or sedation,Hamilton Rating Scale for Depression (HRSD,safety and tolerability profiles,clinical efficacy and safety,Safety assessments included treatment-emergent adverse events (AEs), reasons for discontinuation, and AEs leading to discontinuation,Efficacy and safety,dimensions measuring depression or mental health,Sleep measures,baseline Hamilton Rating Scale for Depression score,nausea and headache,Hamilton Depression scale,psychological dimensions of general health and moderately impaired on physical dimensions,General Health Survey (SF-20) and 15D Measure of Quality of Life,sleep efficiency and REM sleep,sleep,Hamilton Psychiatric Rating Scale for Depression (HAM-D), the Montgomery-Asberg Depression Rating Scale (MADRS), and the Clinician's Global Impressions-Severity of Illness scale (CGI-SI,Sexual dysfunction,percentage of HAMD responders,Average total scores on the Hamilton Rating Scale for Depression (HAM-D,nausea, dyspepsia, anorexia and insomnia,mean HAM-D, MADRS, and CGI-S scores,CGI-Improvement responder rates,baseline and endpoint depression and anxiety severity,tolerability and efficacy,nausea and influenza-like symptoms,final ratings on the Hamilton Rating Scale for Depression (HAM-D21) total score, HAM-D21 depressed mood item, Montgomery-Asberg Depression Rating Scale total score, and Clinical Global Impressions Scale,overall incidence of adverse effects,cognitive improvement on several measures,depressive symptoms,quality of life,adverse events; tolerability profiles,some clinician- and patient-rated sleep disturbance scores,Hamilton Depression Rating Scale and the Montgomery-Asberg Depression Rating Scale (Montgomery and Asberg, 1979)--and a self-rating scale--Levine Pilowsky Depression questionnaire,HAMD sleep factor,Leeds Sleep Evaluation scale and on SIP items relating to sleep and rest, emotional behaviour and ambulation,clinical global improvement severity of illness score,21-item Hamilton Rating Scale for Depression (HAM-D) and the Clinical Global Impressions-Improvement scale (CGI-I), with scores of < or = 7 on the HAM-D and < or = 2 on the CGI,nausea and nervousness,efficacy and safety,21-item Hamilton Rating Scale for Depression (HAM-D), and depressive symptoms,normal objective, and clinician- and patient-rated assessments of sleep,Montgomery and Asberg depression scale (MADRS), the Hamilton depression scale, the clinical global impressions (CGI), and a checklist of symptoms and side-effects,Therapeutic efficacy,sleep efficiency or number of awakenings, Stage 1 or REM sleep, or REM latency,clinical evaluation [Montgomery-Asberg Depression Rating Scale (MADRS), Clinical Global Impressions (CGI)] and quality of life [Functional Status Questionnaire (FSQ,Adverse effects,Hamilton Depression Rating Scale, the Clinical Global Impression (Severity and Improvement) scales, and the Patient Global Impression (Improvement) scale,efficacy (MADRS, CGI, COVI) or in terms of safety, except for the CGI 'severity of illness,mean endpoint scores for all rating scales,cardiovascular effects,Montgomery Asberg Depressive Rating Scale (MADRS,ESRS scores for akathisia,Hamilton depression rating scale (HDRS-17 items) and clinical global impression (CGI) scale,depression ratings,sleep and anxiety,insomnia and asthenia,total REM sleep time,Hamilton Rating Scale for Anxiety,antidepressant efficacy and tolerability,dropout rate due to side effects,mean total endpoint HDRS scores and percentages of CGI very good and good responses,full remission of their depression (HAM-D21 total score,efficacy (HDRS, CGI) or safety (adverse events, laboratory examination, vital signs,antidepressant efficacy (HAM-D, CGI,depression and insomnia,measures of depression, including remission of depressive symptoms,objective measures of sleep, i.e. suppression of REM sleep,cardiac function,Widlöcher psychomotor retardation scale, Sheehan disability scale, and CGI,HAM-D and CGI-Severity scores,Antidepressant efficacy,Mean HDRS,21-item Hamilton Rating Scale for Depression (HAM-D), and Clinical Global Impressions scale for severity and improvement,nausea, other gastrointestinal symptoms, nervousness, dizziness and sleep disorders,nausea,Constipation, dyspepsia, tremor, sweating and abnormal ejaculation,global improvement,Mean values,HAM-D,safety and efficacy,mean Hamilton Rating Scale for Depression (21-item HAM-D) total score,17-item Hamilton Rating Scale for Depression (HAMD), the von Zerssen depression scale (DS), Clinical Global Impression (CGI), and patients' overall evaluation,incidence of discontinuation for adverse events,HDRS,antianxiety effects,steady-state levels,adverse effects,complaints of dry mouth, constipation, and dizziness,dry mouth and dizziness/lightheadedness,17-item Hamilton Rating Scale for Depression (HAM-D-17) total score,17-item Hamilton Rating Scale for Depression (HAM-D) and the Clinical Global Impressions (CGI) scale,Hamilton Anxiety Rating Scale (HARS) and of sleep disturbances,side-effects,overall depression,mean HAM-D total score,Hamilton Depression Rating Scale,sleep quality,24-item Hamilton Rating Scale for Depression and Clinical Global Impressions scale ratings,weight increase and somnolence,weight loss,antidepressant and anxiolytic efficacy,Clinical Global Impression (CGI) score,social functioning,frequency or in severity of adverse events,HAM-D-17 total score,HAM-D scores,17-item Hamilton Depression Rating Scale (HDRS), the Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression (CGI,relieving depression and accompanying symptoms of anxiety,sleep disturbances, nausea, and headaches,rates or mean numbers of adverse events,adverse events,Montgomery-Asberg Depression Rating Scale, CGI-Severity of Illness and CGI-Improvement, and Patient Global Impression of Improvement,ECG or STIs,HAM-D and Clinical Global Impressions scale,REM latency and suppressed REM sleep,Response rates, whether defined by end-of-treatment Hamilton Rating Scale for Depression (HAM-D) score,rates of treatment response,Raskin Depression Scale, the Covi Anxiety Scale, and the Leeds Sleep Questionnaire,Mean scores for most depression scales,Montgomery and Asberg Depression Rating scale (MADRS) score,complaints of dry mouth and dizziness on standing,mood and cognitive functions,percentage of awake and movement time,headache,HAM-A scores,effective and well tolerated,cognitive functioning,adverse drug reactions (ADRs,total HRDS score or in subscores for anxiety or suicidality,degree of depression and anxiety improvement,rate of positive treatment response,Hamilton Depression mood item,remission rates,blood pressure, pulse, or weight,memory performance,nervousness/anxiety and nausea,frequency of adverse events,Hamilton Depression Rating Scale (HDRS,depression subscale of the irritability, depression and anxiety scale,tolerated and safe,Digit Symbol Substitution Test,efficacy and tolerance,Anticholinergic side effects,established rating scales (MADRS, HAM-D, BPRS,PR interval,tremor, rash, nausea and headache occurring with fluoxetine, and drowsiness, dizziness and visual disturbance with dothiepin,I, CGI-S), anxiety (Covi), sleep (Leeds Sleep Evaluation scale) and quality of life (SIP,nausea and nervousness for fluoxetine, and dry mouth, dizziness, and drowsiness for amitriptyline,initial HAM-D score,Nausea,Hamilton depression rating scale (HAMD) total score,21-item Hamilton Rating Scale for Depression, Hamilton Rating Scale for Anxiety, Clinical Global Impressions, Raskin Depression Scale and Covi Anxiety Scale,Clinical Global Impression (CGI), Therapeutic Index (TI), Tolerance Global Impression,dizziness,effective and well tolerated antidepressant,patient and observer ratings of depression,HAM-D sleep disturbance factor,Response and remission rates,symptoms of depression,success rate,Hamilton depression scale scores,MADRS score,sleep questionnaire covers the complaints listed in criteria for insomnia disorders,sleep continuity and increased rapid eye movement (REM) sleep,REM sleep,HAM-D, Clinical Global Impressions, the Visual Analogue Mood Rating Scale (VAMRS), and the Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ,anxiety and suicidality,excessive sweating,Covi Anxiety Scale,total HAM-D score,sinus cycle length,change of HAMD17 total score,number of awakenings,Overall, efficacy ratings,cognitive functions,adverse event,self evaluation scales,mild depressive episodes,generalized tremor,HAMD score,REM latency,drowsiness and disturbed sleep,mean score of Hamilton Rating Scale for Depression (HRSD,Efficacy,adherence and efficacy and adherence,Somatization Factor scores,HAM-A response rate,number of responders,efficacy using the HRSD, Montgomery-Asberg Depression Rating Scale and Clinical Global Impression; for tolerability, adverse events,safe and well tolerated,Insomnia improvement,clinical status at base line (diagnosis, history and duration of the depressive illness, MADRS and HARD diagram scores).(ABSTRACT,sleep efficiency, total sleep time, stage 2 sleep, and shorter wake time,HAM-D-17 and HAM-D-Anxiety,mean total score,Tolerability,tiredness, drowsiness and diarrhoea,Adverse Events Scale,Clinical Global Impressions,agitation, nausea, fatigue, and insomnia,Social Adaptation Self-evaluation Scale total scores,body weight,subjective mood ratings,HAMD total score,Hamilton Depression Rating Scale, the Raskin Depression Scale, the Covi Anxiety Scale, and a Clinical Global Impression,HAM-D) or remission,Anxiolytic activity,efficacy,HAM-D sleep disturbance factor score,response rate,anxiety,total number of adverse events,low insomnia,final Hamilton Depression Rating Scale (HAM-D) score,occurrence of discontinuation rates and treatment-emergent adverse events and by measurement of vital signs and laboratory analytes,nausea, headache, and dizziness with venlafaxine and nausea, headache, and insomnia with fluoxetine,efficacy and tolerability,total HAM-A score,HDRS or MADRS total scores,tolerated,mean scores of all depression rating scales,Suicidal feelings,shaking.,Severe depression,mean scores on the Hamilton Depression Rating Scale,Hamilton Rating Scales for Depression and Anxiety, the Montgomery Asberg Depression Rating Scale, Clinical Global Impressions Scale, Zung Self-Rating Scale for Anxiety and the Leeds Sleep Evaluation Questionnaire,mean reductions in HAM-D total score,anxiety (anxious depression,total score on the Hamilton Rating Scale for Depression and the global improvement score on the Clinical Global Impressions scale,Hamilton Psychiatric Rating Scale for Depression (HAM-D,weight gain,individual HAM-D items including item 4 (insomnia onset,HAM-D response rate,Safety,anxiety symptoms,objective, subjective, and clinician-rated measures of sleep disturbance,Hamilton Depression Rating Scale, a side-effect checklist and a regular ECG assessment,weight change: weight loss,Cognitive performance,overall symptoms of depression,Anxiety measured by HAM-A total mean score,baseline Montgomery and Asberg Depression Rating Scale (MADRS) total score,Efficacy and response time,rate of adverse events,depression, anxiety, and quality of life,agitation and psychic anxiety symptoms,HAM-D remission rate,five individual items, Hamilton depression scale,anxiety scores,HDRS score,work or productivity losses,Hamilton Depression Scale Score,Estimated probabilities of response and remission,Symptoms of anxiety,motor nervousness or restlessness,QRS duration,good tolerability and safety profile,success rates,Headache and nausea,Hamilton Depression score,side effects,Antidepressant efficacy and quality of life in depression,insomnia,21-item Hamilton Rating Scale for Depression (HRSD,number of hospitalisations and duration of stay,Clinical Global Impressions (CGI)-Severity of Illness scale score,HAM-D depressed mood item,frequency and severity of volunteered adverse events,somnolence,Utilisation of medical resources,Vital signs and adverse experiences,frequencies of occurrence of adverse reactions,patient response,clinician- and patient-rated measures of depression symptoms and factors, cognitive functioning, and quality of life, as well as plasma drug concentrations,anticholinergic effects, dizziness, drowsiness, somatosensory disturbance, and excessive sweating,antidepressant efficacy,heart rate,efficacy and acceptability,incidence of treatment-emergent adverse events|Fluoxetine was comparable to amitriptyline in all efficacy measures except the HAMD sleep factor.
21|neurologic function,oesophageal transit time and cholecystic motility,LV stroke volume,Metabolic control and severity of neuropathy,exercise cardiac output,Coronary artery disease, left ventricular hypertrophy, and valvular heart disease,vitro platelet aggregation, albumin excretion rate (AER) or muscle capillary basement membrane thickness,nerve conduction velocity (NCV,postural hypotension,sural nerve zenarestat level and sorbitol suppression,number of fibers,pupillary light reflex,Tendon reflexes and blood pressure fall,cardiovascular reflexes, pupil reflexes and skin vasomotor reflexes,mean NCV of the four motor nerves,collagen and adenosine diphosphate (ADP,paraesthetic symptoms,squatting vagal test,symptomatic diabetic neuropathy,blood pressure, insulin use, or the presence of baseline abnormal heart rate variability,number of myelinated fibers per unit of cross-sectional area of nerve,peripheral nerve function,peripheral or autonomic nerve function,Peripheral nerve function,cholecystic function,Muscle capillary basement membrane thickness,constriction ratio,exercise LVEF,motor nerve conduction velocities and paraesthetic symptom scores,measures (vibration QST, neuropathy rating scores, monofilament examination,median nerve FCV and minimal latency,percentage of regenerating myelinated nerve fibers,vibration perception thresholds, nerve conduction velocities, and nerve action potential amplitudes,severe symptomatic chronic peripheral neuropathy,cardiac output,pupillary light reflex test, cardiovascular autonomic function tests, and nerve conduction study,oesophageal motility and vibration perception,nerve conduction,early clinical signs and symptoms of diabetic neuropathy,Subjective symptoms (including numbness, spontaneous pain, sensation of rigidity, paresthesia in the sole upon walking, heaviness in the foot, and hypesthesia,vibration perception,Neuropathic symptom scores,median nerve FCV,cardiovascular autonomic nerve functions, the ratio of the longest expiratory R-R interval to the shortest inspiratory R-R interval during deep breathing,change in AER,Cardiac abnormalities,Minimum latencies of F-wave of median and tibial motor nerves,adverse reactions,motor (ulnar, median, and peroneal) or sensory (ulnar and radial) nerve conduction velocities, vibration perception thresholds, adjectival symptom scores or tests of autonomic function (mean electrocardiographic R-R interval variability on deep breathing and orthostatic blood pressure response,deterioration in mean vibration threshold,Cardiovascular reflex tests (squatting vagal and sympathetic tests, pressure gain, deep breathing, lying-to-standing, Valsalva maneuver, and orthostatic hypertension), vibration thresholds, tendon reflexes, and muscle strength,maximum velocity of constriction,neurologic decline,nerve sorbitol content,symptoms of pain, numbness, or paresthesia,Exercise LVEF,pupillary light reflex and minimum latency of the F-wave,median sensory amplitude,Efficacy and safety evaluation,deep-breathing, maximum/minimum heart rate (expiration/inspiration ratio,Mild reversible elevations of hepatic transaminases,deterioration of motor nerve conduction velocity and vibration threshold,end diastolic volume,sensory, electrophysiological, and autonomic function,analysed symptoms (pain and paraesthesias) and objective assessments (NCV-DB,worsening of clinical measures of distal symmetric polyneuropathy,diabetic neuropathy,nerve function,electrophysiological measure,Deterioration of vibration threshold,glycaemic control,lying-to-standing heart rate ratio,hypersensitivity reaction,median deterioration in AER,median motor NCV,density of small-diameter,platelet reactivity and microalbuminuria,sensory thresholds,Diabetic neuropathy,pupillary light reflex and F-wave latency,stroke volume,resting diastolic filling rates,electrophysiological measurements of median and tibial motor nerve conduction velocity, F-wave minimum latency, F-wave conduction velocity (FCV), and median sensory nerve conduction velocity (forearm and distal), as well as an assessment of subjective symptoms,Painful and paraesthetic symptoms, vibration sensory threshold, and nerve conduction velocity (NCV,motor and sensory nerve conduction velocity,Sural sensory velocity,motor or sensory nerve conduction velocity,painful symptoms,Motor and sensory nerve conduction, thermal and vibration sensation thresholds, heart rate variation at rest, E/I ratio, pupillary dilation velocity and pupillary reflex latency,neurologic function, including nerve conduction studies (NCSs), quantitative sensory testing (QST), and clinical neuropathy rating scores,NCV,transit time,Vibration perception,clinical examination, neurophysiological measurements, sensory threshold determinations and tests of autonomic nerve function,median motor and median sensory nerves, changes in velocities,mean motor NCV,side effects,Objective, neurophysiological variables (biothesiometry, electromyography, nyctometri,median distal motor latency,heart rate variation and E/I ratio,tibial and peroneal motor nerve conduction velocities,resting LVEF,baseline neurophysiological parameters, duration of diabetes, and presence of retinopathy,postural hypotension deteriorated,Posterior tibial nerve conduction velocity,median motor, median sensory, and peroneal nerves,Painful and paraesthetic symptoms,cool thermal QST,fibrinolytic activities of the extrinsic, tissue-type plasminogen activator (t-PA), or in the intrinsic factor XII-dependent or factor XII-independent (urokinase-like) plasminogen activator systems,nerve functions|In vitro platelet responsiveness to collagen and adenosine diphosphate (ADP) increased in the placebo group (median change max% collagen + 8 (+2 to +30)%; ADP +4.5 (0 to +20)% compared with a fall in the Sorbinil treated patients (median change; collagen -17.5 (-2 to -40)%, p less than 0.05; ADP, -4 (0 to -25)%, p less than 0.05).
958|rate of success,smoking cessation,cessation rates and postcessation weight gain,birth weight,rate of continuous smoking abstinence,7-day point prevalence,chances of recovery from lapses,7-day point prevalence rates,initial abstinence,Mean nicotine substitution,Quit rate,Compliance rates for return visits,Birth weights,abstinence proportions ratios,Mean smoking rates,Weight gain,reduction rates and (b) psychological and physiological processes,SGRQ scores,Retention rates,smoking cessation rates and tobacco withdrawal symptoms,12-month abstinence,cessation efficacy,rate of negative birth outcomes,Alcohol outcomes,smoking cessation rate,prevalence abstinence rate,7-day point prevalence abstinence rates,Rates of adverse pregnancy and birth outcomes,Higher smoking cessation rates,Withdrawal symptoms,Point abstinence,short-term smoking abstinence rates,numbers of cigarettes smoked,nicotine dependence and severity of withdrawal symptoms,blood pressure,withdrawal symptom relief,smoking abstinence,rate of preterm delivery,overall rate of treatment-related adverse events,psychological smoking cessation,rates of dropouts due to adverse events,Rates of sustained abstinence,point prevalence cessation rates,Severe skin reactions,continuous abstinence rate,smoking quit rates,year smoking cessation rates,Plasma nicotine and cotinine values, expired carbon monoxide and withdrawal symptoms,birth weight and preterm delivery,Difficulty in sleeping,cigarette taste,reduction of smoking,insomnia and headache,Failure,overall rate of relapse,severe localized erythema,Mild or moderate side effects,risk for smoking lapses,transient local erythema,side effects and adverse events,withdrawal symptoms, including craving,rate of abstinence from smoking until delivery or the risk of adverse pregnancy or birth outcomes,Cotinine levels,10-wk continuous smoking abstinence,point abstinence at 7 weeks, continuous abstinence at 6- and 12-month follow-up, and self-reported withdrawal symptoms,mood disturbance,Monitoring blood cotinine levels,short- and long-term smoking cessation rates,number of daily cigarettes,abstinence rates,6 month quit rates,longer length of alcohol abstinence,ad lib smoking, smoking satisfaction, and craving,weight gained and relapse,cessation rates,Efficacy and safety,likelihood of quitting smoking,Smoking cessation,rate of smoking,signs of nicotine toxicity,Adverse events,Withdrawal symptoms and nicotine toxicity,smoking rates,relative success rate,prolonged abstinence from 2 weeks post-quit day through 6 months,efficacy of the skin patch,SGRQ score,abstinence rate,tolerated, and adverse event profiles,adverse pregnancy and birth outcomes,mean success rates,quit rates,Smoking reduction,respective success rates,adverse cardiovascular events,nicotine dependence,Prolonged abstinence rates (CO<10 ppm,efficacy and safety,8-week smoking abstinence rate,7-day point prevalence abstinence at 1 week, 8 weeks, and 6 months after quitting and number of days to relapse,initial cessation, number of days to lapse, number of days to relapse, and latency to relapse,early withdrawal symptoms,7-day point prevalence smoking abstinence rate,4-week abstinence rates,Smoking reduction promotes smoking cessation,quit rates and tobacco withdrawal symptoms,self-reported 7-day point prevalence smoking abstinence 6 months after quit day,skin reactions,expired carbon monoxide (CO) and serum and salivary cotinine,Safety and efficacy,continuous abstinence through 7 weeks after cessation,smoking cessation and suppression of withdrawal severity,Fagerstrom score,withdrawal symptoms composite score and abstinence rates,CO or thiocyanate concentrations,Quit rates,prolonged abstinence, assessed through self-report and verified with exhaled carbon monoxide (CO) levels,functional exercise capacity, and delays weight gain,tolerated, and adverse events,daily cigarette consumption and severity of withdrawal symptoms (Wisconsin scale,rate of low birth weight,Withdrawal symptom reporting,expired air carbon monoxide measurements,abstinence,successful quitting,craving for cigarettes, negative affect, and appetite,level of abstinence,sustained abstinence rates,Smoking cessation efficacy,nausea,mean saliva cotinine concentrations,rate of abstinence from the quit date until delivery,daily cigarette smoking on cigarette craving,complete abstinence (self-reported) and expired carbon dioxide concentration less,safety and efficacy,prolonged abstinence,abstinence from the date of smoking cessation until delivery, as validated by measurement of exhaled carbon monoxide or salivary cotinine,rates of point-prevalence abstinence,cardiovascular events,quit smoking,expired carbon monoxide concentration,adverse event rates,effectiveness and safety,Smoking abstinence (verified by saliva cotinine and expired carbon monoxide), cessation self-efficacy, and physical fitness and body weight,daily cigarette consumption or craving,Skin irritation,adverse effects,Abstinence outcomes,smoking-cessation rates,subjects smoking >16 cigarettes/day sustained cessation rates,highest quit rates,levels of expired CO,mood, withdrawal symptoms, pleasant activities and events, self-efficacy, and optimism and pessimism,sustained rate of smoking cessation,mean nicotine substitution based on cotinine determinations,tobacco withdrawal symptoms and enhanced smoking cessation rates,cigarette consumption,nicotine toxicity, and withdrawal symptom relief,CO reductions,withdrawal symptoms,birth weight and gestational age,expired air carbon monoxide measurement,breath carbon monoxide (CO,stopped smoking,time and cotinine values,withdrawal symptoms and abstinence rates,Carbon monoxide-verified abstinence rates and St. George Respiratory Questionnaire (SGRQ,number of cigarettes smoked,baseline smoking rate and baseline trough and peak blood cotinine levels,substantial relapse rate,analyzed craving and withdrawal symptoms,toxin intake,adverse events,relapse risks,Tenseness, difficulty in concentration and feelings of hunger,rate of abstinence from smoking,plasma cotinine, exhaled carbon monoxide and plasma thiocyanate,specific withdrawal symptoms (anger, anxiety, awakening, difficulty concentrating, depression, hunger, impatience, and craving,study (death, myocardial infarction, cardiac arrest, and admission to the hospital due to increased severity of angina, arrhythmia, or congestive heart failure); the secondary end points (admission to the hospital for other reasons and outpatient visits necessitated by increased severity of heart disease); any side effects of therapy; and abstinence from smoking,ratings of adverse effects,tobacco withdrawal symptoms,point-prevalence abstinence and continuous abstinence,Demographic characteristics, smoking history, depression symptoms, and body mass index,sleep disturbance and local skin irritation,craving for smoking,nicotine-dependence score,Withdrawal severity,Self-reported quit rates,craving for alcohol,Baseline mucosal lesions,Craving and withdrawal symptoms,mean value of cotinine in saliva,Continuous smoking abstinence,efficacy and tolerance,general distress,overall success rate for sustained smoking reduction,Smoking behavior and compliance,exhaled carbon monoxide,saliva cotinine,28-day continuous abstinence,success rate,higher long-term rates of smoking cessation,cotinine concentration,point-prevalence abstinence rates,serum levels of nicotine and cotinine at baseline, and withdrawal symptom relief,cessation,Nicotine abstinence rates,throat/mouth irritation and coughing,CO-validated abstinence rates,time to smoking relapse and prolonged abstinence,educational level, duration of smoking, number of cigarettes smoked per day, concomitant disease states or drug use, or Fagerstrom score,continuous abstinence rates,duration of continuous smoking abstinence; abstinence rates,28-day abstinence,absolute rate of abstinence,equivalent 1-year abstinence rates,successfully quit smoking,Minor skin reactions,6-day inpatient stay, daily nicotine and cotinine levels,rates of abstinence,Mean birth weight difference,Overall duration and level of nicotine gum use,frequency of respiratory symptoms,severity of some withdrawal symptoms,behavioural therapy,Time to relapse,daily cigarette smoking and cigarette craving,frequency of nausea,continuous and prolonged abstinence, lapse and recovery events, cost per additional quitter, and side effects and adherence,Sustained abstinence rates,Efficacy,higher quit rates,systemic and local adverse drug events,mean scores,Sustained smoking cessation,Lack of power, contamination, and low attendance,carbon monoxide concentration,continuous abstinence,relapse rate,sustained cessation,level of self-efficacy,increase abstinence,Transient mild or moderate erythema,higher cessation rates,systemic side effects,Abstinence rates,erythema with edema,percentage of nicotine replacement,complete abstinence rates,quitting rates,Success rates,Overall sustained abstinence,knowledge, coping and support resources,short-term quit rates,self-reported smoking abstinence confirmed by expired carbon monoxide measurements,smoking reduction (CPD and thiocyanate concentrations,withdrawal, tension, fatigue, and coping frequency with decreased coping effort; coping-to-urge ratio,Smoking status,successful abstinence,Continuous abstinence,Six-month abstinence rates,body weight nor cessation rates,expired carbon monoxide (CO) levels,self-reported abstinence and end-expired air carbon monoxide (CO,Smoking cessation rates,serious adverse events,Mean compliance,smokers' nicotine withdrawal symptoms,Withdrawal symptom relief,abstinence outcomes,7-day point prevalence abstinence,smoking abstinence rates,smoking outcomes,Cessation rates,smoking reduction,validated point prevalence abstinence at discharge,smoking abstinence (cotinine plus carbon monoxide,Smoking abstinence,compensatory smoking of low tar and nicotine cigarettes,tolerated,rate of continuous abstinence,OR,daily cigarette consumption,Craving,tolerated, and no serious adverse events,smoking cessation rates,Weight and smoking status,quitting rate,Severe reactions,smoking cessation efficacy,weight change and cessation rates,1-year quit rates,Safety,point-prevalence abstinence,eventually achieving long-term abstinence,drinking outcomes,1-year abstinence rates,continuous abstinence, cotinine-verified abstinence, daily cigarette consumption, withdrawal symptoms and adverse events,6-week smoking-cessation rate,dividing serum nicotine and cotinine levels,vomiting,throat irritation (inhaler) and itching (patch,Abstinence,reduced craving and withdrawal,success rates,7-day point prevalence smoking abstinence,side effects,functional exercise capacity,probability of lapsing,CO-confirmed prolonged abstinence rates,Continuous abstinence rates,relapse,Cigarette smoking rates,cessation rate,salivary cotinine levels,Cessation success rates,total abstinence,Abstinence proportions,Body weight,success rate in quitting smoking|A slight increase in adverse cardiovascular events was noted only in the open label-pay group in comparison with the placebo group.
40|symptom score, esophageal manometry, and scintigraphy,Failure rates,superior long-term success,cumulative 12-month remission rate,symptom scores,botulinum toxin injection,pneumatic dilatation,cumulative dysphagia-free state,symptomatic remission,initial failure,Symptoms and esophageal function,equal success rates,esophageal retention,Chi-squares, Wilcoxon rank-sum test, Kaplan-Meier method and log-rank tests,Lower esophageal sphincter pressure,relieving symptoms and improving esophageal function,LES pressure and maximum esophageal diameter,Pneumatic dilatation,surgical management of perforation,relevant complication,Symptom scores,major complications,recurrent dysphagia,LES pressure,recurrence of symptoms,Clinical relapse,cumulative remission rate,symptom scores, and lower oesophageal sphincter pressure, oesophageal barium column height, and oesophageal diameter,symptom score and esophageal function test|The cumulative 12-month remission rate was significantly higher after a single pneumatic dilatation (53%) compared to a single botulinum toxin injection (15%)(P < 0.01).
28|Detection performance,fixation stability,fixation performance,text reading,saccadic amplitude,Outcome variables (response times [RTs] during natural search, number of fixations during natural scene exploration, fixation stability, visual fields, and quality-of-life scores,Visual field size,saccadic behavior,Spatial attention and alertness,social domain,stimulus detection in high-resolution perimetry (HRP,visual skills areas of recognition, mobility, peripheral detection, scanning, tracking, and visual memory,detection performance,visual skills categories,stimulus detection in HRP,saccadic behavior or visual fields,visual functioning,ability to detect visual stimuli,patient's testimonials concerning their visual abilities,saccadic behavior, natural search, and scene exploration,seeing side,restoration of vision,static text reading speed,overall and separate skill improvement scores,Natural search RT|Only with EST did the number of fixations during natural scene exploration increase toward the blind and decrease on the seeing side (follow-up/pre difference, 238%).
173|periprocedural myocardial injury,overall incidence of ARF,liver function tests, renal function tests, graft survival, patient survival, plasma GSH and duration of hospital and ICU stay,II scores, Multiple Organ Failure scores,PSH level,Hemodynamic parameters, oxygen consumption, oxygen delivery, oxygen extraction ratio, and lactates,liver blood flow,postoperative eGFR,renal replacement therapy, mortality, atrial fibrillation, vasoactive medications, and adverse effects,daily Organ Failure Score,Hemodynamics and clinical outcomes,malondialdehyde (MDA,cardiovascular state, liver function, and kidney function,median percent change in eGFR,Interleukin-8,Transplant-free survival,cytokine levels, outcomes, or gastric intramucosal pH,gastric intramucosal pH,LIS and PaO2/FIO2 ratio,CK-MB,partial pressure of oxygen in arterial blood/fractional inspired oxygen 4 h after surgery,proportion of patients developing postoperative renal dysfunction,mean decrease of VO2,NAC improved oxygenation (increase in PaO(2)/FiO(2,liver blood flow index,hemodynamics and graft function,Postoperative clinical data (death, myocardial infarction, low-output syndromes, arrhythmias, bleeding, transfusion requirements, and intensive care unit and hospital lengths of stay) and biochemical markers (creatine kinase MB, troponin T, creatinine, hemoglobin, and platelet levels,MPO and MDA values,arterial and gastric mucosal carbon dioxide tension,systemic vascular resistance,Renal function,Serum cystatin C,postoperative acute renal failure,cytokine levels and gastric intramucosal pH,CK-MB>5 times normal value,microalbuminuria/creatinine ratio (MACR,VO2, oxygen delivery, CI, LVSWI and PvaCO2,patients experiencing postoperative renal dysfunction,Levels of urinary NAG/creatinine ratio, plasma creatinine and serum cystatin C,nuclear factor-kappa B activation, interleukin-6, interleukin-8, and intercellular adhesion molecule-1 expression,FIO2,Plasma interleukin-6, interleukin-8, and soluble intercellular adhesion molecule-1 concentrations,development of ARF,relative change in serum creatinine, peak serum creatinine level, serum cystatin C, and in urinary output,MOD score, use of vasopressor agents and fluid utilisation,transplant-free survival and rate of transplantation,haemodynamic parameters, nasopharyngeal temperature, arterial blood gas changes, plasma cytokine levels, biochemical parameters, intramucosal pH, length of stay in the intensive care unit, duration of of mechanical ventilation and mortality,myeloperoxidase (MPO), malondialdehyde (MDA), interleukin-6, Alpha1-acid glycoprotein (AAGP), and C-reactive protein (CRP,Cardiomyocyte staining,plasma TNF, IL-6, or IL-10 levels,nuclear factor-kappa B activation,postoperative atrial fibrillation,MAP, cardiac index, and left ventricular stroke work index,static lung compliance,incidence of death, myocardial infarction, bleeding, transfusion requirements, intubation time, and hospital length of stay,renal or hepatic injury,number of days of acute lung injury,hospital mortality,myocardial oxidative stress,Activation,rate of AF,tolerated; only nausea and vomiting,renal replacement therapy, length of ventilation, and length of stay in the intensive care unit and hospital,acute renal failure,myocardial damage,stable clinical conditions (hemodynamic values, body temperature, hemoglobin, FIO2,Postoperative graft function,mild vasodilatation, improve oxygen delivery and consumption,Ethane and MDA concentrations,Hemodynamic data and calculated tissue oxygenation parameters,mortality and the required days of inotropic support, mechanical ventilation, and intensive care,Acute renal failure,oxidative response of neutrophils,Mortality,ICU mortality and ICU length of stay,luminol (specific for (*)OH, H(2)O(2), and HOCl(-) radicals) and lucigenin (specific for O(2) (*-)) levels and the difference ratios after reperfusion,PaO2/FIO2 ratio,Levels of malondialdehyde, protein sulfhydril (PSH) groups, reduced gluthation (GSH), activity of myeloperoxidase, catalase and superoxide dismutase enzymes and induced free radical generating capacity,oxygen extraction ratio by the liver,serum creatinine level,Plasma concentrations of tumor necrosis factor-alpha (TNF), interleukin (IL)-6, IL-8, IL-10, and soluble tumor necrosis factor-alpha receptor-p55 (sTNFR-p55,ST segment depression,postoperative renal dysfunction, interventions, complications, or mortality,postoperative interventions and complications, the requirement for renal replacement therapy (RRT), adverse events, hospital mortality, and ICU and hospital length of stay,hemodynamic and pulmonary data (pulmonary capillary wedge pressure, pulmonary vascular resistance (PVR), cardiac index (CI), shunt flow, dynamic lung compliance and static lung compliance,progression of multisystem organ failure,proportion of patients with postoperative renal dysfunction,systemic and pulmonary hemodynamics, oxygen delivery, and oxygen consumption,concentrations of TNF-α, IL-6, IL-8, and IL-10,NAG/creatinine ratio and the albumin/creatinine ratio,nutritive blood flow,hemodynamic response to N-acetylcysteine,oxygen extraction,clearance of indocyanine green,Plasma IL-6,liver function,Creatine kinase-MB levels,oxidative burst response of neutrophils,progression of early postoperative organ dysfunction and improve oxygenation,morbidity and mortality,tolerated, improved respiratory function, and shortened ICU stay,renoprotective effect,serum cytokine levels and gastric intramucosal pH,incidence of postoperative AF,glomerular filtration rate (eGFR,oxidative stress and inflammation,Parasite clearance time,severe adult respiratory distress syndrome (ARDS) and mortality rate,GSH level,pulmonary function,coma recovery times,efficacy and safety,tissue oxygenation,demographic characteristics, ARDS categories, severity of illness (simplified acute physiology score [SAPS II,adverse reactions,hospital mortality and need for renal replacement therapy,VO2 and gastric intramucosal pH,hepatosplanchnic blood flow,shorter ventilator requirement,myocardial ischemia-reperfusion injury,overall mortality,transplant-free survival,Mortality rate,II score and the sequential organ failure assessment (SOFA) score,mortality, morbidity or postoperative graft function,serum cystatin C,left ventricular cardiomyocyte staining,renal dysfunction,ICU and hospital length of stay,MOD score,renal function,postoperative clinical course,higher survival rate,percentage of patients receiving ventilatory support,renal injury as measured by the increases in urinary N-acetyl-beta-d-glucosaminidase (NAG)/creatinine ratio (indicator of renal tubular injury) and urinary albumin/creatinine ratio (indicator of glomerular injury,Pulmonary artery catheter-derived hemodynamics, blood gases, hemoglobin, and arterial lactate,Overall survival,benefits of transplant-free survival,cause mortality,cellular composition and mediators,total antigenic human neutrophil elastase,postoperative organ dysfunction,length of ICU stay,DO2 and VO2,Perioperative hemodynamic and pulmonary data,cTnT levels,mortality rate,urinary NAG/creatinine ratio,baseline SCr and calculated GFR,survival rate,total number of neutrophils, elastase, MPO and interleukin-8,six organ dysfunction parameters, length of intensive care stay, days of mechanical ventilation and mortality,Plasma creatinine and serum cystatin C values,splanchnic blood flow,Interleukin-6 concentrations,Cardiac output,levels of glutathione and cysteine,VO2 when DO2,microalbuminuria and organ dysfunction,simplified acute physiology score (SAPS,still receiving ventilatory support,hemodynamic variables, oxygen delivery (DO2), oxygen consumption (VO2), and oxygen extraction,IL-8 and sTNFR-p55 levels,venoarterial carbon dioxide gradient (PvaCO2,Development of ARDS and mortality,AAGP and CRP values,GSH,Global left ventricular function,cardiovascular SOFA score,Plasma creatinine,whole-body oxygen consumption (VO2), gastric intramucosal pH, and veno-arterial CO2 gradient (veno-arterial PCO2,hemodynamic effects of N-acetylcysteine,Mean (SD), pooled mean arterial pressure (MAP), and cardiac index,microalbuminuria and organ failure,LIS,Rates of deterioration and recovery of liver function,oxygen delivery, cardiac index, stroke index, and left ventricular stroke work index,Respiratory dysfunction,Pulmonary compliance,hypotension requiring inotropic support,absolute liver blood flow index,overall survival,hepatosplanchnic flow and function,cardiovascular, renal, hepatic, haematological and central nervous system,percent change in eGFR,admission parasitemia,Systemic oxidative stress,Tumor necrosis factor-alpha levels,Fractional liver blood flow index (cardiac index-related liver blood flow index,postoperative interventions and complications, the need for RRT,Oxidative stress and inflammation generate edema,rate of survival,complex formation between elastase and alpha 1-proteinase inhibitor,pulmonary fibrin uptake,Hemodynamic and oxygen transport indices,Severity of illness and degree of organ failure,hospital mortality rate,plasma neutrophil elastase activity,Survival; incidence of cerebral oedema, renal failure, and hypotension requiring inotropic support; liver function,oxygenation index (PaO2/FIO2,hemodynamics and postoperative graft function,cardiac index (CI), left ventricular stroke work index (LVSWI,ventilatory support,liver blood flow, hepatosplanchnic oxygen transport-related variables, and liver function,serum creatinine,absolute change in serum creatinine,postoperative increases in A-a oxygen gradient,mortality rate, the need of ventilatory support, the intensive care unit stay, and the PaO2/FIO2 evolution,hemodynamics, oxygen transport variables, and plasma levels of cytokines,respectively Oxygen transport indices, arterial blood gas analyses, Pao2/Fio2 ratio, and shunt,interleukin-6 production,Urinary F2-isoprostane metabolites,Soluble intercellular adhesion molecule-1 concentrations,postoperative A-a oxygen gradient,PaO2/FiO2 ratio,baseline serum bilirubin,1-month mortality rate,whole-blood lactate levels,Nuclear factor-kappa B activation,Microsomal liver function,Postoperative tracheal extubation,lipid peroxidation of the lung epithelium,APACHE (acute physiology and chronic health evaluation,SOFA scores,expired ethane and malondialdehyde (MDA), and oxidized (GSSG) and reduced glutathione (GSH,organ function,transplantation rate,serum creatinine (SCr) levels,VO2,RBC glutathione,Creatine kinase MB isoform (CK-MB) mass levels,intubation time,GSH levels,15 (SD) yrs and Acute Physiology and Chronic health Evaluation,baseline SCr levels,liver graft performance,cardiac index,oxidative stress, inflammation, fluid requirement, multiple organ dysfunction (MOD) score and vasoactive drug requirement,Liver blood flow index and MEGX,hepatorenal ischaemia-reperfusion injury,ARDS,mechanical ventilation,plasma creatinine and serum cystatin C concentrations,Urine N-acetyl-beta-D-glucosaminidase (NAG) and urine creatinine ratio, plasma creatinine, and serum cystatin C levels indicated renal function,urinary albumin/creatinine ratio,Urine NAG/creatinine ratio,MACR,nuclear factor-kappa B activation and circulating cytokine and adhesion molecules,serious adverse events, hospital mortality,oxygen transport and uptake,levels of the major cytokines, duration of ventilation and intensive care unit stay, gastric intramucosal pH and arterial oxygen tension/inspired fractional oxygen ratio,chest radiograph or on survival rate,reactive oxygen species-mediated myocardial stress,veno-arterial PCO2,postoperative biochemical markers (troponin T, creatine kinase MB, creatinine, hemoglobin, and platelets,plasma appearance of monoethylglycinexylidide (MEGX,A daily Organ Failure Score,systemic oxygenation,mortality,lung injury score (LIS,MEGX,cerebral oedema,hemodynamics and survival rates,aminotransferases, prothrombin time, and monoethylglycinexylidide test,adverse effects,survival, graft function or risk of AKI,Release of myeloperoxidase (MPO,fulminant hepatic failure,mortality, lactate clearance times|The transplantation rate was lower in the NAC group but was not significantly different between groups (32% vs 45%; P = .093).
1001|incidence of diabetes mellitus,knowledge and foot self-care scores,Hemoglobin A(1c) levels,baseline foot risk category,patients' attitudes regarding the value and importance of footcare, patients' footcare knowledge, healthcare professionals' footcare knowledge and pattern of service utilization,Health professionals' knowledge scores,knowledge of diabetic foot care,prevalence of some minor foot problems,Attitudes towards footcare,dermatologic abnormalities,serious foot lesions,self-management behavior,Reduction of lower extremity clinical abnormalities,knowledge about diabetic foot problems,Diabetes-related quality-of-life scores,hospitalized with diabetes- or vascular-related admissions,quality of life,self-care|Over 85% of the results for the Semmes-Weinstein monofilaments were the same on the first and second measurement.
43|Age, percent total and third-degree burn, resting energy expenditure, and calorie and protein intake,Corticosteroid-binding globulin and total and free serum cortisol,serum free cortisol,infectious morbidity and shortens length of stay,Nitrogen balance, urinary 3-methylhistidine excretion, urinary cortisol, and clinical status,nitrogen balance,3-methylhistidine excretion,wound infection,better respiratory and nutrition status, and shorter time to healing,pneumonia,deaths,protein metabolism, morbidity, and length of care,incidence of diarrhea, improved glucose tolerance, lower serum triglycerides, reduced total number of infectious episodes and trends toward improved preservation of muscle mass|There was no difference in nitrogen balance between groups, and 3-methylhistidine excretion was higher and serum free cortisol was lower in log-fat--fed patients than in controls.
not found|efficacy and safety,muscle function,Treatment failure,severe side effects,failure rate,muscular score and functional grade,positive treatment response,level of function,Acetylcholine receptor antibody concentrations,efficacious and safe,mean duration of improvement after IVMP|No severe side effects were found.
331|overall QOL scores,OR rate,Median OS,anemia,patients' quality of life (QOL,Quality of life (QOL) outcomes,response and adverse effects,Functional Assessment of Cancer Therapy-Cervix (FACT-Cx), Neurotoxicity Subscale (FACT/GOG-NTX subscale), and Brief Pain Inventory (BPI,myelosuppression,Nausea and vomiting,survival time,longer progression-free survival (PFS) time,diarrhea,overall response rate,Greater myelosuppression,percentage of planned dosages,median times to progression or death,gastrointestinal toxicity,response rates, survival, side effects and quality of life,severe complaints of asthenia,serum creatinine level,overall survival (OS,response rate of Adriamycin,complete remission rates,neurotoxicity subscale,complete remission rate, response duration, progression-free interval, or survival,partial responses,incidence of complete and partial remission,Gastrointestinal toxicity,lower risk of death,objective response (OR) rate, progression-free survival (PFS) and overall survival (OS,Survival,overall survival (OS), with response rate, progression-free survival (PFS), and quality of life (QOL,Toxicity,survival,grade 3/4 toxicities were leukopenia, neutropenia, anemia, thrombocytopenia, and nausea and vomiting,nausea and vomiting,response rate,rate of QOL,Overall (FACT-G) scores,median duration of response,myelosuppression and nephrotoxicity,response and survival rates,thrombocytopenia and leukopenia,nephrotoxicity, peripheral neuropathy, myelosuppression, and ototoxicity,leukopenia and thrombocytopenia,response and PFS,episodic hypersensitivity,unadjusted hazard ratio for overall survival,Median overall survival,overall QOL and pain,QOL scores,mild diarrhea,PFS and survival,leukopenia,initial performance score,response rate and progression-free survival (PFS,response rates,Renal, otic, and peripheral nervous system toxicities,neurotoxicity,toxicity,rate of failure,complete remission rates, response duration, progression-free interval, and survival times,mild thrombocytopenia,myelosuppression, nausea and vomiting, mucositis, rash, and hepatotoxicity,frequency of severe toxicity,overall survival,Leukopenia, renal toxicity, peripheral neurotoxicity, and CNS toxicity,incidence of these toxicities,duration of complete plus partial remission,hematologic toxicity,QOL,Median PFS,partial response,Response rates,Objective response rates,Hematologic toxicity,Median survival,progression-free survival (PFS), or overall survival,response rate, PFS, survival, and toxicity profile,response rate and PFS duration,median survival,antitumor responses,QOL assessment,median survival time,pain scores,pulmonary toxicity,median progression-free interval|The continuous infusion regimen was associated with a significantly greater percentage of patients who experienced no nausea and vomiting (34% versus 18%, P = 0.002).
62|vomiting,overall outcome or tolerability,complete cure,Adverse reactions,Trichophyton violaceum,efficacy, cost, and compliance,therapeutic efficacy,side effects,rapid clearance of tinea capitis,hair regrowth,clinical cure,efficacy and safety,absence of clinical signs, hair regrowth or negative mycology,Microsporum audouinii,Trichophyton mentagrophytes,Microsporum canis,mean time to a sterile culture,hepatotoxicity or other adverse reactions,mycologic cure and either clinical cure,cure rates,mycological cure,Mycological cure,efficacy and tolerability,clinical deterioration,subcutaneous skin damage requiring plastic surgery,Adverse effects,treatment efficacy,time for complete scalp clearing,Complete cure,adverse effects,cure rate|Complete cure was observed at the end of study in 62% patients treated with terbinafine for 6 weeks, in 60% treated for 8 weeks and in 84% patients treated with griseofulvin for 12 weeks.
not found|Major hemorrhage,limb salvage and survival,frequency of in-hospital cardiopulmonary complications,mean ankle-brachial blood-pressure index,Partial lysis,incidence of in-hospital cardiopulmonary complications,TOPAS,bleeding complications,complete dissolution of thrombus,cumulative limb salvage rate,dissolution of the occluding thrombus,duration of hospitalization,risk of amputation or death,intracranial hemorrhage,cumulative survival rate,amputation-free survival rate,hospital mortality,hospital cost,Amputation-free survival rates,blood flow,patient survival rates|Amputation-free survival rates in the urokinase group were 71.8 percent at six months and 65.0 percent at one year, as compared with respective rates of 74.8 percent and 69.9 percent in the surgery group; the 95 percent confidence intervals for the differences were -10.5 to 4.5 percentage points at six months (P=0.43) and -12.9 to 3.1 percentage points at one year (P=0.23).
40|mean scores,severity of pain and burning sensation using visual analog scales,acceptability and efficacy,psychological disability domain and total OHIP-49 score,symptom scores,symptoms and extension of lesions; adverse effects,side-effects,efficacy, relative safety, and tolerability,visual analogue scale (VAS,VAS scores,tolerated, and only transient burning sensations,systemic side effects,clinical response,daily cost of ciclosporin treatment,severity score,Symptomatology,surface area of oral lesions,soreness scores,change in symptoms,patient's pain scores,mucosal erosions and pain sensation,patient quality of life,erosion,visual analogue scale (VAS), the McGill pain score, the Oral Health Impact Profile (OHIP), and Oral Health Quality of Life (OHQoL) questionnaires,severe adverse events,blood concentrations of pimecrolimus,clinical score,daily cost of ciclosporin,partial to complete clinical improvement,symptoms and side effects,sustained remission of EOLP,log diary recording oral function and soreness scores,erythema,pain score (by linear visual analogue scale; 0-100); (ii) clinical score; (iii) clinical resolution; and (iv) patient compliance,clinical and subjective improvement,quality of life,condition improved subsequently relapsed,painful symptoms measured by visual analog scale, the Oral Health Impact Profile score, and objective clinical score,Discomfort scores,ulceration (alpha = 0.068) and erythema,efficacy, ease of application, and adverse effects,partial response, no response and worsening of the symptoms,clinical improvement,total surface area of the lesions, including all white, erythematous, and ulcerative lesions,efficacy and safety,soreness relief following immediate application, oral function and size of erosive/ulcerative area,complete clinical remission,OELP lesion size,clinical signs and occurrence of side effects,swelling or burning sensation,good response,partial improvement,VAS scores, a partial to complete response,signs and symptoms of OLP,Side effects,blood cyclosporine levels,clinical response, pain, burning sensation, area of reticulation, erythema, and ulceration,blood level of pimecrolimus,Mean lesion sizes and mean pain measures,Safety,mean score,patient documentation, measurement of pimecrolimus levels and blood counts,visual analog scale (VAS) and clinical improvement including lesion type and size,serious side-effects,Burning pain,Oral Health Impact Profile score,Hospital Anxiety-Depression (HAD) scale,painful symptoms,clinical candidosis,visual analog scale score,transient burning sensation,complete pain remission,recurrence rates,erosive and ulcerative lesions,good or partial response,side effects,EOLP,reticulation,ulcerative areas,total quality of life score,clinical and symptomatological improvement of OLP,clinical scoring and grid measurement of the target lesion (reticulation, erythema, ulceration,psoriatic lesions,initial therapeutic response,Blood levels,size of the erosive/ulcerated area,pain,Symptom-free state,complete remission,adverse effects,relation to pain,Relapse,Pain severity, burning sensation, and mucosal lesion extension,erosive areas and recorded visual analog scale (VAS) scores|There was no significant difference between changes from baseline median values of pimecrolimus and triamcinolone groups after treatment termination in terms of visual analog scale score (-9.8 +/-
not found|symptom scores of PFR measurement,asthma control,steroid dosage, visual analogue symptom scores, response to beta 2 agonist and peak expiratory flow rate (PFR) measurement|In this study an 8 week treatment with hydroxychloroquine was of no benefit to patients with chronic steroid dependent asthma.
140|Necrotising enterocolitis,longer duration of hospital stay,incidence of NEC,neonatal necrotizing enterocolitis,mortality,necrotising enterocolitis,protection against necrotising enterocolitis,necrotizing enterocolitis (NEC|Infants with necrotising enterocolitis were associated with a significant increase in mortality (p = 0.026) and longer duration of hospital stay (p = 0.002).
645|corrected count increment (CCI,Mean pretransfusion bleeding times,platelet efficacy,posttransfusion platelet count increments and days to next transfusion,mean 1-hour posttransfusion template bleeding times,incidence of grade 2 bleeding,clinical refractoriness,risk of bleeding,Therapeutic efficacy and safety,mean 1-hour posttransfusion platelet corrected count increment (CCI),CCI(1hour,24-h CCI, bleeding, transfusion requirement of red cells and PC, platelet transfusion interval and adverse transfusion reactions,Hemostatic efficacy,Median time,prolonged bleeding times and transfusion intervals,average number of days to next platelet transfusion,therapeutic efficacy and safety,Overall median time to next transfusion,1-hour count increment, time to next transfusion, hemostasis, transfusion reactions, and serious adverse events,proportion of patients with World Health Organization (WHO) grade 2 bleeding,PLT and red blood cell utilization,time to next PLT transfusion,Transfusion reactions,posttransfusion PLT count increments,bleeding events,incidence of grade 3 or 4 bleeding,number of platelet transfusions,1 h corrected count increment (CCI,1- and 24-h count increment (CI), 24-h CCI, time to next PC transfusion, red blood cell (RBC) use, bleeding and adverse events,transfusion-associated bacteremia,24-hour PLT count,Clinical hemostasis, hemorrhagic adverse events, and overall adverse events,Number, frequency, and dose of PLT transfusions; acute transfusion reactions; and adverse events,1-hour corrected count increment (CCI,mean 1-hour posttransfusion PLT corrected count increments (CCIs,Platelet transfusion dose, pretransfusion storage duration, and patient size,blood product utilization,PLT count increments and CCIs,bleeding times,Clinical hemostasis|Transfusion reactions were fewer following PCT platelets (3.0% PCT versus 4.4% control; P =.02).
4|blood loss and change in platelet aggregation.(ABSTRACT TRUNCATED AT 250 WORDS,Pulmonary function,extravascular lung water and cardiac index,extravascular lung water (EVLW,urine and chest tube outputs,platelet activation, platelet aggregation,hemodynamic efficacy and safety,Plasma volume (PV), ECFV, cardiac index, and arterial oxygen content,superior 28-day survival,urine output,mean COP,gastric intramucosal PsCO(2) and arterial PaCO(2) (Ps-aCO(2) gap), gastric intramucosal pH (pHi) and arterial lactate acid concentration 30 min after induction of anesthesia (baseline value), 1 h and 2 h after skin incision, and at the end of surgery,Mortality rates,systolic blood pressure ≤ 70 mm Hg or systolic blood pressure,mean pulmonary arterial occlusion pressure (MPAOP,renal function and lactate clearance,concentrations of molecular markers of activated coagulation and fibrinolysis,Sequential Organ Failure Assessment score, mean arterial pressure, lactate, or central venous oxygen saturation,survival rates,predicted survival,Stat-Crit accuracy,plasma sodium content,concentrations of coagulation factor XIII,plasmin/alpha 2-antiplasmin complex,Colloid osmotic pressure (COP,frequency of adult respiratory distress syndrome,gain of body weight,pulmonary vascular resistance index,transcapillary fluid flux,survival,nausea and vomiting,worst multiple organ dysfunction score (MODS), excluding the cardiovascular component, to Day 14,adverse reactions,negative fluid balance,left ventricular stroke work index and PWP,resolution of acidosis,Cardiac response,blood pressure,hemorrhagic shock,inflammatory response,risk of death,postoperative nausea and vomiting and improves postoperative outcomes,accuracy of colloid oncotic pressure (COP,48-hour mortality; secondary end points included pulmonary edema, increased intracranial pressure, and mortality or neurologic sequelae at 4 weeks,days of mechanical ventilation,Maximum platelet aggregation,Tissue oxygenation,crossmatching of blood,blood loss and coagulation,Hemodynamic parameters (heart rate, capillary filling time, pulse volume, and blood pressure,COP limit the postoperative albumin consumption,requirement for rescue colloid at any time after administration of the study fluid,Haemodynamic parameters and pulmonary function,Platelet function,multiple organ dysfunction,severe bleeding,Likewise, chest tube drainage,POP, MPAOP, POP-MPAOP difference, total sodium intake or net supply of non-colloid fluids,change in AaDO2,relative risk of requirement for rescue colloid,arterial lactate acid concentration,Plasma volume,Hemodynamic response,total blood volume index (TBVI), intrathoracic blood volume index (ITB-VI) and extravascular lung water index (EVLWI,cardiorespiratory functions,obligatory contraction or expansion of ECV,Urine output and improvement of the Glasgow Coma Score,systolic pressure,hydrostatic pressures,mean (+/-SD) numbers of days spent in the ICU,Baseline values for PV, ISFV, ECFV, and oxygen delivery index,platelet function and hemostasis,preload-recruitable cardiac and left ventricular stroke work indices,Perioperative blood loss and coagulation profiles,ejection fraction,platelet aggregation,plasma sodium,Values of sELAM-1,mean arterial pressure, central venous pressure, pulmonary capillary wedge pressure, and cardiac index,APACHE II score,maximum sequential organ function scores,coagulation and fibrinolytic system,mortality,left ventricular preload and left ventricular ejection fraction,Serum concentrations of sICAM-1,Initial hemodynamic stabilization,cumulative fluid balance,higher mortality,extravascular lung water (EVLW - double indicator dilution technique,plasma volume and global end-diastolic volume, confirming plasma volume and preload augmentation,Pulmonary arteriovenous admixture,longest recovery times,baseline Glasgow Coma Scale scores,perioperative weight gains,serum sodium,hemodynamic effects,Hemodynamic stabilization (heart rate, capillary refill time, systolic BP in normal range), plasma volume at the end of fluid resuscitation and incidence of organ dysfunction,proportion of patients with new single-organ and multiple-organ failure,mean (SD plasma volume (saline--53.4,Arterial Lac,risk of intra-abdominal hypertension,Adverse events,Fluid balance,Significant diuresis,volumes of crystalloids and blood required in their resuscitation,Urine flow rates,levels of urea and creatinine,Time to reach HDS,Blood pressure,CVP and PAOP,28-day survival,plasma colloid osmotic pressure,Platelet volume,pulmonary artery wedge pressure (WP) and the WP-COP gradient,Acute renal failure,48-hour mortality,Cardiac output, EVLW, PCWP, serum colloid osmotic pressure (COP), and intrapulmonary shunt fraction (Qs/Qt,mean plasma oncotic pressure (POP,Pulmonary artery occlusion pressure,systemic vascular resistances,Serum concentrations of interleukin (IL)-6, IL-8 and IL-10 and soluble adhesion molecules (sELAM-1 and sICAM-1,Bleeding manifestations, coagulation derangements, and severity of fluid overload,hematocrit, hemoglobin, protein, albumin, blood urea nitrogen (BUN), and creatinine,splanchnic oxygenation,Creatinine clearance values,normal blood pressure and urine output,haemodynamic or lung function variables,renal and thromboembolic complications,tissue oxygenation,clinical severity,4-week mortality,serum albumin, A/G ratio and colloid oncotic pressure,thrombotic risk,Fluid balance, total fluid infused, sodium balance, total sodium infused, COP, or COP-PCWP,intrapulmonary venous admixture, arterial oxygen tension, or time on respirator,total volume,severe hypovolemia,Blood pressure response; survival,Overall survival,HS-HES and HS,Mean arterial pressure (MAP), oxygenation index (PaO₂/FiO₂),arterial lactate (Lac),lactate clearance rate, acute physiology and chronic health evaluation II(APACHEII) score,fluid infusion volume, urine output as well as incidence of multiple organ dysfunction syndrome (MODS), and mortality,EVLW,levels of plasma PAI,factor XIII,cardiac filling pressures,pulmonary capillary wedge pressure, and ventricular arrhythmias,survival rate,maintenance of arterial blood pressure, heart rate, and urine output,platelet function,requirement of inotropes, incidence of organ dysfunction and case fatality rate,Serum albumin,splanchnic blood flow and tissue oxygenation,Infusion rates and 8-hour intake,blood transfusions,burden of MODS,nausea and vomiting, use of rescue antiemetics, severe pain, periorbital edema, and double vision,intrapulmonary venous admixture and improved PaO2,Lung water,Cardiac index,colloid osmotic pressure,systolic blood pressures and cardiac outputs,Endovenous volumes,Qs/Qt and AaDO2,Blood pressure (BP,lactate clearance rate,plasma oncotic pressure, renal function and peripheral oedema,postoperative weight gain,incidence of complications,hemodynamic stability and fluid requirements,intraoperative urine volumes,Qt,postoperative hemoglobin level,mechanical ventilation,lactate clearance,pulmonary capillary wedge pressure,Total intravascular albumin,fluid retention,PV expansion,Physical parameters and hemodynamic variables,28-day survival-HSD,Cardiac index, central venous pressure, pulmonary capillary wedge pressure, systemic and pulmonary vascular resistance indices, arterial oxygen tension, plasma osmolarity, electrolytes, and urinary output,postoperative course,hemodynamic stability,Ejection fractions,Hemodynamic, pulmonary, and renal variables,blood products [packed red blood cell volumes,time to initial recovery,calculated plasma volume expansion,low baseline Glasgow Coma Scale scores,systolic blood pressure,total body blood flow,prothrombin fragment F1 + 2,plasma sodium content and cardiac index,IAP,number of blood transfusions,capillary microvascular flow index, percent of perfused capillaries, and perfused capillary density,activated partial thromboplastin time postsurgery,tissue oxygen tension (ptiO(2,thrombin/antithrombin complex,prothrombin time (PT), activated partial thromboplastin time (APTT) and levels of plasma tissue plasminogen activator (t-PA), and plasminogen activator inhibitor (PAI,severe sepsis,urine flow rate,Interstitial fluid volume (ISFV,Mortality,adverse events,blood pressure, pH, and urine output,Oxygen delivery index,plasma volume and hemodynamic stability,mean arterial blood pressure (MAP), systolic and diastolic pressure, central venous pressure (CVP), and pulmonary artery occlusion pressure (PAOP,cardiac index with increasing pulmonary capillary wedge pressure,renal injury,Postbypass blood loss,anaphylactoid reactions,Mean arterial pressure (MAP,EVLWI, pulmonary shunt fraction, and time on mechanical ventilation,Wedge pressure,Total quantity,Biochemical variables and haemodynamics (transpulmonary thermodilution,diuresis,ECFV,COP-PCWP,death or end-stage kidney failure (dependence on dialysis,albumin,mortality rate,Postoperative values of albumin concentration, circulating albumin mass and pis,serum albumin and plasma oncotic pressure,positive balance,blood loss,length of intensive care unit stay (ICU-LOS,Oxygen consumption and cardiac output,hemodynamic parameters,PaO₂/FiO₂:248.4 ± 17.0,lactate clearance rate,serum colloid oncotic pressure,Haemodynamic stability,overall survival rate, hypertonic infusion,hct using the Stat-Crit, Coulter, and centrifuge methods, and sodium (Na), potassium (K), chloride (Cl), white blood cell count, total protein (TP), and albumin,ITBV,Malaria status,SBP,stroke index,PscO2,maximum gradient of platelet aggregation,Systemic hemodynamics and oxygenation (PaO(2), PaCO(2,Survival to hospital discharge,safety measures,renal function and morbidity,larger amounts of fluid,plasma colloid osmotic pressure (COP,incidence of MODS,plasma volume (PV) loss,extracellular fluid volume, total body water and interstitial fluid volume,requirement for rescue colloid,intrapulmonary shunt (Qs/Qt,ETVL,subcutaneous oxygen tension and collagen accumulation,Maximum aggregation, maximum gradient of aggregation, and platelet volume,estimated blood losses (EBL,Pulmonary shunt fraction (Qsp/Qt,percentage reduction in base deficit at 8 h. Secondary end points included death, the requirement for rescue therapies, and neurological sequelae in survivors,ICU-LOS,perioperative blood loss,Sublingual microcirculation,larger diuresis,cardiac index and myocardial contractility (ejection fraction and mean rate of internal fiber shortening, Vcf,hemodynamic response and lung water following thermal injury,cardiac index, colloid osmotic pressure (COP), pulmonary capillary wedge pressure (PCWP), COP-PCWP gradient, right and left ventricular stroke work indices, and amount of constant positive airway pressure,Fluid balance and pulmonary functions,left ventricular stroke work index,bleeding time,plasminogen activator inhibitor-1,systemic vascular resistance index,colloid osmotic pressure (COP,survival to hospital discharge,alveolar-arterial oxygen partial pressure difference,COP,fluid for successful resuscitation,Arm and thigh circumferences,pulmonary edema or increased intracranial pressure,Haemodynamic data,Release of pro-inflammatory cytokines IL-6 and IL-8,sex, age, cause of hypovolemia, revised trauma score (RTS), Glasgow index, and mean arterial pressure (MAP) on admission,cardiorespiratory recovery with shorter extubation time,sodium balances,fluid balance, major organ complications, the Acute Physiology and Chronic Heath Evaluation II score, and the serum levels of C-reactive protein, interleukin-6, and interleukin-8,serum colloid osmotic pressure,POP fell,Neurologic sequelae,thrombin/antithrombin III complex, prothrombin F1 +2 fragment) platelet activation (betaTG) and compromised coagulation,plasma volume, serum oncotic pressure (pis), serum albumin and total protein concentration, alveolar to arterial oxygen tension differences (AaDO2, FIO2 = 1.0), creatinine clearance, body weight, and fluid and sodium intake,Blood pressure, infused volumes necessary to maintain SBP, and overall survival rates,Survival,circulatory variables, alveolo-arterial oxygen tension difference, incidence of wound infection or postoperative restoration of intestinal activity,efficacy,Operation time, estimated blood loss, and transfusions,severe trauma with respect to resuscitation, fluid volume, gastrointestinal recovery, renal function, and blood product requirements,blood volume deficit,fluid balance and cardiorespiratory functions,tissue plasminogen activator,plasma colloid osmotic pressure (COPP,central pontine myelinolysis; bleeding,mortality, coagulation, or pruritus,Overall complication rates,Total postoperative fluid support,ventilatory parameters, blood gases, pulmonary function tests, ventilator days, or hospital days,pulmonary edema,fluid requirements, superior hemodynamic performance, and shortened intensive care stay,Plasma volume expansion,degree and duration of coagulation impairment,COP measure,postoperative plasma volume,response profile,weight,postoperative lung function and circulatory adaptation,Coagulation parameters (prothrombin time, partial thromboplastin time, fibrinogen, and factor VIII,net lung capillary filtration pressure,Cardiac output and pulmonary wedge pressure (PWP,PV and ECFV,total protein,PaO2,oliguria during a course of therapy, weight gain, number of IL-2 doses, tachycardia, hypotension, vasopressor use, hospital stay, and clinical response rates,left ventricular end-diastolic area,quality of postoperative recovery,Cardiac output and pulmonary wedge pressure,plasma lactate concentrations,pulmonary extravascular thermal volume (ETVL,sublingual microcirculation,Plasma creatinine, urea, electrolytes, urinary volume, and sodium excretion,ICU and hospital LOS, and area under the curve of SOFA score,filling pressures of the heart and improved cardiac output,Blood loss,Serum colloid osmotic pressure (COP), CO, PCWP, the gradient between COP and PCWP (COP-PCWP), and intrapulmonary shunt (Qs/Qt,MAP, arterial Lac, lactate clearance rate and APACHEII score,total number of saline and albumin fluid boluses,hypotension, tachycardia, and oliguria,cardiac index,time to recovery of bowel function or mortality,next morning (AM1), COP,POP and MPAOP,ratio between plasma volume (PV) and ECV,Biometric and perioperative data, hemodynamics and oxygenation,filling pressures of the heart with improved cardiac output,frequency of adult respiratory distress syndrome (ARDS,perioperative blood loss (sum of bleeding during the intraoperative and postoperative 24-h period), transfusion requirements, modified thromboelastography and coagulation variables, hemodynamic parameters, and fluid balance,severity of shock and status with respect to malaria, coma, sepsis, acidosis, and severe anemia,Colloid oncotic pressures, serum albumin and albumin/globulin (A/G) ratios,Cardiac output and Qs/Qt,intestinal edema,Sublingual capillary density,death from any cause during the 28-day period after randomization,Body weight,adequate cardiac output|Survival to hospital discharge in patients with baseline Glasgow Coma Scale scores of 8 or less was correlated with treatment group (P < .05 by logistic regression and P < .01 by Cox proportional-hazards analysis; with survival in the hypertonic saline solution group [34%] vs lactated Ringer's solution group [12%]).
not found|Overall adherence,adherence and adherence levels,depressive psychopathology,adherence,completion of 28 days of PEP|The intervention was associated with the reading of the pamphlet (p=0.07) and an increased use of the diary (p=0.01), but did not reduce depressive psychopathology.
55|adverse response,incidence of later candidiasis|No adverse response to ceftazidime was noted, and the incidence of later candidiasis was similar to that after other broad-spectrum antibiotic combinations.
not found|efficacy and tolerability,extrapyramidal symptoms,Barnes Akathisia Scale,mean change in Simpson Angus Scale,Clinical response|Olanzapine was superior to conventional neuroleptic haloperidol in treatment safety with lower frequency and severity of extrapyramidal symptoms.
not found|postexercise pulmonary capillary blood volume,forced vital capacity and peak expiratory flow rates,FEV1 (PD20,morbidity,Pulmonary function,forced expiratory volume in 1 s (FEV1,index of asthma lability,urinary sodium excretion,pre-exercise (baseline) pulmonary function,preexercise pulmonary function values,Sodium intake,Spirometry and degree of bronchial responsiveness (methacholine challenge test,mean forced expiratory volume,FEV1,bronchial reactivity and mortality,symptom score,peak expiratory flow rate,bronchodilator consumption,deterioration of post-exercise pulmonary function,Forced expiratory volume in 1 s (FEV1,peak expiratory flow,pulmonary function,Exercise-induced asthma (EIA,bronchial reactivity,forced vital capacity (FVC), forced expiratory flow rate at 25%-75% FVC and peak expiratory flow rate,peak flow rate,mean (SD) urine sodium,Dietary salt, airway inflammation, and diffusion capacity,LSD improved and HSD worsened postexercise pulmonary function values,severity of bronchial asthma,PEF measurements,diary cards to record twice daily peak expiratory flow rates, daily symptom scores, and bronchodilator consumption,Postexercise-induced sputum neutrophil and eosinophil differential cell counts and induced sputum supernatant concentration of eosinophil cationic protein, interleukin (IL)-1beta, IL-8, leukotriene (LT) C(4)-E(4), LTB(4), and prostaglandin D(2,lung function,Bronchial reactivity rose on slow sodium,peak expiratory flow (PEF,postexercise pulmonary function values,PEF or PEF amplitude,deleterious alterations,evening peak expiratory flow rate,Pre- and postexercise spirometry, pulmonary diffusion capacity (DLCO) and its subdivisions, and induced sputum,Regressing PD10 against urinary excretion of electrolytes|Median differences between treatments were 5.6% (2.2% to 9.8%) for morning and 7.8% (3.9% to 12.9%) for evening peak expiratory flow rate.
133|shorter operative time,peri-operative outcome index, delayed union, revision surgery and symptoms beyond 16 weeks,smaller wound size,lower complication rate,rate of delayed union,mean shoulder score|The superior plate group had a higher rate of delayed union and had more symptomatic patients than the 3D group (p < 0.05).
not found|sleep bruxism and tooth-grinding activity,pain,efficacy and safety,Clicking and pain,SB outcome variables,signs and symptoms of temporomandibular disorders,wear facets,number of sleep bruxism episodes,sleep bruxism motor activity,number of SB episodes,Sleep variables, bruxism-related motor activity, and subjective reports (pain, comfort, oral salivation, and quality of sleep,signs and symptoms of TMD,pantographic reproducibility index (PRI,number of bruxism episodes per hour of sleep (Epi/h), the number of bursts per hour (Bur/h), and the bruxism time index,muscle activity,nocturnal bite plate,sleep bruxism,prevalence of TMD|A significant reduction in the number of sleep bruxism episodes per hour (decrease of 42%, P < .001) was observed with the MOS.
294|episodes of major bleeding,therapeutic efficiency,frequency of hemorrhagic complications,recurrent thromboembolic events,Recurrent venous thromboembolism,MVO,hemostatic system activation,Overall mortality,Clinical pulmonary embolism,safety and efficacy,fatal pulmonary embolism,complete lysis,incidence of serious complications,Retroperitoneal or intramuscular bleedings,recurrent venous thromboembolism,bleeding complications,Recurrence or extension of DVT,Average treatment costs,pulmonary embolism,pulmonary embolism (LH) and only 1 minor bleeding episode (UH,rate of new pulmonary embolism,efficacy and safety,major bleeding,initial anticoagulant response,Pain and edema,hemorrhagic complications,median improvement of MVO and VC,Minor bleedings,rate of symptomatic pulmonary embolism,thrombus size,therapeutic anticoagulant response,Maximal Venous Outflow (MVO,hospital stay,D-dimer,symptomatic non-fatal pulmonary embolism and one major bleeding episode,Major bleeding,Hospital stay,non-fatal pulmonary emboli,Thromboembolic complications,deep vein thrombosis,incidence of major bleeding,incidence of pulmonary embolism and of bleeding complications,thrombosis of deep veins of the lower extremities,recurrent or extension of DVT, bleeding, the number of days spent in hospital, and costs of treatments,mean phlebographic score,Bleedings|Hospital stay in patients treated with LMWH was 1.2+/-1.4 days in comparison with 5.4+/-1.2 in those treated with standard heparin.
not found|Rates of depression,Edinburgh Postnatal Depression Scale, the Beck Depression Inventory, and the Hamilton Depression Rating Scale,Clinical Global Impression (CGI) and the Hamilton depression scale measured recovery,maternal mood and mother-infant interaction|The interpersonal psychotherapy treatment group showed significant improvement compared to the parenting education control program on all three measures of mood at termination.
82|renal damage,median urinary albumin:creatinine ratio,Myocardial injury,rates of renal impairment or major adverse cardiac events,Preoperative urinary RBP,myocardial injury,myocardial infarction,urinary biomarkers of renal injury,saccadic latency deterioration,Urinary retinol binding protein (RBP) levels,cardiac troponin,saccadic latency deteriorations,renal impairment,incidence of myocardial injury,Urinary retinol binding protein (RBP) and albumin-creatinine ratio (ACR,renal injury,postoperative myocardial injury, myocardial infarction, and renal impairment,median urinary RBP level,serum troponin,median urinary RBP,renal outcome indices,protective effect of RIPC on myocardial injury,Serum and urinary markers of renal and cardiac injury,incidence of myocardial and renal injury|In patients undergoing elective open abdominal aortic aneurysm repair, RIPC reduces the incidence of postoperative myocardial injury, myocardial infarction, and renal impairment.
68|Global VAS pain scores,Pain scores,quality of postoperative analgesia,analgesia,visual analogue scale (VAS,Supplementary analgesic consumption,pain level, amount of oral intake, or pain on full jaw opening,postoperative pain relief,pain scores (VAS,pain medication,Cumulative acetylsalicylic acid requirements,Visual analogue pain scores,Pain relief,pain,postoperative analgesic consumption,pain scores,adverse effects,postoperative pain,pain level; (2) oral intake; (3) number of pain medication doses; and (4) level of pain on jaw opening|Global VAS pain scores were lower in the groups treated with bupivacaine infiltration during the first 24 h after surgery (P < 0.05).
not found|number of high-risk|The option of telephone notification significantly increased the proportion of youth who received posttest counseling and results following community-based testing.
141|relapses of oropharyngeal candidiasis,dysphagia,soreness, change in taste, erythema, removable white plaque, and extent of lesions,Prophylaxis failure due to recurrent or refractory mucosal candidiasis,oropharyngeal candidiasis,Clinical side effects,esophageal lesions,Oral candidiasis score,toxicity (rash,alcohol consumption,Clinical and renal toxicity,mycological success,clinical response,clinical cure,eradication rate with nystatin,rate of fungal infection,oropharyngeal and esophageal candidiasis,Adverse events,oropharyngeal and/or esophageal candidiasis, and the rate of post-treatment relapse,Drug tolerability,Oropharyngeal candidiasis,Resistance,Clinical success,relapses and colonization,Candida albicans carriage,Absolute risk reduction,Dermatophytosis and onychomycosis and cryptococcuria,oropharyngeal candidiasis relapses,time to recurrence of oral candidiasis,seven with oesophageal candidiasis,Clinical cure,oral candidiasis,rates of colonization,initial outbreak or recurrence of oral candidiasis,frequency of episodes of oral candidiasis,efficacy and toxicity,complete response (clearance of all symptoms and signs) or marked improvement,time to development of a fluconazole-refractory infection,safety and effectiveness,Clinical failure,clinical response rates,clinical success (cure or improvement,vaginal candidiasis,history of oral candidiasis,efficacy,transient rises in alanine or aspartate aminotransferase,resistance,nausea, two hepatotoxicity and one rash,time to oral candidiasis, as determined by potassium hydroxide (KOH) smear and fungal culture,efficacy and safety,clinical cure, colonization at the end of treatment, relapse at day 28, and relapse,relapse-free,candidiasis on gingiva,time of recurrence; frequency of antifungal therapy,survival,recurrence of oropharyngeal candidiasis,higher clinical and mycological cure rates,frequent relapses of oral candidiasis,microbiological resistance,gastrointestinal disorders and drug-related adverse events,median annual relapse rates,fluconazole-refractory OPC or EC infections,tolerated,Mild adverse events,clinical response rate,microscopy, time to cure, symptom scores, and safety outcomes,efficacy and tolerance,liver enzyme values,delayed time to onset of histoplasmosis,rate of relapse,OPC or EC,Durability of clinical success,delaying onset of oral candidiasis,Safety and efficacy,severe chills,maintenance of oral candidiasis-free period,percentage of patients with negative cultures,episodes of Candida esophagitis,clinical relapse of oropharyngeal candidiasis,lower response rate,time to development of fluconazole-refractory OPC or EC,CDC classification, CD4+ cell counts, and number of previous episodes of oropharyngeal or esophageal candidiasis,Mean rates of infection relapse,severe nausea,proportion of resistant isolates,Efficacy, tolerability and development of resistance,likely to remain asymptomatic,Clinical tolerance (fever, chills, sweats, nausea, arterial pressure, and pulse rate); biological tolerance (serum creatinine, electrolyte, and magnesium values); clinical score of candidiasis; and serum concentrations of amphotericin,clinical efficacy and tolerability,esophageal candidiasis,clinical relapse,episodes of orophayngeal candidiasis (OPC) or esophageal candidiasis (EC,histoplasmosis and cryptococcosis,CD4 count,survival benefit,Oropharyngeal infection,treatment creatine concentration,side effects (diarrhea and abdominal pain,35 episodes of thrush, one of esophagitis, one of cryptococcemia, and one of dermatophytosis, and preexisting dermatophytosis and onychomycosis,Severity of disease,fungal colonization,Serum amphotericin concentrations,Negative culture plus clinical response,tolerance, efficacy, and pharmacokinetics,oropharyngeal candidiasis (erythema, soreness/burning), extent of oral lesions, and the presence/absence of Candida species on fungal culture,Candida albicans, maximum recorded plasma D0870 concentration, cfu of culture or CD4 cell count,occurrence of oral candidiasis,Failure of prophylaxis,efficacy, safety, and tolerability,safety and efficacy,episode of candidiasis,Microbiological resistance,elevated serum glutamic-oxaloacetic transaminase levels,median time to relapse,bioavailability of itraconazole,safe and effective in preventing oropharyngeal and vaginal candidiasis,resolution of clinical lesions of oral candidiasis,relapse,Efficacy,rates of clearing of infection,invasive fungal infections,Magnesium concentration,total lymphocyte|Patients enrolled in this study had a very high mortality (probability of death: 41.6% after 14 days).
645|Survival after relapse,isolated pelvic recurrence,Endometrial-cancer-related death rates,gastrointestinal toxic effects,Late intestinal problems,disease-free survival,quality of life,5-year survival rate,rates of locoregional relapse (vaginal or pelvic recurrence, or both,median duration,toxicity, date and location of recurrence, and overall survival,Estimated 5-year rates of vaginal recurrence,locoregional recurrence and death, with treatment-related morbidity and survival after relapse,vaginal recurrence,distant metastases,pelvic and vaginal recurrences,Dysuria, frequency, and incontinence,estimated 4-year survival,rates of distant metastases,Treatment-related complications,2-year cumulative incidence of recurrence (CIR,vaginal recurrences,risk of recurrence and death,2-year survival after vaginal recurrence,5-year actuarial locoregional recurrence rates,Rates of acute grade 1-2 gastrointestinal toxicity,locoregional recurrence rate,overall survival,deaths and recurrences,overall recurrence rate and survival,locoregional control and survival,5-year,vaginal and pelvic recurrences,locoregional recurrence,rate of vaginal recurrences,Actuarial 5-year overall survival rates,Grade 3-4 complications,Side effects|The rate of vaginal recurrences was 1.2% in the treatment group versus 3.1% in the control group.
160|incidence of maternal and neonatal complications,incidence of respiratory distress syndrome,proven sepsis,endometritis rate,duration of hospitalization and infection,postpartum febrile morbidity,risk of maternal infections,mean birth weights, perinatal death rates, neonatal infections, or incidences of respiratory distress,Neonatal morbidity,incidence of chorioamnionitis and antepartum hospitalization,Maternal outcome, including chorioamnionitis and cesarean section rates,pregnancy outcome (ie, birth weight, intraventricular hemorrhage, necrotizing enterocolitis, sepsis, respiratory distress syndrome, and perinatal death,hospitalization,chorioamnionitis and fetal heart rate abnormalities,Chorioamnionitis,frequency of prolonged hospital stay,prolonged latencies to labor, delivery, and maternal hospitalization,ultrasonographically estimated fetal weight,mean gestational ages at delivery,overall corrected perinatal survival,maternal hospital stay,prolonged antimicrobial therapy,hospitalization, assessment for fetal heart rate abnormalities, chorioamnionitis, and labor,maternal age, gestation at PROM, maximum maternal temperature, birth weights, maternal hospital days, respiratory distress, maternal sepsis, or delivery routes,Antepartum hospitalization,Neonatal sepsis|Neonatal outcome did not differ in mean birth weights, perinatal death rates, neonatal infections, or incidences of respiratory distress.
not found|episodic memory performance,Questionnaires assessing mood, quality of life and career strain, and a brief neuropsychological test battery,episodic memory, perceived burden or depressive symptoms,recall of personal information, face-name recall, and performance on the Verbal Series Attention Test,memory and functional performance,goal performance and satisfaction, assessed using the Canadian Occupational Performance Measure,depressive symptoms,hostility,negative coping strategies,completed activities of daily living (ADLs) and everyday memory questionnaires,brain function,additional neuropsychologic measures of dementia severity, verbal memory, visual memory, word generation, or motor speed, or to caregiver-assessed patient quality of life,Behavioral changes,ratings of goal performance and satisfaction,Cognitive, behavioural and functional assessment,Gains in recall of face-name associations, orientation, cognitive processing speed, and specific functional tasks,improvement over time in cognitive outcomes,Cognitive rehabilitation,recall and recognition of test material,cognitive and behavioral functioning,cognitive and behavioral performance,memory, verbal fluency, and problem-solving ability, and caregivers were assessed on marital interaction, emotional status, and physical health, along with stress, coping, and social support,face-name association tasks, object recall training, functional tasks (e.g., making change, paying bills), orientation to time and place, visuo-motor speed of processing, and the use of a memory notebook,specific cognitive and functional tasks,regional cerebral metabolic rate for glucose using positron emission tomography and 18F-2-fluoro-2-deoxy-D-glucose|The results showed that following collaborative intervention recall performance in two collaborative tasks became more equally shared between the spouses, reflected in a decrease in recall for the caregiver and in an increase in recall for the spouse with dementia between pre- and post-test; whereas for the other two groups the caregivers dominated collaborative recall both at pre- and post-test.
not found|sustained attention and visual and movement skills,efficacy and safety,cognitive functions of visual sustained attention and visual and movement skills,Positive and Negative Symptom Scale ratings,tolerated without any serious adverse effects,clinical symptoms, side effects, and quality-of-life scores|Compared with placebo, DHEA administration did not produce significant improvement in clinical symptoms, side effects, and quality-of-life scores.
40|Brunnstrom stages of motor recovery, spasticity assessed by the Modified Ashworth Scale (MAS), walking ability (Functional Ambulation Categories [FAC]), and motor functioning (motor items of the FIM instrument,Fugl-Meyer assessment score in the wrist, hand and coordination, as well as power of wrist,grip force, spasticity, pain, dexterity, hand-use in daily life, and quality of life,neural activation patterns,scores of the Brunnstrom stages for the hand and upper extremity and the FIM self-care score,Fugl-Meyer motor assessment (FMA,distal function,FIM motor score,pain and enhances upper limb motor function,recovery of surface sensibility,sensory and attentional deficits,FAC,power of hand flexion, wrist flexion, and wrist extension,motor recovery,motor function as assessed by the Wolf Motor Function Test and Motor Activity Log.,Brunnstrom stages of motor recovery, spasticity assessed by the Modified Ashworth Scale (MAS), and hand-related functioning (self-care items of the FIM instrument,Motor recovery and cortical reorganization,Fugl-Meyer scores of hand, wrist, coordination and power of hand extension,Muscle tone, Fugl-Meyer assessment, and power of wrist and hand,FMA,activation balance,Muscle tone,visual analogue scale score of pain at rest, on movement, and brush-induced tactile allodynia,blinded rating on the Action Research Arm test|Mirror therapy combined with a conventional stroke rehabilitation program enhances lower-extremity motor recovery and motor functioning in subacute stroke patients.
63|radiological evidence of new scars of pyelonephritis,rate of persistent infection,Recurrent infection,clinical pyelonephritis,children renal growth|Recurrent infection in the treated group was common and was not significantly different from the rate of persistent infection in the untreated control group.
888|pain reduction,several quality-of-life measures,Fibromyalgia Impact Questionnaire pain score, BPI least pain score and average interference score, Clinical Global Impressions of Severity scale, area under the curve of pain relief, Multidimensional Fatigue Inventory mental fatigue dimension, Beck Depression Inventory-II total score, and 36-item Short Form Health Survey mental component summary and mental health score,safe and efficacious,Fibromyalgia Impact Questionnaire (FIQ,nausea, headache, constipation, dry mouth, dizziness, diarrhea, and hyperhidrosis,BPI average pain severity, patient-rated scales assessing mood, anxiety, pain, sleep, and stiffness, Clinical Global Impression of Severity (CGI-S), Multidimensional Fatigue Inventory, Cognitive and Physical Functioning Questionnaire, Beck Depression Inventory (BDI), Beck Anxiety Inventory, and Medical Outcome Study Short-Form Health Survey (SF-36,adverse events, and changes in vital sign, laboratory, and ECG measures,physical function on the Short Form 36 (SF-36) physical component summary (PCS) score,BPI score,PGI-Improvement,Brief Pain Inventory (BPI) average pain severity score and Patient Global Impressions of Improvement (PGI-I) score,fatigue (Multidimensional Fatigue Inventory,Overall discontinuation rates,nausea,vital signs, laboratory measures, or ECG measures,pain intensity,rates of FM composite responders and FM pain composite responders,remaining Brief Pain Inventory pain severity and interference scores, Fibromyalgia Impact Questionnaire, Clinical Global Impression of Severity, Patient Global Impression of Improvement, and several quality-of-life measures,Nausea,pain severity,adverse events,Multidimensional Fatigue Inventory total score,effective and safe,headache,mood, stiffness, fatigue and functioning,FM pain composite responders,Fibromyalgia Impact Questionnaire (FIQ) total score (score range 0-80, with 0 indicating no impact) and FIQ pain score,fibromyalgia (FM) symptoms assessed by the Patient Global Impression of Improvement (PGI-I) scale,SF-36 Mental Component Summary,number of tender points,Efficacy and safety,PGIC,fatigue,Safety,nausea and headache,pain, global status, fatigue, and physical and mental function,mean tender point pain threshold, number of tender points, FIQ fatigue, tiredness on awakening, and stiffness scores, Clinical Global Impression of Severity (CGI-Severity) scale, Patient Global Impression of Improvement (PGI-Improvement) scale, Brief Pain Inventory (short form), Medical Outcomes Study Short Form 36, Quality of Life in Depression Scale, and Sheehan Disability Scale,fibromyalgia symptoms and pain severity,efficacy and safety,constipation,global improvement with mean PGI-I scores,visual analog scale, 24-hour morning recall) and a rating of "very much" or "much" improved on the Patient Global Impression of Change scale,CGI-Severity,Patient Global Impression of Change [PGIC] scale); and physical function (a > or = 6-point improvement on the 36-item Short-Form Health Survey [SF-36] Physical Component Summary score,safe and well tolerated,pain and other symptoms,global status,24-hour and weekly recall pain score, PGIC score, SF-36 PCS and mental component summary scores, average pain severity score on the Brief Pain Inventory, Fibromyalgia Impact Questionnaire total score,FIQ pain score,Adverse events,Brief Pain Inventory (BPI) average pain severity,FIQ total score,mean tender point pain threshold,efficacy and tolerability,Brief Pain Inventory average pain severity score,pain,overall improvement,physical function (SF-36 physical functioning domain-100,Multidimensional Fatigue Inventory,Significant pain reductions,tolerated,pain (visual analog scale 24-h morning recall), patient global impression of change (PGIC), and physical functioning (SF-36 Physical Component Summary,FIQ stiffness score,pain (realtime, daily and weekly recall,Brief Pain Inventory average interference from pain score,FM composite responders,BPI average pain severity, mood (including BDI total), anxiety (patient-rated only), stiffness, CGI-S, fatigue, all SF-36 domains (except role-physical and physical component summary), and being less bothered by pain or sleep difficulties,Multiple Ability Self-Report Questionnaire,pain score and a rating of "very much improved" or "much improved" on the Patient's Global Impression of Change (PGIC) scale,safe and well tolerated; nausea, hyperhidrosis, and headache,Short-Form 36 Health Survey (SF-36) Physical Component Summary|Milnacipran was safe and well tolerated by the majority of patients during 27 weeks of treatment; nausea and headache were the most common adverse events.
not found|efficacy and safety,voice alteration and dyspnea,physiologic indicators of gastric, cardiac, or pulmonary functions occurred,total seizure frequency,global evaluation scores,seizure counts and safety|No changes in physiologic indicators of gastric, cardiac, or pulmonary functions occurred.
not found|pain relief,subjective pain relief and appreciation of improvement of mobility,mobility,pain and improved mandibular function,MFIQ, VAS, maximum opening and protrusion, lateral joint tenderness, muscle tenderness, crepitation, and clicking,arthroscopic lysis and lavage (ALL,Joint tenderness and pain on lateral palpation,pain control,Craniomandibular Index (CMI) and Symptom Severity Index (SSI) for jaw function and TMJ pain respectively,pain, mobility, and functional ability,pain, joint noise, jaw mobility, and dietary alterations,maximum incisal opening and pain scores; the overall success rate,severity of pain,Therapeutic success,function and diminishing pain,functional result and in pain control,visual analog scale (VAS) for pain and a mandibular functional impairment questionnaire (MFIQ,pain and function,joint tenderness,visual analog scale for pain and a questionnaire concerning mandibular functional impairment,maximum interincisal opening and protrusion, recording of clicking and crepitation, and palpation for tenderness of the TMJ and jaw muscles,interincisal opening, lateral excursions, occlusal evaluation, deviation on opening, and tenderness to palpation,muscle tenderness and pain,pain|Both groups had significantly less pain in the joint and better jaw opening one year postoperatively.
30|seriously ill or depressed, and average coping and quality of life scores,changes in life satisfaction, perceived health, and number and severity of symptoms,relieving pain,abnormal stool frequency,life satisfaction and symptoms,Life satisfaction,HIV-1 RNA level,abnormal stool frequency of three abnormal stools,adherence, and changes in weight, CD4+ count, depression, anxiety, physical and social function, and mental health,safety and efficacy,dropout rate,serious adverse events or laboratory abnormalities,severe side-effects,quality of life, clinical manifestations, plasma virus loads, or CD4 cell counts,Efficacy and safety,toxicities,safety and effectiveness,CD4 cell count,median HIV-1 plasma viral loads,mild adverse events (AE,stool weight,rate of disease progression,pain intensity, pain relief, sensory perception, quality of life, mood, and function,efficacy and safety,median CD4 cell counts,plasma viral loads, CD4 cell counts, symptoms, and psychometric parameters,safe and well tolerated,Number of symptoms,life satisfaction or symptoms,gastrointestinal disturbances,current pain scores,current pain, worst pain, pain relief, sensory perception, quality of life, mood, or function at study entry or at any time,Symptoms, HIV disease progression, HIV-1 RNA plasma viral loads, CD4 and CD8 cell counts, and scores on standard questionnaires for quality of life, depression, anxiety, and coping,stool weight and frequency,viral load,mean reduction from baseline stool weight,therapeutic failures,Stool frequency and weights|Number of symptoms was reduced in subjects receiving herbs (-2.2, 95% CI -4.1, -0.3) but not in those receiving placebo (-0.3, 95% CI -3.2, +2.7).
4|mean frequency of the target behavior,target behavior,reading condition (B) and the singing condition (C|The singing condition was significantly more effective than the reading condition only in Case Study III.
58|survival,groin relapses,excessive number of groin relapses,progression-free interval,Metastatic involvement of the groin nodes|The groin dissection regimen had significantly better progression-free interval (p = 0.03) and survival (p = 0.04).
32|endoscopic and histologic remissions,acute response and safety profile,clinical and endoscopic activity,laboratory variables and vital signs,clinical and endoscopic remission,Median DAIs,Haematology, chemistry and adverse events,sigmoidoscopic remission,Mean disease activity index,Histologic activity,Clinical remission rates,Distal ulcerative colitis,Clinical remission,liquid stools,Histological Index,frequency of patients with an endoscopic remission,active ulcerative proctitis,tolerated and produced earlier and more complete relief of rectal bleeding,determination of clinical, endoscopic, and histologic remission rates,physician-rated Disease Activity Index (DAI), which included symptom evaluations and sigmoidoscopic findings, by physician-rated Clinical Global Improvement (CGI) scores, and by Patient Global Improvement (PGI) scores,anal burning,A disease activity index (DAI,histologic remission,clinical and sigmoidoscopic remission,adrenal function, monitoring of adverse events, vital signs, and laboratory parameters,Symptoms,clinical remission (clinical activity index,clinical score,adverse events,morning cortisol levels,treatment tolerability and acceptability,CGI scores,tolerability and efficacy,endoscopy and histopathology scores,rate of histologic remission,Endoscopic remission rates,distal ulcerative colitis,Remission rates,Disease Activity Index,Compliance,Mean DAI scores,BDP and 5-ASA,disease status,efficacy,mesalazine enema (Disease Activity Index,efficacy and safety,amount of blood in stools, urgency, straining at stools, and abdominal pain in daily diaries,complete clinical remission,total DAI scores,Disease Activity Index (DAI,Endoscopic remission,remission rates,efficacy and tolerability,Disease Activity Index (DAI) score,rectal bleeding,tolerated,Side effects,quicker clinical and sigmoidoscopic remission,efficacy, tolerability and overall acceptability,Very Much Improved" or "Much Improved,Adverse events, primarily headache and nausea,efficacy, tolerance, and acceptance,Clinical Activity Index, Endoscopic Index, Histological Index, and global efficacy assessment,sigmoidoscopic and improved histological score,efficacy, tolerance and acceptance,Safety and efficacy,abdominal bloating,complete relief of symptoms, and endoscopic and histological evidence of remission or improvement,Disease Activity Index value,Remission,practicality and patient compliance,disease activity index, which represents a score with four variables: stools frequency, rectal bleeding, mucosal appearance, and physician's assessment of disease severity,efficacy, safety and patient tolerability,clinical activity,Clinical improvement, remission and relapse,discomfort,daily evacuations more than usual, evacuations containing blood, sigmoidoscopy appearance, and physician's overall assessment,sigmoidoscopic and histological remission rates,median duration of response to alicaforsen enema treatment,distal ulcerative colitis, proctosigmoiditis, and proctitis,clinical remission; endoscopic remission, histological changes, global assessment and standard safety measures,absence of blood in stools,Recovery,Complete mucosal healing,severe discomfort, pain and retention problems,difficulty in retention,Endoscopic, clinical, and histologic improvement,adverse event reports, clinical laboratory tests, and physical examination,clinical remission,Efficacy and tolerability,Clinical symptoms, endoscopic and histological findings,Histological remission,DAI score,clinical remission rate,tolerability and practicality,endoscopic and histological evaluation of colonic mucosa,side effects,time of initial presentation, symptom resolution, and endoscopic and histologic improvement,symptoms (number of bowel movements per day, quality of stools, presence of blood and mucus, and state of well-being,disease activity index scores,absorbed radioactivity,Disease activity,Improvement or remission,mean disease activity index score,safety profile,PGI ratings,tolerability and safety,Efficacy,Total DAI scores and abbreviated DAI scores,recording of adverse events, laboratory variables and vital signs|At the end of the study 5-ASA suppositories showed significantly better results in all the parameters recorded than placebo (p less than 0.01).
45|pain (visual analogue scale,duration of pain relief,disability,duration of sick leave,pain, muscular contracture and mobility,cost-effectiveness ratio for pain, disability, and quality of life,immediate lessening of pain,pain relief,effectiveness and cost-effectiveness,median duration of pain,clinical effectiveness and cost-effectiveness,low back pain (visual analogue scale,median intensity of pain|Moreover, neuroreflexotherapy intervention was associated with a significantly (P < 0.035) lower number of consultations to private or public specialists, fewer indications of radiographs by primary care physicians, lower cost of drug treatment, and less duration of sick leave throughout the follow-up period.
56|severe post-concussion symptoms,Rivermead head injury follow up questionnaire, a validated and reliable measure of social disability,emotional distress and how well-informed they felt about TBI and available resources,difficulties with everyday activities,injury severity and shorter hospital stay,levels of distress,activity level,indices of socializing, productive employment, anxiety, or depression,Functional Independence Measure (FIM), Brunnstrom stages of motor recovery, timed mobility tasks, and the Jebson hand evaluation,functional independence measure and the functional assessment measure (FIM+FAM,length of stay,social disability,General Health Questionnaire,social morbidity and severity of post-concussion symptoms,Functional Independence Measure (FIM) (primary outcome) and Neurobehavioural Cognitive Status Examination (NCSE) total scores,maximum Glasgow Outcome Scale (GOS) score,hospital anxiety and depression scale,Ashworth Scale, motor status with Brunnstrom's stages, functional status with the FIM instrument, and cognitive status with the Mini-Mental State Examination,longer hospital stay,Barthel index (BI) and the brain injury community rehabilitation outcome-39 (BICRO-39)) focused on levels of activity and participation,cognitive, behavioral, or quality-of-life measures,activity, assessed with the Assessment of Motor and Process Skill,Spasticity,index of activities of daily living,BI and the BICRO-39 total score and self organisation and psychological wellbeing subscales,motor, functional, and cognitive outcomes,Spasticity changes,level of depression, self-esteem, and socialization,greater return-to-duty rate,Defense and Veterans Head Injury Program (DVHIP,shorter length of hospital stay,average length of stay,maximum FIM total score,socialization and self-esteem,elicit ratings of post-concussion symptoms (the Rivermead postconcussion symptoms questionnaire), and changes in work, relationships, leisure, social, and domestic activities (the Rivermead head injury follow up questionnaire,Barthel index, the Functional Independence Measure (FIM), and the Newcastle Independence Assessment Form (NIAF,Median changes on individual subscales,rate of PCS and in life satisfaction|The different intensities of therapy employed in this study showed no evidence of a 'ceiling' effect and the 'intervention group' made significantly more rapid progress on tests of dependency during the period of admission.
53|Body weight, IRI and GPP,lipid, carbohydrate and coagulation profiles,haemostatic indices,mild insulin resistance,Levels of fibrinogen, plasminogen, Factor VII, Factor X and antithrombin III,free thyroxine levels,Markers of lipid, carbohydrate and coagulation profiles,HDL-cholesterol changes,Lipid and biochemical changes,triglyceride levels,Hemostatic and metabolic effects,triglycerides,hemostatic balance, lipid metabolism and glucose tolerance,mean plasma glucose levels,tolerated and equally efficacious regarding contraception and cycle control,fasting serum glucose; insulin; triglycerides and total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol,blood glucose levels,fasting samples and plasma samples,fasting and 2-hour glucose, triglycerides, total cholesterol, HDL-cholesterol, bilirubin, alkaline phosphatase, albumin, and total protein, but not aspartate aminotransferase,total, high-density lipoprotein (HDL) and low-density lipoprotein cholesterol and triglycerides,Fasting glucose levels,carbohydrate metabolism,triglycerides, HDL-cholesterol and apoprotein A1,Total cholesterol and HDL cholesterol,insulin response,carbohydrate metabolism and adrenal and thyroid function,antithrombin III, total and free protein S and fibrinogen,withdrawal bleeding episode,Blood glucose, serum insulin, serum growth hormone and serum glycosylated proteins,hemostatic measurements, lipid profile, glucose tolerance and adverse events,LDL cholesterol,Thyroid stimulating hormone levels,Levels of dehydroepiandrosterone sulfate,percentages of normal menstrual cycles and the percentages of cycles with intermenstrual and withdrawal bleeding,insulin,Mean ± SD LDL cholesterol,apoprotein A1 (Apo-A1,Adverse events,insulin secretion,glucose response,metabolic and hemostatic effects,response of C-peptide to glucose,fasting insulin and fasting C-peptide levels,relative hyperglycemia,Serum cholesterol levels,oral glucose load (2-hours) levels of serum insulin, growth hormone, glucagon, cortisol and blood pyruvate,Metabolic and haemostatic effects,Blood glucose and pyruvate, plasma insulin, and glucagon levels as well as erythrocyte insulin receptors,carbohydrate parameters,lipid profile,SHBG increased 3-fold with DSG-OC,mean levels of fasting insulin and C-peptide,blood pressure, body mass, blood glucose and serum triglycerides,lipids, hemostatic parameters and carbohydrate metabolism,haemostasis, lipids and carbohydrate metabolism,mean body weight,renin substrate and hemostatic parameters,carbohydrate and lipid metabolism,BFG,carbohydrate metabolism (glucose, insulin, glycosylated hemoglobin); adrenal function (total cortisol, cortisol binding globulin, dehydroepiandrosterone sulfate); thyroid function (thyroid stimulating hormone, free thyroxine,antithrombin III levels,fasting glycosylated hemoglobin,lipid parameters, haemostatic parameters, sex hormone-binding globulin (SHBG), cortisol-binding globulin (CBG), carbohydrate metabolism parameters, blood pressure and body weight,mean intraindividual relative changes from baseline to cycle 7 in high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol levels,triglyceride and glucose concentrations,Pancreatic beta-cell function,All blood glucose and insulin values,serum resistin and insulin levels,carbohydrate metabolism, adrenal and thyroid function,LDL-C,mean insulin levels,SI decreased during OCs,carbohydrate metabolism, adrenal or thyroid function,mean levels of fasting glucose and insulin,procoagulant and profibrinolytic parameters,SHBG,mean blood glucose and pyruvate and in mean serum insulin, growth hormone and glucagon,total insulin area,free androgen and dehydroepiandrosterone sulfate levels,serum resistin level,area under the curve for both glucose and insulin,High-density lipoprotein (HDL) cholesterol (p=.02) and triglycerides,Concentrations of cortisol binding globulin and total cortisol,apolipoprotein B levels,Triglycerides,glucose or insulin levels,glucose and triglyceride,plasma cholesterol, lipoproteins including HDL subfractions, triglycerides or glucose concentration,change in glucose,A(1)C levels,incidence of adverse events,insulin sensitivity index (IS(OGTT,total, HDL and LDL cholesterol and SGOT,cholesterol concentration,lipid, hemostatic or carbohydrate parameters,efficacy and tolerability,blood pressure,haemostasis, lipids, carbohydrate metabolism, C-reactive protein (CRP) and sex hormone-binding globulin (SHBG,SI modifications,rise in bilirubin,tolerated,carbohydrate metabolism and liver function,glucose metabolism and liver function,alkaline phosphatase,enzyme serum levels,Basal insulin resistance (HOMA-IR,Body weight and blood pressure,SI and glucose utilization independent of insulin (Sg,glucose tolerance,Insulin sensitivity and lipid metabolism,metabolism and coagulation proteins,insulin sensitivity (SI,Mean ± SD prothrombin fragment 1 + 2 and D-dimer levels,metabolic effects,systolic and diastolic blood pressure or blood glucose levels,circulating levels of resistin,LNG-OC decreased HDL(2)-C and increased HDL(3)-C; HDL-C,mean AUCs,LNG/EE high-density lipoprotein cholesterol decreased and low-density lipoprotein cholesterol and triglycerides,body weight, dietary habits, blood pressure, HDL-cholesterol or carbohydrate metabolism,area under the curve (AUC) for glucose,adverse metabolic effects,euglycemic glucose clamp test; lipid metabolism,risk of diabetes or cardiovascular disease,total cholesterol, HDL and triglycerides,total cholesterol,mean index for insulin resistance (homeostasis model assessment of insulin resistance, HOMA-IR,SI,cycle control,SI decreased with EE/DSG,carbohydrate metabolism and its hormonal profile,Serum resistin levels,HDL fractions,change from baseline to cycle 6 for all indices,hemostatic balance, blood lipid levels and carbohydrate metabolism,Coagulation factor VII and fibrinogen,fasting glucose and insulin levels,plasma total cholesterol, LDL-cholesterol, LDL/HDL-cholesterol ratio and triglyceride concentration,Glucose tolerance and insulin secretion,mean levels of HbA1c and fasting glucose levels,Body weight, fasting blood glucose (GP) (BFG), serum immunoreactive insulin (IRI), serum growth hormone (GH) and serum glycosylated proteins,blood glucose and C-peptide levels,metabolic and haemostatic parameters,total cholesterol, HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol, and triglycerides,coagulatory activity,fasting blood glucose levels,2-hour blood glucose and pyruvate, serum insulin, growth hormone and glucagon,mean glucose, insulin and log homeostatic model assessment,Hemostatic activity,hepatic-induced parameters (SHBG, CBG) and carbohydrate metabolism,serum triglycerides,SBP and CBG,HDL/low-density lipoprotein cholesterol,Glycosylated hemoglobin,HDL-cholesterol,Free fatty acid levels,fasting blood glucose and pyruvate and serum insulin,LDL-cholesterol,glucose and increased insulin responses,atherogenic index, LDL/HDL cholesterol,glucose and insulin parameters,fasting glucose and insulin levels and in glucose rate of disappearance,C-peptide/insulin response,changes in other lipid, hemostatic and carbohydrate parameters,lipid markers,glucose tolerance and insulin resistance,total cholesterol, HDL-cholesterol, and VLDL-cholesterol,fasting plasma glucose values,hemoglobin, hematocrit and total protein levels but alkaline phosphatase, bilirubin and aspartate transaminase (SGOT,serum glucose levels,Factor X. Mean blood pressure fell,Mean ± SD HDL cholesterol,metabolic and haemostatic effects,VLDL-C and triglycerides,high-density lipoprotein (HDL)- and low-density lipoprotein (LDL)-cholesterol levels,DSG-OC increased HDL-C, HDL(2)-C and HDL(3)-C; LDL-C,Fasting blood glucose,C-peptide and free fatty acid levels,lipid metabolism,Sex hormone binding globulin,number of abnormal parameters,renin substrate,body mass,glucose tolerance and insulin secretion,Carbohydrate metabolism,mean insulin sensitivity index [ISI (composite,cholesterol and LDL-cholesterol,basal hormonal, metabolic and lipid levels,fibrinolytic activity,CRP,Oral glucose tolerance test (OGTT|We found that serum resistin level remained unchanged in women receiving ethinylestradiol/desogestrel and was reduced in women treated with formulations containing gestodene.
not found|psychotic impairments|In some respects the residents of the hostel ward had fewer psychotic impairments than those remaining on the wards of the district general hospital, mainly because the latter seem to continue to acquire such defects, while the former have remained relatively unchanged.
11|passage of flatus or stool and tolerating solid food,Frequency of gastritis and esophagitis,laxation and reverse slowing of oral cecal-transit time,nausea, vomiting, and constipation,maximum concentration or area under the concentration curve,BM,Maximum concentrations and area under the concentration curve,small-bowel and colon transit,morphine-induced subjective rating changes,transit time and the drug plasma concentration,pain intensity and pain bothersomeness ratings,morphine-induced delay in oral-cecal transit time,median times to first BM,Stool frequency and symptoms related to constipation,Gastric emptying, small-bowel, and colonic transit,gastrointestinal motility and transit without affecting analgesia,GI motility,incidence of gastritis and esophagitis,Delayed gastrointestinal transit,risk of vomiting and pulmonary aspiration,Adverse events,Median gastric tube reflux volume,proportion of patients having at least one bowel movement (BM,median time until patients were ready for discharge,Gastrointestinal transit time,overall colonic transit,intestinal hypomotility,gastric reflux,time to GI-2 recovery (toleration of solid food and passage of stool) and hospital discharge order written (DCO,complete reversal of analgesia,rate of gastric emptying,adverse events,morbidity and extend hospitalization,pain relief,colonic transit,duodenogastral reflux,intestinal transit,exhaled H2 concentration,Mean time to the hospital discharge order written,Volume of enteral feeding,Gastrointestinal transit time (lactulose hydrogen breath test,gastral reflux,Morphine analgesia and pupil constriction,colonic transit were geometric center of the colonic counts at 24 hours and time for 50% ascending colon emptying,Laxation response, oral-cecal transit time, and central opioid withdrawal symptoms,gastrointestinal transit,constipation and analgesia,bowel motility and increased transit time,tolerated,restoration of bowel function, and visual analog scales (VAS) for pain during rest and movement,Whole-gut transit time,gastric tube reflux, the frequency of pneumonia, and the time until first defecation,frequent bowel movement and better bowel movement quality,gastrointestinal motility and transit, without affecting analgesia,gastric, small-bowel, and colonic transit time,esophageal or gastral mucosal injuries,Weekly BMs and overall patient satisfaction,nausea, vomiting, and hypotension; the incidence of nausea and vomiting,oral-cecal transit times,analgesic effect,Codeine delayed gastric, small-bowel, proximal, and overall colonic transit,small bowel and colon (ascending colon and overall colonic transit,recovery of gastrointestinal function,analgesia,Analgesia and pupil constriction,bowel motility and analgesia,time to first bowel movement,Postoperative ileus (POI,time to the hospital discharge order written,Pain estimation by visual analogue scale,time to hospital discharge order written,reversal of analgesia,gastrointestinal recovery,median time to the first passage of flatus,Oral-cecal transit time,antagonistic effect,shorter time to the first postoperative passage of flatus,return of pain,Average time to first bowel movement,transit time,hospital stay, contribute to readmission, and increase morbidity,resting or active VAS,laxative effects,median time to the first bowel movement,composite of time to recovery of upper and lower GI function,fentanyl requirements,GI recovery,serum acetaminophen concentrations,safety and efficacy,laxation response,recovery of gastrointestinal (GI) function,accelerated time to GI-2,side effects,time until first defecation, ventilation time, and length of intensive care unit stay,pain score,postoperative pain relief,gastrointestinal motility,mean whole-gut transit time,mean colonic geometric center,gastric tube reflux and frequency of pneumonia,Urgency to defecate,average (SD) change,Plasma concentrations,marked laxative effect,time to gastrointestinal (GI) recovery (measured by toleration of solid food and passage of flatus/stool; GI-3,frequency of pneumonia,bowel frequency,time to return of gastrointestinal function,small bowel transit time (SBTT) measured by the lactulose/hydrogen breath test, pain scores and the occurrence of adverse events,oral-cecal transit time,pain scores,gastric emptying,Time to recovery of GI function,GI recovery and time to hospital discharge,gastrointestinal transit time,Efficacy,adverse effects,Mean time to gastrointestinal recovery|No difference in maximum concentration or area under the concentration curve from 0 to 90 min was noted between placebo and methylnaltrexone coadministered with morphine.
244|risk of pneumothorax,mean total duration of oxygen therapy,length of stay or the duration of oxygen treatment,incidence of pulmonary air-leak,outcome of HMD,mortality, requirement for mechanical ventilation, or incidence of pulmonary sequelae,mean levels,overall survival rate,death, length of nursery stay, time receiving oxygen therapy, cost of care, and other measures of morbidity,mortality, cranial ultrasound abnormalities, and pneumothoraces,chronic lung disease of prematurity,Oxygenation,up-transfer or treatment failure,mechanical ventilation,morbidity or death,Pneumothorax,mortality, respiratory outcome, the presence of cerebral ultrasound abnormalities, patent arterial duct, necrotizing enterocolitis, and retinopathy,mortality and complication rates,neonatal survival rate,total duration of oxygen therapy|Secondary analysis showed that the use of CNEP was associated with an increase in mortality, cranial ultrasound abnormalities, and pneumothoraces, which were not statistically significant.
68|problem solving skills,Wisconsin Card Sorting Test (WCST) performance,task-specific self-awareness, general self-awareness or community integration,CIQ (effect size [ES]=0.59) and PQOL,Rated quality-of-life,productivity,subjects' cognitive functioning,global cognitive functioning,verbal and visual memory functions,WCST performance,NP functioning, perceived self-efficacy, and community-based employment,community functioning and quality of life,change in RBANS total score,cognitive functions,Community Integration Questionnaire (CIQ) and Perceived Quality of Life scale (PQOL,WM and attention,Self-Awareness of Deficits Interview (SADI), the Functional Independence Measure (FIM) and the Lawton Instrumental Activities of Daily Living Score (Lawton IADL,neuropsychological WM-test results,neuropsychological WM-demanding tests, rated occupational performance, satisfaction with performance and rated overall health,Neuropsychological Status (RBANS) and Trail-Making, Controlled Oral Word Association, Wechsler Adult Intelligence Scale-III Similarities, and Stroop tests,cognitive, behavioral, or quality-of-life measures,executive functioning,change in RBANS delayed memory score,standardized measures of 'general' self-awareness with collateral reports by informants (e.g. Awareness Questionnaire); 'task-specific' self-awareness (e.g. Assessment of Awareness of Disability) and Self-Regulation Skills Inventory (SRSI,computerized version of the Paced Auditory Serial Addition Task (PASAT) and two computerized matching tasks,trained WM tasks,level of awareness,self-efficacy,greater return-to-duty rate,sustained moderate or severe TBI,self-awareness,Assessment of Motor and Process Skills (AMPS,RBANS total score,Defense and Veterans Head Injury Program (DVHIP,performance in neuropsychological tests assessing memory and executive functions,daily life functioning,symptoms of cognitive problems,meal preparation performance,Individuals' problem-solving skills and self-efficacy,self-awareness during IADL task performance,IADL performances and self-regulation,Role Resumption List (RRL), and two other follow-up measures, the Treatment Goal Attainment (TGA) and the Executive Secretarial Task (EST), were indications of daily life executive functioning,NP functioning,cognitive outcome,external inhibition, increased stimulus salience|Intensive cognitive rehabilitation participants showed greater improvements on the CIQ (effect size [ES]=0.59) and PQOL (ES=0.30) as well as improved self-efficacy for the management of symptoms (ES=0.26) compared with standard neurorehabilitation treatment.
24|Time to graft failure,likelihood of graft survival,venous outflow resistance and systemic BP,risk of early occlusion,incidence of thrombosis,Survival analysis,frequency of side effects,relative risk of thrombosis,cumulative thrombosis rates,overall rate of occlusion,Six major bleeds,rate of thrombosis,Thrombi,vascular perturbations underlying synthetic graft thrombosis,risk of thrombosis,Actuarial analysis of Type,PTFE graft survival,rate of thrombosis of expanded polytetrafluoroethylene (ePTFE) grafts,primary patency rates|Survival analysis revealed a significant difference between fish oil-treated and untreated patients (P < 0.03, Mantel-Cox test), with a power of 90%.
30|determination of the lowest stable methylprednisolone dose and assessment of corticosteroid side effects,unfavorable response,Symptom scores, blood chemistries, pulmonary function tests, airway response to methacholine, and glucocorticoid pharmacokinetics,forced expiratory volume in 1 second and pulmonary function,methylprednisolone clearance,blood chemistry and hematology, adrenal function assessment; bone densitometry, and muscle strength testing,elevated liver enzyme levels,Methacholine response,Efficacy and safety,MPn clearance,corticosteroid side effects,glucocorticoid pharmacokinetics and airway hyperresponsiveness,bronchial hyperresponsiveness,serum IgG, fasting blood sugar, serum cholesterol, and progression of osteoporosis|Differences were observed between the two treatment groups in serum IgG, fasting blood sugar, serum cholesterol, and progression of osteoporosis.
1025|rates of intraoperative events,Eleven intraoperative complications,systemic adverse event,cumulative rate of medical events,incidence of ophthalmologic and systemic complications,medical tests (electrocardiography, complete blood count, and measurement of serum levels of electrolytes, urea nitrogen, creatinine, and glucose,rate of complications,Ophthalmologic and systemic complications,overall rate of complications,Systemic adverse events,hypertension and arrhythmia (principally bradycardia,postoperative events|The cumulative rate of medical events was similar in the two groups, 9.6% in the routine-testing group and 9.7% in the selective-testing group (P = 0.923).
46|MBq,safe and effective and avoids hypothyroidism,levels of thyroid stimulating hormone (TSH,Short Form-36 Health Assessment Scale scores,rate of radiation clearance from blood, thyroid remnant, and whole body,quality of life,remnant cumulated activity per unit administered activity,Quality of life,Basal and rhTSH-stimulated serum thyroglobulin,Successful ablation,successful thyroid ablation rate,TSH, Tg and TgAb,Billewicz scale,TSH serum level,remnant ablation rates,serum thyroglobulin concentration less,ablation rate,small thyroid remnants|The rh-TSH pre-treated patients seem to have a lower uptake compared to those in hypothyroidism induced by L-T4 withdrawal.
4060|adverse drug effects,left ventricular function,left atrium,pharmacological restoration of sinus rhythm,symptoms related to atrial fibrillation,majority of strokes,overall mortality,survival advantage,Walking distance,quality of life,incidence of hospital admission|Of the 3311 patients with echocardiograms, the left atrium was enlarged in 64.7 percent and left ventricular function was depressed in 26.0 percent.
99|composite clearance rates (clinical and histological assessments) and histological clearance rates,response rate, tolerance, and patient compliance,Cure rates,clinical complete response rate,tumor-free rates,clearance rates,safety and clinical efficacy,recurrence rates,safety, tolerance, and efficacy,Clinical and cosmetic responses,Composite clearance rates,cure rate,complete response rate,safety and efficacy,lesion clearance,clinical efficacy,initial inflammatory response,failure rate (persistent or recurrent disease,Increasing severity of erythema, erosion, and scabbing/crusting,Basal cell carcinoma (BCC,adverse events and scoring of local skin reactions (LSRs,complete response rate based on histologic assessment,serious adverse events,Pathologic response,systemic adverse events,efficacy,highest clearance rate,efficacy and safety,histologic clearance,cure of lesions,response rate,partial response (PR,composite response rates (proportion of subjects with clinical and histological clearance) and response rates solely based on histology (proportion of subjects with histological clearance,recurrence of carcinoma,Histological clearance,good cosmetic outcome,Adverse events,Complete response rates,highest histologically complete response rate,Rates of recurrence of facial basal-cell carcinoma,4-year actuarial failure rate,Total operative costs of MMS,Noduloulcerative and superficial lesions,complete response (CR,cosmetic outcome,Histological clearance rates,Cost and safety,Cosmesis and lesion recurrence,Basal cell carcinomas (BCCs,size of lesions,Composite clearance,sustained response rate at 12 months and cosmetic outcome,local skin reactions,Response rates|Intention-to-treat analysis revealed 100% (3/3) histologic clearance in the twice-daily regimen, 87.9% (29/33) clearance in the once every day regimen, 73.3% (22/30) clearance in the twice-daily 3 times/week regimen, and 69.7% (23/33) clearance in the once-daily 3 times/week regimen.
not found|reduction in deaths,tetanus neonatorum death rate,mortality rate,neonatal mortality|In the period up to 20 months following vaccination, the reduction in deaths among 4-14-day-old infants after a single dose of tetanus-diptheria toxoids was about the same as that after two doses.
400|Vaginal bleeding,postpartum blood loss,quantity of total blood from placental delivery,complications or side effects,bleeding from placental delivery,quantity of blood,Complete blood count, urinalysis, liver and renal function, prothrombin time and activity,average blood loss,blood loss,occurrences of postpartum hemorrhage,total blood loss|The average blood loss of group I and II was significantly less than group III and IV (P < 0.01), however, there was no significant difference between group I and group II (P > 0.05).
27|incidences of difficult transfers, blood and/or mucus on the catheter tip, spontaneous miscarriages, and ectopic pregnancies,frequency of easy transfers,degree of confidence and satisfaction,pregnancy rate,clinical pregnancy rates and live birth rates,abortion rate,clinical pregnancy or live birth rates,live-birth/ongoing pregnancy and clinical pregnancy rates,clinical pregnancy rate,ectopic pregnancy, miscarriage and multiple pregnancy,pregnancy rates,ongoing pregnancy/live-birth and clinical pregnancy rates,Implantation and pregnancy rates,highest pregnancy rate (32.3%/ET,implantation rate,pregnancy and implantation rates,rate of implantation and clinical pregnancy,live-birth/ongoing pregnancy rate,clinical pregnancy rate for ultrasound-guided embryo transfer,ongoing pregnancy rate,clinical pregnancy rates,number of clinical pregnancies|Although the clinical pregnancy rate was not statistically different (18.5% in the ultrasound-guided group vs. 17.4% in the clinical touch group), the use of abdominal ultrasound during the embryo transfer procedure provided a greater degree of confidence and satisfaction to both patients and physicians.
not found|Functional Independence Measure (FIM,Pulmonary (complications,motor recovery rates,sick-leave profile,complete relief of back and radicular pain,shorter hospital stay,neurologic recovery,pulmonary complication with MPSS,recovery of motor function,Postoperative complications and functional outcome,efficacy and safety,1 full neurologic grade,severe sepsis and severe pneumonia,motor recovery,Mortality and major morbidity,disabling symptoms,Motor and sensory functions,postoperative discomfort,postoperative pain and length of hospital stay,sensation to pinprick,motor function (neurologic change scores,total number of sick days,6-month FIM,gastrointestinal complication,postoperative narcotic analgesia,neurologic outcomes,complications and mortality,pulmonary side effects|Aged patients with cervical spinal injury may be more likely to have pulmonary side effects (P = 0.029) after high-dose therapy with MPSS and thus deserve special care.
224|grade 4 neutropenia,left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF,Reduced cardiotoxicity and preserved antitumor efficacy,neutropenia and stomatitis/mucositis,palmar-plantar erythrodysesthesia,left ventricular ejection fraction (LVEF,congestive heart failure (CHF,complete plus partial response rate,Antitumor efficacy,Overall response rates,Median survival times,efficacy and toxicity,Median cumulative doxorubicin,objective response rates,overall response rate (complete response and partial response [CR + PR,nausea and vomiting, stomatitis, and leukopenia,Protocol-defined cardiotoxicity,disease progression or unacceptable toxicity,median time to disease progression,Median survival,median time to progression,median duration of response and the median survival,Cardiac function,cardiotoxicity,Activity,Leukopenia, anemia, nausea, and vomiting,objective tumor response rates (World Health Organization criteria), time to progression, and survival,response rate,symptomatic congestive heart failure,Gastrointestinal and hematological toxicities,Response (overall response = complete + partial response rates), time to disease progression, overall survival and cardiac function (left ventricular ejection fraction,Median cumulative doxorubicin dose at onset of cardiotoxicity,median survival,Clinical toxicities,overall response rate,median duration of response,efficacy and tolerability,Vomiting, mucositis, and leukopenia,median TTP,median survival time,injection site toxicity,Cardiotoxicity,alopecia,left ventricular ejection fraction,median time to treatment failure,superior response rate,Complete plus partial response,cardiotoxicity and grade 4 neutropenia,doxorubicin cardiotoxicity,left ventricular failure|Clinical toxicities, commonly associated with doxorubicin, appeared less common with TLC D-99, although the difference was not statistically significant.
28|haemodynamic modifications (heart rate and/or blood pressure fall,incidence of first syncopal recurrence,actuarial rate of absence of minor symptoms,symptomatic recurrences,sympathetic activity preceding syncope,likelihood of syncope,syncopal recurrence,recurrent syncope,repeat tilt testing,responses to head-up tilt,Syncope,free of syncope,spontaneous episodes of vasovagal syncope,systolic blood pressure,abnormal response to carotid sinus massage,recurrences of syncope,orthostatic hypotension while pacing DDI,concentration of plasma CA increase and prevented syncope,postrandomization risk of syncope,median time to first syncopal recurrence,recurrence of two VVSs,VVI (VVI, -31 (SD 19,plasma adrenaline and systemic hypotension,Recurrence of syncope,syncopal episodes,median of 4 episodes of syncope,paced heart rate and avoid bradycardia, arterial hypotension and syncope,24-hour ambulatory BP,diastolic blood pressure,energy and vitality,plasma CA concentrations and syncope,symptomatic pacemaker effect,mean interval between escape beats,time to first recurrence of syncope,venous return,first recurrence of syncope,syncopal and presyncopal episodes and graded their well-being, expressed as the general evaluation of life, general activities, and everyday activities,change in health status,Injurious events,response rates (negative TTT,median time to first syncope,positive therapeutic response,risk of recurrent syncope,recurrence of neurocardiogenic syncope,time to syncope and severity of hypotension,neurally mediated syncope,symptomatic hypotension,myocardial contractility,likelihood of recurrent syncope,refractory vasovagal syncope,intra-arterial monitoring, impedance cardiography, arterial blood sampling and tracer kinetics of simultaneously infused [3H]noradrenaline and [3H]adrenaline,Symptom events,upright pacemaker effect,plasma CA concentration [norepinephrine (NE) and epinephrine (E,Spontaneous syncopal and presyncopal episode recurrence,Acute reproducibility,presyncopes and total vasovagal events,Reproducibility of carotid sinus reflex,profound hypotension,number of falls during one year of follow-up,syncopal events,recurrence of Vasovagal Syncope (VVS,quality of life scoring scale,occurrence of syncope,acute tilt-induced syncope recurrence rates,rate of syncope,total number of syncopal and presyncopal attacks,pacemaker implantation,plasma CA concentrations,distribution of time of vasovagal events (syncopes or presyncopes,syncope recurrences,Initial mean,blood pressure,recurrence of syncope and presyncope,numbers of episodes of syncope and presyncope, and quality-of-life (QOL,occasional presyncope and their quality of life,Baseline supine systolic blood pressure,vasovagal syncope,Falls (without loss of consciousness,particular physical function,severity of attack,SVRI,mean 24-hour ambulatory BP,recurrent syncopal episodes,syncope,baroreceptor afferent flow,prevention of syncope or presyncope provoked by head-up tilt testing,QOL scores,asystolic response to tilt testing,median time to the first syncopal recurrence,occurrence of symptoms,syncopal recurrences,mean+/-standard deviation SBP decrease,catecholamine (CA) concentration,Ambulatory 24-hour BP monitoring took place,recurrence of cardioinhibitory vasovagal syncope,Postural blood pressure measurements,positive for syncope,mean SBP decrease,recurrent tilt-induced vasovagal syncope,actuarial rate of absence of syncopal recurrence,orthostatic tolerance,abolishing syncope,systolic pressure fall caused by carotid sinus massage,blood pressure or heart rate,pacemaker effect,Syncopal events,CLS mode and no syncope,symptom reporting and mean SBP decrease after CSM,mean number of syncopal episodes,time to syncope,response rates (negative tilt test,syncopal attacks,symptom frequency, symptoms during head up tilt, and quality of life,loss of consciousness (or intolerable symptoms,orthostatic hypotension,tilt-induced vasodilatation, syncope or elevated plasma adrenaline,global assessment of therapeutic response,hypotension and syncope, duration of tilt tolerance,Lead dislodgement or repositioning,presyncopal attacks,asystolic response,syncopal recurrence burden,QOL,plasma adrenaline,rate of positive responses,median number of previous syncopal episodes,tilt induced syncope,rate of symptom reporting and attenuated SBP decreases,Pre-syncope,severe side effects,mitral valve prolapse,haemodynamic patterns of tilt-induced vasovagal reflex,Vasovagal Syncope International Study (VASIS,mean duration of follow,complete abolition of syncope since pacing,risk of syncope relapse,low recurrence rate of syncope,cumulative risk of syncope,Vasovagal syncope,syncope recurrence,recurrent neurocardiogenic syncope,symptoms requiring the withdrawal of VVI pacing and premature DVI/DDD reprogramming,risk of syncope,therapeutic efficacy,ventriculo-atrial conduction,SVRI (systemic vascular resistance index) and magnitude of plasma adrenaline,heart rate (electrocardiography), phasic blood pressure (digital photoplethysmography), and thoracic fluid index (transthoracic impedance plethysmography,permanent cardiac pacing (recurrence of syncope,Symptom reproduction and BP and heart rate changes,cardiovascular tests (vasodepression during carotid sinus massage, pacemaker effect, postural blood pressure measurements, and response to head up tilt), and symptoms,milder symptoms,withdrawal symptoms and side effects,recurrence of syncope,mean time to a vasovagal episode (syncope or presyncope,actuarial rates of absence of syncopal recurrences,heart rate,recurrence of symptoms,relative risk reduction in time to syncope with DDD pacing,serious adverse effects|Of the 15 patients initially given metoprolol, 2 (13.3%) did not respond; both were crossed over to verapamil, to which they remained unresponsive.
48|forced expiratory volume,expiratory flow,short-term pulmonary function,pulmonary function and decrease admission rate,Vital signs, O2 saturation by pulse oximetry, PEFR, forced vital capacity, forced expiratory volume at 1 second, and physical examination,FEV1,peak expiratory flow rate,PEFR and SaO2,PEFR and FEV1,clinical asthma score,admission rate and improved FEV1,peak expiratory flow,serum magnesium concentrations,admission rates,blood pressure,forced vital capacity,Hospitalization,Hospital admission rates,PEFR|Magnesium sulfate administration did not at any time significantly improve either FEV1 (F = 0.036, p = 0.96) or PEFR (F = 0.51, p = 0.61).
60|Improvement rate without cure,history of upsetting life events and previous child psychiatric contact,Behavioral and self-concept changes,dry nights,weekly wetting frequency,Achenbach Child Behavior Checklist (CBCL,Piers-Harris Children's Self-Concept Scale and Harter's Perceived Competence Scale for Children (PCSC,Piers-Harris Subscales and in the CBCL Internalizing and Externalizing Scores, and the Social Thought and Attention Problems Subscales,Remission rates,Piers-Harris Self-Concept Scale (P-H), the State-Trait Anxiety Scale (STAIC), and the Nowicki-Strickland Locus of Control test (NSLC,mean number of dry nights,fewest wetting episodes,bladder capacity,total score, and positive changes over time in only 2 Subscales, Scholastic and Social,levels of neuroticism,wetting frequency,prechange and postchange in MFBC,rate of apparatus malfunction,P-H Scale,Treatment efficacy,success rate,response rate,Maternal anger,rate of sustained continence,remission rates,success rate of Arousal Training,complete and partial response rates,Bed-wetting frequency,bed-wetting frequency,number of wet nights,rate of cure,cumulative response,enuresis tolerance scale,levels of extroversion,background demographic variables,relapse rates,serious side effects,Monosymptomatic nocturnal enuresis,subjects' level of emotional and behavioral adjustment,maximum functional bladder capacity (MFBC,remission (28 continuous dry nights) and relapse,improvement rate,Changes in CBCL, STAIC, and NSLC scores|Using Dunn's procedure, a planned comparison showed the control group and delay group did not differ significantly, but both differed significantly from the classic conditioning group (p less than 0.05).
not found|morbidity,relapse-free survival,5-year overall survival,time to recurrence,overall and disease-free survival,relapse or death from breast cancer,4-year overall and relapse-free survivals,disease-free survival, overall survival, or the time to recurrence,disease-free survival (DFS,3-year relapse-free survival rates,3-year survival rates,septic death,mean number of positive nodes,survival,relapse-free or overall survival advantage,5-year DFS,myelodysplastic syndrome or acute myeloid leukemia,disease-free survival rates,frequent morbidity,overall survival,event-free survival,risk of relapse,disease-free and overall survival,4-year event-free survival (intention-to-treat analysis,3-year disease-free survival|The PEGASE 01 adjuvant therapy trial showed that 3-year disease-free survival was significantly better in the HDC arm but overall survival was unchanged.
not found|Clinical Global Impression score,number of (gastrointestinal) side effects,Mental Control Test (EMCT) measuring attention and concentration, Benton Test of Visual Retention-Revised (measures short term visual memory), Rey Test part 1 (measures short term memory and learning curve), Beck Depressive Inventory (BDI) measuring the presence and severeness of a depression in order to exclude depressive patients and Rey Test part 2 (measures long term memory: recognition,activities of daily living as assessed by the Nürnberger-Alters-Beobachtungsskala (NAB,patient's performance,cognitive performance and global assessment scores,sum score in the SKT-test for the determination of attention and memory,psychopathology and cognitive performance,Safety, compliance, and drug dispensation,degree of severity of dementia,number of patients reporting adverse events,psychometric tests (trailmaking test, ADAS, CGI) and electrophysiological investigations (EEG topography,Clinical Global Impressions (CGI Item 2) for psychopathological assessment, the Syndrom-Kurztest (SKT,Cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog), Alzheimer's Disease Cooperative Study Clinical Global Impression of Change (ADCS-CGIC,mental/mnestic performance,cognitive function,efficacy and safety,ADAS cognitive and non-cognitive subscales,mental performance,learning rate,shortterm memory,Number Connection Test,depression,Digit Copying sub-test of the Kendrick battery,Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog), Geriatric Evaluation by Relative's Rating Instrument (GERRI), and Clinical Global Impression of Change (CGIC,Furthermore, subjective perception of memory and concentration,efficacy and tolerability,Saccade duration,frequency of therapy responders,Clinical efficacy,little cognitive and functional decline,tolerated,CGIC,GERRI score,cerebral disorders,ADAS-Cog,self-rating scale for instrumental activities of daily living (Nürnberger-Alters-Alltagsaktivitätenskala,percentage of baseline scores|In the subjective test, the EMCT, the Rey 1 and Rey 2 no significant differences in improvement in time between the groups were observed.
554|chronic gastro-oesophageal reflux,mean gastrointestinal symptom and general well-being scores,frequency of gastroesophageal reflux dis-ease symptoms,tolerated,symptom relapse requiring titration,overall gastroesophageal reflux disease symptom score,satisfactory symptom remission,mean DeMeester acid exposure score,Psychological General Well-being Index and the Gastrointestinal Symptom Rating Scale,symptoms, pH control, and overall quality of life health index,lower oesophageal sphincter pressure,time to treatment failure (Kaplan-Meier analysis,postoperative complications,quality of life|The proportions of patients who remained in remission after 3 years were similar for the two therapies: 90% of surgical patients compared with 93% medically treated for the intention to treat population, p = 0.25
141|Vestibular function,peripheral vestibular function,relief of vertiginous symptoms,earlier recovery of ENG lateralization,symptoms and signs, caloric lateralization on the electronystagmography (ENG), the presence of other pathologic findings in the ENG, and Dizziness Handicap Inventory scores,relapse of symptoms,occurrence of symptoms and signs, degree of caloric lateralization, presence of other ENG pathologic findings, and Dizziness Handicap Inventory scores,vertigo,severity of vestibular paresis,Complete resolution,vertiginous symptoms,recovery of peripheral vestibular function|Analysis of variance showed a significant effect of methylprednisolone (P<0.001) but not of valacyclovir (P=0.43).
98|Functional Independence Measure (FIM), Motor Assessment Scale (MAS) and Rankin Disability Index measured functional outcomes,pain,final upper limb function,presence of neglect or sensory loss,visual analogue scale (VAS,functional outcomes,pain (SROMP) assessed passive range of movement and pain,Skin reactions,pain, range of movement or functional outcomes|Intention to treat analysis showed no significant difference in pain, range of movement or functional outcomes after the intervention phase or at the final assessment.
not found|Estimated graft survival,Plasma levels of soluble interleukin-2 receptors,Actuarial graft survival,donor or recipient characteristics, HLA-mismatching, and ischaemic time,renal function and rejection,Graft function assessed by serum creatinine concentration and glomerular filtration rate measured as plasma iohexol clearance,severe signs of Cyclosporin A (CsA) nephrotoxicity,Primary graft function,allograft function,renal parenchymal diastolic blood flow velocities,renal graft function,Renal plasma flow and anastomotic blood flow,acute rejection rate, trough blood cyclosporine concentrations, blood pressure, number of antihypertensive drugs, hospitalization rate, and adverse event rate,rate of delayed graft function, the rate of rejections, time to first rejection, whole blood CsA concentration, or graft function,rejection episodes,graft function (plasma iohexol clearance), renal plasma flow, anastomotic arterial blood flow, deterioration of renal function, blood pressure, acute rejection, and hospitalization rate,episodes of acute tubular necrosis,Thrombosis leading to graft loss,graft survival,blood concentration,incidence and severity of delayed graft function,cadaveric kidney transplantation,serum creatinine|Actuarial graft survival at 1 yr was different when the two groups were compared (P less than 0.05).
not found|Growth velocities and individual amounts of breastfeeding,rate of weight gain,growth and thermal stability,length of stay,number of infants returned to an incubator, the growth velocity in an open crib and during the first week at home, the proportions of breastfeeding at discharge and during the first week at home, and the hospital readmission rate,mean 24-hour weight gains,abdominal temperature,rate of growth of the skinfolds,birth weight stratum|The rate of weight gain correlated with gross energy intake only and did not differ within or between the two groups.
50|MS relapse rate,survival curves,final 2-year relapse rate,clinical and MRI measures of inflammation and neurodegeneration,relapse rate,disability status scale change (entry expanded disability status scale,relapse rate and improves disability,cumulative number of confirmed relapses,Progression rates,intention-to-treat analysis of time to 1,unconfirmed progression, and progression of 0.5 EDSS units,Disability,safe and well tolerated,frequency of relapses and the formation of active brain lesions,clinical and MRI-monitored disease activity,enhancing lesions,T2 lesion volumes,disabled on entry (Kurtzke disability score,rate ratio,Expanded Disability Status Scale (EDSS,tolerated,Kurtzke Expanded Disability Status Scale,overall survival curves,total number of confirmed relapses|More disabled patients worsened by 0.3 (Cop 1 group) and 0.4 (placebo group) unit.
44|Blood loss, transfusion requirements, coagulation parameters, and complications,intraoperative or postoperative thromboembolic complications,duration of intensive care unit admission,estimated blood loss,blood loss,transfusion requirements,transfusion requirement,perioperative blood loss and the need for autologous blood transfusion,perioperative blood transfusion requirements,blood loss and transfusion requirements,blood transfusion,thrombotic complications,postoperative suction drainage,amount of blood transfused,adverse drug effects,intraoperative blood loss,blood loss, transfusion requirements, days in the intensive care unit, and days in hospital,total amount of blood transfused,bleeding and transfusion requirements,perioperative blood loss|The study demonstrated a significant reduction in estimated blood loss (aprotinin 545 cc, placebo 930 cc) and transfusion requirements (aprotinin 1.1 U, placebo 2.2 U).
36|plasma potassium concentrations,mortality rate,arterial blood pressure,Overall cost,CCr,ratio of FIO2 to PaO2,weight gain,case fatality rate,hypotensive (systolic blood pressure less,Survival,coagulation factors,Renal function,number of infants requiring inotropic support and death or chronic lung disease,intraventricular haemorrhage,duration of normotension, meeting criteria for second bolus, meeting criteria for vasopressor support and cost comparison,pulmonary perfusion and/or ventilation,global cerebral blood flow,qualify for vasopressor infusion,mean arterial blood pressure (MABP), left ventricular output (LVO) and global cerebral blood flow (CBF,fractional urinary sodium excretion,blood pressure,creatinine clearance (CCr) or the urinary sodium excretion rate,normotensive state,volume expander to maintain normal blood pressure,LVO|Dopamine was effective in increasing MABP; both treatments increased LVO, whereas no significant difference between the treatment groups and the control group could be demonstrated with regard to CBF.
not found|numbers of people failing,attendance at the first appointment; secondary outcomes included hospitalization, transfer of care, continuing attendance, discharge, presentation at accident and emergency and death by 1 year,missed initial appointments|The orientation statement only group had significantly fewer missed initial appointments than the control group (28% vs. 56%).
40|Peak nasal inspiratory flow (PNIF,levels of IL-1beta and IL-8,density of cells expressing interleukin4,total X-ray photograph scores,symptom scores,Efficacy and tolerability,TNF-alpha level,number of patients withdrawn because of recurrent or persistent diseases,Morning combined symptom scores (CSS,nasal congestion and discharge scores,clinical outcome,recurrence rate of nasal polyps and chronic rhinosinusitis,PNIF,clinical efficacy and adverse effects,wound healing,symptoms, diary card, and rigid endoscopy scores, acoustic rhinometry, middle meatal swabs, blood tests--CRP, ESR, WBC, and eosinophil count,Morning serum cortisol,CD-3,patients' sense of smell,wound healing, leading to recurrences of sinusitis and polyps,interleukin-5 messenger RNA,total symptom scores,risk of developing an infection,serum morning cortisol values,nasal symptoms,eosinophils,endoscopic combination score (for inflammation, oedema, and polyps), a total symptoms score,efficacy and safety,adrenal suppression,mucosal thickening,allergic sinusitis,nasal scores,percentage of nasal deobstruction,diary card scores,subjective nasal clinical symptoms (nasal discharge, nasal obstruction, postnasal drip and headache), (2) X-ray photographs (ethmoid and maxillary sinuses) and (3) cytokine levels (IL-1beta, IL-8 and TNF-alpha) by enzyme-linked immunosorbent assay,airways' resistance via active anterior rhinomanometry and the volume and area section via acoustic rhinometry,nasal airway patency's parameters,facial pain and sensitivity,Adverse events,recurrence rate of chronic rhinosinusitis and nasal polyps,total nasal symptom scores,symptomatic response and improvement in nasal mucociliary clearance, nasal airway resistance, sinus radiographs, and intranasal bacteriology and appearance,healing with MFNS,efficacy and tolerability,nasal and ocular symptoms,tolerated,Postoperative mean total score for several endoscopic parameters scores,total endoscopic scores,adverse effects,bacterial sinusitis,total number of drug-related adverse events|Budesonide and antral irrigations reduced nasal symptoms more effectively than placebo, and there was a significantly greater reduction in facial pain and sensitivity in the budesonide group than in the placebo group.
52|median TTF,Skin reactions,rate of response based on intention,Cutaneous reactions|The rate of response based on intention to treat patients was 33.3% for miltefosine solution compared with 3.7% for placebo (P = .006).
109|proportion of children with recurrence,preschool behaviour screening questionnaire (BSQ,acceptability and efficacy,Recurrence of convulsion and side effects,mean log-transformed scores on the behaviour rating scales,libido and impotence,efficacy and toxicity,intolerable acute toxic effects,Overall treatment success,efficacy,free of seizures,partial seizures,frequency of behavioural side-effects; behaviour,Hyperactivity,1-year remission,odds ratio for behavioural problems,Serum drug levels,dysmorphic effects and hypersensitivity,failure rates,nausea, vomiting, dizziness, and sedation,Efficacy,Conners parent rating scale,Side effects|The mean log-transformed scores on the behaviour rating scales did not differ significantly between the phenobarbital and phenytoin groups (Conners 2.64 [SD 0.71] vs 2.65 [0.89], p = 0.97; n = 32 in each group: BSQ 2.12 [1.31] vs 2.18 [1.02], p = 0.94; n = 4 vs 3).
242|morbidity and mortality,pneumococcal isolations,antibody responses,higher infection rates,occurrence of pneumococcal bacteremia,incidence of infection|No pneumococcal isolations occurred in the penicillin group while receiving penicillin, although four isolations occurred within one year of stopping penicillin.
20|corrected epidermal atrophy and atypia and improved skin hydration properties,overall appearance of photodamaged skin,skin wrinkles, mottled hyperpigmentation, laxity, lentigines and roughness,Skin biopsies,facial rhytids,global response,histologic features, keratinocyte expression of HLA-DR and intercellular adhesion molecule-1, numbers of epidermal Langerhans' cells and epidermal and dermal T lymphocytes, and vascularity as measured by dermal endothelial cell area,erythema, crusting, pain, itching, swelling, pigmentary changes, and the day of first make-up application,Local irritation and adverse events,intraoperative pain,global responses,mottled hyperpigmentation and fine wrinkles,fine wrinkling and pigmentation,tolerated, and skin irritation,crusting,appearance of photo damaged skin,epidermal and granular layer thickness, decreased melanin content and compaction of the stratum corneum,plasma retinoid levels,Side effects of erythema, peeling, and stinging were usually mild and well tolerated,fine wrinkling, tactile roughness, coarse rhytids, skin laxity/tone, sallowness/yellowing, and overall features,skin roughness,erythema score,vascularity,irritant side effects (erythema and scaling,average upper lip laser-treated wrinkle score,investigator's global evaluation,postoperative erythema,Medium to deep (Grade III,clinical and microscopical manifestations of liver spots,roughness, mottled hyperpigmentation, fine wrinkling, and lentigines,Ra and shadows north-south facial axis values,permanent hyperpigmentation, hypopigmentation, or scarring,Fine wrinkling, mottled hyperpigmentation, and roughness,overall severity of photodamage and sallowness,immunologic markers,histologic changes,postoperative crusting and more rapid reepithelialization,erythemal index,adverse effects (burning, stinging, redness, peeling, dryness, discoloration, itching, and rash,duration of itching,erythema,average upper lip dermabrasion-treated wrinkle score,wrinkle score,rate of resolution of erythema,efficacy,objective skin changes,efficacy and safety,histologic evaluation,Changes in skin biopsies and silicone skin surface replicas,Overall investigator scores,wrinkle improvement and duration of adverse effects,epidermal thickening,efficacy and tolerability,mottles and telangiectasis,elasticity index,fine wrinkling, mottled hyperpigmentation, roughness, and laxity,Local adverse events,good response,Rz, Ra, and shadows,Vivida,tolerated overall,Improvement in rhytides, patients' subjective reports of postoperative pain, time to reepithelialization, degree of postoperative crusting, and duration of postoperative erythema,photoaging effects,photoaging,hyperpigmentation and wrinkle reduction,dryness, peeling, and acne,appearance of photodamaged skin,skin state,safe and effective,skin elasticity index,mean erythemal index,degree of compaction of stratum corneum, thickness of the granular cell layer, and epidermal thickness,rhytide scores,skin condition,perioral wrinkles,degree of epidermal pigmentation,duration of crusting, swelling, and itching postoperatively,epidermal thickness,Treatment response,swelling,Postoperative erythema,Posttreatment erythema,photoaged skin,erythema, crusting, pain, and pigmentary changes,overall severity of photodamage,photographs for erythema, pigmentation, and wrinkle improvement,wrinkle improvement,general skin texture and discoloration,mean epidermal thickness,skin wrinkles, tightness, colour and pores,overall improvement in photodamaged skin,overall modest wrinkle improvement,average upper lip phenol-treated wrinkle score,mottled hyperpigmentation,safety and efficacy,photodamaged skin topography,appearance of photo-damaged skin,significant lightening of hyperpigmented lesions,adverse experiences,frequency of erythema,duration of crusting,variable pulse,pain,dermal thickness,permanent hyperpigmentation, hypopigmentation, or scarring occurred,wrinkles and severity and duration of adverse effects,restoring actinic damage,adverse effects|The laser treatment had a significantly higher erythema score at 1 month and a small but significantly greater improvement in perioral wrinkles at 6 months.
120|comparative efficacy and tolerability,mean number of oocytes retrieved and embryos,Pregnancy rates and live birth rates,Conception rate,Implantation, clinical pregnancy and multiple pregnancy rates,implantation rates,pregnancy rate,pregnancy rates or implantation rates,LH,vitro fertilization and embryo transfer,number of embryos transferred,rate of withdrawals at the individual visits,pregnancy rates (PR,luteal-phase GnRH agonist administration increased luteal-phase serum HCG, estradiol and progesterone concentrations,delivery rates,clinical pregnancy,multiple pregnancy and live birth rates,serum P4 levels,Demographic parameters, infertility etiologies, number of gonadotropin ampules used, number of mature oocytes recovered, rates of testicular sperm usage, number of embryos transferred, and cycle and transfer cancellation rates,Clinical pregnancy rates, implantation rates and live birth rates,safe and well tolerated,LH levels,pregnancy outcome,progesterone profiles and pregnancy outcomes,probability of pregnancy,midluteal estradiol levels,lower embryo implantation, clinical pregnancy, and live birth rates,implantation rate per embryo transfer,late luteal progesterone concentrations,ongoing pregnancy rate,live birth rates,Tolerability,Highest pregnancy rate,multiple pregnancy rate,Elevation of serum progesterone,E2 or P levels, endometrial thickness,Progesterone levels,Endometrial thickness,Pregnancy rates,Plasma P and 17 beta-Estradiol concentrations,pregnancy rates per transfer,embryo quality,Safety parameters,implantation and pregnancy rates,Clinical pregnancy rates,patient satisfaction scores,Pregnancy rates (PRs) and live birth rates per ET,lower E2 levels,Pregnancy rates, ongoing/delivered, failed pregnancy rates, and product satisfaction scores,serious adverse events,luteal phase serum P4 levels,rates of successful pregnancies,Estradiol (E2,Pregnancy, embryo implantation, and live birth rates,pregnancy rates,efficacy and safety,pregnancy rate, rate of spontaneous abortion, proportion of normally developing fetuses or rate of chemical pregnancy,pregnancy or implantation rates,pregnancy and embryo implantation rates,implantation rate,Demographic profile and pregnancy and miscarriage rates,clinical outcome of intracytoplasmic sperm injection (ICSI) and embryo transfer (ET) cycles,specific symptoms and usual safety monitoring,pregnancy rates (PRs,adverse event profiles,biochemical rates,luteal P values,clinical pregnancy rates,SD), number of oocytes,implantation and live birth rates,pregnancy rates and the implantation rates,levels of oestradiol and progesterone,probability of pregnancy in intracytoplasmic sperm injection (ICSI) cycles,E2 or P levels,Furthermore, Estradiol (E(2)), progesterone (P) levels and endometrial thickness,Implantation and live birth rates,Serum levels of P and E2,Clinical pregnancy, ongoing pregnancy, and live birth rates,probability of conception,ongoing pregnancy rates,Implantation rate,serum progesterone (P) and 17-beta-estradiol (E2) and E2/P ratio levels of the luteal phase,number of good quality embryos,abortion rate,spontaneous abortion rates,clinical pregnancy rate,Serum P levels,progesterone,Clinical pregnancy rate per transfer and implantation rate,implantation rate per embryo,pregnancy and implantation rates,Live birth rates,Demographics, stimulation parameters and embryological data,implantation and pregnancy rate,Pregnancy rate,rates of implantation and clinical pregnancy rates,rate of positive beta-human chorionic gonadotrophin per transfer,luteal serum progesterone and oestrogen concentrations,living birth rates per transfer,E2 levels,ongoing pregnancy rate per transfer cycle,Ongoing pregnancy rate,Hormonal levels,pregnancy, implantation and live birth rates,late-midluteal estradiol levels,pregnancy and delivery rates,early pregnancy loss,Efficacy and tolerability,PR per retrieval,Vaginal discharge or irritation,embryo implantation,number of beta-hCG-positive results,ratio of newborn babies per embryo transferred,luteal E(2) level,rate of implantation and abortion, number and reasons of withdrawals, as well as adverse events, assessment of tolerability, and acceptance,failed pregnancy rates,pregnancy rates and ongoing pregnancy rates,miscarriage rate,efficacy, safety and tolerability,P4 levels,Clinical pregnancy rate,plasma progesterone concentrations,clinical PRs,Ongoing pregnancy rates,pregnancy rate and live birth rate,pregnancy rate per embryo transfer, early pregnancy loss, multiple pregnancy rate, and midluteal P and E(2) levels,luteal serum E(2) and P profiles,duration of LPS,ICSI clinical outcomes,median progesterone levels,Similar levels of luteal E2,luteal plasmatic values,vitro fertilization-embryo transfer (IVF-ET,Pregnancy and live birth rates,overall pregnancy rate and miscarriage rate,Live birth rate per transfer,Efficacy,E2/P ratio,Bleeding episodes,number of embryos transferred and the grade of the embryos|Although there was no significant difference in the number of good quality embryos transferred in both groups, the implantation and pregnancy rate were significantly higher in the GnRH-a - treated group compared with placebo controls.
not found|plasma levels of VEGF,vascular endothelial growth factor,duration of COAD,maximal walking distances,levels of VEGF,Red cell rigidity,clinical efficacy and safety,walking distance,Subjective side effects,maximal walking distance with constant-speed, variable-grade treadmill testing,ankle-brachial index,subjective response; claudication and maximum walking distances; ankle systolic indices; maximum blood flow in the lower limb by gravimetric plethysmography; plasma fibrinogen; erythrocyte deformability and whole blood viscosity,initial claudication distance and quality of life assessment,erythrocyte deformability,level of walking claudication pain,Reduction of lower limb paresthesias,subjective response, ankle systolic indices, maximum limb blood flow or whole blood viscosity,efficacy, safety, and tolerance,AEF,total walking distance (TWD,walking distance and blood rheology,red blood cell filterability, plasma fibrinogen concentration and blood viscosity, resting and post-ischemic calf muscle blood flow, and the resting and post-exercise ankle/brachial systolic pressure ratio,pain relief,diabetes mellitus,median of the maximal walking distance,Pentoxifylline efficacy,quality of life,walking distance and quality of life,exercise performance or quality of life,peak ACD,red cell rigidity,efficacy, safety, and cost,pain-free walking distance,postexercise distal flow, ratios, and pressures and enabling faster recuperation of basal pulse rates,level of pain,adverse reactions,Side effects (including headache, palpitations, and diarrhea,efficacy and tolerability,VEGF levels,tolerated,Mean maximal walking distance,initial claudication, toe peak-flow time, pulse reappearance time (PRT/2), and maximum postischemic flow time,efficacy, safety and cost,distal pressure and resting microcirculatory blood flow,mean maximal walking distance,blood flow,walking performance, resting toe pressure, resting and postexercise ankle/brachial pressure ratio, and basal/postischemic toe-pulse ratio,moderate level of pain,serum levels of pentoxifylline and its hydroxy-metabolite,serious drug-related side effects,flux,pain-free walking distance (PFWD,Nausea,painfree walking distance,ACD,initial and absolute claudication distances,whole blood or plasma viscosity,maximal walking distance,exercise tolerance,PXF improved walking distance,walking performance,walking distances,exercise flux (AEF,Circulating VEGF levels,withdrawal rates,Deaths and serious adverse event rates,Claudication distance and walking distance,walking performance (absolute walking time and walking distance on a treadmill ergometer) and by acral plethysmography,absolute claudication distance (ACD,ankle systolic blood pressure ratio ( ASBP -ratio,absolute subjective claudication distance,Cilostazol,farther walking distance of 2 miles,frequency of minor side effects,maximal and painfree walking distances and blood viscosity,mean erythrocyte deformability,claudication distance and mean plasma fibrinogen concentration,blood viscosity|There was a 38% difference at 6 months and 39% at 12 months in favor of PXF.
79|recollection of pain,duration of colonoscopy,severe pain and discomfort,Patient satisfaction,time to recover from sedation,Digit Symbol Substitution Test score,success, difficulty, or duration of the colonoscopy,lighter sedation (median sedation score,Drugs cost for NAPS,Six minor complications,Sedation and pain scores,faster recovery time,complete recovery,recovery of cognitive function,mean arterial pressure, heart rate and end-tidal CO2,Dot Test score,effective analgesia, sedation, amnesia, patient comfort and stable recovery profile without respiratory depression,10-point visual analog scale,Mean time to sedation,Recovery of cognitive and psychomotor functions,patient satisfaction, procedure and recovery times, neuropsychologic function, and complications,safety and efficacy,analgesia (median pain score,10-cm visual analog scale,full recovery sooner,systolic blood pressure,Hemodynamic and respiratory data, pain, discomfort and sedation scores, patient and gastroenterologist satisfaction and recovery profiles,pain (visual analogue scale) and procedure time,Observer's Scale for Sedation and Alertness (OSSA) score,Patient cooperation, endoscopist satisfaction, and level of sedation,endoscopist satisfaction,cardiopulmonary complication rates, pain scores, satisfaction scores, and patients' willingness to repeat colonoscopy,arterial pressure and heart rate,Nausea and vomiting,Pain and discomfort scores,overall satisfaction,Oxygen saturation and hemodynamics,transcutaneous partial pressure of carbon dioxide,hypoventilation,nausea and vomiting,overall mean satisfaction,patient satisfaction, procedure and recovery times, neuropsychological function, and complications,Heart and respiratory rates, blood pressure, and oxygen saturation,mean arterial blood pressure,discharge times,minor complications (1 hypotension and bradycardia, 2 hypotension alone, and 1 tachycardia,patient satisfaction,episodes of hypotension, 1 episode of bradycardia, and 1 rash,visual analogue scale,pain,respiratory rate and oxygen saturation values,Synergistic sedation,depth of sedation,efficacy, safety and recovery characteristics,pain scores,tests reflective of learning, memory, working memory span, and mental speed,Pain and sedation score,Early recovery,oxygen desaturation requiring mask ventilation and 4 episodes of hypotension,oxygen desaturation develop|All patients treated with the synergistic sedation were able to participate (P=0.002), and performed better.
not found|pain,analgesia,pain relief,adverse effects,postoperative pain,adverse effects and/or inadequate relief,nausea, vomiting and drowsiness|In the multiple dosing phase, zomepirac was statistically better than dihydrocodeine. Non-parametric statistical tests indicated highly significant correlations between single- and multiple-dose analgesic measurements for both zomepirac and dihydrocodeine.
94|maternal satisfaction,emetic symptoms,complete response,pruritus,incidence of intraoperative/postoperative nausea,hypotension and vasopressor use,nausea scores, number of vomiting episodes, or patient satisfaction with postoperative nausea and vomiting management,intraoperative, postdelivery vomiting,neurobehavioral exam results,incidence of vomiting and treatment for vomiting,intraoperative nausea,Nausea and vomiting,incidence of nausea,severity of vomiting nor the incidence of nausea,incidence, onset, duration, and severity of pruritus; the onset and severity of pain; and satisfaction,frequency,incidence of intra- or postoperative nausea or vomiting/retching,total incidence of nausea and vomiting,incidence and severity of nausea and vomiting,pulse rate or blood pressure,vomiting prior to delivery,total incidence of nausea and vomiting, incidence of > 4 vomiting episodes,Blood pressure,mean arterial pressure,intraoperative, postdelivery nausea,incidence and severity of nausea,frequency and severity of the nausea and vomiting episodes,Analgesia and nausea,nausea, vomiting, and retching,maternal characteristics,ephedrine requirements,Pain scores,Intraoperative nausea,nausea than vomiting,hypotension after delivery,emesis free,incidence of vomiting and the severity of nausea,frequency of vomiting,intraoperative nausea and vomiting (IONV,perioperative nausea and vomiting,total number of parturients with no vomiting and/or no antiemetic medication,severity of pruritus score,severity or incidence of pain, or requests for analgesic or antipruritic medication,emesis,severity of hypotension,antiemetic efficacy,severity of nausea and vomiting,efficacy and safety,respiratory depression,nausea and vomiting,cumulative pain score,intraoperative nausea and vomiting,efficacy and tolerability,nausea free,incidence and severity of IONV,nausea and vomiting, sedative score, pain score, and side effects,perioperative nausea,nausea and/or vomiting,vasopressor,nausea or vomiting,number of women who complained of nausea,nausea, vomiting, retching, pain relief, itching, and adverse effects,antiemetic efficacy and safety,Side effects,pruritus score,Overall satisfaction with postoperative care,patient's perception of the control of nausea and their overall satisfaction,incidence of PONV and side effects,severe emetic symptoms,frequent incidence of restlessness,frequency of intraoperative nausea and vomiting,nausea/vomiting score, pain score, sedation score, or shivering score,incidence and severity of intraoperative emetic symptoms,Incidence rates for intraoperative nausea,frequency of retching or vomiting,postoperative nausea and vomiting,severity of nausea,retching or vomiting (1 = vomiting or retching, 0 = no vomiting or retching,Total ephedrine consumption,supplementary intraoperative analgesia,postoperative vomiting,antiemetic effect,patient satisfaction,antiemetic medication,frequency and the severity of nausea and vomiting,Maximum analog sedation score,postoperative nausea or vomiting,overall rates for all emesis,Episodes and severity of nausea and vomiting, rescue antiemetic requirement, patient satisfaction, and side effects,frequency of respiratory depression,nausea scores,Nausea or vomiting,Blood pressure, heart rate and vasopressor requirements,neonatal Apgar scores,pruritus, nausea, and vomiting,postoperative nausea and vomiting/retching,nausea,incidence of intra- and postoperative nausea or vomiting,vomiting,Sedation scores,safety and efficacy,Neonatal outcome,Cumulative nausea, vomiting, and pain scores,cumulative perioperative pain score,frequency of nausea and vomiting, sedative score, respiratory depression, and side effects,side effects,frequency of intraoperative nausea,frequency of intraoperative and postoperative vomiting,incidence of vomiting,Neonatal acid-base status and neurobehavioral exams,pruritus, nausea and vomiting,Severity of nausea and number of vomiting episodes,need for rescue antiemetics,verbal pain score,haemodynamic response,Intraoperative antiemetic efficacy,nausea, retching, and vomiting,intraoperative vomiting,Overall patient satisfaction,frequency of nausea,incidence of restlessness,nausea, retching, and vomiting intraoperatively,Frequency and severity of postoperative (24-hour) pruritus, nausea and vomiting, surgical pain, and side effects,respiratory depression (respiratory rate|There was also no difference between the two groups in nausea scores, number of vomiting episodes, or patient satisfaction with postoperative nausea and vomiting management.
99|Odour, maceration, absorption capacity and leakage,maceration,delayed healing ulcers,lymphangitis and/or fever,wound severity score,clinical infection,total mASEPSIS score,and/or tolerability,ulcer area,closure rate,Poor dressing acceptability,mean wear time,Wound area,adverse events,exudate level,Ulcer area and healing|According to the investigators, fewer wounds developed a clinical infection over the four-week follow-up in the test group (33% versus 46%; p = 0.223).
18|volume losses,wellbeing' score,number of patients subjectively improving,leg circumference,mean volume losses,circumference measurements,Volume losses,symptom relief|Analysis of covariance revealed significant mean volume losses for both experimental and control groups, with ponderal index the only significant covariate.
not found|fetal tachycardia and repetitive late decelerations|When misoprostol is used in women with previous cesareans, there is a high frequency of disruption of prior uterine incisions.
not found|neonatal deaths,premature uterine activity,mean arterial and diastolic blood pressure,neonatal complications,tocolytic efficacy and maternal tolerance,time to uterine quiescence,time to uterine quiescence, time gained in utero, recurrence of preterm labor, failure of tocolysis, and pertinent maternal and neonatal outcomes,maternal demographic characteristics,Maternal side effects and haemodynamic changes,number of entry variables, including cervical examination, contraction frequency, and gestational age,maternal side effects,recurrent labor,delay of delivery,Neonatal outcome,adverse side effects, mainly nausea and vomiting,number of neonates admitted into intensive care nor the premature infant center,Efficacy and safety,Apgar scores,side effects,maternal side-effects,efficacy and safety,Apgar scores and umbilical artery and vein pHs,success rate,mean term of delivery,maternal and fetal complications,severe maternal side effects,percentage of deliveries,Prolongation of pregnancy,Maternal pulse rate,efficacy and maternal, fetal, and neonatal outcome,adverse medication effects and recurrent preterm labor,birth weight, estimated gestational age at delivery, or neonatal complications,fetal and neonatal outcome,Maternal side effects,suppression of preterm labor,maternal heart rate,headaches, and with salbutamol, tremors and palpitations,recurrence of preterm labor necessitating further tocolytic attempts,number of admissions to the neonatal intensive care unit (NICU,fetal vascular blood flow,systolic and diastolic blood pressure|The patients in the magnesium sulfate group had more adverse side effects, mainly nausea and vomiting (P =.004).
130|motor activity and intraventricular hemorrhage,IVH/PVH percentage,blood glucose, blood pressure, mean airway pressure, PCO2, PO2,blood pH,hemorrhages,severity of intraventricular hemorrhage,overall incidence of intraventricular hemorrhage,weight, gestational age, Apgar score, way of birth, initial diagnosis, incidence of pneumothorax, mortality and days with MV,incidence of ventricular dilatation,neurodevelopmental handicaps,Blood levels,global incidence of intraventricular hemorrhage,hemorrhage,intraventricular hemorrhage,incidence of intraventricular hemorrhage (IVH,brain hemorrhage|We found that IVH/PVH percentage is lowest in newborns from group III, followed by newborns from group II and group I.
680|get watery diarrhoea,incidence of pneumonia,diarrhoea and pneumonia,mean percentage of CD4+ T lymphocytes and median haemoglobin concentrations,plasma zinc concentrations,pneumonia and mortality,Development (assessed by use of the Griffiths Mental Development Scales), length, and weight,indicators of copper or iron status,change in plasma zinc,Anthropometric indexes, developmental indexes (Bayley Scales of Infant Development; BSID), and morbidity,growth, development, or risk of infection,diarrhea incidence,Weekly morbidity histories,Weight-for-age z score,knee-heel length,episodes of diarrhea, dysentery, and respiratory illness,interleukin-2 production,clinical pneumonia and diarrhoea,delayed hypersensitivity skin reactions, enhanced lymphoproliferative response to PHA, and increased salivary IgA concentrations,incidence of diarrhea,children's morbidity and physical growth,growth, morbidity, or motor development,severity of malaria episodes, prevalence of malaria parasite, mean parasite densities, mean packed cell volume, prevalence of other morbidity, and all cause mortality,incidence of pneumonia and diarrhoea,morbidity, growth, and micronutrient status,prevalence of cough,diarrheal morbidity,iron and zinc for weight-for-age z score, knee-heel length, and BSID psychomotor development,incidents of pneumonia,mean plasma zinc concentration,incidence of infections and hospital admissions,markers of copper or iron status,All cause mortality,diarrhoea and pneumonia morbidity,Weight, length, and other anthropometric indicators,energy intake,mean temperature, and mean parasite densities during malaria episodes, nor in malaria parasite rates, mean parasite densities, and mean packed cell volume,linear growth gain,growth and psychomotor development,number of hospitalizations and decreased number of vaso-occlusive pain crisis,Safety and efficacy,pneumonia-related deaths,Morbidity,fever and cough,BSID psychomotor development index,Growth, final serum copper, and final haemoglobin,plasma zinc concentration,immunocompetence, growth, and zinc, copper, and iron status,rate of pneumonia and diarrhoea,Serum copper and haemoglobin concentrations,plasma zinc concentration, morbidity, and growth of young children,baseline characteristics, attained weight or length at 10 mo, growth velocity, gross motor development, and morbidity,Morbidity data,childhood morbidity,growth, psychomotor development, and incidence of infectious disease,incidence of symptomatic falciparum malaria,diarrhoea,morbidity,Zinc deficiency affects adversely T-helper1 (TH1) functions and cell mediated immunity and interleukin (IL)-2 production,plasma zinc and other indicators of micronutrient status,mean number of malaria episodes,growth, morbidity, and motor development,plasma HIV-1 viral load and the percentage of CD4+ T lymphocytes,bacteriologically positive infections,vomiting,Growth and indexes of body composition and gross motor development,rates of other respiratory tract infections,Morbidity information,small gain in height,Supplement consumption,lymphocyte and granulocyte zinc,mean log(10) HIV-1 viral load,incidence of diarrhoea,Watery diarrhoea,plasma HIV-1 viral load,falciparum malaria,acute lower respiratory tract infection,developmental quotient, hearing and speech, and performance,adverse effects|Weight-for-age z score was higher in the Zn group than in the placebo and Fe+Zn groups, knee-heel length was higher in the Zn and Fe groups than in the placebo group, and the BSID psychomotor development index was higher in the Fe group than in the placebo group.
300|axillary dissection,Telephone questionnaire,physical symptoms and health-related quality of life (HRQoL,quality of life or patient satisfaction,pain management index (PMI,QOL over time (measured by the Functional Assessment of Cancer Therapy-Lung questionnaire and the Palliative Care Quality of Life Index), discussion of patient problems, and satisfaction with communication and general care,Health related quality of life (EORTC QLQ-C30,type and use of cancer-specific therapies,higher social support and lower disease uncertainty,Satisfaction with care,QOL indicators,patient satisfaction, arm morbidity, impact on community nurses, health service costs, surgical cancellations and in-patient nursing dependency,psychosocial problems (uncertainty, anxiety, loneliness, disturbed sleep, loss of control, threat to self esteem), physical or psychological complaints, or in the coping strategies used,Incidence of complications,QOL, and psychosocial functioning and satisfaction with overall care received,pain control,functional decline,ability to perform activities of daily living, physical performance, utilization of health services, and costs,quality of life or NHS resource use,periodic pain assessments,Measuring quality of life,cancer needs, QOL, or psychosocial functioning,pain (Brief Pain Inventory); secondary outcomes of interest were all other symptoms (Memorial Symptom Assessment Scale) and quality of life (Functional Assessment of Cancer Therapy Scale,satisfaction with care, communication, or the discussion of patient problems,satisfaction survey and Maklebusts Ostomy Adjustment Scale,average pain,Amsterdam Pain Management Index (APMI), consisting of an integrated score of patients' Present Pain Intensity, Average Pain Intensity, and Worst Pain Intensity,Leakage along the drain,quality of life (QOL) and cost outcomes,relative hazard of death,patients' quality of life,scores for quality of life (physical component score,incidence of wound complications,QOL assessments included the Center for Epidemiological Studies-Depression Scale , the ambiguity subscale of the Mishel Uncertainty in Illness Scale , the Symptom Distress Scale, and the Short-Form Health Survey (SF-12,explicit use of HRQL data,higher satisfaction,Mean (SD) scores,Quality of life,patient satisfaction and arm function on the affected side 2 months after diagnosis,QOL outcomes,Global health status, emotional functioning, and cognitive functioning,physical and emotional functioning, pain, and psychologic distress assessed monthly by using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) questionnaire and Impact of Event scale (IES,global health status,presence and severity of physical symptoms, psychiatric morbidity, use of and satisfaction with services, and carers' problems,contact rates,SF-36 subscales, activities of daily living, and physical performance,peripheral neuropathy,pain relief,EORTC QLQ-C30 scales/items,psychosocial morbidity,symptoms, HRQoL, mood and 'emotional bother' in 'full-PCT,knowledge and beliefs,quality of life,QOL, psychosocial functioning, or satisfaction,quality of care,average and worst pain levels,confidence treating patients who were receiving CT (confidence), knowledge of adverse effects and reasons to refer the patient to the treatment center (knowledge), and satisfaction with information and shared care of patients (satisfaction,quality-of-life scores,severe dyspnoea,QOL summary scores (total and overall QOL,Type of care, costs, patient satisfaction, ostomy adjustment, and time to achieve ostomy self-care,quality of life, SF-12; physical and mental component scores, (2) anxiety and depression: Hospital Anxiety and Depression Scale and (3) patient satisfaction: Patient Visit-Specific Questionnaire,usual pain intensity,cognitive functioning,Symptom distress, fatigue level, quality of life, and healthcare usage,Cornell Medical Index M-R scales (greater emotional disturbance,psychological functioning,survival,knowledge, confidence, and satisfaction,average and worst pain,costs,anxiety,analgesic prescriptions,global Quality of Life (QoL) scores,symptom severity,survival and health-related quality of life, measured with the use of the Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36), one year after randomization,incidence of pain,physical well-being dimension of health-related quality of life,breast reconstruction surgery,quality of life outcomes,debilitating physical symptom,Pain and nausea levels,Overall costs,median number of seroma aspirations per patient,symptom distress, enforced social dependency, and health perceptions,pain control, sleep, cancer-related symptoms, or analgesic dosing,quality of pain treatment,discussion of pain, and role function,emotional functioning,Patient satisfaction,symptom distress and social dependency,Uncertainty, mood states, well-being, charges, and reimbursement,pain levels,2-year survival,synergistic effects,pain medication level,sexual functioning and cancer worry,Psychosocial functioning, anxiety, and depression,recurrence, time to detection and death rates,patient satisfaction or GP confidence,total per capita health care costs, including HBHC,Social Support Questionnaire and an uncertainty questionnaire,subscale QoL scores and carer burden,satisfaction,Health services utilization,depressive symptoms, symptom distress, functional status, comorbidities, length of hospital stay, age of patient, and stage of disease,patient HRQL over time, measured by the Functional Assessment of Cancer Therapy-General questionnaire, physician-patient communication, and clinical management, measured by content analysis of tape-recorded encounters,subscales of complexity, inconsistency, and unpredictability,depression,HRQL,Symptom Distress Scale, Brief Fatigue Inventory, and Functional Assessment of Cancer Therapy Scale-General version,pain intensity, interference because of pain, adequacy of analgesics used, or pain relief,patient satisfaction,general practitioners' overall satisfaction,duration of drainage,Patient functioning, and patient and caregiver morale and satisfaction with care,hospital doctor,satisfaction with communication, participation in care, or quality of life,scales of depression,quality of life and carer burden,APMI score at baseline, patients' level of physical functioning, patients' level of social functioning, the extent of adherence to pain medication, patients' pain knowledge,patient satisfaction and confidence,mental health,role-emotional and mental health subscales,pain level,Total costs,ratings of pain intensity,quality of life and cost outcomes,quality-of-life outcomes,vomiting,chronic nonspecific symptoms,most satisfaction subscales,pain, mood disturbance, and concerns,SF-36 mental health subscale,symptom distress, and better SF-12 mental and physical QOL over time,Outcome measures: Quality of life, patients' satisfaction, general practitioners' satisfaction, survival, symptom-free survival, progression-free survival, use of resources, and comparison of costs,symptom distress, fatigue, quality of life, and healthcare usage,symptoms or quality of life,patient survival, activities of daily living (ADL), cognitive functioning, or morale,continuity of care,HRQL improvement,1) disease-specific quality of life, including sexual, urinary, and bowel outcomes and cancer worry; 2) depression; 3) dyadic adjustment; and 4) general quality of life,length of survival,complication rate, patient satisfaction, and psychosocial outcomes,health perceptions,normal arm function,global QoL measures,confidence,investigations, number and timing of recurrences and deaths,levels of anxiety, depression and perceived needs,mortality,survival or rates of objective progression|Patients in the augmented group improved significantly over the control group in ratings of pain intensity at its worst, whereas patients in the basic group had better ratings of pain intensity on average.
not found|Inducible displacement,Perioperative blood loss,quality of the fixation,Progressive radiolucent lines,red blood cell count, hemoglobin level, and hematocrit returned to the preoperative levels,perioperative blood loss,tibial components,total blood loss|Between 1 and 2 years, 4 of 24 HA-coated and 10 of 23 cemented implants migrated >0.2 mm and were categorized unstable, which has been shown to have a prognostic value as regards future aseptic loosening.
not found|visual analogue scales,normalization of OT and SVV,equilibrium scores in dynamic posturography, asymmetry index in rotation testing, motion sensitivity quotient (MSQ), and dizziness handicap inventory (DHI,Changes in oscillopsia,standing balance, Timed Up and Go test and Tandem Gait,parameters (VAS, DHI, BBS, mCTSIB,visual analogue scale anxiety score,subsequent relapse,ability to hear,persisting peripheral vestibular deficit,postexercise VAS, DHI (emotional, functional, physical, total), BBS, and mCTSIB (standing on a firm surface with eyes open, standing on a foam surface with eyes open, standing on a foam surface with eyes closed, mCTSIB mean,peak-to-peak magnitude and total amount of anterior-posterior body sway, and of horizontal (shear) ground reaction force,Symptoms, handicap, anxiety and depression, and negative beliefs about symptoms,Dynamic Gait Index,DVA-predictable,dynamic gait index results and anxiety,dynamic visual acuity,vestibulo-ocular reflex (VOR,vertigo intensity and frequency, low-frequency vestibulo-ocular reflex (VOR), posturography and path integration,locomotor stability,total SP values,VOR gain, VOR time constant, and OKN gain,hearing ability, tinnitus and dizziness,Vertigo decreased and independence in activities of daily living,Vertigo intensity and frequency,visual dependence,Vertigo, Dizziness, Imbalance Questionnaire (VDI), which consists of two subscales, the VDI symptom subscale (VDI-ss) and the VDI health-related quality of life (VDI-HRQoL) subscale, and the Vertigo Symptom Scale (VSS,visual analogue scale, physical examination, and need to use the medication,visual acuity,dizziness and imbalance,VSS,VOR response,dynamic visual acuity (DVA,standing balance performance,postural stability,balance ability and functional gait performance,psychological symptoms,hearing improvement,gait velocity and stability,baseline, 3-month, and 6-month assessment of self-reported spontaneous and provoked symptoms of dizziness, dizziness-related quality of life, and objective measurement of postural stability with eyes open and eyes closed,cure rates,optokinetic reflex (OKN) response to 60 degrees/s constant velocity optokinetic stimuli,tinnitus, dizziness or increasing hearing ability,adherence levels,reduced handicap,reductions of eyes-opened length and of eyes-opened correlation function between length and surface,static balance and a dizziness handicap,posturography scores,symptom, disability, balance, and postural stability,balance scores,symptom remission,dizziness handicap questionnaire and a visual analogue scale for anxiety,vertigo,vestibulospinal compensation,benign paroxysmal positional vertigo,dynamic posturography, vestibular time constants, and questionnaires concerning symptoms, symptom-triggers and emotional status,reduced symptoms, anxiety, handicap, and negative beliefs about dizziness,Timed Up and Go test, Tandem Gait and Dynamic Gait Index,VDI-HRQoL mean scores,perception of dysequilibrium,Vestibular time constants,reduction of symptoms,eyes-opened length of the oscillations and eyes-opened and eyes-closed surface of the body sway,dysequilibrium and nausea,symptoms (visual analog scale [VAS]), disability (Dizziness Handicap Inventory [DHI]), balance (Berg Balance Scale [BBS]), and postural stability (modified Clinical Test for Sensory Interaction on Balance [mCTSIB,Balance performance,cure rate,Subjective improvement in health, enablement (ability to understand and cope with symptoms), and adherence,central vestibulospinal compensation,mean scores of the VDI,balance performance,symptoms, postural stability, and dizziness-related handicap,posturography and subjective scores,visual vertigo (SCQ,clear locomotor gains,visual vertigo symptoms,visual vertigo symptom scores,vertigo intensity and frequency with the use of the Vertigo Symptom Scale, the Vertigo Handicap Questionnaire, the Vestibular Disorders Activities of Daily Living Scale, and the Dizziness Handicap Inventory,changes of pitch and loudness,dizziness, only vestibular rehabilitation also improves balance,symptom, disability, balance, and postural stability in chronic unilateral vestibular dysfunction,subjective visual vertical (SVV) for perception, and 3) the total sway path (SP) values,physical indices of balance and subjective indices of symptoms and distress,Dizziness,single leg stance,motion sensitivity and dizziness handicap,VSI mean scores, VDIss mean scores, and VSS mean scores,Static balance tests, tandem walk test, Dynamic Gait Index and subjective rating of the intensity of vertigo,demographics data and duration and intensity of symptoms,Odds ratios,Increased independence and decreased vertigo,Anxiety and depression levels|The use of exercises in the treatment of patients with vestibular deficits has become increasingly popular, and evidence exists that these exercises are beneficial in patients with chronic vestibular deficits.
65|Mean preoperative intraocular pressures,serum markers of collagen synthesis,IOP,Lower IOPs,frequency of complications,overall IOP control,introcular pressure (IOP,intraocular pressure from preoperative level,Efficacy and safety,IOPs and the cumulative probabilities of success,postoperative complications,final postoperative visual acuities,Complications,mean IOP, number of glaucoma medications, and complications,transient elevations of IOP,Complete success rate,final intraocular pressure,Success rates,hypertensive phase,1- and 2-year life-table success rates (success [survival,short- or intermediate-term success rates,Visual acuities,survival rates,successful intraocular pressure control,complications,postoperative intraocular pressure (IOP,IOP reduction,visual acuity,overall success rates,rate of hypertension,Choroidal hemorrhages and/or effusions, corneal decompensation, flat anterior chambers, and phthisis bulbi,Adjunctive medication requirement,postoperative antiglaucoma medication,preoperative visual acuities,mean postoperative IOP,severe complications,postoperative visual acuity, visual field, anterior chamber depth, and short-term or long-term complications,Preoperative IOPs and visual acuities,mean intraocular pressures,postoperative pressure spikes,Early postoperative hypotony,rate of complications,shallow or flat anterior chambers with hypotony,intraocular pressure (IOP), visual acuity, and complication rates,rate of hypotony and surgical complications,Final visual acuity,mean intraocular pressure,collagen synthesis,cataract formation,mean IOP,Visual acuities, implant-related complications, and average IOPs,Surgical success,preoperative mean IOP,Intraocular pressure, visual acuity, and complications,intraocular pressures,life-table success rates,Postoperative intraocular pressure,shallow anterior chamber,success rate,cumulative probabilities of success (intraocular pressure,Mean number of preoperative antiglaucoma medication,intraocular pressure,incidence of complications and the success rate,surgical outcome,cumulative success rate,probability of success,success rate with MMC and without MMC,hyphema,visual acuity, visual field, lens status, and final anterior chamber depth,IOP reductions,final intraocular pressure [IOP,devastating complication,intraocular pressures (IOP,incidence of complications,preoperative IOP, log mean angle of resolution (LogMar) visual acuity, or number of preoperative medications,Postoperative visual acuity, glaucoma medications, and complications,choroidal detachment,Intraocular pressure (IOP) and the appearance of the bleb,cumulative probabilities of success,Complications or inadequate pressure control requiring further surgical intervention,elevated IOP,adjunctive medication requirement,Molteno tube shunt surgery,final success rate,postoperative IOPs, visual acuities, number of medications used, and implant-related complications,Mean numbers of postoperative antiglaucoma medications|The success rate with MMC and without MMC were 90.0%, 77.3% (P < 0.05) at the 1st year, 87.1%, 67.3% (P < 0.05) at the 2nd year, 83.3%, 61.1% (P < 0.05) at the 3rd year, 81.3%, 56.7% (P < 0.05) at the 4th year, and 75.0%, 50.0% (P < 0.05) at the 5th year using Kaplan-Meier life-table analysis.
215|biopsy Gleason score, and baseline serum PSA levels,3-year progression rate,Median cycle length and percentage of time off therapy,serum prostate-specific antigen (PSA) measurements,serum PSA levels despite androgen blockade,biochemical failure,median PSA level,Gleason score,time to androgen-independence of the tumor|Of the 157 cases treated with EBRT, 153 cases (97.5%) had no biochemical failure in the mean follow-up of 17.3 months.
230|New York Heart Association classification,subjective state, hemodynamic parameters, and arrhythmias,Heart failure symptoms,reversible neutropenia,reduction in risk,lower morbidity and mortality,exercise duration (bicycle ergometry,treadmill exercise time, responses to the Minnesota Living With Heart Failure Questionnaire (LWHF), and clinical assessments,mortality and morbidity,mortality and quality of life,Diuretic doses,longer survival,quality of life and for increased arrhythmias,exercise performance,Symptom score,Adverse events,Left ventricular ejection fraction,Quality of life,Increased ventricular arrhythmias,symptom limited exercise tolerance,cardiovascular mortality,deaths,frequency of decompensation from heart failure,adverse events,serious adverse cardiovascular reactions, including hypotension,worsening heart failure,oxygen consumption,placebo mortality,quality of life,Exercise time,morbidity and mortality,physical activity,ejection fraction and plasma norepinephrine,headache,adverse cardiac events and physical activities,adverse effect,hemodynamic parameters of left-ventricular performance,Agranulocytosis,exercise duration, peak VO2, and quality of life,survival,exercise time,efficacy and safety,maximal treadmill exercise time,cardiac status,physical mobility score,hospitalizations,early mortality,tolerated,Adverse effects,quality of life measured with the Minnesota Living With Heart Failure Questionnaire,syncope,adverse effect on survival,exercise duration,degree of dyspnea and patient and physician assessments of clinical status,mean Specific Activity Scale score,hazard of death,borderline significance,exercise capacity,exercise tolerance and quality of life,Mean heart rate and ventricular ectopic activity,exercise tolerance,exercise time, ejection fraction, frequency of ventricular premature complexes or ventricular tachycardia,exercise tolerance, ventricular function, and symptoms of heart failure,overall LWHF score,median exercise time,symptoms or exercise duration,imazodan mortality,Proarrhythmic effects (24-hour electrocardiography,mean ejection fraction,frequency of worsened heart failure,sudden death,ventricular arrhythmias,morbidity,died,Heart rate, ventricular ectopic activity, and mortality rate,dropout rate,Peak VO2,treadmill exercise time,exercise capacity and adverse events,Maximal oxygen consumption,Death and hospitalization for cardiac causes,left ventricular ejection fraction at rest,cumulative incidence of combined adverse cardiac events,cardiac events,combined adverse cardiac events,mortality,Efficacy,severe worsening of heart failure|Treatment with milrinone or digoxin significantly increased treadmill exercise time as compared with placebo (by 82 and 64 seconds respectively; 95 percent confidence limits, 44 and 123, and 30 and 100).
17802|rates of venous thromboembolism,venous thromboembolism,provoked venous thromboembolism,pulmonary embolism or deep-vein thrombosis,symptomatic venous thromboembolism,rates of deep-vein thrombosis,rates of pulmonary embolism,rates of bleeding episodes,occurrence of symptomatic venous thromboembolism|The rates of pulmonary embolism were 0.09 in the rosuvastatin group and 0.12 in the placebo group (hazard ratio, 0.77; 95% CI, 0.41 to 1.45; P=0.42), whereas the rates of deep-vein thrombosis only were 0.09 and 0.20, respectively (hazard ratio, 0.45; 95% CI, 0.25 to 0.79; P=0.004).
22|hemagglutination inhibition titer,immune response,total white cell count or neutrophil count at immunisation, type of cancer, or length of time on treatment for acute lymphoblastic leukaemia,seroconversion rate,low white blood cell (WBC) count,hemagglutination inhibition (HI) titers,Seroconversion rates,protective" titers,HI titers,immune response and the peripheral white blood cell count,protective antibody titres,influenza virus susceptibility,Immune responses,titer of antibody,response rates,Antibody titers,Protective titer rates,Hemagglutinin-inhibition (HAI) antibody titers,response rate,HAI titers,Antibody responses,seroconversion and seroresponse rates,Immunoglobulin levels and neutropenia,geometric mean titers (GMT) and 4-fold rises in HAI titers,Seroresponse rates,antibody titers,tolerated,protective responses,Hemagglutinin-inhibition (HI) antibody titers,Immune response,protective response,seroresponse rates|After the second immunization, children off therapy showed significantly higher antibody titers to both antigens than did children receiving therapy or controls (P less than 0.01 for both A/NJ/76 and A/Vic/75).
1702|hypoxia,Treatment failure,community-acquired pneumonia,treatment failure (persistence of lower chest indrawing or new danger signs,very fast breathing|Treatment failure was 19% in each group (161 patients, pencillin; 167 amoxillin; risk difference -0.4%; 95% CI -4.2 to 3.3) at 48 h. Infancy (age 3-11 months; odds ratio 2.72, 95% CI 1.95 to 3.79), very fast breathing (1.94, 1.42 to 2.65), and hypoxia (1.95, 1.34 to 2.82) at baseline predicted treatment failure by multivariate analysis.
182|recall of diagnostic information,patient satisfaction with communication, mood state or quality of life,retention of information,quality of medical consultations,patient recall, anxiety and depression, satisfaction with and use of the communication aids, and patient preferences for six communication options,quality of life,Average recall,levels of anxiety,patient satisfaction, psychologic adjustment, and recall of information,Levels of depression,cancer patients' satisfaction, recall, and quality of life,degree of information provision; audiotape satisfaction and use; communication satisfaction with oncologist; mood state; and cancer-specific quality of life,length of time required for the consultation,total recall,recall, anxiety, or depression,enhancing satisfaction,perception of being informed about clinical trials, knowledge of information relevant to providing informed consent to a clinical trial, and satisfaction with communication during the consultation,final decision quality scores,Spontaneous (ie, unprompted) recall,degree of information provision, audiotape satisfaction and use, communication satisfaction with oncologist, mood state, and cancer-specific quality of life,sociodemographics, preferences for information, coping styles, and clinical characteristics,recall of the information given during the consultation,Satisfaction,patient satisfaction with communication, mood state, or quality of life,satisfaction, recall, and quality of life,patient satisfaction,recall of having discussed side effects,state anxiety levels|Satisfaction with the tape and letter were uniformly high and they did not differentially affect recall, anxiety, or depression.
109|Intrahepatic recurrence,disease free survival,colorectal carcinoma develop liver metastases,1-year, 2-year, and 3-year disease free survival rates,probability of remaining free of recurrent disease,TTF,nausea,initial tumour relapse,5-year survival rate,1-year, 3-year, and 5-year cumulative survival rates,TTF and survival,4-year liver recurrence-free rate,adverse effect,Survival,Median survival,Grade 3 and 4 toxicities (World Health Organization), mainly stomatitis,median time to progression,rate of intrahepatic recurrence and improve survival,survival,recurrence,median survival,median disease free interval after hepatectomy,4-year recurrence-free rate,time to recurrence and hepatic disease-free survival, not overall survival,dead of disease,risk of death,5-year survival,Two- and 5-year cumulative survivals,Median time to failure (TTF|The 4-year liver recurrence-free rate was 43% in the control group and 67% in the chemotherapy group (P =.03).
not found|pain,asymptomatic with activities of daily living,external rotation,pain scores, range of motion, internal rotation impingement, muscular force, and patient outcomes,shoulder pain with activity,mild pain,headache,mean pain duration, activity of the extremity and hours of sleep,intensity of pain,internal rotation impingement,Age, sex, pain (measured with an analog visual scale) and adverse events,internal rotation,subscapularis pushoff,range of motion in abduction and internal rotation,Pain,free of symptoms|Topical glyceryl trinitrate treatment significantly improved pain scores, range of motion, internal rotation impingement, muscular force, and patient outcomes in patients with supraspinatus tendinopathy.
45|hospital discharge,new-onset tachyarrhythmias,norepinephrine requirements,Gastrointestinal perfusion,systemic blood flow and VO2,Mean arterial pressure, cardiac index, stroke volume index, and left ventricular stroke work index,length of stay,cardiac index and oxygen consumption,Systemic, pulmonary, and regional haemodynamic variables,milrinone requirements,systemic and pulmonary hemodynamic or blood gas,pHi,achievement of MAP goal >24 h without vasopressors,systemic vascular resistance index,28-day mortality,acute coronary syndrome,overall rates of serious adverse events,Efficacy and safety,mortality, organ-failure-free days, length of critical care unit stay, and adverse events,Renal function,systemic vascular resistance,number of days without need for organ support and the occurrence of adverse events,bilirubin concentrations,Mean arterial pressure and PaO2/FIO2,gastric mucosal blood flow,gastric mucosal acidosis and global metabolic changes,arterial pressure,cutaneous reactive hyperaemia or the oscillatory pattern of vascular tone,incidence of sinus tachycardia with DA,cardiac output and global oxygen supply,mean arterial pressure,renal function and SOFA score,gastric tonometry,time to achieve MAP goals,adverse events,septic shock,hemodynamic and tonometric parameters, arterial and mixed venous gases, and lactate and pyruvate blood levels,peripheral vasoconstriction (systemic vascular resistance,catecholamine pressors withdrawn and blood pressure,time to vasopressor withdrawal,systolic arterial pressure,Median time to achieve the MAP goal,intraoperative maximum and minimum values of blood pressure and heart rate, and the time spent with systolic arterial blood pressure,maintain mean arterial pressure (MAP,systolic arterial blood pressure and heart rate,Total bilirubin concentrations,Oxygen delivery index,hemodynamics, lactate metabolism, and gastric tonometric variables,peripheral blood flow or on renal blood flow,efficacy and safety,28-day mortality rate,arrhythmia,partial pressure of carbon dioxide (PCO2) gap (tonometer PCO2-arterial PCO2,adverse event rate ratios,acute circulatory failure,oxygen transport,splanchnic oxygen requirements,systemic and regional hemodynamics,PaO2/FIO2 rates, length of stay, and mortality rate in PICU,blood pressure,cardiac output by decreasing heart rate, increased creatinine clearance, and improved SOFA score,Gastric mucosal pH (pHi,lactate levels,rebound hypotension,cause 28-day mortality,hemodynamic profile, oxygen delivery, oxygen consumption (determined by indirect calorimetry), and gastric intramucosal pH (pHi) (determined by gastric tonometry,terlipressin-linked decrease in Svo2,intraoperative refractory arterial hypotension,rate of death,Splanchnic blood flow and VO2,Mean arterial blood pressure,mortality rate,splanchnic tissue oxygen utilization,died of refractory hypotension,time spent with systolic arterial blood pressure,Mean stay in the PICU,oxygen delivery and oxygen consumption,Systemic and regional hemodynamics and oxygen transport,Rates of serious adverse events,Hemodynamic parameters and Sequential Organ Failure Assessment (SOFA) score,Reactive hyperaemia and oscillatory changes in the Doppler signal,Arterial pressure and systemic vascular resistance,mean arterial pressure, PaO2/FIO2, and survival time,arrhythmic events,platelet count,Mean arterial pressure, systemic vascular resistance, pulmonary vascular resistance, and left and right ventricular stroke work,oscillation frequency of the Doppler signal before ischaemia,catecholamine requirements,90-day mortality,Oxygen consumption (VO2,stroke volume,organ dysfunction, hospital and intensive care unit length of stay, and safety (primarily occurrence of arrhythmias,oxygenation, PaO2/FIO2, heart rate, mean arterial pressure, and mortality,consumption index,Cutaneous vascular reactivity and flow motion response,time to haemodynamic success,Regional blood flow and oxygen transport,oxygen uptake,Blood lactate concentrations,Global hemodynamic variables, oxygen consumption, urine flow, creatinine clearance, and arterial blood lactate levels,heart rate, NE requirements, and incidence of new-onset tachyarrhythmias,28-day all-cause mortality,time to vasoactive-free hemodynamic stability,Acute Physiologic and Chronic Health Evaluation II score,cutaneous microcirculatory response,hemodynamic variables, organ dysfunction, and adverse events,cardiac index,cardiac arrhythmias,lactate/pyruvate ratio,blood flow distribution and regional oxygen transport,Blood urea nitrogen, creatinine, AST, ALT, and urine output,mean arterial blood pressure,systemic and splanchnic oxygen utilization,severe septic shock,mortality rates,Terlipressin and norepinephrine corrected arterial hypotension,time course of SOFA score,mean arterial pressure (MAP) goal,mortality,heart rate,normal systolic arterial blood pressure,Urine flow and creatinine clearance,systemic hemodynamic measurements,systemic and pulmonary hemodynamics (arterial and Swan-Ganz catheters), gastric mucosal blood flow (laser Doppler flowmetry technique), hepatic function (indocyanine green clearance), and blood gases|There were no differences among groups in terms of systemic and regional hemodynamics.
not found|eventual presence of urinary keton bodies and hypoglycemic crisis,mean glycemic values,need of insulin, the maternal body weight gain, the week and mode of delivery, the neonatal weight and the maternal and fetal complications,control of foetal growth,blood glucose levels,mean insulin requirement,metabolic parameters considered (24-hour mean blood glucose and glycosylated hemoglobin,mean insulin requirements|No significant differences in mean insulin requirement at the different stages of gestation were found between the patients receiving CSII and those receiving ICT of either group.
56|frequency of cholangitis following ERCP,serum amylase levels,Bacteremia,absolute risk reduction,liver chemical values,Acute cholangitis,cholangitis,diagnosis of acute pancreatitis,absence of fever, cholangitis, and clinical signs of sepsis,frequency, duration and extent of such temporary symptoms as abdominal discomfort, fever, leukocytosis, hyperamylasemia, hyperamylasuria and cholestasis,post-ERCP pancreatitis,serum amylase level,hyperamylasemia,CRP level, and leukocyte count,normal biliary tracts,leukocyte count and liver function values,malignant distal strictures,septic complications,Incidence of bacteraemia,C-reactive protein (CRP) level,risk of pancreatitis,frequency of pancreatitis and bacterial complications,lack of antibiotic prophylaxis,septicaemia rate,acute cholangitis,Clinical success,number of septicaemias (bacteraemia with fever, rigor, circulatory reactions, leukocytosis or leukopenia,bacteriologic failure (bacteremia,complications (pancreatitis, pancreatic and biliary sepsis,clinical signs of acute pancreatitis with leukocytosis, CRP reaction, and pain,total rate of complications|Incidence of bacteraemia was 6.1% (3 of 49) in group A, 16% (8 of 50) in group B, but this difference is not statistically significant.
25|bout duration,Expanded Disability Status Scale score,ERPs,NRS scores,Scripps Neurological Rating Scale (NRS) and Kurtzke Expanded Disability Status Scale,frequency of improvement,P3 peak latency,Kurtzke functional and expanded disability status scales,CNS IgG production,VAS scores,rate of CNS IgG synthesis,serious adverse events,NRS and VAS scores,disability scores,pyramidal function,visual analog scale (VAS,NRS score and answers to an efficacy questionnaire,clinical disability scores|Changes in NRS scores among methylprednisolone- and placebo-treated patients differed significantly in the first 3 weeks and after 8 weeks (p = 0.005 and p = 0.0007).
not found|abdominal pain postoperatively,frequency and severity of dysmenorrhea,Moderate or severe dysmenorrhea,frequency and severity of dysmenorrhea, dyspareunia, and chronic pelvic pain,efficacy of LPSN,urinary urgency,recurrence of pain,dysmenorrhea,frequency and severity of dysmenorrhea, pelvic pain, and dyspareunia,Relief of lateral pain, back pain, and dyspareunia,midline component of menstrual pain,Acceptable pain,relief of dysmenorrhea, pelvic pain, and deep dyspareunia after surgery according to a multidimensional and an analog pain scale,postoperative ischemic pain,significant relief from menstrual pain,continued relief of menstrual pain,Dysmenorrhea improvement,frequency and severity of postoperative pain,age, history of abdominopelvic surgery, intraperitoneal adhesions, endometriosis, concomitant surgery, and operating time,recurrence of moderate or severe dysmenorrhea,relief of midline pain,cure rate|Relief of lateral pain, back pain, and dyspareunia was variable in both groups.
not found|CMV serostatus, CMV disease, graft outcome, and ganciclovir side effects,Time-to-onset of CMV disease and to viremia,demographics, primary renal disease, graft source, HLA matching, immunosuppressive therapy and donor-recipient CMV antibody status,Ganciclovir resistance,occurrence of CMV infections,time to CMV disease,CMV infection, CMV disease, rejection, opportunistic infections, and possible drug toxicity,incidence of cytomegalovirus (CMV) disease,serum creatinine concentrations,CMV and OB,obliterative bronchiolitis or time to onset of grade 2 bronchiolitis obliterans syndrome,CMV disease and infection,urine cultures positive for CMV,median time to onset of CMV disease,incidence or delayed the onset of CMV disease,Efficacy and safety,biopsy-confirmed acute rejection rate,opportunistic infections, and acute graft rejection,cytomegalovirus syndromes,renal transplantation,Adverse events,neutropenia with valganciclovir,nephrotoxicity,cumulative incidence of all CMV infections (including seroconversions,incidence and severity of CMV disease, length of hospitalization, and patient and allograft survival,Hallucinations and confusion,duration of disease,Overall patient survival,acute allograft rejection,incidence of overt CMV shedding and/or pneumonitis,rate of viral shedding,adverse events,CMV infection,rates of CMV viremia and viruria, herpes simplex virus disease, and the use of inpatient medical resources,lower activated T-cell count (CD3(+)HLA-DR(+) cells,estimated cost of valacyclovir treatment,CMV colitis,risk of CMV disease,incidence of cytomegalovirus disease,Pneumonitis and myocarditis,rate of EBV disease,infection with Candida albicans,length of hospitalization,laboratory-confirmed CMV disease,actuarial incidence of cytomegalovirus disease,tissue invasive disease and recurrent CMV disease,delay between transplantation and CMV infection,survival advantage,number of bacterial infections,incidence of documented cytomegalovirus infection,efficacy, safety, and cost,efficacy and safety,adverse reactions,rate of CMV infection,time to CMV infection and disease the first 6 months after transplantation,CMV,probability of presenting CMV disease,rate of biopsy-confirmed acute graft rejection,frequency of adverse events,PCR evidence for CMV viremia,cytomegalovirus infection,symptomatic CMV disease,tolerated,Cytomegalovirus,incidence of CMV disease and viremia,Reversible leukopenia,Leucopaenia,rate of biopsy-proven acute rejection,peripheral blood leukocytes (PP 65), shell vial culture (blood), and virus isolation/early antigen detection (urine,Liver function tests,leukopenia,cytomegalovirus disease,concanavalin A stimulation,Surveillance blood cultures,Rates of acute rejection, opportunistic infections, adverse events, CMV UL97 ganciclovir-resistance mutations, and laboratory abnormalities,time to asymptomatic CMV infection, symptomatic CMV infections, and end-organ CMV disease,cytomegalovirus (CMV) infection and disease,rate of CMV disease,cytomegalovirus pneumonia,Acute rejection episodes,CMV viremia,confirmed CMV disease,symptomatic herpes-simplex infections,12-month incidence of CMV disease,neurotoxicity,death from CMV disease,Infection rates,severe CMV disease,disease severity,excessive occurrence of cytomegalovirus disease,lymphocyte function,CMV infection and CMV disease) and secondary endpoints (rates of fungal and bacterial infection, allograft rejection, and survival after transplantation,rate of cytomegalovirus infection and disease without affecting the survival rate,infection, disease, or sequelae of cytomegalovirus infection,symptomatic cytomegalovirus disease,CMV illness,median time to onset of CMV infection,time to CMV disease or viremia,rates of other adverse events,Incidences of leukopenia, thrombocytopenia, renal failure, and other adverse events,cytomegalovirus (CMV) disease,median time to CMV antigenemia,CMV disease,freedom from CMV disease (syndrome or tissue-invasive,incidence of allograft rejection,incidence of CMV infection,demography, immunosuppression, or donor/recipient CMV serology,tissue invasive disease,Leukopenia,cytomegalovirus disease and cytomegalovirus viremia,average CMV-associated costs per patient,frequency of clinical infections,morbidity,CMV infection, symptomatic CMV infection, and CMV disease,incidence of CMV disease 90 days after transplantation,time to disease,rate of CMV infection and CMV disease,Lymphocyte proliferation,incidence of CMV infection in both CMV antibody positive,prevalence of obliterative bronchiolitis (OB,allograft survival,CMV disease, plasma viremia, acute graft rejection, graft loss and safety,CMV disease severity, CMV infection, acute rejection, opportunistic infections, ganciclovir resistance, and safety,delayed CMV infection,incidence of CMV disease,safety and efficacy,Time to CMV viremia,CMV-specific immunoglobulin M antibodies, CMV immunofluorescence assay [standard culture tube and shell vial] (blood) and virus isolation (urine and tissue,number of rejection, steroid pulses, and OKT3 treatments,detection of CMV DNA, virus infections other than CMV, acute rejection episodes, and serum creatinine levels,Severity of CMV disease,frequency of CMV or EBV disease,tissue-invasive infection,risk of acute renal allograft rejection,sequelae of cytomegalovirus (CMV) infections,total mortality,morbidity of cytomegalovirus disease,incidence of investigator-treated CMV disease events,CMV diseases,clinically effective and well-tolerated,Symptomatic CMV disease,CMV infection, disease, and disease severity without increased ganciclovir resistance or toxicity,delayed acute rejection,transplant function,rates of recovery of virus from the blood and urine,opportunistic or other herpesvirus infections,Cytomegalovirus disease,risk of acute rejection,time to development of CMV antigenemia,safety profile,incidence of CMV disease, and delayed the onset of CMV infection,incidence of symptomatic disease or viremia,delayed infections,episodes of biopsy proven allograft rejections|This superior protection against CMV disease extends up to 1 year after transplantation and is not associated with ganciclovir resistance.
40|incidence rates of mucositis, pain, xerostomia and taste disturbance,Minimal or absent mucosal inflammation pain or dysphagia,shorter mean radiotherapy duration,mean area under the mucositis curve,colonization index of viridans streptococci,Mucositis reduction,similar time to engraftment,time until healing,severity of radiation-induced mucositis,average time for oral lesion,median fall of the glomerular filtration rate (GFR,severity and duration of chemotherapy-induced oral mucositis,risk of mucositis,grade three or four mucositis,duration of mouth pain,fever,Pain relief,maximal grade of toxicity, duration of Grade 2 or worse mucositis, quality-of-life scores, percentage of weight loss, use of pain medications, hydration requirement, oral infections, and prolonged radiation breaks,severity of subsequent mucositis,Mucosal toxicity,peak stomatitis NCI-CTC grade,protective activity,median duration of grade >or= 2 mucositis,Local-regional control,incidence of TEAEs,percentage of patients with positive cultures of AGNB,plasma levels,pain on swallowing and use of pain medication specifically for mucositis,Visual analogue scale for oral pain and oral function,Stomatitis grade III/IV,percentage of neutrophil phagocytosis and the SAG levels,deaths from disseminated candidiasis,mucositis, dysphagia, and xerostomia,objective and subjective mucositis scores,weight loss, mucositis, pain, nutritional intake,oral mucosal complications,Subsequent mucositis,acute GVHD incidence or severity, survival, or day 100 relapse rates,Mucositis/stomatitis,mean duration of the use of this feeding tube,severity of stomatitis,prevention and reduction of severity of conditioning-induced oral mucositis (OM,pain requiring opioids (chi(2) exact test, NS,ulcerative OM,mean quality-of-life scores,proportion of patients with Grade 2 xerostomia,incidence of adverse events,grade > or =2 acute xerostomia,tumor growth and patient survival,weight changes,oral complications,incidence of chemotherapy-related oral mucositis,mean toxicity score for cryotherapy,development of Grade 3 mucositis and dermatitis,nausea and/or vomiting,severity and duration of oral mucositis,frequency of mucositis grade,Persistent clinical oral candidiasis,mean AUC values,grade 3/4 thrombocytopenia,occurrence of mucositis,body temperature or application of antibiotics,grades of oral mucosa ulceration,Nausea, vomiting, hypotension, and allergic reactions,Confluent mucositis,expression of Ki-67 and PCNA antigens,ulcer free,Acute toxicity,incidence or severity of diarrhea or in overall survival,duration of > or = Grade 3 subjective mucositis,median time of mucositis occurrence,alleviate oral mucositis,longer interval to the development of Grade 3 or greater mucositis,QOL scales,acute radiation morbidity,Oral mucositis,objective score of edema, erythema, erosion and ulcerations,neutrophil phagocytic function,duration and severity of chemotherapy-associated stomatitis,CR rate,radiotherapy duration,elevated mucositis score,aerobic,OM grade (WHO,amount of food intake,number of severe (i.e., grade 3) mucositis scores,severity (CTC-grading) and duration of OM,lactulose-mannitol ratio,mucositis distribution,radiation-induced oropharyngeal mucositis,influenza type symptoms,incidence of grades 3-4 mucositis,severity (maximum extent) of acute radiation therapy side effects,neutrophil functions and prevention of chemotherapy-induced side-effects,radiation-associated xerostomia,toxicity, engraftment, supportive care, response and survival,incidence of HSV infection,severe oral mucositis,tolerance to head-and-neck radiotherapy, decrease mucositis, reduce soreness,disease-free survival,soreness,grades of stomatitis and diarrhea,severity and duration of mucositis,Oral Mucositis Assessment Scale (OMAS) and the World Health Organization (WHO) scale,Colonisation index of Candida species and Gram-negative bacilli,severity of oral mucositis,severity and duration of mucositis, pain measurement, radiation therapy interruption, and quality of life,Major toxicities,healing of mucositis and dermatitis,subjective intolerance, mucositis, dysphagia, dermatitis and nausea,mean duration,intestinal permeability,average repairing time,milder mucositis and dermatitis,incidence of acute perineal skin and bladder toxicity,percentage of patients who developed intermediate or thick pseudomembranes,frequency of grade 2 to 4 mucositis,acute toxicity,oropharyngeal toxicity,incidence of grade 4 oral mucositis,grade 3-4 mucositis,tooth staining,Mucositis and oral pain,Saliva production,Grade 3-4 mucositis,suppression of oral flora and a lowering of the severity of mucositis,mean toxicity score,radiation mucositis and body weight, serum prealbumin level, and blood cell counts,Mucosal reactions, pain and difficulty in swallowing,intensity of radiation-induced mucositis and oral discomfort,median duration of fever,severity of radiation-induced oral/oropharyngeal mucositis,engraftment, acute GVHD, or survival,C-reactive protein (CRP) increase >50mg/L,stage IV disease,tumor response or survival,Grade 3 or higher acute mucositis,salivary flow, xerostomia, mucositis, and quality of life (QOL,grading of acute and late nonhematologic toxicities (mucositis, dysphagia, xerostomia,soreness of the mouth and throat,pain control,total body irradiation (TBI,partial remission,severity of late xerostomia,median maximum neutrophil counts,neutrophil phagocytosis, superoxide anion generation (SAG), prevention of chemotherapy-induced side-effects and cost-effectiveness,mucositis grade,Grade 2 mucositis,incidence of grade > or = 2 graft-versus-host disease,survival time,cervical muscular sclerosis,grade III skin reaction,WHO grade 1-4 oral mucositis,erythema, ulceration, and pain associated with oral mucositis,delayed emesis,IV degree toxicity,cure rates, extend survival, and reduce morbidity,Adverse events,complete remission (CR) rate,radiation-induced oral mucositis,Acute toxicities (mucositis and dysphagia,salivary gland function,Mucositis grade 3-4,nephrotoxicity, gastrointestinal side effects, haematopoietic recovery,Grade 0 mucositis,incidence and duration of ADM-induced oral mucositis,degree of mouth-opening,radiation- and chemotherapy-induced mouth lesions,radiation-related mucositis,quality of life,oral candidiasis,frequency or severity of oral mucositis,incidence of severe (grade 3-4) oral mucositis,Grade 3 or greater mucositis with morning RT,hospitalization for mucositis,incidence of WHO grade 2 or higher OM,frequency of Grade 2 to 4 mucositis,tumour control rates,mucositis area,salivary flow and QOL scores,estimated odds ratio (placebo/active) of developing an intermediate or thick pseudomembrane,percutaneous endoscopic gastrostomy,efficacy and safety,Grade 3 mucositis,average unstimulated salivary flow,pain and mucositis,grade 2 xerostomia,proinflammatory cytokines (tumor necrosis factor, interleukin [IL]-1, and IL-6) and lower levels of anti-inflammatory cytokines (IL-13,occurrence of mucositis, the median duration of oral mucositis,incidence of renal insufficiency,healing of mucositis,Oropharyngeal mucositis,symptomatic grade 3/4 mucositis,frequency of fever and infections,RTOG Grade 3 or greater mucositis,GFR,Overall survival,thickening of oral mucosa,WHO toxicity scale for mucositis, oral assessment scale, and a subjective pain scale,adverse effect of SOD injection,mucositis and dysphagia,Weight,skin reactions,colonization patterns of Candida species, Streptococcus faecalis, staphylococci, and Enterobacteriaceae, Pseudomonadaceae, and Acinetobacter species,plasma glutamine level,parenteral nutrition and morphine, incidence of fever and infections, and duration of neutropenia and hospitalization,incidence, mean duration, and mean area under the curve (AUC) of severe oral gross mucositis,absolute neutrophil count of > 0.5 x 10(9) cells/l,edema, infection, skin pain, or rash,5-year overall survival rate,grade of mucositis, skin reactions and related parameters,mean patient-judged mucositis scores,frequency or type of mouth lesions,locoregional failure, progression-free survival, and overall survival,stomatitis severity, incidence of UOM, peak mouth pain, peak difficulty swallowing, amount of opiate analgesics used, or adverse event type or incidence,mucosal pain,CRP >50mg/L,aerobic pathogenic bacteria,oral ulcerative mucositis,swallowing difficulty,need for percutaneous endoscopic gastrostomy placement,total duration of treatment,Oral mucositis and symptoms,urinary excretion of 51Cr-EDTA and the severity of mucositis,duration of objective oral mucositis,Severe oral mucositis,Patients' weight, taste, oral mucous reaction, and tongue mucous reaction,OM characteristics, fever of unknown origin (FUO) and other infections,oral ulceration,simple visual analogue scale,numbers of salivary enterococci, enterobacteria, and/or Pseudomonas,grade 3 mucositis,mucositis or oral pain,objective severity of mucositis, anorexia, and swallowing difficulty,nausea,amelioration of mucositis,Subjective reporting of discomfort, objective scoring of the severity of mucositis, and the maximal percent of body weight lost,severe mucositis,acute oral mucositis,safety and efficacy,severe leukopenia,clinical evolution of iatrogenic tissue damage,maximum severity of mouth pain and difficulty swallowing,mucositis/stomatitis of grade 2-4,Grade 2 or higher late xerostomia,stomatitis,severity of oral pain,OM severity,length of hospitalization or weight loss,numbers of aerobic and anaerobic bacteria,CR,rates of xerostomia and mucositis,Stomatitis scores,Mucositis score,pain,neutrophilic granulocyte toxicity,incidence and severity of oral/oropharyngeal mucositis,Whole saliva production,episodes of mucositis,duration and severity of stomatitis,adverse effects,detectable plasma concentration of GM-CSF,skin toxicity,Skin and mucosal reactions,average mucositis score,development and severity of mucositis,intensity or duration of mucositis,incidence of severe oral mucositis,radiation mucositis, pain, dysphagia and weight loss,severity of acute side effects,severe (grade 3 or 4) mucositis,need for feeding tubes,mean maximal intensity for NCI score,Mucositis, changes in the oral flora, quality of feeding and changes of total body weight,Oral assessment of mucositis by using World Health Organization (WHO) oral toxicity scale,mean area under the curve stomatitis scores,overall survival rate,degree toxicity,Severity of mucositis,alive without disease recurrence,mean duration of "at least Grade 3" mucositis (WHO,weight loss,duration and severity of objective oral mucositis,Toxicity profiles,duration and severity of subjective oral mucositis,stomatitis and diarrhea,chronic xerostomia grade,positive gain in body weight,frequency,Mean weight loss,tumor response rate,frequency and duration of OM,Engraftment of neutrophil,acute oropharyngeal toxicity,mucositis and xerostomia,frequency of culture-positive herpes simplex virus,mean duration of oral mucositis,severity of mucositis,median IP test score,duration of neutropenia,varying degrees of radiation-induced mucositis,adverse events,Grade 4 mucositis,efficacy/toxicity,Oral pain,incidence of mucositis,acute and chronic xerostomia,Type of mouthwash, incidence, days to onset, and severity of chemotherapy-induced oral mucositis,Oral mucositis and selective elimination of oral flora,frequency and severity of therapy-induced oral mucositis,buccal toxicity,highest serum creatinine value,Antitumor treatment efficacy,morbidity and mortality,mucositis and dermatitis,5-FU-induced mucositis,salivation and decrease oral mucositis,quality of life by impairing eating, swallowing, and talking and by disturbing sleep,frequency and duration of severe oral mucositis,Numeric Rating Scale scores,radiation-induced mucositis,oral mucositis (OMAS, NCI score), oral pain (VAS), oral function and salivary flow rate,occurrence rate of grade 1-2 mucositis of the oral cavity,oral candida,erythema and ulceration,duration of severe mucositis,oral soft tissue disease and oral microbial burden,occurrence of severe oral and intestinal mucositis,Mean maximum grade of objective oral mucositis,incidence of grade > or =2 acute xerostomia, grade > or =3 acute mucositis, and grade > or =2 late xerostomia,oral mucositis (OM) and diarrhea,safety, tolerability and efficacy,cumulative asthenia,salivary lactoferrin concentrations,cumulative incidence of moderate to severe (grade 2 or higher) mucositis,pharyngeal, esophageal, and rectal mucositis,incidence and severity of oral mucositis,serum cytokine levels and the severity of oral mucositis,time to development of severe mucositis,leukopenia,oral mucositis and pain,Nausea,total parenteral nutrition (TPN), narcotic use, hospitalization, weight loss and resumption of oral caloric intake,frequency of severe (WHO grades 3 or 4) mucositis,oral mucositis, pain, xerostomia and taste disturbance,acute xerostomia,platelet recovery, erythrocyte recovery, incidence of veno-occlusive disease, GVHD severity, relapse or survival,later onset of stomatitis,mean of grade 1-4 mucositis, anorexia, difficulty in swallowing, and body weight change,hazard ratio (HR,effective, safe, and well tolerated,lower number of days with fever and a shortened duration of hospital stay,median grade of oral mucositis,Documented infections, use of broad-spectrum antibiotics, and number of days with fever,incidences of grade III-IV mucositis and infection,hematological toxicity,mean questionnaire scores,degree of mucositis,additional toxicity,acute mucositis,ADM-induced mucositis,number of patients with severe objective mucositis,Median saliva production,degree of oropharyngeal and hematological toxicity, radiotherapy duration, and curative effect,degree of mucomembranous reaction,C-reactive protein levels,plasma glutamine level, intestinal permeability (lactulose-mannitol test), and tumor size,total of 11 dose-limiting toxicities (most often skin, respiratory, or oral mucositis,IP test score,incidence of mucositis requiring morphine sulfate (MSO4,Acute nausea/vomiting,Neck dissection,leukocyte recovery,incidence of OM and diarrhea, safety, disease progression, and survival,probability of grade > or = 3 mucositis,oropharyngeal ecology,4-year survival,frequency of chemotherapy-induced mucositis,neutrophil and platelet engraftment,nutritional status and overall patient outcome as assessed by days receiving TPN, number of days required until oral intake resumed, length of hospitalization, number of days and highest grade of mucositis, and quantity and number of days of diarrhea,oral mucositis grade, oral pain, use of analgesic drugs, weight loss, or survival,skin and mucosa reactions,acute grade 2 xerostomia,duration and severity of oral mucositis,radiation-induced early oral mucositis,oral mucomembranous reaction,tolerance problems (vomiting, liver enzyme elevation, generalized erythema,Intensity of mucositis,reduced incidence and mean severity of mucositis,Candida colonisation,Local effectivity,progression of mucositis using the Oral Mucositis Assessing Scale (OMAS,incidence and severity of acute and late toxicities,highest grade of mucositis,Adverse events, mainly rash, pruritus, erythema, mouth and tongue disorders, and taste alteration,Toxicity data,duration of hospitalization,radiation mucositis,mean pain sure and mucositis grade,occurrence rate of skin, oral mucosal, pelvic visceral and systematic adverse reaction,grade three mucositis,tolerated and no adverse events,incidence of loss of taste,median survival,oral discomfort,survival outcomes,incidence and severity of mucositis,complete remission,expression of Ki-67 and PCNA antigens in breast carcinoma,incidence, severity and duration of oral mucositis,burning sensation,frequency of "severe pain,Radiation mucositis,alleviation of radiation-induced mucositis,oral health,maximum mucositis scores,incidence of use of total parenteral nutrition,dysphagia,hematologic toxicity, transfusion requirements, duration of fever, and hepatic toxicity,rates of percutaneous endoscopic gastrostomy placement,severe mucositis and dermatitis,bone pain,Complete blood count,degree of mucositis and dermatitis,World Health Organization (WHO) step analgesic medication and body weight change,toxicity (eg, mouthwash-induced discomfort, taste alteration, and teeth staining,oral mucositis (OM,median subjective pain scores, WHO scores, and oral assessment scores,mucositis, skin reaction, dysphagia,WBC toxicity,grade four mucositis,safe and well tolerated,platelet toxicity,incidence of oral mucositis grade 2-4 and the duration of oral mucositis grade,total oral streptococci,median time to percutaneous endoscopic gastrostomy removal,Grade 2 mucositis and dermatitis earlier and sooner,oral pain,acute xerostomia and mucositis,Skin and oral events,xerostomia and mucositis,Objective Mucositis Score (OMS) and the World Health Organization (WHO) grading system,mean AUC of gross/functional scores and duration of moderate gross mucositis,severe mucosal reactions,median duration of mucositis,Intensity of pain, severity of mucositis and use of opioids,moderate/severe mucositis,preexisting colonization,CRP increase,mucositis,incidence and severity of acute mucositis, acute and late xerostomia,demographic parameters, medical status, quality of life survey and mucosal injury scoring table (based on World Health Organization scales for mucositis,safety and tolerability,Oral mucositis (OM,anesthetic mouth washing and their salivary lactoferrin and albumin levels,objective and subjective mucositis scores and microbiologic counts of the oral flora,severity of radiation mucositis,radiation reactions,Mucositis,median total tumour and biologically effective dose (BED) Gy10,grades of mucositis,Karnofsky performance status, body weight, cutaneous side effects, and alopecia,mucositis incidence and severity,2-year local-regional control, disease-free survival, and overall survival,outcome questionnaire; and daily symptom record diary,mouth pain and difficulty swallowing,risk of oral mucositis,grade of mucositis,albumin and low molecular weight protein urinary excretion,treatment duration, hematologic toxicity, and clinical outcome,mean mucositis scores,Grade > or =3 mucositis,Some mucositis,Hypotension,tolerated,intestinal permeability (IP,functional activation of WBC,eosinophil counts,mean total duration of mucositis,delays in radiotherapy because of grade 3 mucositis,worsens oral mucositis,incidence of severe mucositis,pain, swallowing, drinking, eating, sleeping and taste alterations,Stomatitis,incidence of grade 2 late xerostomia,incidence of oral mucositis of World Health Organization (WHO) grade 3 or 4,median interval to observation of grade > or =2 mucositis,oral mucositis,incidence of grade 3/4 mucositis,Grade 2 or higher acute xerostomia,toxicity,earlier onset of mucositis,gastrointestinal bleeding,Acute mucositis,skin reaction,Salivary lactoferrin,degree of oropharyngeal mucosa reaction, dryness in mouth and radiation dermatitis in cervical region,Mean body weight change,dental plaque levels and the degree of gingivitis and mucositis,mild radiation side-effects,unadjusted chi-square test, and time to first episode of mucositis,incidence of Radiation Therapy Oncology Group grade 3 mucositis,Interval to healing,equal rate of non-compliance,ADM-induced oral mucositis,mucositis scores,median time to development of severe mucositis,oral mucositis daily fraction,feasible and well-tolerated,safety and for OM incidence and severity,narcotics and TPN,treatment-emergent adverse events (TEAEs,Serum interleukin-6,grade of radiation mucositis and blood cell counts,incidence, days to onset, and severity of mucositis,diarrhoea,mucositis and mouthwash toxicity,Duration of moderate/severe mucositis,median number of amifostine doses,development of infection, mucositis and diarrhoea,complete responses (CR) and 6 (24%) partial responses (PR,anorexia,complete eradication of AGNB,severity of oral mucositis and pain scores,delayed mucositis,grade III/IV mucositis,mucositis and ADM-induced leukopenia,number of days with fever, number of oral lesions, plaque score, gingival bleeding score, or occurrence of candidiasis,occurrence rate of grade 3-4 mucositis,mean weight loss,oral flora and irradiation mucositis,Nasogastric tube feeding,grade of oral mucositis,OM,Mucositis, the inflammation and necrosis of mucosal membranes,Toxicity incidences,median progression-free or overall survival times,severity of OM,morbidity of concurrent chemotherapy and radiotherapy,Hemoglobin level,protective effect against 5-FU-induced mucositis,mean onset of mucositis,standard error of the mean) maximum mucositis scores,median length of stay and the median number of days of total parenteral nutrition (TPN,episode of febrile neutropenia,pain visual analogue scale (VAS) scores, mucositis index scores and medical and nursing charts,skin desquamation,oral toxicities,Grade 2 xerostomia,weight, prealbumin level, or blood cell count,degree of oral injury,levels of selected cytokines and mucositis severity|No difference in the visually assessed degree of mucositis or oral pain reported by the patients was found between the study and the control groups.
50|occurrence of TMD signs,myofascial pains symptom status,cumulative incidence rate,presence of symptoms and signs of TMJ dysfunction,disclusion time, as well as, myofascial pains muscular symptom remissions,subjective symptoms,number of tender muscles,disclusion times,incidence of temporomandibular disorders,globus symptom,symptom remissions,frequency of headaches, facial pain, or pain on mandibular movements,frequency of headaches, facial pain, pain on mandibular function, or duration of headaches and facial pain,occlusal centric slides,subjective symptoms of CMD,muscles of mastication and/or jaw joint,disclusion time|There were no significant differences between groups with regard to frequency of headaches, facial pain, pain on mandibular function, or duration of headaches and facial pain.
325|Fluorosis,prevalence of aesthetically important DF ('Mild' and 'Moderate,TF index the child and tooth prevalence of opacities,severity of fluorosis,early forming (Fluorosis Risk Index (FRI) classification I) enamel surfaces,Thystrup-Fejerskov Index (TFI) scores,Dental fluorosis (TF index,Overall, levels of fluorosis,early toothbrushing habits,odds of experiencing fluorosis,fluorosis community index (FCI,prevalence of dental caries,child's birth weight and liking for or swallowing of toothpaste,prevalence of fluorosis by TF1+ case definition,Mean DMFT values,mainly TFI score,Enamel opacities and dental caries,mild fluorosis,Jarman score,Fluorosis prevalence,moderate to severe fluorosis,dental fluorosis prevalences,prevalences of TF,risk of enamel fluorosis,mean DMF score,Fluorosis Risk Index (FRI,TFI score,Risk factor exposure,Caries prevalence,Prevalence of dental fluorosis,Social deprivation,prevalence of caries,dental caries experience,prevalences of fluorosis,behavior problems and dental fluorosis,Thylstrup and Fejerskov (TF) index for fluorosis and the modified Developmental Defects of Enamel (DDE) index,prevalence of fluorosis,TFI scores,Overall prevalence,risk of fluorosis,DF levels,Caries (DMFT, WHO criteria, no radiographs) and dental fluorosis (TF index, dry permanent incisors,Demographic information, details of F history, and dental attendance data,prevalence of dental fluorosis,dental fluorosis,risk of dental fluorosis prevalence|The prevalence of fluorosis among children in ACORN group A-C was significantly greater than in groups D-F.
163|levels of impairment for all pain domains and reduced morphine usage,hemodynamic stability,Pulmonary function (maximal inspiratory lung volume,Time to extubation,arterial oxygen tension,flow and endothelium of internal thoracic artery,faster extubation times,perioperative arrhythmia,quality of recovery,length of stay,respiratory tract infections,VA/Q matching, oxygenation, or atelectasis formation,Median postoperative stay,survival free from myocardial infarction, pulmonary complications, renal failure, and stroke,Time to awakening and time to extubation,30-day survival free from myocardial infarction, pulmonary complications, renal failure, and stroke,AF,hemodynamic function and reduced arrhythmias,troponin I, time to tracheal extubation, and analgesia,peak expiratory flow rate,heart rate and mean arterial pressure,postoperative hospital length of stay and patients' perception of their quality of recovery,hypoxemia,myocardial damage, inflammatory, and stress response,posttraumatic stress subscales,epinephrine serum levels,myocardial cell damage, inflammatory, and stress responses,mean ITA free flow,transcapillary COP-gradient (COPpl-COPif,lung volumes and pulmonary function follows cardiac surgery,Hemodynamics, plasma epinephrine and norepinephrine, cortisol, the myocardial-specific contractile protein troponin T, and other cardiac enzymes,postoperative complications recorded to 14 days and mortality recorded to 720 days,global and regional myocardial function,number of patients showing ventricular fibrillation (VF), atrial fibrillation or heart block after release of the ACC,subcutaneous interstitial tissue,Pain relief,number of Bcl-2 positive cardiomyocytes,mean arterial pressure,oxygen delivery and mixed venous oxygen saturation,Myocardial, inflammatory, and stress responses,acute renal failure,lower visual analog scores with coughing postextubation,postoperative pain,intramyocardial oxygen partial pressure,Hospital stay,intraoperative hemodynamics or ventricular function,Tracheal extubation time, oxygen withdrawal time and ICU stay,ventilation-perfusion (VA/Q) relationships, atelectasis, and oxygenation,CI,vasoactive medication, mean arterial blood pressure,incidence of perioperative dysarrhythmias,perioperative lung functions and pain scores,ELISA, CRP and SAP mere measured with rocket immunoelectrophoresis (RIE,overall incidence of episodic hypoxemia,release of troponin T,postoperative global quality of recovery score,troponin T release,Pain,Intraoperative sinus bradycardia,regional left ventricular function after myocardial revascularization, assessed by transesophageal echocardiography,Plasma levels,extensive bilateral atelectasis,Serum epinephrine levels,cardiac norepinephrine spillover, MAP, systemic vascular resistance index (SVRI), pulmonary capillary wedge pressure (PCWP), GCVF, and Reg-MVO2,splanchnic blood flow nor oxygen delivery and consumption,quality of recovery score,atrial fibrillation (AF,hospital length of stay, quality of recovery, or morbidity,vasoactive and inotropic drugs and fluid balance,cardiac troponin,systemic vascular resistance (SVR,consumption of anesthetics,hemodynamic changes,incidence of tachycardia,Blood glucose values,pulmonary function,Forced vital capacity and forced expiratory volume,acute confusion,PCT, TNF-alpha and leukocyte count,Troponin I, 8-isoprostane, cortisol, C3alpha, interleukin (IL)-6, IL-8, and IL-10,postoperative stress,Hemodynamic measurements and blood sampling,troponin,transcapillary fluid balance,ITA free blood flow,Incidence of perioperative arrhythmias such as atrial fibrillation, serum epinephrine levels, heart rate variability, and hemodynamic parameters,VAS score, SS, and postoperative PaO2,Length of stay and time to eligibility for hospital discharge,cardiac sympathetic activity, myocardial blood flow and metabolism, and central hemodynamics,myocardial oxygen availability,Minnesota Multiphasic Personality Inventory,Ischaemic damage,hospital discharge time,regional left ventricular function,cardiac, renal, and neurologic outcomes,Plasma epinephrine increased perioperatively,perioperative arrhythmias such as atrial fibrillation,Pif,tracheal intubation time and length of hospital stay,morphine analgesia,arrhythmia, inotropic support, intubation time, perioperative myocardial infarction, neurologic events, intensive care stay, pain scores, and analgesia requirement,incidence of arrhythmias and the median intubation time,incidence of stroke,adequate postoperative pulmonary and cardiovascular functions; nausea and vomiting,time to tracheal extubation,plasma concentrations of cardiac troponin,constant hypoxemia,postoperative analgesia,postoperative heart rate,Psychologic morbidity, intraoperative hemodynamics, ventricular function, lung function, and physiotherapy cooperation,transient and almost simultaneous proinflammatory and anti-inflammatory cytokine response,ITA free blood flow significantly via increased VEGF, i-NOS, and adenosine-A2B receptor expressions,mean systolic arterial pressure,splanchnic blood flow,IL-6 and IL-8 levels,serum amyloid P-component (SAP,forced vital capacity, forced expiratory volume in 1 s (FEV1.0) and peak expiratory flow rate (PEFR,release of IL-6, IL-8, and IL-10,plasma levels of bactericidal permeability-increasing protein, lipopolysaccharide-binding protein, and C-reactive protein,metabolic (lactate) or electrocardiographic signs of myocardial ischemia,Mean troponin T levels,Postoperative pain relief and stress hormones,Immunostaining intensity,postoperative spirometry or chest radiograph changes,Procalcitonin (PCT), tumor necrosis factor (TNF-alpha), soluble TNF receptor, human soluble intercellular adhesion molecule-1, C-reactive protein (CRP) and leukocyte count,Levels of postoperative stress, serum cortisol, and beta-endorphin,Vital Capacity,stress response and pain scores,ABG values and PaO2/FiO2 ratio,Pain score,Simultaneously plasma colloid osmotic pressure (COPpl,transcapillary forces (COPpl, COPif, Pif,Regional left ventricular function,episodic hypoxemia,physiotherapy cooperation,total and cardiac sympathetic activity,IL-6,intensity of the immunostaining,Mean arterial pressure,Analgesia,Postoperative length of stay, time to eligibility for hospital discharge, pain and sedation scores, degree of ambulation, lung volumes, and organ morbidities,rapid recovery and shorter hospital stay,C3alpha, troponin I, 8-isoprostane, and cortisol release,CRP concentrations,postoperative myocardial ischemia,Serum morphine,Pain relief, degree of sedation, ambulation, and lung volumes,levels of IL-10,Pulmonary shunt and alveolo-arterial oxygen difference,time to tracheal extubation, duration of postoperative intensive care unit stay, duration of postoperative hospitalization, pain control, urinary free cortisol, cardiopulmonary complication rate, and total hospital charges,incidence of postoperative arrhythmias and improves pain control and overall quality of recovery, allowing earlier extubation and hospital discharge,Mean arterial blood pressure poststernotomy and systemic vascular resistance,cardiac function,plasma cortisol,cytokine production,cortisol response,Postoperative pain management,Postoperative pain,length of postoperative hospital stay,perioperative stress response and postoperative myocardial ischemia,Interstitial fluid colloid osmotic pressure (COPif) and interstitial fluid pressure (Pif,troponin release,Natriuretic peptide concentrations,I concentrations,myocardial ischemia,analgesia, early tracheal extubation and shorter ICU stay,effective analgesia,recovery time, postoperative pulmonary and cardiac parameters, visual analog scale (VAS) scores, and sedation scores (SS,brain natriuretic peptide,Arterial and mixed venous blood gases and hemodynamic variables,length of hospital stay,mean arterial pressure (MAP), great cardiac vein flow (GCVF), and regional myocardial oxygen consumption (Reg-MVO2,myocardial sympathetic response,Haemodynamic effects,SAP plasma levels,major postoperative complications,blood flow of the ITA,Visual analogue scale at rest and on coughing,immunoreactivity rates,neurologic complications,postoperative depression,cardiopulmonary bypass- and surgery-associated stress response and incidence of myocardial ischemia,haemodynamic effects,time to endotracheal extubation, oxygen withdrawal time and intensive care unit length of stay,mean (SD) peak concentrations of atrial natriuretic peptide,Bcl-2 positive cardiomyocytes,cardiac index,Ventilator dependency and analgesia,postoperative myocardial ischemia or infarction,perioperative atrial fibrillation,shunt, VA/Q matching, or oxygenation,biochemical markers of myocardial damage,cardiac sympathetic nerve activity, myocardial blood flow and metabolism, and central hemodynamics,mean arterial pressure (MAP,the Starling forces" (COPpl, COPif, Pif,mean pulmonary arterial pressure,pneumonia,need vasoconstrictors intraoperatively,Interleukin-6 levels,pain,recovery time,catecholamine response,Extubation,pain scores,cytokine levels,New supraventricular arrhythmias,heart rate,myocardial oxygen demand,postoperative ischemia,spirometric data, arterial oxygenation, pulmonary shunt, haemodynamics, use of vasoactive drugs and fluid balance,Postoperative pain scores,Thirty-day survival free from myocardial infarction, pulmonary complications, renal failure, and stroke,intramyocardial partial oxygen pressure,PaCO2|In group E 22 of 44 (50%), in group E+A 10 of 35 (28.6%), in group A 10 of 36 (27.8%), and in the control group 20 of 48 (41.7%) patients developed AF (odds ratio amiodarone/nonamiodarone 0.47 [0.24-0.90]; P = 0.02).
60|Postoperative pain,postoperative pain and recovery,PONV, eating, sleeping or behavioural disturbance,modified objective pain score, and the time taken to first requirement of analgesia,pain relief,induction-incision time,Postoperative analgesia,frequency of vomiting,Motor weakness, time to first micturition, postoperative nausea and vomiting (PONV), eating habits, sleep disturbance and behaviour,time interval between operation and subsequent analgesic administration and the number of analgesic doses,Recovery of consciousness,incidence of vomiting,duration of analgesia,Analgesia,Incidence of adverse effects,time to first requirement for analgesia or number of doses of paracetamol,efficacy, complication rates, and parental satisfaction,analgesic effects,motor weakness,pain and caudal analgesia,time to first micturition,level of consciousness and apparent pain|There was no difference between the groups in time to first requirement for analgesia or number of doses of paracetamol given in the first 24 h. Almost half the boys in the caudal group had motor weakness, and there was a significant increase in time to first micturition in that group.
not found|caries incidence and plaque accumulation,caries incidence,mean approximal caries increment, including initial caries lesions,caries development,incidence of caries,fluoride levels,dental caries,Plaque indices,approximal caries|Frequent, but less than daily, topical fluoride therapy appeared to have little effect in pre-school children consuming water-borne fluoride and receiving other traditionally recommended modalities of prevention.
50|ADHD symptoms,total omega-6/omega-3 ratios,higher AA/EPA,Plasma phospholipid DHA content,Efficacy measure was Conners' Parent/Teacher Rating Scales (CPRS/CTRS,visual short-term memory and errors of commission (continuous performance,subscales scores,CGI scores,lower EPA concentrations,attention-deficit/hyperactivity disorder(AD/HD) symptoms,symptoms,Abbreviated Symptom Questionnaire (ASQ,blood FA composition and behavior,inattention and global Diagnostic and Statistical Manual of Mental Disorders, Fourth edition, total Conners' subscales,alterations in FAs and increased TOVA scores,serum phospholipids and red blood cell membranes (RBC,AD/HD-related symptoms,blood fatty acid composition and visual sustained attention performance,cognitive measures,Attention Problem and Motor Excess of the Revised Behavior Problem Checklist,Fatty acids,ADHD clinical symptoms,oppositional defiant behavior,multiple outcomes,AA/DHA,sustained efficacy,cognitive performance,symptoms of attention-deficit/hyperactivity disorder,Parent impact-emotional (PE) subscale,plasma PUFA composition,Total TOVA scores,FO,n-3 PUFA safety and tolerability,EPA and DHA in the RBC and the teachers' Disruptive Behavior Disorders (DBD) Rating Scale for Attention,plasma phospholipid fatty acid patterns, scores on laboratory measures of inattention and impulsivity (Test of Variables of Attention, Children's Color Trails test) while not taking stimulant medication, and scores on parental behavioral rating scales (Child Behavior Checklist, Conners' Rating Scale,parent version of the Conners' questionnaire,CTRS total score,symptoms of ADHD,Baseline EFA concentrations,Investigator-rated ADHD Rating Scale-IV and Clinical Global Impression (CGI) scale,Conners' parent and teacher rating scales (CRS-P,T), Strengths and Difficulties Questionnaire (SDQ), and Child Health Questionnaire (CHQ,teacher-rated behaviour and oppositional symptoms,symptoms of attention-deficit/hyperactivity disorder (ADHD,higher AA/DHA ratios,tolerated,eicosapentaenoic and docosahexaenoic acids,attention deficit, hyperactivity and impulsivity (AD/HD-related symptoms according to DSM-IV criteria); (2) aggression assessed by both parents and teachers; (3) visual perception (finding symbols out of a table); (4) visual and auditory short-term memory; (5) development of visual-motor integration; (6) continuous performance; (7) impatience,alpha-tocopherol concentrations,omega-6 fatty acid concentrations,plasma and erythrocyte FA profile and continuous performance test results (Test of Variables of Attention; TOVA,Efficacy,fatty acid (FA) composition,objective or subjective measure of ADHD symptoms,proportions of EPA, DHA, and alpha-tocopherol in the plasma phospholipids and red blood cell (RBC) total lipids,EPA improved CTRS inattention/cognitive subscale,disruptive behavior,ability to switch and control attention (Creature Counting|conduct problems rated by parents (-42.7 vs. -9.9%, n = 47, P = 0.05), and attention symptoms rated by teachers (-14.8 vs. +3.4%, n = 47, P = 0.03).
162|gastrointestinal bleeding and one genitourinary bleeding,nonfatal major bleeding,odds ratio for recurrence,higher risk of major hemorrhage,major bleeding episodes,idiopathic deep venous thrombosis,recurrent venous thromboembolism,episodes of pulmonary embolism,123 recurrences of venous thromboembolism,relative risk of major hemorrhage,relative risk of recurrence,pulmonary embolism,recurrence of symptomatic, objectively confirmed venous thromboembolism,23 recurrences of venous thromboembolism,recurrent VTE,recurrence rate,incidence of recurrent venous thromboembolism,26 recurrences of venous thromboembolism,recurrence,non-fatal major bleeding,initial episodes of deep-vein thrombosis,rate ratio,major bleeds,recurrences and major, minor, or fatal bleeding complications,recurrent thrombosis,mortality or the rate of major hemorrhage,incidence of recurrence,rates of recurrent symptomatic venous thromboembolism and bleeding,duration of oral anticoagulant therapy,recurrent episode of venous thromboembolism,rates of recurrence,risk of recurrent venous thromboembolism,rate of recurrent venous thromboembolism,mortality,recurrence of venous thromboembolism,rate of recurrence|Warfarin resulted in a 95 percent reduction in the risk of recurrent venous thromboembolism (95 percent confidence interval, 63 to 99 percent).
32|symptoms of water retention,mean number of bleeding-spotting days per cycle,adrenal and peripheral androgens,Serum total an unbound testosterone (T) and sex hormone binding globulin (SHBG) levels,inflammatory lesion count,Blood pressure and body weight,Menstrual Distress Questionnaire (MDQ) normative T scores; the proportion of subjects with acne; and menstrual symptoms,Cycle control, dysmenorrhea and premenstrual syndrome (PMS,mean objective acne score,Moderate papulopustular acne of the décolleté,clinical efficacy,echogenic texture of the ovaries,Dysmenorrhea and PMS,Efficacy and safety,unacceptable bleeding,bioavailable,withdrawal bleeding,number of lesions and the degree of severity,Serum total and unbound testosterone and sex hormone binding globulin (SHBG,relative frequency of women with complete resolution,acne lesions and plasma androstenedione (A), total testosterone (T), sex hormone binding globulin (SHBG) and "free androgen index" (FAI,Scheduled withdrawal bleedings,symptoms of water retention and impaired concentration,Acne,facial acne lesion counts, an investigator's global assessment, a subject's self-assessment, and an analysis of within-cycle variation (cycle 6) in lesion counts,facial acne lesion counts, the investigator's global assessment, and the subject's self-assessment,number of acne lesions,blood pressure and weight,Tolerability,mean age, body mass index, acne lesion counts, SHBG, DHEAS, or free and total testosterone,Early withdrawal bleeding,efficacy, cycle control and tolerability,normalization of biochemical hyperandrogenism,3 alpha-17 beta-androstanediol,hepatic tolerance,normalization of the echogenic ovarian texture,number of papules and/or pustules of the face from admission to Medication Cycle 6,SHBG with NETA than LNG, bioavailable testosterone (T,reduction (+/-SD) rates,efficacy measures (total comedones, open comedones, closed comedones, papules, pustules, and the subject's self-assessment of study treatment,Type and frequency of adverse events,level of sex hormone-binding globulin (SHBG,mean total scores of PGWBI or POMS,SHBG,Intracyclic bleeding/spotting,inflammatory, noninflammatory and total lesion counts,Changes in weight,percentage of severe/moderate acne,efficacy and safety,relative numbers of comedones, papules, pustules and nodules at cycle 6,sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), and free and total testosterone,LNG reduced androgen levels,acne and seborrhea,sebum production and hair growth on the upper lip and chin,blood pressure and body weight,efficacy and tolerability,Biochemical markers of androgenicity,Hormone levels,tolerated,irregular bleeding and minor side effects,number of comedones, papules, pustules and nodules,Mean acne lesion counts,number of inflammatory and total lesions,inflammatory and total lesion count and the percentage of patients with acne improvement according to the Investigator Global Assessment,levels of total and free testosterone, androstenedione, dehydroepiandrosterone sulfate (DHEAS), sex hormone-binding globulin (SHBG), and luteinizing hormone (LH,proportion of subjects with acne,number and severity of acne lesions,severity of acne and SHBG,time serum free testosterone,number of papules/pustules per half of the face present on admission,Somatic and psychological symptoms,excellent improvement" or "complete resolution" of moderate acne,Cycle control, quality of life and acne,contraceptive efficacy,initial values of plasma SHBG,objective and subjective severity of acne, and related biochemical variables such as sex hormone-binding globulin and free and total testosterone,Emotional well-being,Pre-existing acne,self-administered questionnaires Psychological General Well-Being Index (PGWBI) and the Profile of Mood States (POMS,Inflammatory, noninflammatory, and total lesion counts,free testosterone,clinician global and patient self-assessment scores,Mean SHBG,inflammatory lesions,androgenic markers and acne,elevated total T,facial acne,acne lesions,subjective acne scores,total testosterone and 3 alpha-17 beta-androstanediol glucuronide,levels of SHBG,acne lesion counts and Investigator Static Global Assessment scale ratings,total lesions,median reduction in papules/pustules,clinician global and patient self-assessments,lesion numbers,Estimated Pearl Indices for NOMAC/E2 and DRSP/EE,Efficacy and acceptability,objective (acne counts) and subjective (no, moderate, mild, severe) acne scoring of the facial area,occurrence rate of irregular bleeding and spotting,Efficacy and tolerability,Acne lesions, sebum production, and hair growth on the upper lip, chin, and chest,SHBG elevation,signs of biochemical hyperandrogenism, including elevated FAI,total lesion count,severe acne category,Acne lesion counts and clinician global assessment,Free testosterone,irregular bleeding and side effects,SHBG and acne scores,mean acne score,plasma levels of sex hormone binding globulin,reduction rates,median total acne lesion count,Acne resolution rates,tolerability and quality of life,therapeutic effect, sebum production, and hormone levels,incidences of irregular bleeding and minor side-effects,sex hormone-binding globulin,Investigator Static Global Assessment rating of acne,Efficacy,efficacy and acceptability,acne lesion counts|Both preparations increased plasma levels of sex hormone binding globulin and seemed to decrease those of total and free testosterone, but no statistically significant relationships between acne severity and biochemical variables could be detected.
44|pain,therapeutic gain,efficacy and safety,Acute headaches,safe and well tolerated,nausea, photophobia, and phonophobia,pain relief,analgesic efficacy,Efficacy and safety,recurrence,pain intensity differences, maximum pain intensity difference, number of patients with at least 50% pain reduction, time to 50% pain reduction, maximum pain relief and total pain relief,duration of the aura|Patients receiving dipyrone demonstrated a statistically superior improvement (P<.05 and P<.01) in pain and all associated symptoms compared with control subjects.
not found|Pain relief,pain,Pain scores,analgesic efficacy,Mean postoperative days of pain,analgesic effect,postoperative hemorrhage,visual analog scale,pain levels twice daily using a visual analogue scale,postoperative pain relief,Mean postoperative days of analgesic use|The efficacy of benzydamine hydrochloride (Difflam) spray to relieve pain from postoperative tonsillectomy was assessed, but it was found that it did not relieve the symptoms after operation when compared to matching placebo.
299|probability of response included initial performance status, age, histologic grade, and progesterone receptor concentration,survival,Overall response rates,response rate,longer survival,overall response rate,Survival rates,Median survival durations,moderate toxicities,serum levels and response rates,MPA levels,life-threatening case of pulmonary embolism,poorer progression-free and overall survival times,Median durations of progression-free survival,median survival times|The adjusted relative odds of responding to the high-dose regimen compared with the low-dose regimen was 0.61 (90% confidence interval, 0.36 to 1.04).
not found|risk of PD,Increasing intensity of coffee drinking,risk of Parkinson's disease,nonsteroidal anti-inflammatory drugs and PD,lower risk of PD,risk of Parkinson disease,frequency of diseases of immediate-type hypersensitivity,risk reduction,onset of PD,PD risk,incidence of Parkinson disease (PD,PD and environmental measures (history, status, dosage, duration, and intensity) of smoking, coffee, caffeine, nonsteroidal anti-inflammatory drugs, and non-aspirin nonsteroidal anti-inflammatory drugs,protective effect,risk of developing PD,Odds ratios,relative risks,total caffeine consumption|Compared with nonusers, the relative risks were 0.73 for users of fewer than 2 tablets/week, 0.72 for 2 to 6.9 tablets/week, and 0.62 for 1 or more tablets/day (p trend = 0.03).
35|Main efficacy parameter VAS reduction,Responder rate,effectiveness,compound pain subscore of the Arhus low back rating scale (continuous variable), and a response criterion of a reduction in pain subscore=30,severe and unbearable pain,Total Pain Index,Pain,adverse events,maximal platelet aggregation induced by arachidonic acid,numbers of pain,compound pain subscore,pain component,systemic side-effects,severe pain, radiation or neurological deficit,pain without rescue medication,spontaneous pain, muscular contracture and in both the patient's and physician's opinions,pain free without the permitted rescue medication (tramadol,platelet aggregation,efficacy rating "symptomfree" or "improved,severe allergic reaction,efficacy and safety,finger-floor distance and the degree of lumbar extension,severe and radiating pain accompanied by neurological deficit,Adverse local drug reactions,modified Arhus index, its pain component and the Total Pain Index,VAS reduction,severity, duration, nature and accompaniments of their pain; and in laboratory indices of organ system function,Platelet aggregation,mean maximal arachidonic acid induced platelet aggregation,human platelet aggregation,pain,pain free,number of subjects with adverse events (AEs), withdrawals due to an AE and adverse drug reactions (ADRs,proportion of patients who were pain-free without tramadol,pain scores,partial pain scores, disability and mobility restriction subscores, the total score of the Arhus low back rating scale, the global evaluation of efficacy by investigator and patient, adverse events,efficacy and tolerance,adverse effects,number of pain-free patients (visual analogue scale score,severity of pain, duration, nature and accompaniments of their pain, the Arhus low back pain index and in laboratory indices of organ system function|Acetylsalicylate had a significant inhibitory effect on platelet aggregation compared to Salicis cortex extract (p = 0.001) and placebo (p = 0.001).
28|mean daily symptom score,clinical status (respiratory rate, degree of wheezing and accessory muscle use, total clinical score, and arterial oxygen saturation,sGaw,arterial oxygen tension,clinical effect,number of symptom free days,symptom score,pulmonary hyperinflation,bronchial response,maximum flow at FRC (VmaxFRC,arterial oxygen saturation,Lung function,symptom score or pulmonary function,lung volume or air flow obstruction,improvement of Gaw,Values of thoracic gas volume (TGV), airway conductance (Gaw) and specific airway conductance (sGaw,Symptoms of wheeze and cough,clinical status and lung function,Compliance and forced expiratory flows,Bronchial responsiveness,concentration of histamine,heart rate,clinical symptoms or pulmonary function,number of treatment failures|No significant difference in clinical effect was shown between albuterol and saline in the youngest group of children.
14|tidal volume,Decreased activity and oxygen desaturation,TcPCO2,mean TcPCO2 values,proportion of ventilation to the good lung,breathing increased and static compliance,transcutaneous carbon dioxide pressure,vigorous motor activity and crying,colony counts,Transcutaneous oxygen pressure,functional residual capacity, tidal volume, or dynamic lung compliance,blood gases and ventilation volume,oxygen saturation (SpO(2)), desaturation episodes (SpO(2) < 90% and >or= 20 seconds), and motor activity,minute ventilation,static compliance and the work of breathing of spontaneous breaths,PaO2 or PaCO2,motor activity,low birthweight and respiratory distress syndrome,transcutaneous (tc) oxygen (tcPO2) and carbon dioxide measurements (tcPCO2,cardiorespiratory stability and weaning outcome,transcutaneous carbon dioxide tension,spontaneous respiratory rate,tcPO2 and tcPCO2,episodes of oxygen desaturation,arterial oxygen saturation,respiratory rate, heart rate and transcutaneous oxygen saturation, however, oxygen desaturation episodes,transcutaneous carbon dioxide tension values,mean length of the weaning process,TcPCO2 and PaCO2 values,dynamic compliance, tidal volume/kg, and total, inspiratory and expiratory pulmonary resistance,thoracic gas volumes,duration of SpO(2,numbers of positive tracheal cultures,blood gases and lung mechanics,pulmonary mechanics of spontaneous breaths or arterial blood gases,Sleep state,mean tcPO2 or tcPCO2,heart rate,transcutaneous oxygen and carbon dioxide pressures,Pulmonary resistance,Heart rate, respiratory rate, transcutaneous oxygen saturation and ventilatory parameters,Median fraction of inspiratory oxygen,lung mechanics and blood gases|There were no statistically significant differences in mean TcPCO2 values between the three positions (F = .45; df 2,39; P = .64).
100|delivery time,rates of cesarean section and induction of labor,Labor,Overall duration of labor, and first and second stage of labor,time elapsed from the time of randomization to delivery,labor spontaneously,cervical length,shorter duration of active phase,duration of active labor, the amount of oxytocin given, and number of inductions,likely to deliver by cesarean section,length of birth and use of oxytocin,Duration of labor,Mean time to delivery|Duration of labor was significantly reduced (mean difference 1.7 h, p=0.03) and there was significant reduction in the need for oxytocin infusion to augment labor in the study group compared to the control group (odds ratio 2.0, p=0.018).
not found|Adverse effects,conversion rate of HBsAg|Adverse effects were not observed in all patients receiving the plant.
91|pulmonary tuberculosis,Disease recurrence,complete response (CR), disease-free interval and recurrence rate,response rate,local and systemic side effects,toxicity,efficacy|The result was in favour of BCG, as shown by the measurements with complete response (CR), disease-free interval and recurrence rate.
not found|Fibromyalgia Impact Questionnaire,rating scale utilities,health status,patient made drawing of pain distribution, dolorimetry of tender points, ergometer cycle test, global subjective improvement, and VAS registrations of: pain, disturbed sleep, lack of energy, and depression,pain, medicine use, activity, and depression,chronic pain,helplessness and passive coping,pain reductions,Helplessness, number of days feeling bad, physical dysfunction, and pain in the tender points,quality of life,depression, self-reported pain behaviors, observed pain behaviors, and myalgia scores,pain control,ASES-S,work stability,quality of life and self-efficacy,exercise level since,Indirect costs,pain ratings,self-efficacy,Self-efficacy,Arthritis Self-Efficacy Scale (ASES-S,pain,pain, depression, disability, pain behaviors, and intervening variables,fibromyalgia (FMS) symptoms and increasing physical and psychological well being,rating scale or standard gamble utilities,pain coping,health care costs,knowledge about FM,total direct health care costs|Although improvement across time was found in depression, self-reported pain behaviors, observed pain behaviors, and myalgia scores, no differences in these criteria were found between the behavioral and education/control conditions.
not found|child's runny nose, nasal congestion, cough, and sleep status,sputum thickness,CSPLs, cough frequency or subjective symptom scores,cough counts, latency and total effort,cough frequency,nocturnal cough and sleep quality,proportion of children considered "better" overall,Insomnia,nocturnal symptom relief,symptom scores for the cough frequency and severity during the day, sputum quantity or ease of expectoration,drowsiness,mean CSPL changes,cough,diurnal variation in cough frequency,URI symptoms,speed of action, and objective and subjective measures,cough counts, intensity, latency and total effort expended,sedative effects,individual symptoms,cough frequency and the subjective severity of cough,cough severity,thoracic objectivity,Sleep quality,side effects,sleep quality,insomnia,suppression of cough at night,sputum quantity,cough latency,Cough frequency and subjective scores of cough severity,severity of cough, nasal obstruction, nasal discharge, and throat-clearing,subjective methods and cough counts,body temperature, cough, thoracic objectivity, respiratory function indices,fever,frequency of drowsiness,sneezing and total symptom scores,nasal congestion/runny nose/cough/pain relief scores,30-min intervals: cough bouts, cough components, cough effort, cough intensity, and cough latency,nasal congestion, sneezing, postnasal drainage, and nasal discharge,cough bouts, cough components, and cough effort,satisfaction on sleep,nocturnal cough and sleep difficulty associated with upper respiratory infections,overall night-time relief,cough sound pressure level (CSPL), cough frequency (CF) and subjective scores for cough severity,frequency, severity, and bothersome nature of the nocturnal cough,night-time symptom relief and sleep satisfaction assessments,rate of regression of thoracic symptomatology,symptoms of upper respiratory tract infection,nervousness,quality of sleep,cough: cough sound-pressure levels (CSPLs,symptom improvement|The results showed similar trends in both treatment groups with statistically significant reductions (P < 0.05) in cough sound pressure level (CSPL), cough frequency (CF) and subjective scores for cough severity within treatment groups but little difference between the treatment groups during the study period.
60|reduction of the CAI of 6 points or greater (response,median endoscopic index,Baseline characteristics and disease severity,moderate side effects,levels of C reactive protein,ulcerative colitis scoring system (UCSS) symptoms score and induction of endoscopically confirmed remission,rectal histological activity scores,Serious adverse events,active left-sided ulcerative colitis,Steroid reduction,Powell-Tuck Index, Inflammatory Bowel Disease Questionnaire (IBDQ) score, and rectal histological activities,Powell-Tuck Index,Remission,Clinical response,Seven serious adverse events,Clinical remission rates,efficacy and safety,Complete response,IBDQ scores,rectal histological scores,efficacy and tolerability,IBDQ score,depression of the disease activity,median prestudy clinical activity index (CAI,Powell-Tuck Index, IBDQ score, and histological disease activity scoring|The higher PegIFN dose was associated with a significant decrease in levels of C reactive protein (p=0.003, day 0 v 85).
95|abdominal pain,Successful rectal disimpaction, defecation and fecal incontinence frequencies, occurrence of abdominal pain and watery stools, CTTs (before and after disimpaction), and behavior scores,total incidence rate of adverse events seen,frequency of bowel movements,straining on defaecation (p<0.001), stool consistency (p<0.001) and percentage of hard stools,week stool frequency,side-effect,laboratory tests and physical examinations,frequent bowel movements,encopresis frequency,consistency of stools,PEG + E,Abdominal pain,serious adverse effects,adverse events,fecal incontinence,vomiting,Fecal incontinence and watery stools,BM,Compliance rates,complained abdominal pain,number of stools,faecal impaction,total number of complete and incomplete defaecations per week, pain on defaecation, straining on defaecation, faecal incontinence, stool consistency, global assessment of treatment, adverse events and physical examination,tolerated and colonic transit time (CTT,efficacy, safety, acceptance, and 1-year outcomes,clinical complete remission rate of constipation,behavior scores,side effects,chronic functional constipation,Bristol score of stool consistency,effective clearance of abdominal and rectal lumps,stool consistency,bowel movement frequency, stool consistency, clinical complete remission rate of constipation and abdominal symptoms, and the safety of forlax and lactulose,taking PEG + E,total colonic transit time,incontinence frequency, stool consistency, presence of abdominal pain and flatulence, necessity for step-up medication, and dry weight of feces,defecation frequency,vomiting and meteorism,Stool consistency,Orocecal transit time,efficacy and safety,constipation,success rate,median weekly frequency of bowel movement,number of days on which normal stools,number and frequency of the side-effects,safe and well tolerated,Clinical tolerance,defecation and encopresis frequency/week and successful treatment,abdominal faecal masses, presence and consistency of rectal mass, perineal soiling,flatus,resolution of constipation, fecal incontinence, and abdominal pain,vomiting and flatulence,pain on defaecation,paediatric constipation and evaluate clinical efficacy/side effects,mean number of complete defaecations,stool consistency and frequency,Total protein, albumin, iron, electrolytes, and vitamins B9 (folates), A and D (25OHD3,abdominal pain, straining, and pain at defecation,PEG regarding stool consistency, appetite, fecaloma and use of additional laxatives,Clinical efficacy,Abdominal pain and flatulence scores,frequency of incontinence episodes, and resolution of abdominal pain,abdominal pain and fecal incontinence,tolerated,Successful disimpaction,stool consistency, frequency of bowel movements, fecal incontinence, abdominal pain, straining and acceptance of the drugs,fecal incontinence frequency,efficacy and acceptability,proportion of patients with a successful treatment response: >or=3 bowel movements (BM,encopresis frequency meaningfully|Successful disimpaction was achieved with enemas (80%) and PEG (68%; P = .28).
47|Clinical Global Impressions and Brief Psychiatric Rating scales,diastolic blood pressure (lying and standing,Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI,global severity of illness rating of mild or better,demonstrable anti-psychotic activity,NOSIE scale, "manifest psychosis,Median time to tranquilization,Adverse reactions,Therapeutic efficacy and safety,behavioral, extrapyramidal, and sedative,incidence and severity of side effects,clinical efficacy,BPRS, CGI, or Nosie items or factors or in the reduction of overall psychopathology,side effects,drowsiness and extrapyramidal signs,discharge and termination rates,BPRS and CGI,anticholinergic effects, excitement, dizziness and faintness,BPRS scores,number and severity of adverse experiences,dystonic reactions and akathisia,BPRS, CGI scale, Nurses' Observation Scale for In-patient Evaluation (NOSIE) or side-effect records,improvement rating of moderate or marked,severity of illness on the CGI scale,Side effects|After 3-weeks' treatment, no significant differences were found between the two treatment groups according to the Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI)
56|mean plasma total cholesterol,mild adverse events,plasma LDL cholesterol concentration,ankle/arm pressure ratio,2 quality of life instruments, the Walking Impairment Questionnaire,quality of life domains,walking distance,ankle-brachial index,red cell deformability,adverse events (AE,HDL-cholesterol, and positive instrumental changes,walking performance, ankle-brachial indexes, and questionnaire scores,change in treadmill exercise time and patient-reported measures of physical activity and quality of life based on questionnaires,vascular events,total high-density lipoprotein cholesterol,walking performance and symptoms of intermittent claudication,incidence of coronary heart disease and stroke,fibrinogen levels,arterial edge roughness or amount of aorto-femoral atherosclerosis,progression of atherosclerosis,total cholesterol (TC) and low-density lipoprotein-cholesterol (LDL-C,Walking distances,frequency of patients reporting improvement of lower limb symptoms,LDL-C,fibrinogen,claudication symptoms,ankle/arm pressure index,Pain-free and total walking distance, resting and postexercise ankle-brachial indexes, and questionnaire scores,mean low density lipoprotein (LDL) cholesterol,pain-free walking distance,walking performance, ankle-brachial pressure indexes, and symptoms of claudication,efficacy and tolerability,serious vascular AEs,tolerated,Fibrinogen levels,Plasma fibrinogen,total walking distance,maximum walking distance,Mean arterial blood pressure,severity of intermittent claudication,plaque area,walking ability of peripheral arterial obstructive disease,edge irregularity index,nonfatal myocardial infarction,lumen volume,exercise tests or ankle/arm blood pressure,walking performance,blood pressure, blood lipids, and platelet responsiveness,absolute claudication distance,Maximal walking time,density lipoprotein2 cholesterol levels,coronary heart disease and of stroke,initial claudication distance,Rest Flow values--and consequently also Winsor's index,blood triglycerides and fibrinogen,mean pain-free walking distance,density lipoprotein-cholesterol (HDL-C) levels,reduction of lower limb symptoms,pain-free walking time,Changes in ICD and ACD,low-density lipoprotein cholesterol,absolute claudication distance (ACD,claudication distance values,pain-free walking distance and community-based physical activity,Beneficial effects on non-fatal events,ambulatory ability,viscosity,mean plasma triglycerides,cardiovascular events,total of 10 serious adverse events,blood pressure, red cell deformability, fibrinogen, and lipid levels,initial claudication distance (ICD,serum cholesterol,change in atheroma volume estimated as change in lumen volume of the femoral artery assessed by quantitative arteriography,6 adverse events (AE,roughness of the femoral artery,walking distances and pressure indices,blood lipids,femoral atherosclerosis,doubling of the pain-free walking distance,blood viscosity|After 6 months of therapy, policosanol significantly increased (p < 0.01) the initial claudication distance from 125.9 +/-
429|Rifampin resistance,sensitivity of the Xpert MTB/RIF test,rapid TB case detection rate,sensitivity for smear-negative, culture-positive TB,Median time to detection of resistance,rifampicin resistance,Unlike microscopy, MTB/RIF test sensitivity,Specificity,limit of detection (LOD,sensitivity, specificity, positive and negative predictive values of Xpert MTB/RIF test,Sensitivity and specificity of MTBDR for detection of isoniazid resistance,M. tuberculosis viability,MTB/RIF test sensitivity,rapid diagnosis of tuberculosis and detection of rifampin (RIF) resistance,HIV prevalence,overall sensitivity of the Xpert MTB/RIF assay for culture-positive TB,direct fluorescence microscopy, Genotype MTBDRplus assay (MTBDR), Xpert MTB/RIF assay (Xpert), and liquid mycobacterial culture,immediate identification of rifampicin (RIF) resistance,overall specificity,RMP resistance,Bactec 460TB 12B (BD Diagnostic, USA), Löwenstein-Jensen (LJ) culture and direct microscopy of smears stained with Ziehl,total equivocal results,MTB/RIF test sensitivity for rifampicin resistance,rifampin resistance,Mycobacterium tuberculosis,mycobacteria or mycobacterial DNA,IS6110 LDT sensitivities,Xpert MTB/RIF Assay,overall sensitivity and specificity,sensitivity and specificity of PCR,sensitivity of the MTB/RIF RUO assay,negative predictive value,reduced sensitivity,smear status and culture time-to-positivity,MTBDR, Xpert, and liquid culture,Median time to detection of tuberculosis,specificity for detecting M. tuberculosis,indeterminate rate of MTB/RIF testing,Overall, Xpert MTB/RIF,M. tuberculosis,sensitivity, specificity, and positive and negative predictive values|The GeneXpert MTB/RIF assay is a novel integrated diagnostic device for the diagnosis of tuberculosis and rapid detection of RIF resistance in clinical specimens.
176|Pa(CO2) values,relative tachycardia,pulse rate of 8 beats per minute and 2 beats per minute,severe acute asthma,mean PaO2,oxygen to maintain oxygen saturation,mean increase in PEF,Beta agonist-induced hypokalemia,Peak expiratory flow rate,oxygen tension,PEF,peak expiratory flow rate,Side effects, i.e. tachycardia, blood pressure changes and tremor,systemic side-effects,pulse rate and blood pressure,recovery time (no longer requiring inhaled salbutamol) and persistent moderate to severe asthma,peak expiratory flow,rate of recovery,PaO2,Blood gas pressures,Relief of pulsus paradoxus,cardiovascular side effects,simple clinical score, the heart and respiratory rates, the peak expiratory flow (PEF) and the blood gases,recovery time,mean proportionate increase in FEV,heart rate,plasma theophylline concentration,production of side-effects|There was a significantly larger increase in peak expiratory flow after the first inhaled dose in the group that received inhalation treatment than in the i.v.
54|rapid rate of recovery,postoperative infectious illnesses,patient's emotional and functional outcomes,depression and social isolation,depressive symptoms, inflammatory biomarkers, and post-CABG infections,Efficacy and safety,HAM-D score of at least 18 and history of 2 or more prior episodes of MDD,Beck Depression Inventory, (2) natural killer cell cytotoxicity (NKCC) measured by 51Cr-release assay, (3) infectious illness episodes measured by the Modified Health Review, (4) interleukin (IL)-6 and C reactive protein (CRP,HADS and the Workplace Social Adjustment Scale (WSAS,mean HAM-D difference favoring clinical management,cardiovascular safety, heart rate and rhythm, supine and standing systolic and diastolic blood pressures, electrocardiogram conduction intervals, indexes of heart rate variability, and rate of adverse events,12-week HAM-D scores,Mean HAM-D response,left ventricular ejection fraction (LVEF); secondary measures included surrogate cardiac measures and cardiovascular adverse events, as well as scores on the HAM-D scale and Clinical Global Impression Improvement scale (CGI-I,increase event-free survival,mortality and recurrent infarction,mean (SD) change in HRSD score,17-item Hamilton Rating Scale for Depression (HRSD); LPSS,Remission of depression,change in HRSD (for depression) or ESSI scores (for LPSS,BDI, dSCL-90, and CGI scale,Hospital and Anxiety Depression Scale (HADS,depressive symptoms,depression symptoms,efficacy, cardiovascular effects, and safety,hostility scores,rate of recovery of HRV,Major depressive disorder (MDD,Depressive symptoms,survival,efficacy and safety,mean (SD) LVEF,response rate,remission rates,HAMD-17 scores,psychosocial outcomes,Ham-D, BDI, and CGI,self-reported Beck Depression Inventory II (BDI-II) score,rate of serious adverse cardiac events,baseline 24-item Hamilton Depression Rating Scale (HAM-D) scores of 20 or higher,BDI-II scores,17-item Hamilton Depression Rating Scale (HAMD-17) and the Hostility Scale of the 90-item Symptom Check List (SCL-90,depressive symptomatology on the 17-item Hamilton-Depression Rating Scale (Ham-D), and secondary outcomes the Beck Depression Inventory (BDI) and depression subscale of the Symptom Check List 90 items (dSCL-90) as well as the Clinical Global Impression (CGI) scale,Depression,ventricular premature complex (VPC,Depression and hostility,SD of 24-hour N-N intervals (SDNN,depression, anxiety, hopelessness, stress, and quality of life,blood pressure or conduction intervals,heart rate variability,IL-6,Adverse cardiac events,Infection, depression, and immunity,recovery rate of cardiac autonomic function,emotional distress,cardiac function,QTc interval,Antidepressant efficacy,Covariate-adjusted Hamilton scores,death or recurrent MI,CGI-I and HAM-D measures,hostility,safety of fluoxetine, cardiac function,safety and efficacy,heart rate or rhythm or indexes of heart rate variability,mean (SD) change in ESSI score,Beck Depression Inventory scores,hospital fevers and infectious illness,severe cardiovascular adverse events,rate of recovery of SDNN,antidepressive efficacy,event-free survival,Hamilton Rating Scale for Depression,CGI-I responder rates for sertraline,heart rate,17-item Hamilton Rating Scale for Depression,24-item HAM-D, administered blindly during centralized telephone interviews|Also, hostility scores at week 25 were significantly reduced among patients receiving fluoxetine (p = .02).
68|Levels of platelet CD62p and serum TNF-alpha and IL-6,positive expression of platelet CD62p and the serum TNF-alpha and IL-6,positive expression rate of CD62p in platelet and content of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6,platelet level of CD62p and serum content of TNF-alpha and IL-6,total curative effect|The total curative effect in the treated group were significantly higher than that in the control group (P < 0.05).
243|infection rate,incidence of shunt infection or malfunction,craniotomy infections,overall rate of shunt infection,postoperative wound sepsis,wound sepsis,Time of development of cerebrospinal fluid infection,Classical infection parameters,hypotension,Positive CSF cultures,Adverse reactions,Leucocytosis and temperature,rates of infection,infection rates,incidence of shunt malfunction,risk of shunt malfunction,local infection,average time to infection,cerebrospinal fluid infections,risk of catheter-related infections,postoperative shunt infection,CSF infection,ventricular catheter,incidence of infections occurring,Thirteen shunt infections,postoperative ventriculoperitoneal shunt infections,infection rate with antibiotics,Efficacy,infection or overall malfunction rate,Postoperative infection|Among the patients receiving antibiotics there was an infection rate of 12%, versus 19% among patients receiving placebo.
5681|proportion of babies who had an umbilical arterial pH,metabolic acidosis, defined as an umbilical cord artery pH,Apgar score, neonatal admissions, hypoxic-ischemic encephalopathy, or operative deliveries,fetal distress,fetal blood sampling rate,rate of neonatal acidemia,incidence of metabolic acidosis,number of operative deliveries, low Apgar scores, neonatal admissions, and newborns with hypoxic-ischemic encephalopathy,rate of umbilical-artery metabolic acidosis,operative delivery for fetal distress,incidence of FBS,low 5-minute Apgar scores,caesarean section rate,Fetal blood sampling (FBS,rates of umbilical-artery metabolic acidosis,Neonatal acidemia (umbilical artery pH <7.10), neonatal metabolic acidosis (umbilical artery pH <7.05 and base excess <-12 mmol/l) and operative interventions: caesarean section rate, vacuum outlet (VO) rate and FBS rate,neonatal outcome,VO rate,metabolic acidosis in blood, operative deliveries, Apgar scores, neonatal admissions, and hypoxic-ischemic encephalopathy,operative deliveries for "fetal distress,metabolic acidosis,rates of operative intervention, and neonatal outcome,neonatal acidemia,frequency of unsuspected acidaemia|The number of operative deliveries, low Apgar scores, neonatal admissions, and newborns with hypoxic-ischemic encephalopathy was comparable in both groups.
not found|normal ALT levels,duration of the acute phase of hepatitis,severe hepatic lesions with lower histological activity,serum HCV-RNA,Serum hepatitis C virus RNA,normal ALT levels and no HCV RNA,raised serum aminotransferase concentrations,normal serum aminotransferase,rate of chronic evolution of acute hepatitis C,severe side effects of interferon-alpha,aminotransferase flare-ups,Biochemical and virological parameters,normal serum ALT activity,Serum ALT levels,chronicity rate,Serum HCV-RNA measured by reverse transcription-polymerase chain reaction,normal ALT and no HCV RNA,recurrence,persistent undetectable serum HCV-RNA,serum alanine aminotransferase,persistent liver damage,Biochemical, histological and serological parameters|Anti-hepatitis C virus seroconversion occurred later and at a lower rate in the group of patients who received interferon-alpha.
120|episiotomy pain,stronger analgesia,relative efficacy, safety, and time course of analgesia,drowsiness,highest mean rating for summed pain intensity differences,pain intensity difference [SPID] scores,dizziness and drowsiness,pain intensity, pain relief, and side effects,uterine cramp and episiotomy pain,Highest summed analgesic ratings,analgesic response,pain intensity difference (SPID,aspirin analgesia,pain intensity, pain relief and side effects,analgesic efficacy,pain intensity differences (PID,analgesic effects,uterine cramp, episiotomy, or surgical pain,greatest analgesic response,uterine cramps,pain intensity differences and total pain relief,postpartum pain relief,mean pain intensity scores, began within 1 hr and had similar time-effect patterns,Adverse effects,relative efficacy, safety and time course of analgesia,uterine pain,Side effects|Ketorolac 10 mg gave the highest mean rating for summed pain intensity differences (13.6, p = 0.0002 versus placebo), followed by aspirin (11.9, p = 0.012), ketorolac 5 mg (10.9, p = 0.072) and placebo (8.6).
75|radiographic damage,muscle strength, and joint mobility in the high intensity exercise programme,HAQ score,radiographic progression in large joints,disease activity,emotional status,change scores for flexibility, number of clinically active joints, duration of morning stiffness, or grip strength,functional ability (assessed by the McMaster Toronto Arthritis [MACTAR] Patient Preference Disability Questionnaire and the Health Assessment Questionnaire [HAQ,aerobic capacity, exercise time, and joint counts,aerobic capacity, muscle strength, and joint mobility,median radiographic damage of the large joints,blood mononuclear cell subpopulations, proliferative response, or natural killer cell activity,erythrocyte sedimentation rate, tender joints, or morning stiffness,aerobic capacity, 50-foot walking time, depression, anxiety, and physical activity,swollen joints,retention rate,Resting levels of a number of immune parameters,morning stiffness, a pain score, number of swollen joints, a health assessment score, a functional score, ESR, Hb, the cost of medicine, and progression using X-rays of hands and feet,deterioration of disease activity,Maximal O2 uptake,effectiveness and safety,heart rate at stage 2 and rate of perceived exertion,activities of daily living and reduced joint pain and fatigue,emotional status and disease activity,Exercise tolerance, disease-related measures, and self-reported health status,MACTAR Questionnaire score,aerobic capacity, joint mobility, and muscle strength,functional ability,aerobic capacity,plasma concentrations of interleukin-1 alpha, interleukin-1 beta, and interleukin-6,physical condition, muscle strength, joint mobility, daily functioning (HAQ), and disease activity|The results showed no effect of training on the disease activity or on the progression of the disease.
not found|CA-125 concentrations,safety and tolerability,emotional balance,symptom scores,severity of dysmenorrhoea,Total American Fertility Society scoring,body weight increase,mean total endometriosis scores,Pain,quality of life,mean lumbar BMD,weight,quality of life such as sleep disturbances and anxiety-depression,hirsutism,symptom score,weight gain and acne,visual analogue scale (VAS,serum concentrations of CA-125,pelvic pain and dysmenorrhea,natural history of endometriosis or PRs,concentration of CA-125,side effects,dysmenorrhea,endometriosis scores,painful symptoms of endometriosis,anxiety-depression and sleep disturbances,Pain symptoms,bleeding episodes,efficacy and safety,paid working life,mild, moderate or severe degrees of lower abdominal pain, dysmenorrhoea and deep dyspareunia,anxiety-depression score,Serum concentrations of CA-125,CA-125 changes,frequency,breakthrough bleeding,pain pattern and quality of life,pelvic pain,Hypoestrogenic effects,adverse event profile, laboratory parameters, bone mineral density (BMD), bone markers and bleeding patterns,cumulative pregnancy rate,leg cramps,pain symptoms,VAS score,lack of efficacy, pregnancy, elevated hepatic function tests,sleep disturbances and anxiety-depression score,bone resorption,endometriosis scores, pregnancy rates (PRs), and pain|During the 6-month follow-up after medication, the CA-125 concentrations tended to increase, especially in danazol-treated women.
207|Survival proportions,survival benefit,survival times of patients after the operations and the application of an active drug or placebo,6-month survival,median time from surgery to death,intracranial hypertension,survival,adverse reactions,CSF leak,risk of death,survival advantage,Adverse events,Median survival|This survival advantage was maintained at 1, 2, and 3 years and was statistically significant (P = 0.01) at 3 years.
52|number of patients in remission,positive and negative psychotic symptoms,plasma sulpiride levels and therapeutic response,adverse reactions,motor retardation, delusion, hallucination or disturbance of self-consciousness, social isolation or withdrawal, and recreation or work,Side-effects,16-item Brief Psychiatric Rating Scale (BPRS,Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment of Positive Symptoms (SAPS), Scale for the Assessment of Negative Symptoms, and Hamilton Rating Scale for Depression,final global improvement rating,time course of the total psychiatric rating scales (PRS,total PRS,emotional withdrawal and hallucinatory behavior,total BPRS scores,rate of side-effects and abnormal laboratory test results,baseline SAPS scores,antipsychotic efficacy|The time course of the total psychiatric rating scales (PRS) showed a progressive decline during treatment for both drugs, and at the end of treatment clocapramine proved significantly lower in total PRS than did sulpiride.
not found|pressure ulcers,wound healing,healing time|Results showed that US/UVC treatment had a greater effect on wound healing than did nursing care, either alone or combined with laser.
472|duration of hospital stay,overall duration of pneumonia and incidence of adverse outcomes,basal serum retinol concentration,remission of respiratory signs,mean number of days of fever, rapid respiratory rate, or hypoxia,mean number of days of hospitalization,relative mortality,duration of signs of pneumonia|Children who received vitamin A, however, were less likely to have fever by day 3 (P = 0.008) and were 29% less likely to fail to respond to the first line antibiotic (P = 0.054).
not found|anxiety scores,Hypnotisability,Video Rating Scale for Motor Conversion Symptoms, the D(isabilities) code items from the International Classification of Impairments, Disabilities and Handicaps and the Symptom Checklist-90,Stanford Hypnotic Clinical Scale,conversion symptoms|Significant treatment results for all outcome measures were found for the total sample.
79|hepatorenal syndrome,Spontaneous bacterial peritonitis or spontaneous bacteremia,E. coli counts, quinolone susceptibility, and drug concentrations in feces,incidence of infections,Severe infections (spontaneous bacterial peritonitis, neutrocytic ascites and bacteremia,1-year probability of developing spontaneous bacterial peritonitis,lower incidence of extraperitoneal infections,SBP,overall rate of infection or in survival,peritonitis recurrence,rate of mortality,Cumulative one-year probability of peritonitis recurrence,overall probability of spontaneous bacterial peritonitis recurrence,Death,spontaneous bacterial peritonitis recurrence,bacterial peritonitis recurrences,median duration of follow,probability of spontaneous bacterial peritonitis recurrence,probability of survival,spontaneous bacterial peritonitis,probability of gram-negative infection,gastrointestinal bleeding,survival,efficacy and safety,1-year probability of survival,duration of hospitalization,SBP and sepsis,Six gram-negative bacilli infections,probability of remaining free of bacterial infections,1-year probability of development of spontaneous bacterial peritonitis and hepatorenal syndrome,spontaneous bacterial peritonitis recurrences,spontaneous bacterial peritonitis (SBP,mean time of observation,renal function (serum creatinine level,adverse effects,incidence of SBP,Spontaneous bacterial peritonitis,Extraperitoneal infections,Side effects|Norfloxacin was more effective in the prevention of peritonitis recurrence due to Enterobacteriaceae (0% vs 22%, P = .01).
85|developmental status,median length of therapy,frequency of withdrawal symptoms,restarting opium,Hypertension, hypotension, bradycardia, or desaturations,shorter duration of hospitalization, less severe withdrawal, and reduced hospital cost,amount of opium required to control symptoms, number of treatment failures, and differences in blood pressure, heart rate, and oxygen saturation,Severity of withdrawal and hospital cost,Bayley Scales of Mental Development,withdrawal symptoms,Treatment failures,therapeutic response,duration of hospitalization,total length of treatment/observation,average duration of outpatient phenobarbital use,hospital cost,time with mild withdrawal,severity of NOW,duration of opioid therapy,myocarditis, sudden infant death syndrome, and homicide|Results of one way analysis of variance revealed no differences in developmental status between groups (p greater than 0.10, F = 0.25).
not found|survival,efficacy and safety,survival of at least one twin at six months of age, and survival without neurologic complications,perinatal survival,free of neurologic complications,cystic periventricular leukomalacia|Infants in the laser group also had a lower incidence of cystic periventricular leukomalacia (6 percent vs. 14 percent, P=0.02) and were more likely to be free of neurologic complications at six months of age (52 percent vs. 31 percent, P=0.003).
24|global functioning,severity of PTSD symptoms, level of functioning and physical health,depression symptoms, severity of suicidal ideation, feelings of guilt, and perceived stigmatization,K-SADS-PL hyperarousal,symptoms of PTSD, depression, and anxiety,Health visits,posttraumatic stress disorder and depression symptom severity,symptoms of PTSD, feelings of shame, and abuse-specific parental distress,re-experiencing symptoms,CRI scores,posttraumatic stress disorder symptoms and self-reports of fear and anxiety,maladaptive cognitions,SCARED,Total child PTSD symptoms assessed using child and parent structured interview (Kiddie Schedule for Affective Disorders and Schizophrenia, Present and Lifetime Version,Multiple traumas and higher levels of depression,Symptoms of PTSD and trauma-related feelings of guilt,K-SADS-PL avoidance,Symptoms of PTSD, depression, and related impairment,Children's Reaction Inventory (CRI,Revised Children's Manifest Anxiety Scale (RCMAS) and the Children's Depression Inventory (CDI,total number of PTSD symptoms,serious adverse events,Posttraumatic Stress Symptom Scale,symptoms of PTSD,PTSD symptom change,symptoms and functioning,Preintervention and postintervention scores,PTSD symptom scores,RCMAS and CDI scores,PTSD symptom severity,relation to parent-completed measures and clinician ratings of global functioning,children's IPV-related PTSD and anxiety,total K-SADS-PL,scores on the K-SADS-PL (PTSD symptom clusters), Screen for Child Anxiety Related Emotional Disorders (SCARED) (anxiety), Children's Depression Inventory (depression), Kaufman Brief Intelligence Test (cognitive functioning), and Child Behavior Checklist (total behavior problems,total PTSS-C scores, PTSD-related symptom scale, and the subscales re-experiencing and avoidance,waiting-list,CBT gains,PTSD diagnostic remission,recovery rates,PTSD-non-related symptom scale,PTSD symptoms,efficacy of cognitive-behavioral therapy,PTSD symptoms and impairment in functioning,posttraumatic stress disorder and depression and increased functioning,severe abuse-specific distress|Compared to the WL group, participants who received CBT showed significantly greater improvement in symptoms of PTSD, depression, and anxiety, with significantly better functioning.
24|successful delivery of placenta, while removal of placenta,Success rate for delivery of placenta, blood pressure, pulse rate, blood loss, and various side effects|No adverse effects of clinical importance were registered.
90|septic shock,ICU,need for tracheotomy to withdraw ventilation,shorter periods of invasive ventilation,incidence of nosocomial pneumonia,incidence of reintubation,total duration of ventilatory support,durations of RICU stay and hospital stay,incidence of ventilation associated pneumonia (VAP,durations of invasive mechanical ventilation (MV) and total MV,shorter mechanical ventilation and length of stay, less need for tracheotomy, lower incidence of complications, and improved survival,90-day survival,60-day survival rates,occurrence of VAP, reintubation and hospital mortality,intensive care unit (ICU,Survival rates,time of PIC window,Arterial blood gases, duration of mechanical ventilation, time in the intensive care unit, occurrence of nosocomial pneumonia, and survival at 60 days,MV duration, the length of RICU stay and hospital stay,lower rate of ventilator associated pneumonia (VAP,duration of invasive MV, the risk of VAP and hospital mortality,time in the intensive care unit,type of chronic respiratory failure (CRF), pulmonary function data, age, Simplified Acute Physiology Score (SAPS II), and severity of ACRF on admission,lower incidence of nosocomial pneumonia,severe hypercapnic respiratory failure,similar age, sex, APACHE scores, RR, HR, MAP, PaO2 and PaCO2 at the time of commencement and PIC window,lower hospital mortality,duration of ETMV,nosocomial pneumonia,durations of ICU and hospital stays and the 3-mo survival,shorter duration of invasive MV,hospital stays,Hospital mortality,rate of weaning failure,mean duration of mechanical ventilation,mean period of daily ventilatory support,probability of survival and weaning during ventilation|11) days, P = 0.047] and lower hospital mortality (1/47 vs 7/43, P = 0.025).
61|Proximal screw failure,Screw failure,average blood loss,healing and complications,delayed union and breakage of screws,union and infection rate,deep posterior compartment pressures,elective nail removal,average total duration of the procedures performed without reaming,tibia fractures,average estimated blood loss,duration of fluoroscopy,open type I and II fractures,union time,Isokinetic thigh-muscle strength,Peak average pressures,Nonunions, time to fracture healing, and rate of malunions,time to fracture healing,deltaP values,anterior knee pain,mal-union, delayed union, and device failure,chronic anterior knee pain or functional impairment,Malunion,Durations of hospital stay, and time needed to achieve union,Compartment pressures and deltaP ([diastolic blood pressure] - [compartment pressure,average time to fracture healing|Ender nail still has its superior usefulness in some aspects of treatment of less comminuted unstable tibial shaft fractures, but for the more comminuted unstable tibial shaft fractures, the interlocking nail is undoubtedly better used.
282|movement rating scales, EPS-related adverse events, and use of anti-EPS medications,EPS-related events,free of hospitalization for exacerbation of schizophrenia,tolerated,Time to treatment failure,EPS,effective, well tolerated,CGI final improvement score,Extrapyramidal symptoms (EPS,PANSS, BPRS, and CGI,Positive and Negative Syndrome Scale (PANSS), Brief Psychiatric Rating Scale (BPRS), and Clinical Global Impression (CGI|Time to treatment failure was numerically superior in sertindole-treated patients compared with haloperidol-treated patients, although this difference was not statistically significant.
194|oxygen saturation and MRDAI score,SpO(2) or RDAI,oxygen saturation and clinical modified respiratory distress assessment instrument (MRDAI) scores,ED discharge,length of hospital stay (LOS,respiratory rate (RR), heart rate (HR), oxygen saturation (SpO(2)), Respiratory Distress Assessment Instrument (RDAI), and activity levels,respiratory rate, blood pressure, or respiratory-effort scores,mean clinical score, respiratory rate, and room air saturation over time,inspiratory, expiratory, and total pulmonary resistance,degree of change in the respiratory rate, the heart rate, and the respiratory-effort score and the time that supplemental oxygen was required,hospital admissions,clinical score and pulmonary mechanics,clinical score and respiratory rate,heart rate, respiratory rate and Respiratory Distress Assessment Instrument (RDAI) score,clinical scores or oxygen saturations,room air oxygen saturation, elapsed time to meeting clinical criteria for ED discharge, hospitalization rate, and proportion of patients relapsed within 72 hours of ED discharge (relapse rate,hospital admission within 7 days after the day of enrollment (the initial visit to the emergency department,Relapse rate,changes in clinical scores and oxygen saturations,length of the hospital stay,mean LOS,time from admission until the infant had normal hydration, oxygenation, and minimal respiratory distress,median time,RR,acute bronchiolitis but L-adrenaline,Clinical score, oxygen saturation and heart rate,need for hospital admission or home oxygen,Adverse effects,respiratory rate,RDAI score values,heart rate,adverse effects,length of the hospital stay and the time until the infant was ready for discharge,clinical score,mean percent oxygen saturation|There were no significant overall differences between the groups in the length of the hospital stay (P=0.16) or the time until the infant was ready for discharge (P=0.86).
46|clinical or radiologic incidence of pneumonia,Postextubation problems|There was no difference in the clinical or radiologic incidence of pneumonia.
not found|occurrence of any acts of verbal or physical aggression,personality disorder, psychiatric symptoms, early maladaptive schemas, interpersonal problems, and addiction-related psychosocial impairment,frequency of self-harm episodes,Total costs,Diagnostic Interview Schedule,problematic drinking, social functioning and beliefs about others,alcohol misuse, mental state, beliefs and social functioning,Substance abuse and personality disorders,rates of cluster B personality disorders,personality disturbance,comparison of scores on the Social Problem Solving Inventory and the Social Functioning Questionnaire,cost effective,alcohol consumption,lower anger expression,success; therapist's personal qualities,problem-solving skills,overall social functioning,drug use and alcohol intoxication,psychiatric symptoms, criminality, and psychosocial impairment,counseling attendance and some indication of lower psychosocial impairment,parasuicide events|A 2-way analysis of variance showed that patients with ASPD were more likely to abstain from cocaine use during treatment than patients without ASPD.
490|IMT of combined carotid and femoral arterial walls,number of angina attacks,IDLc,visits systolic blood pressure,recurrent stenosis,arterial IMT,plasma lipids, insulin resistance and blood pressure,morbidity and mortality,plasma lipid levels,thickening of the intima/media complex,thickness of the intima/media complex degree of stenosis, interventricular septal thickness, crurobrachial pressure ratios of dorsalis pedis and posterior tibial arteries, distance to claudication and total vessel diameter,major cardiovascular events,marked reduction in septal thickness,ankle blood pressure index (ABI,arterial wall thickness,concentration of triglycerides,intima/media thickness,risk of clinical outcomes,plasma lipids,Ankle brachial blood pressure index,blood pressure and increases insulin resistance,fasting lipids and on progression of peripheral atherosclerosis,HDLc,rate of restenosis,Blood pressure,tolerated,mortality,IMT,arterial intima-media thickness (IMT) of the carotid and femoral arteries and fasting lipid parameters|Blood pressure was effectively reduced by perindopril irrespective of the associated disease.
77|CvO2,frequency of adverse events,survival,survival with a follow-up time of six months,improved survival,relative risk of death by intractable shock,median tympanic temperature,median tympanic temperature at admission,lactate concentration and O2 extraction ratio,six-month survival curves,survival to hospital discharge with sufficiently good neurologic function to be discharged to home or to a rehabilitation facility,complications,haemodynamics, electrolytes, lactate, arterial pH, CaO2, CvO2 and O2 extraction ratio,cardiac arrest, HF (with or without HT,neurologic outcome,Bladder and tympanic temperature,lower cardiac index, higher systemic vascular resistance, and hyperglycemia,Mild hypothermia|There was no difference in the frequency of adverse events.
200|serum levels of the proinflammatory cytokines (IL-6, IL-8, TNF-alpha), and leukocytes, and the SIRS score,C-reactive protein (CRP,precocious modulation of IL-6 expression,MYocardial Dysrhythmia,Postoperative serum levels of both interleukin-6 and interleukin-8,incidence of postoperative AF and the postoperative peak C-reactive protein (CRP) level,incidence of postoperative AF; secondary end points were length of stay, 30-day major adverse cardiac and cerebrovascular events, and postoperative C-reactive protein (CRP) variations,Higher postoperative peak N-terminus pro-B-type natriuretic peptide levels,Plasma levels of interleukins 6 and 8, P-selectin, soluble intercellular adhesion molecule-1, and lactoferrin,plasma levels,risk of AF,levels of IL-6, IL-8, TNF-alpha and SIRS score,systemic inflammatory response syndrome score,myocardial disease,postoperative CRP level,Blood samples,Peak postoperative values of troponin,length of ICU and hospital stay,length of stay,plasma CRP levels,creatine kinase-MB mass,Plasma levels of selected inflammatory mediators,Concentrations of soluble P-selectin (sP-selectin,neutrophil-endothelial adhesion,occurrence of postoperative AF; secondary endpoints were major adverse in-hospital cardiac and cerebrovascular events and identification of variables predicting postoperative AF,P-selectin levels,incidence of postoperative AF,postoperative interleukin-6 (IL-6) levels,high postoperative CRP levels,incidence of AF,major adverse cardiac and cerebrovascular events, persistent AF at 1 month, and identification of the markers to predict inhospital postoperative AF,Troponin I, myoglobin, creatine kinase-MB mass, and high-sensitivity C-reactive protein,sP-selectin values,systemic inflammatory responses,endothelial progenitor cells,incidence of major adverse cardiac and cerebrovascular events and persistent AF,expression of NF-kappaB,Plasma levels of interleukins (IL-6, IL-8, TNF-alpha), and systemic inflammatory response score (SIRS,intraoperative inotropic agents,incidence of major adverse cardiac and cerebrovascular events,Systemic inflammatory response,leukocyte-endothelial cell interactions,systemic inflammatory response and perioperative morbidity,SD values,Mean,amount of EPCs,High-sensitivity C-reactive protein values,Cytokine levels,SDF-1alpha, granulocyte colony-stimulating factor, and vascular endothelial growth factor,operation time, blood loss, need for inotropic support, intubation time, and length of intensive care unit or hospital stay,plasma levels of any cytokine and number of EPCs,peak levels,Levels of interleukin, IL-6 and IL-8; tumor necrosis factor alpha; SDF-1alpha; granulocyte colony-stimulating factor; and vascular endothelial growth factor,cytokine release and neutrophil adhesion,systemic inflammatory response,postoperative atrial fibrillation,Postoperative clinical outcomes,plasma IL-1 and TNF-alpha,hospital stay,levels of proinflammatory cytokines,inflammatory response,Atrial fibrillation (AF,occurrence of postoperative AF,risk of complications, length of stay, and cost of care,preoperative and postoperative course,myocardial damage,plasma levels of cytokines and cholesterol,postoperative AF,Peak CRP levels,Postoperative peak N-terminal pro-brain natriuretic peptide levels,EPC count,CD11b expression on neutrophils|Atorvastatin significantly reduced the incidence of AF versus placebo (35% versus 57%, P=0.003).
not found|Recurrence of clinical symptoms,relative risk (RR) of CDD recurrence,safety and efficacy,recurrence of CDD,Recurrence of active CDD,serious adverse reactions,recurrences,initial CDD (recurrence rate,Clostridium difficile-associated diarrhoea (RCDAD,Effectiveness|No serious adverse reactions were observed in these patients.
20|attitudes, behaviors and intentions related to sexual activity,intention to engage in sex and increased abstinence,sexual consequences,self-efficacy,sexual intentions, abstinence, and a trend toward fewer virgins initiating intercourse,sexual risk,sexual behavior|Hierarchical logistic regression analyses showed significant effects for the intervention on sexual intentions, abstinence, and a trend toward fewer virgins initiating intercourse for the first time, 19 weeks after baseline.
not found|patency rate,patency, limb salvage, and survival,secondary patency rates,FPA levels,Heparin levels (Anti Xa,patency,anti Xa levels,clotting of blood within the grafts or native vessels,Major complication rates and cardiovascular morbidity,mortality rate,risk of morbidity and mortality,duration of patency, limb salvage rates, and complication rates,FPA,overall complication rate,level of the reconstruction; survival,cumulative 5-year survival rate,Median blood loss,patency and limb salvage,limb salvage rate,levels of fibrinogen, FPA, thrombin antithrombin complex and FM,bypass patency, and mortality and morbidity,median durations of primary patency and limb salvage,graft reocclusion and limb loss,rate of occlusion and bleeding,rest pain or tissue loss,levels of FPA,Primary patency rate,incidence rate of wound hematomas,intraoperative graft thrombosis,ages, indications, bypass graft types, risk classifications (ie, conduit, runoff, or graft failure), or comorbid conditions (except diabetes mellitus,limb salvage rates,Patency,Major hemorrhagic events,Soluble fibrin, measured as fibrin monomers (FM) and fibrinopeptide A (FPA,survival,cumulative limb salvage rates,elevated levels of fibrinogen, fibrinopeptide A (FPA) and thrombin-antithrombin (T-AT) complexes,Graft patency rates, limb salvage rates, and survival rates,graft patency, limb salvage, and survival,overall patency,limb salvage,serious bleeding complications,30-day graft patency, operative blood loss, and hemorrhagic complications,major bleeding events,patent reconstruction at day 1, perioperative blood loss, and the percentage of patients requiring protamin,reoperation because of bleeding,incidence rate of postoperative hematoma,excessive bleeding,Benefits, morbidity, and mortality,Perioperative blood transfusions and complications,immediate postoperative primary graft patency rates,primary patency of peripheral arterial bypass grafts (PABG,heart failure,Graft patency,30-day data for mortality, repeat operation, and recurrent occlusion,operative procedure, complication rate, and hospital course,fibrinogen prothrombin complex, thrombin-antithrombin complex, platelets and antithrombin,graft performance,graft patency,graft occlusion,Levels of FM,patient mortality, morbidity and bypass patency rates,limb salvage or survival rates,early graft patency|Preoperatively and during surgery the patients had elevated levels of fibrinogen, fibrinopeptide A (FPA) and thrombin-antithrombin (T-AT) complexes.
134|negative appraisal of caregiving,sleep quality, depressive symptoms, and quality of life,Pittsburgh Sleep Quality Index (PSQI), Center for Epidemiological Studies-Depression scale (CES-D), and Caregiver Quality of Life-Cancer scale (CQOLC,presence and severity of physical symptoms, psychiatric morbidity, use of and satisfaction with services, and carers' problems,carer strain and quality of life, satisfaction with care, and bereavement outcome,quality of life, more self-efficacy, better communication, and less negative appraisal of caregiving, uncertainty, hopelessness, and symptom distress,overall caregiving mastery, caregiver mastery specific to caregiving tasks, problem-focused or emotion-focused coping,levels of caregiver strain,partners' ratings of their self-efficacy,Legacy improved family communication,caregiver QOL, reducing burden related to patients' symptoms, and caregiving tasks,Global family functioning,burden of patient symptoms,vomiting,caregiving task burden,quality of life,quality of life (QOL,carer distress (GHQ-28,social interaction,appraisal variables (appraisal of illness or caregiving, uncertainty, hopelessness), coping resources (coping strategies, self-efficacy, communication), symptom distress, and quality of life,caregiver QOL, caregiver burden due to patient symptoms, caregiver burden due to tasks, and caregiver mastery,positive caregiver experience,caregiving stress,distress and depression,quality of life and other psychosocial outcomes,Mean scores,family caregivers' QOL, burden, coping, and mastery,preparedness to care, self-efficacy, competence, and anxiety,Actigraphs measured latency, duration, efficiency, and wake after sleep onset (WASO) scores,quality of life scores,Brief Symptom Inventory and Beck Depression Inventory,caregiver QOL,sleep quality and depressive symptoms,hopelessness and less negative appraisal of illness,depression,Legacy activity,quality of life of dyads,Brief Symptom Inventory, Beck Depression Inventory, and Social Adjustment Scale,emotional distress,PSQI and CES-D scores,breathing difficulty and increased religious meaning,stimulus control, relaxation, cognitive therapy, and sleep hygiene elements,stress|The intervention consisted of five sessions and addressed family involvement, optimistic attitude, coping effectiveness, uncertainty reduction, and symptom management.
94|Neuropeptide Y (NPY) concentrations in follicular fluid (FF,time for mobilization, and costs for time and drug consumption,severity of nausea, vomiting, dizziness, and drowsiness,prolactin,pregnancy rate,Hemodynamic variables, sedation and pain scores and the number of patients with the maximum Aldrete recovery score,analgesia requirements,visual analogue scale (VAS,pain intensity and analgesic consumption,abdominal pain, other pain, nausea and stress,pregnancy rate and NPY concentrations,median abdominal pain levels,pain relief, peroperative pain, clouding of memory and the surgeons' assessment of operating conditions,NPY concentrations in FF,Pain relief,Levels of sedation and co-operation,pain tolerance,Time and drug consumption,A visual analogue scale (VAS,Number of oocytes retrieved and fertilization, cleavage and clinical pregnancy rates,levels of vaginal and abdominal pain,5-point scale while severity of pain, and doctor and patient satisfaction,p-deletion and critical flicker fusion scores,Pain and subjective expectations and experiences,hemodynamic parameters, pain, sedation, and recovery score,pain relief,mean and maximum pain, and 'pain now,Pain,anaesthetic effect,Overall, patient satisfaction,plasma remifentanil concentrations,VAS pain ratings,implantation rate,Heart rate (HR), mean arterial pressure (MAP), peripheral oxygen saturation (SpO2), end tidal carbon dioxide (ETCO2) tension, forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC), and amount of remifentanil,number of oocytes,harmful to oocytes or embryos,visual analogue scale,Adverse effects,Intra-operative sedation and co-operation,pain-relieving effect,postoperative abdominal pain,median pain levels,rate of gestation,intraoperative analgesia,level of stress,adequate peroperative analgesia,pain levels,rate of embryo transfers and pregnancies,mean (SD) pain score,pain rating and pain score,Fertility outcomes,State Trait Anxiety Inventory (STAI,Visual analogue scales (VAS,postoperative nausea,average alfentanil dosage requirements,hemodynamic parameters,analgesic effects,postoperative abdominal pain, nausea and stress,incidence rate of abdominal pain,IVF pregnancy rate,pain and anxiety,pain directly related to oocyte aspiration, adequacy of anaesthesia during oocyte aspiration, abdominal pain, or degree of nausea,Time to discharge and costs,Pain intensity and psychological well-being were assessed by means of visual analogue scales (VAS); tiredness, nausea and vomiting and analgesic drug consumption,P-deletion, reaction time, and critical flicker fusion tests revealed similar depression,plasma remifentanil concentrations and pulmonary function tests,mean age, weight, duration of procedure and dose of alfentanil,HR, MAP, ETCO2, SpO2, FEV1, and FVC,abdominal pain,pain relief; secondary end-points were costs, time to discharge and clinical outcome parameters,nausea,Follicular cortisol,pain score,VAS ratings,Pain relief and subjective well-being,Oxygen saturation levels,cumulative scores of pain,oversedation or peri-operative complications,time and costs for drug consumption,pain sensation,pain thresholds,pain,pain scores,take home baby rate,efficacy and acceptability,Hemodynamic variables, sedation, pain, the Aldrete recovery score, and side effects,Plasma remifentanil concentrations|Auricular EA significantly reduces pain intensity and analgesic consumption of the opioid remifentanil during oocyte aspiration in IVF treatment.
52|severe renal or extrarenal toxicity,partial remission (urinary protein-creatinine ratio,serum creatinine and creatinine clearance,remission,serum creatinine, triglyceride, cholesterol, urine protein and creatinine clearance,proteinuria and alleviated renal tubular damage,average CSA level and proteinuria change,complete resolution of proteinuria,serum albumin levels,blood pressure and components of systemic RAS,fractional decline in GFR,proteinuria,steady-state blood pressure and serum concentrations of serum angiotensin-converting enzyme (ACE) and plasma renin activity or angiotensin II (AT-II,Treatment failure,Rates of remission,Baseline clinical, biochemical, and histological features,nephrotic-range proteinuria,hypertension and hypokalemia, while vomiting and reversible alopecia,Efficacy and safety,number of adverse events,urine albumin-to-creatinine (Ua/Uc) ratio and the percentage reduction,complete remission (urinary protein-creatinine ratio,hyperlipidemia and proteinuria,mean score,efficacy and safety,mean urinary protein excretion, the mean serum proteins and plasma cholesterol,sustained remissions,Ua/Uc ratio,serum concentrations of urinary retinol-binding protein and beta(2)-microglobulin,remission of the nephrotic syndrome,blood cholesterol levels,median Ua/Uc ratio,blood pressure,Systolic and diastolic blood pressure reductions,diminution of their proteinuria,prestudy serum cholesterol levels,cushingoid features and serious infections,blood pressure and components of the renin-angiotensin system (RAS,Proteinuria,Partial remission,complete remission,proteinuria and serum albumin levels,proportion of patients who experienced relapse,values of 24-h urinary protein excretion,Cosmetic side effects (hypertrichosis and gum hypertrophy,serum creatinine|Following treatment, complete remission was seen in 53.8% and 47.8% patients in groups I and II, respectively (P = 0.6).
12|continuous cocaine abstinence,weekly assessments of the frequency and quantity of drug and alcohol use, weekly urine toxicology screens and breathalyzer readings,medication adherence,cocaine dependence,positive urinalysis,quantity and frequency of cocaine,total number of weeks abstinent from cocaine,Visual Analogue Scales (VAS,number of cocaine-negative urine tests,rates of cocaine-negative urine tests|Results show that CBT treated subjects remained in treatment longer than those assigned to either DIS/CBT or NTX/CBT therapies.
208|time to return to uninterrupted sleep,resolution of pain,chronic pain and quality-of-life outcomes,relieved pain,frequency of postherpetic neuralgia,progression of the rash,total crusting,quality of life,laboratory adverse events,postherpetic neuralgia,time to a first or a complete cessation of pain,post-herpetic neuralgia,lesion healing, resolution of pain, return to usual activity, and return to uninterrupted sleep,Time to total crusting and healing,Pain reduction,analgesic requirements each day, and adverse events and laboratory abnormalities,risk ratios,time to return to usual daily activity,accelerated time to cessation of acute neuritis,adverse events|Time to total crusting and healing was accelerated for patients receiving acyclovir plus prednisone compared with patients receiving two placebos; the risk ratios were 2.27
29|prevalence of post-bronchioltis wheezing,RDAI, heart and respiratory rate and SpO(2,symptoms of acute bronchiolitis or prevented postbronchiolitic wheezing,mean oxygen requirements, or length of hospital stay,Disease severity,mean duration of symptoms,RDAI score,wheeze and hospitalization rates,respiratory syncytial viral (RSV) bronchiolitis,oxygen saturation, respiratory rate, and RDAI score,length of hospital stay,time from study entry to resolution of respiratory distress, determined by a clinical score derived from the respiratory rate, occurrence of wheezing, chest retraction, and oxygen saturation,time needed for resolution of respiratory distress,rate of hospitalisation or respiratory status,Respiratory Assessment Change Score (RACS,length of hospitalization,Median time,hospital admissions,hospital admission rate,cumulative proportion of in-hospital stay,duration of oxygen therapy,hospital stay, later medical visits or admissions, and adverse events,mean length of hospital stay,heart rate, respiratory rate and Respiratory Distress Assessment Instrument (RDAI) score,frequency of hospital release,shorter hospitalization period,rate of hospital admission, the respiratory status,time to clinical resolution,evolution of respiratory rate, oxygen saturation, clinical score, or pulmonary function tests,Oxygen saturation (SaO2,Duration of hospital admission, time taken to become symptom free, re-admission rates, general practitioner consultation rates, and use of anti-wheeze medication,median length of stay,heart and respiratory rate; respiratory distress index, oxygen saturation, and Silverman Andersen scores,hospital admission within 7 days after the day of enrollment (the initial visit to the emergency department,Poor RACS,Respiratory status,admission rate,prevalence of post-bronchiolitis wheezing,mean 4-hour RACS,mean duration of oxygen therapy,prevalence of wheeze, respiratory symptom scores, or proportion requiring bronchodilators or steroids,Baseline characteristics and respiratory status,respiratory distress assessment instrument (RDAI), heart and respiratory rates, and transcutaneous haemoglobin oxygen saturation (SpO(2,hospital admission after 4 hours of emergency department observation,Respiratory re-admission rates,duration of illness prior to enrollment, pretrial medication use, clinical severity of bronchiolitis, history of atopy, and family history of atopy,chronic respiratory symptoms,postbronchiolitic wheezing,hospitalisation rate,RDAI score values,RACS,clinical score, oxygen saturation, or IV fluid requirement,oxygen saturation, respiratory rate, RDAI measurement twice daily for the first 4 days, and the length of hospitalization,RDAI improvement,length of hospital stay, duration of oxygen therapy and time to clinical improvement during the hospitalization,clinical score or in the SaO2|No significant differences were found between the groups in evolution of respiratory rate, oxygen saturation, clinical score, or pulmonary function tests on day 3.
211|hypoesthesia,number of days on acute medication,Responder rate,responder rate,migraine status, quality of life, level of physical activity, and oxygen uptake,mean monthly rate of acute abortive medication use, mean monthly migraine duration, and mean monthly migraine severity,transformation of episodic migraine,symptoms with migraine,duration, monthly frequency, and intensity of headache,fatigue,weight loss,responder rate, time to onset of action, mean change in migraine days per month, and mean change in rescue medication days per month,weight increase,mean monthly number of migraine episodes,quantity of symptomatic drugs taken,rate of mean monthly migraine episodes,Adverse events,satisfaction with tolerability,frequency of migraine crises,Quality of life,28-day migraine frequency,headache intensity,average weight change,migraine frequency, responder rate, migraine days, and daily rescue medication usage,efficacy reduction in mean monthly migraine frequency,adverse reactions and weight changes,mean monthly (28-day) rate of days with migraine, mean monthly rate of days with headache (migraine and nonmigraine,paresthesia, fatigue, nausea, anorexia, and taste per version,mean standard deviation (SD) of monthly migraine frequency,weight satisfaction,EEG synchronization,serious AEs (depression, abdominal pain, leg pain,efficacy and safety,headache frequency, and migraine associated symptoms,reduction of headache severity,mean monthly days and severity of headache,migraine episodes,weight loss and improved weight satisfaction,chronic daily headache,efficacy and tolerability,migraine headache,development of CDH,tolerated,Adverse effects,number of days of disability,Side effects,Mean monthly migraine frequency,headache duration,migraine and headache days,paresthesia, fatigue, and nausea,dizziness,mean reduction of the frequency of migraine attacks,mean weight gain,efficacy-evaluable,alpha-band phase synchronization,responder rate (proportion of patients with > or =50% reduction in monthly migraine frequency), reductions in mean number of monthly migraine days, severity, duration, and days a month requiring rescue medication, and adverse events,dry mouth,reduction in mean monthly frequency, intensity, duration, rescue medication use, migraine associated symptoms, and adverse events,visual analog scale (VAS), and headache duration,overall deterioration in weight satisfaction,headache days and migraine headache days and generally well tolerated,paresthesia,efficacy, safety, and side effects,paresthesia, weight loss, altered taste, anorexia, and memory impairment,mean functional disability scores,headache days,mean monthly severity of migraine-associated symptoms (photophobia, phonophobia, and nausea), change in the mean monthly frequency f migraine-associated vomiting, and response rates (based on monthly migraine days and total headache days,Frequency, intensity, and duration of migraine headaches as well as MIDAS score and symptomatic medications,role function-restrictive, role function-preventive, and emotional function domains of the MSQ,mean 28-day migraine frequency,Efficacy and tolerability,Frequency, intensity, duration, associated symptoms with headaches, analgesics use, as well as drugs' side effects,nausea,number of migraine days,TEAEs of mild or moderate severity,side effects,mean weight loss,mean (+/-SD) of monthly migraine frequency,reduction in mean monthly migraine days and severity of headache,somnolence,Rescue medication use,monthly migraine frequency,Visual Analog Scale, and headache duration,monthly headache frequency,SD monthly migraine frequency,mean number of migraine days,number of days with migraine,Responder rate for frequency,Migraine-Specific Quality of Life Questionnaire (MSQ) and the Weight Satisfaction Scale Questionnaire,mean SD of monthly headache frequency,migraine frequency,migraine headache frequency, intensity, and duration,mean monthly migraine frequency|A significantly larger proportion of TPM-treated subjects had a > or =75% reduction in monthly migraine frequency compared with placebo (P=0.03).
427|complete relief from upper GI symptoms,Complete heartburn relief,oesophagitis,esophageal acid sensitivity,heartburn-specific questionnaire,relapse rate,concordance analyses, daytime and nighttime heartburn with antacid usage,free of heartburn,overall quality-of-life measures or the HAD scale,median percentages of 24-h heartburn-free days,complete endoscopic healing,frequency and severity of symptoms,rate of complete resolution of heartburn,symptomatic relief,Esophagoscopy, esophageal acid sensitivity, and lower esophageal pressures,early satiety,relief of heartburn,Efficacy and safety,Recurrences of moderate or severe heartburn,symptom relief,erosive reflux oesophagitis, symptom relief,Heartburn,Complete resolution of heartburn,relieving heartburn,relief from key GERD symptoms (heartburn, acid eructation, and pain on swallowing,diarrhea,percentage of heartburn-free days and antacid-free nights,endoscopic appearance of the esophageal mucosa,mild heartburn,Quality of life,patient quality of life,reflux score,erosive oesophagitis,Frequency of gastro-oesophageal reflux disease symptoms and health-related quality of life,Symptom relief,adverse events,incidence of possible or probable treatment-related adverse reactions,severity of heartburn and endoscopic grade,total heartburn relief,relief of symptoms of gastroesophageal reflux,Heartburn-dominant, uninvestigated dyspepsia,symptom control,Reflux index scores, quality of life (SF-36), and the hospital anxiety and depression (HAD) scale and symptom relief,free from key GERD symptoms,quality of life,mean heartburn pain scores,gastro-oesophageal reflux disease symptoms,GerdQ index,Quality of life improvements,general health status dimensions of physical functioning, bodily pain, and vitality,resolution of heartburn,cumulative relapse rates,percentage of heartburn-free days and the time to first and sustained resolution of heartburn,effective and well tolerated,percentages of 24-h heartburn-free days (primary) and nights without heartburn (secondary,proportion of patients in whom heartburn,proportion of patients with complete relief of daytime heartburn,acid regurgitation, dysphagia, epigastric pain, and nausea,efficacy and safety,Total heartburn relief,mean basal pressure,erosive esophagitis,anxiety,Response of low-esophageal-sphincter pressure,gastrointestinal symptoms (epigastric pain, vomiting, nausea, flatulence, retching, and retrosternal feeling of tightness) and safety profiles,Regurgitation and epigastric pain,tolerated,quality of life and symptom severity questionnaires,symptom frequency and severity,reflux dimension of the Gastrointestinal Symptom Rating Scale (GSRS) score,endoscopic classification,mean number of heartburn episodes,heartburn,nonerosive gastroesophageal reflux disease,symptomatic improvement,pathological gastroesophageal reflux,nights without heartburn,abdominal pain and diarrhea,Complete upper GI symptom relief,Gastroesophageal reflux disease (GERD,Daily proportions of patients with no heartburn,median times to relapse,heartburn symptoms of reflux disease,health-related quality of life,severity of oesophagitis or frequency of positive acid perfusion tests,Total time off active treatment, time to failure of intermittent treatment, and outcomes ranked from best to worst,clinical outcomes and quality of life,symptomatic relief of heartburn,Median time to first 24-hour heartburn-free interval,heartburn symptoms,Complete relief,Endoscopic healing,symptomatic response,adequate control of heartburn,Reflux symptom relief,esophageal endoscopic appearance or sphincter pressures,global scores,heartburn-free,complete relief rate,Similar sensitivity,completely symptom free,lower severity of heartburn,percentage of heartburn-free days,frequency and degree of symptoms,adverse events and laboratory assessments,rate of adverse events,Symptoms and quality of life,reflux,chronic heartburn,pain severity of both day and night heartburn,Antacid consumption,complete resolution of heartburn,lower-esophageal-sphincter pressure,reflux score irrespective of H. pylori infection,median number of days off active treatment,esophageal erosions or ulcerations,gastroesophageal reflux disease and heals erosions and ulcerations,Quality-of-life effects,total heartburn relief defined as no heartburn symptoms,Relief of non-reflux symptoms,oesophageal acid hypersensitivity,frequency and the severity of heartburn,Heartburn symptoms,daytime and nighttime heartburn,GERD-associated symptoms (e.g., regurgitation, belching, early satiety,effective and safe,rapid relief of heartburn,healing,heartburn severity,rapidity of symptom relief and 4-week efficacy,frequency and severity of heartburn using the Gastrointestinal Symptom Rating Scale (GSRS) and a patient heartburn diary,total use of rescue antacid medication,rates of complete control of GORD symptoms,symptoms of mild-moderate gastroesophageal reflux disease (GERD,symptomatic relapse,total regurgitation,free of regurgitation,GERD symptoms (heartburn, acid eructation, and pain on swallowing,heartburn relief,safety and symptom relief efficacy,rate of sufficient relief from heartburn,evidence of erosions and ulcerations,percentage of patients self-rated as having minimal or better symptomatic improvement,alginate/antacid relief medication|At two weeks there was no significant difference between placebo and ranitidine, regarding the proportion of patients with complete relief from symptoms or satisfied with treatment.
67|DFU healing,Pain on dressing change,mean time to healing,overall ulcer improvement and less deterioration,healing outcomes and primarily healing speed,AQAg-treated ulcers,Efficacy and safety,All ulcer healing outcomes,Efficacy and tolerance,success rate,Wound size,wound area,Adverse events,pain on dressing changes, the number of dressing changes, and adverse events,Complete healing,total number of dressing changes,proportion of patients with granulation tissue,efficacy and tolerance,Diabetic foot ulcers (DFUs|There was more overall ulcer improvement and less deterioration in AQAg subjects (P = 0.058), particularly in the subset initially using antibiotics (P = 0.02).
400|risk of child mortality,pregnancy outcomes and T cell counts,birth outcomes, hematologic indicators, and counts of T lymphocyte subsets,risk of adverse pregnancy outcomes,HIV disease progression or pregnancy outcomes,red blood cell count and in packed cell volume,adverse pregnancy outcomes,CD4(+), CD8(+), or CD3(+) cell counts,risk of fetal death,risk of low birth weight,CD4 cell counts, viral load, pregnancy outcomes, and maternal and infant mortality,birth weight, duration of gestation, or fetal and neonatal mortality,CD4, CD8, and CD3 counts,Hemoglobin concentrations,adverse birth outcomes,birth outcomes and counts of T lymphocyte subsets,risk of preterm birth,rise in hemoglobin,maternal mortality,risk of low birthweight,child survival,early infant death,reduced risk of low birth weight,severe preterm birth,neonatal or overall child mortality,mean birth weights,30 fetal deaths,maternal CD4 cell counts or viral load,pregnancy outcomes, hematologic indicators, and T cell counts|However, the rise in hemoglobin over this period was significantly lower (P = 0.03) in the zinc group (x +/-
not found|median overall survival,percentage of CD4 or CD4 T-cell subsets,6-month survival,Poor performance status (PS), hepatic metastases, and weight loss,overall survival (OS,prolonged survival,incidence of grade 3/4 flu-like symptoms,percentage of CD56- (NK cells) and CD3/HLA-DR-positive (activated T cells) subsets,tolerated with only additive toxicity,severe and life-threatening toxic events,durable responses,1-year survivals,complete and partial response rate,progression-free survival or overall survival,functional living index,response rate, time to treatment failure (TTF), overall survival, and toxicity,tolerated and produced a noncumulative, transient myelosuppression late,quality of life,overall median survival,severe toxicity,Median duration of response,Nine complete (CRs) and 18 partial responses (PRs,efficacy and toxicity,Median time to progression (TTP,response rate, TTF, or survival,response rates, overall survival, and tolerability,toxicities,survival advantage,fatigue,response rates,Toxicity,Median survival,acceptable level of toxicity,toxicity,Median time to treatment failure (TTF) and median survival,response or survival,overall response rate of BCDT with IL-2/IFN-alpha,survival,duration of partial responses,severe thrombocytopenia,Objective responses, survival, and toxicity,drug safety,median durations of response,OS, time to progression, or OR,lymphopenia, evidence of immune activation,health-related QOL,median survival,overall survival, progression-free survival (PFS), objective response, and safety, and to assess health-related quality of life (QOL) and pharmacokinetics of both drugs and their metabolite, 5-(3-methyltriazen-1-yl)imidazole-4-carboximide (MTIC,Objective response (complete plus partial remission [CR + PR,complete response (CR) and seven partial responses (PR,median progression free survival,constitutional, hemodynamic, and myelosuppressive toxic effects,overall response rate,death,survival benefit,Response or disease stabilization,nonhematologic toxicities,Grade 3 or 4 nonhematologic toxicities,Median PFS time,median survival time,Quality of life,total response rate,Five CRs and 20 PRs,TTF or survival,overall median TTF,median OS,fatigue, nausea and anorexia, flu-like symptoms and neutropenia,Response rates,TTP and survival|Toxicity was worse in the combination arm, with more patients experiencing fatigue, nausea and anorexia, flu-like symptoms and neutropenia.
not found|mean scores,prescribing quality and volume,influenza and pneumococcal immunisation rates,raised total cholesterol,baseline-adjusted CDE recommendation and performance rates,average prescription costs,patient recall of assessment of smoking status and FP use of "quit dates," behavioral advice, and written materials,proportions of GPs implementing the programme and numbers of patients screened and intervened with,frequency and quality of counseling,overall benzodiazepine prescribing rate fell,patient care processes (lab work, nursing, dietary management, ventilator management, ventilator weaning,pneumococcal vaccination rates,effectiveness and efficiency,appropriateness (based upon the guidelines) of sale or no sale of OTC anti-fungals,reporting ADRs overall,physician behaviour,preventive care performance,total length of stay and ICU length of stay fell,cognitive function,overall cost,prescribing of psychotics,Mammography completion,vaccination rates,antibiotic use, diazepam prescribing, drug costs per patient, and a composite process index for diabetes care,mean cost,prescribing of tranexamic acid,health outcomes,psychotic disorder,initial prescriptions,referral rates,frequency of pleasurable activities, and (c) self rated health,proportion of residents with any psychotropic drug, polymedicine, and therapeutic duplication and proportion of residents with nonrecommended and acceptable drugs,Intervention delayed time to first attendance with acute asthma,percentage of records containing at least one periodontal diagnostic notation,cerebral and peripheral vasodilators (CPVD) and antibiotics,angina pectoris,rate of unnecessary use of the 2 target antibiotics,Quality of life,influenza and pneumococcal vaccination rates,preventive cardiovascular care,Rates of ventouse delivery,ADR reporting rates,overall index of preventive performance,total antimicrobial use,Cost effectiveness,influenza vaccination,quality of selective case finding and quality of diagnostic procedures,quality of life,Compliance rates,quality of care,discontinuation rates,number of prescriptions of lipid-lowering drugs per month,Antibiotic dispensing,rates of preventive services,risky sexual behavior,prescription of first-line lipid-lowering drugs,blood pressure control, defined as a blood pressure measurement,quantity of cholesterol testing,sales of asthma medication,Patient satisfaction scores,pneumococcal immunization,endorsement of PSA screening by professional bodies,benzodiazepine hypnotics,proportion of "correct" responses,influenza immunization,anxiety,blood pressure control,minimal intervention" components of the kit, ratings of overall acceptability of delivery, perceptions of cultural and structural barriers to using the kit, and ratings of the overall acceptability of the kit,tetanus immunization,patient quality of life or symptoms,Antibiotic prescribing rates and patients' symptom resolution,pattern of prescription of asthma medicines,antibiotics in caesarean section and use of polyglycolic acid sutures,patient care processes, patient morbidity and mortality outcomes, and resource use,blood pressure,cost-effectiveness,Anxiety and insomnia diagnosis rates,oral rehydration solution (ORS) usage,effectiveness and cost-effectiveness,admissions to hospital or mortality,benzodiazepine prescribing,transfusion risks (eg, viral hepatitis,relative reduction in R05C1 prescription,back pain unit,quality of asthma care,number of prescriptions written,asthma related quality of life,Mean costs of inappropriate prescriptions per practitioner per patient visit,prescription of CPVD,clinical breast examination,recording of review of inhaler technique, smoking habit, and review of asthma symptoms,total number of antibiotic prescriptions,discontinuation of long-acting benzodiazepines,weight and physical activity level,personal care scores,proportion of appropriate outcomes following educational outreach [odds ratio (OR),numbers of patients "at risk of stroke,respiratory infections,total costs,diagnosis of depression,physician reporting of adverse drug reactions,outpatient prescribing costs,median PSA testing rate,percentage of participants attending with acute asthma,PSA testing rates and GP knowledge in key areas relating to prostate cancer and PSA testing,levels of knowledge of prescribers about the appropriate management of acute diarrhoea,blood transfusion practice,knowledge about diarrhoea,number of days that unnecessary levofloxacin or ceftazidime,CDE recommendation and performance rates,provision of preventive care,steroid prescribing,average prescribing cost,prescribing for anxiety diagnoses,Moderate rates of improvement,higher self-reported and observed rates for several risk assessment questions and counseling recommendations,tranexamic acid,patient recall of FP advice about nicotine replacement patches and gum,hypertension control,mean stay in hospital,net annual savings,suspected urinary tract infections,global scores in 4 areas--quality of care, charting, prevention and overall use of medications--and patient ratings of satisfaction with care and preventive practices,clinical outcomes of mortality or nosocomial events,reduced mortality,ADR reports,blood pressure and total cholesterol values,antimicrobial usage,child diarrhoea,total cost of antibiotics prescribed by doctors,proportion of prescribing of the five most frequently used drugs,glycosylated haemoglobin, patient satisfaction with care and treatment, functional health status and professional ability to apply the intervention,hyperlipidaemia OR,risk factors,Prescribing behaviour,acute respiratory tract infection,Baseline prescribing costs,volume of prescribing for ibuprofen, diclofenac and naproxen as a percentage of total NSAID prescribing,primary outcome measure: practices receiving outreach visits,Processes of care, patient symptoms, quality of life, costs, and work days lost,management of patients' problems,time to symptom resolution,index of psychoactive-drug use, measuring both the magnitude and the probable inappropriateness of medication use,physical activity, functional status, self rated health, immunisation status, social contacts, psychological wellbeing, drug usage, and rate of influenza vaccination,Mammography,risk factor management,diagnosis of dementia,hypertension,prescribing practice,Length of stay, intensive care unit transfers, readmission rates, and in-hospital death rates,index of preventive performance,Helicobacter pylori testing,mean stay in the ICU,drug usage, rate of influenza vaccination, functional status, or psychological wellbeing,Overall benzodiazepine prescribing,rates of diuretic or beta-blocker use,mean rate of inappropriate prescribing per control practitioner,loss of memory,antidiarrhoeal sales,net annual cost (cost minimization,peak flow rate, review of inhaler technique, review of asthma symptoms, prophylaxis, occupation, and smoking habit; diabetes: blood glucose concentration, glycaemic control, funduscopy, feet examination, weight, and smoking habit); size of practice disease registers; prescribing in asthma; and use of structured consultation "prompts,diagnoses of hypertension,quality of rural ICU care,mean global scores,CDE recommendation and performance,discussion of dehydration during pharmacy visits,hospital ventilator days,days of enteral nutrition,average improvement|No significant differences were found between the groups for the time to symptom resolution.
not found|total duration of IV use,number of insertion attempts required for total IV therapy,Systemic infection or death,systemic infection or death,length of the neonatal intensive care unit stay and in the incidence of sepsis,incidence of phlebitis,skin punctures,systemic infection (defined as a positive blood or cerebrospinal fluid (CSF) culture treated for at least 5 days) or death,Length of neonatal intensive care unit stay and incidence of sepsis and phlebitis,number of painful IV procedures,sepsis rates,number of courses of antibiotics,incidence of sepsis,number of total catheters utilized,sepsis rates and efficacy of PN delivery,number of skin punctures|Interim analysis (49 neonates) revealed no difference in sepsis rates (CVC group 46%, cannula group 40%, p = 0.57).
43|frequency of cough,ambulatory cough meter, kept cough diaries,cough frequency or score, irrespective of the presence of AHR|Salbutamol or beclomethasone had no effect on cough frequency or score, irrespective of the presence of AHR.
not found|viral replication,anti-HD titer, IgM anti-HD and HBsAg concentration,biological and/or virological relapse,complete response (normal levels of alanine aminotransferase and no detectable serum hepatitis delta virus [HDV] RNA,sustained biochemical or virologic response,Serum HDV-RNA,percentage of hepatitis D virus RNA positivity,ALT levels,relapses,portal inflammation,histologic findings (reduced periportal necrosis and portal and lobular inflammation,alanine aminotransferase values,Serum ALT levels,serum alanine aminotransferase level becomes normal, HDV RNA,serum ALT levels,HDV-RNA negative,histologic deterioration,normal serum ALT levels,hepatic inflammation,positive for hepatitis D virus RNA,Histological improvement,antiviral activity (serum hepatitis delta virus RNA and intrahepatic hepatitis delta antigen,serum alanine aminotransferase values,HDV-RNA levels,normalization of serum ALT levels,clearance of serum HDV-RNA,hepatitis D virus RNA levels|A decrease in the percentage of hepatitis D virus RNA positivity was observed in both groups at the end of treatment.
15|Average weight gain,Social Phobia Inventory (SPIN) and the Sheehan Disability Inventory (SDI,change from baseline to week 4 endpoint in PaRTS-A.
                Improvement from baseline to week 4 endpoint in PaRTS-A total score,Social anxiety disorder (SAD,negligible weight gain,BSPS score,HAM-A psychic anxiety factor scores,response rates,CGI-I,HAM-A scores,Hamilton Rating Scale for Anxiety,Brief Social Phobia Scale (BSPS), Social Phobia Inventory (SPIN), Liebowitz Social Anxiety Scale and Sheehan Disability Scale, as well as Clinical Global Impression-Improvement ratings,Hamilton Anxiety Scale (HAMA-A) score,SAD,core anxiety symptoms,Brief Social Phobia Scale (BSPS) and the Clinical Global Impression of Improvement Scale (CGI,residual GAD symptoms,HAM-A total scores,Headache, weight increase, and increased appetite,rates of remission,Residual GAD symptoms,Anxiety,drowsiness and dry mouth,Clinical Global Impression-Severity Scale (CGI-S) end point score|There was no significant difference in responders (CGI-I score of 1 or 2) versus non-responder (CGI-I score of 3 or more) across the groups.
59|safety and potential efficacy,Facial Grading Scale scores,Facial Grading Scale change scores,Facial Grading Scale,amplitude of the compound motor action potential (CMAP,House-Brackmann Scale,Facial Grading Scale subcomponents,overall improvement of clinical stage,House-Brackmann scores|Individualized facial neuromuscular re-education is more effective in improving facial symmetry in patients with Bell's palsy than conventional therapeutic measures.
65|Response rates,Severity of extrapyramidal symptoms,OCS,body weight,severity of OCS,severe OCS,severity of obsessive-compulsive symptoms (OCS,core symptoms of schizophrenia and motor side effects,motor side-effects, efficacy, safety and quality of life (QOL,extrapyramidal side effects, hyperprolactinemia, and sexual dysfunction,Quality of Life (QOL) measure,PANSS total score,Quality of Life Scale (QLS) Intrapsychic Foundation and Medical Outcomes Study Short Form 36-item instrument (SF-36) Role Functioning Limitations-Emotional subscale scores,Total scores on the Extrapyramidal Symptom Rating Scale,changes in Positive and Negative Syndrome Scale (PANSS) total scores and rates of extrapyramidal symptoms (EPS,safe and effective,safety and efficacy,extrapyramidal symptoms,severity of psychotic and extrapyramidal symptoms,general antipsychotic efficacy,PANSS total scores,five PANSS factor scores (positive symptoms, negative symptoms, disorganized thoughts, and anxiety/depression,total score on the Positive and Negative Syndrome Scale,weight gain,EPS-related adverse events,Brief Psychiatric Rating Scale, Scale for the assessment of Negative Symptoms and Montgomery and Asberg Depression Rating Scale scores,Positive and Negative Syndrome Scale (PANSS) total score, derived Brief Psychiatric Rating Scale (BPRSd) total score, as well as PANSS and BPRSd subscales,efficacy,frequency and severity of extrapyramidal symptoms,psychotic symptoms,Positive and Negative Syndrome Scale factors for positive symptoms and anxiety/depression,efficacy and safety,psychological domain of the World Health Organisation-Quality Of Life [Brief] (WHO-QOL-BREF) scale,severity of positive and affective symptoms,dyskinetic symptoms,comprehensive battery of tests to assess (1) motor skills, (2) attention span, (3) verbal fluency and reasoning, (4) nonverbal fluency and construction, (5) executive skills, and (6) immediate recall,PANSS positive and negative scores and Clinical Global Impression-Severity of Illness scale (CGI-S,Neuropsychological change,Greater weight gain,WHO-QOL-BREF physical, psychological and health satisfaction domains,overall response rate,Hooper Visual Organization Test,Yale-Brown Obsessive Compulsive Scale (YBOCS,mean duration of illness,psychological QOL,tolerated,Positive and Negative Syndrome Scale (PANSS) total, Brief Psychiatric Rating Scale (BPRS) total, and PANSS General Psychopathology scores,general cognitive index,Obsessive-compulsive symptoms,total and negative symptom scores,Total Positive and Negative Syndrome Scale scores and scores on the five Positive and Negative Syndrome Scale factors,tolerated and efficacious,efficacy in negative symptoms (Scale for Assessment of Negative Symptoms summary score,PANSS positive scale scores,Positive and Negative Syndrome Scale total score,adverse events,efficacy, safety|Exploratory within-group analyses of the 6 cognitive domains after a conservative Bonferroni adjustment revealed a significant improvement with olanzapine only on the immediate recall domain, and similar analyses of the 17 individual tests revealed a significant improvement with olanzapine only on the Hooper Visual Organization Test.
102|overall incidence of AVN,rate of union or the development of AVN,femoral head vitality|There was no significant difference between the groups in terms of union (p = 0.93) and AVN at two years (p = 0.85).
23|mean amplitude and increased ratio (turns/amplitude,head position and pain,serious or systemic side effects,efficacy and safety profile,Tsui scores,involuntary activity,Direction of head turning, severity of torticollis, and presence or absence of jerky movements,Efficacy and safety,dystonia and neck pain,activities of daily living (ADL,severity of torticollis, disability, pain, and degree of head turning,spontaneous remission,Adverse events,Tiredness,neck pain,neck posture,pain scores,serious side effects,pain-free,Side effects|The remaining 18 patients completed the study and showed a significant improvement after the injections of botulinum toxin in comparison with that of the placebo.
77|Median hospital stay,serious bile duct injury,FVC,Forced vital capacity (FVC), forced expiratory volume at 1 second (FEV1), and forced expiratory flow,monocyte release of O2- and tumor necrosis factor, neutrophil release of O2- and chemotaxis, and white blood cell count,postoperative septic complications,plasma cortisol or C-reactive protein levels,Pulmonary function,Conversion to open cholecystectomy,complications,incidence of complications,duration of convalescence,hospital stay (postoperative nights in hospital,operation without injury to bile duct, viscera or vessels, minimal pain and discomfort at 4 weeks, no wound infection,FEV1,Postoperative deficits of respiratory function,Peak expiratory flow rate, forced expiratory volume in 1 second, and forced vital capacity,IL-1 and TNF response,IL-6 increase,median time off work,Total cost for LC,hospital costs and social costs,hospital stay or postoperative recovery,Systemic concentrations of interleukin-6 (IL-6), interleukin-1 (IL-1), tumor necrosis factor (TNF), and C-reactive protein (CRP,duration of anesthesia and operation time, perioperative complications or postoperative need for analgetics,median post-operative hospital stay,total cost of each case included cost of investigations, cost of disposable articles for operation, cost of drugs, cost of hospital stay, and cost of operation including anesthesia,Immune function,mean operation time,pain and depression,quality of life scores,Interleukin-1 receptor antagonist (IL-1ra), IL-6, and tumor necrosis factor (TNF-alpha,postoperative hospital stay,Operative time,Systemic acute-phase response,hospital and social costs,time back to work for employed persons,hospital costs,Median sick leave and time for return to normal recreational activities,Intraoperative complications,successful, hospital stay,Median operating times,time to full activity,Postoperative analgesia requirements,plasma IL-6 levels,hospital stay,serum CRP concentrations,monocyte superoxide anion (O2-) and tumor necrosis factor release, neutrophil O2- levels and chemotaxis, total white blood cell counts, partial arterial oxygen pressure, and serum cortisol and C-reactive protein levels,postoperative complication rate,physical and social functioning,physical functioning and depression scores,cytokine levels,success or failure,C-reactive protein (CRP), alpha-1-antitrypsin (AAT), retinol-binding protein (RBP), transferrin, and albumin,hospital stay and time off work,rate of return to normal activities,mean hospital stay,partial arterial oxygen pressure,CRP, AAT, and albumin,pre- and postoperative white blood cell (WBC) counts, postoperative body temperature, and length of postoperative hospitalization,postoperative pain, less restriction of total vital capacity,CRP,shorter hospital stay, less postoperative dysfunction, and quicker return to normal activities|Patients with LCCE had significant less postoperative pain, less restriction of total vital capacity and a shorter postoperative hospital stay as parameters of a diminished operative trauma.
not found|MRR of vitamin A supplementation,mean number of diarrheal episodes,rates of any sign or symptom,potential acute side-effects,intracranial haemorrhage,relative risk of mortality,infant survival,incidence of diarrhea,RI,anthropometric status, or on overall or severe morbidity,pregnancy-related mortality and all-cause female mortality,infant mortality,Breast milk retinol levels,Mean RI values,Acute toxicity,vitamin A deficiency,Cause of death,milk retinol,rate ratio to compare all deaths,cumulative effect of toxicity,safety and toxicity,morbidity and child growth,serum retinol,mortality through 24 weeks of age,vitamin A status, signs of acute toxic effects, anthropometric indicators, and severe morbidity,episodes of bulging of the fontanelle,side effects,Maternal serum retinol,Antibody titers,Child growth,antipolio antibody titer, antitetanus toxoid antibodies, and avidity of antibodies to tetanus,gram fat, milk retinol,mortality; the mortality rate ratio,vitamin A intakes,fetal loss and early infant mortality,rate of fetal loss,intracranial pressure,serum retinol levels,Adverse events,Milk retinol,linear or ponderal growth or infectious disease morbidity,Mortality rate ratios,serum retinol and infant stores,Infant retinol stores,miscarriage, stillbirth, maternal death, or live birth,fetal or early infant survival,Mortality, calculated as mortality rate ratios (MRRs,Seroconversion to OPV and geometric means of antibody titers,mortality rate ratio,risk of death,vitamin A status,Incidence of diarrhea and Acute Respiratory Infection (ARI,mortality,Infant serum retinol,fetal loss and survival,Mean RI fell,24-wk mortality rate,Mortality|Vitamin A supplementation at birth was not significantly associated with mortality: the MRR of vitamin A supplementation compared with placebo, controlled for randomisation to "early BCG" versus "no early BCG" was 1.08 (95% CI 0.79 to 1.47).
60|clinical success rate,failure frequencies,number of failures,presence of marginal gaps|There was no difference between the number of failures caused by post decementations and the presence of marginal gaps observed in the 2 groups (95% confidence intervals, -9.7 to 16.2 and -17.8 to 9.27).
43|prolonged bleeding,frequent sexual activity,menstrual changes,repeat pregnancy,number of missed pills per cycle,adolescent compliance,clinic utilization or satisfaction,Cumulative life table discontinuation rates,Study termination rates,Questionnaire data,mean number of missed pills per cycle,noncompliance level,levels of condom and contraceptive use, and rates of pregnancy and STDs,knowledge of OCs,condom and contraceptive use, rates of pregnancy and STDs, and other outcomes and mediators,rate of continuation and the rate of on-time injections,oral contraceptive pill adherence|More women in the intervention group were not pregnant and still using contraception, and were able to successfully switch contraceptive methods compared to women in the control group.
not found|serum ferritin and hemoglobin,Delayed clamping of the umbilical cord increases the infant's iron endowment at birth and haemoglobin concentration,infant haematological status and iron status at 6 months of age, and analysis was by intention-to-treat,Infant haematological status,clinical jaundice or plethora,total serum bilirubin levels,iron and haematological status,Bilirubin concentration,mean infant ferritin and Hb,maternal or newborn morbidity, in infant behavior in the first hour of life,haemoglobin (Hb) change from cord values,haematological status,Iron stores,odds ratio for iron deficiency anaemia,polycythaemia without symptoms,maternal perceptions of her infant and the experience of giving birth,iron stores,mean infant haemoglobin level,total body iron,Maternal haematological status,Maternal and cord ferritin and hemoglobin values,duration of cord adherence and neonatal and maternal outcomes,rate of jaundice,infant and maternal safety,6-month iron stores,shorter active labors,maternal haemoglobin,ferritin,beneficial haematological effect,red cell mass,infant's hemoglobin and serum ferritin 3 months after delivery,mean corpuscular volume,rate of breast feeding,odds for anemia,Delayed cord clamping and haemoglobin levels,haematological effects,adverse events|Throughout the observation period infant Hb levels in both groups declined, but more rapidly in controls than in the DCC group [difference in Hb change from baseline at 4 months 1.1 g/dl, 95% confidence interval (CI) 0.2; 2.1].
not found|maximal workload, muscle strength, gait speed, and the Berg Balance Scale score,functional capacity, physical aspects, pain, general state of health, vitality, social aspects and mental health,muscle strength and gait,quality of life,cardiovascular fitness (V(O2)max,Berg Balance Scale scores, forward and backward weight-bearing abilities of the affected limbs, and knee flexor strength,postural balance and muscle strength,generic health-related quality of life survey (SF-36,Postural balance and knee flexor strength,cardiovascular fitness, maximal workload, gait speed, and paretic lower-extremity muscle strength,cardiovascular fitness,Berg Balance Scale score and weight-bearing ability, as measured by vertical ground reaction force during four standing tasks (rising from a chair and weight-shifting forward, backward and laterally,motor behaviour|Postural balance and knee flexor strength were improved after aquatic therapy based on the Halliwick and Ai Chi methods in stroke survivors.
198|parental anxiety scores,Amsterdam Preoperative Anxiety and Information Scale (APAIS) questionnaires,lower anxiety,Sensory stimuli and anxiety,Global Mood Scale (GMS,preoperative anxiety levels,Parental anxiety,Parental HR,Modified Yale Preoperative Anxiety Scale (mYPAS) score,level of anxiety,parental preoperative anxiety,low trait anxiety,level of anxiety postoperatively,SCL changes over time,anxiety (mYPAS) and compliance (ICC,anxiety levels,perioperative outcomes,anxious,Parental satisfaction,median recovery (coping) VAS levels,analgesia,parental anxiety,quality of mask induction,cortisol concentrations,maternal anxiety,anxiety and distress,level of parental anxiety,behavioral and physiologic anxiety,anxiety changes,preoperative anxiety,State anxiety and blood pressure,behavioral disorders,anxious on entrance to the operating room,Posthospitalization Behavioral Questionnaire (PHBQ,maternal blood pressure and heart rate,behavioral or physiologic measures of anxiety,anxiety levels and health care attitudes,infant behavioural distress,incidence of electrocardiogram abnormalities,median induction (coping) VAS level,change in anxiety,Observed anxiety in the holding area (T1), entrance to the operating room (T2), and introduction of the anesthesia mask (T3,Preoperative parental anxiety levels,Anxiety and compliance during induction of anesthesia,Postoperative behavioral disorders,pediatric preoperative anxiety,anxiety,emergence delirium,Post Hospitalization Behavior Questionnaire,Mean arterial pressure,Postoperative behavior changes,Posthospital Behavior Questionnaire (PHBQ,Reducing anxiety,parental HR and SCL,parental heart rate (HR), parental blood pressure, and parental skin conductance level (SCL,State-Trait Anxiety Inventory (Y-1/Y-2) instrument (self-report anxiety behavioral instrument that measures trait/baseline and state/situational anxiety,anxiety of the parent and compliance of the child during induction,anxiety and satisfaction,number of anxious children,child's behaviour and the Visual Analogue Scale (VAS,Anxiety,anxiety and desire for information,Preoperative anxiety,Hospital Fears Inventory (HFI) and Behavioural Questionnaire (BQ), and parental anxiety by the Parents' Questionnaire (PQ,A Visual Analog Scale (VAS) and Modified Child Dental Anxiety Scale (MCDAS,percentage of inductions in which compliance of the child,Fear and anxiety,frequency of behavior disorders,anxiety, health care attitudes and satisfaction with the anaesthesia and surgery experience,children's perioperative anxiety,postoperative behavioral changes|The Mann-Whitney U-test showed that the computer group coped significantly better than the control group at induction (P = 0.014) and significantly better than the cartoon group upon recovery (P = 0.016).
200|patients' subjective experience of pain,10-point visual analogue scale,Systolic and diastolic blood pressure, pulse rate and peripheral oxygen saturation,tissue manipulation,minimal discomfort,level of intraoperative pain,cell density parameters or Kowa laser flare-cell meter measurements,discomfort pain scores,no sensation,Safety and efficacy,rate of potential visual acuity recovery,Intraoperative pain scores,safety and efficacy,Central endothelial cell counts,intraoperative pain,subjective experience of pain,level of intraoperative discomfort,pressure or pain,visual analog scale,discomfort or pain,Intraoperative pain,patient cooperation,intraocular sensation,Best corrected visual acuity (BCVA,BCVA improvement,mean pain score,4-point pain scale,discomfort,visual analog pain scale,operative conditions, patient cooperation, and intraoperative complications,patient-reported pain scores for delivery of anesthesia,Systolic blood pressure, pulse rate, oxygen saturation and pain score,blood pressure,pain,patient satisfaction,pain scores,Intraoperative discomfort, postoperative discomfort, and discomfort,5-point satisfaction scale,mean pain score,surgeon satisfaction score,Diastolic blood pressure,cell loss or adverse events,Endothelial cell loss|In a rigorously double-masked, prospective, randomized, controlled trial there was no significant reduction in intraoperative pain when intracameral 1% lidocaine was used during phacoemulsification under topical anesthesia.
153|pain reduction,peak pain score pattern,repositioning and percentage of united fractures,pain relief,number of analgesic medications,Pain,pain alleviation,Visual Analogue Scale (VAS,processing time or time to operation,femoral neck fractures,pain score,visual analog scale (VAS,processing time,pain medication,pain relief treatment,pain,consumption of analgesics of no clinical importance,VAS pain evaluation,analgesic requirement,pain suffered, analgesia required, frequency of pressure sores or ease of operation,pain experienced, the need for supplementary analgesics, or complications during the hospital stay,total consumption of analgesics,intertrochanteric fractures|There was a small significant increase in consumption of analgesics of no clinical importance in patients with skin traction, and no effect of traction type on the processing time or time to operation.
60|internal fixation of humeral shaft fractures,fracture alignment, time to healing, delayed union, and nonunion,complications,elbow ROM,Healing times,American Shoulder and Elbow Surgeons' Score (ASES,Shoulder pain,Radial nerve palsy,ASES scores,average union time,union rate,function of the shoulder and elbow, as determined by the American Shoulder and Elbow Surgeons' score, the visual analogue pain score, range of movement, or the time taken to return to normal activity,restriction of shoulder movements,shoulder range of motion (ROM,rate of union and functional outcome,elbow pain,union time, union rate, functional outcome and the incidence of complications,fracture healing, radial nerve recovery, infection, and elbow and shoulder discomfort,rate of non-union|Healing times did not differ between the two treatment groups (p>0.05).
58|number of infections,infection rate,deep infection,Superficial thromboplebitis|A statistically significant difference was found between the number of infections in the antibiotic groups and the number in the placebo group.